sign in sign up
<<
Home , Flumetasone, Flutrimazole, Fusafungine, Rofleponide, Topical medication

Title of Article PubMed Link Intralesional 5-fluorouracil, and epinephrine mixture for the treatment of verrucae: a prospective placebo-controlled, single-blind http://www.ncbi.nlm.nih.gov/pubmed/15196161 5-FLUOROURACIL randomized study. Treatment of warts with topical pyruvic acid: with and without added 5- http://www.ncbi.nlm.nih.gov/pubmed/9878984 5-FLUOROURACIL fluorouracil. http://www.ncbi.nlm.nih.gov/pubmed/19706088 5-FLUOROURACIL 5% 5-Fluorouracil for treatment of verruca vulgaris in children. 5-FLUOROURACIL Topical treatments for cutaneous warts. http://www.ncbi.nlm.nih.gov/pubmed/22972052 Treatment of common warts with an intralesional mixture of 5- fluorouracil, lidocaine, and epinephrine: a prospective placebo- http://www.ncbi.nlm.nih.gov/pubmed/18261100 5-FLUOROURACIL controlled, double-blind randomized trial. Topical 5% 5-fluorouracil cream in the treatment of plantar warts: a http://www.ncbi.nlm.nih.gov/pubmed/16703777 5-FLUOROURACIL prospective, randomized, and controlled clinical study. Topical 5-fluorouracil has no additional benefit in treating common warts with cryotherapy: a single-centre, double-blind, randomized, http://www.ncbi.nlm.nih.gov/pubmed/16681586 5-FLUOROURACIL placebo-controlled trial. Therapeutic evaluation of intralesional 5% 5-fluorouracil in http://www.ncbi.nlm.nih.gov/pubmed/15187327 5-FLUOROURACIL condyloma acuminata.

Management of intravaginal warts in women with 5-fluorouracil (1%) http://www.ncbi.nlm.nih.gov/pubmed/10872909 5-FLUOROURACIL in vaginal hydrophilic : a placebo-controlled double-blind study. Relationship of genital wart burden to therapeutic response to http://www.ncbi.nlm.nih.gov/pubmed/9310224 5-FLUOROURACIL fluorouracil/epinephrine injectable gel. Treatment of extensive vulvar condylomata acuminata with topical 5- http://www.ncbi.nlm.nih.gov/pubmed/2371597 5-FLUOROURACIL fluorouracil. [Adjuvant 5-fluorouracil lacquer administration for reducing the rate of recurrence of condylomata acuminata following laser surgery http://www.ncbi.nlm.nih.gov/pubmed/2741263 5-FLUOROURACIL treatment].

A comparison of a 5% potassium hydroxide with a 5- http://www.ncbi.nlm.nih.gov/pubmed/25039244 fluorouracil and combination in the treatment of patients 5-FLUOROURACIL with anogenital warts: a randomized, open-label clinical trial. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating http://www.ncbi.nlm.nih.gov/pubmed/25950503 5-FLUOROURACIL Actinic Keratosis: A Randomized Clinical Trial Medication Title of Article PubMed Link A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% http://www.ncbi.nlm.nih.gov/pubmed/25257941 salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of 5-FLUOROURACIL hyperkeratotic actinic keratosis Optimized permeation enhancer for topical delivery of 5-fluorouracil- http://www.ncbi.nlm.nih.gov/pubmed/26697777 5-FLUOROURACIL loaded elastic using Design Expert: part II A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for http://www.ncbi.nlm.nih.gov/pubmed/26580872 5-FLUOROURACIL Actinic Keratosis Evaluation of the therapeutic results of actinic keratosis treated with topical 5% fluorouracil by reflectance confocal laser microscopy: http://www.ncbi.nlm.nih.gov/pubmed/26131881 5-FLUOROURACIL preliminary study 5- L-methylfolate as adjunctive therapy for SSRI-resistant major METHYLTETRAHYD depression: results of two randomized, double-blind, parallel- http://www.ncbi.nlm.nih.gov/pubmed/23212058 ROFOLATE sequential trials.

Comparative assessment of adherence measures and resource use 5- in SSRI/SNRI-treated patients with depression using second- http://www.ncbi.nlm.nih.gov/pubmed/24372461 METHYLTETRAHYD generation antipsychotics or L-methylfolate as adjunctive therapy. ROFOLATE 5- METHYLTETRAHYD Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders http://www.ncbi.nlm.nih.gov/pubmed/8257478 ROFOLATE with depression: results of a double-blind multicenter study

Supplementation with B vitamins or n-3 fatty acids and depressive 5- symptoms in cardiovascular disease survivors: ancillary findings from http://www.ncbi.nlm.nih.gov/pubmed/22648722 METHYLTETRAHYD the SUpplementation with FOLate, vitamins B-6 and B-12 and/or ROFOLATE OMega-3 fatty acids (SU.FOL.OM3) randomized trial. 5- Effects of prenatal fish-oil and 5-methyltetrahydrofolate METHYLTETRAHYD supplementation on cognitive development of children at 6.5 y of http://www.ncbi.nlm.nih.gov/pubmed/21849596 ROFOLATE age. 5- METHYLTETRAHYD Effect of B-vitamins and n-3 PUFA supplementation for 5 years on http://www.ncbi.nlm.nih.gov/pubmed/21801476 ROFOLATE blood pressure in patients with CVD. Medication Title of Article PubMed Link Cognitive function after supplementation with B vitamins and long- 5- chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 http://www.ncbi.nlm.nih.gov/pubmed/21593490 METHYLTETRAHYD randomized trial. ROFOLATE 5- METHYLTETRAHYD Effects of B vitamins and omega 3 fatty acids on cardiovascular http://www.ncbi.nlm.nih.gov/pubmed/21115589 ROFOLATE diseases: a randomised placebo controlled trial. 5- METHYLTETRAHYD 5-methyltetrahydrofolate administration is associated with prolonged http://www.ncbi.nlm.nih.gov/pubmed/18587236 ROFOLATE survival and reduced inflammation in ESRD patients. 5-methyltetrahydrofolate rapidly improves endothelial function and 5- decreases superoxide production in human vessels: effects on http://www.ncbi.nlm.nih.gov/pubmed/16940192 METHYLTETRAHYD vascular tetrahydrobiopterin availability and endothelial nitric oxide ROFOLATE synthase coupling. 5- METHYLTETRAHYD Acute effects of 5-methyltetrahydrofolate on endothelial function and http://www.ncbi.nlm.nih.gov/pubmed/19748251 ROFOLATE asymmetric dimethylarginine in patients with chronic heart failure. 5- METHYLTETRAHYD Improvement of endothelial function in uraemic patients on peritoneal http://www.ncbi.nlm.nih.gov/pubmed/17595187 ROFOLATE dialysis: a possible role for 5-MTHF administration. 5- METHYLTETRAHYD 5-methyltetrahydrofolate, the active form of folic acid, restores http://www.ncbi.nlm.nih.gov/pubmed/9462523 ROFOLATE endothelial function in familial hypercholesterolemia. 5- METHYLTETRAHYD Determination of 5-methyltetrahydrofolate in cerebrospinal fluid of http://www.ncbi.nlm.nih.gov/pubmed/16624264 ROFOLATE paediatric patients: reference values for a paediatric population. 5- METHYLTETRAHYD Effect of serum folate status on total folate and 5- http://www.ncbi.nlm.nih.gov/pubmed/23676422 ROFOLATE methyltetrahydrofolate in human . 5- METHYLTETRAHYD Association between low red blood cell 5-methyltetrahydrofolate and http://www.ncbi.nlm.nih.gov/pubmed/23430668 ROFOLATE hyperhomocysteinaemia with hypertension : a cross-sectional study. 5- METHYLTETRAHYD High-dose short-term folate administration modifies ambulatory blood http://www.ncbi.nlm.nih.gov/pubmed/19603054 ROFOLATE pressure in postmenopausal women. A placebo-controlled study. Medication Title of Article PubMed Link 5- METHYLTETRAHYD Methylenetetrahydrofolate reductase 677 T allele protects against http://www.ncbi.nlm.nih.gov/pubmed/18222012 ROFOLATE persistent HBV in West Africa. 5- The folic acid metabolite L-5-methyltetrahydrofolate effectively METHYLTETRAHYD reduces total serum homocysteine level in orthotopic liver transplant http://www.ncbi.nlm.nih.gov/pubmed/17522618 ROFOLATE recipients: a double-blind placebo-controlled study. 5- Effect of homocysteine lowering by 5-methyltetrahydrofolate on redox METHYLTETRAHYD status in hyperhomocysteinemia. http://www.ncbi.nlm.nih.gov/pubmed/16680068 ROFOLATE 6-THIOGUANINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3272126 Treatment of with 6-thioguanine. 6-THIOGUANINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8113459 6-Thioguanine treatment of psoriasis: experience in 81 patients. 6-Thioguanine therapy for psoriasis causing toxic hepatic 6-THIOGUANINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8496447 venoocclusive disease. Clinical clearing of psoriasis by 6-thioguanine correlates with https://www.ncbi.nlm.nih.gov/pubmed/?term=1060605 6-THIOGUANINE cutaneous T-cell depletion via apoptosis: evidence for selective 5 effects on activated T lymphocytes. 6-thioguanine in the treatment of psoriasis: a case report and https://www.ncbi.nlm.nih.gov/pubmed/?term=1200100 6-THIOGUANINE literature review. [Review] [18 refs] 5 Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive https://www.ncbi.nlm.nih.gov/pubmed/?term=1245139 6-THIOGUANINE disease. 6 Reactivation of cutaneous psoriasis during abatacept therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2103664 ABATACEPT spondyloarthropathy. 8 Therapeutic hotline. Abatacept: our experience of use in two patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2141061 ABATACEPT with refractory psoriasis and psoriatic arthritis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2201706 ABATACEPT Abatacept-induced psoriasis. 2 ABATACEPT, Letter: A case of generalized guttate psoriasis induced by etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=2169669 ETANERCEPT with relapse after abatacept. 1

A novel topical agent in the treatment of seborrheic keratoses: A https://www.ncbi.nlm.nih.gov/pubmed/28796288 proof of concept study by clinical and dermoscopic evaluation. Medication Title of Article PubMed Link

Efficacy of Trichloro-Acetic Acid Peel Alone Versus Combined https://www.ncbi.nlm.nih.gov/pubmed/27504543 ACETIC ACID Topical Magnesium Ascorbyl Phosphate for Epidermal Melasma. Noninvasive Treatment of Pyogenic Granulomas in Young Children https://www.ncbi.nlm.nih.gov/pubmed/26589346 ACETIC ACID with Topical Timolol and Trichloroacetic Acid. Efficacy of 1% acetic acid in the treatment of chronic wounds infected with Pseudomonas aeruginosa: prospective randomised https://www.ncbi.nlm.nih.gov/pubmed/25851059 ACETIC ACID controlled clinical trial. Topical treatment with acetylcysteine: clinical and experimental http://www.ncbi.nlm.nih.gov/pubmed/23346662 ACETYLCYSTEINE effects. ACETYLCYSTEINE Topical N-acetylcysteine for lamellar ichthyosis. http://www.ncbi.nlm.nih.gov/pubmed/10584733

N-acetylcysteine, an antioxidant sulfhydryl substance, promotes the http://www.ncbi.nlm.nih.gov/pubmed/23527731 ACETYLCYSTEINE healing of ulcers in patients with bullous morphea. Comparison of the efficacy of topical N-acetyl-cysteine and a topical - combination therapy in the treatment of meibomian http://www.ncbi.nlm.nih.gov/pubmed/21751879 ACETYLCYSTEINE gland dysfunction. Topical N-acetylcysteine accelerates wound healing in vitro and in http://www.ncbi.nlm.nih.gov/pubmed/24798751 ACETYLCYSTEINE vivo via the PKC/Stat3 pathway. Effectiveness of nebulized N-acetylcysteine solution in children with http://www.ncbi.nlm.nih.gov/pubmed/24953914 ACETYLCYSTEINE acute bronchiolitis.

Effects of N-acetylcysteine on outcomes in chronic obstructive http://www.ncbi.nlm.nih.gov/pubmed/15866309 pulmonary disease (Bronchitis Randomized on NAC Cost-Utility ACETYLCYSTEINE Study, BRONCUS): a randomised placebo-controlled trial. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, http://www.ncbi.nlm.nih.gov/pubmed/23348146 ACETYLCYSTEINE randomized, placebo-controlled HIACE study. Topical N-acetylcysteine improves wound healing comparable to http://www.ncbi.nlm.nih.gov/pubmed/25583306 ACETYLCYSTEINE dexpanthenol: an experimental study https://www.ncbi.nlm.nih.gov/pubmed/?term=2958245 ACETYLCYSTEINE Topical N-acetylcysteine in ichthyosis: Experience in 18 patients. 1 Topical use of N-acetylcysteine for reduction of skin reaction to ACETYLCYSTEINE https://www.ncbi.nlm.nih.gov/pubmed/?term=6403989 radiation therapy. Medication Title of Article PubMed Link Surgically Induced Necrotizing Scleritis Following Strabismus Surgery Treated Successfully with Topical N-acetylcysteine in a Child with https://www.ncbi.nlm.nih.gov/pubmed/?term=2814073 ACETYLCYSTEINE Congenital Fibrosis of Extraocular Muscles and Varadi Papp 2 Syndrome. Topical N-acetylcysteine reduces interleukin-1-alpha in tear fluid after https://www.ncbi.nlm.nih.gov/pubmed/?term=1955166 ACETYLCYSTEINE laser subepithelial keratectomy. 8 Topical N-acetylcysteine accelerates wound healing in vitro and in https://www.ncbi.nlm.nih.gov/pubmed/?term=2479875 ACETYLCYSTEINE vivo via the PKC/Stat3 pathway. 1 Topical N-acetylcysteine for the treatment of lamellar ichthyosis: an https://www.ncbi.nlm.nih.gov/pubmed/?term=2460205 ACETYLCYSTEINE improved formula. 7 Ulcers caused by bullous morphea: successful therapy with N- https://www.ncbi.nlm.nih.gov/pubmed/?term=2352773 ACETYLCYSTEINE acetylcysteine and topical wound care. 1 Efficacy of topical N-acetylcysteine in the treatment of meibomian https://www.ncbi.nlm.nih.gov/pubmed/?term=2065347 ACETYLCYSTEINE gland dysfunction. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1469680 ACETYLCYSTEINE Topical N-acetylcysteine treatment in neonatal ichthyosis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1186208 ACETYLCYSTEINE N-acetylcysteine in chronic blepharitis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1058473 ACETYLCYSTEINE Topical N-acetylcysteine for lamellar ichthyosis. 3 Oral acitretin in psoriasis: and vitamin A concentrations in ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=1350412 plasma, skin and adipose tissue. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=1827799 plus UVB and acitretin alone. A 12-month treatment of severe psoriasis with acitretin: results of a ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=1827800 Canadian open multicenter study.

ACITRETIN Photochemotherapy for severe psoriasis without or in combination https://www.ncbi.nlm.nih.gov/pubmed/?term=1838750 with acitretin: a randomized, double-blind comparison study. Efficiency of acitretin in combination with UV-B in the treatment of ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2138875 severe psoriasis. Serum lipid changes during acitretin (etretin) treatment of psoriasis ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2459874 and palmo-plantar pustulosis. Benefit of progressively increasing doses during the initial treatment ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2522405 with acitretin in psoriasis. Medication Title of Article PubMed Link ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2526824 Side-effect profile of acitretin therapy in psoriasis.

ACITRETIN A double-blind comparison of acitretin and etretinate in combination https://www.ncbi.nlm.nih.gov/pubmed/?term=2527054 with bath PUVA in the treatment of extensive psoriasis. A double-blind, placebo-controlled trial of acitretin for the treatment of ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2530251 psoriasis. ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2532840 Acitretin treatment of severe psoriasis. Acitretin in the treatment of severe psoriasis: a randomized double- ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2532846 blind study comparing acitretin and etretinate. Acitretin versus etretinate in severe psoriasis. A double-blind ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2532847 randomized Nordic multicenter study in 168 patients.

ACITRETIN A double-blind comparison of acitretin and etretinate in the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2563606 of severe psoriasis. Results of a Nordic multicentre study. ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2967310 Acitretin improves psoriasis in a dose-dependent fashion.

ACITRETIN supplementation results in decreased hypertriglyceridemia in https://www.ncbi.nlm.nih.gov/pubmed/?term=2969924 patients with psoriasis undergoing etretinate or acitretin therapy. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2971692 results of a German multicenter study. Randomized double-blind multicenter study comparing acitretin- ACITRETIN PUVA, etretinate-PUVA and placebo-PUVA in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2976000 severe psoriasis. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A ACITRETIN randomized double-blind parallel study comparing acitretin and https://www.ncbi.nlm.nih.gov/pubmed/?term=2976406 etretinate. Pharmacokinetics of etretinate and acitretin with special reference to ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=7900497 treatment of psoriasis. [Review] [257 refs] Acitretin does not prevent psoriasis relapse related to cyclosporin A ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=8123582 tapering. Pseudoallergic hepatitis after a single intake of 10 mg acitretin ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=8578970 (Neotigason) for treatment of psoriasis pustulosa. Medication Title of Article PubMed Link Failure of combination therapy with acitretin and cyclosporin A in 3 ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=9031805 patients with erythrodermic psoriasis. [Review] [11 refs] Acitretin therapy is effective for psoriasis associated with human ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=9197824 immunodeficiency virus infection. The combination of oral acitretin and bath PUVA for the treatment of ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=9390336 severe psoriasis. The effect of addition of calcipotriol ointment (50 micrograms/g) to ACITRETIN https://www.ncbi.nlm.nih.gov/pubmed/?term=9536227 acitretin therapy in psoriasis. The effects of oral liarozole on epidermal proliferation and ACITRETIN differentiation in severe plaque psoriasis are comparable with those https://www.ncbi.nlm.nih.gov/pubmed/?term=9988537 of acitretin. Acitretin in psoriasis: an overview of adverse effects. [Review] [28 https://www.ncbi.nlm.nih.gov/pubmed/?term=1045914 ACITRETIN refs] 0 Coexistence of morphea and psoriasis responding to acitretin https://www.ncbi.nlm.nih.gov/pubmed/?term=1056849 ACITRETIN treatment. 0 Psoriasis associated with HCV and exacerbated by interferon alpha: https://www.ncbi.nlm.nih.gov/pubmed/?term=1105393 ACITRETIN complete clearance with acitretin during interferon alpha treatment 0 for chronic active hepatitis. Consensus conference: acitretin in combination with UVB or PUVA in https://www.ncbi.nlm.nih.gov/pubmed/?term=1156874 ACITRETIN the treatment of psoriasis. [Review] [75 refs] 5 Efficacy of acitretin and commercial tanning bed therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1270708 ACITRETIN psoriasis. 9 The efficacy of calcipotriol + acitretin combination therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1281433 ACITRETIN psoriasis: comparison with acitretin monotherapy. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1285823 ACITRETIN Efficacy of acitretin in severe psoriasis. 1 Single-center retrospective study of long-term use of low-dose https://www.ncbi.nlm.nih.gov/pubmed/?term=1475464 ACITRETIN acitretin (Soriatane) for psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1500931 ACITRETIN An impressive therapeutic result of nail psoriasis to acitretin. 7 A review of acitretin, a systemic retinoid for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1608665 ACITRETIN psoriasis. [Review] [74 refs] 8 Punctate palmoplantar keratoderma (Buschke-Fischer-Brauer https://www.ncbi.nlm.nih.gov/pubmed/?term=1616742 ACITRETIN disease) with psoriasis: a rare association showing excellent 2 response to acitretin. Medication Title of Article PubMed Link Apolipoprotein E gene polymorphisms are associated with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1643380 ACITRETIN but do not determine disease response to acitretin. 8 Occupational trachyonychia due to psoriasis: report of a case https://www.ncbi.nlm.nih.gov/pubmed/?term=1648728 ACITRETIN successfully treated with oral acitretin. 9 Increased suicidal tendency in a case of psoriasis vulgaris under https://www.ncbi.nlm.nih.gov/pubmed/?term=1664315 ACITRETIN acitretin treatment. 2 Novel combination regimens: biologics and acitretin for the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1676633 ACITRETIN of psoriasis-- a case series. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1676633 ACITRETIN Combination therapy with acitretin for psoriasis. 5 A woman with sudden bilateral sensorineural hearing loss after https://www.ncbi.nlm.nih.gov/pubmed/?term=1685893 ACITRETIN treatment psoriasis with acitretin. 8 Low-dose acitretin is associated with fewer adverse events than high- https://www.ncbi.nlm.nih.gov/pubmed/?term=1692404 ACITRETIN dose acitretin in the treatment of psoriasis. 9 Acitretin induces capillary leak syndrome in a patient with pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=1709736 ACITRETIN psoriasis. 1 The efficacy of combination treatment with narrowband UVB (TL-01) https://www.ncbi.nlm.nih.gov/pubmed/?term=1771826 ACITRETIN and acitretin vs narrowband UVB alone in plaque-type psoriasis: a 5 retrospective study. Combination of acitretin and oral calcitriol for treatment of plaque- https://www.ncbi.nlm.nih.gov/pubmed/?term=1772166 ACITRETIN type psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1821142 ACITRETIN Combination of efalizumab and acitretin in chronic plaque psoriasis. 8 Comparative study of histopathological and immunohistochemical https://www.ncbi.nlm.nih.gov/pubmed/?term=1825174 ACITRETIN findings in skin biopsies from patients with psoriasis before and after 5 treatment with acitretin. https://www.ncbi.nlm.nih.gov/pubmed/?term=1845952 ACITRETIN Erythroderma in a patient taking acitretin for plaque psoriasis. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1860871 ACITRETIN Acitretin is a safe treatment option for infantile pustular psoriasis. 3 An updated review of acitretin--a systemic retinoid for the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1862468 ACITRETIN of psoriasis. [Review] [85 refs] 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1928975 ACITRETIN Evaluation of the efficacy of acitretin therapy for nail psoriasis. 5 Medication Title of Article PubMed Link

Efficacy and safety of combination Acitretin and Pioglitazone therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1938066 ACITRETIN in patients with moderate to severe chronic plaque-type psoriasis: a 0 randomized, double-blind, placebo-controlled clinical trial. Effect of Chinese herbal medicine combined with acitretin in https://www.ncbi.nlm.nih.gov/pubmed/?term=1940795 ACITRETIN treating psoriasis of blood-heat syndrome type. 3

Severe nail psoriasis with a rapid response to acitretin.[Erratum https://www.ncbi.nlm.nih.gov/pubmed/?term=1945676 ACITRETIN appears in Clin Exp Dermatol. 2009 Dec;34(8):944 Note: Lopez 6 Castillo, V [corrected to Lopez, V]; Molina Gallardo, I [corrected to Molina, I]; Marti Fajardo, N [corrected to Marti, N]; Mart https://www.ncbi.nlm.nih.gov/pubmed/?term=1999852 ACITRETIN A review of acitretin for the treatment of psoriasis. [Review] [83 refs] 9 Development, evaluation and clinical studies of Acitretin loaded https://www.ncbi.nlm.nih.gov/pubmed/?term=2085853 ACITRETIN nanostructured lipid carriers for topical treatment of psoriasis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2178720 ACITRETIN Efficacy of low-dose acitretin in the treatment of psoriasis. 7 Acitretin for the treatment of psoriasis: an assessment of national https://www.ncbi.nlm.nih.gov/pubmed/?term=2181850 ACITRETIN trends. 8 NAPSI utilization as an evaluation method of nail psoriasis in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2257003 ACITRETIN using acitretin. 0 Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 https://www.ncbi.nlm.nih.gov/pubmed/?term=2281688 ACITRETIN mg in adult patients with severe plaque type psoriasis: a randomized, 1 double blind, parallel group, dose ranging study. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than https://www.ncbi.nlm.nih.gov/pubmed/?term=2291339 ACITRETIN on Th2 cells in treatment of psoriasis vulgaris. 1 Treatment of severe nail psoriasis with acitretin: an impressive https://www.ncbi.nlm.nih.gov/pubmed/?term=2338402 ACITRETIN therapeutic result. 4 Liraglutide in combination with acitretin for severe recalcitrant https://www.ncbi.nlm.nih.gov/pubmed/?term=2383412 ACITRETIN psoriasis. 5 Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the https://www.ncbi.nlm.nih.gov/pubmed/?term=2389145 ACITRETIN Spanish Academy of Dermatology and Venereology. 3 The effect of acitretin treatment on insulin resistance, retinol-binding https://www.ncbi.nlm.nih.gov/pubmed/?term=2402188 ACITRETIN protein-4, leptin, and adiponectin in psoriasis vulgaris: a 9 noncontrolled study. Medication Title of Article PubMed Link Complete and rapid regression of primary cutaneous follicular https://www.ncbi.nlm.nih.gov/pubmed/?term=2403438 ACITRETIN lymphoma with repeated of acitretin for 6 palmoplantar psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2460198 ACITRETIN Acitretin in psoriasis: an evolving scenario. [Review] 2 Low-dose acitretin in treatment of plaque-type psoriasis: descriptive https://www.ncbi.nlm.nih.gov/pubmed/?term=2497835 ACITRETIN study of efficacy and safety. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2517592 ACITRETIN Acquired ichthyosis during acitretin therapy for psoriasis vulgaris. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2567344 ACITRETIN Efficacy and safety of Tripterygium wilfordii hook F versus acitretin in 3 moderate to severe psoriasis vulgaris: a randomized clinical trial. Drug fever as an adverse effect of acitretin in complicated psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2613364 ACITRETIN patient. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2691933 ACITRETIN Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A 0 Meta-Analysis of Comparisons with Acitretin. [Review] Effectiveness and Safety of Acitretin in Children with Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2744378 ACITRETIN Psoriasis: A Multicenter Retrospective Analysis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2799801 ACITRETIN Optimizing acitretin use in patients with plaque psoriasis. 9 Whole Exome Sequencing in Psoriasis Patients Contributes to https://www.ncbi.nlm.nih.gov/pubmed/?term=2814608 ACITRETIN Studies of Acitretin Treatment Difference.[Erratum appears in Int J 0 Mol Sci. 2017 Sep 04;18(9):; PMID: 28869550] Cushing's Syndrome Induced by High-Potency Topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2829714 ACITRETIN in Two Children with Palmoplantar Psoriasis Taking 3 Acitretin. Efficacy and safety of total glucosides of paeony combined with https://www.ncbi.nlm.nih.gov/pubmed/?term=2840034 ACITRETIN acitretin in the treatment of moderate-to-severe plaque psoriasis: a 1 double-blind, randomised, placebo-controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=2909445 ACITRETIN Management of pediatric psoriasis with acitretin: A review. [Review] 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2909890 ACITRETIN Efficacy and safety of acitretin monotherapy in children with pustular 9 psoriasis: results from 15 cases and a literature review. [Review] Medication Title of Article PubMed Link Pivotal role of Acitretin nanovesicular gel for effective treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2950354 ACITRETIN psoriasis: ex vivo-in vivo evaluation study. 1 Association of IL36RN mutations with clinical features, therapeutic https://www.ncbi.nlm.nih.gov/pubmed/?term=2961999 ACITRETIN response to acitretin, and frequency of recurrence in patients with 8 generalized pustular psoriasis. ACITRETIN, A comparative study of histopathological findings in skin biopsies https://www.ncbi.nlm.nih.gov/pubmed/?term=2526526 PHOTOTHERAPY, from patients with psoriasis before and after treatment with acitretin, 1 METHOTREXATE methotrexate and phototherapy. ACITRETIN, https://www.ncbi.nlm.nih.gov/pubmed/?term=3013473 TAZAROTENE Pharmacokinetics of tazarotene and acitretin in psoriasis. [Review] 5 Combining etanercept and acitretin in the therapy of chronic plaque ACITRETIN, https://www.ncbi.nlm.nih.gov/pubmed/?term=1841040 psoriasis: a 24-week, randomized, controlled, investigator-blinded ETANERCEPT 8 pilot trial. ACITRETIN, https://www.ncbi.nlm.nih.gov/pubmed/?term=1876302 Serum levels of IL-17 and IL-22 are reduced by etanercept, but not ETANERCEPT 7 by acitretin, in patients with psoriasis: a randomized-controlled trial. ACITRETIN, Acitretin narrow-band TL-01 phototherapy but not etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=1947006 ETANERCEPT, treatment improves a localized inflammatory linear verrucous 8 PHOTOTHERAPY epidermal naevus with concomitant psoriasis. Rapid downregulation of innate immune cells, interleukin-12 and ACITRETIN, https://www.ncbi.nlm.nih.gov/pubmed/?term=2334361 interleukin-23 in generalized pustular psoriasis with infliximab in INFLIXIMAB 1 combination with acitretin. [Review] ACITRETIN, Adherence to acitretin and home narrowband ultraviolet B https://www.ncbi.nlm.nih.gov/pubmed/?term=1861970 PHOTOTHERAPY phototherapy in patients with psoriasis. 9 ACITRETIN, https://www.ncbi.nlm.nih.gov/pubmed/?term=1900234 A randomized comparison of acitretin-narrow-band TL-01 PHOTOTHERAPY 4 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. ACITRETIN, ADALIM Refractory generalized pustular psoriasis responsive to a https://www.ncbi.nlm.nih.gov/pubmed/?term=2283448 UMAB combination of adalimumab and acitretin. 8 ACITRETIN, CYCLO Sequential therapy using cyclosporine and acitretin for treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1549976 SPORINE total body psoriasis. 0 Serum concentrations of interleukin-2 and tumour necrosis factor- ACITRETIN, CYCLO https://www.ncbi.nlm.nih.gov/pubmed/?term=2514333 alpha under cyclosporine versus acitretin treatment in plaque-type SPORINE 7 psoriasis. Medication Title of Article PubMed Link Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis ACITRETIN, METHO https://www.ncbi.nlm.nih.gov/pubmed/?term=2306672 patients with significant palmoplantar involvement: a prospective, TREXATE 0 randomized study. ACITRETIN, METHO https://www.ncbi.nlm.nih.gov/pubmed/?term=2841417 The acitretin and methotrexate combination therapy for psoriasis TREXATE 7 vulgaris achieves higher effectiveness and less liver fibrosis. ACITRETIN, PHOTO Combined treatment of psoriasis with acitretin and UVB phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2527051 THERAPY compared with acitretin alone and UVB alone. Successful use of acitretin in conjunction with narrowband ultraviolet ACITRETIN, PHOTO https://www.ncbi.nlm.nih.gov/pubmed/?term=1549143 B phototherapy in a child with severe pustular psoriasis, von THERAPY 8 Zumbusch type. Two-stage therapy for childhood generalized pustular psoriasis: low- ACITRETIN, PHOTO https://www.ncbi.nlm.nih.gov/pubmed/?term=1678049 dose cyclosporin for induction and maintenance with THERAPY 3 acitretin/narrowband ultraviolet B phototherapy. ACITRETIN, PHOTO Home narrowband UV-B phototherapy in combination with low-dose https://www.ncbi.nlm.nih.gov/pubmed/?term=1879447 THERAPY acitretin in patients with moderate to severe psoriasis. 4 ACITRETIN, PHOTO Narrow band ultraviolet-B versus Goeckerman therapy for psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2651583 THERAPY with and without acitretin: A retrospective study. 6 Safety and tolerability of combination acyclovir 5% and 1% cream in adolescents with recurrent herpes http://www.ncbi.nlm.nih.gov/pubmed/22004219 ACYCLOVIR simplex labialis ACYCLOVIR A new topical treatment protocol for oral hairy leukoplakia http://www.ncbi.nlm.nih.gov/pubmed/20813564 A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin http://www.ncbi.nlm.nih.gov/pubmed/17178496 (25%) together with acyclovir cream (5%) in the treatment of oral ACYCLOVIR hairy leukoplakia Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo- http://www.ncbi.nlm.nih.gov/pubmed/16838235 ACYCLOVIR controlled, clinic-initiated trial

Comparison of efficacy of oral valacyclovir and topical acyclovir in the http://www.ncbi.nlm.nih.gov/pubmed/16340195 ACYCLOVIR treatment of keratitis: a randomized clinical trial ACYCLOVIR Role of acyclovir gel in herpes simplex: clinical implications http://www.ncbi.nlm.nih.gov/pubmed/12883465 Medication Title of Article PubMed Link Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV http://www.ncbi.nlm.nih.gov/pubmed/12019102 ACYCLOVIR radiation-induced herpes labialis Evaluation of the activity and safety of CS21 barrier genital gel® compared to topical and placebo in symptoms of genital https://www.ncbi.nlm.nih.gov/pubmed/24010876 ACYCLOVIR herpes recurrences: a randomized clinical trial.

Randomized clinical study comparing Compeed cold sore patch to https://www.ncbi.nlm.nih.gov/pubmed/18462303 ACYCLOVIR acyclovir cream 5% in the treatment of herpes simplex labialis. Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo- https://www.ncbi.nlm.nih.gov/pubmed/16838235 ACYCLOVIR controlled, clinic-initiated trial. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, https://www.ncbi.nlm.nih.gov/pubmed/12060504 ACYCLOVIR aciclovir-controlled trial. Effective treatment of herpes simplex labialis with penciclovir cream: https://www.ncbi.nlm.nih.gov/pubmed/11934185 ACYCLOVIR combined results of two trials. A clinical evaluation of a novel liposomal carrier for acyclovir in the https://www.ncbi.nlm.nih.gov/pubmed/10397661 ACYCLOVIR topical treatment of recurrent herpes labialis. Double-masked trial of topical acyclovir and in the treatment https://www.ncbi.nlm.nih.gov/pubmed/1911657 ACYCLOVIR of herpes zoster ocular inflammation.

Silica gel is as effective as acyclovir cream in patients with recurrent https://www.ncbi.nlm.nih.gov/pubmed/18569274 ACYCLOVIR herpes labialis: results of a randomized, open-label trial.

Comparison of new topical treatments for herpes labialis: efficacy of https://www.ncbi.nlm.nih.gov/pubmed/11559210 penciclovir cream, acyclovir cream, and n-docosanol cream against ACYCLOVIR experimental cutaneous herpes simplex virus type 1 infection.

The role of topical 5% acyclovir and 1% hydrocortisone cream https://www.ncbi.nlm.nih.gov/pubmed/20873400 ACYCLOVIR (Xerese™) in the treatment of recurrent herpes simplex labialis. Topical application vs. acyclovir for the treatment of recurrent https://www.ncbi.nlm.nih.gov/pubmed/15278008 ACYCLOVIR herpes simplex lesions. Double-blind controlled trial of topical acyclovir in https://www.ncbi.nlm.nih.gov/pubmed/7048919 ACYCLOVIR simplex virus . Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/6280052 ACYCLOVIR A trial of topical acyclovir in genital herpes simplex virus infections. Successful treatment of severe psoriasis and psoriatic arthritis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1532756 ADALIMUMAB adalimumab. 1 Adalimumab: efficacy and safety in psoriasis and rheumatoid https://www.ncbi.nlm.nih.gov/pubmed/?term=1537977 ADALIMUMAB arthritis. [Review] [14 refs] 7 Extensive plaque psoriasis successfully treated with adalimumab https://www.ncbi.nlm.nih.gov/pubmed/?term=1588819 ADALIMUMAB (Humira). 1 Adalimumab effectively controlled recalcitrant generalized pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=1642816 ADALIMUMAB psoriasis in an adolescent. 0 Clinical response to adalimumab treatment in patients with moderate https://www.ncbi.nlm.nih.gov/pubmed/?term=1701073 ADALIMUMAB to severe psoriasis: double-blind, randomized controlled trial and 8 open-label extension study. https://www.ncbi.nlm.nih.gov/pubmed/?term=1730590 ADALIMUMAB Treatment of psoriasis with adalimumab. 4 Adalimumab treatment is associated with improvement in health- https://www.ncbi.nlm.nih.gov/pubmed/?term=1736526 ADALIMUMAB related quality of life in psoriasis: patient-reported outcomes from a 4 phase II randomized controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=1757429 ADALIMUMAB Adalimumab for severe psoriasis and psoriatic arthritis: an open-label 9 study in 30 patients previously treated with other biologics. Adalimumab therapy for moderate to severe psoriasis: A randomized, https://www.ncbi.nlm.nih.gov/pubmed/?term=1793641 ADALIMUMAB controlled phase III trial. 1

Impact of adalimumab treatment on health-related quality of life and https://www.ncbi.nlm.nih.gov/pubmed/?term=1804752 ADALIMUMAB other patient-reported outcomes: results from a 16-week randomized 1 controlled trial in patients with moderate to severe plaque psoriasis. Impact of adalimumab treatment on patient-reported outcomes: https://www.ncbi.nlm.nih.gov/pubmed/?term=1805849 ADALIMUMAB results from a Phase III clinical trial in patients with moderate to 4 severe plaque psoriasis. Adalimumab: a new alternative biologic agent for chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1827552 ADALIMUMAB psoriasis. 1 Adalimumab for the treatment of severe psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=1829410 ADALIMUMAB arthritis. [Review] [77 refs] 6 Medication Title of Article PubMed Link Sustained efficacy and safety of adalimumab in psoriasis treatment: https://www.ncbi.nlm.nih.gov/pubmed/?term=1855977 ADALIMUMAB a retrospective study of 49 patients with and without a history of TNF- 8 alpha antagonist treatment. https://www.ncbi.nlm.nih.gov/pubmed/?term=1856927 ADALIMUMAB Long-term efficacy of adalimumab in generalized pustular psoriasis. 6 Palmoplantar psoriasis: a paradoxical adverse reaction induced by https://www.ncbi.nlm.nih.gov/pubmed/?term=1862483 ADALIMUMAB adalimumab. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1863822 ADALIMUMAB Successful response to narrow-band UVB in a patient undergoing 9 concomitant treatment with adalimumab for psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1876155 ADALIMUMAB Adalimumab: safe and successful in severe pustular psoriasis. 0 Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United https://www.ncbi.nlm.nih.gov/pubmed/?term=1883174 ADALIMUMAB States general population norms: results from a randomized, 4 controlled Phase III study. Adalimumab for treatment of moderate to severe psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=1883772 ADALIMUMAB psoriatic arthritis. 8 Recurrent hyperglycemia during adalimumab treatment in a patient https://www.ncbi.nlm.nih.gov/pubmed/?term=1893641 ADALIMUMAB with psoriasis. 8 Influence of body mass index, comorbidities and prior systemic https://www.ncbi.nlm.nih.gov/pubmed/?term=1903622 ADALIMUMAB therapies on the response of psoriasis to adalimumab: an exploratory 5 analysis from the APHRODITE data. Efficacy of adalimumab in plaque psoriasis: experience on 28 https://www.ncbi.nlm.nih.gov/pubmed/?term=1911275 ADALIMUMAB patients. 6 Adalimumab therapy of psoriasis and psoriatic arthritis in a patient https://www.ncbi.nlm.nih.gov/pubmed/?term=1911911 ADALIMUMAB with cirrhosis of the liver. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1913777 ADALIMUMAB Treatment of severe facial psoriasis with adalimumab. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1917041 ADALIMUMAB Adalimumab: in plaque psoriasis. [Review] [35 refs] 2 First case report of adalimumab-induced psoriasis in Crohn's https://www.ncbi.nlm.nih.gov/pubmed/?term=1926253 ADALIMUMAB disease. 2 Medication Title of Article PubMed Link A multicenter open-label experience on the response of psoriasis to https://www.ncbi.nlm.nih.gov/pubmed/?term=1930957 ADALIMUMAB Adalimumab and effect of dose escalation in non-responders: the 0 Aphrodite project. https://www.ncbi.nlm.nih.gov/pubmed/?term=1934866 ADALIMUMAB Proteinuria in a patient using adalimumab for psoriasis. 7 Adalimumab treatment for severe recalcitrant chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1943853 ADALIMUMAB psoriasis. 5 Development of bullous pemphigoid during treatment of psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1943855 ADALIMUMAB with adalimumab. 5 Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1946243 ADALIMUMAB severe potentially irreversible cutaneous side effect of TNF-alpha 3 blockers. Onset of palmoplantar pustular psoriasis while on adalimumab for https://www.ncbi.nlm.nih.gov/pubmed/?term=1970184 ADALIMUMAB psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply 4 an anti-psoriatic treatment adverse reaction?. Adalimumab in the treatment of psoriasis: pooled efficacy and safety https://www.ncbi.nlm.nih.gov/pubmed/?term=1979982 ADALIMUMAB results from three pivotal studies. [Review] [8 refs] 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1980468 ADALIMUMAB Adalimumab for the treatment of psoriasis. [Review] [4 refs] 9 Treatment of nail psoriasis with adalimumab: an open label unblinded https://www.ncbi.nlm.nih.gov/pubmed/?term=1980782 ADALIMUMAB study. 5 Marked improvement in nail psoriasis during treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=1985105 ADALIMUMAB adalimumab. 9 Treatment of erythrodermic psoriasis in HCV+ patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=1989168 ADALIMUMAB adalimumab. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1990344 ADALIMUMAB Adalimumab in the management of palmoplantar psoriasis. 3 Adalimumab treatment of a patient with psoriasis suppurativa https://www.ncbi.nlm.nih.gov/pubmed/?term=1991717 ADALIMUMAB Hallopeau associated osteoarthropathy. 9 Impact of adalimumab on symptoms of psoriatic arthritis in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=1994043 ADALIMUMAB with moderate to severe psoriasis: a pooled analysis of randomized 7 clinical trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=2002794 ADALIMUMAB Adalimumab in the management of palmoplantar psoriasis. 3 Medication Title of Article PubMed Link Rapid remission of psoriasis with reversible leucopenia after two https://www.ncbi.nlm.nih.gov/pubmed/?term=2005581 ADALIMUMAB injections with adalimumab. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2007823 ADALIMUMAB Psoriasis and its treatment with adalimumab. [Review] [57 refs] 1 Extent and clinical consequences of antibody formation against https://www.ncbi.nlm.nih.gov/pubmed/?term=2015702 ADALIMUMAB adalimumab in patients with plaque psoriasis. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2021926 ADALIMUMAB The effect of adalimumab on reducing depression symptoms in 5 patients with moderate to severe psoriasis: a randomized clinical trial. Clinical manifestations and responsiveness to adalimumab are https://www.ncbi.nlm.nih.gov/pubmed/?term=2044807 ADALIMUMAB similar in patients with ankylosing spondylitis with and without 9 concomitant psoriasis. Adalimumab in Japanese patients with moderate to severe chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2050739 ADALIMUMAB plaque psoriasis: efficacy and safety results from a Phase II/III 8 randomized controlled study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2056928 ADALIMUMAB Pregnancy during adalimumab use for psoriasis. 8 Efficacy and safety of adalimumab across subgroups of patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2060525 ADALIMUMAB moderate to severe psoriasis. 4 Superimposed linear psoriasis unmasked by therapy with https://www.ncbi.nlm.nih.gov/pubmed/?term=2062185 ADALIMUMAB adalimumab. 1 Adalimumab for psoriasis: practical experience in a U.K. tertiary https://www.ncbi.nlm.nih.gov/pubmed/?term=2071622 ADALIMUMAB referral centre. 5

Effects of adalimumab versus placebo on risk of symptom worsening https://www.ncbi.nlm.nih.gov/pubmed/?term=2093207 ADALIMUMAB in psoriasis and subsequent impacts on health-related quality-of-life: 0 analysis of pooled data from two randomized, double-blind, placebo- controlled, multicentre clinical trials. Adalimumab for moderate to severe chronic plaque psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2108354 ADALIMUMAB efficacy and safety of retreatment and disease recurrence following 3 withdrawal from therapy.

Efficacy and safety of adalimumab among patients with moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2111052 ADALIMUMAB severe psoriasis with co-morbidities: Subanalysis of results from a 6 randomized, double-blind, placebo-controlled, phase III trial. Medication Title of Article PubMed Link

Adalimumab for treatment of moderate to severe chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2117330 ADALIMUMAB psoriasis of the hands and feet: efficacy and safety results from 4 REACH, a randomized, placebo-controlled, double-blind trial. Efficacy and safety of adalimumab in patients with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2121463 ADALIMUMAB previously treated with anti-tumour necrosis factor agents: 1 subanalysis of BELIEVE. Resolution of adalimumab-induced psoriasis after vitamin D https://www.ncbi.nlm.nih.gov/pubmed/?term=2129012 ADALIMUMAB deficiency treatment. 9 Papillary thyroid carcinoma in a patient with severe psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2149671 ADALIMUMAB receiving adalimumab. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2150445 ADALIMUMAB Recalcitrant pustular psoriasis successfully treated with adalimumab. 2 The effects of adalimumab treatment and psoriasis severity on self- https://www.ncbi.nlm.nih.gov/pubmed/?term=2161656 ADALIMUMAB reported work productivity and activity impairment for patients with 0 moderate to severe psoriasis. Interaction between adalimumab with concurrent pregabalin and https://www.ncbi.nlm.nih.gov/pubmed/?term=2169912 ADALIMUMAB duloxetine administration in a psoriasis patient with diabetic 9 peripheral neuropathy. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: https://www.ncbi.nlm.nih.gov/pubmed/?term=2175249 ADALIMUMAB results from an open-label extension study for patients from 1 REVEAL. Anti-tumor necrosis factor alpha treatment with adalimumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2176446 ADALIMUMAB improves significantly endothelial function and decreases 7 inflammatory process in patients with chronic psoriasis. Efficacy of adalimumab in the treatment of psoriasis: a retrospective https://www.ncbi.nlm.nih.gov/pubmed/?term=2178720 ADALIMUMAB study of 15 patients in daily practice. 3 Mycobacterium fortuitum infection following adalimumab treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2181851 ADALIMUMAB for psoriasis and subsequent complication-free treatment with 5 alternate TNF-a blockers. The long-term safety of adalimumab treatment in moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2183459 ADALIMUMAB psoriasis: a comprehensive analysis of all adalimumab exposure in 7 all clinical trials. [Review] Medication Title of Article PubMed Link Development of sarcoidosis during adalimumab therapy for chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2183480 ADALIMUMAB plaque psoriasis. 8 Generalized pustular psoriasis-like eruptions induced after the first https://www.ncbi.nlm.nih.gov/pubmed/?term=2195797 ADALIMUMAB use of adalimumab in the treatment of psoriatic arthritis. 8 New-onset psoriasis associated with adalimumab: a report of two https://www.ncbi.nlm.nih.gov/pubmed/?term=2197128 ADALIMUMAB cases. 0 Efficacy and safety of adalimumab when added to inadequate https://www.ncbi.nlm.nih.gov/pubmed/?term=2202370 ADALIMUMAB therapy for the treatment of psoriasis: results of PRIDE, an open- 2 label, multicentre, phase IIIb study. High-field MRI and powerdoppler sonography: supplementary imaging, techniques in assessing disease activity in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2213867 ADALIMUMAB psoriasis arthritis (PsA) and rheumatoid arthritis (RA) receiving 3 adalimumab. Alopecia areata during treatment of psoriasis with adalimumab and https://www.ncbi.nlm.nih.gov/pubmed/?term=2230184 ADALIMUMAB leflunomide: a case and review of the literature. [Review] 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2241462 ADALIMUMAB Topical treatment habits in psoriasis patients receiving adalimumab. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2241681 ADALIMUMAB Adalimumab therapy for psoriasis in real-world practice: efficacy, 8 safety and results in biologic-naive vs. non-naive patients. Long-term outcomes of interruption and retreatment vs. continuous https://www.ncbi.nlm.nih.gov/pubmed/?term=2242958 ADALIMUMAB therapy with adalimumab for psoriasis: subanalysis of REVEAL and 6 the open-label extension study. Successful treatment with adalimumab in a patient with psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2250667 ADALIMUMAB arthritis and generalized pustular psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2255583 ADALIMUMAB Safety and efficacy of Adalimumab in the treatment of moderate to 6 severe palmo-plantar psoriasis: an open label study.

Adalimumab: long-term safety in 23 458 patients from global clinical https://www.ncbi.nlm.nih.gov/pubmed/?term=2256297 ADALIMUMAB trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing 2 spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. [Review] Medication Title of Article PubMed Link

Efficacy, safety and medication cost implications of adalimumab 40 https://www.ncbi.nlm.nih.gov/pubmed/?term=2256414 ADALIMUMAB mg weekly dosing in patients with psoriasis with suboptimal response 8 to 40 mg every other week dosing: results from an open-label study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2257157 ADALIMUMAB TNF-alpha inhibitor (adalimumab) induced psoriasis: a case report. 1 An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new https://www.ncbi.nlm.nih.gov/pubmed/?term=2270280 ADALIMUMAB therapeutic option for good responders to the initial induction 2 treatment. Multiple eruptive squamous cell carcinoma in a patient with chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2275890 ADALIMUMAB plaque psoriasis on adalimumab. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2283496 ADALIMUMAB Effect of adalimumab on sleep parameters in patients with psoriasis 8 and obstructive sleep apnea: a randomized controlled trial. An assessment of adalimumab efficacy in three Phase III clinical https://www.ncbi.nlm.nih.gov/pubmed/?term=2288084 ADALIMUMAB trials using the European Consensus Programme criteria for 3 psoriasis treatment goals. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic https://www.ncbi.nlm.nih.gov/pubmed/?term=2289734 ADALIMUMAB therapies are switched to adalimumab: results from PROGRESS, an 8 open-label Phase IIIB trial. Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to https://www.ncbi.nlm.nih.gov/pubmed/?term=2292871 ADALIMUMAB adalimumab is the most cost-effective measure in different 5 scenarios. An inflammatory verrucous epidermal nevus concomitant with https://www.ncbi.nlm.nih.gov/pubmed/?term=2312201 ADALIMUMAB psoriasis: treatment with adalimumab. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2315189 ADALIMUMAB Adalimumab-induced psoriasis in a patient with Crohn's disease. 7 Influence of psoriatic arthritis on the efficacy of adalimumab and on https://www.ncbi.nlm.nih.gov/pubmed/?term=2317891 ADALIMUMAB the treatment response of other markers of psoriasis burden: 6 subanalysis of the BELIEVE study. Medication Title of Article PubMed Link

Effects of the tumor necrosis factor-alpha antagonist adalimumab on https://www.ncbi.nlm.nih.gov/pubmed/?term=2320403 ADALIMUMAB arterial inflammation assessed by positron emission tomography in 9 patients with psoriasis: results of a randomized controlled trial. Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in https://www.ncbi.nlm.nih.gov/pubmed/?term=2337732 ADALIMUMAB a patient receiving adalimumab therapy. 2 Successful treatment of psoriasis with interrupted adalimumab use: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2348887 ADALIMUMAB case report. 1 Central retinal vein occlusion and subsequent neovascular glaucoma https://www.ncbi.nlm.nih.gov/pubmed/?term=2369263 ADALIMUMAB after adalimumab treatment for psoriasis. 5 Efficacy of adalimumab across subgroups of patients with moderate- https://www.ncbi.nlm.nih.gov/pubmed/?term=2379001 ADALIMUMAB to-severe chronic plaque psoriasis of the hands and/or feet: post hoc 8 analysis of REACH. Adalimumab for the treatment of psoriasis in real life: a retrospective https://www.ncbi.nlm.nih.gov/pubmed/?term=2390999 ADALIMUMAB cohort of 119 patients at a single Spanish centre. 3 Adalimumab in the treatment of plaque-type psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2393091 ADALIMUMAB arthritis. 6 Adherence to adalimumab in patients with moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2401128 ADALIMUMAB psoriasis. 0 Effects of adalimumab therapy in adult subjects with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2403335 ADALIMUMAB severe psoriasis on Th17 pathway. 8 Possible drug-drug interaction between adalimumab and duloxetine https://www.ncbi.nlm.nih.gov/pubmed/?term=2408504 ADALIMUMAB and/or pregabalin in a psoriasis patient. 1 Extent and consequences of antibody formation against adalimumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2435235 ADALIMUMAB in patients with psoriasis: one-year follow-up. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2455259 ADALIMUMAB Efficacy of adalimumab in the treatment of moderate-to-severe 1 psoriasis: A retrospective study of 100 patients in daily practice. https://www.ncbi.nlm.nih.gov/pubmed/?term=2460535 ADALIMUMAB Woronoff ring associated with adalimumab therapy for psoriasis. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2463886 ADALIMUMAB A case of inverse psoriasis successfully treated with adalimumab. 8 The effect of adalimumab on key drivers in the pathogenesis of https://www.ncbi.nlm.nih.gov/pubmed/?term=2464098 ADALIMUMAB psoriasis. 9 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2470815 ADALIMUMAB Infective endocarditis complicating adalimumab therapy for psoriasis. 5 Impact of obesity on the effectiveness of adalimumab for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2472129 ADALIMUMAB treatment of psoriasis: a retrospective study of 30 patients in daily 0 practice. A case of nail psoriasis-associated psoriatic arthritis successfully https://www.ncbi.nlm.nih.gov/pubmed/?term=2481384 ADALIMUMAB treated with adalimumab. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2484651 ADALIMUMAB Adalimumab for the treatment of moderate to severe psoriasis: 8 subanalysis of effects on scalp and nails in the BELIEVE study. Suicide and depression in a patient with psoriasis receiving https://www.ncbi.nlm.nih.gov/pubmed/?term=2493491 ADALIMUMAB adalimumab: the role of the dermatologist. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2494770 ADALIMUMAB Occurrence of psoriatic plaques on previous adalimumab 9 sites during disease relapse in a patient with pustular psoriasis. A case of acute generalized pustular psoriasis of von Zumbusch https://www.ncbi.nlm.nih.gov/pubmed/?term=2498116 ADALIMUMAB treated with adalimumab. 1 Paradoxical flare of pustular psoriasis triggered by ustekinumab, https://www.ncbi.nlm.nih.gov/pubmed/?term=2498475 ADALIMUMAB which responded to adalimumab therapy. 7 Treatment of severe psoriasis and psoriatic arthritis with adalimumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2500737 ADALIMUMAB in an HIV-positive patient. 3 Complete primary treatment failure of adalimumab in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2505575 ADALIMUMAB photoaggravated psoriasis. 1 Predictors of adalimumab drug survival in psoriasis differ by reason https://www.ncbi.nlm.nih.gov/pubmed/?term=2508845 ADALIMUMAB for discontinuation: long-term results from the Bio-CAPTURE 1 registry.

Adalimumab retreatment successfully restores clinical response and https://www.ncbi.nlm.nih.gov/pubmed/?term=2528427 ADALIMUMAB health-related quality of life in patients with moderate to severe 5 psoriasis who undergo therapy interruption. Pulmonary sarcoidosis and latent tuberculosis in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2561213 ADALIMUMAB psoriasis treated with adalimumab. 2 Adalimumab in the treatment of moderate-to-severe chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2566514 ADALIMUMAB psoriasis in patients switching from other biologics. 3 Medication Title of Article PubMed Link Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the https://www.ncbi.nlm.nih.gov/pubmed/?term=2591678 ADALIMUMAB previous reports on biologic treatments for psoriasis patients with 6 hemodialysis for renal failure. [Review] Autoimmune hemolytic anemia during adalimumab treatment for https://www.ncbi.nlm.nih.gov/pubmed/?term=2594835 ADALIMUMAB plaque psoriasis. 7 Patient reported health outcomes and non-adherence in psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2608840 ADALIMUMAB patients receiving adalimumab or ustekinumab for moderate to 4 severe plaque psoriasis. Case of psoriasis vulgaris developing ulcerative colitis during https://www.ncbi.nlm.nih.gov/pubmed/?term=2611105 ADALIMUMAB adalimumab treatment. 5 Five-year analysis from the ESPRIT 10-year postmarketing https://www.ncbi.nlm.nih.gov/pubmed/?term=2619024 ADALIMUMAB surveillance registry of adalimumab treatment for moderate to severe 0 psoriasis. Palmoplantar pustular psoriasis induced by adalimumab: a case https://www.ncbi.nlm.nih.gov/pubmed/?term=2625040 ADALIMUMAB report and literature review. [Review] 8 Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis https://www.ncbi.nlm.nih.gov/pubmed/?term=2654791 ADALIMUMAB of Results from Three Double-Blind, Placebo-Controlled Clinical 8 Trials. Cerebral tuberculoma with pulmonary tuberculosis in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2656677 ADALIMUMAB psoriasis treated with adalimumab, an anti-tumor necrosis factor- 6 alpha agent. https://www.ncbi.nlm.nih.gov/pubmed/?term=2658624 ADALIMUMAB Adalimumab: A Review in Chronic Plaque Psoriasis. [Review] 2 Adalimumab drug survival in patients with psoriasis, Crohn's disease, https://www.ncbi.nlm.nih.gov/pubmed/?term=2670280 ADALIMUMAB and rheumatoid arthritis: Relevant differences using the same 0 treatment. Persistence and failure rates of adalimumab monotherapy in biologic- https://www.ncbi.nlm.nih.gov/pubmed/?term=2689266 ADALIMUMAB naive patients with psoriasis: A retrospective study. 0 The development of chronic inflammatory demyelinating https://www.ncbi.nlm.nih.gov/pubmed/?term=2708649 ADALIMUMAB polyneuropathy during adalimumab treatment in a patient with 1 psoriasis vulgaris. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2716826 ADALIMUMAB Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in 5 Patients With Moderate-to-Severe Hand and/or Foot Psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2732464 ADALIMUMAB Real-life 9-year experience with adalimumab in psoriasis and 6 psoriatic arthritis: results of a single-centre, retrospective study. Effects of maxacalcitol ointment on skin lesions in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2745063 ADALIMUMAB psoriasis receiving treatment with adalimumab. 4 Impact of immunogenicity on pharmacokinetics, efficacy and safety https://www.ncbi.nlm.nih.gov/pubmed/?term=2754584 ADALIMUMAB of adalimumab in adult patients with moderate to severe chronic 8 plaque psoriasis. Impact of adalimumab treatment on cardiovascular risk biomarkers in https://www.ncbi.nlm.nih.gov/pubmed/?term=2777469 ADALIMUMAB psoriasis: Results of a pilot study. 4 Healthcare resource utilization, healthcare costs and dose escalation https://www.ncbi.nlm.nih.gov/pubmed/?term=2778353 ADALIMUMAB in psoriasis patients initiated on ustekinumab versus adalimumab: a 4 retrospective claim study. Body Region Involvement and Quality of Life in Psoriasis: Analysis of https://www.ncbi.nlm.nih.gov/pubmed/?term=2781591 ADALIMUMAB a Randomized Controlled Trial of Adalimumab. 5 Adalimumab Dose Tapering in Psoriasis: Predictive Factors for https://www.ncbi.nlm.nih.gov/pubmed/?term=2786814 ADALIMUMAB Maintenance of Complete Clearance. 5 Anti-adalimumab antibodies in psoriasis: lack of clinical utility and https://www.ncbi.nlm.nih.gov/pubmed/?term=2794062 ADALIMUMAB laboratory evidence. 4 Pathway Analysis of Skin from Psoriasis Patients after Adalimumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2800598 ADALIMUMAB Treatment Reveals New Early Events in the Anti-Inflammatory 5 Mechanism of Anti-TNF-alpha. Value of ultrasonography findings for nail psoriasis before and after https://www.ncbi.nlm.nih.gov/pubmed/?term=2804435 ADALIMUMAB adalimumab administration. 0 Relapsing polychondritis associated with psoriasis vulgaris https://www.ncbi.nlm.nih.gov/pubmed/?term=2826605 ADALIMUMAB successfully treated with adalimumab: A case report with published 1 work review. [Review] Clinical similarity of biosimilar ABP 501 to adalimumab in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2829155 ADALIMUMAB treatment of patients with moderate to severe plaque psoriasis: A 2 randomized, double-blind, multicenter, phase III study. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2831962 ADALIMUMAB Resolution of psoriatic lesions on the gingiva and hard palate 1 following administration of adalimumab for cutaneous psoriasis. Effectiveness of adalimumab in the treatment of scalp and nail https://www.ncbi.nlm.nih.gov/pubmed/?term=2835292 ADALIMUMAB affection in patients with moderate to severe plaque psoriasis in 9 routine clinical practice. https://www.ncbi.nlm.nih.gov/pubmed/?term=2847896 ADALIMUMAB Adalimumab in paediatric psoriasis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2857022 ADALIMUMAB First Case Report of Aseptic Meningitis Induced by Adalimumab 3 Administered for Treatment of Chronic Plaque Psoriasis. Correlation between trough serum levels of adalimumab and https://www.ncbi.nlm.nih.gov/pubmed/?term=2860412 ADALIMUMAB absolute PASI score in a series of patients with psoriasis. 7 Importance of immunogenicity testing for cost-effective management https://www.ncbi.nlm.nih.gov/pubmed/?term=2863288 ADALIMUMAB of psoriasis patients treated with adalimumab. 3 Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative https://www.ncbi.nlm.nih.gov/pubmed/?term=2873799 ADALIMUMAB Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and 4 Ankylosing Spondylitis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2880999 ADALIMUMAB Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide. [Review] 3 Adalimumab for treating childhood plaque psoriasis: a clinical trial https://www.ncbi.nlm.nih.gov/pubmed/?term=2882920 ADALIMUMAB evaluation. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2899300 ADALIMUMAB Adalimumab for nail psoriasis: Efficacy and safety from the first 26 5 weeks of a phase 3, randomized, placebo-controlled trial. Guillain-Barre syndrome in a patient on adalimumab for the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2926745 ADALIMUMAB of psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2938025 ADALIMUMAB Safety of Adalimumab Dosed Every Week and Every Other Week: 1 Focus on Patients with Hidradenitis Suppurativa or Psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2946969 ADALIMUMAB Adalimumab-related alopecia in a patient affected by psoriasis. 6 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2946974 ADALIMUMAB Mycobacterium marinum infection contracted from seaweed wrap in 8 a psoriasis patient undergoing treatment with adalimumab. Anti-TNF therapy-induced lupus erythematosus-like syndrome in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2965410 ADALIMUMAB patient treated with adalimumab for cutaneous psoriasis. 1 ADALIMUMAB, Apremilast and adalimumab: a novel combination therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2615837 APREMILAST recalcitrant psoriasis. 0 ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=1769206 ETANERCEPT Adalimumab vs. etanercept in psoriasis. 4 ADALIMUMAB, Adalimumab treats psoriasis in patients previously treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1953986 ETANERCEPT etanercept: a case series. 1 ADALIMUMAB, Adalimumab for psoriasis patients who are non-responders to https://www.ncbi.nlm.nih.gov/pubmed/?term=1957302 ETANERCEPT etanercept: open-label prospective evaluation. 4 ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2049447 Efficacy and safety of adalimumab in patients with plaque psoriasis ETANERCEPT 9 who have shown an unsatisfactory response to etanercept. ADALIMUMAB, Paradoxical worsening of psoriasis when switching from etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=2052487 ETANERCEPT to adalimumab: a case series. 4 Switching from etanercept to adalimumab is effective and safe: ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2064979 results in 30 patients with psoriasis with primary failure, secondary ETANERCEPT 8 failure or intolerance to etanercept. Comparative effectiveness without head-to-head trials: a method for ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2083130 matching-adjusted indirect comparisons applied to psoriasis ETANERCEPT 2 treatment with adalimumab or etanercept. Switching to adalimumab in patients with moderate to severe ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2085440 psoriasis who have failed on etanercept: a retrospective case cohort ETANERCEPT 8 study. [Review] An open-label, prospective cohort pilot study to evaluate the efficacy ADALIMUMAB, and safety of etanercept in the treatment of moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2145555 ETANERCEPT plaque psoriasis in patients who have not had an adequate response 0 to adalimumab. ADALIMUMAB, Psoriasis treatment patterns with etanercept and adalimumab in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2266832 ETANERCEPT United States health plan population. 1 Medication Title of Article PubMed Link

ADALIMUMAB, Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha https://www.ncbi.nlm.nih.gov/pubmed/?term=2329538 ETANERCEPT agents, etanercept and adalimumab, in elderly patients affected by 3 psoriasis and psoriatic arthritis: an observational long-term study. ADALIMUMAB, Predicting treatment response in psoriasis using serum levels of https://www.ncbi.nlm.nih.gov/pubmed/?term=2355092 ETANERCEPT adalimumab and etanercept: a single-centre, cohort study. 5 ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2385558 Comment on 'Predicting treatment response in psoriasis using serum ETANERCEPT 4 levels of adalimumab and etanercept: a single-centre, cohort study'. Comment on 'Predicting treatment response in psoriasis using serum ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2385561 levels of adalimumab and etanercept: a single-centre, cohort study': ETANERCEPT 9 reply from authors. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2480747 psoriasis in daily practice care: results from the BioCAPTURE ETANERCEPT 1 network. Disease control for patients with psoriasis receiving continuous ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2521723 versus interrupted therapy with adalimumab or etanercept: a clinical ETANERCEPT 4 practice study. Baseline anti-dsDNA concentrations and previous treatments predict ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2530629 response to Adalimumab and Etanercept: a retrospective ETANERCEPT 5 investigation of 146 psoriasis patients. Patterns of medication utilization and costs associated with the use ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2572602 of etanercept, adalimumab, and ustekinumab in the management of ETANERCEPT 9 moderate-to-severe psoriasis. ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2618398 Efficacy and safety of etanercept and adalimumab with and without a ETANERCEPT 2 loading dose for psoriasis: A systematic review. [Review] ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2655892 Characterizing patients with psoriasis on injectable biologics ETANERCEPT 4 adalimumab, etanercept, and ustekinumab: A chart review study.

Body mass index predicts discontinuation due to ineffectiveness and ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2698985 female sex predicts discontinuation due to side-effects in patients ETANERCEPT 2 with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t Medication Title of Article PubMed Link

ADALIMUMAB, Comparison of the 1- and 5-year effectiveness of adalimumab, https://www.ncbi.nlm.nih.gov/pubmed/?term=2757986 ETANERCEPT etanercept and ustekinumab in patients with psoriasis in daily clinical 4 practice: results from the prospective BioCAPTURE registry. Determination of adalimumab and etanercept trough levels and drug ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2794338 antibodies in long-term psoriasis treatment: a single-centre cohort ETANERCEPT 4 study. Open-label study of etanercept treatment in patients with moderate- ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2819627 to-severe plaque psoriasis who lost a satisfactory response to ETANERCEPT 0 adalimumab. ADALIMUMAB, Economic Impact of Above-Label Dosing with Etanercept, https://www.ncbi.nlm.nih.gov/pubmed/?term=2844877 ETANERCEPT Adalimumab, or Ustekinumab in Patients with Psoriasis. 8 Adalimumab, etanercept and ustekinumab for treating plaque ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2910562 psoriasis in children and young people: systematic review and ETANERCEPT 1 economic evaluation. [Review] ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2913286 Comment on "Efficacy and safety of etanercept and adalimumab with ETANERCEPT 6 and without a loading dose for psoriasis: A systematic review". Comparison of Adalimumab and Etanercept for the Treatment of ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2930493 Moderate to Severe Psoriasis: An Indirect Comparison Using ETANERCEPT 3 Individual Patient Data from Randomized Trials. ADALIMUMAB, Biologic therapy for psoriasis: an update on the tumor necrosis factor https://www.ncbi.nlm.nih.gov/pubmed/?term=1616741 ETANERCEPT, inhibitors infliximab, etanercept, and adalimumab, and the T-cell- 2 INFLIXIMAB targeted therapies efalizumab and alefacept. [Review] [39 refs] ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=1971055 ETANERCEPT, Management of severe psoriasis with TNF antagonists. Adalimumab, 3 INFLIXIMAB etanercept and infliximab. [Review] [112 refs] ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2212626 ETANERCEPT, Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab 4 INFLIXIMAB for moderate-to-severe plaque psoriasis. ADALIMUMAB, Onychomycosis in patients of nail psoriasis on biologic therapy: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2352759 ETANERCEPT, randomized, prospective open label study comparing Etanercept, 7 INFLIXIMAB Infliximab and Adalimumab. Medication Title of Article PubMed Link ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2560082 ETANERCEPT, Etanercept for patients with psoriasis who did not respond or who lost 8 INFLIXIMAB their response to adalimumab or infliximab. ADALIMUMAB, ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=1563876 INFLIXIMAB, Advances in therapy for psoriasis: an overview of infliximab, 3 PIMECROLIMUS, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and TAZAROTENE pimecrolimus. [Review] [61 refs] ADALIMUMAB, ETANERCEPT, Switching to adalimumab for psoriasis patients with a suboptimal https://www.ncbi.nlm.nih.gov/pubmed/?term=2141449 PHOTOTHERAPY, response to etanercept, methotrexate, or phototherapy: efficacy and 5 METHOTREXATE safety results from an open-label study. ADALIMUMAB, ETANERCEPT, Changes in C-reactive protein in patients with moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2442299 PHOTOTHERAPY, psoriasis switched to adalimumab therapy after suboptimal response 2 METHOTREXATE to etanercept, methotrexate or phototherapy. ADALIMUMAB, Routine Laboratory Parameter Dynamics and Laboratory Adverse https://www.ncbi.nlm.nih.gov/pubmed/?term=2822416 ETANERCEPT, Events in Psoriasis Patients on Long-term Treatment with 6 USTEKINUMAB Adalimumab, Etanercept, and Ustekinumab. ADALIMUMAB, A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2615478 GUSELKUMAB Psoriasis. 7

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2805736 antibody, compared with adalimumab for the continuous treatment of GUSELKUMAB 0 patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2805736 antibody, compared with adalimumab for the treatment of patients GUSELKUMAB 1 with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p ADALIMUMAB, Successful treatment of recalcitrant palmoplantar pustular psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1897462 INFLIXIMAB with sequential use of infliximab and adalimumab. 9 ADALIMUMAB, Infliximab and adalimumab-induced psoriasis in Crohn's disease: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2145388 INFLIXIMAB paradoxical side effect. 6 Medication Title of Article PubMed Link ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2191070 Cutaneous pseudolymphoma induced by adalimumab and INFLIXIMAB 4 reproduced by infliximab in a patient with arthropathic psoriasis. ADALIMUMAB, Severe infliximab-induced psoriasis treated with adalimumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2299833 INFLIXIMAB switching. 0 ADALIMUMAB, Plasma trough levels of adalimumab and infliximab in terms of clinical https://www.ncbi.nlm.nih.gov/pubmed/?term=2303917 INFLIXIMAB efficacy during the treatment of psoriasis. 9 Anti-adalimumab and anti-infliximab antibodies developed in ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2341422 psoriasis vulgaris patients reduced the efficacy of biologics: report of INFLIXIMAB 5 two cases. Implementing therapeutic goals in maintenance treatment of ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2378297 psoriasis with biologics: adalimumab can be more cost-effective than INFLIXIMAB 8 infliximab or ustekinumab in real life. ADALIMUMAB, Influence of neutralizing antibodies to adalimumab and infliximab on https://www.ncbi.nlm.nih.gov/pubmed/?term=2432976 INFLIXIMAB the treatment of psoriasis. 4 ADALIMUMAB, Infliximab and adalimumab, unlike ustekinumab, increase serum KL- https://www.ncbi.nlm.nih.gov/pubmed/?term=2591932 INFLIXIMAB 6 levels in Japanese patients with psoriasis. 4 ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2774339 Adalimumab administration after infliximab therapy is a successful INFLIXIMAB 7 treatment strategy for generalized pustular psoriasis. ADALIMUMAB, Efficacy of adalimumab and methotrexate combination therapy on https://www.ncbi.nlm.nih.gov/pubmed/?term=2542547 INFLIXIMAB, generalized pustular psoriasis patients unresponsive to infliximab 9 METHOTREXATE monotherapy due to anti-infliximab antibody development. Efficacy and safety results from the randomized controlled ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=1804752 comparative study of adalimumab vs. methotrexate vs. placebo in METHOTREXATE 3 patients with psoriasis (CHAMPION). ADALIMUMAB, Adalimumab may be better or no worse than methotrexate in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1848959 METHOTREXATE treatment of psoriasis. 3

ADALIMUMAB, Benefit-risk analysis of adalimumab versus methotrexate and https://www.ncbi.nlm.nih.gov/pubmed/?term=2093330 METHOTREXATE placebo in the treatment of moderate to severe psoriasis: comparison 1 of adverse event-free response days in the CHAMPION trial. Medication Title of Article PubMed Link Effectiveness of adalimumab dose escalation, combination therapy of ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2319438 adalimumab with methotrexate, or both in patients with psoriasis in METHOTREXATE 9 daily practice. Analysis of body regions and components of PASI scores during ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2480987 adalimumab or methotrexate treatment for patients with moderate-to- METHOTREXATE 8 severe psoriasis. ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2594655 CCL20 and IL22 Messenger RNA Expression After Adalimumab vs METHOTREXATE 4 Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial. Efficacy of Adalimumab Compared With Methotrexate or Placebo ADALIMUMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2626773 Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial METHOTREXATE 1 in Patients With Psoriasis. ADALIMUMAB, Adalimumab-Induced Pityriasis Lichenoides Chronica That https://www.ncbi.nlm.nih.gov/pubmed/?term=2652223 METHOTREXATE Responded Well to Methotrexate in a Patient With Psoriasis. 5

ADALIMUMAB, Efficacy and safety of adalimumab every other week versus https://www.ncbi.nlm.nih.gov/pubmed/?term=2847897 METHOTREXATE methotrexate once weekly in children and adolescents with severe 5 chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. ADALIMUMAB, Adalimumab plus narrowband ultraviolet B light phototherapy for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2145554 PHOTOTHERAPY treatment of moderate to severe psoriasis. 6 ADALIMUMAB,ETAN Relevance of laboratory investigations in monitoring patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2142897 ERCEPT psoriasis on etanercept or adalimumab. 5 Reply to: Comment on "Efficacy and safety of etanercept and ADALIMUMAB,ETAN https://www.ncbi.nlm.nih.gov/pubmed/?term=2913286 adalimumab with and without a loading dose for psoriasis: A ERCEPT 7 systematic review". ADALIMUMAB,INFLI Polymorphisms associated with adalimumab and infliximab response https://www.ncbi.nlm.nih.gov/pubmed/?term=2919255 XIMAB in moderate-to-severe plaque psoriasis. 2 ALPHA- LACTALBUMIN- http://www.ncbi.nlm.nih.gov/pubmed/15215482 OLEIC ACID Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid. ALPHA- LACTALBUMIN- http://www.ncbi.nlm.nih.gov/pubmed/15483294 OLEIC ACID Treatment of warts. Medication Title of Article PubMed Link AMINOLEVULINIC Photodynamic therapy with 20% aminolevulinic acid for the treatment http://www.ncbi.nlm.nih.gov/pubmed/17988339 ACID of recalcitrant viral warts in an Asian population. AMINOLEVULINIC Pretreatment of plantar warts with azone enhances the effect of 5- http://www.ncbi.nlm.nih.gov/pubmed/16566731 ACID aminolevulinic acid photodynamic therapy. Comparative study of aminolevulic acid photodynamic therapy plus AMINOLEVULINIC pulsed dye laser versus pulsed dye laser alone in treatment of viral http://www.ncbi.nlm.nih.gov/pubmed/15910187 ACID warts.

AMINOLEVULINIC Photodynamic therapy with 5-aminolaevulinic acid or placebo for http://www.ncbi.nlm.nih.gov/pubmed/10768434 ACID recalcitrant foot and hand warts: randomised double-blind trial. Recalcitrant hand and foot warts successfully treated with AMINOLEVULINIC photodynamic therapy with topical 5-aminolaevulinic acid: a pilot http://www.ncbi.nlm.nih.gov/pubmed/10354167 ACID study. AMINOLEVULINIC Photodynamic therapy with topical delta-aminolaevulinic acid for the http://www.ncbi.nlm.nih.gov/pubmed/11485845 ACID treatment of plantar warts. AMINOLEVULINIC Efficacy of 3.6% topical ALA-PDT for the treatment of severe acne http://www.ncbi.nlm.nih.gov/pubmed/26875889 ACID vulgaris

AMINOLEVULINIC Aminolevulinic acid and methyl aminolevulinate equally effective in http://www.ncbi.nlm.nih.gov/pubmed/26841041 ACID topical photodynamic therapy for non-melanoma skin cancers AMINOLEVULINIC Topical Photodynamic Therapy with 5-Aminolevulinic Acid for http://www.ncbi.nlm.nih.gov/pubmed/26687616 ACID Cervical High-risk HPV Infection

Comparison between photodynamic therapy with topical application http://www.ncbi.nlm.nih.gov/pubmed/26379947 AMINOLEVULINIC of 5-aminolevulinic acid and CO2 laser therapy in the treatment of ACID cervical condylomata acuminate: a randomized controlled trial Inhibition of histamine-induced pruritus by topical tricyclic http://www.ncbi.nlm.nih.gov/pubmed/7298924 AMITRIPTYLINE antidepressants. AMITRIPTYLINE Topical amitriptyline in healthy volunteers. http://www.ncbi.nlm.nih.gov/pubmed/12945021 Topical amitriptyline and ketamine in neuropathic pain syndromes: an http://www.ncbi.nlm.nih.gov/pubmed/16202956 AMITRIPTYLINE open-label study.

A double-blind, placebo-controlled trial of a topical treatment for http://www.ncbi.nlm.nih.gov/pubmed/20496177 AMITRIPTYLINE chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Medication Title of Article PubMed Link A pilot study examining topical amitriptyline, ketamine, and a http://www.ncbi.nlm.nih.gov/pubmed/12966259 AMITRIPTYLINE combination of both in the treatment of neuropathic pain

Topical 2% amitriptyline and 1% ketamine in neuropathic pain http://www.ncbi.nlm.nih.gov/pubmed/15983466 AMITRIPTYLINE syndromes: a randomized, double-blind, placebo-controlled trial

Topical amitriptyline combined with ketamine for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/23545913 AMITRIPTYLINE erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. Topical amitriptyline-ketamine for treatment of rectal, genital, and http://www.ncbi.nlm.nih.gov/pubmed/23159965 AMITRIPTYLINE perineal pain and discomfort. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain http://www.ncbi.nlm.nih.gov/pubmed?term=21847539 AMITRIPTYLINE caused by radiation skin reaction: a pilot study. Topical amitriptyline and ketamine for post-herpetic neuralgia and http://www.ncbi.nlm.nih.gov/pubmed/26809783 AMITRIPTYLINE other forms of neuropathic pain Amitriptyline 2% cream vs. 0.75% cream in the treatment of painful diabetic neuropathy (Double blind, randomized clinical trial http://www.ncbi.nlm.nih.gov/pubmed/26664395 AMITRIPTYLINE of efficacy and safety) Topical amitriptyline and ketamine for the treatment of neuropathic http://www.ncbi.nlm.nih.gov/pubmed/26488799 AMITRIPTYLINE pain Systematic review of topical amitriptyline for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/26059975 AMITRIPTYLINE neuropathic pain Systematic review of topical amitriptyline for the treatment of Amitriptyline https://www.ncbi.nlm.nih.gov/pubmed/26059975 neuropathic pain. Use of amitriptyline cream in the management of entry dyspareunia Amitriptyline https://www.ncbi.nlm.nih.gov/pubmed/22622338 due to provoked vestibulodynia Central neuropathic pain in a patient with multiple sclerosis treated Amitriptyline https://www.ncbi.nlm.nih.gov/pubmed/22851976 successfully with topical amitriptyline.

Amitriptyline Topical 2% amitriptyline and 1% ketamine in neuropathic pain https://www.ncbi.nlm.nih.gov/pubmed/15983466 syndromes: a randomized, double-blind, placebo-controlled trial. Amitriptyline 2% cream vs. capsaicin 0.75% cream in the treatment Amitriptyline of painful diabetic neuropathy (Double blind, randomized clinical trial https://www.ncbi.nlm.nih.gov/pubmed/26664395 of efficacy and safety). Amitriptyline Topical amitriptyline in healthy volunteers https://www.ncbi.nlm.nih.gov/pubmed/12945021 Medication Title of Article PubMed Link

Amitriptyline Effective use of topical amitriptyline hydrochloride 2.5% and https://www.ncbi.nlm.nih.gov/pubmed/19112806 ketamine hydrochloride 0.5% for analgesia in refractory proctodynia Topical amitriptyline-ketamine for treatment of rectal, genital, and Amitriptyline https://www.ncbi.nlm.nih.gov/pubmed/23159965 perineal pain and discomfort. and lysine acetylsalicylate in the combined treatment http://www.ncbi.nlm.nih.gov/pubmed/16784013 AMPHOTERICIN of nasal polyposis associated with mycotic infection. Therapeutic effect of intracameral amphotericin B injection in the http://www.ncbi.nlm.nih.gov/pubmed/17667615 AMPHOTERICIN treatment of fungal keratitis. Topical amphotericin B and subconjunctival injection of (combination therapy) versus topical amphotericin B (monotherapy) http://www.ncbi.nlm.nih.gov/pubmed/20565316 AMPHOTERICIN in treatment of keratomycosis. A targeted peritransplant strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort http://www.ncbi.nlm.nih.gov/pubmed/22790447 AMPHOTERICIN analysis. Use of nebulized amphotericin B in the treatment of allergic http://www.ncbi.nlm.nih.gov/pubmed/21234103 AMPHOTERICIN bronchopulmonary aspergillosis in cystic fibrosis. Efficacious treatment of non-dermatophyte mould onychomycosis http://www.ncbi.nlm.nih.gov/pubmed/22236569 AMPHOTERICIN with topical amphotericin B. Prophylactic application of nebulized liposomal amphotericin B in http://www.ncbi.nlm.nih.gov/pubmed/21577031 AMPHOTERICIN hematologic patients with neutropenia.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: a http://www.ncbi.nlm.nih.gov/pubmed/15637558 AMPHOTERICIN randomized, placebo-controlled, double-blind pilot trial.

Topical amphotericin B in ultradeformable : Formulation, http://www.ncbi.nlm.nih.gov/pubmed/26709977 AMPHOTERICIN skin penetration study, antifungal and antileishmanial activity in vitro Topical Amphotericin B solid lipid nanoparticles: Design and http://www.ncbi.nlm.nih.gov/pubmed/26700229 AMPHOTERICIN development Prophylactic application of nebulized liposomal amphotericin B in AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/21577031 hematologic patients with neutropenia A pilot randomized trial of nebulized amphotericin in patients with AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/26666774 allergic bronchopulmonary aspergillosis Medication Title of Article PubMed Link Role of nebulized amphotericin B in the management of allergic AMPHOTERICIN bronchopulmonary aspergillosis in cystic fibrosis: Case report and https://www.ncbi.nlm.nih.gov/pubmed/24824366 review of literature Role of inhaled amphotericin in allergic bronchopulmonary AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/24625938 aspergillosis Allergic bronchopulmonary aspergillosis in a lung transplant patient AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/12431500 successfully treated with nebulized amphotericin Feasibility, tolerability, and outcomes of nebulized liposomal AMPHOTERICIN amphotericin B for Aspergillus infection prevention in lung https://www.ncbi.nlm.nih.gov/pubmed/20061165 transplantation Effects of nebulized amphotericin B and for AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/25466805 chronic cough-related laryngeal sensations AMPHOTERICIN Inhaled for lower airway infections https://www.ncbi.nlm.nih.gov/pubmed/24673698 AMPHOTERICIN A review on the clinical use of inhaled amphotericin B https://www.ncbi.nlm.nih.gov/pubmed/19466905 10 years of prophylaxis with nebulized liposomal amphotericin B and AMPHOTERICIN the changing epidemiology of Aspergillus spp. infection in lung https://www.ncbi.nlm.nih.gov/pubmed/26339864 transplantation Efficiency and safety of inhaled amphotericin B lipid complex AMPHOTERICIN (Abelcet) in the prophylaxis of invasive fungal infections following https://www.ncbi.nlm.nih.gov/pubmed/19010204 lung transplantation Safety of aerosolized liposomal versus deoxycholate amphotericin B AMPHOTERICIN formulations for prevention of invasive fungal infections following lung https://www.ncbi.nlm.nih.gov/pubmed/17461997 transplantation: a retrospective study Invasive Microascus trigonosporus Species Complex Pulmonary AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/26075134 Infection in a Lung Transplant Recipient Keratitis by a rare pathogen Colletotrichum gloeosporioides: A case AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/28501467 report Successful Treatment of Lasiodiplodia theobromae Keratitis - AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/27843433 Assessing the Role of Effect of anti-fungal nasal lavage with amphotericin B on nasal AMPHOTERICIN https://www.ncbi.nlm.nih.gov/pubmed/11945184 polyposis https://www.ncbi.nlm.nih.gov/pubmed/28935221 AMPHOTERICIN Thermal stability of mafenide and amphotericin B topical solution. Amphotericin B releasing topical nanoemulsion for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/28712917 AMPHOTERICIN and aspergillosis. Medication Title of Article PubMed Link Combination liposomal amphotericin B, and oral amphotericin B for treatment of gastrointestinal Mucorales in an https://www.ncbi.nlm.nih.gov/pubmed/28580237 AMPHOTERICIN immunocompromised patient. Combined intrastromal injection of amphotericin B and topical fluconazole in the treatment of resistant cases of keratomycosis: a https://www.ncbi.nlm.nih.gov/pubmed/28503064 AMPHOTERICIN retrospective study.

New perspectives in the topical delivery of optimized amphotericin https://www.ncbi.nlm.nih.gov/pubmed/28007632 B loaded nanoemulsions using excipients with innate anti-fungal AMPHOTERICIN activities: A mechanistic and histopathological investigation. Topical Amphotericin B solid lipid nanoparticles: Design and https://www.ncbi.nlm.nih.gov/pubmed/26700229 AMPHOTERICIN development. Development of anthralin short-contact therapy in psoriasis: survey of ANTHRALIN https://www.ncbi.nlm.nih.gov/pubmed/?term=1532790 published clinical trials. The effect of triethanolamine application on anthralin-induced ANTHRALIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2142172 inflammation and therapeutic effect in psoriasis. "Ditrawash"--a novel remover of dithranol (anthralin) for short contact ANTHRALIN https://www.ncbi.nlm.nih.gov/pubmed/?term=2609870 therapy of psoriasis. Anthralin- combination therapy in the treatment of ANTHRALIN https://www.ncbi.nlm.nih.gov/pubmed/?term=3355198 chronic plaque psoriasis. A comparative study of calcipotriol and anthralin for chronic plaque ANTHRALIN https://www.ncbi.nlm.nih.gov/pubmed/?term=9522242 psoriasis in a day care treatment center. ANTHRALIN https://www.ncbi.nlm.nih.gov/pubmed/?term=9609979 Topical anthralin therapy for refractory nail psoriasis. Topical anthralin for psoriasis vulgaris: evaluation of 70 Japanese https://www.ncbi.nlm.nih.gov/pubmed/?term=1093535 ANTHRALIN patients. 0 Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand https://www.ncbi.nlm.nih.gov/pubmed/?term=1256682 ANTHRALIN in the involved skin of psoriasis vulgaris following topical anthralin 9 therapy. ANTHRALIN, COAL UVABA therapy for psoriasis. Efficacy with shortened treatment times TAR, PHOTOTHERA with the combined use of , anthralin, and metal halide https://www.ncbi.nlm.nih.gov/pubmed/?term=2033137 PY ultraviolet machines. ANTHRALIN, Short-contact anthralin treatment augments therapeutic efficacy of https://www.ncbi.nlm.nih.gov/pubmed/?term=7545705 CYCLOSPORINE cyclosporine in psoriasis: a clinical and pathologic study. Medication Title of Article PubMed Link An open-label, single-arm pilot study in patients with severe plaque- https://www.ncbi.nlm.nih.gov/pubmed/?term=1841987 APREMILAST type psoriasis treated with an oral anti-inflammatory agent, 9 apremilast. https://www.ncbi.nlm.nih.gov/pubmed/?term=2005084 APREMILAST Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti- 9 inflammatory activity in vitro and in a model of psoriasis. Apremilast mechanism of action and application to psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2225791 APREMILAST psoriatic arthritis. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2271280 APREMILAST Apremilast as a treatment for psoriasis. [Review] 0 Efficacy of apremilast in the treatment of moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2274870 APREMILAST psoriasis: a randomised controlled trial. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2274870 APREMILAST Apremilast: a step forward in the treatment of psoriasis?. 3 Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, https://www.ncbi.nlm.nih.gov/pubmed/?term=2303076 APREMILAST double-blind, placebo-controlled, parallel-group, dose-comparison 7 study. New developments in the management of psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2356935 APREMILAST arthritis: a focus on apremilast. [Review] 9

Improvements in patient-reported outcomes with apremilast, an oral https://www.ncbi.nlm.nih.gov/pubmed/?term=2366375 APREMILAST phosphodiesterase 4 inhibitor, in the treatment of moderate to severe 2 psoriasis: results from a phase IIb randomized, controlled study. Novel systemic for psoriasis: mechanism of action for https://www.ncbi.nlm.nih.gov/pubmed/?term=2368019 APREMILAST apremilast, a specific inhibitor of PDE4. 7 Efficacy, tolerability, and pharmacodynamics of apremilast in https://www.ncbi.nlm.nih.gov/pubmed/?term=2398616 APREMILAST recalcitrant plaque psoriasis: a phase II open-label study. 2 Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, https://www.ncbi.nlm.nih.gov/pubmed/?term=2608904 APREMILAST randomized, controlled trial (Efficacy and Safety Trial Evaluating the 7 Effects of Apremilast in Psoriasis [ESTEEM] 1). https://www.ncbi.nlm.nih.gov/pubmed/?term=2622091 APREMILAST Apremilast: A Review in Psoriasis and Psoriatic Arthritis. [Review] 1 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2624373 APREMILAST Apremilast for the treatment of psoriasis. [Review] 5

Efficacy and safety of apremilast, an oral phosphodiesterase 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2635794 APREMILAST inhibitor, in patients with moderate-to-severe plaque psoriasis over 4 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). https://www.ncbi.nlm.nih.gov/pubmed/?term=2635831 APREMILAST Apremilast for psoriasis and psoriatic arthritis. [Review] 7 Apremilast in the treatment of psoriasis and psoriatic arthritis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2638290 APREMILAST [Review] 6 Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on https://www.ncbi.nlm.nih.gov/pubmed/?term=2648194 APREMILAST Apremilast. [Review] 1

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2654924 APREMILAST difficult-to-treat nail and scalp psoriasis: Results of 2 phase III 9 randomized, controlled trials (ESTEEM 1 and ESTEEM 2). A new therapeutic for the treatment of moderate-to-severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2669212 APREMILAST psoriasis: apremilast. 5 Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2678335 APREMILAST Arthritis. [Review] 0 Apremilast for the Treatment of Moderate to Severe Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2682014 APREMILAST Psoriasis: A Critique of the Evidence. [Review] 8 Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate https://www.ncbi.nlm.nih.gov/pubmed/?term=2683705 APREMILAST With Improvements in Quality of Life in Patients With Moderate to 2 Severe Plaque Psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2684814 APREMILAST Use of Apremilast in Combination With Other Therapies for 5 Treatment of Chronic Plaque Psoriasis: A Retrospective Study. Improvement of Nail and Scalp Psoriasis Using Apremilast in https://www.ncbi.nlm.nih.gov/pubmed/?term=2695431 APREMILAST Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week 1 Randomized, Placebo-Controlled Trial Results. Medication Title of Article PubMed Link

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2702123 APREMILAST palmoplantar psoriasis: Results of a pooled analysis from phase II 9 PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical Apremilast in the therapy of moderate-to-severe chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2730770 APREMILAST psoriasis. [Review] 7 Pharmacodynamic assessment of apremilast for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2737672 APREMILAST moderate-to-severe plaque psoriasis. [Review] 9 Apremilast (Otezla). No progress in plaque psoriasis or psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2748664 APREMILAST arthritis. [Review] 1

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient- https://www.ncbi.nlm.nih.gov/pubmed/?term=2753824 APREMILAST reported outcomes in the treatment of moderate to severe psoriasis: 1 results of two phase III randomized, controlled trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=2784661 APREMILAST Real-World Experience With Apremilast in Treating Psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2784694 APREMILAST Appearance of lentigines in psoriasis patients treated with apremilast. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2813257 APREMILAST Safety evaluation of apremilast for the treatment of psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2821386 APREMILAST Apremilast: A Review in Psoriasis and Psoriatic Arthritis. [Review] 2 Apremilast for the management of moderate to severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2827677 APREMILAST psoriasis. [Review] 7

Evaluation of the Physician Global Assessment and Body Surface https://www.ncbi.nlm.nih.gov/pubmed/?term=2830085 APREMILAST Area Composite Tool for Assessing Psoriasis Response to 7 Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. Long-term safety and tolerability of apremilast in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2841634 APREMILAST psoriasis: Pooled safety analysis for >=156 weeks from 2 phase 3, 2 randomized, controlled trials (ESTEEM 1 and 2). A Novel Apremilast Nail Lacquer Formulation for the Treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2845582 APREMILAST Nail Psoriasis. 9 Medication Title of Article PubMed Link Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2859718 APREMILAST Arthritis. [Review] 2 Real-world, single-centre experience of apremilast for the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2862100 APREMILAST of moderate to severe psoriasis. 2 Efficacy and Safety of Apremilast in Patients With Moderate Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2880999 APREMILAST Psoriasis With Lower BSA: Week 16 Results from the UNVEIL 5 Study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2881095 APREMILAST The Use of Apremilast to Treat Psoriasis During Deployment. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2892556 APREMILAST Apremilast in psoriasis - a prospective real-world study. 0 Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body https://www.ncbi.nlm.nih.gov/pubmed/?term=2913285 APREMILAST surface area (PGA x BSA) composite tool: An analysis of apremilast 3 phase 3 ESTEEM data. Real-World Clinical Experience With Apremilast in a Large US https://www.ncbi.nlm.nih.gov/pubmed/?term=2924085 APREMILAST Retrospective Cohort Study of Patients With Moderate to Severe 9 Plaque Psoriasis. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive https://www.ncbi.nlm.nih.gov/pubmed/?term=2946223 APREMILAST Patients With Moderate Plaque Psoriasis: 52-Week Results of 1 UNVEIL. APREMILAST, Apremilast and Narrowband Ultraviolet-B Combination Therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2903624 PHOTOTHERAPY Treating Moderate-to-Severe Plaque Psoriasis. 8

APREMILAST, ETAN The efficacy and safety of apremilast, etanercept and placebo in https://www.ncbi.nlm.nih.gov/pubmed/?term=2776824 ERCEPT patients with moderate-to-severe plaque psoriasis: 52-week results 2 from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). Comparative efficacy and incremental cost per responder of APREMILAST, METH https://www.ncbi.nlm.nih.gov/pubmed/?term=2747697 methotrexate versus apremilast for methotrexate-naive patients with OTREXATE 3 psoriasis. [Review] APREMILAST, SECU Apremilast and Secukinumab Combined Therapy in a Patient With https://www.ncbi.nlm.nih.gov/pubmed/?term=2716827 KINUMAB Recalcitrant Plaque Psoriasis. 5 Emerging Oral Immunomodulators for the Treatment of Psoriasis: A APREMILAST, TOFA https://www.ncbi.nlm.nih.gov/pubmed/?term=2626772 Review of Phase III Clinical Trials for Apremilast and Tofacitinib. CITINIB 2 [Review] Medication Title of Article PubMed Link prodrugs: synthesis of 2-substituted 2-methyl-4H-1,3- http://www.ncbi.nlm.nih.gov/pubmed/2291862 ASPIRIN benzodioxin-4-ones and their screening for prodrug potential AZATHIOPRINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1478769 Azathioprine: a forgotten alternative for treatment of severe psoriasis. AZATHIOPRINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9674409 Psoriasis and bullous pemphigoid treated with azathioprine. Improvement of anti-TNFalpha antibody-induced pustular psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2285393 AZATHIOPRINE by azathioprine. 9 Azathioprine for the Rare Case of Nonspecific Interstitial Pneumonitis https://www.ncbi.nlm.nih.gov/pubmed/?term=2631727 AZATHIOPRINE in a Patient with Psoriasis. 7 Effectiveness of azathioprine pulse therapy in prolonging remission https://www.ncbi.nlm.nih.gov/pubmed/?term=2708714 AZATHIOPRINE of psoriasis. 3 Effectiveness of weekly azathioprine pulse in the treatment of chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2766314 AZATHIOPRINE plaque psoriasis: an open-label study. 5 Effectiveness of weekly azathioprine pulse in the treatment of chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2873684 AZATHIOPRINE plaque psoriasis: an open-label study: reply to author. 3 Azathioprine Is Useful for Maintaining Long-term Remission Induced by for the Treatment of Ulcerative Colitis: An Inverse https://pubmed.ncbi.nlm.nih.gov/31118391 AZATHIOPRINE Probability of a Treatment Weighing Analysis. Azathioprine hypersensitivity presenting as sweet syndrome in a child https://pubmed.ncbi.nlm.nih.gov/22253154 AZATHIOPRINE with ulcerative colitis. Azathioprine and 6-mercaptopurine for maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/27192092 AZATHIOPRINE ulcerative colitis. [Review] Endoscopic aspect of a severe CMV colitis induced by azathioprine in https://pubmed.ncbi.nlm.nih.gov/27981297 AZATHIOPRINE a patient with ulcerative colitis. Treatment efficacy and safety of low-dose azathioprine in chronic active ulcerative colitis patients: A meta-analysis and systemic https://pubmed.ncbi.nlm.nih.gov/27450969 AZATHIOPRINE review. [Review]

Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma in https://pubmed.ncbi.nlm.nih.gov/27311871 AZATHIOPRINE a patient treated with azathioprine for ulcerative colitis. Effect of Early Versus Late Azathioprine Therapy in Pediatric https://pubmed.ncbi.nlm.nih.gov/27271489 AZATHIOPRINE Ulcerative Colitis. Medication Title of Article PubMed Link

Generalized Pyoderma Gangrenosum Associated with Ulcerative https://pubmed.ncbi.nlm.nih.gov/27149138 AZATHIOPRINE Colitis: Successful Treatment with Infliximab and Azathioprine. Colonic small cell neuroendocrine carcinoma in a patient with long- https://pubmed.ncbi.nlm.nih.gov/27103360 AZATHIOPRINE standing ulcerative colitis treated with azathioprine. Squamous cell carcinoma arising from a presacral cyst in a patient with ulcerative colitis under azathioprine and infliximab: first case https://pubmed.ncbi.nlm.nih.gov/26857617 AZATHIOPRINE report. Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose https://pubmed.ncbi.nlm.nih.gov/26754306 AZATHIOPRINE intensification plus azathioprine. Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by https://pubmed.ncbi.nlm.nih.gov/26252649 AZATHIOPRINE Reducing Inflammation. https://pubmed.ncbi.nlm.nih.gov/25518053 AZATHIOPRINE Long-term efficacy and safety of azathioprine in ulcerative colitis. Safe azathioprine treatment in a pediatric ulcerative colitis patient https://pubmed.ncbi.nlm.nih.gov/25036765 AZATHIOPRINE with TPMT*16 by thiopurine metabolite monitoring. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent https://pubmed.ncbi.nlm.nih.gov/24983979 AZATHIOPRINE ulcerative colitis. Hodgkin's lymphoma rectosigmoid in a patient with ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/24849639 AZATHIOPRINE on long-term azathioprine therapy. Combination therapy with infliximab and azathioprine is superior to https://pubmed.ncbi.nlm.nih.gov/24512909 AZATHIOPRINE monotherapy with either agent in ulcerative colitis. The long-term efficacy of azathioprine in steroid-dependent ulcerative https://pubmed.ncbi.nlm.nih.gov/24164382 AZATHIOPRINE colitis. An unusual complication in ulcerative colitis during treatment with https://pubmed.ncbi.nlm.nih.gov/23709557 AZATHIOPRINE azathioprine and infliximab: Isospora belli as 'Casus belli'. Can azathioprine 6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: what is the most https://pubmed.ncbi.nlm.nih.gov/23576085 AZATHIOPRINE appropriate time for this?. [Review] EML4-ALK-positive non-small cell lung cancer in a patient treated https://pubmed.ncbi.nlm.nih.gov/23052178 AZATHIOPRINE with azathioprine for ulcerative colitis. Medication Title of Article PubMed Link Azathioprine and 6-mercaptopurine for maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/22972046 AZATHIOPRINE ulcerative colitis. [Review] Pleomorphic malignant histiocytoma: a rare skin cancer in a patient https://pubmed.ncbi.nlm.nih.gov/22761209 AZATHIOPRINE on azathioprine for ulcerative colitis. Acute generalized exanthematous pustulosis induced by azathioprine https://pubmed.ncbi.nlm.nih.gov/21540908 AZATHIOPRINE in a patient with ulcerative colitis.

Recurrent atrial fibrillation in a patient with ulcerative colitis treated https://pubmed.ncbi.nlm.nih.gov/21496410 AZATHIOPRINE with azathioprine: case report and review of the literature. [Review] Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: https://pubmed.ncbi.nlm.nih.gov/21367409 AZATHIOPRINE HLA haplotype characterization. https://pubmed.ncbi.nlm.nih.gov/20198426 AZATHIOPRINE Azathioprine and ulcerative colitis: a "second-look" meta-analysis. Early onset steroid-dependent ulcerative colitis is a predictor of https://pubmed.ncbi.nlm.nih.gov/20110928 AZATHIOPRINE azathioprine response: a longitudinal 12-month follow-up study.

Azathioprine, mucosal healing in ulcerative colitis, and the https://pubmed.ncbi.nlm.nih.gov/19906011 AZATHIOPRINE chemoprevention of colitic cancer: a clinical-practice-based forecast.

Azathioprine maintains long-term steroid-free remission through 3 https://pubmed.ncbi.nlm.nih.gov/19705415 AZATHIOPRINE years in patients with steroid-dependent ulcerative colitis.

Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in https://pubmed.ncbi.nlm.nih.gov/19648821 both smokers and nonsmokers with Crohn's disease, while AZATHIOPRINE decreases the risk of colectomy in ulcerative colitis. Maintenance treatment with azathioprine in ulcerative colitis: outcome https://pubmed.ncbi.nlm.nih.gov/19623172 AZATHIOPRINE and predictive factors after drug withdrawal.

Efficacy of methotrexate in Crohn's disease and ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/19552632 AZATHIOPRINE patients unresponsive or intolerant to azathioprine /mercaptopurine. Meta-analysis: the efficacy of azathioprine and mercaptopurine in https://pubmed.ncbi.nlm.nih.gov/19392869 AZATHIOPRINE ulcerative colitis. Medication Title of Article PubMed Link Azathioprine hypersensitivity presenting as a neutrophilic dermatosis https://pubmed.ncbi.nlm.nih.gov/19178493 AZATHIOPRINE in a man with ulcerative colitis. The 17-year single-center experience with the use of azathioprine to https://pubmed.ncbi.nlm.nih.gov/18657949 AZATHIOPRINE maintain remission in ulcerative colitis. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 https://pubmed.ncbi.nlm.nih.gov/18485129 AZATHIOPRINE patients. Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of https://pubmed.ncbi.nlm.nih.gov/18470616 AZATHIOPRINE ulcerative colitis relapse. Exposing the weaknesses: a systematic review of azathioprine https://pubmed.ncbi.nlm.nih.gov/17932752 AZATHIOPRINE efficacy in ulcerative colitis. [Review] [31 refs] Drug-induced pulmonary toxicity in a patient treated with mesalazine https://pubmed.ncbi.nlm.nih.gov/18074739 AZATHIOPRINE and azathioprine for ulcerative colitis. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. [Review] [16 https://pubmed.ncbi.nlm.nih.gov/17598094 AZATHIOPRINE refs] Azathioprine and 6-mercaptopurine for maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/17253451 AZATHIOPRINE ulcerative colitis. [Review] [37 refs] A case of interstitial pneumonitis in a patient with ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/17226917 AZATHIOPRINE treated with azathioprine. Steroid dependent ulcerative colitis: azathioprine use is finally https://pubmed.ncbi.nlm.nih.gov/16954812 AZATHIOPRINE "evidence-based". Azathioprine versus mesalamine in steroid-dependent ulcerative https://pubmed.ncbi.nlm.nih.gov/16472614 AZATHIOPRINE colitis: long-awaited results?.

Randomised controlled trial of azathioprine and 5-aminosalicylic acid https://pubmed.ncbi.nlm.nih.gov/15972298 AZATHIOPRINE for treatment of steroid dependent ulcerative colitis. Hypersensitivity reaction to azathioprine in a patient with ulcerative https://pubmed.ncbi.nlm.nih.gov/15472540 AZATHIOPRINE colitis. Infrequent manifestations.

Efficacy and safety of thiopurinic immunomodulators (azathioprine https://pubmed.ncbi.nlm.nih.gov/15233695 AZATHIOPRINE and mercaptopurine) in steroid-dependent ulcerative colitis. Medication Title of Article PubMed Link

Diffuse febrile dermatosis in a patient with active ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/15191207 under treatment with steroids and azathioprine: a case of Sweet's AZATHIOPRINE syndrome. Case report and review of literature. [Review] [55 refs]

A prospective randomized observer-blind 2-year trial of azathioprine https://pubmed.ncbi.nlm.nih.gov/15180735 monotherapy versus azathioprine and olsalazine for the maintenance AZATHIOPRINE of remission of steroid-dependent ulcerative colitis. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the https://pubmed.ncbi.nlm.nih.gov/14567458 AZATHIOPRINE Edinburgh experience of outcome. Role and side-effects of TPMT polymorphisms of 6-MP and azathioprine in the treatment of steroid-resistant and -dependent https://pubmed.ncbi.nlm.nih.gov/14505139 AZATHIOPRINE ulcerative colitis. Low-dose azathioprine is effective and safe for maintenance of https://pubmed.ncbi.nlm.nih.gov/14505127 AZATHIOPRINE remission in patients with ulcerative colitis. Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with https://pubmed.ncbi.nlm.nih.gov/12867808 AZATHIOPRINE ulcerative colitis.

Azathioprine or 6-mercaptopurine before colectomy for ulcerative https://pubmed.ncbi.nlm.nih.gov/12479645 AZATHIOPRINE colitis is not associated with increased postoperative complications. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid- https://pubmed.ncbi.nlm.nih.gov/12452938 AZATHIOPRINE refractory ulcerative colitis. Azathioprine or methotrexate in the treatment of patients with steroid- dependent or steroid-resistant ulcerative colitis: results of an open- https://pubmed.ncbi.nlm.nih.gov/12269968 label study on efficacy and tolerability in inducing and maintaining AZATHIOPRINE remission. The beneficial effect of azathioprine on maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/11993510 AZATHIOPRINE severe ulcerative colitis. AZATHIOPRINE Oral azathioprine for steroid refractory severe ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/11569720 Safety and efficacy of azathioprine in the maintenance of ciclosporin- https://pubmed.ncbi.nlm.nih.gov/11552900 AZATHIOPRINE induced remission of ulcerative colitis. AZATHIOPRINE Rectal lymphoma in ulcerative colitis treated with azathioprine. https://pubmed.ncbi.nlm.nih.gov/11507370 Medication Title of Article PubMed Link Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient https://pubmed.ncbi.nlm.nih.gov/11293451 AZATHIOPRINE with ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/11151878 AZATHIOPRINE Intravenous azathioprine in severe ulcerative colitis: a pilot study. Mycophenolate mofetil versus azathioprine in patients with chronic https://pubmed.ncbi.nlm.nih.gov/10811328 AZATHIOPRINE active ulcerative colitis: a 12-month pilot study. Role of azathioprine in severe ulcerative colitis: one-year, placebo- https://pubmed.ncbi.nlm.nih.gov/10659481 AZATHIOPRINE controlled, randomized trial. Severe complications of ulcerative colitis after high-dose https://pubmed.ncbi.nlm.nih.gov/10433019 AZATHIOPRINE and azathioprine treatment. Experiences with 6-mercaptopurine and azathioprine therapy in https://pubmed.ncbi.nlm.nih.gov/9890469 AZATHIOPRINE pediatric patients with severe ulcerative colitis. AZATHIOPRINE, Long-term maintenance treatment of moderate-to-severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1920764 INFLIXIMAB, psoriasis with infliximab in combination with methotrexate or 2 METHOTREXATE azathioprine in a retrospective cohort. Effects of topical sprays on allergy-induced nasal obstruction in http://www.ncbi.nlm.nih.gov/pubmed/23834132 children Double-blind, placebo-controlled trial of reformulated azelastine nasal http://www.ncbi.nlm.nih.gov/pubmed/19807985 AZELASTINE spray in patients with seasonal allergic rhinitis The effects of the nasal and azelastine in http://www.ncbi.nlm.nih.gov/pubmed/18681089 AZELASTINE nasal allergen provocation Open-label evaluation of azelastine in patients with http://www.ncbi.nlm.nih.gov/pubmed/15899111 AZELASTINE seasonal allergic rhinitis and nonallergic vasomotor rhinitis Azelastine eye drops in the treatment of perennial allergic http://www.ncbi.nlm.nih.gov/pubmed/12705171 AZELASTINE conjunctivitis Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, http://www.ncbi.nlm.nih.gov/pubmed/10923605 AZELASTINE and daytime somnolence in perennial allergic rhinitis Corticosteroid-sparing effect of azelastine in the management of http://www.ncbi.nlm.nih.gov/pubmed/8542104 AZELASTINE bronchial Effects of intranasal azelastine on the response to nasal allergen http://www.ncbi.nlm.nih.gov/pubmed/11802037 AZELASTINE challenge Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or http://www.ncbi.nlm.nih.gov/pubmed/10329808 AZELASTINE systemic Medication Title of Article PubMed Link Topical azelastine has a 12-hour duration of action as assessed by histamine challenge-induced exudation of alpha 2-macroglobulin into http://www.ncbi.nlm.nih.gov/pubmed/9146938 AZELASTINE human nasal airways AZELASTINE The effect of azelastine on the early allergic response http://www.ncbi.nlm.nih.gov/pubmed/1349259

Long-term, randomized safety study of MP29-02 (a novel intranasal http://www.ncbi.nlm.nih.gov/pubmed/24607046 formulation of azelastine hydrochloride and propionate in AZELASTINE an advanced delivery system) in subjects with chronic rhinitis. Clinically relevant effect of a new intranasal therapy (MP29-02) in http://www.ncbi.nlm.nih.gov/pubmed/23652808 AZELASTINE allergic rhinitis assessed by responder analysis. Intranasal phototherapy versus azelastine in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/23228884 AZELASTINE seasonal allergic rhinitis.

Efficacy and safety of azelastine 0.15% nasal spray administered http://www.ncbi.nlm.nih.gov/pubmed/22287431 AZELASTINE once daily in patients with allergy to Texas mountain cedar pollen.

A multicenter randomized double-blind 2-week comparison study of http://www.ncbi.nlm.nih.gov/pubmed/21832863 azelastine nasal spray 0.1% versus levocabastine nasal spray 0.05% AZELASTINE in patients with moderate-to-severe allergic rhinitis. A role for the intranasal formulation of azelastine hydrochloride/ in the treatment of allergic http://www.ncbi.nlm.nih.gov/pubmed/25913181 AZELASTINE rhinitis Azithromycin 1.5% ophthalmic solution: efficacy and treatment http://www.ncbi.nlm.nih.gov/pubmed/22872200 AZITHROMYCIN modalities in chronic blepharitis. Clinical and microbiologic effects of subgingivally delivered 0.5% http://www.ncbi.nlm.nih.gov/pubmed/18980521 AZITHROMYCIN azithromycin in the treatment of chronic periodontitis. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops http://www.ncbi.nlm.nih.gov/pubmed/18203079 AZITHROMYCIN (T1225) in healthy volunteers. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% http://www.ncbi.nlm.nih.gov/pubmed/22157392 AZITHROMYCIN in the treatment of contact lens-related dry eye. A topical azithromycin preparation for the treatment of acne vulgaris http://www.ncbi.nlm.nih.gov/pubmed/15370397 AZITHROMYCIN and rosacea. Microbiological efficacy of 3-day treatment with azithromycin 1.5% http://www.ncbi.nlm.nih.gov/pubmed/18988154 AZITHROMYCIN eye-drops for purulent bacterial conjunctivitis. Medication Title of Article PubMed Link Efficacy and safety of azithromycin 1.5% eye drops in paediatric http://www.ncbi.nlm.nih.gov/pubmed/24526744 AZITHROMYCIN population with purulent bacterial conjunctivitis

A comparison of azithromycin and tobramycin eye drops on epithelial http://www.ncbi.nlm.nih.gov/pubmed/22420841 AZITHROMYCIN wound healing and tolerance after penetrating keratoplasty Efficacy of azithromycin 1% ophthalmic solution for treatment of http://www.ncbi.nlm.nih.gov/pubmed/21083761 AZITHROMYCIN ocular surface disease from posterior blepharitis Topical azithromycin therapy for meibomian gland dysfunction: http://www.ncbi.nlm.nih.gov/pubmed/20489573 AZITHROMYCIN clinical response and lipid alterations Evaluation of effectiveness and tolerance of treatment with http://www.ncbi.nlm.nih.gov/pubmed/19517846 AZITHROMYCIN azithromycin 1.5% eye drops in bacterial conjunctivitis Assessment of efficacy of topical azithromycin 1.5 per cent ophthalmic solution for the treatment of meibomian gland https://www.ncbi.nlm.nih.gov/pubmed/28677153 AZITHROMYCIN dysfunction. Preventing Long-Term Ocular Complications of Trachoma With https://www.ncbi.nlm.nih.gov/pubmed/28161923 AZITHROMYCIN Topical Azithromycin: A 3-Year Follow-up Study. Topical azithromycin for the prevention of Lyme borreliosis: a https://www.ncbi.nlm.nih.gov/pubmed/28007428 AZITHROMYCIN randomised, placebo-controlled, phase 3 efficacy trial. Comparison of therapeutic effects of topical azithromycin solution https://www.ncbi.nlm.nih.gov/pubmed/27500111 AZITHROMYCIN and systemic doxycycline on posterior blepharitis. Comparison effect of azithromycin gel 2% with gel 1% in https://www.ncbi.nlm.nih.gov/pubmed/27169103 AZITHROMYCIN patients with acne. Topical liposomal azithromycin in the treatment of acute cutaneous https://www.ncbi.nlm.nih.gov/pubmed/27073044 AZITHROMYCIN leishmaniasis.

Nebulized /colimycin: a treatment option in recalcitrant BACITRACIN https://www.ncbi.nlm.nih.gov/pubmed/18575008 chronic rhinosinusitis with Staphylococcus aureus? A double-blind, randomized, placebo-controlled, cross-over pilot study Bacitracin versus mupirocin for Staphylococcus aureus nasal BACITRACIN https://www.ncbi.nlm.nih.gov/pubmed/10349956 colonization Unilateral balsalazide-induced eosinophilic pneumonia in an https://pubmed.ncbi.nlm.nih.gov/21127763 BALSALAZIDE ulcerative colitis patient. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of https://pubmed.ncbi.nlm.nih.gov/19743890 BALSALAZIDE active ulcerative colitis. [Review] [31 refs] Medication Title of Article PubMed Link Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a https://pubmed.ncbi.nlm.nih.gov/19633577 BALSALAZIDE randomized, double-blind study. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta- https://pubmed.ncbi.nlm.nih.gov/18683049 BALSALAZIDE analysis. [Review] [26 refs] Balsalazide disodium for the treatment of ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/19072352 BALSALAZIDE [46 refs]

Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in https://pubmed.ncbi.nlm.nih.gov/18806701 the treatment of acute mild-to-moderate ulcerative colitis and BALSALAZIDE uncomplicated diverticulitis of the colon. [Review] [38 refs] A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in https://pubmed.ncbi.nlm.nih.gov/17117598 BALSALAZIDE the treatment of ulcerative colitis. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment https://pubmed.ncbi.nlm.nih.gov/15507864 BALSALAZIDE of acute mild-to-moderate ulcerative colitis. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational https://pubmed.ncbi.nlm.nih.gov/14871283 BALSALAZIDE study. Treatment of ulcerative colitis with balsalazide: response to Drs https://pubmed.ncbi.nlm.nih.gov/12650813 BALSALAZIDE Johnson, Green, and Pruitt. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. https://pubmed.ncbi.nlm.nih.gov/12526969 BALSALAZIDE Hanauer.

Balsalazide is superior to mesalamine in the time to improvement of https://pubmed.ncbi.nlm.nih.gov/12492193 BALSALAZIDE signs and symptoms of acute mild-to-moderate ulcerative colitis. Balsalazide: a review of its therapeutic use in mild-to-moderate https://pubmed.ncbi.nlm.nih.gov/12109930 BALSALAZIDE ulcerative colitis. [Review] [48 refs] A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in https://pubmed.ncbi.nlm.nih.gov/12094857 BALSALAZIDE the treatment of active, mild-to-moderate ulcerative colitis. Medication Title of Article PubMed Link

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, https://pubmed.ncbi.nlm.nih.gov/11856080 BALSALAZIDE 3 g, as sole therapy in the management of ulcerative colitis. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed https://pubmed.ncbi.nlm.nih.gov/11856079 BALSALAZIDE active ulcerative colitis.

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three https://pubmed.ncbi.nlm.nih.gov/11709512 times daily) maintained remission of ulcerative colitis but high dose BALSALAZIDE balsalazide (3.0 g twice daily) was superior in preventing relapses. Review article: balsalazide therapy in ulcerative colitis. [Review] [32 https://pubmed.ncbi.nlm.nih.gov/11563993 BALSALAZIDE refs] Balsalazide led to greater remission rates and tolerance than https://pubmed.ncbi.nlm.nih.gov/10075949 BALSALAZIDE mesalamine in acute ulcerative colitis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2680023 BARICITINIB A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. http://www.pccarx.com/about-pcca/pcca- BASE - LIPODERM® Technical Report: PCCA Lipoderm® and studies/studies/item/166-pcca-lipoderm-and- ACTIVEMAX™ Study lorazepam-transdermal-study http://www.pccarx.com/about-pcca/pcca- news/item/106-lipoderm-transdermal-is-only-proven- BASE - LIPODERM® Lipoderm® Transdermal Is Only Proven Base To Deliver Up to Four base-to-deliver-up-to-four--at-once ACTIVEMAX™ Medications At Once Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon http://www.ncbi.nlm.nih.gov/pubmed/9850360 beclomethasone dipropionate at approximately half the total daily BECLOMETHASONE dose Beclomethasone dipropionate nasal aerosol spray in allergic rhinitis: http://www.ncbi.nlm.nih.gov/pubmed/4073600 BECLOMETHASONE a comparison of three delivery systems Importance of system in steroid aerosol therapy via http://www.ncbi.nlm.nih.gov/pubmed/12406667 BECLOMETHASONE Comparison of furoate administered by metered dose http://www.ncbi.nlm.nih.gov/pubmed/12166539 BECLOMETHASONE with beclomethasone dipropionate Medication Title of Article PubMed Link

Comparison of the effect on bronchial hyperresponsiveness of http://www.ncbi.nlm.nih.gov/pubmed/10867599 beclomethasone dipropionate administered via a novel multidose dry- BECLOMETHASONE inhaler or a conventional pressurised metered dose inhaler

Efficacy and maintenance strategies of two-compound formulation http://www.ncbi.nlm.nih.gov/pubmed/23621170 calcipotriol and dipropionate gel (Xamiol® gel) in the BETAMETHASONE treatment of scalp psoriasis: results from a study in 885 patients. An Open Label Prospective Randomized Trial to Compare the Efficacy of Coal Tar-Salicylic Acid Ointment Versus http://www.ncbi.nlm.nih.gov/pubmed/25484388 Calcipotriol/Betamethasone Dipropionate Ointment in the Treatment BETAMETHASONE of Limited Chronic Plaque Psoriasis. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate http://www.ncbi.nlm.nih.gov/pubmed/25346093 psoriasis: blinded interim analysis of a phase IV, multicenter, BETAMETHASONE randomized, controlled, prospective study. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: http://www.ncbi.nlm.nih.gov/pubmed/25307472 effectiveness, safety and influence on children's quality of life in daily BETAMETHASONE practice. Comparative efficacy of methotrexate and mini pulse betamethasone http://www.ncbi.nlm.nih.gov/pubmed/24292313 BETAMETHASONE in the treatment of . BETAMETHASONE Topical betamethasone for prevention of radiation dermatitis. http://www.ncbi.nlm.nih.gov/pubmed/17561562 Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a http://www.ncbi.nlm.nih.gov/pubmed/19456797 BETAMETHASONE double-blind, randomized pilot study. The DESIRE study--psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and http://www.ncbi.nlm.nih.gov/pubmed/19726275 BETAMETHASONE betamethasone dipropionate in daily clinical practice. A potent steroid cream is superior to emollients in reducing acute radiation dermatitis in breast cancer patients treated with adjuvant http://www.ncbi.nlm.nih.gov/pubmed/23827771 radiotherapy. A randomised study of betamethasone versus two BETAMETHASONE moisturizing creams. Medication Title of Article PubMed Link Topical betamethasone and hyaluronidase in the treatment of phimosis in boys: a double-blind, randomized, placebo-controlled http://www.ncbi.nlm.nih.gov/pubmed/21756378 BETAMETHASONE trial. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical in the treatment of extensive scalp psoriasis in http://www.ncbi.nlm.nih.gov/pubmed/25412565 BETAMETHASONE adolescents ages 12 to 17 years Topical calcipotriol/betamethasone dipropionate for psoriasis http://www.ncbi.nlm.nih.gov/pubmed/26858069 BETAMETHASONE vulgaris: A systematic review Development and validation of an UHPLC method for the determination of in cream, gel, ointment and http://www.ncbi.nlm.nih.gov/pubmed/26708266 BETAMETHASONE Intralesional Acetonide Versus Topical Betamethasone Valearate in the Management of Localized Alopecia http://www.ncbi.nlm.nih.gov/pubmed/26691357 BETAMETHASONE Areata

Efficacy of topical azathioprine and betamethasone versus http://www.ncbi.nlm.nih.gov/pubmed/26623403 betamethasone-only emollient cream in 2-18 years old patients with BETAMETHASONE moderate-to-severe atopic dermatitis: A randomized controlled trial Corticosteroid nasal irrigations after endoscopic sinus surgery in the http://www.ncbi.nlm.nih.gov/pubmed/22566474 BETAMETHASONE management of chronic rhinosinusitis. A prospective randomized study to assess the efficacy of post- http://www.ncbi.nlm.nih.gov/pubmed/7561468 BETAMETHASONE operative nasal medication after endonasal surgery. A prospective treatment trial of nasal polyps in adults with cystic http://www.ncbi.nlm.nih.gov/pubmed/10953842 BETAMETHASONE fibrosis.

A randomized double-blind study to compare the effects of nasal http://www.ncbi.nlm.nih.gov/pubmed/12472517 fluticasone and betamethasone on the hypothalamo-pituitary-adrenal BETAMETHASONE axis and bone turnover in patients with nasal polyposis. A prospective randomized blinded cross-over trial using nasal drops in patients with nasal polyposis: an evaluation of effectiveness and http://www.ncbi.nlm.nih.gov/pubmed/16955767 BETAMETHASONE comfort level of two head positions. Topical nasal steroids for treating nasal polyposis in people with http://www.ncbi.nlm.nih.gov/pubmed/26098667 BETAMETHASONE cystic fibrosis Medication Title of Article PubMed Link

BETAMETHASONE Epidermal cytokeratin and immunocyte responses during treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1373949 of psoriasis with calcipotriol and betamethasone valerate.

Double-blind, right/left comparison of calcipotriol and betamethasone BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=1670840 valerate in treatment of psoriasis vulgaris.[Erratum appears in Lancet 1991 Apr 20;337(8747):988] BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=1673003 Calcipotriol and betamethasone valerate for psoriasis. Intermittent corticosteroid maintenance treatment of psoriasis: a BETAMETHASONE double-blind multicenter trial of augmented betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1809589 dipropionate ointment in a pulse dose treatment regimen. Liposome encapsulation improves efficacy of betamethasone BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=2076716 dipropionate in atopic eczema but not in psoriasis vulgaris. Therapeutic response to a dermatologic patch and betamethasone BETAMETHASONE valerate 0.1 percent cream in the management of chronic plaques in https://www.ncbi.nlm.nih.gov/pubmed/?term=2190758 psoriasis. 0.05 percent betamethasone dipropionate in optimized cream vehicle BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=2649319 for psoriasis. A controlled clinical trial of a new formulation of betamethasone BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=2692821 dipropionate cream in once-daily treatment of psoriasis. Efficacy and safety of twice-daily augmented betamethasone BETAMETHASONE dipropionate lotion versus propionate solution in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=7585843 with moderate-to-severe scalp psoriasis. Comparative effects of calcipotriol solution (50 micrograms/ml) and BETAMETHASONE betamethasone 17-valerate solution (1 mg/ml) in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=7999600 scalp psoriasis. diacetate ointment 0.05% versus betamethasone BETAMETHASONE dipropionate ointment 0.05% in moderate-severe plaque-type https://www.ncbi.nlm.nih.gov/pubmed/?term=8428041 psoriasis. Topical 0.05% betamethasone dipropionate: efficacy in psoriasis with BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=8547019 once a day vs. twice a day application. Comparison of fluticasone propionate ointment, 0.005%, and BETAMETHASONE betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=8646866 of psoriasis. Medication Title of Article PubMed Link Comparison of safety and efficacy of fluticasone propionate cream, BETAMETHASONE 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=8646870 moderate-to-severe psoriasis.

Epidermal cell DNA content and intermediate filaments keratin 10 BETAMETHASONE and vimentin after treatment of psoriasis with calcipotriol cream once https://www.ncbi.nlm.nih.gov/pubmed/?term=8949429 daily, twice daily and in combination with 17-butyrate cream or betamethasone 17-valerate cream: a comparat Augmented betamethasone: efficacy in psoriasis with different dosing BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=8961896 frequencies. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=9039301 psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Calcipotriol in psoriasis vulgaris: a controlled trial comparing BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=9268756 betamethasone dipropionate + salicylic acid. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with BETAMETHASONE https://www.ncbi.nlm.nih.gov/pubmed/?term=9602870 calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study.

BETAMETHASONE Calcipotriol ointment in nail psoriasis: a controlled double-blind https://www.ncbi.nlm.nih.gov/pubmed/?term=9892909 comparison with betamethasone dipropionate and salicylic acid. Double-blind clinical study reveals synergistic action between alpha- https://www.ncbi.nlm.nih.gov/pubmed/?term=1087724 BETAMETHASONE hydroxy acid and betamethasone towards topical treatment of 5 scalp psoriasis. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. https://www.ncbi.nlm.nih.gov/pubmed/?term=1131424 BETAMETHASONE betamethasone valerate 1% lotion. 0 Treatment of psoriasis with a new combination of calcipotriol and https://www.ncbi.nlm.nih.gov/pubmed/?term=1158601 BETAMETHASONE betamethasone dipropionate: a flow cytometric study. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1190784 BETAMETHASONE Betamethasone valerate foam for treatment of nonscalp psoriasis. 0 Betamethasone valerate in foam vehicle is effective with both daily https://www.ncbi.nlm.nih.gov/pubmed/?term=1190784 BETAMETHASONE and twice a day dosing: a single-blind, open-label study in the 7 treatment of scalp psoriasis. Medication Title of Article PubMed Link A new calcipotriol/betamethasone formulation with rapid onset of https://www.ncbi.nlm.nih.gov/pubmed/?term=1212594 BETAMETHASONE action was superior to monotherapy with betamethasone 3 dipropionate or calcipotriol in psoriasis vulgaris. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to https://www.ncbi.nlm.nih.gov/pubmed/?term=1217410 BETAMETHASONE calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a 5 randomized, double-blind, vehicle-controlled clinical trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=1222397 BETAMETHASONE Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a 6 new formulation for the treatment of psoriasis. [Review] [21 refs]

Efficacy of betamethasone valerate mousse in comparison with https://www.ncbi.nlm.nih.gov/pubmed/?term=1253460 BETAMETHASONE standard therapies on scalp psoriasis: an open, multicentre, 7 randomized, controlled, cross-over study on 241 patients. Once daily application of a combination of calcipotriol and https://www.ncbi.nlm.nih.gov/pubmed/?term=1496117 BETAMETHASONE betamethasone dipropionate (Dovobet, Daivobet) for the treatment of 3 psoriasis.

The effect of the combination of calcipotriol and betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1500910 BETAMETHASONE dipropionate versus both monotherapies on epidermal proliferation, 4 keratinization and T-cell subsets in chronic plaque psoriasis.

The impact of a two-compound product containing calcipotriol and https://www.ncbi.nlm.nih.gov/pubmed/?term=1537735 BETAMETHASONE betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life 5 in patients with psoriasis vulgaris: a randomized controlled trial.

Efficacy of treatment with calcipotriol/betamethasone dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=1553989 BETAMETHASONE followed by calcipotriol alone compared with tacalcitol for the 4 treatment of psoriasis vulgaris: a randomised, double-blind trial. Calcipotriol/betamethasone dipropionate: a review of its use in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1566334 BETAMETHASONE treatment of psoriasis vulgaris. 4 Efficacy and local safety of a calcipotriol/ betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1570159 BETAMETHASONE dipropionate ointment in elderly patients with psoriasis vulgaris. 1 Medication Title of Article PubMed Link

A two-compound product containing calcipotriol and betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1594221 BETAMETHASONE dipropionate provides rapid, effective treatment of psoriasis vulgaris 5 regardless of baseline disease severity. [Review] [15 refs] https://www.ncbi.nlm.nih.gov/pubmed/?term=1640263 BETAMETHASONE Treatment of guttate psoriasis with a new two-compound product 2 containing calcipotriol and betamethasone dipropionate. Consistency of data in six phase III clinical studies of a two- https://www.ncbi.nlm.nih.gov/pubmed/?term=1640560 BETAMETHASONE compound product containing calcipotriol and betamethasone 6 dipropionate ointment for the treatment of psoriasis. Calcipotriol-betamethasone ointment versus calcipotriol ointment in https://www.ncbi.nlm.nih.gov/pubmed/?term=1642597 BETAMETHASONE the treatment of psoriasis vulgaris. 3 A new formulation of an occlusive containing https://www.ncbi.nlm.nih.gov/pubmed/?term=1644162 BETAMETHASONE betamethasone valerate 0.1% in the treatment of mild to moderate 2 psoriasis. Calcipotriol/betamethasone dipropionate for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1655357 BETAMETHASONE psoriasis. [Review] [94 refs] 5

A 52-week randomized safety study of a calcipotriol/betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1670464 BETAMETHASONE dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in 8 the treatment of psoriasis vulgaris.

Efficacy results of a 52-week, randomised, double-blind, safety study https://www.ncbi.nlm.nih.gov/pubmed/?term=1713573 BETAMETHASONE of a calcipotriol/betamethasone dipropionate two-compound product 8 (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Treatment of psoriasis vulgaris with the two-compound product https://www.ncbi.nlm.nih.gov/pubmed/?term=1716325 BETAMETHASONE calcipotriol/betamethasone dipropionate followed by different 6 formulations of calcipotriol. Treatment of scalp psoriasis with betamethasone dipropionate and https://www.ncbi.nlm.nih.gov/pubmed/?term=1722502 BETAMETHASONE calcipotriol two-compound product. 6

Pulsed dye laser versus treatment with calcipotriol/betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1736526 BETAMETHASONE dipropionate for localized refractory plaque psoriasis: effects on T- 5 cell infiltration, epidermal proliferation and keratinization. Medication Title of Article PubMed Link Calcipotriol and betamethasone dipropionate for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1755166 BETAMETHASONE psoriasis: a 52-week study. 2

Efficacy, safety and quality of life of calcipotriol/betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1793493 BETAMETHASONE dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment 7 of psoriasis vulgaris: a randomized, multicentre, clinical trial. Calcipotriol plus betamethasone dipropionate scalp formulation is https://www.ncbi.nlm.nih.gov/pubmed/?term=1846344 BETAMETHASONE effective and well tolerated in the treatment of scalp psoriasis: a 8 phase II study. Calcipotriol used as monotherapy or combination therapy with https://www.ncbi.nlm.nih.gov/pubmed/?term=1848093 BETAMETHASONE betamethasone dipropionate in the treatment of nail psoriasis. 3 A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same https://www.ncbi.nlm.nih.gov/pubmed/?term=1906770 BETAMETHASONE vehicle for the treatment of scalp psoriasis: a randomized, double- 9 blind, controlled trial. Treatment of nail psoriasis with a two-compound formulation of https://www.ncbi.nlm.nih.gov/pubmed/?term=1921211 BETAMETHASONE calcipotriol plus betamethasone dipropionate ointment. 0

Efficacy and safety of calcipotriol plus betamethasone dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=1941625 BETAMETHASONE scalp formulation compared with calcipotriol scalp solution in the 9 treatment of scalp psoriasis: a randomized controlled trial. Quality of life in patients with scalp psoriasis treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1945381 BETAMETHASONE calcipotriol/betamethasone dipropionate scalp formulation: a 0 randomized controlled trial. Generalized pustular psoriasis (von Zumbusch) following the use of https://www.ncbi.nlm.nih.gov/pubmed/?term=1950856 BETAMETHASONE calcipotriol and betamethasone dipropionate ointment: a report of two 5 cases. Treatments for scalp psoriasis with emphasis on calcipotriol plus https://www.ncbi.nlm.nih.gov/pubmed/?term=1958505 BETAMETHASONE betamethasone dipropionate gel (Xamiol). 9 Treatment of plaque psoriasis with the two-compound product https://www.ncbi.nlm.nih.gov/pubmed/?term=2005569 BETAMETHASONE calcipotriol/betamethasone dipropionate versus both monotherapies: 4 an immunohistochemical study. Iatrogenic adrenal insufficiency associated with calcipotriol- https://www.ncbi.nlm.nih.gov/pubmed/?term=2008908 BETAMETHASONE betamethasone topical combination in psoriasis. 3 Medication Title of Article PubMed Link The remarkable beneficial effect of adding oral simvastatin to topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2023275 BETAMETHASONE betamethasone for treatment of psoriasis: a double-blind, 8 randomized, placebo-controlled study.

Mixed treatment comparison of a two-compound formulation (TCF) https://www.ncbi.nlm.nih.gov/pubmed/?term=2114283 BETAMETHASONE product containing calcipotriol and betamethasone dipropionate with 3 other topical treatments in psoriasis vulgaris. [Review] The two-compound formulation of calcipotriol and betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=2114283 BETAMETHASONE dipropionate for treatment of moderately severe body and scalp 4 psoriasis - an introduction. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately https://www.ncbi.nlm.nih.gov/pubmed/?term=2114283 BETAMETHASONE severe scalp psoriasis: a systematic review of direct and indirect 8 evidence. [Review] Efficacy and safety of the Betamethasone valerate 0.1% plaster in https://www.ncbi.nlm.nih.gov/pubmed/?term=2128440 BETAMETHASONE mild-to-moderate chronic plaque psoriasis: a randomized, parallel- 7 group, active-controlled, phase III study. Calcipotriol plus betamethasone dipropionate gel compared with https://www.ncbi.nlm.nih.gov/pubmed/?term=2129310 BETAMETHASONE tacalcitol ointment and the gel vehicle alone in patients with psoriasis 7 vulgaris: a randomized, controlled clinical trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=2150424 BETAMETHASONE Calcipotriol/betamethasone dipropionate: a review of its use in the 8 treatment of psoriasis vulgaris of the trunk, limbs and scalp. [Review] Effective treatment and improvement of quality of life in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2156454 BETAMETHASONE scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol- 0 gel): results. https://www.ncbi.nlm.nih.gov/pubmed/?term=2210360 BETAMETHASONE Use of a psoriasis plaque test in the development of a gel formulation 4 of calcipotriol and betamethasone dipropionate for scalp psoriasis. Consensus on the use of the fixed combination https://www.ncbi.nlm.nih.gov/pubmed/?term=2314970 BETAMETHASONE calcipotriol/betamethasone dipropionate in the treatment of plaque 7 psoriasis. Medication Title of Article PubMed Link

Efficacy and maintenance strategies of two-compound formulation https://www.ncbi.nlm.nih.gov/pubmed/?term=2362117 BETAMETHASONE calcipotriol and betamethasone dipropionate gel (Xamiol gel) in the 0 treatment of scalp psoriasis: results from a study in 885 patients. Betamethasone valerate dressing is non-inferior to calcipotriol- betamethasone dipropionate ointment in the treatment of patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2425646 BETAMETHASONE with mild-to-moderate chronic plaque psoriasis: results of a 0 randomized assessor-blinded multicentre trial.

Real-life effectiveness of once-daily calcipotriol and betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=2453350 BETAMETHASONE dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- 3 and 12-week interim results from the PRO-long study. Calcipotriol/betamethasone dipropionate ointment in mild-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2459312 BETAMETHASONE moderate paediatric psoriasis: long-term daily clinical practice data in 9 a prospective cohort. https://www.ncbi.nlm.nih.gov/pubmed/?term=2468473 BETAMETHASONE Pooled safety analysis of calcipotriol plus betamethasone 9 dipropionate gel for the treatment of psoriasis on the body and scalp. Expert recommendations: the use of the fixed combination https://www.ncbi.nlm.nih.gov/pubmed/?term=2468474 BETAMETHASONE calcipotriol and betamethasone dipropionate gel for the topical 0 treatment of psoriasis. [Review] Safety and efficacy of calcipotriol plus betamethasone dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=2498027 BETAMETHASONE gel in the treatment of scalp psoriasis in adolescents 12-17 years of 7 age. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study https://www.ncbi.nlm.nih.gov/pubmed/?term=2505216 BETAMETHASONE protocol for a randomized controlled trial.[Erratum appears in Trials. 1 2016;17:357; PMID: 27460232] https://www.ncbi.nlm.nih.gov/pubmed/?term=2510939 BETAMETHASONE Alternative treatment with calcipotriol plus betamethasone 5 dipropionate gel in psoriasis vulgaris using a short-contact approach. A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when https://www.ncbi.nlm.nih.gov/pubmed/?term=2511696 BETAMETHASONE compared to betamethasone diproprionate ointment (64 mg/g) in 7 patients with nail psoriasis. Medication Title of Article PubMed Link Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate https://www.ncbi.nlm.nih.gov/pubmed/?term=2534609 BETAMETHASONE psoriasis: blinded interim analysis of a phase IV, multicenter, 3 randomized, controlled, prospective study. Efficacy of an innovative aerosol foam formulation of fixed https://www.ncbi.nlm.nih.gov/pubmed/?term=2570853 BETAMETHASONE combination calcipotriol plus betamethasone dipropionate in patients 1 with psoriasis vulgaris. A Novel Aerosol Foam Formulation of Calcipotriol and https://www.ncbi.nlm.nih.gov/pubmed/?term=2622473 BETAMETHASONE Betamethasone Has No Impact on HPA Axis and Calcium 3 Homeostasis in Patients With Extensive Psoriasis Vulgaris.

Real-life effectiveness of once-daily calcipotriol and betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=2633706 BETAMETHASONE dipropionate gel vs. ointment formulations in psoriasis vulgaris: final 9 analysis of the 52-week PRO-long study. Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone https://www.ncbi.nlm.nih.gov/pubmed/?term=2650382 BETAMETHASONE versus calcipotriol/betamethasone gel in daily clinical 4 practice. Calcipotriol and betamethasone dipropionate exert additive inhibitory https://www.ncbi.nlm.nih.gov/pubmed/?term=2679480 BETAMETHASONE effects on the cytokine expression of inflammatory dendritic cell-Th17 5 cell axis in psoriasis. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented https://www.ncbi.nlm.nih.gov/pubmed/?term=2688578 BETAMETHASONE Betamethasone Dipropionate 0.05% Lotion for the Treatment of 2 Moderate Plaque Psoriasis. Topical calcipotriol/betamethasone dipropionate for psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2692440 BETAMETHASONE vulgaris: A systematic review. [Review] 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2695431 BETAMETHASONE Improvement in Extensive Moderate Plaque Psoriasis With a Novel 9 Emollient Spray Formulation of Betamethasone Dipropionate 0.05. Effective treatment of severe nail psoriasis using topical calcipotriol https://www.ncbi.nlm.nih.gov/pubmed/?term=2708895 BETAMETHASONE with betamethasone dipropionate gel. 2 Medication Title of Article PubMed Link

Enhanced vasoconstrictor potency of the fixed combination https://www.ncbi.nlm.nih.gov/pubmed/?term=2730658 BETAMETHASONE calcipotriol plus betamethasone dipropionate in an innovative aerosol 9 foam formulation vs. other corticosteroid psoriasis treatments. Calcipotriol plus betamethasone dipropionate aerosol foam provides https://www.ncbi.nlm.nih.gov/pubmed/?term=2753175 BETAMETHASONE superior efficacy vs. gel in patients with psoriasis vulgaris: 2 randomized, controlled PSO-ABLE study. Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2766324 BETAMETHASONE Psoriasis. [Review] 5 Fixed combination calcipotriol plus betamethasone dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=2793697 BETAMETHASONE aerosol foam in the treatment of psoriasis vulgaris: rationale for 2 development and clinical profile. [Review] DFD-01: a novel topical formulation of betamethasone dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=2796726 BETAMETHASONE for the treatment of extensive psoriasis. [Review] 2 Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=2799552 BETAMETHASONE Aerosol Foam Compared with Betamethasone 17-Valerate- 1 Medicated Plaster for the Treatment of Psoriasis. Treatment of nail psoriasis with Pulse Dye Laser plus calcipotriol https://www.ncbi.nlm.nih.gov/pubmed/?term=2811892 BETAMETHASONE betametasona gel vs. Nd:YAG plus calcipotriol betamethasone gel: 6 An intrapatient left-to-right controlled study. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of https://www.ncbi.nlm.nih.gov/pubmed/?term=2823622 BETAMETHASONE the PSO-ABLE Study.[Erratum appears in Am J Clin Dermatol. 2017 3 May 24;:; PMID: 28540589] A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2830104 BETAMETHASONE results of a 64-week multinational randomized phase IV study in 3 1790 patients (PSO-TOP). Atorvastatin as adjunctive therapy for chronic plaque type psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2854087 BETAMETHASONE versus betamethasone valerate alone: A randomized, double-blind, 0 placebo-controlled trial. Low systemic exposure and calcemic effect of https://www.ncbi.nlm.nih.gov/pubmed/?term=2947687 BETAMETHASONE calcipotriol/betamethasone ointment in rats with -induced 8 psoriasis-like dermatitis. Medication Title of Article PubMed Link BETAMETHASONE, Topical therapy for psoriasis with the use of augmented https://www.ncbi.nlm.nih.gov/pubmed/?term=1086322 CALCIPOTRIENE betamethasone and calcipotriene on alternate weeks. 5 BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1252237 Early onset of action and efficacy of a combination of calcipotriene CALCIPOTRIENE 0 and betamethasone dipropionate in the treatment of psoriasis. Use of calcipotriene cream (Dovonex cream) following acute BETAMETHASONE, treatment of psoriasis vulgaris with the calcipotriene/betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1673450 CALCIPOTRIENE dipropionate two-compound product (Taclonex): a randomized, 5 parallel-group clinical trial. BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1684102 CALCIPOTRIENE A betamethasone-calcipotriene combination for psoriasis. 3

BETAMETHASONE, A new scalp formulation of calcipotriene plus betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1869467 CALCIPOTRIENE compared with its active ingredients and the vehicle in the treatment 8 of scalp psoriasis: a randomized, double-blind, controlled trial. Comparing 0.05% spray to calcipotriene BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1918089 0.005% betamethasone dipropionate 0.064% ointment for the CALCIPOTRIENE 6 treatment of moderate to severe plaque psoriasis. BETAMETHASONE, Calcipotriene/betamethasone in the treatment of psoriasis: a review https://www.ncbi.nlm.nih.gov/pubmed/?term=1966363 CALCIPOTRIENE article. [Review] [51 refs] 4 Short- and long-term safety assessment of a two-compound ointment BETAMETHASONE, containing calcipotriene/betamethasone dipropionate https://www.ncbi.nlm.nih.gov/pubmed/?term=2068414 CALCIPOTRIENE (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary- 7 adrenal axis function in patients with psoriasis vulgaris. A calcipotriene/betamethasone dipropionate two-compound scalp BETAMETHASONE, formulation in the treatment of scalp psoriasis in Hispanic/Latino and https://www.ncbi.nlm.nih.gov/pubmed/?term=2096466 CALCIPOTRIENE Black/African American patients: results of the randomized, 8-week, 0 double-blind phase of a clinical trial. BETAMETHASONE, Spotlight on calcipotriene/betamethasone dipropionate in psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2196711 CALCIPOTRIENE vulgaris of the trunk, limbs, and scalp. [Review] 7

BETAMETHASONE, Calcipotriene plus betamethasone dipropionate topical suspension https://www.ncbi.nlm.nih.gov/pubmed/?term=2337733 CALCIPOTRIENE for the treatment of mild to moderate psoriasis vulgaris on the body: 4 a randomized, double-blind, vehicle-controlled trial. Medication Title of Article PubMed Link Effect of calcipotriene plus betamethasone dipropionate topical BETAMETHASONE, suspension on the hypothalamic-pituitary-adrenal axis and calcium https://www.ncbi.nlm.nih.gov/pubmed/?term=2398616 CALCIPOTRIENE homeostasis in subjects with extensive psoriasis vulgaris: an open, 1 non-controlled, 8-week trial. Using a single product (calcipotriene/betamethasone topical BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2406335 suspension) vs multiple products to manage body and scalp CALCIPOTRIENE 2 psoriasis: comparisons in resource utilization and costs. Calcipotriene-betamethasone dipropionate topical suspension in the BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2527947 management of psoriasis: a status report on available data with an CALCIPOTRIENE 4 overview of practical clinical application. Treatment of paediatric scalp psoriasis with BETAMETHASONE, calcipotriene/betamethasone dipropionate scalp formulation: https://www.ncbi.nlm.nih.gov/pubmed/?term=2530747 CALCIPOTRIENE effectiveness, safety and influence on children's quality of life in daily 2 practice. Safety and efficacy of calcipotriene plus betamethasone dipropionate BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2541256 topical suspension in the treatment of extensive scalp psoriasis in CALCIPOTRIENE 5 adolescents ages 12 to 17 years. Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2556657 versus topical suspension in the treatment of plaque psoriasis: a CALCIPOTRIENE 3 randomized pilot study of patient preference. BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2560770 Real-life treatment profile of calcipotriene and betamethasone CALCIPOTRIENE 5 dipropionate topical suspension in patients with psoriasis vulgaris. Superior efficacy of calcipotriene and betamethasone dipropionate BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2644490 aerosol foam versus ointment in patients with psoriasis vulgaris--A CALCIPOTRIENE 7 randomized phase II study. Efficacy and Safety of Calcipotriene Plus Betamethasone BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2665994 Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a CALCIPOTRIENE 1 Randomized Phase III Study (PSO-FAST). BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2704950 CALCIPOTRIENE Calcipotriene/betamethasone foam (Enstilar) for psoriasis. 9 BETAMETHASONE, Calcipotriene and betamethasone dipropionate for the topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2708990 CALCIPOTRIENE treatment of plaque psoriasis. [Review] 6 Medication Title of Article PubMed Link Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus BETAMETHASONE, Betamethasone Dipropionate is Highly Efficacious in Patients With https://www.ncbi.nlm.nih.gov/pubmed/?term=2753799 CALCIPOTRIENE Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled 5 Studies. The Aerosol Foam Formulation of the Fixed Combination BETAMETHASONE, Calcipotriene Plus Betamethasone Dipropionate Improves the Health- https://www.ncbi.nlm.nih.gov/pubmed/?term=2753799 CALCIPOTRIENE Related Quality of Life in Patients With Psoriasis Vulgaris: Results 9 from the Randomized PSO-FAST Study. Budget impact model in moderate-to-severe psoriasis vulgaris BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2858187 assessing effects of calcipotriene and betamethasone dipropionate CALCIPOTRIENE 3 foam on per-patient standard of care costs. BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2865901 Calcipotriene betamethasone dipropionate aerosol foam in the CALCIPOTRIENE 6 treatment of plaque psoriasis: a review of the literature. [Review] A Comparative Study to Evaluate Epidermal Barrier Integrity of BETAMETHASONE, Psoriasis Patients Treated With Calcipotriene/Betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=2880998 CALCIPOTRIENE Topical Suspension Versus Betamethasone Dipropionate 0.05% 9 Lotion. Topical calcipotriene 0.005% and betamethasone dipropionate BETAMETHASONE, 0.064% maintains efficacy of etanercept after step-down dose in https://www.ncbi.nlm.nih.gov/pubmed/?term=2181850 CALCIPOTRIENE, patients with moderate-to-severe plaque psoriasis: results of an open 9 ETANERCEPT label trial.

BETAMETHASONE, Combined treatment with low-dose cyclosporine and https://www.ncbi.nlm.nih.gov/pubmed/?term=2175615 CYCLOSPORINE calcipotriol/betamethasone dipropionate ointment for moderate-to- 3 severe plaque psoriasis: a randomized controlled open-label study. BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1785263 METHOTREXATE Methotrexate-betamethasone weekly oral pulse in psoriasis. 6 BETAMETHASONE, Comparison of betamethasone valerate solution with phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=9779265 PHOTOTHERAPY (UVB comb) in scalp psoriasis treatment. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1698300 the treatment of intertriginous psoriasis: a double-blind, randomized PIMECROLIMUS 1 controlled study. Medication Title of Article PubMed Link BETAMETHASONE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2277910 Exclusive plaque psoriasis of the lips: efficacy of combination therapy TACROLIMUS 3 of topical tacrolimus, calcipotriol, and betamethasone dipropionate. BETAMETHASONE, Tazarotene cream (0.1%) in combination with betamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1577678 TAZAROTENE valerate foam (0.12%) for plaque-type psoriasis. 4 http://www.ncbi.nlm.nih.gov/pubmed/20051659 BLEOMYCIN Intralesional pingyangmycin treatment for resistant plantar warts. Intralesional bleomycin in the treatment of cutaneous warts: a http://www.ncbi.nlm.nih.gov/pubmed/19439878 BLEOMYCIN randomized clinical trial comparing it with cryotherapy.

Compared therapeutic efficacy between intralesional bleomycin and http://www.ncbi.nlm.nih.gov/pubmed/18328198 BLEOMYCIN cryotherapy for common warts: a randomized clinical trial. Dermojet delivery of bleomycin for the treatment of recalcitrant http://www.ncbi.nlm.nih.gov/pubmed/16766336 BLEOMYCIN plantar warts. Intralesional bleomycin sulfate injection for the treatment of verruca http://www.ncbi.nlm.nih.gov/pubmed/16707633 BLEOMYCIN plantaris. Pulsed dye laser and intralesional bleomycin for treatment of http://www.ncbi.nlm.nih.gov/pubmed/11870793 BLEOMYCIN resistant viol hand warts. Dermatography with bleomycin as a new treatment for verrucae http://www.ncbi.nlm.nih.gov/pubmed/9109018 BLEOMYCIN vulgaris.

Intralesional injection of bleomycin sulphate into resistant warts in http://www.ncbi.nlm.nih.gov/pubmed/1711753 BLEOMYCIN renal transplant recipients versus non-transplant warty patients. Therapeutic evaluation for intralesional injection of bleomycin sulfate http://www.ncbi.nlm.nih.gov/pubmed/2454980 BLEOMYCIN in 143 resistant warts. http://www.ncbi.nlm.nih.gov/pubmed/2431013 BLEOMYCIN Reduced dose of bleomycin in the treatment of recalcitrant warts. Treatment of viral warts with pressure-sensitive adhesive tape http://www.ncbi.nlm.nih.gov/pubmed/2412498 BLEOMYCIN containing bleomycin sulfate. https://www.ncbi.nlm.nih.gov/pubmed/?term=2245541 BRODALUMAB Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. 2 Impact of brodalumab treatment on psoriasis symptoms and health- https://www.ncbi.nlm.nih.gov/pubmed/?term=2407985 BRODALUMAB related quality of life: use of a novel patient-reported outcome 2 measure, the Psoriasis Symptom Inventory. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2484634 BRODALUMAB Population pharmacokinetics of brodalumab in healthy adults and 7 adults with psoriasis from single and multiple dose studies. Safety and efficacy of brodalumab for psoriasis after 120 weeks of https://www.ncbi.nlm.nih.gov/pubmed/?term=2531309 BRODALUMAB treatment. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2555388 BRODALUMAB Efficacy and safety of brodalumab in subpopulations of patients with 9 difficult-to-treat moderate-to-severe plaque psoriasis. Use of brodalumab for the treatment of psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2591762 BRODALUMAB arthritis. [Review] 4 Brodalumab -an IL-17RA monoclonal antibody for psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2598581 BRODALUMAB psoriatic arthritis. [Review] 3 Phase 3 Studies Comparing Brodalumab with Ustekinumab in https://www.ncbi.nlm.nih.gov/pubmed/?term=2642272 BRODALUMAB Psoriasis. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2662707 BRODALUMAB Brodalumab versus ustekinumab in psoriasis. 5 Improvement in Psoriasis Signs and Symptoms Assessed by the https://www.ncbi.nlm.nih.gov/pubmed/?term=2677310 BRODALUMAB Psoriasis Symptom Inventory with Brodalumab Treatment in Patients 8 with Psoriatic Arthritis. A prospective phase III, randomized, double-blind, placebo-controlled https://www.ncbi.nlm.nih.gov/pubmed/?term=2691440 BRODALUMAB study of brodalumab in patients with moderate-to-severe plaque 6 psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2703766 BRODALUMAB Rebound pustular psoriasis after brodalumab discontinuation. 1 Efficacy and safety of brodalumab in patients with generalized https://www.ncbi.nlm.nih.gov/pubmed/?term=2710651 BRODALUMAB pustular psoriasis and psoriatic erythroderma: results from a 52- 0 week, open-label study. Brodalumab established as an effective interleukin-17 receptor https://www.ncbi.nlm.nih.gov/pubmed/?term=2753559 BRODALUMAB antagonist in psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2771876 BRODALUMAB Brodalumab for the treatment of psoriasis. [Review] 0 A Review of Brodalumab, an IL-17 Receptor Antagonist, for https://www.ncbi.nlm.nih.gov/pubmed/?term=2812209 BRODALUMAB Moderate-to-Severe Plaque Psoriasis. [Review] 2 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2819790 BRODALUMAB Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque 1 Psoriasis: A Systematic Review and Meta-Analysis. [Review] Pharmacokinetic drug evaluation of brodalumab for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2846054 BRODALUMAB psoriasis. [Review] 9 Early relapse of psoriasis after stopping brodalumab: a retrospective https://www.ncbi.nlm.nih.gov/pubmed/?term=2858570 BRODALUMAB cohort study in 77 patients. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2865000 BRODALUMAB Brodalumab: the first anti-IL-17 receptor agent for psoriasis. [Review] 1

Rapid onset of action in patients with moderate-to-severe psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2871108 BRODALUMAB treated with brodalumab: A pooled analysis of data from two phase 3 9 randomized clinical trials (AMAGINE-2 and AMAGINE-3). Spotlight on brodalumab in the treatment of moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2874409 BRODALUMAB plaque psoriasis: design, development, and potential place in 8 therapy. [Review] A review article on brodalumab in the treatment of moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2887978 BRODALUMAB severe plaque psoriasis. [Review] 9 Psychiatric adverse events during treatment with brodalumab: https://www.ncbi.nlm.nih.gov/pubmed/?term=2898595 BRODALUMAB Analysis of psoriasis clinical trials. [Review] 6 The comparative efficacy of brodalumab in patients with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2932354 BRODALUMAB severe psoriasis: a systematic literature review and network meta- 2 analysis. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2935771 BRODALUMAB The budget impact of brodalumab for the treatment of moderate-to- 3 severe plaque psoriasis on US commercial health plans. https://www.ncbi.nlm.nih.gov/pubmed/?term=2944768 BRODALUMAB In response to Lebwohl et al, "Psychiatric adverse events during 7 treatment with brodalumab: Analysis of psoriasis clinical trials". Reply to: "Psychiatric adverse events during treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=2944768 BRODALUMAB brodalumab: Analysis of psoriasis clinical trials". 8 Medication Title of Article PubMed Link BRODALUMAB, GUSELKUMAB, Systematic review of interleukin-12, interleukin-17, and interleukin-23 https://www.ncbi.nlm.nih.gov/pubmed/?term=2480070 IXEKIZUMAB, pathway inhibitors for the treatment of moderate-to-severe chronic 3 SECUKINUMAB, plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, TILDRAKIZUMAB guselkumab, secukinumab, ixekizumab, and brodalumab. [Rev BRODALUMAB, A systematic review and meta-analysis of the efficacy and safety of GUSELKUMAB, the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, https://www.ncbi.nlm.nih.gov/pubmed/?term=2953269 IXEKIZUMAB, secukinumab, ixekizumab, brodalumab, guselkumab and 3 SECUKINUMAB, tildrakizumab for the treatment of moderate to severe plaque TILDRAKIZUMAB psoriasis. [R BRODALUMAB, Transitioning Between Brodalumab and Secukinumab in Moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2753799 SECUKINUMAB Severe Psoriasis: An Early Look. 3 Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, http://www.ncbi.nlm.nih.gov/pubmed/21703973 BUDESONIDE randomized, multicenter study

The effects of serum and urinary levels of topical intranasal http://www.ncbi.nlm.nih.gov/pubmed/20109316 irrigations with budesonide added to saline in patients with recurrent BUDESONIDE polyposis after endoscopic sinus surgery Intranasal budesonide treatment for children with mild obstructive http://www.ncbi.nlm.nih.gov/pubmed/18595959 BUDESONIDE sleep apnea syndrome Effects of topical formoterol alone and in combination with http://www.ncbi.nlm.nih.gov/pubmed/17215115 BUDESONIDE budesonide in a pollen season model of allergic rhinitis

Topical treatment with aqueous of palmitate http://www.ncbi.nlm.nih.gov/pubmed/15144464 BUDESONIDE and budesonide in a pollen-season model of allergic rhinitis Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults http://www.ncbi.nlm.nih.gov/pubmed/12740264 BUDESONIDE with mild-to-moderate asthma Holding chambers versus nebulisers for inhaled steroids in chronic http://www.ncbi.nlm.nih.gov/pubmed/16437434 BUDESONIDE asthma A study of the effect of nasal steroid sprays in perennial allergic http://www.ncbi.nlm.nih.gov/pubmed/11555762 BUDESONIDE rhinitis patients with rhinitis medicamentosa Nebulized budesonide is as effective as nebulized adrenaline in http://www.ncbi.nlm.nih.gov/pubmed/8628614 BUDESONIDE moderately severe croup Medication Title of Article PubMed Link The efficacy of nebulized budesonide in -treated http://www.ncbi.nlm.nih.gov/pubmed/8632929 BUDESONIDE outpatients with croup

Nasal inhalation of the budesonide from a spacer for http://www.ncbi.nlm.nih.gov/pubmed/2244675 BUDESONIDE the treatment of patients with pollen rhinitis and asthma http://www.ncbi.nlm.nih.gov/pubmed/6721271 BUDESONIDE Use of spacers to facilitate inhaled corticosteroid treatment of asthma Nebulised budesonide using a novel device in patients with oral http://www.ncbi.nlm.nih.gov/pubmed/25504995 BUDESONIDE steroid-dependent asthma Pulmonary drug delivery from the Taifun dry powder inhaler is http://www.ncbi.nlm.nih.gov/pubmed/11010599 BUDESONIDE relatively independent of the patient's inspiratory effort The efficacy and safety of budesonide inhalation suspension: a nebulizable corticosteroid for persistent asthma in infants and young http://www.ncbi.nlm.nih.gov/pubmed/10407712 BUDESONIDE children The efficacy and safety of budesonide inhalation suspension via transnasal nebulization compared with oral corticosteroids in chronic http://www.ncbi.nlm.nih.gov/pubmed/26281053 BUDESONIDE rhinosinusitis with nasal polyps Effect of budesonide transnasal nebulization in patients with http://www.ncbi.nlm.nih.gov/pubmed/25483598 BUDESONIDE eosinophilic chronic rhinosinusitis with nasal polyps A pilot study of the effects of intranasal budesonide delivered by http://www.ncbi.nlm.nih.gov/pubmed/24574125 BUDESONIDE NasoNeb® on patients with perennial allergic rhinitis Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double- http://www.ncbi.nlm.nih.gov/pubmed/24188203 BUDESONIDE blind, placebo-controlled study BUDESONIDE Nebulized budesonide to treat acute asthma in children http://www.ncbi.nlm.nih.gov/pubmed/15079179 Randomized, controlled trial of inhaled budesonide as an adjunct to http://www.ncbi.nlm.nih.gov/pubmed/9523927 BUDESONIDE oral in acute asthma Comparative study of budesonide as a nebulized suspension vs http://www.ncbi.nlm.nih.gov/pubmed/9519224 BUDESONIDE pressurized metered-dose inhaler in adult asthmatics Post-operative budesonide irrigations for patients with polyposis: a http://www.ncbi.nlm.nih.gov/pubmed/26363164 BUDESONIDE blinded, randomized controlled trial

Therapeutic effect of inhaled budesonide (Pulmicort® Turbuhaler) on http://www.ncbi.nlm.nih.gov/pubmed/24164087 BUDESONIDE the inflammatory response to one-lung ventilation Medication Title of Article PubMed Link Intrasinus administration of topical budesonide to allergic patients http://www.ncbi.nlm.nih.gov/pubmed/12150618 BUDESONIDE with chronic rhinosinusitis following surgery Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary http://www.ncbi.nlm.nih.gov/pubmed/7656936 BUDESONIDE Sarcoidosis Clinical effectiveness of nebulised budesonide in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/16924568 BUDESONIDE acute asthma attacks

Comparison of hydrofluoroalkane-beclomethasone dipropionate http://www.ncbi.nlm.nih.gov/pubmed/11694816 BUDESONIDE Autohaler with budesonide Turbuhaler in asthma control Budesonide suspension nebulization treatment in Chinese pediatric patients with cough variant asthma: a multi-center observational http://www.ncbi.nlm.nih.gov/pubmed/26517446 BUDESONIDE study Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children: a double-blind, randomized, http://www.ncbi.nlm.nih.gov/pubmed/24384609 BUDESONIDE controlled trial The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal http://www.ncbi.nlm.nih.gov/pubmed/24449682 BUDESONIDE polyposis The efficacy and safety of a short course of budesonide inhalation suspension via transnasal nebulization in chronic rhinosinusitis with http://www.ncbi.nlm.nih.gov/pubmed/22730816 BUDESONIDE nasal polyps Topical therapy with high-volume budesonide nasal irrigations in http://www.ncbi.nlm.nih.gov/pubmed/26431825 BUDESONIDE difficult-to-treat chronic rhinosinusitis https://www.ncbi.nlm.nih.gov/pubmed/23704078 BUDESONIDE Effect of intranasal budesonide irrigations on intraocular pressure. Budesonide nasal irrigations in the postoperative management of https://www.ncbi.nlm.nih.gov/pubmed/23776108 BUDESONIDE chronic rhinosinusitis

The effects of serum and urinary cortisol levels of topical intranasal https://www.ncbi.nlm.nih.gov/pubmed/20109316 irrigations with budesonide added to saline in patients with recurrent BUDESONIDE polyposis after endoscopic sinus surgery.

The Effectiveness of Budesonide Nasal Irrigation After Endoscopic https://www.ncbi.nlm.nih.gov/pubmed/27440128 BUDESONIDE Sinus Surgery in Chronic Rhinosinusitis With Asthma Medication Title of Article PubMed Link Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of https://www.ncbi.nlm.nih.gov/pubmed/19128710 BUDESONIDE significant adrenal suppression

Safety analysis of long-term budesonide nasal irrigations in patients https://www.ncbi.nlm.nih.gov/pubmed/26879335 BUDESONIDE with chronic rhinosinusitis post endoscopic sinus surgery. Safety of long-term high-volume sinonasal budesonide irrigations for https://www.ncbi.nlm.nih.gov/pubmed/26750509 BUDESONIDE chronic rhinosinusitis. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal https://www.ncbi.nlm.nih.gov/pubmed/24449682 BUDESONIDE polyposis. A New Formulation of Oral Viscous Budesonide in Treating https://www.ncbi.nlm.nih.gov/pubmed/?term=2725366 BUDESONIDE Paediatric Eosinophilic Oesophagitis: A Pilot Study. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2702529 BUDESONIDE Oral viscous budesonide can be successfully delivered through a 8 variety of vehicles to treat eosinophilic esophagitis in children. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide https://www.ncbi.nlm.nih.gov/pubmed/?term=2741604 BUDESONIDE Foam in Patients with Ulcerative Proctitis and Ulcerative 5 Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Systemic secondary amyloidosis in a 70-year-old patient with Crohn's https://www.ncbi.nlm.nih.gov/pubmed/?term=2347880 BUDESONIDE disease: treatment with oral budesonide. 7 Comparison of two dosing methods for induction of response and https://www.ncbi.nlm.nih.gov/pubmed/?term=1922998 BUDESONIDE remission with oral budesonide in active pediatric Crohn's disease: a 8 randomized placebo-controlled trial. Oral budesonide for the therapy of post-liver transplant de novo https://www.ncbi.nlm.nih.gov/pubmed/?term=1861867 BUDESONIDE inflammatory bowel disease: a case series and systematic review of 6 the literature. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, https://www.ncbi.nlm.nih.gov/pubmed/?term=2788957 BUDESONIDE and Histologic Parameters Compared With Placebo in Patients With 4 Eosinophilic Esophagitis. A Randomized Controlled Comparison of Esophageal Clearance https://www.ncbi.nlm.nih.gov/pubmed/?term=2692108 BUDESONIDE Times of Oral Budesonide Preparations. 3 BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=8964430 Oral budesonide therapy for ulcerative colitis: a topical tale. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2808167 BUDESONIDE Treatment of oral mucosal manifestations of chronic graft-versus- 7 host disease: dexamethasone vs. budesonide. [Review] Formulation of budesonide for the treatment of oral https://www.ncbi.nlm.nih.gov/pubmed/?term=2541126 BUDESONIDE chronic graft-versus-host disease. 2 Oral budesonide for induction of remission in ulcerative colitis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2649771 BUDESONIDE [Review][Update of Cochrane Database Syst Rev. 9 2010;(10):CD007698; PMID: 20927762] Adrenal Suppression in Children Treated With Oral Viscous https://www.ncbi.nlm.nih.gov/pubmed/?term=2595008 BUDESONIDE Budesonide for Eosinophilic Esophagitis. 8 Efficacy and safety of oral budesonide suspension in pediatric https://www.ncbi.nlm.nih.gov/pubmed/?term=2490750 BUDESONIDE patients with eosinophilic esophagitis. 2 Efficacy of nebulised budesonide versus oral prednisolone in acute https://www.ncbi.nlm.nih.gov/pubmed/?term=2490313 BUDESONIDE severe asthma. 1 Randomised, double-blind, placebo-controlled trial of oral budesonide https://www.ncbi.nlm.nih.gov/pubmed/?term=2542521 BUDESONIDE for prophylaxis of acute intestinal graft-versus-host disease after 4 allogeneic stem cell transplantation (PROGAST). https://www.ncbi.nlm.nih.gov/pubmed/?term=2513812 BUDESONIDE Oral viscous budesonide as a first-line approach to esophageal 1 stenosis in epidermolysis bullosa: an open-label trial in six children. Oral budesonide as a therapy for protein-losing enteropathy in https://www.ncbi.nlm.nih.gov/pubmed/?term=2488925 BUDESONIDE children after the Fontan operation. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2453414 BUDESONIDE Once versus three times daily dosing of oral budesonide for active 2 Crohn's disease: a double-blind, double-dummy, randomised trial. Use of oral budesonide in the management of protein-losing https://www.ncbi.nlm.nih.gov/pubmed/?term=2402937 BUDESONIDE enteropathy due to restrictive cardiomyopathy. 9 Comparison of budesonide and dexamethasone for local treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2390347 BUDESONIDE oral chronic graft-versus-host disease. 6 Eosinophilic esophagitis: treatment with oral viscous budesonide. https://www.ncbi.nlm.nih.gov/pubmed/?term=2305038 BUDESONIDE [Review] 7 Identification of budesonide metabolites in human urine after oral https://www.ncbi.nlm.nih.gov/pubmed/?term=2257306 BUDESONIDE administration. 0 Systemic effects of oral budesonide in hematopoietic transplant: https://www.ncbi.nlm.nih.gov/pubmed/?term=2232713 BUDESONIDE implications of drug interaction with . 3 Medication Title of Article PubMed Link Oral budesonide as a therapy for protein-losing enteropathy in https://www.ncbi.nlm.nih.gov/pubmed/?term=2212919 BUDESONIDE patients having undergone Fontan palliation. 5 The use of oral budesonide in adolescents and adults with protein- https://www.ncbi.nlm.nih.gov/pubmed/?term=2178441 BUDESONIDE losing enteropathy after the Fontan operation. 0 Oral budesonide treatment for protein-losing enteropathy in Fontan- https://www.ncbi.nlm.nih.gov/pubmed/?term=2166053 BUDESONIDE palliated patients. 9 Oral viscous budesonide therapy in children with epidermolysis https://www.ncbi.nlm.nih.gov/pubmed/?term=2159365 BUDESONIDE bullosa and proximal esophageal strictures. 0 An adult case of eosinophilic pyloric stenosis maintained on https://www.ncbi.nlm.nih.gov/pubmed/?term=2140985 BUDESONIDE remission with oral budesonide. 9 Oral budesonide for induction of remission in ulcerative colitis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2092776 BUDESONIDE [Review][Update in Cochrane Database Syst Rev. 2 2015;10:CD007698; PMID: 26497719] https://www.ncbi.nlm.nih.gov/pubmed/?term=2045715 BUDESONIDE Oral viscous budesonide is effective in children with eosinophilic 7 esophagitis in a randomized, placebo-controlled trial. Use of oral budesonide in the management of protein-losing https://www.ncbi.nlm.nih.gov/pubmed/?term=2017214 BUDESONIDE enteropathy after the Fontan operation. 0 Grapefruit juice interaction with oral budesonide: equal effect on https://www.ncbi.nlm.nih.gov/pubmed/?term=1969418 BUDESONIDE immediate-release and delayed-release formulations. 4 Pharmacokinetics and pharmacodynamic action of budesonide after https://www.ncbi.nlm.nih.gov/pubmed/?term=1920372 BUDESONIDE in healthy subjects and patients with oral 4 chronic graft-versus-host disease. Oral budesonide for maintenance of remission of Crohn's disease: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1903597 BUDESONIDE pooled safety analysis. 2 Oral formulations of budesonide: a novel treatment for inflammatory https://www.ncbi.nlm.nih.gov/pubmed/?term=1918026 BUDESONIDE bowel disease. [Review] [54 refs] 3 Oral budesonide for maintenance treatment of collagenous colitis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1892682 BUDESONIDE randomized, double-blind, placebo-controlled trial. 6 Budesonide for local therapy of complex oral mucosal immune- https://www.ncbi.nlm.nih.gov/pubmed/?term=1858560 BUDESONIDE mediated inflammatory diseases: case reports. 5 Effect of high-dose on pharmacokinetics of oral https://www.ncbi.nlm.nih.gov/pubmed/?term=1804857 BUDESONIDE budesonide and vice versa: a double drug interaction study. 3 Localized eosinophilic ileitis with mastocytosis successfully treated https://www.ncbi.nlm.nih.gov/pubmed/?term=1791914 BUDESONIDE with oral budesonide. 9 Medication Title of Article PubMed Link Oral viscous budesonide: a potential new therapy for eosinophilic https://www.ncbi.nlm.nih.gov/pubmed/?term=1758126 BUDESONIDE esophagitis in children. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1745156 BUDESONIDE Oral budesonide in the treatment of chronic refractory pouchitis. 9 A short course of oral prednisone followed by intranasal budesonide https://www.ncbi.nlm.nih.gov/pubmed/?term=1665208 BUDESONIDE is an effective treatment of severe nasal polyps. 5 Pharmacokinetic/pharmacodynamic modeling of total lymphocytes https://www.ncbi.nlm.nih.gov/pubmed/?term=1663389 BUDESONIDE and selected subtypes after oral budesonide. 0 Gastrointestinal transit, release and plasma pharmacokinetics of a https://www.ncbi.nlm.nih.gov/pubmed/?term=1639034 BUDESONIDE new oral budesonide formulation. 9 Budesonide offers no advantage when added to oral dexamethasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1594251 BUDESONIDE in the treatment of croup. 1 Oral budesonide therapy improves quality of life in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1554932 BUDESONIDE collagenous colitis. 6 Evaluation of oral budesonide in the treatment of active distal https://www.ncbi.nlm.nih.gov/pubmed/?term=1551023 BUDESONIDE ulcerative colitis. 3 Oral budesonide in the management of Crohn's disease. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=1451903 BUDESONIDE [38 refs] 5 Oral budesonide significantly improves water in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=1273744 BUDESONIDE with ileostomy for Crohn disease. 4 Replacement of conventional by oral pH-modified https://www.ncbi.nlm.nih.gov/pubmed/?term=1264361 BUDESONIDE release budesonide in active and inactive Crohn's disease: results of 8 an open, prospective, multicenter trial. Budesonide: a novel treatment for oral chronic graft versus host https://www.ncbi.nlm.nih.gov/pubmed/?term=1262710 BUDESONIDE disease. 1 A pharmacoscintigraphic evaluation of oral budesonide given as https://www.ncbi.nlm.nih.gov/pubmed/?term=1262276 BUDESONIDE controlled-release (Entocort) capsules. 1 Evaluation of oral budesonide for treatment of mild and moderate https://www.ncbi.nlm.nih.gov/pubmed/?term=1181576 BUDESONIDE exacerbations of Crohn's disease in children. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1176379 BUDESONIDE Oral budesonide approved for active Crohn's disease. 9 Drug Points: Anaphylactic-like reaction associated with oral https://www.ncbi.nlm.nih.gov/pubmed/?term=1103067 BUDESONIDE budesonide. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1100723 BUDESONIDE Oral budesonide in the treatment of primary sclerosing cholangitis. 8 Medication Title of Article PubMed Link Intranasal budesonide spray as an adjunct to oral antibiotic therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1092393 BUDESONIDE for acute sinusitis in children. 8 Oral budesonide in the treatment of patients with primary biliary https://www.ncbi.nlm.nih.gov/pubmed/?term=1065525 BUDESONIDE cirrhosis with a suboptimal response to ursodeoxycholic acid. 2 Efficacy of nebulized budesonide compared to oral prednisolone in https://www.ncbi.nlm.nih.gov/pubmed/?term=1050368 BUDESONIDE acute bronchial asthma. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1050007 BUDESONIDE Oral budesonide and ursodeoxycholic acid for treatment of primary 5 biliary cirrhosis: results of a prospective double-blind trial. Low dose oral pH modified release budesonide for maintenance of BUDESONIDE steroid induced remission in Crohn's disease. The Budesonide Study https://www.ncbi.nlm.nih.gov/pubmed/?term=9616309 Group. BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=9468258 Oral budesonide for lymphocytic colitis. Oral budesonide therapy for steroid-dependent ulcerative colitis: a BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=9663828 pilot trial. Oral budesonide is as effective as oral prednisolone in active Crohn's BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=9301500 disease. The Global Budesonide Study Group. Treatment of active and postactive ileal and colonic Crohn's disease BUDESONIDE with oral pH-modified-release budesonide. German Budesonide https://www.ncbi.nlm.nih.gov/pubmed/?term=9164517 Study Group.

BUDESONIDE A comparison of nebulized budesonide with oral prednisolone in the https://www.ncbi.nlm.nih.gov/pubmed/?term=8988070 treatment of exacerbations of obstructive pulmonary disease. Oral budesonide versus prednisolone in patients with active BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=8964395 extensive and left-sided ulcerative colitis.

BUDESONIDE Oral pH-modified release budesonide versus 6- in https://www.ncbi.nlm.nih.gov/pubmed/?term=8889459 active Crohn's disease. German/Austrian Budesonide Study Group. Oral budesonide as maintenance treatment for Crohn's disease: a BUDESONIDE placebo-controlled, dose-ranging study. Canadian Inflammatory https://www.ncbi.nlm.nih.gov/pubmed/?term=8536887 Bowel Disease Study Group. BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=7600794 Contact allergy to budesonide in an oral spray. Medication Title of Article PubMed Link Oral budesonide for active Crohn's disease. Canadian Inflammatory BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=8078529 Bowel Disease Study Group. Oral budesonide for treatment of autoimmune chronic active BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=7696446 hepatitis. Treatment of active Crohn's disease with an oral slow-release BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=8503403 budesonide formulation. BUDESONIDE https://www.ncbi.nlm.nih.gov/pubmed/?term=8161666 Oral budesonide in active Crohn's disease. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX R (Cortiment RMMX R) for active, mild-to- https://pubmed.ncbi.nlm.nih.gov/31700630 BUDESONIDE moderate ulcerative colitis.

Middle-term prognosis in patients with ulcerative colitis who achieved https://pubmed.ncbi.nlm.nih.gov/31381615 BUDESONIDE clinical and endoscopic remission by budesonide rectal foam. Budesonide MMX: efficacy and safety profile in the treatment of https://pubmed.ncbi.nlm.nih.gov/31106602 BUDESONIDE ulcerative colitis. [Review] Preparation and characterization of pH-sensitive nanoparticles of https://pubmed.ncbi.nlm.nih.gov/30174414 BUDESONIDE budesonide for the treatment of ulcerative colitis.

A proposed treatment algorithm for mild to moderate ulcerative colitis- https://pubmed.ncbi.nlm.nih.gov/29616331 BUDESONIDE with an emphasis on budesonide foam and mucosal healing. A safety evaluation of budesonide MMX for the treatment of https://pubmed.ncbi.nlm.nih.gov/29473429 BUDESONIDE ulcerative colitis. [Review] Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to- https://pubmed.ncbi.nlm.nih.gov/28779419 moderate ulcerative colitis with distal active inflammation: double- BUDESONIDE blind, randomized study. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled https://pubmed.ncbi.nlm.nih.gov/28333362 BUDESONIDE Trial.

Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to- https://pubmed.ncbi.nlm.nih.gov/28333203 BUDESONIDE Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. Central Serous Chorioretinopathy in a Patient with Ulcerative Colitis https://pubmed.ncbi.nlm.nih.gov/28328626 BUDESONIDE with Pouchitis on Budesonide-EC. Medication Title of Article PubMed Link Budesonide foam for mild to moderate distal ulcerative colitis: A https://pubmed.ncbi.nlm.nih.gov/27699863 BUDESONIDE systematic review and meta-analysis. BUDESONIDE Budesonide for the treatment of ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/27157244

Budesonide-hydroxypropyl-beta-cyclodextrin inclusion complex in https://pubmed.ncbi.nlm.nih.gov/26674842 binary poloxamer 407/403 system for ulcerative colitis treatment: A BUDESONIDE physico-chemical study from micelles to hydrogels. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal https://pubmed.ncbi.nlm.nih.gov/26577683 BUDESONIDE Healing in Patients with Distal Ulcerative Colitis. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative https://pubmed.ncbi.nlm.nih.gov/26541989 BUDESONIDE Colitis. [Review] BUDESONIDE Budesonide rectal foam (Uceris) for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/26529134 Oral budesonide for induction of remission in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/26497719 BUDESONIDE [Review] Budesonide MMX for the Induction of Remission of Mild to Moderate https://pubmed.ncbi.nlm.nih.gov/26094251 BUDESONIDE Ulcerative Colitis: A Pooled Safety Analysis. Budesonide MMX( R): a review of its use in patients with mild to https://pubmed.ncbi.nlm.nih.gov/25920500 BUDESONIDE moderate ulcerative colitis. [Review] Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two https://pubmed.ncbi.nlm.nih.gov/25588902 BUDESONIDE phase 3 studies. BUDESONIDE Letter: budesonide MMX for ulcerative colitis?. https://pubmed.ncbi.nlm.nih.gov/24849158 Review article: integrating budesonide-MMX into treatment https://pubmed.ncbi.nlm.nih.gov/24641622 BUDESONIDE algorithms for mild-to-moderate ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/24502535 BUDESONIDE The role of Budesonide-MMX in active ulcerative colitis. [Review] Budesonide multi-matrix system formulation for treating ulcerative https://pubmed.ncbi.nlm.nih.gov/24484392 BUDESONIDE colitis. Novel extended release budesonide formulation for treatment of https://pubmed.ncbi.nlm.nih.gov/24219763 BUDESONIDE ulcerative colitis. [Review] Once-daily budesonide MMX in active, mild-to-moderate ulcerative https://pubmed.ncbi.nlm.nih.gov/23436336 BUDESONIDE colitis: results from the randomised CORE II study. BUDESONIDE Budesonide (Uceris) for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/23507873 Budesonide MMX and mesalamine to induce remission in patients https://pubmed.ncbi.nlm.nih.gov/23352592 BUDESONIDE with ulcerative colitis. Medication Title of Article PubMed Link Once-daily budesonide MMX R extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results https://pubmed.ncbi.nlm.nih.gov/22892337 BUDESONIDE from the CORE I study. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double- https://pubmed.ncbi.nlm.nih.gov/21453882 BUDESONIDE dummy, randomised trial. Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for https://pubmed.ncbi.nlm.nih.gov/21434575 BUDESONIDE ulcerative colitis. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX R 9 mg extended-release tablets in patients with https://pubmed.ncbi.nlm.nih.gov/21122499 BUDESONIDE active left-sided ulcerative colitis. Oral budesonide for induction of remission in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/20927762 BUDESONIDE [Review] Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and https://pubmed.ncbi.nlm.nih.gov/20491741 efficacy of budesonide or mesalazine in active left-sided BUDESONIDE ulcerative colitis. BUDESONIDE Budesonide for ulcerative colitis. [Review] [44 refs] https://pubmed.ncbi.nlm.nih.gov/16944997

Colonic spread and serum pharmacokinetics of budesonide foam in https://pubmed.ncbi.nlm.nih.gov/16128685 BUDESONIDE patients with mildly to moderately active ulcerative colitis. Evaluation of oral budesonide in the treatment of active distal https://pubmed.ncbi.nlm.nih.gov/15510233 BUDESONIDE ulcerative colitis. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam https://pubmed.ncbi.nlm.nih.gov/15362749 and betamethasone enemas in patients with active distal ulcerative BUDESONIDE colitis. Effect of budesonide on remission and relapse rate in distal https://pubmed.ncbi.nlm.nih.gov/12126250 BUDESONIDE ulcerative colitis and proctitis. Budesonide vs Saline Nasal Irrigation in Allergic Rhinitis: A https://pubmed.ncbi.nlm.nih.gov/32393099 BUDESONIDE Randomized Placebo-Controlled Trial. Effects of surgery and on eosinophilic granulomatosis with polyangiitis with otitis media and sinusitis: a case https://pubmed.ncbi.nlm.nih.gov/32345078 BUDESONIDE report. Medication Title of Article PubMed Link Latest developments on topical therapies in chronic rhinosinusitis. https://pubmed.ncbi.nlm.nih.gov/31789928 BUDESONIDE [Review]

Predictors of efficacy for combination oral and topical corticosteroids https://pubmed.ncbi.nlm.nih.gov/31609091 BUDESONIDE to treat patients with chronic rhinosinusitis with nasal polyps. Budesonide nasal irrigation improved Lund-Kennedy endoscopic score of chronic rhinosinusitis patients after endoscopic sinus https://pubmed.ncbi.nlm.nih.gov/30788581 BUDESONIDE surgery.

Budesonide irrigation with olfactory training improves outcomes https://pubmed.ncbi.nlm.nih.gov/29901865 BUDESONIDE compared with olfactory training alone in patients with olfactory loss. Effect of Budesonide Added to Large-Volume, Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical https://pubmed.ncbi.nlm.nih.gov/29879268 BUDESONIDE Trial. Contralateral sinus involvement of surgically treated unilateral allergic https://pubmed.ncbi.nlm.nih.gov/28501959 BUDESONIDE fungal rhinosinusitis.

Safety analysis of long-term budesonide nasal irrigations in patients https://pubmed.ncbi.nlm.nih.gov/26879335 BUDESONIDE with chronic rhinosinusitis post endoscopic sinus surgery. Safety of long-term high-volume sinonasal budesonide irrigations for https://pubmed.ncbi.nlm.nih.gov/26750509 BUDESONIDE chronic rhinosinusitis. Topical therapy with high-volume budesonide nasal irrigations in https://pubmed.ncbi.nlm.nih.gov/26431825 BUDESONIDE difficult-to-treat chronic rhinosinusitis.

The Effectiveness of Budesonide Nasal Irrigation After Endoscopic https://pubmed.ncbi.nlm.nih.gov/27440128 BUDESONIDE Sinus Surgery in Chronic Rhinosinusitis With Asthma. Post-operative budesonide irrigations for patients with polyposis: a https://pubmed.ncbi.nlm.nih.gov/26363164 BUDESONIDE blinded, randomized controlled trial. Impact of saline irrigation and topical corticosteroids on the https://pubmed.ncbi.nlm.nih.gov/25556553 BUDESONIDE postsurgical sinonasal microbiota. BUDESONIDE Infected cochlear implant after large-volume nasal irrigation. https://pubmed.ncbi.nlm.nih.gov/25226373 Budesonide nasal irrigations in the postoperative management of https://pubmed.ncbi.nlm.nih.gov/23776108 BUDESONIDE chronic rhinosinusitis. Medication Title of Article PubMed Link

Postoperative care for Samter's triad patients undergoing endoscopic https://pubmed.ncbi.nlm.nih.gov/21997904 BUDESONIDE sinus surgery: a double-blinded, randomized controlled trial.

The effects of serum and urinary cortisol levels of topical intranasal https://pubmed.ncbi.nlm.nih.gov/20109316 irrigations with budesonide added to saline in patients with recurrent BUDESONIDE polyposis after endoscopic sinus surgery. Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of https://pubmed.ncbi.nlm.nih.gov/19128710 BUDESONIDE significant adrenal suppression. CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=7604767 Treatment of psoriasis: role of calcipotriene. [Review] [13 refs] Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=7822519 study. Calcipotriene Study Group. Comparative study of calcipotriene (MC 903) ointment and CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=7929921 ointment in the treatment of psoriasis. CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=8035754 Calcipotriene for psoriasis. Topical calcipotriene has no short-term effect on calcium and bone CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=8609254 metabolism of patients with psoriasis.

CALCIPOTRIENE A multicenter trial of calcipotriene ointment and halobetasol ointment https://www.ncbi.nlm.nih.gov/pubmed/?term=8708035 compared with either agent alone for the treatment of psoriasis. Long-term effectiveness and safety of topical calcipotriene for CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=8903286 psoriasis. Calcipotriene Study Group. Calcipotriene ointment applied once a day for psoriasis: a double- CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=8961897 blind, multicenter, placebo-controlled study. Topical calcipotriene ointment and etretinate: another combination CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9146555 therapy for psoriasis vulgaris. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9344188 review of the literature and results of a survey sent to 100 dermatologists. [Review] [25 refs] The use of topical calcipotriene/calcipotriol in conditions other than CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9344189 plaque-type psoriasis. [Review] [21 refs] Medication Title of Article PubMed Link Calcipotriene-induced improvement in psoriasis is associated with CALCIPOTRIENE reduced interleukin-8 and increased interleukin-10 levels within https://www.ncbi.nlm.nih.gov/pubmed/?term=9536226 lesions. Evaluating the safety of calcipotriene 30 g per day in patients with CALCIPOTRIENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9590465 psoriasis: a parallel group, vehicle-controlled study.

CALCIPOTRIENE Calcipotriene ointment and halobetasol ointment in the long-term https://www.ncbi.nlm.nih.gov/pubmed/?term=9738781 treatment of psoriasis: effects on the duration of improvement. Treatment of psoriasis with calcipotriene plus psoralen-UV-A-bath https://www.ncbi.nlm.nih.gov/pubmed/?term=1041117 CALCIPOTRIENE therapy. 5 Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective https://www.ncbi.nlm.nih.gov/pubmed/?term=1100371 CALCIPOTRIENE cohort study of the cost of psoriasis treatment with topical 5 corticosteroids versus topical calcipotriene. Combination regimens of topical calcipotriene in chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1111516 CALCIPOTRIENE psoriasis: systematic review of efficacy and tolerability. [Review] [30 7 refs] https://www.ncbi.nlm.nih.gov/pubmed/?term=1176611 CALCIPOTRIENE Psoriasis in infancy: therapy with calcipotriene ointment. 9

A randomized, multicenter study of calcipotriene ointment and https://www.ncbi.nlm.nih.gov/pubmed/?term=1701074 CALCIPOTRIENE clobetasol propionate foam in the sequential treatment of localized 4 plaque-type psoriasis: short- and long-term outcomes. An unusual bullous eruption in a patient with psoriasis: Calcipotriene https://www.ncbi.nlm.nih.gov/pubmed/?term=2046619 CALCIPOTRIENE phototoxicity. 3 Pilot, multicenter, double-blind, randomized placebo-controlled https://www.ncbi.nlm.nih.gov/pubmed/?term=2059929 CALCIPOTRIENE bilateral comparative study of a combination of calcipotriene and 2 nicotinamide for the treatment of psoriasis.

Efficacy and safety of calcipotriene 0.005% foam for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2258779 CALCIPOTRIENE plaque-type psoriasis: results of two multicenter, randomized, double- 1 blind, vehicle-controlled, phase III clinical trials.[Erratum appears in Am J Clin Dermatol. 2012 Dec 1;13(6):422] Medication Title of Article PubMed Link A multicenter, randomized, double-blind study of the efficacy and https://www.ncbi.nlm.nih.gov/pubmed/?term=2354591 CALCIPOTRIENE safety of calcipotriene foam, 0.005%, vs vehicle foam in the 2 treatment of plaque-type psoriasis of the scalp. Clobetasol Emulsion Foam and Calcipotriene 0.005% Foam https://www.ncbi.nlm.nih.gov/pubmed/?term=2953745 CALCIPOTRIENE Combination Therapy for the Maintenance of Treatment Response in 2 Patients With Moderate Plaque Psoriasis. CALCIPOTRIENE, Comparison of calcipotriene (Dovonex) with a coal tar emulsion https://www.ncbi.nlm.nih.gov/pubmed/?term=1020606 COAL TAR (Exorex) in treating psoriasis in adults: a pilot study. 5 Efficacy and tolerability of a cosmetically acceptable coal tar solution CALCIPOTRIENE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2051316 in the treatment of moderate plaque psoriasis: a controlled COAL TAR 0 comparison with calcipotriene (calcipotriol) cream. CALCIPOTRIENE, Combination phototherapy of psoriasis with calcipotriene and narrow- https://www.ncbi.nlm.nih.gov/pubmed/?term=9091500 PHOTOTHERAPY band (311 nm) UVB. CALCIPOTRIENE, Topical calcipotriene in combination with UVB phototherapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=9169336 PHOTOTHERAPY psoriasis. Preliminary study of the efficacy and tolerability of combination CALCIPOTRIENE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2309431 therapy with calcipotriene ointment 0.005% and tacrolimus ointment TACROLIMUS 4 0.1% in the treatment of stable plaque psoriasis.

CALCIPOTRIENE, A comparison of tazarotene 0.1% gel once daily plus mometasone https://www.ncbi.nlm.nih.gov/pubmed/?term=1111023 TAZAROTENE furoate 0.1% cream once daily versus calcipotriene 0.005% ointment 3 twice daily in the treatment of plaque psoriasis. An observation study evaluating the efficacy of tazarotene plus CALCIPOTRIENE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1114708 corticosteroid in treating plaque psoriasis in patients switched from TAZAROTENE 6 treatment with calcipotriene +/- corticosteroid. CALCIPOTRIENE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1114708 Evaluating the potential clinical benefits of switching patients with TAZAROTENE 7 plaque psoriasis from calcipotriene to tazarotene treatment. Combination of calcipotriene (Dovonex) ointment and tazarotene CALCIPOTRIENE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1206348 (Tazorac) gel versus clobetasol ointment in the treatment of plaque TAZAROTENE 9 psoriasis: a pilot study. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient https://pubmed.ncbi.nlm.nih.gov/31986898 CANNABIDIOL Palliative Medicine Population. Cannabidiol induces antioxidant pathways in keratinocytes by https://pubmed.ncbi.nlm.nih.gov/31518892 CANNABIDIOL targeting BACH1. Medication Title of Article PubMed Link Myorelaxant Effect of Transdermal Cannabidiol Application in https://pubmed.ncbi.nlm.nih.gov/31698733 CANNABIDIOL Patients with TMD: A Randomized, Double-Blind Trial. A therapeutic effect of cbd-enriched ointment in inflammatory skin https://pubmed.ncbi.nlm.nih.gov/30993303 CANNABIDIOL diseases and cutaneous scars. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through https://pubmed.ncbi.nlm.nih.gov/30033591 CANNABIDIOL PPARgamma- and CB2 receptor-dependent pathways. https://pubmed.ncbi.nlm.nih.gov/23869687/ CANNABIDIOL Epigenetic control of skin differentiation genes by phytocannabinoids. Cannabidiol bioavailability after nasal and transdermal application: https://pubmed.ncbi.nlm.nih.gov/20545522/ CANNABIDIOL effect of permeation enhancers. permeation of Delta8- https://pubmed.ncbi.nlm.nih.gov/15025853/ CANNABIDIOL tetrahydrocannabinol, cannabidiol and cannabinol.

Tolerability of the capsaicin 8% patch following pretreatment with http://www.ncbi.nlm.nih.gov/pubmed/24664539 lidocaine or tramadol in patients with peripheral neuropathic pain: a CAPSAICIN multicentre, randomized, assessor-blinded study. High concentration capsaicin for treatment of peripheral neuropathic pain: effect on somatosensory symptoms and identification of http://www.ncbi.nlm.nih.gov/pubmed/24286590 CAPSAICIN treatment responders. Treatment of peripheral neuropathic pain by topical capsaicin: Impact http://www.ncbi.nlm.nih.gov/pubmed/24259265 CAPSAICIN of pre-existing pain in the QUEPP-study. A comparative evaluation of local application of the combination of eutectic mixture of local anesthetics and capsaicin for attenuation of http://www.ncbi.nlm.nih.gov/pubmed/23400973 CAPSAICIN venipuncture pain.

0.025% capsaicin gel for the treatment of painful diabetic neuropathy: http://www.ncbi.nlm.nih.gov/pubmed/23228119 CAPSAICIN a randomized, double-blind, crossover, placebo-controlled trial. Short-term efficacy of topical capsaicin therapy in severely affected http://www.ncbi.nlm.nih.gov/pubmed/22842953 CAPSAICIN fibromyalgia patients. Efficacy of a 0.1% capsaicin hydrogel patch for myofascial neck pain: http://www.ncbi.nlm.nih.gov/pubmed/22681259 CAPSAICIN a double-blinded randomized trial.

Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in http://www.ncbi.nlm.nih.gov/pubmed/21612836 CAPSAICIN an open-label study of patients with peripheral neuropathic pain. Medication Title of Article PubMed Link Effectiveness and safety of topical capsaicin cream in the treatment http://www.ncbi.nlm.nih.gov/pubmed/21104944 CAPSAICIN of chronic soft tissue pain. A multicenter, randomized, double-blind, controlled study of NGX- 4010, a high-concentration capsaicin patch, for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/21087403 CAPSAICIN postherpetic neuralgia. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% http://www.ncbi.nlm.nih.gov/pubmed/20973322 CAPSAICIN of capsaicin versus placebo. CAPSAICIN Capsaicin jelly against migraine pain. http://www.ncbi.nlm.nih.gov/pubmed/20456192 Topical capsaicin therapy for uremic pruritus in patients on http://www.ncbi.nlm.nih.gov/pubmed/20404425 CAPSAICIN hemodialysis. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study http://www.ncbi.nlm.nih.gov/pubmed/20113411 CAPSAICIN with an open-label extension.

Comparison of topical capsaicin and betamethasone in the treatment http://www.ncbi.nlm.nih.gov/pubmed/18988089 CAPSAICIN of chronic skin lesions due to sulfur mustard exposure. Controlled trial of high-concentration capsaicin patch for treatment of http://www.ncbi.nlm.nih.gov/pubmed/18541884 CAPSAICIN painful HIV neuropathy. Topical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover http://www.ncbi.nlm.nih.gov/pubmed/12912865 CAPSAICIN study. Topical capsaicin therapy in humans with hemodialysis-related http://www.ncbi.nlm.nih.gov/pubmed/12842288 CAPSAICIN pruritus. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic http://www.ncbi.nlm.nih.gov/pubmed/12043933 CAPSAICIN neuropathy. Topical application of capsaicin for the treatment of localized pain in http://www.ncbi.nlm.nih.gov/pubmed/11203735 CAPSAICIN the temporomandibular joint area. CAPSAICIN Treatment of prurigo nodularis with topical capsaicin. http://www.ncbi.nlm.nih.gov/pubmed/11209117 Topical application of hydrochloride, capsaicin and a combination of both produces analgesia in chronic human http://www.ncbi.nlm.nih.gov/pubmed/10848721 neuropathic pain: a randomized, double-blind, placebo-controlled CAPSAICIN study. Topical capsaicin in the management of HIV-associated peripheral http://www.ncbi.nlm.nih.gov/pubmed/10687326 CAPSAICIN neuropathy. Medication Title of Article PubMed Link http://www.ncbi.nlm.nih.gov/pubmed/26857302 CAPSAICIN Effective pain relief of post-herpetic neuralgia with capsaicin patch Considerable Variability in the Efficacy of 8% Capsaicin Topical Patches in the Treatment of Chronic Pruritus in 3 Patients with http://www.ncbi.nlm.nih.gov/pubmed/26848223 CAPSAICIN Notalgia Paresthetica A randomized clinical trial of efficacy and safety of the topical and capsaicin in the treatment of painful diabetic http://www.ncbi.nlm.nih.gov/pubmed/26109991 CAPSAICIN neuropathy Liposomal topical capsaicin in post-herpetic neuralgia: a safety pilot http://www.ncbi.nlm.nih.gov/pubmed/25807130 CAPSAICIN study Bioequivalence study of two oral formulations of cefadroxil in healthy http://www.ncbi.nlm.nih.gov/pubmed/18368950 CEFADROXIL volunteers

Evaluation of the effect of topical cefadroxil on bacterial load of doi: 10.5455/2319-2003.ijbcp20130606 pathogenic staphylococci in anterior nares in human volunteers, CEFADROXIL comparative study between oral vs. topical cefadroxil Topical spraying of cefazolin and reduces deep sternal wound infections after heart surgery: a multicenter, large volume, http://www.ncbi.nlm.nih.gov/pubmed/26721465 CEFAZOLIN retrospective study Cefazolin-Gentamicin versus -Ceftazidime Eye Drops for http://www.ncbi.nlm.nih.gov/pubmed/23056669 CEFAZOLIN Bacterial Corneal Ulcers;a Randomized Clinical Trial Comparison of topical 0.3% to fortified tobramycin-cefazolin http://www.ncbi.nlm.nih.gov/pubmed/10879638 CEFAZOLIN in the therapy of bacterial keratitis

Exogenous pulmonary surfactant as a vehicle for antimicrobials: http://www.ncbi.nlm.nih.gov/pubmed/24876994 CEFEPIME assessment of surfactant-antibacterial interactions in vitro Novel use of antimicrobial hand sanitizer in treatment of nosocomial http://www.ncbi.nlm.nih.gov/pubmed/19226024 CEFEPIME acinetobacter infection WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β- https://www.ncbi.nlm.nih.gov/pubmed/28333332 CEFEPIME lactamases. https://www.ncbi.nlm.nih.gov/pubmed/?term=Tissue+ Tissue penetration and exposure of cefepime in patients with diabetic penetration+and+exposure+of+cefepime+in+patients CEFEPIME foot infections. +with+diabetic+foot+infections. Medication Title of Article PubMed Link Defining the impact of severity of illness on time above the MIC thres https://www.ncbi.nlm.nih.gov/pubmed/?term=Defining hold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' +the+impact+of+severity+of+illness+on+time+above+ CEFEPIME window. the+MIC+threshold+for+cefepime https://www.ncbi.nlm.nih.gov/pubmed/?term=Translati Translational Efficacy of Humanized Exposures of Cefepime, onal+Efficacy+of+Humanized+Exposures+of+Cefepi Ertapenem, and Levofloxacin against Extended-Spectrum-β- me%2C+Ertapenem%2C+and+Levofloxacin+against Lactamase-Producing Escherichia coli in a Murine Model of +Extended-Spectrum-%CE%B2-Lactamase- CEFEPIME Complicated . Producing+Escherichia+coli+in+a

Improved Accuracy of Cefepime Susceptibility Testing for Extended- https://www.ncbi.nlm.nih.gov/pubmed/27903600 Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On- CEFEPIME Demand Digital Dispensing Method. Topical compositions comprising hydroxy acids and cannabinoids for https://www.google.com/patents/US20170042791 CEFEPIME skin care https://www.researchgate.net/publication/326880333_ Formulation and evaluation of cefixime trihydrate topical gel for Formulation_and_evaluation_of_cefixime_trihydrate_t CEFIXIME wound infections opical_gel_for_wound_infections Preparation and evaluation of mucin-gelatin mucoadhesive http://www.ncbi.nlm.nih.gov/pubmed/17613033 CEFTRIAXONE microspheres for rectal delivery of ceftriaxone sodium. Enteral, oral, and rectal absorption of ceftriaxone using glyceride http://www.ncbi.nlm.nih.gov/pubmed/3391054 CEFTRIAXONE enhancers. Early Results of Adjuvant Topical Treatment of Recurrent https://www.ncbi.nlm.nih.gov/pubmed/28081583 CEFTRIAXONE Osteomyelitis with Absorbable Antibiotic Carriers. A pilot study evaluating the prescribing of ceftriaxone in hospitals in https://www.ncbi.nlm.nih.gov/pubmed/28657382 CEFTRIAXONE Ghana: findings and implications. Evaluation of ceftriaxone utilization in medical and emergency wards of Tikur Anbessa specialized hospital: a prospective cross-sectional https://www.ncbi.nlm.nih.gov/pubmed/26891697 CEFTRIAXONE study. CEFTRIAXONE Pulmonary Embolism After Ceftriaxone-Induced Anaphylaxis https://www.ncbi.nlm.nih.gov/pubmed/28570226 The effect of hypoxia and cycloxygenase inhibitors on nasal polyp https://www.ncbi.nlm.nih.gov/pubmed/21315485 CELECOXIB derived fibroblasts.

A comparison of the efficacy and safety of mupirocin cream and http://www.ncbi.nlm.nih.gov/pubmed/11952661 CEPHALEXIN cephalexin in the treatment of secondarily infected eczema Medication Title of Article PubMed Link Mupirocin cream is as effective as oral cephalexin in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/9866667 CEPHALEXIN secondarily infected wounds Severe cutaneous psoriasis after certolizumab pegol treatment: https://www.ncbi.nlm.nih.gov/pubmed/?term=1988825 CERTOLIZUMAB report of a case. 7

Successful treatment of moderate to severe plaque psoriasis with the https://www.ncbi.nlm.nih.gov/pubmed/?term=2241394 CERTOLIZUMAB PEGylated Fab' certolizumab pegol: results of a phase II randomized, 4 placebo-controlled trial with a re-treatment extension. https://www.ncbi.nlm.nih.gov/pubmed/?term=2816582 CERTOLIZUMAB Certolizumab pegol for the treatment of psoriasis. [Review] 8 Comparison of Nasal Saline Irrigation Bottle Contamination Between https://www.clinicaltrials.gov/ct2/show/NCT02413125 CHITORHINO Two Solutions Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis http://www.ncbi.nlm.nih.gov/pubmed/16299322 serogroup C polysaccharide-CRM197 conjugate vaccine mixed with CHITOSAN chitosan

Analgesic efficacy and safety of morphine-chitosan nasal solution in http://www.ncbi.nlm.nih.gov/pubmed/18254761 CHITOSAN patients with moderate to severe pain following orthopedic surgery CHITOSAN Intranasal delivery of morphine http://www.ncbi.nlm.nih.gov/pubmed/11907197 Chitosan gel-embedded moxifloxacin niosomes: An efficient http://www.ncbi.nlm.nih.gov/pubmed/26794314 CHITOSAN antimicrobial hybrid system for burn infection Chitosan gel formulations containing egg yolk oil and epidermal http://www.ncbi.nlm.nih.gov/pubmed/25997244 CHITOSAN growth factor for dermal burn treatment Topical vs Combination in the Management of http://www.ncbi.nlm.nih.gov/pubmed/25121008 CIPROFLOXACIN Discharging Chronic Suppurative Otitis Media

A randomised controlled trial of active chronic otitis media comparing http://www.ncbi.nlm.nih.gov/pubmed/22804826 courses of eardrops versus one-off topical treatments suitable for CIPROFLOXACIN primary, secondary and tertiary healthcare settings Effect of ciprofloxacin/dexamethasone versus ciprofloxacin/hydrocortisone on lipopolysaccharide-induced http://www.ncbi.nlm.nih.gov/pubmed/21493267 CIPROFLOXACIN experimental otitis media Medication Title of Article PubMed Link Aqueous humor tyrosinase activity is indicative of iris melanocyte https://www.ncbi.nlm.nih.gov/pubmed/28712540 CIPROFLOXACIN toxicity. Prospective, Randomized Clinical Trial of Povidone-Iodine 1.25% Solution Versus Topical Antibiotics for Treatment of Bacterial https://www.ncbi.nlm.nih.gov/pubmed/27984024 CIPROFLOXACIN Keratitis. A novel gel based on an ionic complex from a dendronized polymer and ciprofloxacin: Evaluation of its use for controlled topical drug https://www.ncbi.nlm.nih.gov/pubmed/27612709 CIPROFLOXACIN release. Efficacy and Safety of Ciprofloxacin Plus in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized https://www.ncbi.nlm.nih.gov/pubmed/28006041 CIPROFLOXACIN Clinical Trial. A comparison between the effectiveness of , single- dose clarithromycin and topical in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/21923567 CLARITHROMYCIN erythrasma.

An unreported side effect of topical clarithromycin when used https://www.ncbi.nlm.nih.gov/pubmed/10487437 CLARITHROMYCIN successfully to treat Mycobacterium avium-intracellulare keratitis.

Clindamycin Phosphate 1.2%/ 0.025% Gel for the Treatment http://www.ncbi.nlm.nih.gov/pubmed/26155323 CLINDAMYCIN of Acne Vulgaris: Which Patients are Most Likely to Benefit the Most?

The efficacy and tolerability of a fixed combination clindamycin http://www.ncbi.nlm.nih.gov/pubmed/25844612 (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with CLINDAMYCIN facial acne vulgaris: gender as a clinically relevant outcome variable Topical therapy for acne in women: is there a role for clindamycin http://www.ncbi.nlm.nih.gov/pubmed/25372252 CLINDAMYCIN phosphate-benzoyl peroxide gel? Clindamycin phosphate-tretinoin combination gel revisited: status https://www.ncbi.nlm.nih.gov/pubmed/28398420 CLINDAMYCIN report on a specific formulation used for acne treatment. Antimicrobial activity of topical agents against Propionibacterium acnes: an in vitro study of clinical isolates from a hospital in https://www.ncbi.nlm.nih.gov/pubmed/27896620 CLINDAMYCIN Shanghai, China.

When do efficacy outcomes in clinical trials correlate with clinical https://www.ncbi.nlm.nih.gov/pubmed/27529706 relevance? analysis of clindamycin phosphate 1.2%-benzoyl peroxide CLINDAMYCIN 3.75% gel in moderate to severe acne vulgaris. Medication Title of Article PubMed Link The extinction of topical erythromycin therapy for acne vulgaris and https://www.ncbi.nlm.nih.gov/pubmed/27425633 CLINDAMYCIN concern for the future of topical clindamycin. Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a https://www.ncbi.nlm.nih.gov/pubmed/27272079 CLINDAMYCIN 21-Day Treatment Period. A multicentre, randomized, single-blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once-daily gel versus https://www.ncbi.nlm.nih.gov/pubmed/27075705 clindamycin 1% twice-daily gel in the treatment of mild to moderate CLINDAMYCIN acne vulgaris in Chinese patients. A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide https://www.ncbi.nlm.nih.gov/pubmed/26915831 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of CLINDAMYCIN mild-to-moderate acne vulgaris. Efficacy, tolerability, impact on quality of life and sebostatic activity of three topical preparations for the treatment of mild to moderate facial https://www.ncbi.nlm.nih.gov/pubmed/25236322 CLINDAMYCIN acne vulgaris. Treating umbilical granuloma with topical clobetasol propionate cream at home is as effective as treating it with topical silver nitrate in http://www.ncbi.nlm.nih.gov/pubmed/25297721 CLOBETASOL the clinic

Efficacy of laser phototherapy in comparison to topical clobetasol for http://www.ncbi.nlm.nih.gov/pubmed/24887747 CLOBETASOL the treatment of oral lichen planus: a randomized controlled trial Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo--part II: rheological http://www.ncbi.nlm.nih.gov/pubmed/24767976 characterization and in vivo assessment through CLOBETASOL dermatopharmacokinetic and pilot clinical studies Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia http://www.ncbi.nlm.nih.gov/pubmed/24226568 CLOBETASOL areata in children: a randomized clinical trial Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized http://www.ncbi.nlm.nih.gov/pubmed/23067089 CLOBETASOL double-blind trial The efficacy of '0.05% Clobetasol + 2.5% sulphate' cream vs. '0.05% Clobetasol alone' cream in the treatment of the chronic hand http://www.ncbi.nlm.nih.gov/pubmed/18284511 CLOBETASOL eczema: a double-blind study Medication Title of Article PubMed Link

Comparative efficacy of topical 1% and 1% in http://www.ncbi.nlm.nih.gov/pubmed/16428155 CLOTRIMAZOLE tinea cruris and tinea corporis: a randomized, double-blind trial. A double-blind randomized comparative trial: 1% cream versus clotrimazole 1% cream twice daily in Candida and http://www.ncbi.nlm.nih.gov/pubmed/11486455 CLOTRIMAZOLE dermatophyte skin infections Topical treatment of interdigital tinea pedis: compared http://www.ncbi.nlm.nih.gov/pubmed/10570555 CLOTRIMAZOLE with clotrimazole Local antibacterial therapy for the inflammatory diseases of the http://www.ncbi.nlm.nih.gov/pubmed/22951697 CLOTRIMAZOLE external and middle Randomized, comparative, double-blind, double-dummy, multicenter trial of buccal and clotrimazole troches for the http://www.ncbi.nlm.nih.gov/pubmed/20974574 treatment of oropharyngeal candidiasis: study of miconazole CLOTRIMAZOLE Lauriad® efficacy and safety (SMiLES)

Single-dose oral fluconazole versus topical clotrimazole in patients http://www.ncbi.nlm.nih.gov/pubmed/20649710 CLOTRIMAZOLE with pityriasis versicolor: A double-blind randomized controlled trial

Corneal ulceration in south-east Asia III: prevention of fungal keratitis http://www.ncbi.nlm.nih.gov/pubmed/16916874 CLOTRIMAZOLE at the village level in south India using topical antibiotics A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two http://www.ncbi.nlm.nih.gov/pubmed/15078430 formats) with oral single dose fluconazole (Diflucan) in vulvovaginal CLOTRIMAZOLE mycoses Topical as an alternative in the treatment of acute http://www.ncbi.nlm.nih.gov/pubmed/12942250 CLOTRIMAZOLE vulvovaginal candidosis Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the http://www.ncbi.nlm.nih.gov/pubmed/10536434 treatment of interdigital tinea pedis: a randomized, double-blind, multi- CLOTRIMAZOLE centre, 8-week clinical trial Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal containing sulfanilamide, http://www.ncbi.nlm.nih.gov/pubmed/9132982 aminacrine hydrochloride, and allantoin in the treatment of CLOTRIMAZOLE symptomatic trichomoniasis Medication Title of Article PubMed Link Comparison of the efficacy and safety of oral fluconazole and topical http://www.ncbi.nlm.nih.gov/pubmed/8698375 CLOTRIMAZOLE clotrimazole in patients with candida balanitis Treatment of superficial mycoses in the tropics: Whitfield's ointment http://www.ncbi.nlm.nih.gov/pubmed/8002148 CLOTRIMAZOLE versus clotrimazole A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the http://www.ncbi.nlm.nih.gov/pubmed/8186134 CLOTRIMAZOLE treatment of tinea pedis

Does have anti-inflammatory properties? A double-blind http://www.ncbi.nlm.nih.gov/pubmed/8217759 comparative study with 1% clotrimazole/1% hydrocortisone in CLOTRIMAZOLE clinically diagnosed fungal infection of the skin Combination dermatological products: a comparison of betamethasone dipropionate/clotrimazole/gentamicin sulphate and http://www.ncbi.nlm.nih.gov/pubmed/2960577 CLOTRIMAZOLE flumethasone pivalate/ cream Comparison of and clotrimazole vaginal tablets in the http://www.ncbi.nlm.nih.gov/pubmed/3520601 CLOTRIMAZOLE treatment of vulvovaginal candidosis Treatment of vaginal candidosis using clotrimazole vaginal cream: http://www.ncbi.nlm.nih.gov/pubmed/3896661 CLOTRIMAZOLE single dose versus 3-day therapy

Multicenter double-blind contralateral comparison of naftifin and http://www.ncbi.nlm.nih.gov/pubmed/6388169 CLOTRIMAZOLE clotrimazole cream in patients with and candidiasis

Double-blind investigation of R-42470 (terconazole cream 0.4%) and http://www.ncbi.nlm.nih.gov/pubmed/6529776 CLOTRIMAZOLE clotrimazole (cream 1%) for the topical treatment of mycotic vaginitis Single blind comparison of 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute http://www.ncbi.nlm.nih.gov/pubmed/6329405 CLOTRIMAZOLE vaginal candidosis

A double-blind comparison of nitrate 1% cream with http://www.ncbi.nlm.nih.gov/pubmed/6337618 CLOTRIMAZOLE clotrimazole 1% cream in the treatment of dermatophytoses CLOTRIMAZOLE Topical clotrimazole in tinea pedis http://www.ncbi.nlm.nih.gov/pubmed/320670 Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, https://www.ncbi.nlm.nih.gov/pubmed/28120351 CLOTRIMAZOLE randomised clinical trial. Medication Title of Article PubMed Link The Effects of Ozonated and Clotrimazole Cream for https://www.ncbi.nlm.nih.gov/pubmed/27548492 CLOTRIMAZOLE Treatment of Vulvovaginal Candidiasis. A comparison of Locacorten-Vioform and clotrimazole in otomycosis: https://www.ncbi.nlm.nih.gov/pubmed/26600419 CLOTRIMAZOLE A systematic review and one-way meta-analysis. COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=1610712 Re-examining crude coal tar treatment for psoriasis. Detection of DNA adducts in skin biopsies of coal tar-treated COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=2127679 psoriasis patients: immunofluorescence and 32P postlabeling. Formation of DNA adducts in the skin of psoriasis patients, in human COAL TAR skin in organ culture, and in mouse skin and lung following topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2299199 application of coal-tar and juniper tar.

COAL TAR Low concentration dithranol and coal tar (Psorin) in psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2590619 comparison with alcoholic coal tar extract and allantoin (Alphosyl). Effectiveness of a new coal tar preparation in the treatment of COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=2590625 chronic plaque-type psoriasis. Effect of UVB therapy and a coal tar bath on short contact dithranol COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=3042009 treatment for psoriasis. Lack of additive effect of coal tar combined with dithranol for COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=3214958 psoriasis. COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=3256465 Treatment of psoriasis with a combination of dithranol and coal tar.

The importance of the coal tar bath in the Ingram treatment of COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=3281703 psoriasis. Evaluation by evaporimetry and laser Doppler flowmetry.[Erratum appears in Br J Dermatol 1988 Jul;119(1):140] Quantitation of polycyclic aromatic hydrocarbons, 1-hydroxypyrene, COAL TAR and mutagenicity in urine of coal tar-treated psoriasis patients and https://www.ncbi.nlm.nih.gov/pubmed/?term=8049634 untreated volunteers. Comparative effects of calcipotriol ointment (50 micrograms/g) and COAL TAR 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating https://www.ncbi.nlm.nih.gov/pubmed/?term=9158266 plaque psoriasis. COAL TAR https://www.ncbi.nlm.nih.gov/pubmed/?term=9169338 Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?. Medication Title of Article PubMed Link A double blind, randomized, controlled clinical trial to assess the https://www.ncbi.nlm.nih.gov/pubmed/?term=1116796 COAL TAR efficacy of a new coal tar preparation (Exorex) in the treatment of 5 chronic, plaque type psoriasis. Crude coal tar treatment every day versus every other day for plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1155889 COAL TAR psoriasis. 0 Comparison of calcipotriol and coal tar in conjunction with sun https://www.ncbi.nlm.nih.gov/pubmed/?term=1156016 COAL TAR exposure in chronic plaque psoriasis: a pilot study. 3 The effects of topical corticosteroids and a coal tar preparation on https://www.ncbi.nlm.nih.gov/pubmed/?term=1256682 COAL TAR dithranol-induced irritation in patients with psoriasis. 4 Observer-blind, randomized, intrapatient comparison of a novel 1% https://www.ncbi.nlm.nih.gov/pubmed/?term=1293224 COAL TAR coal tar preparation (Exorex) and calcipotriol cream in the treatment 2 of plaque type psoriasis. Calcipotriol versus coal tar: a prospective randomized study in stable https://www.ncbi.nlm.nih.gov/pubmed/?term=1452170 COAL TAR plaque psoriasis. 5 Double-blind, randomised, multicentre, parallel group study https://www.ncbi.nlm.nih.gov/pubmed/?term=1475464 COAL TAR comparing a 1% coal tar preparation (Exorex) with a 5% coal tar 4 preparation (Alphosyl) in chronic plaque psoriasis. Dandruff, seborrheic dermatitis, and psoriasis drug products https://www.ncbi.nlm.nih.gov/pubmed/?term=1744734 COAL TAR containing coal tar and menthol for over-the-counter human use; 1 amendment to the monograph. Final rule. A novel LCD (coal tar) solution for psoriasis does not discolor https://www.ncbi.nlm.nih.gov/pubmed/?term=1973552 COAL TAR naturally light or color-processed hair in an exaggerated exposure 0 test model. No increased risk of cancer after coal tar treatment in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2001649 COAL TAR psoriasis or eczema. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2048646 COAL TAR Tolerability and cosmetic acceptability of liquor carbonis distillate 3 (coal tar) solution 15% as topical therapy for plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2094195 COAL TAR An evidence-based review of the efficacy of coal tar preparations in 1 the treatment of psoriasis and atopic dermatitis. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2167191 COAL TAR Novel stain-free lecithinized coal tar formulation for psoriasis. 1 Medication Title of Article PubMed Link DNA adducts in skin biopsies and 1-hydroxypyrene in urine of https://www.ncbi.nlm.nih.gov/pubmed/?term=2181045 COAL TAR psoriasis patients and healthy volunteers following treatment with 6 coal tar. Comparative evaluation of topical calcipotriol versus coal tar and https://www.ncbi.nlm.nih.gov/pubmed/?term=2398615 COAL TAR salicylic acid ointment in chronic plaque psoriasis. 9 Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10- epoxide-DNA adducts and chromosomal aberration in children with https://www.ncbi.nlm.nih.gov/pubmed/?term=2519742 COAL TAR psoriasis repeatedly exposed to crude coal tar ointment and UV 9 radiation. Review of the mechanism of action of coal tar in psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2881411 COAL TAR [Review][Erratum appears in J Dermatolog Treat. 2018 May;29(3):x; 7 PMID: 29415583] COAL Effect of treatment with methotrexate and coal tar on adipokine levels https://www.ncbi.nlm.nih.gov/pubmed/?term=2466591 TAR, METHOTREXA and indices of insulin resistance and sensitivity in patients with 0 TE psoriasis vulgaris. COAL https://www.ncbi.nlm.nih.gov/pubmed/?term=2873101 TAR, METHOTREXA Methotrexate iontophoresis versus coal tar ointment in palmoplantar 7 TE psoriasis: A pilot study. COAL https://www.ncbi.nlm.nih.gov/pubmed/?term=2150703 TAR, PHOTOTHERA Comparison of clobetasol propionate cream plus coal tar vs. topical 6 PY psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. COAL https://www.ncbi.nlm.nih.gov/pubmed/?term=2647689 TAR, PHOTOTHERA Crude Coal Tar and Ultraviolet (UV) A radiation (Modified 9 PY Goeckerman Technique) in Treatment of Psoriasis. COAL https://www.ncbi.nlm.nih.gov/pubmed/?term=1987437 Topical tazarotene vs. coal tar in stable plaque psoriasis.[Erratum TAR, TAZAROTENE 6 appears in Clin Exp Dermatol. 2010 Aug;35(6):685] NICE guidance on colistimethate sodium and tobramycin for http://www.ncbi.nlm.nih.gov/pubmed/24429083 COLISTIMETHATE pseudomonas lung infection in cystic fibrosis Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic http://www.ncbi.nlm.nih.gov/pubmed/23135343 COLISTIMETHATE fibrosis: a randomised study Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic http://www.ncbi.nlm.nih.gov/pubmed/18060092 COLISTIMETHATE fibrosis Medication Title of Article PubMed Link Inhaled as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated http://www.ncbi.nlm.nih.gov/pubmed/19732088 COLISTIMETHATE pneumonia: a comparative cohort study. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by http://www.ncbi.nlm.nih.gov/pubmed/20876621 COLISTIMETHATE Gram-negative bacteria A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment http://www.ncbi.nlm.nih.gov/pubmed?term=22085766 of nosocomial pneumonia associated with multidrug-resistant COLISTIMETHATE Pseudomonas aeruginosa. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a http://www.ncbi.nlm.nih.gov/pubmed?term=20973727 COLISTIMETHATE matched case-control study. Inhaled colistin for the treatment of tracheobronchitis and pneumonia http://www.ncbi.nlm.nih.gov/pubmed?term=20658485 COLISTIMETHATE in critically ill children without cystic fibrosis.

Treatment of recurrent Stenotrophomonas maltophilia ventilator- http://www.ncbi.nlm.nih.gov/pubmed?term=20736426 COLISTIMETHATE associated pneumonia with doxycycline and aerosolized colistin. http://www.ncbi.nlm.nih.gov/pubmed?term=20119725 COLISTIMETHATE Colistin administration to pediatric and neonatal patients.

Nebulized bacitracin/colimycin: a treatment option in recalcitrant http://www.ncbi.nlm.nih.gov/pubmed?term=18575008 chronic rhinosinusitis with Staphylococcus aureus? A double-blind, COLISTIMETHATE randomized, placebo-controlled, cross-over pilot study. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a http://www.ncbi.nlm.nih.gov/pubmed?term=18060758 COLISTIMETHATE prospective study. Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic http://www.ncbi.nlm.nih.gov/pubmed?term=18060092 COLISTIMETHATE fibrosis. Effect of long-term nebulized colistin on lung function and quality of http://www.ncbi.nlm.nih.gov/pubmed?term=17547727 COLISTIMETHATE life in patients with chronic bronchial sepsis. http://www.ncbi.nlm.nih.gov/pubmed?term=16396919 COLISTIMETHATE Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. COLISTIMETHATE Chronic Rhinosinusitis in Patients with Cystic Fibrosis https://www.ncbi.nlm.nih.gov/pubmed Medication Title of Article PubMed Link COLISTIMETHATE Chronic Rhinosinusitis in Patients with Cystic Fibrosis. https://www.ncbi.nlm.nih.gov/pubmed/27393775 Multi-drug resistant Pseudomonas aeruginosa keratitis and its https://www.ncbi.nlm.nih.gov/pubmed/27050354 COLISTIMETHATE effective treatment with topical colistimethate.

Exogenous pulmonary surfactant as a vehicle for antimicrobials: https://www.ncbi.nlm.nih.gov/pubmed/24876994 COLISTIMETHATE assessment of surfactant-antibacterial interactions in vitro. https://www.ncbi.nlm.nih.gov/pubmed/27682964 COLISTIMETHATE Stability study of sodium colistimethate-loaded lipid nanoparticles. Efficacy and toxicity of high-dose nebulized colistin for critically ill COLISTIN surgical patients with ventilator-associated pneumonia caused by https://www.ncbi.nlm.nih.gov/pubmed/28458172 multidrug-resistant Acinetobacter baumannii Efficacy of nebulized colistin-based therapy without concurrent COLISTIN intravenous colistin for ventilator-associated pneumonia caused by https://www.ncbi.nlm.nih.gov/pubmed/28449463 carbapenem-resistant Acinetobacter baumannii Nebulized colistin for treatment of ventilator-associated pneumonia COLISTIN caused by multidrug-resistant Gram-negative bacteria: we still need https://www.ncbi.nlm.nih.gov/pubmed/26113262 to straighten out the dose!

COLLAGENASE Topical silver sulfadiazine vs collagenase ointment for the treatment http://www.ncbi.nlm.nih.gov/pubmed/22703794 (SANTYL) of partial thickness burns in children: a prospective randomized trial COLLAGENASE Wound healing in partial-thickness burn wounds treated with http://www.ncbi.nlm.nih.gov/pubmed/7673302 (SANTYL) collagenase ointment versus silver sulfadiazine cream Nursing preference of topical silver sulfadiazine versus collagenase COLLAGENASE ointment for treatment of partial thickness burns in children: survey http://www.ncbi.nlm.nih.gov/pubmed/25198082 (SANTYL) follow-up of a prospective randomized trial [A clinical study of gelatamp colloidal silver gelatin on https://www.ncbi.nlm.nih.gov/pubmed/19007075 COLLOIDAL SILVER preventing the complication of teeth extraction]. Colloidal silver: a novel treatment for Staphylococcus aureus https://www.ncbi.nlm.nih.gov/pubmed/24431107 COLLOIDAL SILVER biofilms? Colloidal silver-based nanogel as nonocclusive dressing for multiple https://www.ncbi.nlm.nih.gov/pubmed/27453869 COLLOIDAL SILVER superficial pellet wounds. Efficacy of a new medical device based on colloidal silver and carbossimetyl beta glucan in treatment of upper airways disease in https://www.ncbi.nlm.nih.gov/pubmed/21946445 COLLOIDAL SILVER children. Medication Title of Article PubMed Link Efficacy of some colloidal silver preparations and silver salts against https://www.ncbi.nlm.nih.gov/pubmed/24390313 Proteus bacteria, one possible cause of rheumatoid arthritis. COLLOIDAL SILVER Nano-colloidal silver and chitosan bioactive wound dressings in https://www.ncbi.nlm.nih.gov/pubmed/30207850 COLLOIDAL SILVER managing diabetic foot ulcers: case series. The effectiveness of topical colloidal silver in recalcitrant chronic https://www.ncbi.nlm.nih.gov/pubmed/29178954 COLLOIDAL SILVER rhinosinusitis: a randomized crossover control trial. Topical Colloidal Silver for the Treatment of Recalcitrant Chronic https://www.ncbi.nlm.nih.gov/pubmed/29696011 COLLOIDAL SILVER Rhinosinusitis. Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a http://www.ncbi.nlm.nih.gov/pubmed/25060803 CORTICOSTEROID randomized clinical trial

Efficacy of honey in comparison to topical corticosteroid for treatment http://www.ncbi.nlm.nih.gov/pubmed/25019115 of recurrent minor aphthous ulceration: a randomized, blind, CORTICOSTEROID controlled, parallel, double-center clinical trial CYCLOBENZAPRIN Skin Permeation and Antinociception of Compounded Topical http://www.ncbi.nlm.nih.gov/pubmed/26685496 E Cyclobenzaprine Hydrochloride Formulations Retrospective Evaluation on the Activities of 2 CYCLOBENZAPRIN Compounded Topical Creams and Voltaren Gel in Chronic http://www.ncbi.nlm.nih.gov/pubmed/26352120 E Noncancer Pain Studies of the effect of cyclosporine in psoriasis in vivo: combined CYCLOSPORINE effects on activated T lymphocytes and epidermal regenerative https://www.ncbi.nlm.nih.gov/pubmed/?term=1372027 maturation. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1401280 clinical significance when viewed as a risk factor for cardiovascular disease. Hypertriglyceridemia in patients with psoriasis treated with CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1401300 cyclosporine. Differential effects of cyclosporine and etretinate on serum cytokine CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1401309 levels in patients with psoriasis. Cyclosporine therapy for psoriasis: a cell cycle-derived dosing CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1401311 schedule. Medication Title of Article PubMed Link

CYCLOSPORINE Bullous pemphigoid and severe erythrodermic psoriasis: combined https://www.ncbi.nlm.nih.gov/pubmed/?term=1430380 low-dose treatment with cyclosporine and systemic steroids. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1478774 Topical cyclosporine is ineffective in the treatment of psoriasis. Can maintenance cyclosporine be used in psoriasis without CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1493094 decreasing renal function?. [Review] [69 refs] CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1493100 Psoriasis symposium. Cyclosporine. Alterations in renal function in psoriasis patients treated with CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1552052 cyclosporine, 5 mg/kg/day. Morphologic renal changes during cyclosporine treatment of CYCLOSPORINE psoriasis. Studies on pretreatment and posttreatment kidney biopsy https://www.ncbi.nlm.nih.gov/pubmed/?term=1564147 specimens. Intralesional cyclosporine for psoriasis. Relationship of dose, tissue CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1599264 levels, and efficacy. The development of B-cell lymphoma in a patient with psoriasis CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1613146 treated with cyclosporine.

Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell- CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1677800 cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. Multiple eruptive benign keratoses associated with cyclosporine CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1732322 therapy for psoriasis. Cyclosporine in psoriasis: a multicenter dose-finding study in severe CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1732342 plaque psoriasis. The German Multicenter Study. Hypertriglyceridemia in patients with psoriasis treated with CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1791223 cyclosporine. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1822409 Cyclosporine A in psoriasis. [Review] [62 refs] Cyclosporine for plaque-type psoriasis. Results of a multidose, CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1986287 double-blind trial. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1986292 Systemic treatment of severe psoriasis--the role of cyclosporine. Medication Title of Article PubMed Link CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1998383 Psoriasis, cyclosporine, and pregnancy. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=1999519 Bullous pemphigoid and psoriasis: treatment with cyclosporine. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2041556 Cyclosporine for treatment of psoriasis. Worldwide experience with Sandimmune (cyclosporine) in CYCLOSPORINE autoimmune diseases: multiple sclerosis, rheumatoid arthritis, https://www.ncbi.nlm.nih.gov/pubmed/?term=2096278 psoriasis. Is cyclosporine blood concentration monitoring necessary in patients CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2190392 treated for severe chronic plaque form psoriasis?. Acrodermatitis continua-type of pustular psoriasis responds to low- CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2212157 dose cyclosporine. Cyclosporine A in the treatment of psoriasis: a clinical and CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2230215 mechanistic perspective. [Review] [15 refs] Differential effects of cyclosporine A on Langerhans cells and CYCLOSPORINE regulatory T-cell populations in severe psoriasis: an https://www.ncbi.nlm.nih.gov/pubmed/?term=2252524 immunohistochemical and flow cytometric analysis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2254478 Rapid response of von Zumbusch psoriasis to cyclosporine. Systemic and local administration of cyclosporine in the treatment of CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2277131 psoriasis. Effects of cyclosporine on renal function in psoriasis patients. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2277137 [Review] [42 refs] Effects of cyclosporine on immunologic mechanisms in psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2277141 [Review] [119 refs] Placebo-controlled study of psoriasis patients treated topically with a CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2298950 10% cyclosporine gel. Intralesional cyclosporine in the treatment of psoriasis. A clinical, CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2298969 immunologic, and pharmacokinetic study. Low predictive value of cyclosporine level for efficacy or renal CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2349691 dysfunction in psoriasis and idiopathic nephrotic syndrome. Two distinct squamous cell carcinomas in a psoriasis patient CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2584466 receiving low-dose cyclosporine maintenance treatment. Medication Title of Article PubMed Link

CYCLOSPORINE Cyclosporine therapy for psoriasis: serum creatinine measurements https://www.ncbi.nlm.nih.gov/pubmed/?term=2778110 are an unreliable predictor of decreased renal function. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2787338 and immunologic study. Effects of cyclosporine A treatment on psoriasis. I: Influence of low- CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=2837854 dose cyclosporine on human monocyte function in vitro. The effects of cyclosporine A on T lymphocyte and dendritic cell CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3260052 subpopulations in psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3260053 Cyclosporine A in psoriasis: an immunohistological study. Low-dose cyclosporine effective in severe psoriasis: a double-blind CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3289211 study. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3346422 Topical cyclosporine in psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381276 Long-term cyclosporine in the management of psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381279 Cyclosporine for the treatment of psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381301 Cyclosporine maintenance therapy in psoriasis. Combination of cyclosporine A and topical corticosteroid in the CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381302 treatment of psoriasis. Resistant severe psoriasis controlled with systemic cyclosporine CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381303 therapy. Cyclosporine for psoriasis: beneficial effect in refractory skin and joint CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381304 disease. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=3381305 Low-dose cyclosporine A in severe psoriasis. Effects of cyclosporine on cytokines and cytokine receptors in CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=7490364 psoriasis. Low-dose cyclosporine A improves severe disabling psoriasis in Latin CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=7591445 America. Latin American Multicenter Study. Medication Title of Article PubMed Link Duration of remission during maintenance cyclosporine therapy for CYCLOSPORINE psoriasis. Relationship to maintenance dose and degree of https://www.ncbi.nlm.nih.gov/pubmed/?term=7611794 improvement during initial therapy. Long-term maintenance therapy with cyclosporine and posttreatment CYCLOSPORINE survey in severe psoriasis: results of a multicenter study. German https://www.ncbi.nlm.nih.gov/pubmed/?term=7657870 Multicenter Study. Cyclosporine: a new therapeutic option for severe, recalcitrant CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=7727196 psoriasis. Renal structure and function effects after low dose cyclosporine in CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=7774069 psoriasis patients: a preliminary report. Additive effects of calcipotriol and cyclosporine A: from in vitro CYCLOSPORINE experiments to in vivo applications in the treatment of severe https://www.ncbi.nlm.nih.gov/pubmed/?term=7994616 psoriasis. A novel therapeutic approach to psoriasis with combination CYCLOSPORINE calcipotriol ointment and very low-dose cyclosporine: results of a https://www.ncbi.nlm.nih.gov/pubmed/?term=8021375 multicenter placebo-controlled study. Development of human papillomavirus-associated Buschke- CYCLOSPORINE Lowenstein penile carcinoma during cyclosporine therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=8040428 generalized pustular psoriasis. Combination of etretinate with cyclosporine in the treatment of severe CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8188867 recalcitrant psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8245246 Effect of cyclosporine on genital psoriasis and lichen planus. Development of human papillomavirus-associated Buschke- CYCLOSPORINE Lowenstein penile carcinoma during cyclosporine therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=8393464 generalized pustular psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8651712 Long-term safety of cyclosporine in the treatment of psoriasis. Efficacy and pharmacokinetics of two formulations of cyclosporine A CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8786246 in patients with psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8859044 Treatment of psoriasis by cyclosporine and grapefruit juice. Adenocarcinoma of the mouth in a patient with psoriasis under short- CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8864632 term cyclosporine therapy. [Review] [9 refs] Medication Title of Article PubMed Link Long-term low-dose cyclosporine therapy for severe psoriasis: CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8912566 effects on renal function and structure. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=8959979 Cyclosporine and angiogenesis in psoriasis. Cyclosporine as maintenance therapy in patients with severe CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9091474 psoriasis. Effects of cyclosporine on cytokines and cytokine receptors in CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9092768 psoriasis. Alleviation of HIV-associated psoriasis and psoriatic arthritis with CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9308575 cyclosporine. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9344222 Long-term low-dose cyclosporine therapy for psoriasis. CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9466216 Risk of cancer with cyclosporine in psoriasis. Calcipotriol improves the efficacy of cyclosporine in the treatment of CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9553911 psoriasis vulgaris. Individual pharmacodynamics assessed by antilymphocyte action CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9585801 predicts clinical cyclosporine efficacy in psoriasis. Effect of obesity on cyclosporine trough concentrations in psoriasis CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9706187 patients. Cyclosporine consensus conference: with emphasis on the treatment CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9738783 of psoriasis. [Review] [74 refs] Efficacy of cyclosporine plus etretinate in the treatment of CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9784049 erythrodermic psoriasis (three case reports). Eruptive angiomas after treatment with cyclosporine in a patient with CYCLOSPORINE https://www.ncbi.nlm.nih.gov/pubmed/?term=9828895 psoriasis. 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress https://www.ncbi.nlm.nih.gov/pubmed/?term=1059475 CYCLOSPORINE induction and promote resolution of psoriasis in human skin grafts 6 transplanted on to SCID mice. https://www.ncbi.nlm.nih.gov/pubmed/?term=1110752 CYCLOSPORINE Cyclosporine in the treatment of psoriasis. 2 Intermittent short courses of cyclosporine microemulsion for the long- https://www.ncbi.nlm.nih.gov/pubmed/?term=1126054 CYCLOSPORINE term management of psoriasis: a 2-year cohort study. 0 Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 https://www.ncbi.nlm.nih.gov/pubmed/?term=1170262 CYCLOSPORINE patients. 0 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1170896 CYCLOSPORINE Cyclosporine in childhood psoriasis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1175283 CYCLOSPORINE Bilateral femoral avascular necrosis in a man with psoriasis: 4 responsibility of topical corticosteroids and role of cyclosporine. Body-weight-independent dosing of cyclosporine micro-emulsion and https://www.ncbi.nlm.nih.gov/pubmed/?term=1244433 CYCLOSPORINE three times weekly maintenance regimen in severe psoriasis. A 6 randomised study. The FDA guidelines for the treatment of psoriasis using cyclosporine https://www.ncbi.nlm.nih.gov/pubmed/?term=1246978 CYCLOSPORINE A: are they adequate?. [Review] [18 refs] 3 Risk of malignancies in psoriasis patients treated with cyclosporine: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1254252 CYCLOSPORINE 5 y cohort study. 4 Primary cutaneous CD30+ large T-cell lymphoma in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=1277147 CYCLOSPORINE psoriasis treated with cyclosporine. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1546187 CYCLOSPORINE Association of cyclosporine and 311 nM UVB in the treatment of 5 moderate to severe forms of psoriasis: a new strategic approach. Early and explosive development of nodular basal cell carcinoma and https://www.ncbi.nlm.nih.gov/pubmed/?term=1562475 CYCLOSPORINE multiple keratoacanthomas in psoriasis patients treated with 3 cyclosporine. Epstein-Barr virus-associated lymphoproliferative disease after long- https://www.ncbi.nlm.nih.gov/pubmed/?term=1569250 CYCLOSPORINE standing cyclosporine therapy for psoriasis: a case of spontaneous 7 regression. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1574379 CYCLOSPORINE transgenic mice. 6 Adult T-cell lymphoma/leukaemia developing in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=1664893 CYCLOSPORINE psoriasis treated with long-term cyclosporine. 5 Cyclosporine A in the treatment of psoriasis: a clinical and https://www.ncbi.nlm.nih.gov/pubmed/?term=1678863 CYCLOSPORINE mechanistic perspective. [Review] [15 refs] 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1704320 CYCLOSPORINE Cyclosporine resolves generalized pustular psoriasis of pregnancy. 9 Optimal time for therapeutic drug monitoring of cyclosporine https://www.ncbi.nlm.nih.gov/pubmed/?term=1761481 CYCLOSPORINE microemulsion in patients with psoriasis. 3 Preprandial vs. postprandial pharmacokinetics of cyclosporine in https://www.ncbi.nlm.nih.gov/pubmed/?term=1765117 CYCLOSPORINE patients with psoriasis. 9 Medication Title of Article PubMed Link An open-label study to evaluate the transition of patients with chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=1766854 CYCLOSPORINE plaque psoriasis from cyclosporine to alefacept. 0 A comparison of two cyclosporine dosage regimens for the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1785263 CYCLOSPORINE of severe psoriasis. 2 Rebound of psoriasis after efalizumab discontinuation, despite being https://www.ncbi.nlm.nih.gov/pubmed/?term=1794136 CYCLOSPORINE on high-dose cyclosporine. 8 Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in https://www.ncbi.nlm.nih.gov/pubmed/?term=1820908 CYCLOSPORINE autoimmune inflammation through pharmacogenomic study of 9 cyclosporine A in psoriasis. Efficacy of short-term cyclosporine treatment to control psoriasis- https://www.ncbi.nlm.nih.gov/pubmed/?term=1897157 CYCLOSPORINE related events during efalizumab therapy. 7

Weight loss improves the response of obese patients with moderate- https://www.ncbi.nlm.nih.gov/pubmed/?term=1899685 CYCLOSPORINE to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: 8 a randomized, controlled, investigator-blinded clinical trial. Generalized pustular psoriasis of pregnancy successfully treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1991526 CYCLOSPORINE cyclosporine. 1 Cyclosporine and psoriasis: 2008 National Psoriasis Foundation https://www.ncbi.nlm.nih.gov/pubmed/?term=1993292 CYCLOSPORINE Consensus Conference. [Review] [117 refs] 6 Clinical outcome evaluation following cyclosporine a treatment in https://www.ncbi.nlm.nih.gov/pubmed/?term=2037802 CYCLOSPORINE moderate to severe psoriasis: a retrospective study. 5 Treatment of psoriasis with cyclosporine in patients with hepatitis C https://www.ncbi.nlm.nih.gov/pubmed/?term=2063380 CYCLOSPORINE infection: risk or opportunity?. 3 Development of pemphigus vulgaris in a patient with psoriasis treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2063381 CYCLOSPORINE with cyclosporine. 3 Eruptive nevi in a patient receiving cyclosporine A for psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2064405 CYCLOSPORINE treatment. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2124476 CYCLOSPORINE Psoriasis relapse evaluation with week-end cyclosporine A treatment: 3 results of a randomized, double-blind, multicenter study. In response to "Treatment of psoriasis with cyclosporine in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2141450 CYCLOSPORINE with hepatitis C infection: risk or opportunity?". 1 Pemphigus vulgaris with plaque-type psoriasis successfully treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2166803 CYCLOSPORINE with cyclosporine monotherapy. 5 Medication Title of Article PubMed Link Coexistence of adult T-cell leukaemia /lymphoma and psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2226650 CYCLOSPORINE treated with cyclosporine. 9 Downregulation of circulating CD4+ CD25(bright) Foxp3+ T cells by https://www.ncbi.nlm.nih.gov/pubmed/?term=2241724 CYCLOSPORINE cyclosporine therapy and correlation with clinical response in 5 psoriasis patients: report of three cases. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2317102 CYCLOSPORINE descriptive study in a series of 20 patients. 1 Maintenance treatment of psoriasis with cyclosporine A: comparison https://www.ncbi.nlm.nih.gov/pubmed/?term=2331797 CYCLOSPORINE between continuous and weekend therapy. 4 Levels of cyclosporine in breast milk and passage into the circulation https://www.ncbi.nlm.nih.gov/pubmed/?term=2333610 CYCLOSPORINE of the infant of a mother with psoriasis. 5 Cyclosporine as maintenance therapy in patients with severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2386686 CYCLOSPORINE psoriasis. [Review] 3 Cyclosporine regimens in plaque psoriasis: an overview with special https://www.ncbi.nlm.nih.gov/pubmed/?term=2398364 CYCLOSPORINE emphasis on dose, duration, and old and new treatment approaches. 7 [Review] Combined clinical, capillaroscopic and ultrasound evaluation during https://www.ncbi.nlm.nih.gov/pubmed/?term=2435524 CYCLOSPORINE treatment of plaque psoriasis with oral cyclosporine. 2 Combination therapy of cyclosporine and anti-tumor necrosis factor https://www.ncbi.nlm.nih.gov/pubmed/?term=2564026 CYCLOSPORINE alpha in psoriasis: a case series of 10 patients. 1 Pustular Psoriasis of Pregnancy Successfully Treated With https://www.ncbi.nlm.nih.gov/pubmed/?term=2636053 CYCLOSPORINE Cyclosporine. 4 Clinical experience with systemic cyclosporine A treatment in severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2665120 CYCLOSPORINE childhood psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2695431 CYCLOSPORINE Comparison of Guidelines for the Use of Cyclosporine for Psoriasis: 4 A Critical Appraisal and Comprehensive Review. [Review] Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in https://www.ncbi.nlm.nih.gov/pubmed/?term=2709670 CYCLOSPORINE Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical 9 Trial. Systemic cyclosporine treatment in severe childhood psoriasis: A https://www.ncbi.nlm.nih.gov/pubmed/?term=2777198 CYCLOSPORINE retrospective chart review. 2 Enhancement of physicochemical properties of nanocolloidal carrier https://www.ncbi.nlm.nih.gov/pubmed/?term=2840516 CYCLOSPORINE loaded with cyclosporine for topical treatment of psoriasis: in vitro 5 diffusion and in vivo hydrating action. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2946975 CYCLOSPORINE Clinical improvement of a patient with both amyopathic 4 dermatomyositis and psoriasis following treatment with cyclosporine. Superficial granulomatous pyoderma in a patient with ulcerative https://pubmed.ncbi.nlm.nih.gov/30460989 CYCLOSPORINE colitis successfully treated with cyclosporine A. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory https://pubmed.ncbi.nlm.nih.gov/26856754 CYCLOSPORINE to Steroids. [Review]

Infliximab versus cyclosporine for severe ulcerative colitis refractory https://pubmed.ncbi.nlm.nih.gov/30313056 CYCLOSPORINE to steroids: A protocol for systematic review and meta-analysis. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine https://pubmed.ncbi.nlm.nih.gov/29506124 CYCLOSPORINE Induction Therapy. Cyclosporine for severe steroid-refractory ulcerative colitis: https://pubmed.ncbi.nlm.nih.gov/29327818 CYCLOSPORINE commenting the comment.

Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid- https://pubmed.ncbi.nlm.nih.gov/28675163 Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA CYCLOSPORINE Registry (1989-2013): A Nationwide Multicenter Study.

Impact of Infliximab and Cyclosporine on the Risk of Colectomy in https://pubmed.ncbi.nlm.nih.gov/28590343 Hospitalized Patients with Ulcerative Colitis Complicated by CYCLOSPORINE Cytomegalovirus-A Multicenter Retrospective Study.

The Effective Treatment with Cyclosporine of a Ulcerative Colitis https://pubmed.ncbi.nlm.nih.gov/28566594 Patient with Concurrent Idiopathic Thrombocytopenic Purpura Who CYCLOSPORINE Subsequently Developed Spontaneous Pneumomediastinum.

Does the Cyclosporine Still Have a Potential Role in the Treatment of https://pubmed.ncbi.nlm.nih.gov/26343066 CYCLOSPORINE Acute Severe Steroid-Refractory Ulcerative Colitis?. Cyclosporine A regulates pro-inflammatory cytokine production in https://pubmed.ncbi.nlm.nih.gov/25155925 CYCLOSPORINE ulcerative colitis. Medication Title of Article PubMed Link Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/25046008 CYCLOSPORINE attacks.

Rescue therapy with cyclosporine or infliximab is not associated with https://pubmed.ncbi.nlm.nih.gov/24297054 an increased risk for postoperative complications in patients CYCLOSPORINE hospitalized for severe steroid-refractory ulcerative colitis.

Long-term increase in serum cholesterol levels in ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/24138131 patients treated with cyclosporine: an underdiagnosed side effect CYCLOSPORINE frequently associated with other drug-related complications. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta- https://pubmed.ncbi.nlm.nih.gov/23114475 CYCLOSPORINE analysis. [Review]

Cyclosporine in patients with severe steroid refractory ulcerative https://pubmed.ncbi.nlm.nih.gov/23110487 CYCLOSPORINE colitis in the era of infliximab. Review article. [Review] What is the importance of infliximab and cyclosporine in the treatment of corticosteroid-refractory severe ulcerative colitis?. https://pubmed.ncbi.nlm.nih.gov/23576083 CYCLOSPORINE [Review] Cyclosporine: does it matter if it is given for Crohn's colitis or https://pubmed.ncbi.nlm.nih.gov/22955259 CYCLOSPORINE ulcerative colitis?. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective https://pubmed.ncbi.nlm.nih.gov/22398101 CYCLOSPORINE observational study. Infliximab or cyclosporine for acute severe ulcerative colitis: a https://pubmed.ncbi.nlm.nih.gov/22098019 CYCLOSPORINE retrospective analysis. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational https://pubmed.ncbi.nlm.nih.gov/21438096 CYCLOSPORINE study. Cyclosporine in the management of severe ulcerative colitis while https://pubmed.ncbi.nlm.nih.gov/21538721 CYCLOSPORINE breast-feeding. Successive treatment with cyclosporine and infliximab in steroid- https://pubmed.ncbi.nlm.nih.gov/21386832 CYCLOSPORINE refractory ulcerative colitis. Medication Title of Article PubMed Link Long-term efficacy and safety of cyclosporine as a rescue therapy in acute, steroid-refractory severe ulcerative colitis: switching to https://pubmed.ncbi.nlm.nih.gov/21278580 infliximab is more effective than treating with concomitant CYCLOSPORINE immunomodulators. Cyclosporine is safe and effective in patients with severe ulcerative https://pubmed.ncbi.nlm.nih.gov/20679905 CYCLOSPORINE colitis. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to https://pubmed.ncbi.nlm.nih.gov/21122535 CYCLOSPORINE thiopurines. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A https://pubmed.ncbi.nlm.nih.gov/20614157 CYCLOSPORINE treatment for ulcerative colitis. CYCLOSPORINE Treatment of fulminant ulcerative colitis with cyclosporine A. https://pubmed.ncbi.nlm.nih.gov/19891581 Predictive factors of poor response to intravenous cyclosporine in https://pubmed.ncbi.nlm.nih.gov/19388796 CYCLOSPORINE steroid-refractory ulcerative colitis. Cyclosporine treatment of steroid-refractory ulcerative colitis during https://pubmed.ncbi.nlm.nih.gov/19137604 CYCLOSPORINE pregnancy. Treatment of choice for acute severe steroid-refractory ulcerative https://pubmed.ncbi.nlm.nih.gov/18266232 CYCLOSPORINE colitis is cyclosporine. [Review] [12 refs] Cyclosporine in the treatment of severe steroid refractory ulcerative https://pubmed.ncbi.nlm.nih.gov/19405256 CYCLOSPORINE colitis: a retrospective analysis of 24 cases. Cyclosporine and infliximab as rescue therapy for each other in https://pubmed.ncbi.nlm.nih.gov/18928936 CYCLOSPORINE patients with steroid-refractory ulcerative colitis. Leukocytapheresis in a girl with severe ulcerative colitis refractory to https://pubmed.ncbi.nlm.nih.gov/18421764 CYCLOSPORINE corticosteroids, infliximab, and cyclosporine A. Severe systemic cytomegalovirus infections in patients with steroid- refractory ulcerative colitis treated by an oral microemulsion form of https://pubmed.ncbi.nlm.nih.gov/18359591 CYCLOSPORINE cyclosporine: report of two cases. Predictive factors of response to cyclosporine in steroid-refractory https://pubmed.ncbi.nlm.nih.gov/18047542 CYCLOSPORINE ulcerative colitis.

Multidrug resistance gene-1 polymorphisms and resistance to https://pubmed.ncbi.nlm.nih.gov/17206635 CYCLOSPORINE cyclosporine A in patients with steroid resistant ulcerative colitis. Treatment of ulcerative colitis refractory to steroid therapy by oral https://pubmed.ncbi.nlm.nih.gov/17119387 CYCLOSPORINE microemulsion cyclosporine (Neoral). Medication Title of Article PubMed Link Incidence of colectomy during long-term follow-up after cyclosporine- https://pubmed.ncbi.nlm.nih.gov/16716758 CYCLOSPORINE induced remission of severe ulcerative colitis. Rectal malignant lymphoma complicating ulcerative colitis treated https://pubmed.ncbi.nlm.nih.gov/16460502 CYCLOSPORINE with long-term cyclosporine A. CYCLOSPORINE Infliximab or cyclosporine for severe ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/16401502 CYCLOSPORINE Cyclosporine for severe ulcerative colitis. [Review] [25 refs] https://pubmed.ncbi.nlm.nih.gov/16368919 Disseminated intravascular coagulation associated with systemic cytomegalovirus infection during cyclosporine therapy for ulcerative https://pubmed.ncbi.nlm.nih.gov/16328610 CYCLOSPORINE colitis: report of a case. Cyclosporine in the treatment of severe attack of ulcerative colitis: a https://pubmed.ncbi.nlm.nih.gov/16373009 CYCLOSPORINE systematic review. [Review] [47 refs] CYCLOSPORINE Infliximab or cyclosporine for severe ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/16230092 Intravenous cyclosporine for the treatment of severe steroid https://pubmed.ncbi.nlm.nih.gov/16007496 CYCLOSPORINE refractory ulcerative colitis: what is the cost?. Cyclosporine A for induction of remission in severe ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/15674937 CYCLOSPORINE [Review] [54 refs]

Benign intracranial hypertension during corticosteroid therapy for https://pubmed.ncbi.nlm.nih.gov/15365415 CYCLOSPORINE idiopathic ulcerative colitis: another indication for cyclosporine?. Intravenous cyclosporine in severe ulcerative colitis: how low can you https://pubmed.ncbi.nlm.nih.gov/15168819 CYCLOSPORINE go?. https://pubmed.ncbi.nlm.nih.gov/15131824 CYCLOSPORINE Open questions concerning cyclosporine therapy in ulcerative colitis. Reversible posterior leukoencephalopathy due to oral cyclosporine in https://pubmed.ncbi.nlm.nih.gov/15030042 CYCLOSPORINE severe ulcerative colitis. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the https://pubmed.ncbi.nlm.nih.gov/14567458 CYCLOSPORINE Edinburgh experience of outcome. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg https://pubmed.ncbi.nlm.nih.gov/14517785 CYCLOSPORINE intravenous cyclosporine in severe ulcerative colitis. Infliximab salvage therapy after cyclosporine in an acute flare of https://pubmed.ncbi.nlm.nih.gov/12677271 CYCLOSPORINE chronic ulcerative colitis. Oral cyclosporine in patients with active severe ulcerative colitis not https://pubmed.ncbi.nlm.nih.gov/12385545 CYCLOSPORINE responding to steroids. Medication Title of Article PubMed Link Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine https://pubmed.ncbi.nlm.nih.gov/12014423 CYCLOSPORINE maintenance therapy. Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant https://pubmed.ncbi.nlm.nih.gov/11837932 CYCLOSPORINE ulcerative colitis. Effects of cyclosporine in steroid-refractory severe acute ulcerative https://pubmed.ncbi.nlm.nih.gov/11743259 CYCLOSPORINE colitis. Comments on experimental use of intravenous cyclosporine (CsA) https://pubmed.ncbi.nlm.nih.gov/11758550 CYCLOSPORINE alone to treat severe ulcerative colitis. CYCLOSPORINE Cyclosporine, or cyclosporine not, for severe ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/11720331 CYCLOSPORINE Can cyclosporine go it alone in severe ulcerative colitis?. https://pubmed.ncbi.nlm.nih.gov/11696281 https://pubmed.ncbi.nlm.nih.gov/11475136 CYCLOSPORINE Cyclosporine in ulcerative colitis: state of the art. [Review] [31 refs] Nocardia asteroides lung abscess in acute ulcerative colitis treated https://pubmed.ncbi.nlm.nih.gov/11467663 CYCLOSPORINE with cyclosporine. Intravenous cyclosporine in severe ulcerative colitis: ready to stand https://pubmed.ncbi.nlm.nih.gov/11313325 CYCLOSPORINE alone?. Intravenous cyclosporine versus intravenous corticosteroids as single https://pubmed.ncbi.nlm.nih.gov/11313301 CYCLOSPORINE therapy for severe attacks of ulcerative colitis. Aspergillus fumigatus pneumonia during cyclosporine treatment for https://pubmed.ncbi.nlm.nih.gov/11051412 CYCLOSPORINE ulcerative colitis. Recurrent septicemia with lethal outcome during and after https://pubmed.ncbi.nlm.nih.gov/10897389 CYCLOSPORINE cyclosporine therapy in severe ulcerative colitis. CYCLOSPORINE, Cessation of cyclosporine therapy by treatment with etanercept in https://www.ncbi.nlm.nih.gov/pubmed/?term=1648832 ETANERCEPT patients with severe psoriasis. 8 CYCLOSPORINE, Subacute annular generalized pustular psoriasis treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1776360 ETANERCEPT etanercept and cyclosporine combination. 0 CYCLOSPORINE, Etanercept treatment in a hemodialysis patient with severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1893767 ETANERCEPT cyclosporine-resistant psoriasis and hepatitis C virus infection. 2 CYCLOSPORINE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2225990 Successful treatment of von Zumbusch generalized pustular ETANERCEPT 8 psoriasis with cyclosporine after eruption post etanercept injection. CYCLOSPORINE, Generalized pustular psoriasis of Zambusch: case report of https://www.ncbi.nlm.nih.gov/pubmed/?term=2309431 ETANERCEPT successful disease control with cyclosporine and etanercept. 2 Medication Title of Article PubMed Link CYCLOSPORINE, Pediatric pustular psoriasis responsive to cyclosporine bridged to https://www.ncbi.nlm.nih.gov/pubmed/?term=2944763 ETANERCEPT etanercept: A treatment approach. 8 CYCLOSPORINE, Efficacy of cyclosporine in the treatment of a case of infliximab- https://www.ncbi.nlm.nih.gov/pubmed/?term=1930957 INFLIXIMAB induced erythrodermic psoriasis. 1 CYCLOSPORINE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2521974 Erythrodermic CD8+ pseudolymphoma during infliximab treatment in INFLIXIMAB 1 a patient with psoriasis: use of cyclosporine as a rescue therapy. Cost-effectiveness comparison of therapy for psoriasis with a CYCLOSPORINE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1180743 methotrexate-based regimen versus a rotation regimen of modified METHOTREXATE 6 cyclosporine and methotrexate. CYCLOSPORINE, Methotrexate versus cyclosporine in moderate-to-severe chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=1291730 METHOTREXATE plaque psoriasis. 2 CYCLOSPORINE, Systemic therapies for psoriasis: methotrexate, retinoids, and https://www.ncbi.nlm.nih.gov/pubmed/?term=1875536 METHOTREXATE cyclosporine. [Review] [121 refs] 2

CYCLOSPORINE, High prevalence of potential drug-drug interactions for psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2013038 METHOTREXATE patients prescribed methotrexate or cyclosporine for psoriasis: 3 associated clinical and economic outcomes in real-world practice. CYCLOSPORINE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2206772 Disseminated, eruptive molluscum contagiosum lesions in a psoriasis METHOTREXATE 8 patient under treatment with methotrexate and cyclosporine. CYCLOSPORINE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2497954 METHOTREXATE Methotrexate and cyclosporine in psoriasis revisited. 2 CYCLOSPORINE, Transition from methotrexate and cyclosporine to other therapies https://www.ncbi.nlm.nih.gov/pubmed/?term=1457809 METHOTREXATE, including retinoids, ultraviolet light and biologic agents in the 3 PHOTOTHERAPY management of patients with psoriasis. [Review] [97 refs] CYCLOSPORINE, Cyclosporine is superior to tacrolimus in liver transplant recipients https://www.ncbi.nlm.nih.gov/pubmed/?term=2516382 TACROLIMUS with recurrent psoriasis. 9 Effect of a dexamethasone Sinu-Foam™ middle meatal spacer on endoscopic sinus surgery outcomes: a randomized, double-blind, http://www.ncbi.nlm.nih.gov/pubmed/22253199 DEXAMETHASONE placebo-controlled trial

Comparison of analgesic effect of preoperative topical and http://www.ncbi.nlm.nih.gov/pubmed/24968759 DICLOFENAC ketorolac on postoperative pain after photorefractive keratectomy. Medication Title of Article PubMed Link A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the http://www.ncbi.nlm.nih.gov/pubmed/23908551 DICLOFENAC treatment of acute uncomplicated ankle sprain. Randomized controlled trial of diclofenac sodium gel in knee http://www.ncbi.nlm.nih.gov/pubmed/19932833 DICLOFENAC osteoarthritis. Comparative study of actinic keratosis treatment with 3% diclofenac http://www.ncbi.nlm.nih.gov/pubmed/24173178 DICLOFENAC sodium and 5% 5-fluorouracil. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod http://www.ncbi.nlm.nih.gov/pubmed/21418281 DICLOFENAC cream for the treatment of actinic keratoses. Long-term tolerability of topical diclofenac sodium 1% gel for http://www.ncbi.nlm.nih.gov/pubmed/23204844 DICLOFENAC osteoarthritis in seniors and patients with comorbidities. Efficacy and safety of diclofenac diethylamine 2.32% gel in acute http://www.ncbi.nlm.nih.gov/pubmed/22525762 DICLOFENAC ankle sprain. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double- http://www.ncbi.nlm.nih.gov/pubmed/15477437 DICLOFENAC blind, vehicle-controlled clinical trial. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and http://www.ncbi.nlm.nih.gov/pubmed/19380203 DICLOFENAC oral diclofenac for knee osteoarthritis. DICLOFENAC Topical diclofenac solution http://www.ncbi.nlm.nih.gov/pubmed/19943711 An open-label, long-term safety and tolerability trial of diclofenac http://www.ncbi.nlm.nih.gov/pubmed?term=22030938 DICLOFENAC sodium 1% gel in patients with knee osteoarthritis. Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled http://www.ncbi.nlm.nih.gov/pubmed?term=22104466 DICLOFENAC safety results. Safety profile of topical diclofenac: a meta-analysis of blinded, http://www.ncbi.nlm.nih.gov/pubmed?term=21231861 DICLOFENAC randomized, controlled trials in musculoskeletal conditions. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three http://www.ncbi.nlm.nih.gov/pubmed?term=21174485 randomized, double-blind, parallel-group, placebo-controlled, DICLOFENAC multicentre trials.

Efficacy and safety of diclofenac diethylamine 1.16% gel in acute http://www.ncbi.nlm.nih.gov/pubmed/23964752 DICLOFENAC neck pain: a randomized, double-blind, placebo-controlled study. Medication Title of Article PubMed Link Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, http://www.ncbi.nlm.nih.gov/pubmed/23889885 DICLOFENAC controlled and non-inferiority trial A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the http://www.ncbi.nlm.nih.gov/pubmed/23908551 DICLOFENAC treatment of acute uncomplicated ankle sprain DICLOFENAC Effect of 1.5% Topical Diclofenac on Clinical Neuropathic Pain http://www.ncbi.nlm.nih.gov/pubmed/25955980 DICLOFENAC Topical NSAIDs for chronic musculoskeletal pain in adults http://www.ncbi.nlm.nih.gov/pubmed/22972108 DICLOFENAC Topical NSAIDs for acute musculoskeletal pain in adults http://www.ncbi.nlm.nih.gov/pubmed/26068955 Can diclofenac ester prodrug promote direct penetration across the http://jocpr.com/vol6-iss7-2014/JCPR-2014-6-7-2701- DICLOFENAC skin 2713.pdf DICLOFENAC Topical NSAIDs effect on corneal sensitivity http://www.ncbi.nlm.nih.gov/pubmed/25826326 Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle- http://www.ncbi.nlm.nih.gov/pubmed/26506138 DICLOFENAC controlled, 4 week study http://www.medicinenet.com/diclofenac- DICLOFENAC GENERIC NAME: DICLOFENAC 3% - TOPICAL - topical/article.htm SODIUM https://www.us.sandoz.com/mediacentre/news/news_112113.shtml DICLOFENAC 1.5% The reciprocal effects of pain intensity and activity limitations: https://www.ncbi.nlm.nih.gov/pubmed/23446086 W/W implications for outcomes assessment in clinical trials Pooled safety analysis of diclofenac sodium topical solution 1.5% DICLOFENAC 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or https://www.ncbi.nlm.nih.gov/pubmed/22791985 W/W older Efficacy and safety of diclofenac sodium 2% topical solution for DICLOFENAC 2.0% osteoarthritis of the knee: a randomized, double-blind, vehicle- https://www.ncbi.nlm.nih.gov/pubmed/26506138 W/W controlled, 4 week study.

DICLOFENAC 2.0% Bioequivalence of diclofenac sodium 2% and 1.5% topical solutions https://www.ncbi.nlm.nih.gov/pubmed/26077436 W/W relative to oral diclofenac sodium in healthy volunteers DICLOFENAC 2.0% http://www.medscape.com/viewarticle/819436 W/W Topical Diclofenac 2% (Pennsaid) for Knee OA Pain Clears FDA DICLOFENAC 2.0% http://www.rxlist.com/pennsaid-drug.htm W/W PENNSAID (diclofenac sodium) Topical Solution DICLOFENAC 2.0% http://www.horizonpharma.com/pennsaid/ W/W PENNSAID® (diclofenac sodium topical solution) 2% w/w Medication Title of Article PubMed Link Horizon Pharma plc Announces Settlement of PENNSAID(R) http://ir.horizon- DICLOFENAC 2.0% (diclofenac sodium topical solution) 2% w/w Patent Litigation With pharma.com/releasedetail.cfm?releaseid=966551 W/W Amneal Pharmaceuticals LLC Topical diclofenac versus placebo: a double blind, randomized https://www.ncbi.nlm.nih.gov/pubmed/10606379 DICLOFENAC GEL clinical trial in patients with osteoarthritis of the knee The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma https://www.ncbi.nlm.nih.gov/pubmed/27067393 DICLOFENAC GEL (nBCC): A phase II, randomized controlled trial DINITROCHLOROBE Efficacy of human lymphoblastoid interferon in the therapy of http://www.ncbi.nlm.nih.gov/pubmed/3008054 NZENE resistant condyloma acuminata. DINITROCHLOROBE http://www.ncbi.nlm.nih.gov/pubmed/75477 NZENE Unilateral dinitrochlorobenzene immunopathy of recalcitrant warts. DINITROCHLOROBE Treatment of disseminated facial warts through contact http://www.ncbi.nlm.nih.gov/pubmed/16638403 NZENE immunotherapy with diphenylcyclopropenone (DPCP). The effects of topical doxepin on responses to histamine, substance Doxepin https://www.ncbi.nlm.nih.gov/pubmed/9349334 P and prostaglandin E2 in human skin. Doxepin cream vs betamethasone cream for treatment of chronic Doxepin https://www.ncbi.nlm.nih.gov/pubmed/21675494 skin lesions due to sulfur mustard.

Doxepin Relief of pruritus in patients with atopic dermatitis after treatment https://www.ncbi.nlm.nih.gov/pubmed/8089287 with topical doxepin cream. The Doxepin Study Group. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human Doxepin https://www.ncbi.nlm.nih.gov/pubmed/10848721 neuropathic pain: a randomized, double-blind, placebo-controlled study Oral topical doxepin rinse: analgesic effect in patients with oral Doxepin https://www.ncbi.nlm.nih.gov/pubmed/11590072 mucosal pain due to cancer or cancer therapy Transdermal and Topical Drug Administration in the Treatment of Doxepin https://www.ncbi.nlm.nih.gov/pubmed/29562618 Pain. Single application of topical doxycycline hyclate in the management http://www.ncbi.nlm.nih.gov/pubmed/24035110 DOXYCYCLINE of recurrent aphthous stomatitis The effect of topical doxycycline usage on gingival crevicular fluid MMP-8 levels of chronic and aggressive periodontitis patients: a pilot http://www.ncbi.nlm.nih.gov/pubmed/16958738 DOXYCYCLINE study Medication Title of Article PubMed Link Subgingival topical doxycycline versus mechanical debridement for supportive periodontal therapy: a single blind randomized controlled http://www.ncbi.nlm.nih.gov/pubmed/16433404 DOXYCYCLINE two-center study Pseudomonas exit-site infection: treatment outcomes with topical http://www.ncbi.nlm.nih.gov/pubmed/26613039 DOXYCYCLINE gentamicin in addition to systemic antibiotics Non-surgical periodontal therapy with adjunctive topical doxycycline: a double-masked, randomized, controlled multicenter study. II. http://www.ncbi.nlm.nih.gov/pubmed/15830639 DOXYCYCLINE Microbiological results A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous https://www.ncbi.nlm.nih.gov/pubmed/28406394 pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines DOXYCYCLINE (BLISTER) trial. Therapeutic potential of AAV-mediated MMP-3 secretion from https://www.ncbi.nlm.nih.gov/pubmed/28158775 DOXYCYCLINE corneal endothelium in treating glaucoma. Econazole Nitrate Foam 1% Improves the of Tinea Pedis. https://www.ncbi.nlm.nih.gov/pubmed/27602974 ECONAZOLE Cutaneous alternariosis in an immunocompetent patient. https://www.ncbi.nlm.nih.gov/pubmed/28329593 Clotrimazole and econazole inhibit Streptococcus mutans biofilm and https://www.ncbi.nlm.nih.gov/pubmed/27764679 ECONAZOLE virulence in vitro. Skin permeation of econazole nitrate formulated in an enhanced https://www.ncbi.nlm.nih.gov/pubmed/27761948 ECONAZOLE hydrophilic multiple emulsion. https://www.ncbi.nlm.nih.gov/pubmed/?term=Pickerin g+emulsions+based+on+cyclodextrins%3A+a+smart+ Pickering based on cyclodextrins: A smart solution for solution+for+antifungal++derivatives+topical+del ECONAZOLE antifungal azole derivatives topical delivery. ivery EGCG HSPA5 is an essential host factor for Ebola virus infection. http://www.ncbi.nlm.nih.gov/pubmed/25017472 Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral http://www.ncbi.nlm.nih.gov/pubmed/?term=21338496 EGCG doses of green tea extract.

Effects of green tea catechins and theanine on preventing influenza http://www.ncbi.nlm.nih.gov/pubmed EGCG infection among healthcare workers: a randomized controlled trial. Medication Title of Article PubMed Link

Results of a phase II randomized, double-blind, placebo-controlled http://www.ncbi.nlm.nih.gov/pubmed/24388920?dopt= trial of Polyphenon E in women with persistent high-risk HPV Abstract EGCG infection and low-grade cervical intraepithelial neoplasia. Protective effects of green tea extracts (polyphenon E and EGCG) on http://www.ncbi.nlm.nih.gov/pubmed/14512803 EGCG human cervical lesions. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into http://www.ncbi.nlm.nih.gov/pubmed/25260897 EGCG hepatocytes. Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus http://www.ncbi.nlm.nih.gov/pubmed/24903990 EGCG replication in vitro. Inhibition of influenza virus internalization by (-)-epigallocatechin-3- http://www.ncbi.nlm.nih.gov/pubmed/23954192 EGCG gallate.

A proprietary topical preparation containing EGCG-stearate and http://www.ncbi.nlm.nih.gov/pubmed/22583482 EGCG glycerin with inhibitory effects on herpes simplex virus: case study. Digallate dimers of (-)-epigallocatechin gallate inactivate herpes http://www.ncbi.nlm.nih.gov/pubmed/21947401 EGCG simplex virus. Green tea extract and its major component epigallocatechin gallate http://www.ncbi.nlm.nih.gov/pubmed/18313149 EGCG inhibits hepatitis B virus in vitro. Sinecatechins (Polyphenon E) ointment for treatment of external http://www.ncbi.nlm.nih.gov/pubmed/?term=EGCG+a EGCG genital warts and possible future indications. nd+warts Topical Polyphenon E in the treatment of external genital and http://www.ncbi.nlm.nih.gov/pubmed/?term=18363746 EGCG perianal warts: a randomized controlled trial. Sinecatechins, a defined green tea extract, in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/?term=18515521 EGCG external anogenital warts: a randomized controlled trial. Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus http://clinicaltrials.gov/ct2/show/NCT01744587?term= EGCG Reactivation in Remission Patients (NPC) EGCG&rank=2 Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in http://clinicaltrials.gov/ct2/show/NCT01433289?term= EGCG HIV-1-Infected Individuals EGCG&rank=11 Effects of Tea Catechin Consumption on the Prophylaxis of Influenza http://clinicaltrials.gov/ct2/show/NCT01008020?term= EGCG Infection EGCG&rank=22 http://clinicaltrials.gov/ct2/show/NCT00812448?term= EGCG Catechin Containing Mask for the Prevention of Influenza Infection EGCG&rank=35 Medication Title of Article PubMed Link Pharmacokinetic Study of Topically Applied Veregen 15% Compared http://clinicaltrials.gov/ct2/show/study/NCT01082302? EGCG With Oral Intake of Green Tea Beverage term=EGCG&rank=74 Gargling With Green Tea for Prophylaxis of Influenza Infection in http://clinicaltrials.gov/ct2/show/NCT01225770?term= EGCG Teenagers EGCG&rank=77 http://clinicaltrials.gov/ct2/show/NCT01018615?term= Safety, Metabolism, and Antioxidant Activity of Silymarin and Green EGCG&cond=%22Virus+Diseases%22&rank=4 EGCG Tea Extract in Patients With Chronic Hepatitis C Pharmacokinetics and safety of green tea polyphenols after multiple- dose administration of epigallocatechin gallate and polyphenon E in http://www.ncbi.nlm.nih.gov/pubmed/12960117 EGCG healthy individuals. A single ascending dose study of epigallocatechin gallate in healthy http://www.ncbi.nlm.nih.gov/pubmed/12760312 EGCG volunteers. Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and http://www.ncbi.nlm.nih.gov/pubmed/24299662 liver function in obese women: randomised, double-blind, placebo- EGCG controlled clinical trial.

Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive http://www.ncbi.nlm.nih.gov/pubmed/24039182 EGCG deficits in Down syndrome mouse models and in humans. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage http://www.ncbi.nlm.nih.gov/pubmed/23988418 EGCG ovarian cancer. A pilot study to evaluate the safety and efficacy of an oral dose of (-)- epigallocatechin-3-gallate-rich polyphenon E in patients with mild to http://www.ncbi.nlm.nih.gov/pubmed/23846486 EGCG moderate ulcerative colitis.

Epigallocatechin-3-gallate improves acne in humans by modulating http://www.ncbi.nlm.nih.gov/pubmed/23096708 EGCG intracellular molecular targets and inhibiting P. acnes. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor- http://www.ncbi.nlm.nih.gov/pubmed/22827973 EGCG negative breast cancer. Phase 2 trial of daily, oral Polyphenon E in patients with http://www.ncbi.nlm.nih.gov/pubmed/22760587 EGCG asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Medication Title of Article PubMed Link Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, http://www.ncbi.nlm.nih.gov/pubmed/21649457 EGCG and placebo-controlled clinical trial. Effect of green tea extract on obese women: a randomized, double- http://www.ncbi.nlm.nih.gov/pubmed/18468736 EGCG blind, placebo-controlled clinical trial. Effect of nutrient mixture and black grapes on the pharmacokinetics of orally administered (-)epigallocatechin-3-gallate from green tea http://www.ncbi.nlm.nih.gov/pubmed/18446840 EGCG extract: a human study. A preliminary investigation of the impact of catechol-O- methyltransferase genotype on the absorption and metabolism of http://www.ncbi.nlm.nih.gov/pubmed/21445620 EGCG green tea catechins. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated http://www.ncbi.nlm.nih.gov/pubmed/15580809 EGCG dosing in healthy volunteers. Blood and urine levels of tea catechins after ingestion of different http://www.ncbi.nlm.nih.gov/pubmed/9568793 EGCG amounts of green tea by human volunteers. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients http://www.ncbi.nlm.nih.gov/pubmed/26607642 EGCG with breast cancer receiving adjuvant radiotherapy Influence of intranasal epinephrine and lidocaine spray on olfactory https://www.ncbi.nlm.nih.gov/pubmed/21846929 EPINEPHRINE function tests in healthy human subjects. https://www.ncbi.nlm.nih.gov/pubmed/29424323 ERYTHROMYCIN Topical Delivery of Erythromycin Through Cubosomes for Acne. Randomized clinical trial of topical mupirocin versus oral https://www.ncbi.nlm.nih.gov/pubmed/3149884 ERYTHROMYCIN erythromycin for impetigo.

Bacterial resistance and therapeutic outcome following three months https://www.ncbi.nlm.nih.gov/pubmed/12361129 ERYTHROMYCIN of topical acne therapy with 2% erythromycin gel versus its vehicle.

Systemic exposure of topical erythromycin in comparison to oral https://www.ncbi.nlm.nih.gov/pubmed/25139487 ERYTHROMYCIN administration and the effect on cytochrome P450 3A4 activity. The extinction of topical erythromycin therapy for acne vulgaris and https://www.ncbi.nlm.nih.gov/pubmed/27425633 ERYTHROMYCIN concern for the future of topical clindamycin. Topical 5% benzoyl peroxide and 3% erythromycin gel: experience https://www.ncbi.nlm.nih.gov/pubmed/24183219 ERYTHROMYCIN with 191 patients with papulopustular acne. Medication Title of Article PubMed Link A comparison between the effectiveness of erythromycin, single- dose clarithromycin and topical fusidic acid in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/21923567 ERYTHROMYCIN erythrasma.

A randomized, single-blind comparison of topical clindamycin + https://www.ncbi.nlm.nih.gov/pubmed/17309451 benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in ERYTHROMYCIN the treatment of mild to moderate facial acne vulgaris.

A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical 3% erythromycin/5% https://www.ncbi.nlm.nih.gov/pubmed/12362264 benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the ERYTHROMYCIN treatment of moderate acne vulgaris of the face.

The efficacy and safety of a combination benzoyl https://www.ncbi.nlm.nih.gov/pubmed/11281433 peroxide/clindamycin topical gel compared with benzoyl peroxide ERYTHROMYCIN alone and a benzoyl peroxide/erythromycin combination product. A placebo-controlled clinical trial to compare a gel containing a combination of (0.05%) and erythromycin (2%) with gels https://www.ncbi.nlm.nih.gov/pubmed/10592405 containing isotretinoin (0.05%) or erythromycin (2%) alone in the ERYTHROMYCIN topical treatment of acne vulgaris. Clinical efficacy and safety of a topical combination of retinaldehyde https://www.ncbi.nlm.nih.gov/pubmed/10564319 ERYTHROMYCIN 0.1% with erythromycin 4% in acne vulgaris. Effects of topical erythromycin on ecology of aerobic cutaneous https://www.ncbi.nlm.nih.gov/pubmed/8913472 ERYTHROMYCIN bacterial flora. A double-blind controlled evaluation of the sebosuppressive activity https://www.ncbi.nlm.nih.gov/pubmed/8751022 ERYTHROMYCIN of topical erythromycin-zinc complex. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% https://www.ncbi.nlm.nih.gov/pubmed/8549289 ERYTHROMYCIN erythromycin. Surgical pearl: erythromycin ointment for topical antibiotic wound https://www.ncbi.nlm.nih.gov/pubmed/7896958 ERYTHROMYCIN care. Inhibition of erythromycin-resistant propionibacteria on the skin of https://www.ncbi.nlm.nih.gov/pubmed/8148274 ERYTHROMYCIN acne patients by topical erythromycin with and without zinc. Efficacy of topical erythromycin in treatment of perianal streptococcal https://www.ncbi.nlm.nih.gov/pubmed/8415314 ERYTHROMYCIN dermatitis. Medication Title of Article PubMed Link Effect of a topical erythromycin-zinc formulation on sebum delivery. Evaluation by combined photometric-multi-step samplings with https://www.ncbi.nlm.nih.gov/pubmed/8252759 ERYTHROMYCIN Sebutape. Influence of topical erythromycin preparations for acne vulgaris on https://www.ncbi.nlm.nih.gov/pubmed/8219662 ERYTHROMYCIN skin surface pH. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and https://www.ncbi.nlm.nih.gov/pubmed/1535215 ERYTHROMYCIN combination therapy.

A clinical trial comparing the safety and efficacy of a topical https://www.ncbi.nlm.nih.gov/pubmed/1827802 ERYTHROMYCIN erythromycin-zinc formulation with a topical clindamycin formulation. ERYTHROMYCIN Topical erythromycin and zinc for acne. https://www.ncbi.nlm.nih.gov/pubmed/1826114

A clinical trial comparing the safety and efficacy of a topical https://www.ncbi.nlm.nih.gov/pubmed/2138180 ERYTHROMYCIN erythromycin-zinc formulation with a topical clindamycin formulation. ERYTHROMYCIN Topical erythromycin and zinc therapy for acne. https://www.ncbi.nlm.nih.gov/pubmed/2138176 Efficacy and tolerability of combined topical treatment of acne https://www.ncbi.nlm.nih.gov/pubmed/2534292 ERYTHROMYCIN vulgaris with tretinoin and erythromycin in general practice. ERYTHROMYCIN Topical erythromycin preparations. https://www.ncbi.nlm.nih.gov/pubmed/3819105 An evaluation of a 2% erythromycin ointment in the topical therapy of https://www.ncbi.nlm.nih.gov/pubmed/3157709 ERYTHROMYCIN acne vulgaris. Acne treatment with topical erythromycin and zinc: effect of https://www.ncbi.nlm.nih.gov/pubmed/6234335 ERYTHROMYCIN Propionibacterium acnes and free composition. Topical erythromycin v clindamycin therapy for acne. A multicenter, https://www.ncbi.nlm.nih.gov/pubmed/6230999 ERYTHROMYCIN double-blind comparison. ERYTHROMYCIN Is topical erythromycin base non-allergenic?. https://www.ncbi.nlm.nih.gov/pubmed/6861493 Adverse reactions to topical clindamycin, erythromycin and https://www.ncbi.nlm.nih.gov/pubmed/6228388 ERYTHROMYCIN tetracycline. [Review] [19 refs] Effects of treatment with erythromycin 1.5 percent topical solution or clindamycin phosphate 1.0 percent topical solution on P. acnes https://www.ncbi.nlm.nih.gov/pubmed/6220870 ERYTHROMYCIN counts and free fatty acid levels. Benzoyl peroxide versus topical erythromycin in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/6218815 ERYTHROMYCIN acne vulgaris. https://www.ncbi.nlm.nih.gov/pubmed/7051813 ERYTHROMYCIN Oral v topical erythromycin therapies for chlamydial conjunctivitis. Medication Title of Article PubMed Link Evaluation of topical erythromycin and oral tetracycline in acne https://www.ncbi.nlm.nih.gov/pubmed/6214377 ERYTHROMYCIN vulgaris. Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/6213379 ERYTHROMYCIN acne vulgaris. The efficacy of a topical preparation containing erythromycin in the https://www.ncbi.nlm.nih.gov/pubmed/6212272 ERYTHROMYCIN treatment of acne. Intermittent trachoma chemotherapy: a controlled trial of topical https://www.ncbi.nlm.nih.gov/pubmed/7020973 ERYTHROMYCIN tetracycline or erythromycin. https://www.ncbi.nlm.nih.gov/pubmed/6457568 ERYTHROMYCIN Topical erythromycin vs blank vehicle in a multiclinic acne study. ERYTHROMYCIN Clinical trial of topical erythromycin in inflammatory acne. https://www.ncbi.nlm.nih.gov/pubmed/6456140 Contribution to the interpretation of the occurrence of unsuccessful therapeutical results in acne vulgaris with topical erythromycin https://www.ncbi.nlm.nih.gov/pubmed/6452774 ERYTHROMYCIN (Propionibact. acnes). Topical erythromycin with zinc in acne. A double-blind controlled https://www.ncbi.nlm.nih.gov/pubmed/6452464 ERYTHROMYCIN study. https://www.ncbi.nlm.nih.gov/pubmed/6452463 ERYTHROMYCIN Topical erythromycin solution in acne. Results of a multiclinic trial. ERYTHROMYCIN Topical erythromycin for acne vulgaris. https://www.ncbi.nlm.nih.gov/pubmed/6452297 Effects of topical erythromycin on aerobic and anaerobic surface https://www.ncbi.nlm.nih.gov/pubmed/6162344 ERYTHROMYCIN flora. Etanercept in the treatment of psoriatic arthritis and psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1097237 ETANERCEPT randomised trial. 1 Etanercept for severe psoriasis and psoriatic arthritis: observations https://www.ncbi.nlm.nih.gov/pubmed/?term=1184137 ETANERCEPT on combination therapy. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1221825 ETANERCEPT Generalised pustular psoriasis induced by cyclosporin a withdrawal 2 responding to the tumour necrosis factor alpha inhibitor etanercept. Etanercept for severe psoriasis and psoriatic arthritis: observations https://www.ncbi.nlm.nih.gov/pubmed/?term=1236645 ETANERCEPT on combination therapy. 2 Etanercept, a TNF antagonist for treatment for psoriatic arthritis and https://www.ncbi.nlm.nih.gov/pubmed/?term=1272828 ETANERCEPT psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1462778 ETANERCEPT Etanercept as monotherapy in patients with psoriasis. 6 Medication Title of Article PubMed Link Successful treatment of recalcitrant palmoplantar psoriasis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1465578 ETANERCEPT etanercept. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1467608 ETANERCEPT A randomized trial of etanercept as monotherapy for psoriasis. 2 Etanercept for the treatment of psoriasis: combination therapy with https://www.ncbi.nlm.nih.gov/pubmed/?term=1517616 ETANERCEPT other modalities. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1531498 ETANERCEPT Etanercept in psoriasis treatment. [Review] [17 refs] 9 Etanercept for the treatment of psoriasis and psoriatic arthritis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1537977 ETANERCEPT [Review] [28 refs] 5 The treatment of psoriasis and psoriatic arthritis with etanercept: https://www.ncbi.nlm.nih.gov/pubmed/?term=1545034 ETANERCEPT practical considerations on monotherapy, combination therapy, and 0 safety. [Review] [31 refs] https://www.ncbi.nlm.nih.gov/pubmed/?term=1546154 ETANERCEPT Etanercept in psoriasis. [Review] [51 refs] 9 Rapid onset of cutaneous squamous cell carcinoma of the penis in a https://www.ncbi.nlm.nih.gov/pubmed/?term=1558360 ETANERCEPT patient with psoriasis on etanercept therapy. 8 Safety and efficacy study on etanercept in patients with plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1565683 ETANERCEPT psoriasis. 3 Etanercept: a review of its use in the management of plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1579968 ETANERCEPT psoriasis and psoriatic arthritis. [Review] [43 refs] 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1590079 ETANERCEPT The treatment of psoriasis with etanercept. [Review] [43 refs] 6 A global phase III randomized controlled trial of etanercept in https://www.ncbi.nlm.nih.gov/pubmed/?term=1594899 ETANERCEPT psoriasis: safety, efficacy, and effect of dose reduction. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1610187 ETANERCEPT Etanercept and psoriasis, from clinical studies to real life. 5 Population pharmacokinetic modeling of subcutaneously https://www.ncbi.nlm.nih.gov/pubmed/?term=1622278 ETANERCEPT administered etanercept in patients with psoriasis. 5 Etanercept improves the health-related quality of life of patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1624315 ETANERCEPT psoriasis: results of a phase III randomized clinical trial. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1630255 ETANERCEPT Puerto Rico psoriasis study group: efficacy and safety of etanercept. 9 Patient-reported outcomes of psoriasis improvement with etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=1630765 ETANERCEPT therapy: results of a randomized phase III trial. 7 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1638477 ETANERCEPT Etanercept and demyelinating disease in a patient with psoriasis. 7 Spotlight on etanercept in plaque psoriasis and psoriatic arthritis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1639289 ETANERCEPT [Review] [19 refs] 2 Effects of etanercept on quality of life, fatigue, and depression in https://www.ncbi.nlm.nih.gov/pubmed/?term=1639913 ETANERCEPT psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1639915 ETANERCEPT Etanercept and clinical outcomes, fatigue, and depression in 0 psoriasis: double-blind placebo-controlled randomised phase III trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=1640263 ETANERCEPT Etanercept for psoriasis: two case reports. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1640311 ETANERCEPT Etanercept for the treatment of severe childhood psoriasis. 7 Etanercept monotherapy for a patient with psoriasis, psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=1644307 ETANERCEPT arthritis, and concomitant hepatitis C infection. 9 Etanercept for psoriasis in the pediatric population: experience in https://www.ncbi.nlm.nih.gov/pubmed/?term=1644541 ETANERCEPT nine patients. 7 Clinical response in psoriasis patients discontinued from and then https://www.ncbi.nlm.nih.gov/pubmed/?term=1646701 ETANERCEPT reinitiated on etanercept therapy.[Erratum appears in J Dermatolog 8 Treat. 2006;17(3):192] https://www.ncbi.nlm.nih.gov/pubmed/?term=1648506 ETANERCEPT Etanercept for the treatment of psoriasis. [Review] [16 refs] 0 Efficacy of etanercept in an integrated multistudy database of https://www.ncbi.nlm.nih.gov/pubmed/?term=1648832 ETANERCEPT patients with psoriasis. 0 Patients with psoriasis respond to continuous open-label etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=1648832 ETANERCEPT treatment after initial incomplete response in a randomized, placebo- 1 controlled trial. Treatment of coexisting bullous pemphigoid and psoriasis with the https://www.ncbi.nlm.nih.gov/pubmed/?term=1648832 ETANERCEPT tumor necrosis factor antagonist etanercept. 3 Etanercept therapy improves symptoms and allows tapering of other https://www.ncbi.nlm.nih.gov/pubmed/?term=1648832 ETANERCEPT medications in children and adolescents with moderate to severe 5 psoriasis. Etanercept monotherapy in patients with psoriasis: a summary of https://www.ncbi.nlm.nih.gov/pubmed/?term=1648833 ETANERCEPT safety, based on an integrated multistudy database. 5 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1656936 ETANERCEPT Once-weekly administration of high-dosage Etanercept in patients 1 with plaque psoriasis: results of a pilot experience (power study). Use of alefacept and etanercept in 3 patients whose psoriasis failed https://www.ncbi.nlm.nih.gov/pubmed/?term=1671348 ETANERCEPT to respond to etanercept. 1 Etanercept therapy in two patients with psoriasis and concomitant https://www.ncbi.nlm.nih.gov/pubmed/?term=1671348 ETANERCEPT hepatitis C. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1679276 ETANERCEPT Treatment of erythrodermic psoriasis with etanercept. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1687224 ETANERCEPT Safety of etanercept in psoriasis: a critical review. [Review] [86 refs] 1 Psoriasis after treatment of juvenile idiopathic arthritis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1690559 ETANERCEPT etanercept. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1690836 ETANERCEPT Etanercept for the treatment of psoriasis in the elderly. 5 Initial experience with routine administration of etanercept in https://www.ncbi.nlm.nih.gov/pubmed/?term=1696543 ETANERCEPT psoriasis. 2 Pharmacokinetics of subcutaneously administered etanercept in https://www.ncbi.nlm.nih.gov/pubmed/?term=1699586 ETANERCEPT subjects with psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1702381 ETANERCEPT Henoch-Schonlein purpura after etanercept therapy for psoriasis. 1 Ability to develop rhus allergic contact dermatitis in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=1705253 ETANERCEPT psoriasis receiving etanercept. 6 Etanercept and efalizumab for the treatment of psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1708385 ETANERCEPT systematic review. [Review] [77 refs] 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1709737 ETANERCEPT Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. 6 A randomized, open-label trial of continuous versus interrupted https://www.ncbi.nlm.nih.gov/pubmed/?term=1711319 ETANERCEPT etanercept therapy in the treatment of psoriasis. 0 Acute myelogenous leukemia in a patient receiving etanercept for https://www.ncbi.nlm.nih.gov/pubmed/?term=1719064 ETANERCEPT psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1719958 ETANERCEPT Comparison of clinical and pharmacokinetic profiles of etanercept 25 0 mg twice weekly and 50 mg once weekly in patients with psoriasis. Medication Title of Article PubMed Link Severe psoriasis pustulosa palmaris et plantaris (Barber-Konigsbeck) https://www.ncbi.nlm.nih.gov/pubmed/?term=1724396 ETANERCEPT treated successfully with soluble tumour necrosis factor receptor 8 fusion protein (etanercept). Modeling the exposure-response relationship of etanercept in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1724477 ETANERCEPT treatment of patients with chronic moderate to severe plaque 5 psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1731173 ETANERCEPT Our experience with etanercept in the treatment of psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1740839 ETANERCEPT Two years of experience with etanercept in recalcitrant psoriasis. 3 Psoriasis and hepatitis C treated with anti-TNF alpha therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1745929 ETANERCEPT (etanercept). 0 Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 https://www.ncbi.nlm.nih.gov/pubmed/?term=1747838 ETANERCEPT month-old child successfully treated with etanercept. 9 Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an https://www.ncbi.nlm.nih.gov/pubmed/?term=1749284 ETANERCEPT updated review. [Review] [74 refs] 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1750286 ETANERCEPT Mechanisms of action of etanercept in psoriasis. [Review] [34 refs] 8 Etanercept and efalizumab treatment for high-need psoriasis. Effects https://www.ncbi.nlm.nih.gov/pubmed/?term=1752046 ETANERCEPT and side effects in a prospective cohort study in outpatient clinical 3 practice. Development of Crohn disease in a patient on etanercept for https://www.ncbi.nlm.nih.gov/pubmed/?term=1757387 ETANERCEPT psoriasis. 8 Long-term safety and efficacy of 50 mg of etanercept twice weekly in https://www.ncbi.nlm.nih.gov/pubmed/?term=1757693 ETANERCEPT patients with psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1785330 ETANERCEPT High-dose initiation of etanercept in psoriatic arthritis and plaque 9 psoriasis: efficacy, safety and impact on patients' quality of life. https://www.ncbi.nlm.nih.gov/pubmed/?term=1785331 ETANERCEPT Etanercept-induced lichenoid reaction pattern in psoriasis. 4 The rapid onset of multiple squamous cell carcinomas during https://www.ncbi.nlm.nih.gov/pubmed/?term=1785437 ETANERCEPT etanercept treatment for psoriasis. 0 Effects of etanercept therapy on fatigue and symptoms of depression https://www.ncbi.nlm.nih.gov/pubmed/?term=1791620 ETANERCEPT in subjects treated for moderate to severe plaque psoriasis for up to 4 96 weeks. Medication Title of Article PubMed Link Etanercept therapy for severe plaque psoriasis in a patient who https://www.ncbi.nlm.nih.gov/pubmed/?term=1795600 ETANERCEPT underwent a liver transplant. 9 Conversion to positive tuberculosis test during etanercept treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1796618 ETANERCEPT of psoriasis. 5 Effect of etanercept on insulin sensitivity in nine patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1817974 ETANERCEPT psoriasis. 5 Etanercept treatment for children and adolescents with plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1819986 ETANERCEPT psoriasis. 3 Etanercept at different dosages in the treatment of generalized https://www.ncbi.nlm.nih.gov/pubmed/?term=1828568 ETANERCEPT pustular psoriasis: a case series. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1832298 ETANERCEPT Rapid response of nail psoriasis to etanercept. 2 Safety of etanercept therapy in a patient with psoriasis, Down's https://www.ncbi.nlm.nih.gov/pubmed/?term=1835519 ETANERCEPT syndrome and concomitant hepatitis C virus infection. 6 Etanercept: an overview of its role in the treatment of psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1836354 ETANERCEPT [Review] [36 refs] 5 Psoriasis treatment with etanercept and efalizumab: clinical https://www.ncbi.nlm.nih.gov/pubmed/?term=1838444 ETANERCEPT strategies influencing treatment outcome. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1842703 ETANERCEPT Successful treatment with etanercept of von Zumbusch pustular 8 psoriasis in a patient with human immunodeficiency virus. Use of etanercept in the treatment of psoriasis and psoriatic arthritis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1847397 ETANERCEPT [Review] [38 refs] 8 Patient-reported outcomes and health-care resource utilization in https://www.ncbi.nlm.nih.gov/pubmed/?term=1848966 ETANERCEPT patients with psoriasis treated with etanercept: continuous versus 5 interrupted treatment. Effects of etanercept on C-reactive protein levels in psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=1850360 ETANERCEPT psoriatic arthritis. 0 Effective control of psoriasis by etanercept in a patient with HCV- https://www.ncbi.nlm.nih.gov/pubmed/?term=1857372 ETANERCEPT related diseases. 3 Severe generalized exanthema due to etanercept given for severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1859283 ETANERCEPT plaque psoriasis. 3 Recurrent varicella in an adult psoriasis patient treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1866782 ETANERCEPT etanercept. 5 Medication Title of Article PubMed Link

Once weekly administration of etanercept 50 mg is efficacious and https://www.ncbi.nlm.nih.gov/pubmed/?term=1867336 ETANERCEPT well tolerated in patients with moderate-to-severe plaque psoriasis: a 5 randomized controlled trial with open-label extension. Rapid onset and fatal outcome of two squamous cell carcinomas of https://www.ncbi.nlm.nih.gov/pubmed/?term=1868817 ETANERCEPT the genitalia in a patient treated with etanercept for cutaneous 1 psoriasis. Cytomegalovirus complicating biological immunosuppressive therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1877990 ETANERCEPT in two patients with psoriasis receiving treatment with etanercept or 1 efalizumab. Low-dose etanercept therapy in moderate to severe psoriasis in https://www.ncbi.nlm.nih.gov/pubmed/?term=1878906 ETANERCEPT Korean. 7 Development of pemphigus vulgaris in a patient with psoriasis treated https://www.ncbi.nlm.nih.gov/pubmed/?term=1879324 ETANERCEPT with etanercept. 2 Economic evaluation of etanercept in the management of chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=1880841 ETANERCEPT plaque psoriasis. 3 Etanercept provides a more physiological approach in the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1883772 ETANERCEPT of psoriasis. [Review] [93 refs] 7 ILVEN: is it psoriasis? Debate based on successful treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=1900235 ETANERCEPT etanercept. 7 Utilization pattern of etanercept and its cost implications in moderate https://www.ncbi.nlm.nih.gov/pubmed/?term=1903213 ETANERCEPT to severe psoriasis in a managed care population. 1 Treatment of psoriasis with etanercept in a patient with a history of https://www.ncbi.nlm.nih.gov/pubmed/?term=1904050 ETANERCEPT primary B-cell lymphoma. 8 Etanercept in the treatment and retreatment of psoriasis in daily https://www.ncbi.nlm.nih.gov/pubmed/?term=1904993 ETANERCEPT clinical practice. 6 Etanercept therapy for psoriasis in a patient with concomitant https://www.ncbi.nlm.nih.gov/pubmed/?term=1906936 ETANERCEPT hepatitis C and liver transplant. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1911912 ETANERCEPT Angiokeratoma induced by injection of etanercept for psoriasis. 5 Recall injection-site reactions to etanercept in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=1912039 ETANERCEPT psoriasis. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1920766 ETANERCEPT Adolescent plaque psoriasis: our experience using etanercept. 8 Medication Title of Article PubMed Link Persistent hypoglycemia in a patient with diabetes taking etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=1921769 ETANERCEPT for the treatment of psoriasis. 3 Leukemic phase of follicular lymphoma after treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=1922225 ETANERCEPT etanercept in a patient with psoriasis. 2 Efalizumab therapy for psoriasis in patients with inadequate https://www.ncbi.nlm.nih.gov/pubmed/?term=1922225 ETANERCEPT responses to etanercept. 5 Lichen planopilaris noted during etanercept therapy in a child with https://www.ncbi.nlm.nih.gov/pubmed/?term=1925043 ETANERCEPT severe psoriasis. 5 Influence and variation of the body mass index in patients treated https://www.ncbi.nlm.nih.gov/pubmed/?term=1930956 ETANERCEPT with etanercept for plaque-type psoriasis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1933602 ETANERCEPT A case of tuberculosis in a patient on Efalizumab and Etanercept for 8 treatment of refractory palmopustular psoriasis and psoriatic arthritis. Effects of etanercept on urine neopterin levels in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1934865 ETANERCEPT psoriasis in a controlled, open-label study. 6 Severe hypoglycemia after initiation of anti-tumor necrosis factor https://www.ncbi.nlm.nih.gov/pubmed/?term=1938953 ETANERCEPT therapy with etanercept in a patient with generalized pustular 9 psoriasis and type 2 diabetes mellitus. https://www.ncbi.nlm.nih.gov/pubmed/?term=1945379 ETANERCEPT Sustained improvement in joint pain and nail symptoms with 4 etanercept therapy in patients with moderate-to-severe psoriasis. Etanercept in severe, recalcitrant psoriasis: clinical response, safety https://www.ncbi.nlm.nih.gov/pubmed/?term=1947005 ETANERCEPT profile and predictors of response based on a single institution's 6 experience. Effect of calcipotriol on etanercept partial responder psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1947912 ETANERCEPT vulgaris and psoriatic arthritis patients. 8 Improvements in patient-reported outcomes in moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1956349 ETANERCEPT psoriasis patients receiving continuous or paused etanercept 7 treatment over 54 weeks: the CRYSTEL study. Patients with moderate-to-severe psoriasis recapture clinical https://www.ncbi.nlm.nih.gov/pubmed/?term=1956666 ETANERCEPT response during re-treatment with etanercept. 5 Efficacy and safety of etanercept in psoriasis after switching from https://www.ncbi.nlm.nih.gov/pubmed/?term=1965844 ETANERCEPT other treatments: an observational study. 4 Facial granulomatous nodules during etanercept treatment for https://www.ncbi.nlm.nih.gov/pubmed/?term=1970300 ETANERCEPT psoriasis. 0 Medication Title of Article PubMed Link Once-weekly administration of etanercept 50 mg improves patient- https://www.ncbi.nlm.nih.gov/pubmed/?term=1975250 ETANERCEPT reported outcomes in patients with moderate-to-severe plaque 5 psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1989599 ETANERCEPT Effective treatment of psoriasis with etanercept is linked to 1 suppression of IL-17 signaling, not immediate response TNF genes. Comparison of ustekinumab and etanercept for moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2007170 ETANERCEPT psoriasis. 1 Comparison of two etanercept regimens for treatment of psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2012456 ETANERCEPT and psoriatic arthritis: PRESTA randomised double blind multicentre 3 trial. Efficacy and safety of etanercept in children and adolescents aged > https://www.ncbi.nlm.nih.gov/pubmed/?term=2018538 ETANERCEPT or = 8 years with severe plaque psoriasis. 6 Combining etanercept with traditional agents in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2033781 ETANERCEPT psoriasis: a review of the clinical evidence. [Review] 6 Sequential treatment with biologics: switching from efalizumab to https://www.ncbi.nlm.nih.gov/pubmed/?term=2038469 ETANERCEPT etanercept in 35 patients with high-need psoriasis. 0 Coexisting bullous pemphigoid and psoriasis successfully treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2040380 ETANERCEPT with etanercept. 0 Efficacy and safety of ustekinumab and etanercept for the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2044682 ETANERCEPT of psoriasis. [Review] [65 refs] 5 Etanercept treatment patterns in managed-care patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2045929 ETANERCEPT psoriasis or psoriatic arthritis. 8 Safety of etanercept in patients with psoriasis and hepatitis C virus https://www.ncbi.nlm.nih.gov/pubmed/?term=2046618 ETANERCEPT assessed by liver histopathology: preliminary data. 4 New-onset psoriasis associated with etanercept therapy. [Review] [10 https://www.ncbi.nlm.nih.gov/pubmed/?term=2050741 ETANERCEPT refs] 1 Etanercept: an evolving role in psoriasis and psoriatic arthritis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2058649 ETANERCEPT [Review] [34 refs] 8 Etanercept therapy for psoriasis in a patient with active pulmonary https://www.ncbi.nlm.nih.gov/pubmed/?term=2058650 ETANERCEPT tuberculosis. 6 Beneficial neurological effects observed in a patient with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2058650 ETANERCEPT treated with etanercept. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2058650 ETANERCEPT A patient with psoriasis and vitiligo treated with etanercept. 9 Medication Title of Article PubMed Link Etanercept therapy for psoriasis in a patient with numerous https://www.ncbi.nlm.nih.gov/pubmed/?term=2058651 ETANERCEPT comorbidities. 0 Etanercept in a patient with severe psoriasis and latent viral hepatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2058651 ETANERCEPT disease and latent tuberculosis. 4 Treating psoriasis with etanercept in italian clinical practice: https://www.ncbi.nlm.nih.gov/pubmed/?term=2058651 ETANERCEPT prescribing practices and duration of remission following 6 discontinuation. https://www.ncbi.nlm.nih.gov/pubmed/?term=2060525 ETANERCEPT Long-term etanercept in pediatric patients with plaque psoriasis. 6 Patient-reported outcomes in pediatric patients with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2061948 ETANERCEPT undergoing etanercept treatment: 12-week results from a phase III 9 randomized controlled trial. The role of endothelial cell apoptosis in the effect of etanercept in https://www.ncbi.nlm.nih.gov/pubmed/?term=2063301 ETANERCEPT psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2063378 ETANERCEPT Subgroup analyses of etanercept in pediatric patients with psoriasis. 1 Continuous treatment of plaque-type psoriasis with etanercept: an https://www.ncbi.nlm.nih.gov/pubmed/?term=2064634 ETANERCEPT observational long-term experience. 5 Long-term safety and efficacy of etanercept in patients with psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2068414 ETANERCEPT an open-label study. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2080830 ETANERCEPT Psoriasis: Is ustekinumab superior to etanercept for psoriasis?. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2083344 ETANERCEPT Intermittent etanercept therapy in pediatric patients with psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2084034 ETANERCEPT Combination of skin, joint and quality of life outcomes with etanercept 9 in psoriasis and psoriatic arthritis in the PRESTA trial. Assessment of the long-term safety and effectiveness of etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=2085089 ETANERCEPT for the treatment of psoriasis in an adult population. 5 Transient paresis of the right recurrent laryngeal nerve after https://www.ncbi.nlm.nih.gov/pubmed/?term=2092374 ETANERCEPT treatment with etanercept for plaque-type psoriasis. 7 Efficacy and safety of etanercept in patients with psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2092374 ETANERCEPT hepatitis C. 9 Medication Title of Article PubMed Link The role of etanercept on the expression of markers of T helper 17 https://www.ncbi.nlm.nih.gov/pubmed/?term=2094304 ETANERCEPT cells and their precursors in skin lesions of patients with psoriasis 6 vulgaris. https://www.ncbi.nlm.nih.gov/pubmed/?term=2094305 ETANERCEPT Treatment of psoriasis with different dosage regimens of etanercept: 0 preliminary results from the Talpharanta Plastic Study Group. Etanercept therapy in patients with psoriasis and concomitant HCV https://www.ncbi.nlm.nih.gov/pubmed/?term=2094307 ETANERCEPT infection. 1 Is etanercept safe for treating plaque psoriasis in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2095665 ETANERCEPT chronic hepatitis C virus infection?. [Review] 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2095667 ETANERCEPT Disseminated superficial porokeratosis secondary to 4 immunosuppression induced by etanercept for extensive psoriasis. The ACCEPT study: ustekinumab versus etanercept in moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2116264 ETANERCEPT severe psoriasis patients. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2122088 ETANERCEPT Treatment of severe nail psoriasis with etanercept. 9 Cost per responder analysis of ustekinumab and etanercept for https://www.ncbi.nlm.nih.gov/pubmed/?term=2125488 ETANERCEPT moderate to severe plaque psoriasis. 6 Expression of antimicrobial peptides and proteins in etanercept- https://www.ncbi.nlm.nih.gov/pubmed/?term=2132434 ETANERCEPT treated psoriasis patients. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2137111 ETANERCEPT Recalcitrant palmoplantar pustular psoriasis treated with etanercept. 2 Relapsing polychondritis-like ear disease responding to etanercept in https://www.ncbi.nlm.nih.gov/pubmed/?term=2149671 ETANERCEPT two patients with psoriasis and psoriatic arthritis. 7 Etanercept in the treatment of psoriasis and psoriatic arthritis with https://www.ncbi.nlm.nih.gov/pubmed/?term=2154329 ETANERCEPT concomitant hepatitis C virus infection: clinical and virological study in 0 three patients. Patient satisfaction with injection devices: a randomized controlled https://www.ncbi.nlm.nih.gov/pubmed/?term=2155777 ETANERCEPT study comparing two different etanercept delivery systems in 8 moderate to severe psoriasis. Efficacy and safety of briakinumab vs. etanercept and placebo in https://www.ncbi.nlm.nih.gov/pubmed/?term=2157498 ETANERCEPT patients with moderate to severe chronic plaque psoriasis. 3 Medication Title of Article PubMed Link Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept https://www.ncbi.nlm.nih.gov/pubmed/?term=2157498 ETANERCEPT and placebo in patients with moderate to severe chronic plaque 4 psoriasis. The role of inflammatory markers in assessing disease severity and https://www.ncbi.nlm.nih.gov/pubmed/?term=2179072 ETANERCEPT response to treatment in patients with psoriasis treated with 8 etanercept.

A randomized study comparing the combination of nbUVB and https://www.ncbi.nlm.nih.gov/pubmed/?term=2179780 ETANERCEPT etanercept to etanercept monotherapy in patients with psoriasis who 5 do not exhibit an excellent response after 12 weeks of etanercept. A retrospective study to investigate racial and ethnic variations in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2181850 ETANERCEPT treatment of psoriasis with etanercept. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2183933 ETANERCEPT Development of myelodysplastic syndrome evolving to acute myeloid 4 leukemia in a patient receiving etanercept for psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2191069 ETANERCEPT Long-term efficacy of etanercept for psoriasis in daily practice. 9 Effects of etanercept treatment on lipid profile in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2198300 ETANERCEPT moderate-to-severe chronic plaque psoriasis: a retrospective cohort 7 study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2201454 ETANERCEPT Moderate to severe plaque psoriasis with scalp involvement: a 1 randomized, double-blind, placebo-controlled study of etanercept. Integrated safety analysis: short- and long-term safety profiles of https://www.ncbi.nlm.nih.gov/pubmed/?term=2201514 ETANERCEPT etanercept in patients with psoriasis. 9 Self-reported health outcomes in patients with psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2203515 ETANERCEPT arthritis randomized to two etanercept regimens. 7 Translating clinical activity and gene expression signatures of https://www.ncbi.nlm.nih.gov/pubmed/?term=2205059 ETANERCEPT etanercept and ciclosporin to the psoriasis xenograft SCID mouse 7 model. Refractory erythrodermic psoriasis in a child with an excellent https://www.ncbi.nlm.nih.gov/pubmed/?term=2206879 ETANERCEPT outcome by using etanercept. 6 Medication Title of Article PubMed Link Multiple squamous cell carcinomas in the setting of psoriasis treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2209800 ETANERCEPT with etanercept: a report of four cases and review of the literature. 6 [Review] Patient-reported outcomes in moderate-to-severe plaque psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2218830 ETANERCEPT with scalp involvement: results from a randomized, double-blind, 2 placebo-controlled study of etanercept. Successful treatment of systemic cold contact urticaria with https://www.ncbi.nlm.nih.gov/pubmed/?term=2221211 ETANERCEPT etanercept in a patient with psoriasis. 2

The efficacy and safety of etanercept when used with as-needed https://www.ncbi.nlm.nih.gov/pubmed/?term=2225122 ETANERCEPT adjunctive topical therapy in a randomised, double-blind study in 6 subjects with moderate-to-severe psoriasis (the PRISTINE trial). https://www.ncbi.nlm.nih.gov/pubmed/?term=2225848 ETANERCEPT Comparison of health-related quality of life in rheumatoid arthritis, 2 psoriatic arthritis and psoriasis and effects of etanercept treatment. Marked improvement in nail psoriasis during treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=2235315 ETANERCEPT etanercept. 6 Long-term etanercept use for severe generalized psoriasis in an HIV- https://www.ncbi.nlm.nih.gov/pubmed/?term=2239559 ETANERCEPT infected individual: a case study. 6 Membranous glomerulonephritis, psoriasis and etanercept. A chance https://www.ncbi.nlm.nih.gov/pubmed/?term=2242195 ETANERCEPT or causal association?. [Review] 3 Etanercept suppresses regenerative hyperplasia in psoriasis by https://www.ncbi.nlm.nih.gov/pubmed/?term=2245854 ETANERCEPT acutely downregulating epidermal expression of interleukin (IL)-19, IL- 9 20 and IL-24. Severe cutaneous and arthritic psoriasis in patient with AIDS: a good https://www.ncbi.nlm.nih.gov/pubmed/?term=2248166 ETANERCEPT outcome with therapy using etanercept. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2248166 ETANERCEPT Psoriasis, lymphoma and etanercept: is there a correlation?. 5 Efficacy of etanercept for the treatment of psoriasis: an overview of https://www.ncbi.nlm.nih.gov/pubmed/?term=2268654 ETANERCEPT the Italian clinical experience from the real-life setting and 4 independent studies. [Review] Etanercept downregulates the Th17 pathway and decreases the IL- https://www.ncbi.nlm.nih.gov/pubmed/?term=2269976 ETANERCEPT 17+/IL-10+ cell ratio in patients with psoriasis vulgaris. 1 Medication Title of Article PubMed Link Etanercept provides an effective, safe and flexible short- and long- https://www.ncbi.nlm.nih.gov/pubmed/?term=2281256 ETANERCEPT term treatment regimen for moderate-to-severe psoriasis: a 8 systematic review of current evidence. [Review] Results of three analytical approaches on long-term efficacy of https://www.ncbi.nlm.nih.gov/pubmed/?term=2284668 ETANERCEPT etanercept for psoriasis in daily practice. 9 Open label study to evaluate the efficacy of re-treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=2285924 ETANERCEPT etanercept in patients with psoriasis. 0 A 24-week randomized clinical trial investigating the efficacy and https://www.ncbi.nlm.nih.gov/pubmed/?term=2301320 ETANERCEPT safety of two doses of etanercept in nail psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2306502 ETANERCEPT The effect of etanercept on hepatic fibrosis risk in patients with non- 0 alcoholic fatty liver disease, metabolic syndrome, and psoriasis. Treatment of severe psoriasis with etanercept in a pancreas-kidney https://www.ncbi.nlm.nih.gov/pubmed/?term=2314652 ETANERCEPT transplant recipient. 1 Entecavir and intermittent etanercept therapy in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2314775 ETANERCEPT concurrent hepatitis B virus infection and psoriasis. 5 Etanercept improves quality of life outcomes and treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2314919 ETANERCEPT satisfaction in patients with moderate to severe plaque psoriasis in 6 clinical practice. Long-term response to etanercept monotherapy in moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2321077 ETANERCEPT severe psoriasis: assessment in daily practice by the maintenance of 1 low values of PASI and BSA. Paradoxical reaction to etanercept: development of pyoderma https://www.ncbi.nlm.nih.gov/pubmed/?term=2334313 ETANERCEPT gangraenosum during therapy of psoriasis arthritis. 7 OBSERVE-5 interim analysis: an observational postmarketing safety https://www.ncbi.nlm.nih.gov/pubmed/?term=2335756 ETANERCEPT registry of etanercept for the treatment of psoriasis. 9 Crusted complicates etanercept therapy in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2352242 ETANERCEPT severe psoriasis. 6 Long-term management of HIV/hepatitis C virus associated psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2361945 ETANERCEPT with etanercept. 9 A randomized study to evaluate the efficacy and safety of adding https://www.ncbi.nlm.nih.gov/pubmed/?term=2364325 ETANERCEPT topical therapy to etanercept in patients with moderate to severe 6 plaque psoriasis. Etanercept decreases the innate immune wounding response in https://www.ncbi.nlm.nih.gov/pubmed/?term=2380256 ETANERCEPT psoriasis. 9 Medication Title of Article PubMed Link Improvement in aspects of sleep with etanercept and optional https://www.ncbi.nlm.nih.gov/pubmed/?term=2384898 ETANERCEPT adjunctive topical therapy in patients with moderate-to-severe 9 psoriasis: results from the PRISTINE trial. Cost effectiveness of moderate to severe psoriasis therapy with https://www.ncbi.nlm.nih.gov/pubmed/?term=2397573 ETANERCEPT etanercept and ustekinumab in the United States. 9 Etanercept urticaria in a patient with psoriasis desensitized using a https://www.ncbi.nlm.nih.gov/pubmed/?term=2408505 ETANERCEPT new method. 4 Determinants of drug survival for etanercept in a long-term daily https://www.ncbi.nlm.nih.gov/pubmed/?term=2411702 ETANERCEPT practice cohort of patients with psoriasis. 3 Cardiometabolic biomarkers in chronic plaque psoriasis before and https://www.ncbi.nlm.nih.gov/pubmed/?term=2421901 ETANERCEPT after etanercept treatment. 2 Acute transverse myelitis during treatment with etanercept for severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2435528 ETANERCEPT plaque psoriasis. 0 Italian perspective on psoriasis, spondyloarthritis, rheumatoid arthritis and juvenile idiopathic arthritis: immunopathology and role of https://www.ncbi.nlm.nih.gov/pubmed/?term=2440457 ETANERCEPT etanercept. Abstracts of a Seminars in Research. October 14-15, 1 2011. Italy. Manifestation of Crohn's disease in a young woman during the https://www.ncbi.nlm.nih.gov/pubmed/?term=2454853 ETANERCEPT course of treatment for severe form of chronic plaque psoriasis with 7 etanercept. Early tissue responses in psoriasis to the antitumour necrosis factor- https://www.ncbi.nlm.nih.gov/pubmed/?term=2460199 ETANERCEPT alpha biologic etanercept suggest reduced interleukin-17 receptor 7 expression and signalling. https://www.ncbi.nlm.nih.gov/pubmed/?term=2464614 ETANERCEPT First fatal case of systemic suppurative/necrotizing granulomatous 4 disease following etanercept therapy for psoriasis. Etanercept for psoriasis and psoriatic arthritis in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2465863 ETANERCEPT Charcot-Marie-Tooth disease. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2470326 ETANERCEPT Juvenile generalized pustular psoriasis treated with etanercept. 8 Pattern of response in patients with moderate-to-severe psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2486169 ETANERCEPT treated with etanercept. 6 Medication Title of Article PubMed Link A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2498098 ETANERCEPT agent vs. Etanercept 50 mg twice weekly in patients with moderate to 8 severe plaque psoriasis (REFINE). Safety and efficacy of etanercept in children with the JIA categories https://www.ncbi.nlm.nih.gov/pubmed/?term=2503408 ETANERCEPT extended oligoarthritis, enthesitis-related arthritis and psoriasis 1 arthritis. Retreatment in patients with psoriasis achieving response with https://www.ncbi.nlm.nih.gov/pubmed/?term=2508783 ETANERCEPT etanercept after relapse due to treatment interruption: results from 9 the CRYSTEL study. Employment is maintained and sick days decreased in https://www.ncbi.nlm.nih.gov/pubmed/?term=2509109 ETANERCEPT psoriasis/psoriatic arthritis patients with etanercept treatment. 0 Survival rate of etanercept for psoriasis in real life: a multicentre https://www.ncbi.nlm.nih.gov/pubmed/?term=2511519 ETANERCEPT observational study. 4 OBSERVE-5: observational postmarketing safety surveillance https://www.ncbi.nlm.nih.gov/pubmed/?term=2526423 ETANERCEPT registry of etanercept for the treatment of psoriasis final 5-year 9 results. https://www.ncbi.nlm.nih.gov/pubmed/?term=2538197 ETANERCEPT Treatment adherence to different etanercept regimens, continuous 1 vs. intermittent, in patients affected by plaque-type psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2549017 ETANERCEPT Hepatotoxicity due to etanercept abated after dose reduction in a 2 patient with pustular psoriasis and without compromised efficacy. https://www.ncbi.nlm.nih.gov/pubmed/?term=2561108 ETANERCEPT Improvements in patient-reported outcomes in patients with psoriasis 4 receiving etanercept plus topical therapies: results from REFINE. Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2561760 ETANERCEPT etanercept, vascular function and endothelial progenitor cells in 5 psoriasis. Impact of early vs. late disease onset on treatment response to https://www.ncbi.nlm.nih.gov/pubmed/?term=2591355 ETANERCEPT etanercept in patients with psoriasis. 0 Long-term Management of Moderate to Severe Plaque Psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2595182 ETANERCEPT Patients With Etanercept: A Case Series. 5 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2606569 ETANERCEPT Multiple lentigines in psoriasis patients treated with etanercept. 0 Efficacy and cost of etanercept in long-term psoriasis: Rational use in https://www.ncbi.nlm.nih.gov/pubmed/?term=2608459 ETANERCEPT clinical practice. 0 Anal canal adenocarcinoma in a patient with psoriasis treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=2672883 ETANERCEPT etanercept. 0 Long-term safety and efficacy of etanercept in children and https://www.ncbi.nlm.nih.gov/pubmed/?term=2677577 ETANERCEPT adolescents with plaque psoriasis. 5 The effects of etanercept on replication, proliferation, survival, and https://www.ncbi.nlm.nih.gov/pubmed/?term=2680555 ETANERCEPT apoptosis markers in moderate to severe psoriasis. 6 Treatment of psoriasis with etanercept: the typical patient profile. https://www.ncbi.nlm.nih.gov/pubmed/?term=2707304 ETANERCEPT [Review] 6

Interleukin levels and macrophagic density in periumbilical fat tissue https://www.ncbi.nlm.nih.gov/pubmed/?term=2728477 ETANERCEPT in patients affected by moderate-to-severe psoriasis with metabolic 7 syndrome, before and after etanercept treatment. https://www.ncbi.nlm.nih.gov/pubmed/?term=2729798 ETANERCEPT An observational study to evaluate the long-term outcomes of 1 treatment with etanercept in patients with plaque-type psoriasis. Positive correlation between etanercept concentration and the https://www.ncbi.nlm.nih.gov/pubmed/?term=2743619 ETANERCEPT decrease in Psoriasis Area and Severity Index scale value. 3 Persistence and Failure Rates of Monotherapy Etanercept in Biologic- https://www.ncbi.nlm.nih.gov/pubmed/?term=2753800 ETANERCEPT Naive Psoriasis Patients: A Retrospective Study. 8 Combination Therapy of Etanercept and Fumarates versus https://www.ncbi.nlm.nih.gov/pubmed/?term=2757648 ETANERCEPT Etanercept Monotherapy in Psoriasis: A Randomized Exploratory 3 Study.

Cardiovascular Risk Evaluation through Heart Rate Variability (HRV) https://www.ncbi.nlm.nih.gov/pubmed/?term=2766391 ETANERCEPT Analysis in Patients with Psoriasis before and after 12 Weeks of 8 Etanercept Therapy: A Preliminary Prospective Study.

The EGALITY study: a confirmatory, randomized, double-blind study https://www.ncbi.nlm.nih.gov/pubmed/?term=2778789 ETANERCEPT comparing the efficacy, safety and immunogenicity of GP2015, a 0 proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Medication Title of Article PubMed Link The utility of etanercept in chronic stable plaque psoriasis: Results https://www.ncbi.nlm.nih.gov/pubmed/?term=2785299 ETANERCEPT from an open-label, prospective, single arm study. 0 The association between etanercept serum concentration and https://www.ncbi.nlm.nih.gov/pubmed/?term=2842067 ETANERCEPT psoriasis severity is highly age-dependent. 6 Polymorphisms associated with etanercept response in moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2847012 ETANERCEPT severe plaque psoriasis. 7 Impact of pharmacogenomics upon the therapeutic response to https://www.ncbi.nlm.nih.gov/pubmed/?term=2875056 ETANERCEPT etanercept in psoriasis and psoriatic arthritis. [Review] 7 Pregnancy and infant outcomes including major congenital https://www.ncbi.nlm.nih.gov/pubmed/?term=2875827 ETANERCEPT malformations among women with chronic inflammatory arthritis or 4 psoriasis, with and without etanercept use. Effectiveness of etanercept in children with plaque psoriasis in real https://www.ncbi.nlm.nih.gov/pubmed/?term=2878399 ETANERCEPT practice: a one-year multicenter retrospective study. 1 A 12-year-old Girl with Severe Plaque Psoriasis and Down Syndrome https://www.ncbi.nlm.nih.gov/pubmed/?term=2887193 ETANERCEPT Treated Successfully with Etanercept. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2896973 ETANERCEPT Erythrodermic Psoriasis and Hepatitis C Infection Treated with 0 Pegylated Interferon and Anti-TNFalpha alpha(Etanercept) Therapy. https://www.ncbi.nlm.nih.gov/pubmed/?term=2927075 ETANERCEPT Safety and efficacy of etanercept monotherapy for moderate-to- 8 severe plaque psoriasis: A prospective 12-week follow-up study. ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2248351 EXCIMER LASER, Effective treatment of etanercept and phototherapy-resistant 3 PHOTOTHERAPY psoriasis using the excimer laser. ETANERCEPT, Biologic therapy for psoriasis: the tumor necrosis factor inhibitors https://www.ncbi.nlm.nih.gov/pubmed/?term=1255362 INFLIXIMAB infliximab and etanercept. [Review] [15 refs] 7 ETANERCEPT, Biologic therapy for psoriasis--the first wave: infliximab, etanercept, https://www.ncbi.nlm.nih.gov/pubmed/?term=1285199 INFLIXIMAB efalizumab, and alefacept. [Review] [22 refs] 0 ETANERCEPT, An overview of infliximab, etanercept, efalizumab, and alefacept as https://www.ncbi.nlm.nih.gov/pubmed/?term=1466795 INFLIXIMAB biologic therapy for psoriasis. [Review] [41 refs] 3 ETANERCEPT, Biological therapy for psoriasis: an overview of infliximab, etanercept, https://www.ncbi.nlm.nih.gov/pubmed/?term=1473046 INFLIXIMAB efalizumab and alefacept. [Review] [34 refs] 6 ETANERCEPT, Infliximab in the treatment of psoriasis in patients previously treated https://www.ncbi.nlm.nih.gov/pubmed/?term=1748271 INFLIXIMAB with etanercept. 5 Medication Title of Article PubMed Link ETANERCEPT, Efficiency and safety of etanercept after acute hepatitis induced by https://www.ncbi.nlm.nih.gov/pubmed/?term=1947914 INFLIXIMAB infliximab for psoriasis. 8 The efficacy and safety of infliximab in patients with plaque psoriasis ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2215379 who had an inadequate response to etanercept: results of a INFLIXIMAB 2 prospective, multicenter, open-label study. Effect of infliximab on health-related quality of life and disease ETANERCEPT, activity by body region in patients with moderate-to-severe psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2398616 INFLIXIMAB and inadequate response to etanercept: results from the PSUNRISE 0 trial. Efficacy, tolerability and safety of switching from etanercept to ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2523117 infliximab for the treatment of moderate-to-severe psoriasis: A INFLIXIMAB 6 multicenter, open-label trial (TANGO). A prospective randomized controlled trial comparing infliximab and ETANERCEPT, etanercept in patients with moderate-to-severe chronic plaque-type https://www.ncbi.nlm.nih.gov/pubmed/?term=2741689 INFLIXIMAB psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison 1 Evaluation (PIECE) study. ETANERCEPT, Etanercept or infliximab for psoriasis? An independent randomized https://www.ncbi.nlm.nih.gov/pubmed/?term=2830030 INFLIXIMAB clinical trial. 1 ETANERCEPT, Successful treatment of psoriasis and psoriatic arthritis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1502378 INFLIXIMAB, etanercept and methotrexate in a patient newly unresponsive to 9 METHOTREXATE infliximab. Comparison of ixekizumab with etanercept or placebo in moderate-to- ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2607210 severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two IXEKIZUMAB 9 phase 3 randomised trials. ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2788929 Short- and long-term safety outcomes with ixekizumab from 7 clinical IXEKIZUMAB 2 trials in psoriasis: Etanercept comparisons and integrated data.

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non- ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2807444 Responders: A Subanalysis from Two Phase III Randomized Clinical IXEKIZUMAB 6 Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and - 3).[Erratum appears in Am J Clin Dermatol. 2018 Mar 29;:; PMID: Medication Title of Article PubMed Link Efficacy of ixekizumab compared to etanercept and placebo in ETANERCEPT, patients with moderate-to-severe plaque psoriasis and non-pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=2832247 IXEKIZUMAB palmoplantar involvement: results from three phase 3 trials 4 (UNCOVER-1, UNCOVER-2 and UNCOVER-3). Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2903624 Manufacturer-Recommended Dosing Regimens in Moderate to IXEKIZUMAB 9 Severe Plaque Psoriasis. Etanercept therapy allows the tapering of methotrexate and ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=1821150 sustained clinical responses in patients with moderate to severe METHOTREXATE 0 psoriasis. ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=1854731 METHOTREXATE Etanercept combined with methotrexate for high-need psoriasis. 0 The combination of etanercept and methotrexate increases the ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=1877989 effectiveness of treatment in active psoriasis despite inadequate METHOTREXATE 0 effect of methotrexate therapy. A randomized, double-blind, placebo-controlled study to evaluate the ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2253344 addition of methotrexate to etanercept in patients with moderate to METHOTREXATE 7 severe plaque psoriasis. ETANERCEPT, Topical co-delivery of methotrexate and etanercept using lipid https://www.ncbi.nlm.nih.gov/pubmed/?term=2877963 METHOTREXATE nanoparticles: A targeted approach for psoriasis management. 7 Utilization of narrow-band ultraviolet light B therapy and etanercept ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=1838020 for the treatment of psoriasis (UNITE): efficacy, safety, and patient- PHOTOTHERAPY 6 reported outcomes. ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2146653 Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is PHOTOTHERAPY 2 more effective than etanercept monotherapy at 6 weeks. ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2169703 Combined treatment with etanercept 50 mg once weekly and narrow- PHOTOTHERAPY 2 band ultraviolet B phototherapy in chronic plaque psoriasis.

ETANERCEPT, A randomized, 'head-to-head' pilot study comparing the effects of https://www.ncbi.nlm.nih.gov/pubmed/?term=2270284 PHOTOTHERAPY etanercept monotherapy vs. etanercept and narrowband ultraviolet B 6 (NB-UVB) phototherapy in obese psoriasis patients. ETANERCEPT, Synergism between narrowband ultraviolet B phototherapy and https://www.ncbi.nlm.nih.gov/pubmed/?term=2383411 PHOTOTHERAPY etanercept for the treatment of plaque-type psoriasis. 3 Medication Title of Article PubMed Link ETANERCEPT, Synergism between narrowband ultraviolet B phototherapy and https://www.ncbi.nlm.nih.gov/pubmed/?term=2383411 PHOTOTHERAPY etanercept for the treatment of plaque-type psoriasis. 7 ETANERCEPT, Etanercept combined with systemic drugs or phototherapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2552946 PHOTOTHERAPY treatment of psoriasis. [Review] 3 Tildrakizumab versus placebo or etanercept for chronic plaque ETANERCEPT, psoriasis (reSURFACE 1 and reSURFACE 2): results from two https://www.ncbi.nlm.nih.gov/pubmed/?term=2859604 TILDRAKIZUMAB randomised controlled, phase 3 trials.[Erratum appears in Lancet. 3 2017 Jul 15;390(10091):230; PMID: 28721878] ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2605136 Tofacitinib versus etanercept or placebo in moderate-to-severe TOFACITINIB 5 chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Tofacitinib versus etanercept or placebo in patients with moderate to ETANERCEPT, https://www.ncbi.nlm.nih.gov/pubmed/?term=2727119 severe chronic plaque psoriasis: patient-reported outcomes from a TOFACITINIB 5 Phase 3 study. ETANERCEPT, Sacroiliitis in a psoriasis patient after switching from etanercept to https://www.ncbi.nlm.nih.gov/pubmed/?term=2419231 USTEKINUMAB ustekinumab. 8

ETANERCEPT,INFLI Safety and efficacy of alefacept, efalizumab, etanercept and https://www.ncbi.nlm.nih.gov/pubmed/?term=1854730 XIMAB infliximab in treating moderate to severe plaque psoriasis: a meta- 0 analysis of randomized controlled trials. [Review] [64 refs] ETANERCEPT,IXEKI https://www.ncbi.nlm.nih.gov/pubmed/?term=2924086 Cost Per Additional Responder Associated With Ixekizumab and ZUMAB 0 Etanercept in the Treatment of Moderate-to-Severe Psoriasis. Secukinumab provides better relief from the impact of psoriasis on ETANERCEPT,SEC daily activities and personal relationships than etanercept: results of https://www.ncbi.nlm.nih.gov/pubmed/?term=2783271 UKINUMAB two phase 3 placebo-controlled randomized clinical trials in moderate- 7 to-severe psoriasis. ETANERCEPTINFLI Sequential use of infliximab and etanercept in generalized pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=1703666 XIMAB psoriasis. 4 Etodolac Containing Topical Niosomal Gel: Formulation Development https://www.ncbi.nlm.nih.gov/pubmed/27478643 ETODOLAC and Evaluation. Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug etodolac via its transformation into an https://www.ncbi.nlm.nih.gov/pubmed/26945484 ETODOLAC ionic . Medication Title of Article PubMed Link In vitro and in vivo characteristics of a thermogelling rectal delivery https://www.ncbi.nlm.nih.gov/pubmed/19479384 ETODOLAC system of etodolac. Bioavailability and bioequivalence of two formulations of etodolac https://www.ncbi.nlm.nih.gov/pubmed/8445537 ETODOLAC (tablets and suppositories). Pharmacokinetic study of etodolac after ; "in https://www.ncbi.nlm.nih.gov/pubmed/1840326 ETODOLAC vitro" release kinetics.

Etodolac transdermal cubosomes for the treatment of rheumatoid https://www.ncbi.nlm.nih.gov/pubmed/28535740 ETODOLAC arthritis: ex vivo permeation and in vivo pharmacokinetic studies. Formulation and evaluation of etodolac lecithin organogel http://innovareacademics.in/journals/index.php/ijpps/a ETODOLAC transdermal delivery systems rticle/view/5154 Design, Development, and Evaluation of Transdermal Patches http://www.jonrpt.com/upload1/06-Y.pdf ETODOLAC containing Anti- inflammatory drug Etodolac http://contents.xj- storage.jp/xcontents/45860/dad30405/ce66/4fa9/b836 ETODOLAC Patent Granted in Canada for Ionic Liquid Etodolac for Patches /1a492c381e00/20150529174136287s.pdf

A randomized, multi-Center, double-blind, placebo-controlled phase http://www.sciencedirect.com/science/article/pii/S152 II/III trial to evaluate the efficacy, tolerability and safety of MRX-7EAT 6590013006664# ETODOLAC Etodolac-Lidocaine Topical Patch in the treatment of pain An ionic liquid-in-water microemulsion as a potential carrier for topical http://www.ncbi.nlm.nih.gov/pubmed/?term=ETODOL delivery of poorly water soluble drug: Development, ex-vivo and in- AC+topical ETODOLAC vivo evaluation Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in http://www.ncbi.nlm.nih.gov/pubmed/26703278 ETOROLAC patients having phacoemulsification The assessment of changes in macular thickness in diabetic and non- diabetic patients: the effect of topical ketorolac on macular thickness http://www.ncbi.nlm.nih.gov/pubmed/25799211 ETOROLAC change after ND:YAG laser capsulotomy

ETOROLAC ESTER Synthesis, physicochemical properties and in vitro permeation http://www.ncbi.nlm.nih.gov/pubmed/17627494 DERIVATIVES studies of new ketorolac ester derivatives EXCIMER LASER https://www.ncbi.nlm.nih.gov/pubmed/?term=9388408 308 nm UVB excimer laser for psoriasis. Medication Title of Article PubMed Link 308-nm excimer laser for the treatment of psoriasis: a dose-response https://www.ncbi.nlm.nih.gov/pubmed/?term=1081585 EXCIMER LASER study. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1117667 EXCIMER LASER 308-nm excimer laser therapy for psoriasis. 4 A review of the 308-nm excimer laser in the treatment of psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1176612 EXCIMER LASER [Review] [5 refs] 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1200431 EXCIMER LASER High-dose 308-nm excimer laser for the treatment of psoriasis. 6 Efficacy of the 308-nm excimer laser for treatment of psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=1206348 EXCIMER LASER results of a multicenter study. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1208168 EXCIMER LASER Treatment of inverse psoriasis with the 308 nm excimer laser. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1239976 EXCIMER LASER Medium-dose 308-nm excimer laser for the treatment of psoriasis. 1 Remissions of psoriasis with excimer laser treatment. [Review] [6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1254677 EXCIMER LASER refs] 7 308-nm excimer laser for the treatment of psoriasis: induration-based https://www.ncbi.nlm.nih.gov/pubmed/?term=1281050 EXCIMER LASER dosimetry. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1284774 EXCIMER LASER Remissions of psoriasis with excimer laser treatment. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1500482 EXCIMER LASER A 308-nm excimer laser for the treatment of scalp psoriasis. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1514809 EXCIMER LASER 308-nm excimer laser for the treatment of scalp psoriasis. 3 A maintenance protocol for psoriasis plaques cleared by the 308 nm https://www.ncbi.nlm.nih.gov/pubmed/?term=1520415 EXCIMER LASER excimer laser. 9 Comparison of the efficacy and safety of the 308 nm excimer laser https://www.ncbi.nlm.nih.gov/pubmed/?term=1580430 EXCIMER LASER for the treatment of localized psoriasis in adults and in children: a 9 pilot study. Use of the 308-nm excimer laser for psoriasis and vitiligo. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=1642750 EXCIMER LASER [45 refs] 4 Excimer laser versus narrow-band UVB (311 nm) in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1690229 EXCIMER LASER psoriasis vulgaris. 0 Clinical efficacy of a 308 nm excimer laser for treatment of psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1798606 EXCIMER LASER vulgaris. 0 Medication Title of Article PubMed Link The effectiveness of PUVA treatment in severe psoriasis is https://www.ncbi.nlm.nih.gov/pubmed/?term=1808659 EXCIMER LASER significantly increased by additional UV 308-nm excimer laser 0 sessions. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and https://www.ncbi.nlm.nih.gov/pubmed/?term=1871774 EXCIMER LASER palmoplantar psoriasis. [Review] [31 refs] 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1925359 EXCIMER LASER Treating vitiligo and psoriasis with the excimer laser. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2093217 EXCIMER LASER The use of the 308-nm excimer laser for the treatment of psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2140137 EXCIMER LASER 308-nm Excimer laser treatment of palmoplantar psoriasis. 6 Treatment of plaque-type psoriasis with the 308 nm excimer laser in https://www.ncbi.nlm.nih.gov/pubmed/?term=2233523 EXCIMER LASER combination with dithranol or calcipotriol. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2254839 EXCIMER LASER Clinical efficacy of /salicylic acid ointment combined with 4 308-nm excimer laser for treatment of psoriasis vulgaris. Excimer laser therapy for hairline psoriasis: a useful addition to the https://www.ncbi.nlm.nih.gov/pubmed/?term=2262228 EXCIMER LASER scalp psoriasis treatment algorithm. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2285924 EXCIMER LASER Treatment of psoriasis and long-term maintenance using 308 nm 7 excimer laser, clobetasol spray, and calcitriol ointment: a case series.

Supraerythemogenic excimer laser in combination with clobetasol https://www.ncbi.nlm.nih.gov/pubmed/?term=2454779 EXCIMER LASER spray and calcitriol ointment for the treatment of generalized plaque 1 psoriasis: Interim results of an open label pilot study. Plaque-based sub-blistering dosimetry: Reaching PASI-75 after two https://www.ncbi.nlm.nih.gov/pubmed/?term=2455254 EXCIMER LASER treatments with 308-nm excimer laser in a generalized psoriasis 8 patient. Successful use of the excimer laser for generalized psoriasis in an https://www.ncbi.nlm.nih.gov/pubmed/?term=2578096 EXCIMER LASER ustekinumab non-responder. 1 An open label pilot study of supraerythemogenic excimer laser in https://www.ncbi.nlm.nih.gov/pubmed/?term=2632977 EXCIMER LASER combination with clobetasol spray and calcitriol ointment for the 4 treatment of generalized plaque psoriasis. Medication Title of Article PubMed Link A randomised half body prospective study of low and medium dose https://www.ncbi.nlm.nih.gov/pubmed/?term=2768021 EXCIMER LASER regimens using the 308nm excimer laser in the treatment of localised 9 psoriasis. Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) https://www.ncbi.nlm.nih.gov/pubmed/?term=2816873 EXCIMER LASER therapy in psoriasis patients?. 5 EXCIMER LASER, Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new https://www.ncbi.nlm.nih.gov/pubmed/?term=1467490 PHOTOTHERAPY phototherapeutic approach. 4 Comparison of the 308-nm excimer laser and a 308-nm excimer EXCIMER LASER, https://www.ncbi.nlm.nih.gov/pubmed/?term=1584010 lamp with 311-nm narrowband ultraviolet B in the treatment of PHOTOTHERAPY 8 psoriasis. EXCIMER LASER, https://www.ncbi.nlm.nih.gov/pubmed/?term=1776360 Excimer laser for psoriasis: a review of theories regarding enhanced PHOTOTHERAPY 9 efficacy over traditional UVB phototherapy. [Review] [13 refs] Pilot evaluation of supra-erythemogenic phototherapy with excimer EXCIMER LASER, https://www.ncbi.nlm.nih.gov/pubmed/?term=1971121 laser in the treatment of patients with moderate to severe plaque PHOTOTHERAPY 9 psoriasis. EXCIMER LASER, A review of protocols for 308 nm excimer laser phototherapy in https://www.ncbi.nlm.nih.gov/pubmed/?term=2220608 PHOTOTHERAPY psoriasis. [Review] 3 EXCIMER LASER, Targeted phototherapy using 308 nm Xecl monochromatic excimer https://www.ncbi.nlm.nih.gov/pubmed/?term=2305324 PHOTOTHERAPY laser for psoriasis at difficult to treat sites. 7

EXCIMER LASER, Single administration of lesion-limited high-dose (TURBO) ultraviolet https://www.ncbi.nlm.nih.gov/pubmed/?term=2312629 PHOTOTHERAPY B using the excimer laser: clinical clearing in association with 0 apoptosis of epidermal and dermal T cell subsets in psoriasis. EXCIMER https://www.ncbi.nlm.nih.gov/pubmed/?term=2309431 LASER,PHOTOTHE Therapeutic modalities for localized psoriasis: 308-nm UVB excimer 6 RAPY laser versus nontargeted phototherapy. [Review] FILIPENDULA In vitro and in vivo assessment of meadowsweet https://www.ncbi.nlm.nih.gov/pubmed/27721054 ULMARIA (Filipendula ulmaria) as anti-inflammatory agent. Evaluation of the Antibacterial Activity of Green Propolis Extract and Meadowsweet Extract Against Staphylococcus aureus https://europepmc.org/article/med/28333678 FILIPENDULA Bacteria: Importance in Would Care ULMARIA Preparations. Medication Title of Article PubMed Link Study to compare the efficacy and safety of fluconazole cream with flutrimazole cream in the treatment of superficial mycosis: a http://www.ncbi.nlm.nih.gov/pubmed/19558428 FLUCONAZOLE multicentre, randomised, double-blind, phase III trial. Fluconazole mouthrinses for oral candidiasis in postirradiation, http://www.ncbi.nlm.nih.gov/pubmed/12142873 FLUCONAZOLE transplant, and other patients. Comparison of efficacy of fluconazole mouthrinse and clotrimazole http://www.ncbi.nlm.nih.gov/pubmed/20415933 FLUCONAZOLE mouthpaint in the treatment of oral candidiasis. FLUCONAZOLE Topical fluconazole therapy of Candida keratitis. http://www.ncbi.nlm.nih.gov/pubmed/8776563 A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer http://www.ncbi.nlm.nih.gov/pubmed/21781012 FLUCONAZOLE for treatment of onychomycosis: therapeutic trial. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole http://www.ncbi.nlm.nih.gov/pubmed/7636666 suspension versus . The Multicenter Fluconazole Study FLUCONAZOLE Group. Combination of fluconazole and urea in a nail lacquer for http://www.ncbi.nlm.nih.gov/pubmed/15897169 FLUCONAZOLE treating onychomycosis. Fluconazole nasal spray in the treatment of allergic fungal sinusitis: a http://www.ncbi.nlm.nih.gov/pubmed/15586870 FLUCONAZOLE pilot study. The comparison of solitary topical or fluconazole http://www.ncbi.nlm.nih.gov/pubmed/21097785 FLUCONAZOLE application in the treatment of Candida fungal keratitis. Combined application of 5% and 0.2% fluconazole for the http://www.ncbi.nlm.nih.gov/pubmed/24396961 FLUCONAZOLE treatment of fungal keratitis. Development and evaluation of new microemulsion-based hydrogel http://www.ncbi.nlm.nih.gov/pubmed/25591952 FLUCONAZOLE formulations for topical delivery of fluconazole Thermoresponsive fluconazole gels for topical delivery: rheological and mechanical properties, in vitro drug release and anti-fungal http://www.ncbi.nlm.nih.gov/pubmed/24160864 FLUCONAZOLE efficacy An evaluation of nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in http://www.ncbi.nlm.nih.gov/pubmed/16338779 the time to relief of symptoms in patients with vulvovaginal FLUCONAZOLE candidiasis. A randomized controlled trial assessing the efficacy of fluconazole in http://www.ncbi.nlm.nih.gov/pubmed/16243128 FLUCONAZOLE the treatment of pediatric tinea capitis Medication Title of Article PubMed Link Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/15623951 FLUCONAZOLE onychomycosis FLUCONAZOLE Fluconazole in the treatment of tinea corporis and tinea cruris http://www.ncbi.nlm.nih.gov/pubmed/9568414 FLUCONAZOLE Topical fluconazole therapy of Candida keratitis http://www.ncbi.nlm.nih.gov/pubmed/8776563 A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer http://www.ncbi.nlm.nih.gov/pubmed/21781012 FLUCONAZOLE for treatment of onychomycosis: therapeutic trial http://www.ncbi.nlm.nih.gov/pubmed/12060505 FLUCONAZOLE Fluconazole versus ketoconazole in the treatment of Study to compare the efficacy and safety of fluconazole cream with flutrimazole cream in the treatment of superficial mycosis: a http://www.ncbi.nlm.nih.gov/pubmed/19558428 FLUCONAZOLE multicentre, randomised, double-blind, phase III trial Efficacy and safety of a single oral 150 mg dose of fluconazole for http://www.ncbi.nlm.nih.gov/pubmed/25887336 FLUCONAZOLE the treatment of vulvovaginal candidiasis in Japan A comparative study to evaluate efficacy, safety and cost- effectiveness between Whitfield's ointment + oral fluconazole versus http://www.ncbi.nlm.nih.gov/pubmed/24347774 FLUCONAZOLE topical 1% butenafine in tinea infections of skin Topical amphotericin B and subconjunctival injection of fluconazole (combination therapy) versus topical amphotericin B (monotherapy) http://www.ncbi.nlm.nih.gov/pubmed/20565316 FLUCONAZOLE in treatment of keratomycosis Comparison of efficacy of fluconazole mouthrinse and clotrimazole http://www.ncbi.nlm.nih.gov/pubmed/20415933 FLUCONAZOLE mouthpaint in the treatment of oral candidiasis Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: http://www.ncbi.nlm.nih.gov/pubmed/17645378 FLUCONAZOLE a placebo-controlled study Comparison between fluconazole and ketoconazole effectivity in the http://www.ncbi.nlm.nih.gov/pubmed/17576325 FLUCONAZOLE treatment of pityriasis versicolor An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in http://www.ncbi.nlm.nih.gov/pubmed/16338779 the time to relief of symptoms in patients with vulvovaginal FLUCONAZOLE candidiasis A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients http://www.ncbi.nlm.nih.gov/pubmed/8645677 FLUCONAZOLE undergoing radiotherapy for head and neck tumours Medication Title of Article PubMed Link Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. http://www.ncbi.nlm.nih.gov/pubmed/2184513 FLUCONAZOLE ketoconazole https://www.ncbi.nlm.nih.gov/pubmed/27672689 FLUCONAZOLE PURLs: Yeast infection in pregnancy? Think twice about fluconazole. New Generation of Fluconazole: A Review on Existing Researches https://www.ncbi.nlm.nih.gov/pubmed/27138299 FLUCONAZOLE and Technologies. FORMULATION AND EVALUATION OF TOPICAL AND file:///C:/Users/shweta/Downloads/article_wjpps_1480 ETHOSOMAL GELS OF FLUCONAZOLE BP AND 495905%20(1).pdf FLUCONAZOLE BP Genotyping and Persistence of Candida albicans from Pregnant https://www.ncbi.nlm.nih.gov/pubmed/27882525 FLUCONAZOLE Women with Vulvovaginal Candidiasis. A Novel Vehicle for Enhanced Drug Delivery Across the Human Nail https://www.ncbi.nlm.nih.gov/pubmed/27125057 FLUCONAZOLE for the Treatment of Onychomycosis. The effect of pre-operative topical or diclofenac on pupil http://www.ncbi.nlm.nih.gov/pubmed/11040914 FLURBIPROFEN dilatation. Flurbiprofen local action transcutaneous (LAT): clinical evaluation in http://www.ncbi.nlm.nih.gov/pubmed/7541355 FLURBIPROFEN the treatment of acute ankle sprains. Efficacy and tolerability of a topical NSAID patch (local action transcutaneous flurbiprofen) and oral diclofenac in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/9132322 FLURBIPROFEN soft-tissue rheumatism. Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract http://www.ncbi.nlm.nih.gov/pubmed/23833362 FLURBIPROFEN surgery. A Prospective, Open-label Study to Compare the Efficacy and the Safety of Topical Etabonate and Topical Flurbiprofen http://www.ncbi.nlm.nih.gov/pubmed/23285440 Sodium in Patients with Post-Operative Inflammation after Cataract FLURBIPROFEN Extraction. Multiple applications of flurbiprofen and chlorhexidine chips in patients with chronic periodontitis: a randomized, double blind, http://www.ncbi.nlm.nih.gov/pubmed/22092475 FLURBIPROFEN parallel, 2-arms clinical trial. Intracrevicular application of 0.3% Flurbiprofen gel and 0.3% gel as anti inflammatory agent. A comparative clinical http://www.ncbi.nlm.nih.gov/pubmed/11665396 FLURBIPROFEN study. Medication Title of Article PubMed Link Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision http://www.ncbi.nlm.nih.gov/pubmed/26600636 cataract surgery in patients with senile cataract: A randomized, FLURBIPROFEN double-blind study Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and http://www.ncbi.nlm.nih.gov/pubmed/25231972 FLURBIPROFEN percutaneous absorption mechanism Ocular safety of nasal spray in patients with http://www.ncbi.nlm.nih.gov/pubmed/23806459 FLUTICASONE perennial allergic rhinitis: a 2-year study. An integrated analysis of the efficacy of fluticasone furoate nasal spray versus placebo on the nasal symptoms of perennial allergic http://www.ncbi.nlm.nih.gov/pubmed/23676578 FLUTICASONE rhinitis.

The effect of intranasal fluticasone propionate irrigations on salivary http://www.ncbi.nlm.nih.gov/pubmed/24124056 cortisol, intraocular pressure, and posterior subcapsular cataracts in FLUTICASONE postsurgical chronic rhinosinusitis patients. Once-daily fluticasone furoate is efficacious in patients with http://www.ncbi.nlm.nih.gov/pubmed/23062392 FLUTICASONE symptomatic asthma on low-dose inhaled corticosteroids.

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol http://www.ncbi.nlm.nih.gov/pubmed/24429127 only for prevention of exacerbations of COPD: two replicate double- FLUTICASONE blind, parallel-group, randomised controlled trials.

Fluticasone furoate nasal spray reduces symptoms of uncomplicated http://www.ncbi.nlm.nih.gov/pubmed/22614920 FLUTICASONE acute rhinosinusitis: a randomised placebo-controlled study. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal http://www.ncbi.nlm.nih.gov/pubmed/23127291 FLUTICASONE allergic rhinitis. Fluticasone propionate aqueous nasal spray is safe and effective for http://www.ncbi.nlm.nih.gov/pubmed/8414833 FLUTICASONE children with seasonal allergic rhinitis. Comparison of esomeprazole to aerosolized, swallowed fluticasone http://www.ncbi.nlm.nih.gov/pubmed/19533356 FLUTICASONE for eosinophilic esophagitis.

Effects of FESS and additional fluticasone propionate nasal drops on http://www.ncbi.nlm.nih.gov/pubmed/23944945 FLUTICASONE psychological well-being in nasal polyposis with asthma. Medication Title of Article PubMed Link Effect of nasal anti-inflammatory treatment in chronic obstructive http://www.ncbi.nlm.nih.gov/pubmed/23883807 FLUTICASONE pulmonary disease.

Superiority of tacrolimus 0.1% ointment compared with fluticasone http://www.ncbi.nlm.nih.gov/pubmed/19416227 0.005% in adults with moderate to severe atopic dermatitis of the FLUTICASONE face: results from a randomized, double-blind trial. Comparison of sensory attributes and immediate efficacy of intranasal and fluticasone propionate in allergic rhinitis: a http://www.ncbi.nlm.nih.gov/pubmed/23112411 FLUTICASONE randomized controlled trial. Fluticasone nasal spray as an adjunct to Amoxicillin for acute http://www.ncbi.nlm.nih.gov/pubmed/24302188 FLUTICASONE sinusitis in children: a randomized controlled trial. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with http://www.ncbi.nlm.nih.gov/pubmed/18254486 FLUTICASONE seasonal allergic rhinitis.

Treatment with intranasal fluticasone propionate significantly http://www.ncbi.nlm.nih.gov/pubmed/15196285 FLUTICASONE improves ocular symptoms in patients with seasonal allergic rhinitis. Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with http://www.ncbi.nlm.nih.gov/pubmed/26679480 FLUTICASONE polyposis after endoscopic sinus surgery The reservoir effect of topical steroids in vitiliginous skin: A cross- http://www.ncbi.nlm.nih.gov/pubmed/26144851 FLUTICASONE sectional study Effect of intranasal steroids on rhinosinusitis after radiotherapy for http://www.ncbi.nlm.nih.gov/pubmed/26740194 FLUTICASONE nasopharyngeal carcinoma: clinical study A prospective randomized blinded clinical trial: large-volume nasal irrigation with fluticasone propionate in the early postoperative period http://www.ncbi.nlm.nih.gov/pubmed/25845978 FLUTICASONE following septoplasty

The use of large volume low pressure nasal saline with fluticasone http://www.ncbi.nlm.nih.gov/pubmed/24972936 FLUTICASONE propionate for the treatment of pediatric acute rhinosinusitis

Comparison of the effects of fluticasone propionate, aqueous nasal http://www.ncbi.nlm.nih.gov/pubmed/10520057 spray and levocabastine on inflammatory cells in nasal lavage and FLUTICASONE clinical activity during the pollen season in seasonal rhinitics Medication Title of Article PubMed Link Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the http://www.ncbi.nlm.nih.gov/pubmed/8757203 increase in bronchial responsiveness during the pollen season in FLUTICASONE allergic rhinitis Effect of short-term treatment with fluticasone propionate nasal spray http://www.ncbi.nlm.nih.gov/pubmed/7893587 FLUTICASONE on the response to nasal allergen challenge Other anti-inflammatory uses of intranasal corticosteroids in upper http://www.ncbi.nlm.nih.gov/pubmed/10929865 FLUTICASONE respiratory inflammatory diseases A comparison of fluticasone propionate nasal spray and cetirizine in http://www.ncbi.nlm.nih.gov/pubmed/26108088 FLUTICASONE ragweed fall seasonal allergic rhinitis

Long-term, randomized safety study of MP29-02 (a novel intranasal http://www.ncbi.nlm.nih.gov/pubmed/24607046 formulation of azelastine hydrochloride and fluticasone propionate in FLUTICASONE an advanced delivery system) in subjects with chronic rhinitis Effective treatment of mild-to-moderate nasal polyposis with http://www.ncbi.nlm.nih.gov/pubmed/19936370 FLUTICASONE fluticasone delivered by a novel device Effects of intranasal fluticasone and salmeterol on allergen-induced http://www.ncbi.nlm.nih.gov/pubmed/16677243 FLUTICASONE nasal responses Placebo-controlled, randomized, double-blind study evaluating the http://www.tandfonline.com/doi/abs/10.1080/0001648 efficacy of fluticasone propionate nasal spray for the treatment of 0310002140 FLUTICASONE patients with hyposmia/anosmia Corticosteroid nasal irrigations after endoscopic sinus surgery in the https://www.ncbi.nlm.nih.gov/pubmed/22566474 FLUTICASONE management of chronic rhinosinusitis https://www.researchgate.net/profile/Glenis_Scadding /publication/11857606_Topical_corticosteroids_in_chr onic_rhinosinusitis_A_randomized_double- blind_placebo- controlled_trial_using_fluticasone_propionate_aqueou s_nasal_spray/links/09e41511b9e83bd7eb000000/To pical-corticosteroids-in-chronic-rhinosinusitis-A- Topical corticosteroids in chronic rhinosinusitis: a randomized, double- randomized-double-blind-placebo-controlled-trial- blind, placebo-controlled trial using fluticasone propionate aqueous using-fluticasone-propionate-aqueous-nasal-spray.pdf FLUTICASONE nasal spray Medication Title of Article PubMed Link http://journals.lww.com/co- otolaryngology/Abstract/2012/02000/Nasal_irrigation_ FLUTICASONE Nasal irrigation with or without drugs: the evidence with_or_without_drugs___the.11.aspx MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic http://www.ingentaconnect.com/content/ocean/aap/20 rhinitis: A randomized, double-blind, placebo-controlled trial of 12/00000033/00000004/art00005 FLUTICASONE efficacy and safety Effect of fluticasone on neuropeptides in nasal lavage in persistent https://www.ncbi.nlm.nih.gov/pubmed/20635787 FLUTICASONE allergic rhinitis. FLUTICASONE Fluticasone propionate: topical or systemic effects? http://www.ncbi.nlm.nih.gov/pubmed/8735854 The efficacy of fluticasone propionate aqueous nasal spray for http://www.ncbi.nlm.nih.gov/pubmed/9001827 FLUTICASONE allergic rhinitis and its relationship to topical effects. No clear potentiation of antidepressant medication effects by folic http://www.ncbi.nlm.nih.gov/pubmed/20805005 FOLIC ACID acid+vitamin B12 in a large community sample. Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised http://www.ncbi.nlm.nih.gov/pubmed/20592433 FOLIC ACID controlled trial.

Effect of homocysteine-lowering therapy on arterial elasticity and http://www.ncbi.nlm.nih.gov/pubmed/18206891 FOLIC ACID metabolic parameters in metformin-treated diabetic patients. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic http://www.ncbi.nlm.nih.gov/pubmed/23765945 attack: a prespecified secondary analysis of a randomized, placebo- FOLIC ACID controlled trial and meta-analysis.

Weekly iron folate supplementation in adolescent girls--an effective http://www.ncbi.nlm.nih.gov/pubmed/23618489 FOLIC ACID nutritional measure for the management of iron deficiency anaemia. Absorption of folic acid from a capsule compared to a http://www.ncbi.nlm.nih.gov/pubmed/22579722 FOLIC ACID standard tablet. MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in http://www.ncbi.nlm.nih.gov/pubmed/22230384 FOLIC ACID hypertensive Chinese adults. Effect of folic acid intervention on ALT concentration in hypertensives without known hepatic disease: a randomized, double-blind, http://www.ncbi.nlm.nih.gov/pubmed/22085872 FOLIC ACID controlled trial. Medication Title of Article PubMed Link Effect of folic acid supplementation on homocysteine, serum total antioxidant capacity, and malondialdehyde in patients with type 2 http://www.ncbi.nlm.nih.gov/pubmed/21869730 FOLIC ACID diabetes mellitus. Effect of folic acid supplementation on biochemical indices in http://www.ncbi.nlm.nih.gov/pubmed/21802161 FOLIC ACID overweight and obese men with type 2 diabetes. Dietary folate intakes and effects of folic acid supplementation on http://www.ncbi.nlm.nih.gov/pubmed/21272148 FOLIC ACID folate concentrations among Japanese pregnant women. Folic acid supplementation may cure hot flushes in postmenopausal http://www.ncbi.nlm.nih.gov/pubmed/20230331 FOLIC ACID women: a prospective cohort study. Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid http://www.ncbi.nlm.nih.gov/pubmed/18551467 FOLIC ACID bioavailability. Effects of multivitamin and folic acid supplementation in http://www.ncbi.nlm.nih.gov/pubmed/14700145 FOLIC ACID malnourished children. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of http://www.ncbi.nlm.nih.gov/pubmed/14696754 FOLIC ACID hyperhomocysteinemia in ESRD. FOLIC ACID Acute absorption of folic acid from a fortified low-fat spread. http://www.ncbi.nlm.nih.gov/pubmed/14506483 Low-Dose folic acid supplementation decreases plasma http://www.ncbi.nlm.nih.gov/pubmed/11339442 FOLIC ACID homocysteine concentrations: a randomised trial. Folic acid alters methotrexate availability in patients with rheumatoid http://www.ncbi.nlm.nih.gov/pubmed/10990220 FOLIC ACID arthritis. Effect of folic acid supplementation in pregnancy on preeclampsia: http://www.ncbi.nlm.nih.gov/pubmed/24349782 FOLIC ACID the folic acid clinical trial study. High folate and low vitamin B-12 intakes during pregnancy are associated with small-for-gestational age infants in South Indian http://www.ncbi.nlm.nih.gov/pubmed/24108785 FOLIC ACID women: a prospective observational cohort study. Impact of folate intake on prostate cancer recurrence following http://www.ncbi.nlm.nih.gov/pubmed/24095905 FOLIC ACID definitive therapy: data from CaPSURE™. Association between low-dose folic acid supplementation and blood lipids concentrations in male and female subjects with http://www.ncbi.nlm.nih.gov/pubmed/24002360 FOLIC ACID atherosclerosis risk factors. A pilot study of folic acid supplementation for improving homocysteine levels, cognitive and depressive status in eating http://www.ncbi.nlm.nih.gov/pubmed/23848107 FOLIC ACID disorders. Medication Title of Article PubMed Link Short-term folinic acid supplementation improves vascular reactivity http://www.ncbi.nlm.nih.gov/pubmed/23660169 FOLIC ACID in HIV-infected individuals: a randomized trial. Is there an effect of folic acid supplementation on the coagulation factors and C-reactive protein concentrations in subjects with http://www.ncbi.nlm.nih.gov/pubmed/23175323 FOLIC ACID atherosclerosis risk factors? Effect of folic Acid supplementation on the folate status of buccal http://www.ncbi.nlm.nih.gov/pubmed/15247137 FOLIC ACID mucosa and lymphocytes. High dosage folic acid supplementation, oral cleft recurrence and http://www.ncbi.nlm.nih.gov/pubmed/23380913 FOLIC ACID fetal growth. FOLIC ACID 5'- METHYLTETRAHYD Randomized clinical trial of folate supplementation in patients with http://www.ncbi.nlm.nih.gov/pubmed/19672935 ROFOLIC ACID peripheral arterial disease. FOLIC ACID 5'- METHYLTETRAHYD Folate for depressive disorders: systematic review and meta-analysis http://www.ncbi.nlm.nih.gov/pubmed/15260915 ROFOLIC ACID of randomized controlled trials. FOLIC ACID 5'- METHYLTETRAHYD [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in http://www.ncbi.nlm.nih.gov/pubmed/16600937 ROFOLIC ACID preventing a decline in blood folate concentrations during lactation. Red blood cell folate concentrations increase more after FOLIC ACID 5'- supplementation with [6S]-5-methyltetrahydrofolate than with folic http://www.ncbi.nlm.nih.gov/pubmed/16825690 METHYLTETRAHYD acid in women of childbearing age. ROFOLIC ACID FOLIC ACID 5'- Comparison of the effect of low-dose supplementation with L-5- METHYLTETRAHYD methyltetrahydrofolate or folic acid on plasma homocysteine: a http://www.ncbi.nlm.nih.gov/pubmed/12600857 ROFOLIC ACID randomized placebo-controlled study. FOLIC ACID 5'- METHYLTETRAHYD Increases in blood folate indices are similar in women of childbearing http://www.ncbi.nlm.nih.gov/pubmed/12421850 ROFOLIC ACID age supplemented with [6S]-5-methyltetrahydrofolate and folic acid. A double-blind, randomized trial of local formic acid puncture technique in the treatment of common warts. http://www.ncbi.nlm.nih.gov/pubmed/20527136 FORMIC ACID Topical formic acid puncture technique for the treatment of common http://www.ncbi.nlm.nih.gov/pubmed/11589750 FORMIC ACID warts. Medication Title of Article PubMed Link

Topical treatment of rhinosinusitis with fusafungine nasal spray. A http://www.ncbi.nlm.nih.gov/pubmed/12572527 FUSAFUNGINE double-blind, placebo-controlled, parallel-group study in 20 patients Topical gabapentin in the treatment of localized and generalized http://www.ncbi.nlm.nih.gov/pubmed/18757655 GABAPENTIN vulvodynia. Skin permeation and antinociception of topical gabapentin http://www.ncbi.nlm.nih.gov/pubmed/25906628 GABAPENTIN formulations. Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment http://www.ncbi.nlm.nih.gov/pubmed/26685497 GABAPENTIN Time

GENERAL http://www.ncbi.nlm.nih.gov/pubmed/25185277 CORTICOSTEROIDS The effect of nasal irrigation in the treatment of allergic rhinitis

GENERAL http://www.ncbi.nlm.nih.gov/pubmed/10442545 CORTICOSTEROIDS Advances in the medical treatment of nasal polyps GENERAL Topical nasal steroids for treating nasal polyposis in people with http://www.ncbi.nlm.nih.gov/pubmed/26098667 GLUCORTICOIDS cystic fibrosis.

Pharmacokinetics and absorption of paromomycin and gentamicin http://www.ncbi.nlm.nih.gov/pubmed/23877689 GENTAMICIN from topical creams used to treat cutaneous leishmaniasis Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections http://www.ncbi.nlm.nih.gov/pubmed/22659765 of moderate severity: a randomized, controlled, multicenter clinical GENTAMICIN trial Effect of gentamicin-absorbed collagen in wound healing in pilonidal http://www.ncbi.nlm.nih.gov/pubmed/20819439 GENTAMICIN sinus surgery: a prospective randomized study Topical ciprofloxacin versus topical gentamicin for chronic otitis http://www.ncbi.nlm.nih.gov/pubmed/12596948 GENTAMICIN media Gentamicin induces functional type VII collagen in recessive https://www.ncbi.nlm.nih.gov/pubmed/28691931 GENTAMICIN dystrophic epidermolysis bullosa patients.

A randomized, blinded, multicenter trial of a gentamicin vancomycin https://www.ncbi.nlm.nih.gov/pubmed/27989501 GENTAMICIN gel (DFA-02) in patients undergoing abdominal surgery. Medication Title of Article PubMed Link Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of https://www.ncbi.nlm.nih.gov/pubmed/27044796 GENTAMICIN a Randomized Open-Label Controlled Trial. Topical spraying of cefazolin and gentamicin reduces deep sternal wound infections after heart surgery: a multicenter, large volume, https://www.ncbi.nlm.nih.gov/pubmed/26721465 GENTAMICIN retrospective study. Meta-analysis of local gentamicin for prophylaxis of surgical site https://www.ncbi.nlm.nih.gov/pubmed/26614505 GENTAMICIN infections in colorectal surgery.

Pulpal Responses to Direct Capping with Betamethasone/Gentamicin https://www.ncbi.nlm.nih.gov/pubmed/26525553 Cream and Mineral Trioxide Aggregate: Histologic and Micro- GENTAMICIN Computed Tomography Assessments. https://www.ncbi.nlm.nih.gov/pubmed/?term=2467946 GUSELKUMAB Guselkumab (an IL-23-specific mAb) demonstrates clinical and 9 molecular response in patients with moderate-to-severe psoriasis. Information contributed by meta-analysis in exposure-response https://www.ncbi.nlm.nih.gov/pubmed/?term=2485204 GUSELKUMAB modeling: application to phase 2 dose selection of guselkumab in 2 patients with moderate-to-severe psoriasis. First-in-human study to assess guselkumab (anti-IL-23 mAb) https://www.ncbi.nlm.nih.gov/pubmed/?term=2751597 GUSELKUMAB pharmacokinetics/safety in healthy subjects and patients with 8 moderate-to-severe psoriasis. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2832940 GUSELKUMAB Plaque Psoriasis. [Review] 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2904388 GUSELKUMAB Guselkumab for psoriasis: a critical appraisal of Phase III studies. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2947077 GUSELKUMAB Guselkumab for the Treatment of Psoriasis. [Review] 8 Guselkumab for the treatment of moderate-to-severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2947834 GUSELKUMAB psoriasis. [Review] 4 Guselkumab: human monoclonal antibody against interleukin-23 for https://www.ncbi.nlm.nih.gov/pubmed/?term=2977125 GUSELKUMAB moderate to severe psoriasis. [Review] 4 A safety evaluation of guselkumab for the treatment of psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2989779 GUSELKUMAB [Review] 0 GUSELKUMAB,TILD Review of phase III trial data on IL-23 inhibitors tildrakizumab and https://www.ncbi.nlm.nih.gov/pubmed/?term=2866777 RAKIZUMAB guselkumab for psoriasis. [Review] 7 Medication Title of Article PubMed Link

Topical Tacrolimus versus Hydrocortisone on Atopic Dermatitis in http://www.ncbi.nlm.nih.gov/pubmed/26329939 HYDROCORTISONE Paediatric Patients: A Randomized Controlled Trial Listeria meningitis complicating a patient with ulcerative colitis on https://pubmed.ncbi.nlm.nih.gov/26358724 HYDROCORTISONE concomitant infliximab and hydrocortisone. [Review] Acute pancreatitis due to hydrocortisone in a patient with ulcerative https://pubmed.ncbi.nlm.nih.gov/12911675 HYDROCORTISONE colitis.

Low Pentasa dosage versus hydrocortisone in the topical treatment https://pubmed.ncbi.nlm.nih.gov/7733079 HYDROCORTISONE of active ulcerative colitis: a randomized, double-blind study. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality https://pubmed.ncbi.nlm.nih.gov/7732340 HYDROCORTISONE of two topical treatment regimens. Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone https://pubmed.ncbi.nlm.nih.gov/3319460 HYDROCORTISONE enemas in ulcerative colitis. Systemic absorption from hydrocortisone foam enema in ulcerative https://pubmed.ncbi.nlm.nih.gov/2882324 HYDROCORTISONE colitis. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of foam https://pubmed.ncbi.nlm.nih.gov/3931745 HYDROCORTISONE and prednisolone 21-phosphate enemas. https://pubmed.ncbi.nlm.nih.gov/6307809 HYDROCORTISONE ACTH vs. hydrocortisone in ulcerative colitis. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical https://pubmed.ncbi.nlm.nih.gov/6305758 HYDROCORTISONE trial. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone https://pubmed.ncbi.nlm.nih.gov/7002739 HYDROCORTISONE foam. Retrograde spread of hydrocortisone containing foam given https://pubmed.ncbi.nlm.nih.gov/509112 HYDROCORTISONE intrarectally in ulcerative colitis. Mucosal biopsy in ulcerative colitis for evaluating topical https://pubmed.ncbi.nlm.nih.gov/4149065 HYDROCORTISONE hydrocortisone therapy. Treatment of ulcerative colitis with hydrocortisone enemas. Comparison of absorption and clinical response with hydrocortisone https://pubmed.ncbi.nlm.nih.gov/5507287 HYDROCORTISONE alcohol and hydrocortisone acetate. Medication Title of Article PubMed Link Treatment of ulcerative colitis with hydrocrotisone enemas: relationship of hydrocortisone absorption, adrenal suppression, and https://pubmed.ncbi.nlm.nih.gov/5472850 HYDROCORTISONE clinical response.

Treatment of ulcerative colitis with hydrocortisone alcohol retention https://pubmed.ncbi.nlm.nih.gov/6018350 HYDROCORTISONE enemas: a topical and systemic anti-inflammatory agent. II. THE TREATMENT OF ULCERATIVE COLITIS WITH https://pubmed.ncbi.nlm.nih.gov/14274418 HYDROCORTISONE HYDROCORTISONE ALCOHOL RETENTION ENEMAS. Rectal hydrocortisone for ulcerative colitis refractory to oral https://pubmed.ncbi.nlm.nih.gov/13713786 HYDROCORTISONE corticosteroids. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for https://pubmed.ncbi.nlm.nih.gov/13760840 HYDROCORTISONE ulcerative colitis. Studies on the absorption of hydrocortisone from the colon of https://pubmed.ncbi.nlm.nih.gov/13615735 HYDROCORTISONE patients with idiopathic ulcerative colitis. The longterm treatment of ulcerative colitis with hydrocortisone, https://pubmed.ncbi.nlm.nih.gov/13474175 HYDROCORTISONE prednisone and prednisolone. Treatment of ulcerative colitis with local hydrocortisone https://pubmed.ncbi.nlm.nih.gov/13436814 HYDROCORTISONE hemisuccinate sodium. HYDROXYUREA https://www.ncbi.nlm.nih.gov/pubmed/?term=2597635 Hydroxyurea in the management of therapy resistant psoriasis. Combination low-dose cyclosporin (Neoral) and hydroxyurea for https://www.ncbi.nlm.nih.gov/pubmed/?term=1021580 HYDROXYUREA severe recalcitrant psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1023363 HYDROXYUREA Use of hydroxyurea in psoriasis. [Review] [33 refs] 8 Dermatomyositis-like eruption and leg ulceration caused by https://www.ncbi.nlm.nih.gov/pubmed/?term=1035416 HYDROXYUREA hydroxyurea in a patient with psoriasis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1068117 HYDROXYUREA Hydroxyurea in psoriasis. 1 Dermatomyositis-like eruption and leg ulceration caused by https://www.ncbi.nlm.nih.gov/pubmed/?term=1084451 HYDROXYUREA hydroxyurea in a patient with psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1170352 HYDROXYUREA Rediscovering hydroxyurea: its role in recalcitrant psoriasis. 8 Mucocutaneous adverse effects of hydroxyurea: a prospective study https://www.ncbi.nlm.nih.gov/pubmed/?term=1195266 HYDROXYUREA of 30 psoriasis patients. 0 Medication Title of Article PubMed Link HYDROXYUREA, Successful treatment of recalcitrant psoriasis with a combination of https://www.ncbi.nlm.nih.gov/pubmed/?term=1466026 INFLIXIMAB infliximab and hydroxyurea. 9 Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly HYDROXYUREA, https://www.ncbi.nlm.nih.gov/pubmed/?term=1785263 dose to treat moderate-to-severe chronic plaque psoriasis: a METHOTREXATE 5 comparative study. Alkyl ester prodrugs for improved topical delivery of ibuprofen http://www.ncbi.nlm.nih.gov/pubmed/11495290 Transdermal delivery of ibuprofen and its prodrugs by passive http://www.ijppsjournal.com/Vol2Suppl1/381.pdf IBUPROFEN diffusion and iontophoresis Topical gel formulation of ibuprofen in the treatment of acute and chronic joint and soft tissue pain. Results of a non-interventional http://www.ncbi.nlm.nih.gov/pubmed/23678669 IBUPROFEN observational trial Oral versus topical Ibuprofen for chronic knee pain: a prospective http://www.ncbi.nlm.nih.gov/pubmed/20859315 IBUPROFEN randomized pilot study IBUPROFEN Effects of ibuprofen topical gel on muscle soreness http://www.ncbi.nlm.nih.gov/pubmed/19952809 Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo- http://www.ncbi.nlm.nih.gov/pubmed/14994406 IBUPROFEN controlled study

IBUPROFEN WITH 3- http://www.ncbi.nlm.nih.gov/pubmed/19703357 HYDROXYBUTYRIC Characterisation of a novel conjugate of ibuprofen with 3- ACID hydroxybutyric acid oligomers Pharmacokinetics of daily self-application of imiquimod 3.75% cream http://www.ncbi.nlm.nih.gov/pubmed/22232733 IMIQUIMOD in adult patients with external anogenital warts. Randomized clinical trial of imiquimod: an adjunct to treating cervical http://www.ncbi.nlm.nih.gov/pubmed/21907959 IMIQUIMOD dysplasia. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled http://www.ncbi.nlm.nih.gov/pubmed/21876641 IMIQUIMOD studies. Efficacy and safety of imiquimod versus podophyllotoxin in the http://www.ncbi.nlm.nih.gov/pubmed/20938374 IMIQUIMOD treatment of anogenital warts.

Imiquimod 5% cream for external genital or perianal warts in human http://www.ncbi.nlm.nih.gov/pubmed/19466962 immunodeficiency virus-positive patients treated with highly active IMIQUIMOD antiretroviral therapy: an open-label, noncomparative study. Medication Title of Article PubMed Link Comparison of cryotherapy to imiquimod 5% in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/18574113 IMIQUIMOD anogenital warts.

Earlier eradication of intra-anal warts with argon plasma coagulator http://www.ncbi.nlm.nih.gov/pubmed/17914655 combined with imiquimod cream compared with argon plasma IMIQUIMOD coagulator alone: a prospective, randomized trial.

Human papillomavirus-type predict the clinical outcome of imiquimod http://www.ncbi.nlm.nih.gov/pubmed/17653883 IMIQUIMOD therapy for women with vulvar condylomata acuminata. IMIQUIMOD Effect of imiquimod in anogenital warts from HIV-positive men. http://www.ncbi.nlm.nih.gov/pubmed/17513167 Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in http://www.ncbi.nlm.nih.gov/pubmed/17229604 IMIQUIMOD external anogenital warts. IMIQUIMOD Treatment of flat warts with 5% imiquimod cream. http://www.ncbi.nlm.nih.gov/pubmed/17062069 An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in http://www.ncbi.nlm.nih.gov/pubmed/16820073 IMIQUIMOD women. [Efficacy and safety of 5% imiquimod cream in external genital warts: http://www.ncbi.nlm.nih.gov/pubmed/16327713 IMIQUIMOD a 6 month follow-up evaluation]. Evaluation of imiquimod 5% cream to modify the natural history of http://www.ncbi.nlm.nih.gov/pubmed/16107978 IMIQUIMOD herpes labialis: a pilot study. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double- http://www.ncbi.nlm.nih.gov/pubmed/16103328 IMIQUIMOD blind, placebo-controlled trial. Topical imiquimod 5% cream in external anogenital warts: a http://www.ncbi.nlm.nih.gov/pubmed/15492435 IMIQUIMOD randomized, double-blind, placebo-controlled study. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous http://www.ncbi.nlm.nih.gov/pubmed/14660271 IMIQUIMOD warts. Safety and efficacy of locally applied imiquimod cream 5% for the http://www.ncbi.nlm.nih.gov/pubmed/14648072 IMIQUIMOD treatment of condylomata acuminata of the .

Topical imiquimod 5% cream as an effective treatment for external http://www.ncbi.nlm.nih.gov/pubmed/12567169 IMIQUIMOD genital and perianal warts in different patient populations. Medication Title of Article PubMed Link Topical imiquimod yields systemic effects due to unintended oral http://www.ncbi.nlm.nih.gov/pubmed/26818707 IMIQUIMOD uptake

Giant Condyloma Acuminate Due to Human Papillomavirus Type 16 http://www.ncbi.nlm.nih.gov/pubmed/26734121 IMIQUIMOD in an Infant Successfully Treated with Topical Imiquimod Therapy Imiquimod cream efficacy in the treatment of periocular nodular basal http://www.ncbi.nlm.nih.gov/pubmed/25885553 IMIQUIMOD cell carcinoma: a non-randomized trial Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled http://www.ncbi.nlm.nih.gov/pubmed/25775634 IMIQUIMOD trial Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/25633200 IMIQUIMOD proliferating superficial infantile hemangioma Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a http://www.ncbi.nlm.nih.gov/pubmed/25066012 IMIQUIMOD noninferiority randomized controlled trial Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized http://www.ncbi.nlm.nih.gov/pubmed/24754529 IMIQUIMOD intraindividual comparison study Acyloxyamines as prodrugs of anti-inflammatory carboxylic acids for http://www.ncbi.nlm.nih.gov/pubmed/6527246 INDOMETHACIN improved delivery through skin REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, http://www.ncbi.nlm.nih.gov/pubmed/26562569 INDOMETHACIN BROMFENAC 0.09%, AND NEPAFENAC 0.1 Rheological and textural properties of microemulsion-based polymer http://www.ncbi.nlm.nih.gov/pubmed/26204348 INDOMETHACIN gels with indomethacin Effect of a topical copper indomethacin gel on inflammatory http://www.ncbi.nlm.nih.gov/pubmed/25792809 INDOMETHACIN parameters in a rat model of osteoarthritis Efficacy and safety of infliximab monotherapy for plaque-type https://www.ncbi.nlm.nih.gov/pubmed/?term=1141019 INFLIXIMAB psoriasis: a randomised trial. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1193774 INFLIXIMAB Response of severe psoriasis to infliximab. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1202022 INFLIXIMAB The effectiveness of tumor necrosis factor alpha antibody (infliximab) 7 in treating recalcitrant psoriasis: a report of 2 cases. Medication Title of Article PubMed Link Treatment of psoriasis with the chimeric monoclonal antibody against https://www.ncbi.nlm.nih.gov/pubmed/?term=1206348 INFLIXIMAB tumor necrosis factor alpha, infliximab. 6 Rapid response to infliximab in severe pustular psoriasis, von https://www.ncbi.nlm.nih.gov/pubmed/?term=1212156 INFLIXIMAB Zumbusch type. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1239978 INFLIXIMAB Infliximab for the treatment of severe pustular psoriasis. 1 Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor https://www.ncbi.nlm.nih.gov/pubmed/?term=1242666 INFLIXIMAB necrosis factor inhibitor infliximab. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1246346 INFLIXIMAB Infliximab for psoriasis and psoriatic arthritis. 1 Pharmacodynamic and pharmacokinetic response to anti-tumor https://www.ncbi.nlm.nih.gov/pubmed/?term=1252237 INFLIXIMAB necrosis factor-alpha monoclonal antibody (infliximab) treatment of 3 moderate to severe psoriasis vulgaris. https://www.ncbi.nlm.nih.gov/pubmed/?term=1275218 INFLIXIMAB Treatment of severe recalcitrant plaque psoriasis with single-dose 4 intravenous tumour necrosis factor-alpha antibody (infliximab). Infliximab monotherapy provides rapid and sustained benefit for https://www.ncbi.nlm.nih.gov/pubmed/?term=1278917 INFLIXIMAB plaque-type psoriasis. 1 Striking and rapid improvement of plaque psoriasis with infliximab. A https://www.ncbi.nlm.nih.gov/pubmed/?term=1283555 INFLIXIMAB report of two cases. 0 CD30+ T-cell lymphoma in a patient with psoriasis treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1289021 INFLIXIMAB ciclosporin and infliximab. [Review] [17 refs] 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1289413 INFLIXIMAB Infliximab for psoriasis. [Review] [32 refs] 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1465011 INFLIXIMAB Infliximab-induced remission of extensive plaque psoriasis. 4 Erythrodermic, recalcitrant psoriasis: clinical resolution with https://www.ncbi.nlm.nih.gov/pubmed/?term=1466026 INFLIXIMAB infliximab. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1487133 INFLIXIMAB Successful treatment of pediatric psoriasis with infliximab. 7 Recalcitrant, generalized pustular psoriasis: rapid and lasting https://www.ncbi.nlm.nih.gov/pubmed/?term=1499611 INFLIXIMAB therapeutic response to antitumour necrosis factor-alpha antibody 4 (infliximab). Infliximab monotherapy in psoriasis: a case of rapid clinical and https://www.ncbi.nlm.nih.gov/pubmed/?term=1509002 INFLIXIMAB histological response. 1 Medication Title of Article PubMed Link

Human immunodeficiency virus-associated psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=1509938 INFLIXIMAB arthritis treated with infliximab.[Erratum appears in Br J Dermatol. 8 2004 Jun;150(6):1235 Note: Gabbay, S [corrected to Gubbay, S]] Treatment of recalcitrant pustular psoriasis with infliximab: effective https://www.ncbi.nlm.nih.gov/pubmed/?term=1514951 INFLIXIMAB reduction of chemokine expression. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1517616 INFLIXIMAB Serum sickness due to infliximab in a patient with psoriasis. 6 Infliximab (Remicade) for acute, severe pustular and erythrodermic https://www.ncbi.nlm.nih.gov/pubmed/?term=1520285 INFLIXIMAB psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1525090 INFLIXIMAB Use of infliximab in the treatment of psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1530379 INFLIXIMAB Pustular psoriasis induced by infliximab. 0 New development in the treatment of psoriasis--infliximab. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=1531500 INFLIXIMAB [22 refs] 8 Infliximab induction therapy for patients with severe plaque-type https://www.ncbi.nlm.nih.gov/pubmed/?term=1538918 INFLIXIMAB psoriasis: a randomized, double-blind, placebo-controlled trial. 7 Psoriasis and its treatment with infliximab-mediated tumor necrosis https://www.ncbi.nlm.nih.gov/pubmed/?term=1545033 INFLIXIMAB factor alpha blockade. [Review] [86 refs] 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1546187 INFLIXIMAB Infliximab monotherapy for refractory psoriasis: preliminary results. 1 Fatal fulminant legionnaires' disease in a patient with severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1578784 INFLIXIMAB erythodermic psoriasis treated with infliximab after long-term steroid 3 therapy. Remission and time of resolution of nail psoriasis during infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1579355 INFLIXIMAB therapy. 4 Unexpected onset of psoriasis during infliximab treatment: comment https://www.ncbi.nlm.nih.gov/pubmed/?term=1581867 INFLIXIMAB on the article by Beuthien et al. 9 Infliximab treatment results in significant improvement in the quality https://www.ncbi.nlm.nih.gov/pubmed/?term=1588815 INFLIXIMAB of life of patients with severe psoriasis: a double-blind placebo- 2 controlled trial. Successful infliximab therapy of psoriasis vulgaris and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=1602935 INFLIXIMAB arthritis in a patient with cirrhosis. 7 Medication Title of Article PubMed Link Successful treatment of Von Zumbusch pustular psoriasis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1609199 INFLIXIMAB infliximab. 9 Onset of flexural psoriasis during infliximab treatment for Crohn's https://www.ncbi.nlm.nih.gov/pubmed/?term=1619739 INFLIXIMAB disease. 8 Infliximab for the treatment of psoriasis: clinical experience at the https://www.ncbi.nlm.nih.gov/pubmed/?term=1619878 INFLIXIMAB State University of New York at Buffalo. 1 Infliximab induction and maintenance therapy for moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1622661 INFLIXIMAB psoriasis: a phase III, multicentre, double-blind trial. 4 The role of lesional T cells in recalcitrant psoriasis during infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1628029 INFLIXIMAB therapy. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1642815 INFLIXIMAB Infliximab for inpatient psoriasis management--is there a role?. 1 Programmed cell death of keratinocytes in infliximab-treated plaque- https://www.ncbi.nlm.nih.gov/pubmed/?term=1644577 INFLIXIMAB type psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1648588 INFLIXIMAB Infliximab associated new-onset psoriasis. 7 Sustained efficacy and safety of infliximab in psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1657325 INFLIXIMAB retrospective study of 73 patients. 8 Hepatitis: a rare, but important, complication of infliximab therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1668160 INFLIXIMAB psoriasis. 6 Improvement in quality of life with infliximab induction and https://www.ncbi.nlm.nih.gov/pubmed/?term=1670464 INFLIXIMAB maintenance therapy in patients with moderate-to-severe psoriasis: a 9 randomized controlled trial. Chimeric monoclonal antibody to tumor necrosis factor alpha https://www.ncbi.nlm.nih.gov/pubmed/?term=1670782 INFLIXIMAB (infliximab) in psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1673890 INFLIXIMAB Psoriasis onset during infliximab treatment: description of two cases. 3 Life-threatening pustular and erythrodermic psoriasis responding to https://www.ncbi.nlm.nih.gov/pubmed/?term=1677410 INFLIXIMAB infliximab. 8 Infliximab for severe, treatment-resistant psoriasis: a prospective, https://www.ncbi.nlm.nih.gov/pubmed/?term=1679276 INFLIXIMAB open-label study. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1685680 INFLIXIMAB Infliximab for the treatment of psoriasis. [Review] [50 refs] 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1690130 INFLIXIMAB Three years' experience with infliximab in recalcitrant psoriasis. 1 Medication Title of Article PubMed Link Induction of lesional and circulating leukocyte apoptosis by infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1703965 INFLIXIMAB in a patient with moderate to severe psoriasis. 6 Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2- https://www.ncbi.nlm.nih.gov/pubmed/?term=1706806 INFLIXIMAB year experience. 3 A randomized comparison of continuous vs. intermittent infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1709737 INFLIXIMAB maintenance regimens over 1 year in the treatment of moderate-to- 8 severe plaque psoriasis. Downregulation of the inhibitor of apoptosis protein survivin in https://www.ncbi.nlm.nih.gov/pubmed/?term=1710738 INFLIXIMAB keratinocytes and endothelial cells in psoriasis skin following 8 infliximab therapy. A follow-up study in 28 patients treated with infliximab for severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1722387 INFLIXIMAB recalcitrant psoriasis: evidence for efficacy and high incidence of 4 biological autoimmunity. Osteomyelitis occurring during infliximab treatment of severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1737318 INFLIXIMAB psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1745138 INFLIXIMAB Treatment of pustular psoriasis with infliximab. 4 A review of biologic treatments for psoriasis with emphasis on https://www.ncbi.nlm.nih.gov/pubmed/?term=1748734 INFLIXIMAB infliximab. [Review] [11 refs] 7 Successful treatment of severe psoriatic arthritis with infliximab in an https://www.ncbi.nlm.nih.gov/pubmed/?term=1757844 INFLIXIMAB 11-year-old child suffering from linear psoriasis along lines of 5 Blaschko. Infliximab treatment improves productivity among patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1767338 INFLIXIMAB moderate-to-severe psoriasis. 0 Infliximab, as sole or combined therapy, induces rapid clearing of https://www.ncbi.nlm.nih.gov/pubmed/?term=1771153 INFLIXIMAB erythrodermic psoriasis. [Review] [10 refs] 0 Severe bout of cutaneous psoriasis in a patient with psoriasic arthritis https://www.ncbi.nlm.nih.gov/pubmed/?term=1788823 INFLIXIMAB undergoing treatment with infliximab. 0 Two cases of atopic dermatitis-like conditions induced in psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1789473 INFLIXIMAB patients treated with infliximab. 0 Cutaneous adverse reaction to infliximab: report of psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1795601 INFLIXIMAB developing in 3 patients. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1795885 INFLIXIMAB Pustular psoriasis induced by infliximab. 9 Medication Title of Article PubMed Link Psoriasis, erythema nodosum, and nummular eczema onset in an https://www.ncbi.nlm.nih.gov/pubmed/?term=1796317 INFLIXIMAB ankylosing spondylitis patient treated with infliximab. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1802848 INFLIXIMAB Severe neutrophilia induced by infliximab for psoriasis. 9 Infliximab in dermatological treatment: beyond psoriasis. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=1808154 INFLIXIMAB [106 refs] 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1808327 INFLIXIMAB Baseline nail disease in patients with moderate to severe psoriasis 2 and response to treatment with infliximab during 1 year. https://www.ncbi.nlm.nih.gov/pubmed/?term=1808659 INFLIXIMAB Infliximab in recalcitrant generalized pustular arthropatic psoriasis. 3 Severe psoriasis in an African American woman treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1817353 INFLIXIMAB infliximab therapy for 6 years. 4 Infliximab for patients with plaque psoriasis and severe psychiatric https://www.ncbi.nlm.nih.gov/pubmed/?term=1821143 INFLIXIMAB comorbidity. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1823992 INFLIXIMAB Manifestation of palmoplantar pustulosis during or after infliximab 5 therapy for plaque-type psoriasis: report on five cases. Palmoplantar pustular psoriasis: successful therapy with efalizumab https://www.ncbi.nlm.nih.gov/pubmed/?term=1831145 INFLIXIMAB after non-response to infliximab. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1834153 INFLIXIMAB Infliximab for the treatment of severe pustular psoriasis: 6 years later. 4 Guttate psoriasis induced by infliximab in a child with Crohn's https://www.ncbi.nlm.nih.gov/pubmed/?term=1838317 INFLIXIMAB disease. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1839169 INFLIXIMAB Onset of psoriasis induced by infliximab. 0 Severe recalcitrant nail psoriasis responding dramatically to https://www.ncbi.nlm.nih.gov/pubmed/?term=1846243 INFLIXIMAB infliximab: report of two patients. 8 A review of the treatment of psoriasis with infliximab. [Review] [20 https://www.ncbi.nlm.nih.gov/pubmed/?term=1847397 INFLIXIMAB refs] 3 Gastric MALT lymphoma in a patient receiving infliximab for https://www.ncbi.nlm.nih.gov/pubmed/?term=1854731 INFLIXIMAB psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1862737 INFLIXIMAB Infliximab improves health-related quality of life in the presence of 5 comorbidities among patients with moderate-to-severe psoriasis. Medication Title of Article PubMed Link Long-term management of generalized pustular psoriasis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1862769 INFLIXIMAB infliximab: case series. 9 Infliximab-induced pityriasis lichenoides chronica in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=1868053 INFLIXIMAB psoriasis. 1 Recommendations for the long-term treatment of psoriasis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1868526 INFLIXIMAB infliximab: a dermatology expert group consensus. [6 refs] 1 The relationship between quality of life and skin clearance in https://www.ncbi.nlm.nih.gov/pubmed/?term=1878493 INFLIXIMAB moderate-to-severe psoriasis: lessons learnt from clinical trials with 4 infliximab. [Review] [38 refs] Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of https://www.ncbi.nlm.nih.gov/pubmed/?term=1883770 INFLIXIMAB treatment. 2 Palmoplantar pustular psoriasis: successful therapy with efalizumab https://www.ncbi.nlm.nih.gov/pubmed/?term=1885307 INFLIXIMAB after non-response to infliximab. 7 Infliximab rescue of efalizumab withdrawal flare and psoriasis- https://www.ncbi.nlm.nih.gov/pubmed/?term=1885579 INFLIXIMAB precipitated depression. 6 Development of new-onset psoriasis in a patient receiving infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1906159 INFLIXIMAB for treatment of rheumatoid arthritis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1909484 INFLIXIMAB A case of infliximab-induced psoriasis. 7 Adverse drug events in infliximab-treated patients compared with the https://www.ncbi.nlm.nih.gov/pubmed/?term=1913776 INFLIXIMAB general and psoriasis populations. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1919630 INFLIXIMAB Generalized pustular psoriasis of pregnancy treated with infliximab. 9 Development of primary varicella infection during infliximab treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1929302 INFLIXIMAB for psoriasis. 7 Occurrence of plantar pustular psoriasis during treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=1929877 INFLIXIMAB infliximab. 0 Infliximab treatment for severe psoriasis in a patient with active https://www.ncbi.nlm.nih.gov/pubmed/?term=1946738 INFLIXIMAB hepatitis B virus infection. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1950153 INFLIXIMAB Disseminated systemic Nocardia farcinica infection complicating 4 alefacept and infliximab therapy in a patient with severe psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1956721 INFLIXIMAB Infliximab for the treatment of adults with psoriasis. 5 Medication Title of Article PubMed Link Peripheral neuropathy in two patients with psoriasis in treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=1962363 INFLIXIMAB infliximab. 0 Predictive factors of eczema-like eruptions among patients without https://www.ncbi.nlm.nih.gov/pubmed/?term=1968438 INFLIXIMAB cutaneous psoriasis receiving infliximab: a cohort study of 92 1 patients. Persistent expression of CD26/DPPIV after treatment with infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1973498 INFLIXIMAB in psoriasis despite clinical improvement. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1981822 INFLIXIMAB Treatment of severe psoriasis with infliximab: report of two cases. 1 Psoriasis induced by infliximab in a patient suffering from Crohn's https://www.ncbi.nlm.nih.gov/pubmed/?term=1982207 INFLIXIMAB disease. 0 Infliximab for the treatment of psoriasis in Greece: 4 years of clinical https://www.ncbi.nlm.nih.gov/pubmed/?term=1990606 INFLIXIMAB experience at a single centre. 9 Atypical presentation of histoplasmosis in a patient with psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2012042 INFLIXIMAB psoriatic arthritis on infliximab therapy. 6 Development of diffuse psoriasis with alopecia during treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2013844 INFLIXIMAB Crohn's disease with infliximab. 8 A dramatic response to a single dose of infliximab as rescue therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2014883 INFLIXIMAB in acute generalized pustular psoriasis of von Zumbusch associated 8 with a neutrophilic cholangitis. Infliximab therapy induces increased polyclonality of CD4+CD25+ https://www.ncbi.nlm.nih.gov/pubmed/?term=2019954 INFLIXIMAB regulatory T cells in psoriasis. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2033812 INFLIXIMAB Drug-induced hepatitis and lupus during infliximab treatment for 7 psoriasis: case report and literature review. [Review] [26 refs] Therapeutic hotline: Re-induction may be useful to manage psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2041582 INFLIXIMAB relapse during long-term maintenance treatment with infliximab: a 8 retrospective analysis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2050721 INFLIXIMAB Influence of infliximab on keratinocyte apoptosis in psoriasis patients. 3 Infliximab monotherapy in Japanese patients with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2054703 INFLIXIMAB severe plaque psoriasis and psoriatic arthritis. A randomized, double- 9 blind, placebo-controlled multicenter trial. Fatal influenza A(H1N1) respiratory tract infection in a patient having https://www.ncbi.nlm.nih.gov/pubmed/?term=2056692 INFLIXIMAB psoriasis treated with infliximab. 8 Medication Title of Article PubMed Link Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the https://www.ncbi.nlm.nih.gov/pubmed/?term=2062823 INFLIXIMAB EXPRESS Trial.[Erratum appears in Dermatology. 2011 8 Feb;222(1):4] https://www.ncbi.nlm.nih.gov/pubmed/?term=2067353 INFLIXIMAB Successful treatment of hand and foot psoriasis with infliximab. 6 Infliximab efficacy in nail psoriasis. A retrospective study in 48 https://www.ncbi.nlm.nih.gov/pubmed/?term=2070782 INFLIXIMAB patients. 9 The impact of methodological approaches for presenting long-term https://www.ncbi.nlm.nih.gov/pubmed/?term=2073331 INFLIXIMAB clinical data on estimates of efficacy in psoriasis illustrated by three- 4 year treatment data on infliximab. Occurrence of pustular psoriasis after treatment of Crohn disease https://www.ncbi.nlm.nih.gov/pubmed/?term=2079624 INFLIXIMAB with infliximab. 1 Psoriasis induced by infliximab in a Saudi patient with ankylosing https://www.ncbi.nlm.nih.gov/pubmed/?term=2084482 INFLIXIMAB spondylitis. 1 Therapeutic hotline. Infliximab for treatment of resistant pyoderma https://www.ncbi.nlm.nih.gov/pubmed/?term=2086840 INFLIXIMAB gangrenosum associated with ulcerative colitis and psoriasis. A case 8 report. Central retinal vein occlusion following infliximab treatment for plaque- https://www.ncbi.nlm.nih.gov/pubmed/?term=2088341 INFLIXIMAB type psoriasis. 4 Infliximab-induced psoriasis in children with inflammatory bowel https://www.ncbi.nlm.nih.gov/pubmed/?term=2124002 INFLIXIMAB disease. 0 Psoriasis and psoriatic arthritis induced in a patient treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=2125486 INFLIXIMAB infliximab for Crohn's disease. 8 Infliximab treatment for psoriasis in 120 patients on therapy for a https://www.ncbi.nlm.nih.gov/pubmed/?term=2153330 INFLIXIMAB minimum of one year: a review. 2 Moderate to severe psoriasis treated with infliximab - 53 patients: https://www.ncbi.nlm.nih.gov/pubmed/?term=2160380 INFLIXIMAB patients profile, efficacy and adverse effects. 8 Infliximab partially impairs the anti-Mycobacterium tuberculosis https://www.ncbi.nlm.nih.gov/pubmed/?term=2162392 INFLIXIMAB immune responses of severe psoriasis patients with positive 5 tuberculin skin-test. "Paradoxical" adverse effects caused by anti-tumor necrosis factor- https://www.ncbi.nlm.nih.gov/pubmed/?term=2172771 INFLIXIMAB alpha biological drugs: appearance of psoriasis in a patient treated 9 with infliximab for rheumatoid arthritis. Medication Title of Article PubMed Link Secondary leprosy infection in a patient with psoriasis during https://www.ncbi.nlm.nih.gov/pubmed/?term=2177890 INFLIXIMAB treatment with infliximab. 2 Autoantibodies in psoriasis as predictors for loss of response and https://www.ncbi.nlm.nih.gov/pubmed/?term=2180116 INFLIXIMAB anti-infliximab antibody induction. 0 Infliximab-induced palmoplantar psoriasis in a patient with ankylosing https://www.ncbi.nlm.nih.gov/pubmed/?term=2180818 INFLIXIMAB spondylitis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2194646 INFLIXIMAB Exacerbation of infliximab-induced palmoplantar psoriasis under 8 ustekinumab therapy in a patient with ankylosing spondylitis. Different response rates between palmoplantar involvement and https://www.ncbi.nlm.nih.gov/pubmed/?term=2213410 INFLIXIMAB diffuse plaque psoriasis in patients treated with infliximab. 0 Sequential therapy in plaque psoriasis using the " Hit and Run " https://www.ncbi.nlm.nih.gov/pubmed/?term=2225063 INFLIXIMAB approach: infliximab followed by efalizumab. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2239809 INFLIXIMAB Infliximab-induced psoriasis during therapy for Crohn's disease. 5 Infliximab for the treatment of psoriasis in the U.K.: 9 years' https://www.ncbi.nlm.nih.gov/pubmed/?term=2240454 INFLIXIMAB experience of infusion reactions at a single centre. 5 Development of diffuse alopecia with psoriasis-like eruptions during https://www.ncbi.nlm.nih.gov/pubmed/?term=2250842 INFLIXIMAB administration of infliximab for Crohn's disease. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2255902 INFLIXIMAB Letter: Human papilloma virus and molluscum contagiosum lesions 4 related to infliximab therapy for psoriasis: a case series. Body weight increment in patients treated with infliximab for plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2262141 INFLIXIMAB psoriasis. 5 The onset of psoriasis during the treatment of inflammatory bowel https://www.ncbi.nlm.nih.gov/pubmed/?term=2276700 INFLIXIMAB diseases with infliximab: should biological therapy be suspended?. 7 [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2278069 INFLIXIMAB Acute alveolitis following infliximab therapy for psoriasis. 6 Cutaneous Mycobacterium haemophilum infection in a patient https://www.ncbi.nlm.nih.gov/pubmed/?term=2281653 INFLIXIMAB receiving infliximab for psoriasis. 2 Immunosuppressant and infliximab-resistant generalized pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=2281712 INFLIXIMAB psoriasis successfully treated with granulocyte and monocyte 9 adsorption apheresis. Medication Title of Article PubMed Link Infliximab monotherapy for Chinese patients with moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2288404 INFLIXIMAB plaque psoriasis: a randomized, double-blind, placebo-controlled 0 multicenter trial. Combination therapy of infliximab and granulocyte/monocyte https://www.ncbi.nlm.nih.gov/pubmed/?term=2300729 INFLIXIMAB adsorption apheresis for refractory pustular psoriasis with psoriatic 1 arthritis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2309042 INFLIXIMAB Psoriasis triggered by infliximab in a patient with Behcet's disease. 3 Serum chemerin is increased in patients with chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2311070 INFLIXIMAB psoriasis and normalizes following treatment with infliximab. 8 Flexural or inverse psoriasis in a patient with hidradenitis suppurativa https://www.ncbi.nlm.nih.gov/pubmed/?term=2314904 INFLIXIMAB receiving treatment with infliximab. 8 Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric https://www.ncbi.nlm.nih.gov/pubmed/?term=2327434 INFLIXIMAB Crohn disease and a potential association with IL-23 receptor 1 polymorphisms. Incidence and risk factors for treatment failure with infliximab in https://www.ncbi.nlm.nih.gov/pubmed/?term=2329425 INFLIXIMAB psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2343540 INFLIXIMAB Infliximab-associated psoriasis in children with Crohn's disease may 3 require withdrawal of anti-tumor necrosis factor therapy. Autoantibody induction and adipokine levels in patients with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2357242 INFLIXIMAB treated with infliximab. 9

Efficacy and safety of infliximab as continuous or intermittent therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2362169 INFLIXIMAB in patients with moderate-to-severe plaque psoriasis: results of a 8 randomized, long-term extension trial (RESTORE2). Drug-induced lupus and autoimmune hepatitis secondary to https://www.ncbi.nlm.nih.gov/pubmed/?term=2365118 INFLIXIMAB infliximab for psoriasis. 2 Acute treatment of generalized pustular psoriasis of von Zumbusch https://www.ncbi.nlm.nih.gov/pubmed/?term=2368021 INFLIXIMAB with single-dose infliximab. 5 Infliximab does not lead to reduction in the interferon-gamma and https://www.ncbi.nlm.nih.gov/pubmed/?term=2382424 INFLIXIMAB lymphoproliferative responses of patients with moderate to severe 3 psoriasis. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2390944 INFLIXIMAB Development of chronic inflammatory demyelinating polyneuropathy 0 in a patient receiving infliximab for psoriasis. [Review] Infliximab-induced psoriasis in treatment of Crohn's disease- https://www.ncbi.nlm.nih.gov/pubmed/?term=2398616 INFLIXIMAB associated ankylosing spondylitis: case report and review of 142 9 cases. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2399027 INFLIXIMAB Infliximab in psoriasis and psoriatic arthritis. [Review] 8 Generalized pustular psoriasis triggered by infliximab in two patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2412764 INFLIXIMAB with Crohn's disease. 2 Long-term durability and dose escalation patterns in infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=2438842 INFLIXIMAB therapy for psoriasis. 5 Pityriasis rosea-like arranged eruption after infliximab therapy in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2461753 INFLIXIMAB patient with psoriasis vulgaris. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2467335 INFLIXIMAB Long-term efficacy and safety of infliximab maintenance therapy in 7 patients with plaque-type psoriasis in real-world practice. Treatment of psoriasis: focus on clinic-based management with https://www.ncbi.nlm.nih.gov/pubmed/?term=2477757 INFLIXIMAB infliximab. [Review] 1 Successful treatment with infliximab of sibling cases with generalized https://www.ncbi.nlm.nih.gov/pubmed/?term=2491092 INFLIXIMAB pustular psoriasis caused by deficiency of interleukin-36 receptor 4 antagonist. Rapidly developed neurosyphilis in a psoriasis patient under https://www.ncbi.nlm.nih.gov/pubmed/?term=2511139 INFLIXIMAB treatment with infliximab: a case report. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2512811 INFLIXIMAB Complementary data for long-term infliximab use in psoriasis. 1 Reply to 'complementary data for long-term infliximab use in https://www.ncbi.nlm.nih.gov/pubmed/?term=2512811 INFLIXIMAB psoriasis'. 2 Pustular psoriasis occurring after total colectomy for ulcerative colitis https://www.ncbi.nlm.nih.gov/pubmed/?term=2529787 INFLIXIMAB and relieved by administration of infliximab. 7 Divergent gene activation in peripheral blood and tissues of patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2533371 INFLIXIMAB with rheumatoid arthritis, psoriatic arthritis and psoriasis following 5 infliximab therapy. First experience with therapy of severe forms of psoriasis with https://www.ncbi.nlm.nih.gov/pubmed/?term=2541871 INFLIXIMAB biosimilar infliximab. 5 Medication Title of Article PubMed Link Long-term study of infliximab for psoriasis in daily practice: drug https://www.ncbi.nlm.nih.gov/pubmed/?term=2549331 INFLIXIMAB survival depends on combined treatment, obesity and infusion 4 reactions. https://www.ncbi.nlm.nih.gov/pubmed/?term=2551552 INFLIXIMAB Psoriasis-associated IgA nephropathy under infliximab therapy. 9 Safety observations in 12095 patients with psoriasis enrolled in an https://www.ncbi.nlm.nih.gov/pubmed/?term=2560778 INFLIXIMAB international registry (PSOLAR): experience with infliximab and other 6 systemic and biologic therapies. Absence of varicella zoster virus reactivation after infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=2567634 INFLIXIMAB administration for plaque psoriasis. 1 Late paradoxical development of pyoderma gangrenosum in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2578659 INFLIXIMAB psoriasis patient treated with infliximab. 2 Serum infliximab concentrations and disease activity: a descriptive https://www.ncbi.nlm.nih.gov/pubmed/?term=2586470 INFLIXIMAB study of patients with psoriasis. 3 Successful use of infliximab as first line treatment for severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2640337 INFLIXIMAB childhood generalized pustular psoriasis. 8 A systematic review on the efficacy and safety of Infliximab in https://www.ncbi.nlm.nih.gov/pubmed/?term=2652892 INFLIXIMAB patients with psoriasis. [Review] 4 Juvenile generalized pustular psoriasis with IL36RN mutation treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2662719 INFLIXIMAB with short-term infliximab. 8 Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=2670492 INFLIXIMAB psoriasis or psoriatic erythroderma: Results from the prospective 6 post-marketing surveillance. Health-related quality-of-life improvements during 98 weeks of https://www.ncbi.nlm.nih.gov/pubmed/?term=2686947 INFLIXIMAB infliximab therapy in patients with plaque-type psoriasis in real-world 7 practice. Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2717051 INFLIXIMAB with an IL-36RN deficiency treated with infliximab: Case report and 3 review of the literature. https://www.ncbi.nlm.nih.gov/pubmed/?term=2743819 INFLIXIMAB Infliximab in patients with psoriasis and other inflammatory diseases: 7 evaluation of adverse events in the treatment of 168 patients. The infliximab biosimilar in the treatment of moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2747345 INFLIXIMAB plaque psoriasis. 2 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2788258 INFLIXIMAB Efficacy and safety of dose escalation of infliximab therapy in 6 Japanese patients with psoriasis: Results of the SPREAD study. Combination therapy of infliximab and ciclosporin in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2794323 INFLIXIMAB recalcitrant psoriasis: a case series. 8 Lewis-Sumner syndrome associated with infliximab therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2822598 INFLIXIMAB psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2841964 INFLIXIMAB A dramatic response to a single dose of infliximab in a patient with 7 prolonged pustular psoriasis derived from inverse psoriasis. Hepatitis due to EBV-reactivation under infliximab in a psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2877195 INFLIXIMAB patient. 3 Effectiveness and safety of infliximab for 11 years in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2916652 INFLIXIMAB erythrodermic psoriasis and psoriatic arthritis. 6 Psoriasis improvement after gastric bandage in a patient partial https://www.ncbi.nlm.nih.gov/pubmed/?term=2921469 INFLIXIMAB responder to infliximab. 5 INFLIXIMAB, Successful treatment of severe recalcitrant psoriasis with https://www.ncbi.nlm.nih.gov/pubmed/?term=1126017 METHOTREXATE combination infliximab and methotrexate. 2 INFLIXIMAB, Addition of low-dose methotrexate to infliximab in the treatment of a https://www.ncbi.nlm.nih.gov/pubmed/?term=1287390 METHOTREXATE patient with severe, recalcitrant pustular psoriasis. 7 INFLIXIMAB, Infliximab combined with methotrexate as long-term treatment for https://www.ncbi.nlm.nih.gov/pubmed/?term=1636527 METHOTREXATE erythrodermic psoriasis. 5 INFLIXIMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=1640991 Sustained effects of low dose infliximab in combination with METHOTREXATE 7 methotrexate in the management of chronic recalcitrant psoriasis. INFLIXIMAB, Infliximab- and methotrexate-resistant rebound of psoriasis after https://www.ncbi.nlm.nih.gov/pubmed/?term=1696544 METHOTREXATE discontinuation of efalizumab (Raptiva). 4 INFLIXIMAB, Long-term control of recalcitrant psoriasis with combination infliximab https://www.ncbi.nlm.nih.gov/pubmed/?term=1912039 METHOTREXATE and methotrexate. 0 Efficacy and safety of infliximab vs. methotrexate in patients with INFLIXIMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2191071 moderate-to-severe plaque psoriasis: results of an open-label, active- METHOTREXATE 3 controlled, randomized trial (RESTORE1). INFLIXIMAB, Childhood generalized pustular psoriasis: longtime remission with https://www.ncbi.nlm.nih.gov/pubmed/?term=2564404 METHOTREXATE combined infliximab and methotrexate treatment. 4 Medication Title of Article PubMed Link INFLIXIMAB, Complete reversion of anti-infliximab immunization by methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=2611922 METHOTREXATE combination in a patient with psoriasis. 8 Development of psoriasis scalp with alopecia during treatment of INFLIXIMAB, https://www.ncbi.nlm.nih.gov/pubmed/?term=2417436 Crohn's disease with infliximab and rapid response to both diseases USTEKINUMAB 9 to ustekinumab.

Intranasal insulin influences the olfactory performance of patients https://www.ncbi.nlm.nih.gov/pubmed/26275583 INSULIN with smell loss, dependent on the body mass index: A pilot study. Fungal cultures on cyanoacrylate skin surface strippings as a dose- finding method for topical . A placebo-controlled study with http://www.ncbi.nlm.nih.gov/pubmed/7658304 0.25% and 0.50% itraconazole cream.

Efficacy of topical and systemic itraconazole as a broad-spectrum http://www.ncbi.nlm.nih.gov/pubmed/15887725 ITRACONAZOLE antifungal agent in mycotic corneal ulcer. A preliminary study. Comparison of topical itraconazole 1% with topical natamycin 5% for http://www.ncbi.nlm.nih.gov/pubmed/15829804 ITRACONAZOLE the treatment of filamentous fungal keratitis.

D-optimal experimental approach for designing topical microemulsion http://www.ncbi.nlm.nih.gov/pubmed/25445834 of itraconazole: Characterization and evaluation of antifungal efficacy ITRACONAZOLE against a standardized Tinea pedis infection model in Wistar rats Treatment of tinea capitis caused by Microsporum ferrugineum with http://www.ncbi.nlm.nih.gov/pubmed/16856430 ITRACONAZOLE itraconazole. Itraconazole in the treatment of seborrheic dermatitis: a new http://www.ncbi.nlm.nih.gov/pubmed/14693026 ITRACONAZOLE treatment modality. Comparison of topical itraconazole 1% with topical natamycin 5% for http://www.ncbi.nlm.nih.gov/pubmed/15829804 ITRACONAZOLE the treatment of filamentous fungal keratitis

Single dose (400 mg) versus 7 day (200 mg) daily dose itraconazole http://www.ncbi.nlm.nih.gov/pubmed/20046175 ITRACONAZOLE in the treatment of tinea versicolor: a randomized clinical trial

Efficacy of topical and systemic itraconazole as a broad-spectrum http://www.ncbi.nlm.nih.gov/pubmed/15887725 ITRACONAZOLE antifungal agent in mycotic corneal ulcer. A preliminary study Medication Title of Article PubMed Link A randomized trial of 5% solution nail lacquer in association with itraconazole pulse therapy compared with http://www.ncbi.nlm.nih.gov/pubmed/12890209 itraconazole alone in the treatment of Candida fingernail ITRACONAZOLE onychomycosis Fungal cultures on cyanoacrylate skin surface strippings as a dose- finding method for topical antifungals. A placebo-controlled study with http://www.ncbi.nlm.nih.gov/pubmed/7658304 ITRACONAZOLE 0.25% and 0.50% itraconazole cream Statin-associated rhabdomyolysis triggered by drug-drug interaction https://www.ncbi.nlm.nih.gov/pubmed/27605198 ITRACONAZOLE with itraconazole. Subcutaneous Infection Associated with Trichosporon ovoides: A https://www.ncbi.nlm.nih.gov/pubmed/26493614 ITRACONAZOLE Case Report and Review of Literature. https://www-scopus- com.ezproxy.lib.uh.edu/record/display.uri?eid=2-s2.0- 84865188861&origin=resultslist&sort=plf- f&src=s&st1=Effect+of+various+penetration+enhance rs+on+permeation+kinetic+of+itraconazole+for+the+t opical+drug+delivery+system&st2=&sid=745578b17e c17776d86f8ed91fa649e4&sot=b&sdt=b&sl=129&s=T ITLE-ABS- KEY%28Effect+of+various+penetration+enhancers+o n+permeation+kinetic+of+itraconazole+for+the+topica Effect of various penetration enhancers on permeation kinetic of l+drug+delivery+system%29&relpos=0&citeCnt=1&se ITRACONAZOLE itraconazole for the topical drug delivery system archTerm= Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2245541 IXEKIZUMAB psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2280896 IXEKIZUMAB Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2280896 IXEKIZUMAB Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. 7 Early clinical response as a predictor of subsequent response to https://www.ncbi.nlm.nih.gov/pubmed/?term=2403255 IXEKIZUMAB ixekizumab treatment: results from a phase II study of patients with 4 moderate-to-severe plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2475288 IXEKIZUMAB Population exposure-response model to support dosing evaluation of 0 ixekizumab in patients with chronic plaque psoriasis. Medication Title of Article PubMed Link IL-17 induces inflammation-associated gene products in blood https://www.ncbi.nlm.nih.gov/pubmed/?term=2499959 IXEKIZUMAB monocytes, and treatment with ixekizumab reduces their expression 1 in psoriasis patient blood. A 52-week, open-label study of the efficacy and safety of ixekizumab, https://www.ncbi.nlm.nih.gov/pubmed/?term=2524255 IXEKIZUMAB an anti-interleukin-17A monoclonal antibody, in patients with chronic 8 plaque psoriasis. Improvement of scalp and nail lesions with ixekizumab in a phase 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2569378 IXEKIZUMAB trial in patients with chronic plaque psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2574848 IXEKIZUMAB Ixekizumab for treatment of psoriasis. [Review] 5 A high level of clinical response is associated with improved patient- https://www.ncbi.nlm.nih.gov/pubmed/?term=2577378 IXEKIZUMAB reported outcomes in psoriasis: analyses from a phase 2 study in 1 patients treated with ixekizumab. https://www.ncbi.nlm.nih.gov/pubmed/?term=2656907 IXEKIZUMAB Targeting IL-17 with ixekizumab in patients with psoriasis. [Review] 2 Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2666670 IXEKIZUMAB moderate-to severe plaque psoriasis. [Review] 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2684229 IXEKIZUMAB Ixekizumab for psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2684229 IXEKIZUMAB Ixekizumab for psoriasis--Authors' reply. 7 Effect of Ixekizumab Treatment on Work Productivity for Patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2695384 IXEKIZUMAB With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 8 3 Randomized Phase 3 Clinical Trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=2714892 IXEKIZUMAB Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis. 2 Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2729980 IXEKIZUMAB Psoriasis. 9

Phase 3, open-label, randomized study of the pharmacokinetics, https://www.ncbi.nlm.nih.gov/pubmed/?term=2750094 IXEKIZUMAB efficacy and safety of ixekizumab following subcutaneous 9 administration using a prefilled or an in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). Medication Title of Article PubMed Link Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2753799 IXEKIZUMAB Psoriasis With Significant Nail Involvement: Results From UNCOVER 6 3. Ixekizumab for treatment of adults with moderate-to-severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2769066 IXEKIZUMAB psoriasis and psoriatic arthritis. [Review] 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2769249 IXEKIZUMAB Impact of ixekizumab on psoriasis itch severity and other psoriasis 8 symptoms: Results from 3 phase III psoriasis clinical trials. Treatment outcomes with ixekizumab in patients with moderate-to- severe psoriasis who have or have not received prior biological https://www.ncbi.nlm.nih.gov/pubmed/?term=2769657 IXEKIZUMAB therapies: an integrated analysis of two Phase III randomized 7 studies. Sustained response with ixekizumab treatment of moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2775946 IXEKIZUMAB severe psoriasis with scalp involvement: results from three phase 3 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal https://www.ncbi.nlm.nih.gov/pubmed/?term=2782517 IXEKIZUMAB Antibody, for Moderate-to-Severe Plaque Psoriasis. [Review] 4 Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2788767 IXEKIZUMAB [Review] 5

Ixekizumab treatment improves fingernail psoriasis in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2791015 IXEKIZUMAB moderate-to-severe psoriasis: results from the randomized, 6 controlled and open-label phases of UNCOVER-3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2795973 IXEKIZUMAB Psoriasis. 8 Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2795973 IXEKIZUMAB Psoriasis. 9

Inflammatory bowel disease among patients with psoriasis treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2802782 IXEKIZUMAB with ixekizumab: A presentation of adjudicated data from an 5 integrated database of 7 randomized controlled and uncontrolled trials.[Erratum appears in J Am Acad Dermatol. 2017 Aug;77(2):390- Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2813894 IXEKIZUMAB [Review] 6 Medication Title of Article PubMed Link Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.[Erratum https://www.ncbi.nlm.nih.gov/pubmed/?term=2819025 IXEKIZUMAB appears in J Eur Acad Dermatol Venereol. 2017 Oct;31(10 ):1764; 5 PMID: 29059512] The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled https://www.ncbi.nlm.nih.gov/pubmed/?term=2837046 IXEKIZUMAB Phase 3 studies of patients with moderate-to-severe plaque 7 psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2854287 IXEKIZUMAB Comparison of ixekizumab with ustekinumab in moderate-to-severe 4 psoriasis: 24-week results from IXORA-S, a phase III study. Impact of ixekizumab treatment on skin-related personal relationship https://www.ncbi.nlm.nih.gov/pubmed/?term=2857374 IXEKIZUMAB difficulties in moderate-to-severe psoriasis patients: 12-week results 3 from two Phase 3 trials. Efficacy and safety of ixekizumab treatment in Japanese patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2863502 IXEKIZUMAB with moderate-to-severe plaque psoriasis: Subgroup analysis of a 6 placebo-controlled, phase 3 study (UNCOVER-1). https://www.ncbi.nlm.nih.gov/pubmed/?term=2865270 IXEKIZUMAB Spotlight on ixekizumab for the treatment of moderate-to-severe 2 plaque psoriasis: design, development, and use in therapy. [Review] Cost per additional responder for ixekizumab and other FDA- https://www.ncbi.nlm.nih.gov/pubmed/?term=2876005 IXEKIZUMAB approved biologics in moderate-to-severe plaque psoriasis. 6 Improvements in psoriasis within different body regions vary over https://www.ncbi.nlm.nih.gov/pubmed/?term=2879225 IXEKIZUMAB time following treatment with ixekizumab. 9 Impact of ixekizumab on facial psoriasis and related quality of life https://www.ncbi.nlm.nih.gov/pubmed/?term=2888146 IXEKIZUMAB measures in moderate-to-severe psoriasis patients: 12-week results 2 from two phase III trials.

Impact of Ixekizumab Treatment on Depressive Symptoms and https://www.ncbi.nlm.nih.gov/pubmed/?term=2890312 IXEKIZUMAB Systemic Inflammation in Patients with Moderate-to-Severe 2 Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.

Efficacy and safety of ixekizumab for the treatment of moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2891738 IXEKIZUMAB severe plaque psoriasis: Results through 108 weeks of a 3 randomized, controlled phase 3 clinical trial (UNCOVER-3). Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2892916 IXEKIZUMAB Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results 8 from a Phase III Clinical Trial and Long-term Extension. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral http://www.ncbi.nlm.nih.gov/pubmed/24531792 neuropathy (CIPN): a University of Rochester CCOP study of 462 KETAMINE cancer survivors. Comparison of topical tramadol and ketamine in pain treatment after http://www.ncbi.nlm.nih.gov/pubmed/23521170 KETAMINE tonsillectomy. http://www.ncbi.nlm.nih.gov/pubmed/22714779 KETAMINE Topical (S)-ketamine for pain management of postherpetic neuralgia.

Reduction of allodynia in patients with complex regional pain http://www.ncbi.nlm.nih.gov/pubmed/19703730 KETAMINE syndrome: A double-blind placebo-controlled trial of topical ketamine. KETAMINE Topical ketamine and morphine for post-tonsillectomy pain. http://www.ncbi.nlm.nih.gov/pubmed/18186954

Topical 2% amitriptyline and 1% ketamine in neuropathic pain http://www.ncbi.nlm.nih.gov/pubmed/15983466 KETAMINE syndromes: a randomized, double-blind, placebo-controlled trial. Topically administered ketamine reduces capsaicin-evoked http://www.ncbi.nlm.nih.gov/pubmed/16340591 KETAMINE mechanical hyperalgesia.

A Novel Compound Analgesic Cream (Ketamine, Pentoxifylline, http://www.ncbi.nlm.nih.gov/pubmed/26547813 KETAMINE Clonidine, DMSO) for Complex Regional Pain Syndrome Patients Comparison of the Effects of Topical Ketamine and Tramadol on http://www.ncbi.nlm.nih.gov/pubmed/26044602 KETAMINE Postoperative Pain After Mandibular Molar Extraction KETAMINE Analgesic effects of topical ketamine http://www.ncbi.nlm.nih.gov/pubmed/24847738 Synergistic effects of tetrandrine on the antifungal activity of topical ketoconazole cream in the treatment of dermatophytoses: a clinical http://www.ncbi.nlm.nih.gov/pubmed/21725874 KETOCONAZOLE trial Efficacious and safe management of moderate to severe scalp using clobetasol propionate 0·05% http://www.ncbi.nlm.nih.gov/pubmed/21707573 combined with ketoconazole shampoo 2%: a randomized, controlled KETOCONAZOLE study Medication Title of Article PubMed Link Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of Candida-infected http://www.ncbi.nlm.nih.gov/pubmed/20228983 KETOCONAZOLE denture stomatitis

Comparative efficacy and tolerability of Ketomousse (ketoconazole http://www.ncbi.nlm.nih.gov/pubmed/18422916 foam 1%) and ketoconazole cream 2% in the treatment of pityriasis KETOCONAZOLE versicolor: results of a prospective, multicentre, randomised study An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the http://www.ncbi.nlm.nih.gov/pubmed/18677657 KETOCONAZOLE treatment of seborrheic dermatitis In vitro ocular metabolism and bioactivation of ketoconazole in rat, https://www.ncbi.nlm.nih.gov/pubmed/28139372 KETOCONAZOLE rabbit and human.

A highly sensitive LC-MS/MS method for determination of https://www.ncbi.nlm.nih.gov/pubmed/27379747 ketoconazole in human plasma: Application to a clinical study of the KETOCONAZOLE exposure to ketoconazole in patients after topical administration. KETOCONAZOLE Topical delivery of acyclovir and ketoconazole. https://www.ncbi.nlm.nih.gov/pubmed/25005585 Comparative assessment of the efficacy of topical ketoconazole and topical in cases of pityriasis versicolor at a tertiary care https://www.ncbi.nlm.nih.gov/pmc/articles/PMC49764 hospital in eastern India: A prospective, open, randomized controlled 28/ KETOCONAZOLE trial

A randomized, double-blind, phase III trial in moderate osteoarthritis http://www.ncbi.nlm.nih.gov/pubmed/23996292 knee pain comparing topical ketoprofen gel with ketoprofen-free gel

A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in http://www.ncbi.nlm.nih.gov/pubmed/23542612 Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) KETOPROFEN and oral celecoxib for knee pain associated with osteoarthritis Topical ketoprofen TDS patch versus diclofenac gel: efficacy and http://www.ncbi.nlm.nih.gov/pubmed/17138642 KETOPROFEN tolerability in benign sport related soft-tissue injuries Topical ketoprofen patch in the treatment of tendinitis: a randomized, http://www.ncbi.nlm.nih.gov/pubmed/16078335 KETOPROFEN double blind, placebo controlled study An open, randomized study of ketoprofen in patients in surgery for http://www.ncbi.nlm.nih.gov/pubmed/9263157 KETOPROFEN Achilles or patellar tendinopathy Medication Title of Article PubMed Link

KETOPROFEN 1- http://www.ncbi.nlm.nih.gov/pubmed/12648015 ALKYLAZACYCLOAL Ketoprofen 1-alkylazacycloalkan-2-one esters as dermal prodrugs: in KAN-2-ONE ESTERS vivo and in vitro evaluations

Comparison of topical dorzolamide and ketorolac treatment for http://www.ncbi.nlm.nih.gov/pubmed/25428176 KETOROLAC cystoid macular edema in retinitis pigmentosa and Usher's syndrome

Comparison of ketorolac 0.4% and nepafenac 0.1% for the http://www.ncbi.nlm.nih.gov/pubmed/25385061 prevention of cystoid macular oedema after phacoemulsification: KETOROLAC prospective placebo-controlled randomised study Pulmonary and nasal deposition of ketorolac tromethamine solution https://www.ncbi.nlm.nih.gov/pubmed/22525081 KETOROLAC (SPRIX) following intranasal administration. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal https://www.ncbi.nlm.nih.gov/pubmed/26840902 KETOROLAC Spray (KSPN) for Acute Migraine. Nasal Ketorolac Challenge Using Acoustic Rhinometry in Patients https://www.ncbi.nlm.nih.gov/pubmed/27758759 KETOROLAC With Aspirin-Exacerbated Respiratory Disease. Nasal delivery of analgesic ketorolac tromethamine thermo- and ion- https://www.ncbi.nlm.nih.gov/pubmed/25957699 KETOROLAC sensitive in situ hydrogels. Preparation and characterization of spray-dried mucoadhesive https://www.ncbi.nlm.nih.gov/pubmed/22023210 KETOROLAC microspheres of ketorolac for . Characterization and treatment of postsurgical dental implant pain https://www.ncbi.nlm.nih.gov/pubmed/24564610 KETOROLAC employing intranasal ketorolac.

Pharmacokinetics and safety of ketorolac following single intranasal https://www.ncbi.nlm.nih.gov/pubmed/17192497 KETOROLAC and intramuscular administration in healthy volunteers. KETOROLAC Development and evaluation of nasal formulations of ketorolac. https://www.ncbi.nlm.nih.gov/pubmed/11195429 Design and evaluation of in-situ nasal gel of ketorolac https://www.ncbi.nlm.nih.gov/pubmed/18981612 KETOROLAC tromethamine. Comparison of intranasal ketorolac tromethamine pharmacokinetics https://www.ncbi.nlm.nih.gov/pubmed/23143939 KETOROLAC in younger and older adults. Effect of a Combination of Intranasal Ketorolac and Nitrous Oxide on the Success of the Inferior Alveolar Nerve Block in Patients with https://www.ncbi.nlm.nih.gov/pubmed/29153730 Symptomatic Irreversible Pulpitis: A Prospective, Randomized, KETOROLAC Double-blind Study. Medication Title of Article PubMed Link The safety and analgesic efficacy of intranasal ketorolac in patients https://www.ncbi.nlm.nih.gov/pubmed/19020154 KETOROLAC with postoperative pain. Intranasal ketorolac for pain secondary to third molar impaction https://www.ncbi.nlm.nih.gov/pubmed/20207062 KETOROLAC surgery: a randomized, double-blind, placebo-controlled trial. Intranasal ketorolac for postoperative pain: a phase 3, double-blind, https://www.ncbi.nlm.nih.gov/pubmed/19594851 KETOROLAC randomized study. Intranasal ketorolac challenge for the diagnosis of aspirin- https://www.ncbi.nlm.nih.gov/pubmed/16937750 KETOROLAC exacerbated respiratory disease. KETOROLAC Intranasal ketorolac for acute postoperative pain. https://www.ncbi.nlm.nih.gov/pubmed/20557145 Sniffing out endodontic pain: use of an intranasal analgesic in a https://www.ncbi.nlm.nih.gov/pubmed/21419286 KETOROLAC randomized clinical trial. Effect size comparison of ketorolac nasal spray and commonly prescribed oral combination opioids for pain relief after third molar https://www.ncbi.nlm.nih.gov/pubmed/26616001 KETOROLAC extraction surgery. Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and https://www.ncbi.nlm.nih.gov/pubmed/22711895 KETOROLAC efficacy data from a phase II clinical trial. KETOROLAC FATTY Evaluation of physicochemical properties, skin permeation and http://www.ncbi.nlm.nih.gov/pubmed/17978504 ESTER accumulation profiles of ketorolac fatty ester prodrugs http://www.ncbi.nlm.nih.gov/pubmed/3486267 LEUCOVORIN Topical folinic acid therapy in methotrexate-induced oral ulceration A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic http://www.ncbi.nlm.nih.gov/pubmed/26198316 LEUCOVORIN colorectal cancer A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial http://www.ncbi.nlm.nih.gov/pubmed/17996212 LEVOFLOXACIN flora. A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic http://www.ncbi.nlm.nih.gov/pubmed/19205719 LEVOFLOXACIN blepharoconjunctivitis. Corneal penetration of levofloxacin into the human aqueous humour: http://www.ncbi.nlm.nih.gov/pubmed/14641263 LEVOFLOXACIN a comparison with ciprofloxacin Short-term comparative study of the effects of preserved and http://www.ncbi.nlm.nih.gov/pubmed/20550489 LEVOFLOXACIN unpreserved topical levofloxacin on the human ocular surface. Medication Title of Article PubMed Link Levofloxacin inhalation solution (MP-376) in patients with cystic http://www.ncbi.nlm.nih.gov/pubmed/21471106 LEVOFLOXACIN fibrosis with Pseudomonas aeruginosa. A review of safety and efficacy of levofloxacin 0.5% ophthalmic solution in the treatment of external ocular infections and in http://www.ncbi.nlm.nih.gov/pubmed/26638552 LEVOFLOXACIN prophylaxis of postoperative endophthalmitis

Two Different Concentrations of Topical Levofloxacin for the http://www.ncbi.nlm.nih.gov/pubmed/26348840 LEVOFLOXACIN Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis

Comparison of Drug Concentrations in Human Aqueous Humor after http://www.ncbi.nlm.nih.gov/pubmed/26078713 the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% LEVOFLOXACIN Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions https://www.ncbi.nlm.nih.gov/pubmed/26172919 LEVOFLOXACIN Levofloxacin and Tobramycin for Severe Bacterial Keratouveitis.

Bilateral Morganella Morganii keratitis in a patient with facial topical https://www.ncbi.nlm.nih.gov/pubmed/28659135 LEVOFLOXACIN corticosteroid-induced rosacea-like dermatitis: a case report. Porous dressings of modified chitosan with poly(2-hydroxyethyl https://www.ncbi.nlm.nih.gov/pubmed/?term=Porous+ LEVOFLOXACIN acrylate) for topical wound delivery of levofloxacin. dressings+of+modified+chitosan+with+poly Comparison of the anti-inflammatory effects of 0.1% https://www.ncbi.nlm.nih.gov/pmc/articles/PMC51450 combined with levofloxacin 0.5% and tobramycin/dexamethasone 90/ LEVOFLOXACIN eye drops after cataract surgery

[Comparison between topical anaesthesia with versus http://www.ncbi.nlm.nih.gov/pubmed/24332687 LIDOCAINE lidocaine plus adrenaline for outpatient laser dacryocystorhinostomy]. Treatment for postoperative wound pain in gynecologic laparoscopic http://www.ncbi.nlm.nih.gov/pubmed/22861076 LIDOCAINE surgery: topical lidocaine patches.

Lidocaine analgesia for removal of wound vacuum-assisted closure http://www.ncbi.nlm.nih.gov/pubmed/23343829 LIDOCAINE dressings: a randomized double-blinded placebo-controlled trial. The effect of buffered lidocaine in local anesthesia: a prospective, http://www.ncbi.nlm.nih.gov/pubmed/23566722 LIDOCAINE randomized, double-blind study. A prospective, randomized, double-blind study comparing the http://www.ncbi.nlm.nih.gov/pubmed/23404424 LIDOCAINE efficacy of topical anesthetics in nasal endoscopy. Medication Title of Article PubMed Link Phase III, randomized, double-blind, placebo-controlled trial of topical 2 % lidocaine for the prevention and treatment of oral mucosal pain http://www.ncbi.nlm.nih.gov/pubmed/23892504 LIDOCAINE in children. Evaluation of three topical anaesthetic agents against pain: a clinical http://www.ncbi.nlm.nih.gov/pubmed/17217210 LIDOCAINE study.

5% lidocaine-medicated plaster vs other relevant interventions and http://www.ncbi.nlm.nih.gov/pubmed/21039364 LIDOCAINE placebo for post-herpetic neuralgia (PHN): a systematic review. A comparison of the lidocaine patch 5% vs 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6- http://www.ncbi.nlm.nih.gov/pubmed/17406167 LIDOCAINE week, randomized, parallel-group study. Lidocaine adrenaline gel versus tetracaine adrenaline cocaine gel for topical anesthesia in linear scalp and facial http://www.ncbi.nlm.nih.gov/pubmed/7838644 LIDOCAINE lacerations in children aged 5 to 17 years. Lidocaine eye drops attenuate pain associated with ophthalmic http://www.ncbi.nlm.nih.gov/pubmed/20237042 LIDOCAINE postherpetic neuralgia. http://www.ncbi.nlm.nih.gov/pubmed/21679552 LIDOCAINE Lidocaine patches reduce pain in trauma patients with rib fractures. Lidocaine-prilocaine cream versus tetracaine gel for procedural pain http://www.ncbi.nlm.nih.gov/pubmed/11918521 LIDOCAINE in children. Randomized, double-blind, placebo-controlled trial using lidocaine http://www.ncbi.nlm.nih.gov/pubmed/20113941 LIDOCAINE patch 5% in traumatic rib fractures. The analgesic effect of a metered-dose 8% lidocaine pump spray in http://www.ncbi.nlm.nih.gov/pubmed/19224814 LIDOCAINE posttraumatic peripheral neuropathy: a pilot study. LIDOCAINE Topical lidocaine for the treatment of postherpetic neuralgia. http://www.ncbi.nlm.nih.gov/pubmed/17443559 Novel topical formulation of lidocaine provides significant pain relief for insertion: pharmacokinetic evaluation and http://www.ncbi.nlm.nih.gov/pubmed/25455873 LIDOCAINE randomized placebo-controlled trial. Pupil dilation with intra-cameral lidocaine versus topical midriatics http://www.ncbi.nlm.nih.gov/pubmed/25363172 LIDOCAINE during phacoemulsification. Pain management prior to nasogastric tube placement: atomized http://www.ncbi.nlm.nih.gov/pubmed/25842396 LIDOCAINE lidocaine. Topical lidocaine gel with and without subconjunctival lidocaine http://www.ncbi.nlm.nih.gov/pubmed/25037012 LIDOCAINE injection for : a within-patient study. Medication Title of Article PubMed Link Novel approach for pain control in patients undergoing prostate biopsy: iliohypogastric nerve block with or without topical application http://www.ncbi.nlm.nih.gov/pubmed/25703911 LIDOCAINE of prilocaine-lidocaine: a randomized controlled trial Is Nebulized Lidocaine Adequate Topical Anesthesia for Diagnostic http://www.ncbi.nlm.nih.gov/pubmed/25653254 LIDOCAINE Transnasal Tracheoscopy? Novel topical formulation of lidocaine provides significant pain relief for intrauterine device insertion: pharmacokinetic evaluation and http://www.ncbi.nlm.nih.gov/pubmed/25455873 LIDOCAINE randomized placebo-controlled trial

A Randomized Trial of 1% vs 2% Lignocaine by the Spray-as-You- http://www.ncbi.nlm.nih.gov/pubmed/25811287 LIDOCAINE Go Technique for Topical Anesthesia During Flexible Bronchoscopy EMLA versus TAC for topical anesthesia of extremity wounds in http://www.ncbi.nlm.nih.gov/pubmed/9250639 LIDOCAINE children.

Management of pain associated with debridement of leg ulcers: a http://www.ncbi.nlm.nih.gov/pubmed/20569291 randomized, multicentre, pilot study comparing nitrous oxide-oxygen LIDOCAINE mixture inhalation and lidocaïne-prilocaïne cream. http://www.ncbi.nlm.nih.gov/pubmed/11062570 LIDOCAINE Reduction in pain associated with open carpal tunnel decompression. Efficacy of combination of 0.2% GTN and lignocaine ointments in wound healing and pain relief after Milligan Morgan http://www.ncbi.nlm.nih.gov/pubmed/24486687 hemorrhoidectomy--a comparison with lignocaine and 0.2% GTN LIDOCAINE ointments separately. Randomized trial of lidocaine ointment versus placebo for the http://www.ncbi.nlm.nih.gov/pubmed/12468168 LIDOCAINE treatment of postpartum perineal pain. http://www.ncbi.nlm.nih.gov/pubmed/11229943 LIDOCAINE LET versus EMLA for pretreating lacerations: a randomized trial. EMLA cream as a for the repeated mechanical debridement of venous leg ulcers: a double-blind, placebo-controlled http://www.ncbi.nlm.nih.gov/pubmed/10025747 LIDOCAINE study. Repeated treatment with lidocaine/prilocaine cream (EMLA) as a topical anaesthetic for the cleansing of venous leg ulcers. A http://www.ncbi.nlm.nih.gov/pubmed/8105630 LIDOCAINE controlled study. Medication Title of Article PubMed Link Digital image analysis of erythema development after experimental thermal injury to human skin: effect of postburn topical local http://www.ncbi.nlm.nih.gov/pubmed/10320183 LIDOCAINE anesthetics (EMLA). Topical anesthetic EMLA for postoperative wound pain in stereotactic gamma knife radiosurgery: a perspective, randomized, placebo- http://www.ncbi.nlm.nih.gov/pubmed/21647846 LIDOCAINE controlled study. Efficacy of topical 1% lidocaine in the symptomatic treatment of pain associated with oral mucosal trauma or minor oral aphthous ulcer: a http://www.ncbi.nlm.nih.gov/pubmed/22247928 randomized, double-blind, placebo-controlled, parallel-group, single- LIDOCAINE dose study. Using a topical anaesthetic cream to reduce pain during sharp http://www.ncbi.nlm.nih.gov/pubmed/12964231 LIDOCAINE debridement of chronic leg ulcers. Plasma concentrations and analgesic effect of EMLA http://www.ncbi.nlm.nih.gov/pubmed/1972836 LIDOCAINE (lidocaine/prilocaine) cream for the cleansing of leg ulcers. The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/23438341 LIDOCAINE postherpetic neuralgia: a crossover study design. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic http://www.ncbi.nlm.nih.gov/pubmed/22769236 LIDOCAINE neuralgia. Postherpetic neuralgia: topical lidocaine is effective in nociceptor- http://www.ncbi.nlm.nih.gov/pubmed/15778907 LIDOCAINE deprived skin. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes http://www.ncbi.nlm.nih.gov/pubmed/11977110 LIDOCAINE zoster. Topical acetylsalicylic acid versus lidocaine for postherpetic http://www.ncbi.nlm.nih.gov/pubmed/10591045 LIDOCAINE neuralgia: results of a double-blind comparative clinical trial. LIDOCAINE Topical lidocaine gel relieves postherpetic neuralgia. http://www.ncbi.nlm.nih.gov/pubmed/7847866 LIPID Evaluation of TNF-α serum level in patients with recalcitrant multiple http://www.ncbi.nlm.nih.gov/pubmed/24910383 EXTRACT common warts, treated by lipid garlic extract. http://www.ncbi.nlm.nih.gov/pubmed/19241201 Development of the loratadine gel for enhanced transdermal delivery Pre-formulation studies of the H1- loratadine for a http://www.ncbi.nlm.nih.gov/pubmed/15945456 LORATADINE topical Medication Title of Article PubMed Link

A randomized, double-blind, placebo-controlled comparison of http://www.ncbi.nlm.nih.gov/pubmed/11952027 emedastine 0.05% ophthalmic solution with loratadine 10 mg and LORATADINE their combination in the human conjunctival allergen challenge model LOXASPERSE/XYLI https://www.ncbi.nlm.nih.gov/pubmed/20885412 TOL Antimicrobial effects of the combination of chlorhexidine and xylitol. LOXASPERSE/XYLI Topical anti-infective sinonasal irrigations: update and literature https://www.ncbi.nlm.nih.gov/pubmed/24717876 TOL review. https://www.ncbi.nlm.nih.gov/pubmed/?term=%5D+Xy litol+pediatric+topical+oral++to+prevent+dental+ LOXASPERSE/XYLI Xylitol pediatric topical oral syrup to prevent dental caries: a double- caries%3A+a+double- TOL blind randomized clinical trial of efficacy. blind+randomized+clinical+trial+of+efficacy LOXASPERSE/XYLI https://clinicaltrials.gov/ct2/show/NCT01823445?intr= TOL Xylitol Disk Use in Adults With Dry Mouth xylitol&draw=1&rank=4 LOXASPERSE/XYLI Bronchoscopic assessment of airway retention time of aerosolized https://www.ncbi.nlm.nih.gov/pubmed/16483382?dopt TOL xylitol. =Abstract LOXASPERSE/XYLI The osmolyte xylitol reduces the salt concentration of airway surface https://www.ncbi.nlm.nih.gov/pubmed/11027360?dopt TOL liquid and may enhance bacterial killing. =Abstract LOXASPERSE/XYLI Effects of xylitol wipes on cariogenic bacteria and caries in young https://www.ncbi.nlm.nih.gov/pubmed/22699675?dopt TOL children. =Abstract LOXASPERSE/XYLI Xylitol nasal irrigation in the management of chronic rhinosinusitis: a https://www.ncbi.nlm.nih.gov/pubmed/21994147 TOL pilot study. https://www.ncbi.nlm.nih.gov/pubmed/?term=Antiadhe LOXASPERSE/XYLI sive+effects+of+xylitol+on+otopathogenic+bacteria TOL Antiadhesive effects of xylitol on otopathogenic bacteria. LOXASPERSE/XYLI https://www.ncbi.nlm.nih.gov/pubmed/14726144 TOL Alternative sugars as potential carriers for dry powder . LOXASPERSE/XYLI The in vitro mucolytic effect of xylitol and dornase alfa on chronic https://www.ncbi.nlm.nih.gov/pubmed/28658521 TOL rhinosinusitis mucus. Topical xylitol administration by parents for the promotion of oral LOXASPERSE/XYLI health in infants: a caries prevention experiment at a Finnish Public https://www.ncbi.nlm.nih.gov/pubmed/23879257 TOL Health Centre. LOXASPERSE/XYLI https://www.ncbi.nlm.nih.gov/pubmed/27888909 TOL Topical Therapies for Refractory Chronic Rhinosinusitis Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=Compari son+of+nasal+hyperosmolar+xylitol+and+xylometazol Comparison of nasal hyperosmolar xylitol and xylometazoline ine+solutions+on+quality+of+life+in+patients+with+inf LOXASPERSE/XYLI solutions on quality of life in patients with inferior turbinate erior+turbinate+hypertrophy+secondary+to+nonallergi TOL hypertrophy secondary to nonallergic rhinitis. c+rhinitis LOXASPERSE/XYLI https://www.ncbi.nlm.nih.gov/pubmed/?term=Xylitol+a TOL Xylitol and its usage in ENT practice. nd+its+usage+in+ENT+practice LOXASPERSE/XYLI https://www.ncbi.nlm.nih.gov/pubmed/22899694 TOL Are we ready for definitive clinical guidelines on xylitol/polyol use?

The present invention is a method and pharmaceutical composition https://www.google.com/patents/US6599883 LOXASPERSE/XYLI for prevention and/or treatment of upper respiratory infections TOL PATENT including otitis media by nasal administration of xylitol. https://www.google.com/patents/US20120328537?dq =xylitol+powder+topical+use&hl=en&sa=X&ved=0ahU LOXASPERSE/XYLI KEwj60YHw0avXAhUm6oMKHenEBqAQ6AEIKDAA TOL PATENT Topical wound management formulation https://www.google.com/patents/US6716819?dq=xylit ol+powder+topical+use&hl=en&sa=X&ved=0ahUKEwj LOXASPERSE/XYLI Use of xylitol to reduce ionic strength and activate endogenous 60YHw0avXAhUm6oMKHenEBqAQ6AEIRDAE TOL PATENT antimicrobials for prevention and treatment of infections https://www.google.com/patents/US20080207771?dq =xylitol+powder+topical+use&hl=en&sa=X&ved=0ahU LOXASPERSE/XYLI KEwj60YHw0avXAhUm6oMKHenEBqAQ6AEIUjAG TOL PATENT Topical Compositions https://www.google.com/patents/US5861440?dq=xylit ol+powder+topical+use&hl=en&sa=X&ved=0ahUKEwi LOXASPERSE/XYLI Rkary0qvXAhUB5YMKHZWQCrs4ChDoAQg8MAM TOL PATENT Cosmetic and medicinal topical preparations http://pccarx.com/about-pcca/pcca- studies/studies/item/181-technical-report- Technical Report: Characterization of the Physical and characterization-of-physical-and-microbiological- LOXASPERSE™ Microbiological Properties of LoxaSperse™. properties-of-loxasperse Medication Title of Article PubMed Link http://pccarx.com/about-pcca/pcca- studies/studies/item/182-technical-report-antimicrobial- Technical Report: Antimicrobial Effectiveness Testing of a effectiveness-testing-of-a-budesonide-loxasperse- LOXASPERSE™ Budesonide LoxaSperse™ Dispersion. dispersion http://pccarx.com/about-pcca/pcca- studies/studies/item/183-technical-report-antimicrobial- Technical Report: Antimicrobial Effectiveness Testing of a effectiveness-testing-of-a-gentamicin-loxasperse- LOXASPERSE™ Gentamicin LoxaSperse™ Dispersion. dispersion http://pccarx.com/about-pcca/pcca- studies/studies/item/184-technical-report-antimicrobial- Technical Report: The Antimicrobial Activity of Itraconazole and activity-of-itraconazole-and-loxasperse-against- LOXASPERSE™ LoxaSperse™ Against Biofilms of C. albicans. biofilms-of-c-albicans http://www.pccarx.com/about-pcca/pcca- studies/studies/item/196-technical-report-antimicrobial- effectiveness-testing-of-antihistamine-and- LoxaSperse™ Technical Report: Antimicrobial Effectiveness Testing corticosteroid-in-loxasperse-dispersion LOXASPERSE™ of Antihistamine and Corticosteroid in Dispersion http://www.pccarx.com/about-pcca/pcca- studies/studies/item/226-technical-report- LoxaSperse™ Technical Report: Microbiological Quality of microbiological-quality-of-loxasperse-dispersion- LOXASPERSE™ LoxaSperse Dispersion Evaluated by Mikrocount® Combi evaluated-by-mikrocount-combi Technical Report: Evaluating the Effects of LoxaSperse™ Using an http://beta.pccarx.com/pdf_files/98871_Loxasperse_T LOXASPERSE™ In Vitro Model of Human Respiratory Tract Tissue R_RespTract.pdf Treatment of refractory melasma with combination of topical 5% magnesium ascorbyl phosphate and fluorescent pulsed light in Asian http://www.ncbi.nlm.nih.gov/pubmed/24168559 MAGNESIUM patients. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled http://www.ncbi.nlm.nih.gov/pubmed/17367443 MAGNESIUM pilot study. Effect of Topical Application of the Cream Containing Magnesium 2% on Treatment of Diaper Dermatitis and Diaper Rash in Children A http://www.ncbi.nlm.nih.gov/pubmed/26894161 MAGNESIUM Clinical Trial Study Efficacy of transdermal magnesium ascorbyl phosphate delivery after ultrasound treatment with microbubbles in gel-type surrounding http://www.ncbi.nlm.nih.gov/pubmed/26838887 MAGNESIUM medium in mice Medication Title of Article PubMed Link Topical verapamil HCl, topical trifluoperazine, and topical magnesium MAGNESIUM sulfate for the treatment of Peyronie's disease--a placebo-controlled https://www.ncbi.nlm.nih.gov/pubmed/17367443 SULFATE pilot study. MAGNESIUM https://www.ncbi.nlm.nih.gov/pubmed/18251369 SULFATE Extensive cervical prolapse during labor: a case report. MAGNESIUM Permeation of topically applied Magnesium ions through human skin https://www.ncbi.nlm.nih.gov/pubmed/27624531 SULFATE is facilitated by hair follicles

MAGNESIUM The Acute Effects of Flotation Restricted Environmental Stimulation https://www.ncbi.nlm.nih.gov/pubmed/23478477 SULFATE Technique on Recovery From Maximal Eccentric Exercise MELALEUCA Successful topical treatment of hand warts in a paediatric patient with http://www.ncbi.nlm.nih.gov/pubmed/18940708 ALTERNIFOLIA (Melaleuca alternifolia). MELALEUCA http://www.ncbi.nlm.nih.gov/pubmed/26787146 ALTERNIFOLIA Therapeutic Potential of Tea Tree Oil for Scabies Hydrogels Containing Nanocapsules and Nanoemulsions of Tea Tree MELALEUCA Oil Provide Antiedematogenic Effect and Improved Skin Wound http://www.ncbi.nlm.nih.gov/pubmed/26328444 ALTERNIFOLIA Healing MELOXICAM Topical NSAIDs for acute pain in adults. http://www.ncbi.nlm.nih.gov/pubmed/20556778 Update on the use of topical NSAIDs for the treatment of soft tissue and musculoskeletal pain: a review of recent data and current http://www.ncbi.nlm.nih.gov/pubmed/20631465 MELOXICAM treatment options. Meloxicam transdermal delivery: effect of eutectic point on the rate http://www.ncbi.nlm.nih.gov/pubmed/24711894 MELOXICAM and extent of skin permeation. Formulation of meloxicam gel for topical application: In vitro and in http://www.ncbi.nlm.nih.gov/pubmed/21134852 MELOXICAM vivo evaluation. Comparison of the efficacy and safety of a novel meloxicam ophthalmic formulation with a reference diclofenac solution in http://www.ncbi.nlm.nih.gov/pubmed/19203564 MELOXICAM cataract surgery Postoperative analgesia is not different after local vs of meloxicam in patients undergoing inguinal hernia http://www.ncbi.nlm.nih.gov/pubmed/11698316 MELOXICAM repair. Enhanced anti-inflammatory activity of carbopol loaded meloxicam http://www.ncbi.nlm.nih.gov/pubmed/24657163 MELOXICAM nanoethosomes gel. Azathioprine and 6-mercaptopurine for maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/27192092 MERCAPTOPURINE ulcerative colitis. [Review] Medication Title of Article PubMed Link Rare cause of rectal stenosis in a patient with long-term use of https://pubmed.ncbi.nlm.nih.gov/30301770 MERCAPTOPURINE Infliximab and Mercaptopurine for ulcerative colitis. Oral Cancer in a Patient Receiving Mercaptopurine for Ulcerative https://pubmed.ncbi.nlm.nih.gov/26721940 MERCAPTOPURINE Colitis. 6-mercaptopurine-induced hepatotoxicity during the treatment of https://pubmed.ncbi.nlm.nih.gov/25636015 MERCAPTOPURINE ulcerative colitis: a case study. Safe use of allopurinol and low-dose mercaptopurine therapy during https://pubmed.ncbi.nlm.nih.gov/22407929 MERCAPTOPURINE pregnancy in an ulcerative colitis patient. Can azathioprine 6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: what is the most https://pubmed.ncbi.nlm.nih.gov/23576085 MERCAPTOPURINE appropriate time for this?. [Review] Azathioprine and 6-mercaptopurine for maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/22972046 MERCAPTOPURINE ulcerative colitis. [Review] Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot https://pubmed.ncbi.nlm.nih.gov/22607563 MERCAPTOPURINE study. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose https://pubmed.ncbi.nlm.nih.gov/22147254 MERCAPTOPURINE reduction.

Efficacy of methotrexate in Crohn's disease and ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/19552632 MERCAPTOPURINE patients unresponsive or intolerant to azathioprine /mercaptopurine. Meta-analysis: the efficacy of azathioprine and mercaptopurine in https://pubmed.ncbi.nlm.nih.gov/19392869 MERCAPTOPURINE ulcerative colitis. Co-prescribing azathiopurine or 6-mercaptopurine and 5- https://pubmed.ncbi.nlm.nih.gov/18839420 MERCAPTOPURINE aminosalicylate compounds in ulcerative colitis. Squamous dysplasia of the rectum in a patient with ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/17717741 MERCAPTOPURINE treated with 6-mercaptopurine. Azathioprine and 6-mercaptopurine for maintenance of remission in https://pubmed.ncbi.nlm.nih.gov/17253451 MERCAPTOPURINE ulcerative colitis. [Review] [37 refs] Chemoprevention of colorectal neoplasia in ulcerative colitis: the https://pubmed.ncbi.nlm.nih.gov/16616360 MERCAPTOPURINE effect of 6-mercaptopurine. Chemoprevention of colorectal neoplasia in ulcerative colitis: the https://pubmed.ncbi.nlm.nih.gov/16234048 MERCAPTOPURINE effect of 6-mercaptopurine. Medication Title of Article PubMed Link

Development of hepatocellular carcinoma following treatment with 6- https://pubmed.ncbi.nlm.nih.gov/16136376 mercaptopurine for ulcerative colitis: investigation of chromosomal MERCAPTOPURINE aberration by comparative genomic hybridization.

Efficacy and safety of thiopurinic immunomodulators (azathioprine https://pubmed.ncbi.nlm.nih.gov/15233695 MERCAPTOPURINE and mercaptopurine) in steroid-dependent ulcerative colitis. A search for the optimal duration of treatment with 6-mercaptopurine https://pubmed.ncbi.nlm.nih.gov/15056086 MERCAPTOPURINE for ulcerative colitis. Cumulative experience with short- and long-term toxicity to 6- mercaptopurine in the treatment of Crohn's disease and ulcerative https://pubmed.ncbi.nlm.nih.gov/12960720 MERCAPTOPURINE colitis.

Azathioprine or 6-mercaptopurine before colectomy for ulcerative https://pubmed.ncbi.nlm.nih.gov/12479645 MERCAPTOPURINE colitis is not associated with increased postoperative complications. Experiences with 6-mercaptopurine and azathioprine therapy in https://pubmed.ncbi.nlm.nih.gov/9890469 MERCAPTOPURINE pediatric patients with severe ulcerative colitis. 6-Mercaptopurine in chronic ulcerative colitis: two steps forward with https://pubmed.ncbi.nlm.nih.gov/9890462 MERCAPTOPURINE another step back?. http://www.jcor.in/article.asp?issn=2320- Use of topical meropenem in management of hospital acquired 3897;year=2014;volume=2;issue=1;spage=23;epage MEROPENEM Pseudomonas ocular infections =25;aulast=Pande MEROPENEM Microbial keratitis after corneal laser refractive surgery. http://www.ncbi.nlm.nih.gov/pubmed/21797693 http://www.ncbi.nlm.nih.gov/pubmed/?term=Minimum +Inhibitory+Concentrations+of+Standard+and+Novel Minimum Inhibitory Concentrations of Standard and Novel +Antimicrobials+for+Isolates+from+Bacterial+Keratitis MEROPENEM Antimicrobials for Isolates from Bacterial Keratitis A Retrospective Study to Evaluate the Use of Nebulised Meropenem http://thorax.bmj.com/content/67/Suppl_2/A103.2 MEROPENEM at a Large UK Adult CF Centre http://www.ncbi.nlm.nih.gov/pubmed/?term=Aerosoliz ed+colistin+as+adjunctive+treatment+of+ventilator- associated+pneumonia+due+to+multidrug- Aerosolized colistin as adjunctive treatment of ventilator-associated resistant+Gram- pneumonia due to multidrug-resistant Gram-negative bacteria: A negative+bacteria%3A+A+prospective+study MEROPENEM prospective study Medication Title of Article PubMed Link Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo https://pubmed.ncbi.nlm.nih.gov/31489829 MESALAMINE studies. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative https://pubmed.ncbi.nlm.nih.gov/30478770 MESALAMINE Colitis. A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced https://pubmed.ncbi.nlm.nih.gov/29849018 MESALAMINE Hypersensitivity Reactions.

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission https://pubmed.ncbi.nlm.nih.gov/29361097 Status Following Short-Term and Long-Term Treatment With MESALAMINE Multimatrix Mesalamine: A Prospective, Open-Label Study.

Mesalamine Enemas for Induction of Remission in Oral Mesalamine- https://pubmed.ncbi.nlm.nih.gov/28369299 MESALAMINE refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study.

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective https://pubmed.ncbi.nlm.nih.gov/28368909 as Three Times Daily in Maintenance of Remission in Ulcerative MESALAMINE Colitis: A Randomized, Noninferiority, Multi-center Trial. Mesalamine desensitization in a patient with treatment refractory ulcerative colitis and aspirin and anti-inflammatory drug https://pubmed.ncbi.nlm.nih.gov/28284977 MESALAMINE hypersensitivity. Once daily vs multiple daily mesalamine therapy for mild to moderate https://pubmed.ncbi.nlm.nih.gov/27214762 MESALAMINE ulcerative colitis: a meta-analysis. [Review]

Randomized clinical trial: pharmacokinetics and safety of multimatrix https://pubmed.ncbi.nlm.nih.gov/26893546 MESALAMINE mesalamine for treatment of pediatric ulcerative colitis. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic https://pubmed.ncbi.nlm.nih.gov/26861051 MESALAMINE factors. Long-Term Benefit of Mesalamine Granules for Patients Who https://pubmed.ncbi.nlm.nih.gov/26563167 MESALAMINE Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Medication Title of Article PubMed Link

Once-daily Mesalamine Formulation for Maintenance of Remission in https://pubmed.ncbi.nlm.nih.gov/26368296 MESALAMINE Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/26313693 MESALAMINE Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized https://pubmed.ncbi.nlm.nih.gov/25724700 MESALAMINE Controlled Trial. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with https://pubmed.ncbi.nlm.nih.gov/25193617 MESALAMINE MMX R formulated delayed-release mesalamine. High- and low-dose oral delayed-release mesalamine in children with https://pubmed.ncbi.nlm.nih.gov/25419597 MESALAMINE mild-to-moderately active ulcerative colitis. Protein-losing gastropathy caused by mesalamine in a patient with https://pubmed.ncbi.nlm.nih.gov/25254535 MESALAMINE ulcerative colitis. Ultra-high dose of mesalamine to treat steroid-dependent ulcerative https://pubmed.ncbi.nlm.nih.gov/25175785 MESALAMINE colitis. Mesalamine treatment mimicking relapse in a child with ulcerative https://pubmed.ncbi.nlm.nih.gov/24974209 MESALAMINE colitis. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: https://pubmed.ncbi.nlm.nih.gov/24951843 MESALAMINE concept proved but more data needed. Long-term safety and tolerability of once-daily mesalamine granules https://pubmed.ncbi.nlm.nih.gov/24874460 MESALAMINE in the maintenance of remission of ulcerative colitis. Mesalamine dose escalation reduces fecal calprotectin in patients https://pubmed.ncbi.nlm.nih.gov/24793028 MESALAMINE with quiescent ulcerative colitis. Ulcerative colitis flair induced by mesalamine suppositories https://pubmed.ncbi.nlm.nih.gov/24707159 MESALAMINE hypersensitivity. Education and imaging. Gastrointestinal: Asymptomatic rectal perforation and massive pneumoretroperitoneum in patient with https://pubmed.ncbi.nlm.nih.gov/23782117 MESALAMINE ulcerative colitis treated with mesalamine enemas.

Randomised clinical trial: evaluation of the efficacy of mesalazine https://pubmed.ncbi.nlm.nih.gov/23734840 (mesalamine) suppositories in patients with ulcerative colitis and MESALAMINE active rectal inflammation -- a placebo-controlled study. Medication Title of Article PubMed Link Long-term mesalamine maintenance in ulcerative colitis: which is https://pubmed.ncbi.nlm.nih.gov/23514878 MESALAMINE more important? Adherence or daily dose.

Impact of MMX R mesalamine on improvement and maintenance of https://pubmed.ncbi.nlm.nih.gov/22648999 MESALAMINE health-related quality of life in patients with ulcerative colitis. Extended-release mesalamine granules for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/23115226 MESALAMINE [Review] Multi-Matrix System (MMX R) mesalamine for the treatment of mild-to- https://pubmed.ncbi.nlm.nih.gov/22970981 MESALAMINE moderate ulcerative colitis. [Review] Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a https://pubmed.ncbi.nlm.nih.gov/22644954 MESALAMINE systematic review and meta-analysis. [Review] Once-daily MMX( R) mesalamine for endoscopic maintenance of https://pubmed.ncbi.nlm.nih.gov/22565161 MESALAMINE remission of ulcerative colitis. Once-daily versus multiple-daily mesalamine for patients with https://pubmed.ncbi.nlm.nih.gov/22435504 MESALAMINE ulcerative colitis: a meta-analysis. Mesalamine in the treatment and maintenance of remission of https://pubmed.ncbi.nlm.nih.gov/22390554 MESALAMINE ulcerative colitis. [Review] Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term https://pubmed.ncbi.nlm.nih.gov/21837775 MESALAMINE maintenance of quiescent ulcerative colitis. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and https://pubmed.ncbi.nlm.nih.gov/21894226 MESALAMINE meta-analysis. [Review] Maintaining remission in ulcerative colitis--role of once daily extended- https://pubmed.ncbi.nlm.nih.gov/21448448 MESALAMINE release mesalamine. [Review] New desensitization regimen with mesalamine granules in a patient https://pubmed.ncbi.nlm.nih.gov/20848496 MESALAMINE with ulcerative colitis and mesalamine intolerance. Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient https://pubmed.ncbi.nlm.nih.gov/20535023 MESALAMINE with aspirin hypersensitivity and ulcerative colitis.

Impact of a patient-support program on mesalamine adherence in https://pubmed.ncbi.nlm.nih.gov/21122501 MESALAMINE patients with ulcerative colitis--a prospective study. Medication Title of Article PubMed Link

Clinical trial: once-daily mesalamine granules for maintenance of https://pubmed.ncbi.nlm.nih.gov/20937044 MESALAMINE remission of ulcerative colitis - a 6-month placebo-controlled trial. MESALAMINE Once-daily mesalamine granules for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/20594123 Inducing and maintaining remission in ulcerative colitis: role of high- https://pubmed.ncbi.nlm.nih.gov/20495466 MESALAMINE dose, extended-release mesalamine. [Review] Saccharomyces boulardii plus rifaximin in mesalamine-intolerant https://pubmed.ncbi.nlm.nih.gov/20104184 MESALAMINE ulcerative colitis. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of https://pubmed.ncbi.nlm.nih.gov/20064514 MESALAMINE remission of ulcerative colitis. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double- https://pubmed.ncbi.nlm.nih.gov/20049950 MESALAMINE blind, randomized study. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double- https://pubmed.ncbi.nlm.nih.gov/20049949 MESALAMINE blind, randomized study. Mesalamine inhibits epithelial beta-catenin activation in chronic https://pubmed.ncbi.nlm.nih.gov/19879273 MESALAMINE ulcerative colitis. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is https://pubmed.ncbi.nlm.nih.gov/19766640 MESALAMINE effective for patients with moderately active ulcerative colitis. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/19448588 MESALAMINE [Review] [1 refs] MESALAMINE Mesalamine enema-induced exacerbation of ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/19444457 Mesalamine once daily is more effective than twice daily in patients https://pubmed.ncbi.nlm.nih.gov/19375519 MESALAMINE with quiescent ulcerative colitis. Comment: Mesalamine-associated hypersensitivity myocarditis in https://pubmed.ncbi.nlm.nih.gov/19141654 MESALAMINE ulcerative colitis and the Kounis syndrome. Effect of extended MMX mesalamine therapy for acute, mild-to- https://pubmed.ncbi.nlm.nih.gov/18671232 MESALAMINE moderate ulcerative colitis. MESALAMINE Mesalamine-induced pleuritis in a patient with ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/18629902 Mesalamine foam enema versus mesalamine liquid enema in active https://pubmed.ncbi.nlm.nih.gov/19086960 MESALAMINE left-sided ulcerative colitis. Mesalamine hypersensitivity and Kounis syndrome in a pediatric https://pubmed.ncbi.nlm.nih.gov/19084925 MESALAMINE ulcerative colitis patient. Medication Title of Article PubMed Link Mesalamine with MMX technology for the treatment of ulcerative https://pubmed.ncbi.nlm.nih.gov/19072380 MESALAMINE colitis. [Review] [90 refs] Progression to colorectal neoplasia in ulcerative colitis: effect of https://pubmed.ncbi.nlm.nih.gov/18848502 MESALAMINE mesalamine. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous https://pubmed.ncbi.nlm.nih.gov/18834420 MESALAMINE mesalamine treatment. Erythrocyte-mediated delivery of dexamethasone in patients with mild- to-moderate ulcerative colitis, refractory to mesalamine: a https://pubmed.ncbi.nlm.nih.gov/18721243 MESALAMINE randomized, controlled study. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/18477967 MESALAMINE [53 refs]

N-acetyl-L-cysteine combined with mesalamine in the treatment of https://pubmed.ncbi.nlm.nih.gov/18473409 MESALAMINE ulcerative colitis: randomized, placebo-controlled pilot study. Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of https://pubmed.ncbi.nlm.nih.gov/18470616 MESALAMINE ulcerative colitis relapse. Mesalamine-associated hypersensitivity myocarditis in ulcerative https://pubmed.ncbi.nlm.nih.gov/18430794 MESALAMINE colitis.

MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate https://pubmed.ncbi.nlm.nih.gov/18377346 MESALAMINE formulation for the treatment of ulcerative colitis. [Review] [64 refs]

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) https://pubmed.ncbi.nlm.nih.gov/18080055 compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to MESALAMINE moderately active ulcerative colitis: The ASCEND I trial. MESALAMINE Once-daily mesalamine (Lialda) for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/17375030 Toxic epidermal necrosis associated with mesalamine in a patient https://pubmed.ncbi.nlm.nih.gov/17309074 MESALAMINE with ulcerative colitis. Once-daily, high-concentration MMX mesalamine in active ulcerative https://pubmed.ncbi.nlm.nih.gov/17241860 MESALAMINE colitis. Medication Title of Article PubMed Link

Effect of once- or twice-daily MMX mesalamine (SPD476) for the https://pubmed.ncbi.nlm.nih.gov/17234558 MESALAMINE induction of remission of mild to moderately active ulcerative colitis. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in https://pubmed.ncbi.nlm.nih.gov/17117598 MESALAMINE the treatment of ulcerative colitis. Variation in severity assessment and initial mesalamine dose https://pubmed.ncbi.nlm.nih.gov/16917398 MESALAMINE selection for ulcerative colitis in community practice. Oral mesalamine and clinical remission are associated with a https://pubmed.ncbi.nlm.nih.gov/16804389 MESALAMINE decrease in the extent of long-standing ulcerative colitis. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, https://pubmed.ncbi.nlm.nih.gov/16699478 MESALAMINE compliance, and chemoprevention. [Review] [62 refs] Azathioprine versus mesalamine in steroid-dependent ulcerative https://pubmed.ncbi.nlm.nih.gov/16472614 MESALAMINE colitis: long-awaited results?.

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the https://pubmed.ncbi.nlm.nih.gov/16279903 MESALAMINE treatment of moderately active ulcerative colitis: the ASCEND II trial.

Mesalamine-induced lung injury in a patient with ulcerative colitis and https://pubmed.ncbi.nlm.nih.gov/15770345 MESALAMINE a confounding autoimmune background: a case report. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind https://pubmed.ncbi.nlm.nih.gov/15758622 MESALAMINE randomized controlled trial. Ulcerative colitis occurring in the course of rheumatoid arthritis: a https://pubmed.ncbi.nlm.nih.gov/15609700 MESALAMINE case successfully treated with mesalamine enema. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a https://pubmed.ncbi.nlm.nih.gov/15017515 MESALAMINE dose-finding study with newly developed mesalamine. A pilot feasibility study of once daily versus conventional dosing https://pubmed.ncbi.nlm.nih.gov/15017487 MESALAMINE mesalamine for maintenance of ulcerative colitis. Epidermal growth factor enemas with oral mesalamine for mild-to- https://pubmed.ncbi.nlm.nih.gov/12878742 MESALAMINE moderate left-sided ulcerative colitis or proctitis.

Balsalazide is superior to mesalamine in the time to improvement of https://pubmed.ncbi.nlm.nih.gov/12492193 MESALAMINE signs and symptoms of acute mild-to-moderate ulcerative colitis. Medication Title of Article PubMed Link A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in https://pubmed.ncbi.nlm.nih.gov/12094857 MESALAMINE the treatment of active, mild-to-moderate ulcerative colitis. Distal ulcerative colitis refractory to rectal mesalamine: role of https://pubmed.ncbi.nlm.nih.gov/12045777 MESALAMINE transdermal nicotine versus oral mesalamine. Bronchiolitis obliterans in a patient with ulcerative colitis receiving https://pubmed.ncbi.nlm.nih.gov/11687866 MESALAMINE mesalamine. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative https://pubmed.ncbi.nlm.nih.gov/11515848 colitis: comparison of orally administered mesalamine and MESALAMINE sulfasalazine. MESALAMINE Oral mesalamine prodrug approved for active ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/10984803 Balsalazide led to greater remission rates and tolerance than https://pubmed.ncbi.nlm.nih.gov/10075949 MESALAMINE mesalamine in acute ulcerative colitis. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative https://pubmed.ncbi.nlm.nih.gov/10022641 colitis. Spanish Group for the Study of Crohn's Disease and MESALAMINE Ulcerative Colitis (GETECCU). METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=1451315 The efficacy of methotrexate in psoriasis--a review of 40 cases. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=1493099 Psoriasis symposium. Methotrexate. Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=1512092 decision analysis. Disseminated histoplasmosis in patients receiving low-dose METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=1739293 methotrexate therapy for psoriasis. Neutropenia due to low-dose methotrexate therapy for psoriasis and METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=1921820 rheumatoid arthritis may be fatal. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=1970018 Cyclosporin versus methotrexate toxicity in psoriasis. Methotrexate induced pneumonitis in a young woman with psoriasis METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2213769 and rheumatoid arthritis. Cytotoxic and immunologic effects of methotrexate in psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2230211 [Review] [17 refs] Medication Title of Article PubMed Link METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2292232 The practical use of methotrexate in psoriasis. [Review] [94 refs] Methotrexate-induced cirrhosis requiring liver transplantation in three METHOTREXATE patients with psoriasis. A word of caution in light of the expanding https://www.ncbi.nlm.nih.gov/pubmed/?term=2327848 use of this 'steroid-sparing' agent. Pharmacokinetics of small doses of methotrexate in patients with METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2455425 psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2496860 Methotrexate dosage in patients aged over 50 with psoriasis. Development of metastatic skin cancer during methotrexate therapy METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2566246 for psoriasis. Fasting plasma homocysteine as a sensitive parameter of antifolate METHOTREXATE effect: a study of psoriasis patients receiving low-dose methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=2582708 treatment. Short-term methotrexate administration by low-dose infusion--does it METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2591092 influence clearance of psoriasis?. Detection of hepatotoxicity associated with methotrexate therapy for METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2774596 psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=2913960 Topical methotrexate therapy for psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=3042816 Methotrexate in psoriasis: revised guidelines. [Review] [99 refs] METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=3184363 Methotrexate therapy for psoriasis. Reactivation of cutaneous radionecrosis associated with METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=3256453 methotrexate therapy for psoriasis. Pancytopenia following low-dose oral methotrexate therapy for METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=3373706 psoriasis. Liver fibrosis quantified by image analysis in methotrexate-treated METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=7678843 patients with psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=7829167 Short term methotrexate therapy in psoriasis. Methotrexate therapy of psoriasis: differential sensitivity of METHOTREXATE proliferating lymphoid and epithelial cells to the cytotoxic and growth- https://www.ncbi.nlm.nih.gov/pubmed/?term=7829873 inhibitory effects of methotrexate. Medication Title of Article PubMed Link

PUVA and methotrexate therapy of psoriasis: how closely do METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=7917986 dermatology departments follow treatment guidelines? Psoriasis Audit Workgroup of the British Association of Dermatologists. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=7971565 Methotrexate in childhood psoriasis. The use of methotrexate for treatment of psoriasis in patients with METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8034807 HIV infection. [Review] [20 refs] METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8071528 Methotrexate dose in psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8123573 Methotrexate revisited: effects of long-term treatment in psoriasis. Fulminant hepatic failure after methotrexate and PUVA therapy for METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8308218 psoriasis. Severe megaloblastic anemia in a patient receiving low-dose METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8349867 methotrexate for psoriasis. Treatment of gastrointestinal symptoms associated with METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8445064 methotrexate therapy for psoriasis. Sequential liver biopsies during long-term methotrexate treatment for METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8555032 psoriasis: a reappraisal. Interruption of long-term methotrexate treatment in psoriasis. METHOTREXATE Evaluation of clinical course and laboratory parameters after https://www.ncbi.nlm.nih.gov/pubmed/?term=8615062 discontinuation and reintroduction of weekly oral methotrexate. Methotrexate osteopathy in long-term, low-dose methotrexate METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8629827 treatment for psoriasis and rheumatoid arthritis.

The value of dynamic hepatic scintigraphy and serum aminoterminal METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8731673 propeptide of type III procollagen for early detection of methotrexate- induced hepatic damage in psoriasis patients. Methotrexate and other chemotherapeutic agents used to treat METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8785891 psoriasis. [Review] [128 refs] Accelerated nodulosis in a patient with psoriasis and arthritis during METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8835577 treatment with methotrexate. Accelerated nodulosis in a patient with psoriasis and arthritis during METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=8923389 treatment with methotrexate. Medication Title of Article PubMed Link Methotrexate-induced toxic epidermal necrolysis in a patient with METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9146556 psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9167333 Methotrexate for psoriasis. [Review] [113 refs] Epstein-Barr virus-associated lymphoproliferative disease during METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9236525 methotrexate therapy for psoriasis. Methotrexate use in psoriasis and psoriatic arthritis. [Review] [75 METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9361156 refs] Intermittent, short term use of methotrexate for exacerbations of METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9466209 psoriasis. METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9520032 Methotrexate in psoriasis: consensus conference. [Review] [18 refs] Pharmacokinetics of low doses of methotrexate in patients with METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9551702 psoriasis over the early period of treatment. Cutaneous ulceration: an unusual sign of methotrexate toxicity--first METHOTREXATE https://www.ncbi.nlm.nih.gov/pubmed/?term=9640483 report in a patient without psoriasis.

METHOTREXATE Cost-effectiveness and cost-benefit analysis of using methotrexate vs https://www.ncbi.nlm.nih.gov/pubmed/?term=9875201 Goeckerman therapy for psoriasis. A pilot study. Low dose cyclosporin A and methotrexate in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1008687 METHOTREXATE psoriasis. 2 Urinary adenosine and aminoimidazolecarboxamide excretion in https://www.ncbi.nlm.nih.gov/pubmed/?term=1041115 METHOTREXATE methotrexate-treated patients with psoriasis. 6 Pulmonary function changes in patients with psoriasis on https://www.ncbi.nlm.nih.gov/pubmed/?term=1045808 METHOTREXATE methotrexate therapy. 1 Combination treatment with methotrexate and cyclosporin for severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1046880 METHOTREXATE recalcitrant psoriasis. 0 Exfoliative dermatitis after long-term methotrexate treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1049472 METHOTREXATE severe psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1058215 METHOTREXATE Methotrexate in the treatment of psoriasis. 8 Pulmonary toxicity in a patient with psoriasis receiving methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=1067196 METHOTREXATE therapy. [Review] [21 refs] 5 The use of folic acid supplementation in psoriasis patients receiving https://www.ncbi.nlm.nih.gov/pubmed/?term=1097148 METHOTREXATE methotrexate: a survey in the United Kingdom. 1 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1117604 METHOTREXATE Systemic therapy of psoriasis using methotrexate. [Review] [9 refs] 1 Treatment of psoriatic arthritis with antitumour necrosis factor-alpha https://www.ncbi.nlm.nih.gov/pubmed/?term=1126002 METHOTREXATE antibody clears skin lesions of psoriasis resistant to treatment with 0 methotrexate. Methotrexate in psoriasis: 26 years' experience with low-dose long- https://www.ncbi.nlm.nih.gov/pubmed/?term=1130538 METHOTREXATE term treatment. 0 A clinical study to determine the efficacy and safety of 1% https://www.ncbi.nlm.nih.gov/pubmed/?term=1167900 METHOTREXATE methotrexate/Azone (MAZ) gel applied topically once daily in patients 5 with psoriasis vulgaris. Pneumonitis complicating methotrexate therapy for pustular https://www.ncbi.nlm.nih.gov/pubmed/?term=1168329 METHOTREXATE psoriasis. 0 Risk-benefit assessment of methotrexate in the treatment of severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1170230 METHOTREXATE psoriasis. [Review] [122 refs] 2 Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis-- https://www.ncbi.nlm.nih.gov/pubmed/?term=1177152 METHOTREXATE short- and long-term toxicity in 104 patients. 3 Management of psoriasis vulgaris with methotrexate 0.25% in a https://www.ncbi.nlm.nih.gov/pubmed/?term=1190783 METHOTREXATE hydrophilic gel: a placebo-controlled, double-blind study. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1212156 METHOTREXATE Short-term methotrexate therapy in psoriasis: a study of 197 patients. 4 Pharmacokinetics and pharmacodynamics of low-dose methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=1220763 METHOTREXATE in the treatment of psoriasis. 4 The combination of calcipotriol and methotrexate compared with https://www.ncbi.nlm.nih.gov/pubmed/?term=1258838 METHOTREXATE methotrexate and vehicle in psoriasis: results of a multicentre 6 placebo-controlled randomized trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=1283446 METHOTREXATE Psoriasis, vasculitis and methotrexate. 5 Methotrexate and psoriasis in the era of new biologic agents. https://www.ncbi.nlm.nih.gov/pubmed/?term=1472689 METHOTREXATE [Review] [83 refs] 3 Monitoring methotrexate-induced hepatic fibrosis in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1487127 METHOTREXATE psoriasis: are serial liver biopsies justified?. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1515391 METHOTREXATE Liver biopsy in patients without psoriasis receiving methotrexate: 7 what guidelines are medical dermatologists following?. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1516522 METHOTREXATE Methotrexate in severe childhood psoriasis. 2 Efficacy of concomitant use of PUVA and methotrexate in disease https://www.ncbi.nlm.nih.gov/pubmed/?term=1551836 METHOTREXATE clearance time in plaque type psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1566090 METHOTREXATE Methotrexate for generalized pustular psoriasis in a 2-year-old child. 9 Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar https://www.ncbi.nlm.nih.gov/pubmed/?term=1567270 METHOTREXATE psoriasis. 6

Methotrexate reduces incidence of vascular diseases in veterans with https://www.ncbi.nlm.nih.gov/pubmed/?term=1569247 METHOTREXATE psoriasis or rheumatoid arthritis. [Review] [32 refs][Erratum appears 1 in J Am Acad Dermatol. 2005 Apr;52(4):670 Note: Prodanowich, Srdjan [corrected to Prodanovich, Srdjan]] Low-dose methotrexate pharmacokinetics and pharmacodynamics in https://www.ncbi.nlm.nih.gov/pubmed/?term=1573322 METHOTREXATE the therapy of severe psoriasis. 4 Methotrexate for psoriasis: current European practice. A postal https://www.ncbi.nlm.nih.gov/pubmed/?term=1575229 METHOTREXATE survey. 0

Replacement of routine liver biopsy by procollagen III aminopeptide https://www.ncbi.nlm.nih.gov/pubmed/?term=1578781 METHOTREXATE for monitoring patients with psoriasis receiving long-term 2 methotrexate: a multicentre audit and health economic analysis. Severe vertigo requiring hospitalization whilst taking low-dose oral https://www.ncbi.nlm.nih.gov/pubmed/?term=1580769 METHOTREXATE methotrexate for psoriasis. 4 Folate supplementation during methotrexate therapy for patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1619878 METHOTREXATE psoriasis. [Review] [29 refs] 7 The potential of pharmacogenetics in optimizing the use of https://www.ncbi.nlm.nih.gov/pubmed/?term=1622559 METHOTREXATE methotrexate for psoriasis. [Review] [51 refs] 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1630951 METHOTREXATE Gynaecomastia with oligospermia: an unusual complication of low- 2 dose methotrexate for pustular psoriasis. [Review] [10 refs] A liver fibrosis cocktail? Psoriasis, methotrexate and genetic https://www.ncbi.nlm.nih.gov/pubmed/?term=1631646 METHOTREXATE hemochromatosis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1634302 METHOTREXATE Monitoring liver function during methotrexate therapy for psoriasis: 4 are routine biopsies really necessary?. [Review] [49 refs] Medication Title of Article PubMed Link Use of amino terminal type III procollagen peptide (P3NP) assay in https://www.ncbi.nlm.nih.gov/pubmed/?term=1667947 METHOTREXATE methotrexate therapy for psoriasis.[Erratum appears in Postgrad Med 7 J. 2006 Aug;82(970):482] https://www.ncbi.nlm.nih.gov/pubmed/?term=1670465 METHOTREXATE Folic acid supplementation during treatment of psoriasis with 0 methotrexate: a randomized, double-blind, placebo-controlled trial. Modified combined methotrexate PUVA therapy in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1670782 METHOTREXATE recalcitrant psoriasis: a preliminary report. 8 Methotrexate and ciclosporin combination for the treatment of severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1671615 METHOTREXATE psoriasis. 3 Cytotoxic and immunologic effects of methotrexate in psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1678863 METHOTREXATE [Review] [17 refs] 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1684454 METHOTREXATE Folic acid supplementation and methotrexate therapy for psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1691138 METHOTREXATE The treatment of psoriasis vulgaris: 1% topical methotrexate gel. 6 Liver injury in long-term methotrexate treatment in psoriasis is https://www.ncbi.nlm.nih.gov/pubmed/?term=1691888 METHOTREXATE relatively infrequent. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1695148 METHOTREXATE Nitric oxide levels in patients with psoriasis treated with methotrexate. 6 Differential clinical response to alefacept in combination with https://www.ncbi.nlm.nih.gov/pubmed/?term=1719959 METHOTREXATE methotrexate in two patients with refractory palmar psoriasis. 3 [Review] [12 refs] Caffeine consumption and methotrexate dosing requirement in https://www.ncbi.nlm.nih.gov/pubmed/?term=1726996 METHOTREXATE psoriasis and psoriatic arthritis. 7 The effect of methotrexate on the expression of cell adhesion https://www.ncbi.nlm.nih.gov/pubmed/?term=1730945 METHOTREXATE molecules and activation molecule CD69 in psoriasis. 4 Psoriasis patients with diabetes type 2 are at high risk of developing https://www.ncbi.nlm.nih.gov/pubmed/?term=1739984 METHOTREXATE liver fibrosis during methotrexate treatment. 8 Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in https://www.ncbi.nlm.nih.gov/pubmed/?term=1741019 METHOTREXATE psoriasis.[Erratum appears in J Invest Dermatol. 2008 8 Oct;128(10):2545-6] Niosomal methotrexate gel in the treatment of localized psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=1755804 METHOTREXATE phase I and phase II studies. 6 Medication Title of Article PubMed Link Disseminated molluscum contagiosum in a patient with chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=1769206 METHOTREXATE plaque psoriasis taking methotrexate. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1785435 METHOTREXATE Disseminated cryptococcal infection in a patient with severe psoriasis 8 treated with efalizumab, methotrexate and ciclosporin. Pulmonary lymphoma developed during long-term methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=1787507 METHOTREXATE therapy for psoriasis. 1 Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life https://www.ncbi.nlm.nih.gov/pubmed/?term=1798630 METHOTREXATE and safety. A randomized controlled trial. 2 A pilot study of pharmacokinetically guided dosing of oral https://www.ncbi.nlm.nih.gov/pubmed/?term=1803150 METHOTREXATE methotrexate in the initial phase of psoriasis treatment. 4 Detection of subclinical joint involvement in psoriasis with bone https://www.ncbi.nlm.nih.gov/pubmed/?term=1807668 METHOTREXATE scintigraphy and its response to oral methotrexate. 9 Reliability of the Roenigk classification of liver damage after https://www.ncbi.nlm.nih.gov/pubmed/?term=1808700 METHOTREXATE methotrexate treatment for psoriasis: a clinicopathologic study of 160 0 liver biopsy specimens. Methotrexate-induced papular eruption following treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1809434 METHOTREXATE psoriasis. 7 The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission- https://www.ncbi.nlm.nih.gov/pubmed/?term=1816316 METHOTREXATE induction period of treatment for moderate-to-severe plaque 5 psoriasis. Methotrexate and liver function: a study of 13 psoriasis cases treated https://www.ncbi.nlm.nih.gov/pubmed/?term=1818196 METHOTREXATE with different cumulative dosages. 9 Genetic variation in efflux transporters influences outcome to https://www.ncbi.nlm.nih.gov/pubmed/?term=1825669 METHOTREXATE methotrexate therapy in patients with psoriasis. 2 Systemic methotrexate treatment in childhood psoriasis: further https://www.ncbi.nlm.nih.gov/pubmed/?term=1842977 METHOTREXATE experience in 24 children from India. 5 Hodgkin's lymphoma in a patient of psoriasis treated with long-term, https://www.ncbi.nlm.nih.gov/pubmed/?term=1879706 METHOTREXATE low-dose methotrexate therapy. 3 Methotrexate for psoriasis in the era of biological therapy. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=1880109 METHOTREXATE [25 refs] 5 Multiple toxic effects of low-dose methotrexate in a patient treated for https://www.ncbi.nlm.nih.gov/pubmed/?term=1899713 METHOTREXATE psoriasis. 9 Medication Title of Article PubMed Link Outcomes of methotrexate therapy for psoriasis and relationship to https://www.ncbi.nlm.nih.gov/pubmed/?term=1901669 METHOTREXATE genetic polymorphisms. 7 Liposomal methotrexate hydrogel for treatment of localized psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=1904337 METHOTREXATE preparation, characterization and laser targeting. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1917578 METHOTREXATE Methotrexate treatment in 13 children with severe plaque psoriasis. 2 Infectious complications in patients with psoriasis and rheumatoid https://www.ncbi.nlm.nih.gov/pubmed/?term=1921323 METHOTREXATE arthritis treated with antitumor necrosis factor agents and 5 methotrexate. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long- https://www.ncbi.nlm.nih.gov/pubmed/?term=1927353 METHOTREXATE term, high cumulative dose methotrexate therapy. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1936373 METHOTREXATE Methotrexate: understanding the risk in psoriasis patients. 8 Methotrexate and psoriasis: 2009 National Psoriasis Foundation https://www.ncbi.nlm.nih.gov/pubmed/?term=1938952 METHOTREXATE Consensus Conference. [104 refs] 4 Hepatotoxicity rates do not differ in patients with rheumatoid arthritis https://www.ncbi.nlm.nih.gov/pubmed/?term=1957813 METHOTREXATE and psoriasis treated with methotrexate. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1967169 METHOTREXATE Comment on: Liver fibrosis in patients with psoriasis and psoriatic 7 arthritis on long-term, high cumulative dose methotrexate therapy. Comment on: Hepatotoxicity rates do not differ in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1985811 METHOTREXATE rheumatoid arthritis and psoriasis treated with methotrexate. 9 Daily practice assessment of liver injury in patients with psoriasis on https://www.ncbi.nlm.nih.gov/pubmed/?term=1990317 METHOTREXATE methotrexate. 9 Methotrexate versus traditional Chinese medicine in psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1992548 METHOTREXATE randomized, placebo-controlled trial to determine efficacy, safety and 9 quality of life. Severe 20-nail psoriasis successfully treated by low dose https://www.ncbi.nlm.nih.gov/pubmed/?term=1995164 METHOTREXATE methotrexate. 4 A case of aseptic pleuropericarditis in a patient with chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2017870 METHOTREXATE psoriasis under methotrexate therapy. 9 Efficacy and safety of mycophenolate mofetil vs. methotrexate for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2038467 METHOTREXATE treatment of chronic plaque psoriasis. 3 Erythema gyratum repens-like eruption occuring in resolving https://www.ncbi.nlm.nih.gov/pubmed/?term=2046567 METHOTREXATE psoriasis during methotrexate therapy. 0 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2104444 METHOTREXATE Use of methotrexate in patients with psoriasis. [Review] 8 Fumarates vs. methotrexate in moderate to severe chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2117556 METHOTREXATE psoriasis: a multicentre prospective randomized controlled clinical 4 trial. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate https://www.ncbi.nlm.nih.gov/pubmed/?term=2119894 METHOTREXATE current practice and identify key questions toward optimizing 6 methotrexate use in the clinic. [Review] Nail psoriasis successfully treated with intralesional methotrexate: https://www.ncbi.nlm.nih.gov/pubmed/?term=2122855 METHOTREXATE case report. 4 Methotrexate in psoriasis: a systematic review of treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2138845 METHOTREXATE modalities, incidence, risk factors and monitoring of liver toxicity. 4 [Review] Methotrexate or fumarates: which is the best oral treatment for https://www.ncbi.nlm.nih.gov/pubmed/?term=2145719 METHOTREXATE psoriasis?. 9 Relationship between methotrexate dosing and clinical response in https://www.ncbi.nlm.nih.gov/pubmed/?term=2156407 METHOTREXATE patients with moderate to severe psoriasis: subanalysis of the 1 CHAMPION study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2157117 METHOTREXATE Methotrexate and psoriasis: consensus conference. 6 Effect of methotrexate on serum levels of IL-22 in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2165906 METHOTREXATE psoriasis. 5 Familial juvenile generalized pustular psoriasis: response to https://www.ncbi.nlm.nih.gov/pubmed/?term=2167550 METHOTREXATE methotrexate. 2 Rapidly fatal acute ATLL emerging after methotrexate therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2172968 METHOTREXATE disseminated psoriasis. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2174473 METHOTREXATE Systemic therapy of psoriasis: methotrexate. [Review] 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2186015 METHOTREXATE Monitoring methotrexate hepatotoxicity in psoriasis. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2195030 METHOTREXATE Weekly vs. daily administration of oral methotrexate (MTX) for 0 generalized plaque psoriasis: a randomized controlled clinical trial. Medication Title of Article PubMed Link Liver fibrosis screening for patients with psoriasis taking https://www.ncbi.nlm.nih.gov/pubmed/?term=2196734 METHOTREXATE methotrexate: a cross-sectional study comparing transient 1 elastography and liver biopsy. A 52-week trial comparing briakinumab with methotrexate in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2202998 METHOTREXATE with psoriasis. 0 Acute methotrexate toxicity seen as plaque psoriasis ulceration and https://www.ncbi.nlm.nih.gov/pubmed/?term=2213685 METHOTREXATE necrosis: A diagnostic clue. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2227683 METHOTREXATE Briakinumab versus Methotrexate for Psoriasis. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2227683 METHOTREXATE Briakinumab versus Methotrexate for Psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2230961 METHOTREXATE Methotrexate polyglutamates as a marker of patient compliance and 4 clinical response in psoriasis: a single-centre prospective study. Response to the letter to editor re: "Methotrexate and psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2242111 METHOTREXATE consensus conference". 5 Coexistence of psoriasis and bullous pemphigoid: remission with low- https://www.ncbi.nlm.nih.gov/pubmed/?term=2242914 METHOTREXATE dose methotrexate. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2244015 METHOTREXATE Methotrexate in psoriasis: do we need to give a test dose?. 2 Methotrexate vs. fumaric acid esters in moderate-to-severe chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2267224 METHOTREXATE plaque psoriasis: data registry report on the efficacy under daily life 8 conditions. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque- https://www.ncbi.nlm.nih.gov/pubmed/?term=2283038 METHOTREXATE type psoriasis: a prospective, randomized, double-blind, dose- 9 ranging study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2288219 METHOTREXATE Assessment of methotrexate hepatotoxicity in psoriasis patients: a 0 prospective evaluation of four serum fibrosis markers. https://www.ncbi.nlm.nih.gov/pubmed/?term=2302972 METHOTREXATE Methotrexate-induced liver cirrhosis in a patient of psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2350463 METHOTREXATE Antiangiogenic effect of methotrexate and PUVA on psoriasis. 2 Medication Title of Article PubMed Link The effect of folate supplementation on methotrexate efficacy and https://www.ncbi.nlm.nih.gov/pubmed/?term=2357555 METHOTREXATE toxicity in psoriasis patients and folic acid use by dermatologists in 0 the USA. [Review] Remission of bullous pemphigoid after rituximab treatment in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2362475 METHOTREXATE psoriasis patient on regular low-dose methotrexate. 2 Effect of the systemic use of methotrexate on the oxidative stress https://www.ncbi.nlm.nih.gov/pubmed/?term=2366099 METHOTREXATE and paraoxonase enzyme in psoriasis patients. 5 The role of systemic use of methotrexate on the oxidative stress in https://www.ncbi.nlm.nih.gov/pubmed/?term=2377115 METHOTREXATE patients with psoriasis should be evaluated with a randomized 5 controlled trial. Biomarkers for methotrexate-induced liver injury: urinary protein https://www.ncbi.nlm.nih.gov/pubmed/?term=2383098 METHOTREXATE profiling of psoriasis patients. 9 Systemic methotrexate therapy for psoriasis: past, present and https://www.ncbi.nlm.nih.gov/pubmed/?term=2383793 METHOTREXATE future. [Review] 2 One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: https://www.ncbi.nlm.nih.gov/pubmed/?term=2411686 METHOTREXATE the TRANSIT randomized trial in moderate-to-severe plaque 8 psoriasis. Transition to ustekinumab in patients with moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2411695 METHOTREXATE psoriasis and inadequate response to methotrexate: a randomized 9 clinical trial (TRANSIT). Bullous drug eruption in a patient with psoriasis after a test dose of https://www.ncbi.nlm.nih.gov/pubmed/?term=2412485 METHOTREXATE methotrexate. 7 Partial reversal of androgenetic alopecia with methotrexate therapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2415314 METHOTREXATE for psoriasis. 0 Association of disease severity with IL-1 levels in methotrexate- https://www.ncbi.nlm.nih.gov/pubmed/?term=2428377 METHOTREXATE treated psoriasis patients. 3 Low-dose methotrexate - a therapeutical kick in TNF-alpha https://www.ncbi.nlm.nih.gov/pubmed/?term=2450231 METHOTREXATE antagonist treatment for recalcitrant psoriasis vulgaris. 4 Diagnostic accuracy of noninvasive markers of liver fibrosis in https://www.ncbi.nlm.nih.gov/pubmed/?term=2458807 METHOTREXATE patients with psoriasis taking methotrexate: a systematic review and 5 meta-analysis. [Review] Methotrexate and liver fibrosis in people with psoriasis: a systematic https://www.ncbi.nlm.nih.gov/pubmed/?term=2460616 METHOTREXATE review of observational studies. [Review] 1 Medication Title of Article PubMed Link 'Short-term treatment with methotrexate does not affect https://www.ncbi.nlm.nih.gov/pubmed/?term=2467361 METHOTREXATE microvascular endothelial function in patients with psoriasis'. 7 Disseminated molluscum contagiosum in a patient on methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=2468587 METHOTREXATE therapy for psoriasis. 0 Current practice of methotrexate use for psoriasis: results of a https://www.ncbi.nlm.nih.gov/pubmed/?term=2473109 METHOTREXATE worldwide survey among dermatologists. 3 Erythrodermic psoriasis with bullous pemphigoid: combination https://www.ncbi.nlm.nih.gov/pubmed/?term=2488508 METHOTREXATE treatment with methotrexate and compound . 7 The use of transient elastography and FibroTest for monitoring https://www.ncbi.nlm.nih.gov/pubmed/?term=2496479 METHOTREXATE hepatotoxicity in patients receiving methotrexate for psoriasis. 2 Folate supplementation reduces the side effects of methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=2497271 METHOTREXATE therapy for psoriasis. [Review] 8 The use of self-administered subcutaneous methotrexate for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2511697 METHOTREXATE treatment of psoriasis. 0 The efficacy of methotrexate plus pioglitazone vs. methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=2520986 METHOTREXATE alone in the management of patients with plaque-type psoriasis: a 8 single-blinded randomized controlled trial. Palmoplantar pustular psoriasis following initiation of a beta-blocker: https://www.ncbi.nlm.nih.gov/pubmed/?term=2527947 METHOTREXATE disease control with low-dose methotrexate. 7 Fatal thrombotic thrombocytopenic purpura in a psoriasis patient https://www.ncbi.nlm.nih.gov/pubmed/?term=2532526 METHOTREXATE treated with ustekinumab and methotrexate. 0 Acute severe methotrexate toxicity in patients with psoriasis: a case https://www.ncbi.nlm.nih.gov/pubmed/?term=2540147 METHOTREXATE series and discussion. 8 Combining biologics with methotrexate in psoriasis: a systematic https://www.ncbi.nlm.nih.gov/pubmed/?term=2547081 METHOTREXATE review. [Review] 5 Methotrexate in pediatric plaque-type psoriasis: Long-term daily https://www.ncbi.nlm.nih.gov/pubmed/?term=2548587 METHOTREXATE clinical practice results from the Child-CAPTURE registry. 0

The effects of tumour necrosis factor inhibitors, methotrexate, non- https://www.ncbi.nlm.nih.gov/pubmed/?term=2556136 METHOTREXATE steroidal anti-inflammatory drugs and corticosteroids on 2 cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. [Review] Medication Title of Article PubMed Link No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting https://www.ncbi.nlm.nih.gov/pubmed/?term=2568981 METHOTREXATE glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis 1 patients. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing https://www.ncbi.nlm.nih.gov/pubmed/?term=2572137 METHOTREXATE Scheme, Dose Adjustments, Maximum Dose and Folic Acid 2 Supplementation. [Review] Relapse in psoriasis with two different tapering regimens of https://www.ncbi.nlm.nih.gov/pubmed/?term=2575132 METHOTREXATE methotrexate: a randomized open-label controlled study. 9 Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia https://www.ncbi.nlm.nih.gov/pubmed/?term=2575135 METHOTREXATE responding to methotrexate. [Review] 6

Methotrexate use and risk of lung disease in psoriasis, psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=2577011 METHOTREXATE arthritis, and inflammatory bowel disease: systematic literature review 3 and meta-analysis of randomised controlled trials. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2577955 METHOTREXATE Systemic methotrexate for the treatment of psoriasis. [Review] 1 Immunogenicity of biologic treatments for psoriasis: therapeutic https://www.ncbi.nlm.nih.gov/pubmed/?term=2596306 METHOTREXATE consequences and the potential value of concomitant methotrexate. 2 [Review] Diffuse Large B-Cell Lymphoma of the Gingiva in a Patient on Long- https://www.ncbi.nlm.nih.gov/pubmed/?term=2605378 METHOTREXATE Term Use of Methotrexate Being Treated for Psoriasis. 1

Magnetic resonance elastography and transient elastography as non- https://www.ncbi.nlm.nih.gov/pubmed/?term=2610826 METHOTREXATE invasive analyses for liver fibrosis: can they obviate the need for liver 2 biopsy in psoriasis patients treated with methotrexate?. [Review] ACP Journal Club. Review: Methotrexate does not increase risk for https://www.ncbi.nlm.nih.gov/pubmed/?term=2619258 METHOTREXATE lung disease in psoriasis, psoriatic arthritis, or IBD. 7 Microemulsions mediated effective delivery of methotrexate hydrogel: https://www.ncbi.nlm.nih.gov/pubmed/?term=2620432 METHOTREXATE more than a tour de force in psoriasis therapeutics. 6 The Use of Methotrexate, Alone or in Combination With Other https://www.ncbi.nlm.nih.gov/pubmed/?term=2626773 METHOTREXATE Therapies, for the Treatment of Palmoplantar Psoriasis. 5 Can pretreatment serum calcium level predict the efficacy of https://www.ncbi.nlm.nih.gov/pubmed/?term=2641630 METHOTREXATE methotrexate in the treatment of severe plaque psoriasis?. 3 Medication Title of Article PubMed Link Adherence of self-administered subcutaneous methotrexate in https://www.ncbi.nlm.nih.gov/pubmed/?term=2644635 METHOTREXATE patients with chronic plaque-type psoriasis. 8 Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2646735 METHOTREXATE novel therapeutic insights coming from a meta-analysis of the 6 literature data. Methotrexate in Moderate to Severe Psoriasis: Review of the https://www.ncbi.nlm.nih.gov/pubmed/?term=2661448 METHOTREXATE Literature and Expert Recommendations. [Review] 6 Methotrexate regulates Th-1 response by suppressing caspase-1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2670791 METHOTREXATE and cytokines in psoriasis patients. 3 Methotrexate in psoriasis under real-world conditions: long-term https://www.ncbi.nlm.nih.gov/pubmed/?term=2685201 METHOTREXATE efficacy and tolerability. 0 Functionalized gold nanoparticles for topical delivery of methotrexate https://www.ncbi.nlm.nih.gov/pubmed/?term=2685209 METHOTREXATE for the possible treatment of psoriasis. 7 Topical psoriasis therapies and unmet patient needs: the importance https://www.ncbi.nlm.nih.gov/pubmed/?term=2691935 METHOTREXATE of optimizing methotrexate. 6 Pharmacokinetic profile of methotrexate in psoriatic skin via the oral or subcutaneous route using dermal microdialysis showing higher https://www.ncbi.nlm.nih.gov/pubmed/?term=2700500 METHOTREXATE methotrexate bioavailability in psoriasis plaques than in non-lesional 5 skin. Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of https://www.ncbi.nlm.nih.gov/pubmed/?term=2716819 METHOTREXATE Published Trials.[Erratum appears in PLoS One. 3 2016;11(7):e0158928; PMID: 27380015] Psoriasis Patients Treated With Biologics and Methotrexate Have a https://www.ncbi.nlm.nih.gov/pubmed/?term=2740271 METHOTREXATE Reduced Rate of Myocardial Infarction: A Collaborative Analysis 7 Using International Cohorts. Methotrexate treatment provokes apoptosis of proliferating https://www.ncbi.nlm.nih.gov/pubmed/?term=2743548 METHOTREXATE keratinocyte in psoriasis patients. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2743821 METHOTREXATE Ulcerations due to methotrexate toxicity in a psoriasis patient. 1 Quality of life and patient benefit following transition from https://www.ncbi.nlm.nih.gov/pubmed/?term=2751507 METHOTREXATE methotrexate to ustekinumab in psoriasis. 0 Image Gallery: Complete remission of aggressive desmoid-type https://www.ncbi.nlm.nih.gov/pubmed/?term=2765074 METHOTREXATE fibromatosis after low-dose methotrexate for 2 weeks in a child with 9 psoriasis. Medication Title of Article PubMed Link Low dose methotrexate induced asymptomatic keratinocyte https://www.ncbi.nlm.nih.gov/pubmed/?term=2771483 METHOTREXATE dystrophy in a patient of psoriasis vulgaris. 4 A case of methotrexate intoxication in a patient with psoriasis who https://www.ncbi.nlm.nih.gov/pubmed/?term=2785960 METHOTREXATE drank beetroot juice during methotrexate treatment. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2789478 METHOTREXATE Cardiovascular event risk assessment in psoriasis patients treated 9 with tumor necrosis factor-alpha inhibitors versus methotrexate. Effectiveness and safety of Methotrexate in psoriasis: an eight-year https://www.ncbi.nlm.nih.gov/pubmed/?term=2800149 METHOTREXATE experience with 218 patients. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2801256 METHOTREXATE Should methotrexate remain the first-line drug for psoriasis?. 3 An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a https://www.ncbi.nlm.nih.gov/pubmed/?term=2801256 METHOTREXATE 52 week, multicentre, randomised, double-blind, placebo-controlled, 4 phase 3 trial. The investigation of antimicrobial peptides expression and its related https://www.ncbi.nlm.nih.gov/pubmed/?term=2806706 METHOTREXATE interaction with methotrexate treatment in patients with psoriasis 5 vulgaris. Determinants for drug survival of methotrexate in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2807867 METHOTREXATE psoriasis, split according to different reasons for discontinuation: 2 results of the prospective MTX-CAPTURE.

Diagnostic performance of transient elastography for detection of https://www.ncbi.nlm.nih.gov/pubmed/?term=2830332 METHOTREXATE methotrexate-induced liver injury using Roenigk classification in 9 Asian patients with psoriasis: a retrospective study.

Evaluation of psoriasis severity and inflammatory responses under https://www.ncbi.nlm.nih.gov/pubmed/?term=2835292 METHOTREXATE concomitant treatment with methotrexate plus micronutrients for 8 psoriasis vulgaris: a randomized double blind trial. Transient Elastography May Improve Detection of Liver Fibrosis in https://www.ncbi.nlm.nih.gov/pubmed/?term=2842226 METHOTREXATE Psoriasis Patients Treated with Methotrexate. 6 HLA-Cw6-positive patients with psoriasis show improved response to https://www.ncbi.nlm.nih.gov/pubmed/?term=2851299 METHOTREXATE methotrexate treatment. 3 Medication Title of Article PubMed Link Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2857155 METHOTREXATE Mechanistic Insights, Current Issues and Novel Delivery Approaches. 4 [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2883300 METHOTREXATE Drug survival of methotrexate in psoriasis. 7

Evaluation of oxidative stress via protein expression of glutathione S- https://www.ncbi.nlm.nih.gov/pubmed/?term=2883826 METHOTREXATE transferase and cytochrome p450 (CYP450) isoenzymes in psoriasis 3 vulgaris patients treated with methotrexate. Poor early response to methotrexate portends inadequate long-term https://www.ncbi.nlm.nih.gov/pubmed/?term=2899300 METHOTREXATE outcomes in patients with moderate-to-severe psoriasis: Evidence 7 from 2 phase 3 clinical trials. Combination Topical PUVAsol with Methotrexate Versus https://www.ncbi.nlm.nih.gov/pubmed/?term=2933642 METHOTREXATE Methotrexate in the Treatment of Palmoplantar Psoriasis. 6 Effectiveness of and factors associated with clinical response to https://www.ncbi.nlm.nih.gov/pubmed/?term=2951218 METHOTREXATE methotrexate under daily life conditions in Asian patients with 1 psoriasis: A retrospective cohort study. Methotrexate Monotherapy for Induction and Maintenance of Clinical https://pubmed.ncbi.nlm.nih.gov/30201358 METHOTREXATE Remission in Ulcerative Colitis: Dead on Arrival. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free https://pubmed.ncbi.nlm.nih.gov/29964043 METHOTREXATE Response or Remission in Ulcerative Colitis. https://pubmed.ncbi.nlm.nih.gov/27243641 METHOTREXATE The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. Methotrexate for maintenance of remission in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/26263042 METHOTREXATE [Review] https://pubmed.ncbi.nlm.nih.gov/25162749 METHOTREXATE Methotrexate for induction of remission in ulcerative colitis. [Review] Methotrexate in ulcerative colitis: a nationwide retrospective cohort https://pubmed.ncbi.nlm.nih.gov/23542534 METHOTREXATE from the Veterans Affairs Health Care System. METHOTREXATE Methotrexate: a drug of the future in ulcerative colitis?. [Review] https://pubmed.ncbi.nlm.nih.gov/21466494 Methotrexate in paediatric ulcerative colitis: a retrospective survey at https://pubmed.ncbi.nlm.nih.gov/20937047 METHOTREXATE a single tertiary referral centre. Efficacy of methotrexate in ulcerative colitis: failure or promise. https://pubmed.ncbi.nlm.nih.gov/20186931 METHOTREXATE [Review] Medication Title of Article PubMed Link Methotrexate for maintenance of remission in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/19588435 METHOTREXATE [Review] [27 refs]

Efficacy of methotrexate in Crohn's disease and ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/19552632 METHOTREXATE patients unresponsive or intolerant to azathioprine /mercaptopurine. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous https://pubmed.ncbi.nlm.nih.gov/17559377 METHOTREXATE administration. Methotrexate for induction of remission in ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/17943916 METHOTREXATE [31 refs] METHOTREXATE Oral methotrexate in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/15709988 https://pubmed.ncbi.nlm.nih.gov/15371936 METHOTREXATE Low-dose methotrexate in ulcerative colitis: still a matter of debate. METHOTREXATE Methotrexate in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/12562464 Azathioprine or methotrexate in the treatment of patients with steroid- dependent or steroid-resistant ulcerative colitis: results of an open- https://pubmed.ncbi.nlm.nih.gov/12269968 label study on efficacy and tolerability in inducing and maintaining METHOTREXATE remission. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and https://pubmed.ncbi.nlm.nih.gov/10594394 METHOTREXATE ulcerative colitis. METHOTREXATE, Comparison of the Efficacy of Methotrexate and Narrow-Band https://www.ncbi.nlm.nih.gov/pubmed/?term=2547061 PHOTOTHERAPY Ultraviolet B for the Treatment of Plaque-Type Psoriasis. 1 Methotrexate, but not narrowband ultraviolet B radiation, suppresses METHOTREXATE, https://www.ncbi.nlm.nih.gov/pubmed/?term=2883669 interleukin-33 mRNA levels in psoriatic plaques and protein levels in PHOTOTHERAPY 0 serum of patients with psoriasis. Intratympanic methylprednisolone versus gentamicin in patients with METHYLPREDNISO unilateral Ménière's disease: a randomised, double-blind, https://www.ncbi.nlm.nih.gov/pubmed/27865535 LONE comparative effectiveness trial. A Clinical Trial Comparing the Safety and Efficacy METHYLPREDNISO of Topical Tacrolimus versus Methylprednisolone in Ocular Graft- https://www.ncbi.nlm.nih.gov/pubmed/27086024 LONE versus-Host Disease. Fast itch relief in an experimental model METHYLPREDNISO for methylprednisolone aceponate topical corticosteroid activity, https://www.ncbi.nlm.nih.gov/pubmed/24612282 LONE based on allergic contact eczema to nickel sulphate. Medication Title of Article PubMed Link Comparison of efficacy and ocular surface toxicity METHYLPREDNISO of topical preservative-free methylprednisolone and preserved https://www.ncbi.nlm.nih.gov/pubmed/24351572 LONE prednisolone in the treatment of acute anterior uveitis. METHYLPREDNISO Urinary profile of methylprednisolone and its metabolites after oral https://www.ncbi.nlm.nih.gov/pubmed/23792784 LONE and topical administrations.

METHYLPREDNISO Methylprednisolone applied directly to the round window reduces https://www.ncbi.nlm.nih.gov/pubmed/21150199 LONE dizziness after cochlear implantation: a randomized clinical trial. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream METHYLPREDNISO and metronidazole 0.75% gel in the treatment of seborrhoeic https://www.ncbi.nlm.nih.gov/pubmed/19954391 LONE dermatitis: a randomized clinical study. Efficacy and safety of methylprednisolone aceponate ointment 0.1% METHYLPREDNISO compared to tacrolimus 0.03% in children and adolescents with an https://www.ncbi.nlm.nih.gov/pubmed/17298428 LONE acute flare of severe atopic dermatitis. Topical steroids versus systemic antifungals in the treatment of METHYLPREDNISO chronic paronychia: an open, randomized double-blind and double https://www.ncbi.nlm.nih.gov/pubmed/12077585 LONE dummy study. METHYLPREDNISO Topical corticosteroid therapy for acute radiation dermatitis: a https://www.ncbi.nlm.nih.gov/pubmed/12072066 LONE prospective, randomized, double-blind study. METHYLPREDNISO Topical nonpreserved methylprednisolone therapy for https://www.ncbi.nlm.nih.gov/pubmed/10201607 LONE keratoconjunctivitis sicca in Sjögren syndrome. METHYLPREDNISO TOPICAL CORTICOSTEROIDS BUT NOT CALCINEURIN https://www.ncbi.nlm.nih.gov/pubmed/26403410 LONE INHIBITORS INDUCED ATROPHY AFTER FOUR WEEKS.

Evaluation of methylprednisolone aceponate, tacrolimus and https://www.ncbi.nlm.nih.gov/pubmed/21084037 METHYLPREDNISO combination thereof in the psoriasis plaque test using sum score, 20- LONE MHz-ultrasonography and optical coherence tomography.

METHYLPREDNISO therapy using the Silverstein Microwick in sudden https://www.ncbi.nlm.nih.gov/pubmed/17851934 LONE sensorineural hearing loss after failure of conventional treatment.

METHYLPREDNISO A randomized, controlled study of the safety and efficacy https://www.ncbi.nlm.nih.gov/pubmed/12139679 LONE of topical corticosteroid treatments of sunburn in healthy volunteers. METHYLPREDNISO [Topical methylprednisolone vs lidocaïne for the prevention of https://www.ncbi.nlm.nih.gov/pubmed/12946491 LONE postoperative sore throat]. Medication Title of Article PubMed Link Percutaneous absorption of methylprednisolone aceponate METHYLPREDNISO following topical application of Advantan lotion on intact, inflamed and https://www.ncbi.nlm.nih.gov/pubmed/9603667 LONE stripped skin of male volunteers. Comparison of the local and systemic side effects METHYLPREDNISO of methylprednisolone aceponate and mometasone furoate applied https://www.ncbi.nlm.nih.gov/pubmed/8408793 LONE as ointments with equal antiinflammatory activity. Granulocytapheresis versus methylprednisolone in patients with https://pubmed.ncbi.nlm.nih.gov/18823440 METHYLPREDNISOLONE acute ulcerative colitis: 12-month follow up. Atypical presentation of pioderma gangrenosum complicating https://pubmed.ncbi.nlm.nih.gov/18803362 METHYLPREDNISOLONE ulcerative colitis: rapid disappearance with methylprednisolone. Steatohepatitis during methylprednisolone therapy for ulcerative https://pubmed.ncbi.nlm.nih.gov/12603510 METHYLPREDNISOLONE colitis exacerbation. Methylprednisolone acetate versus oral prednisolone in moderately https://pubmed.ncbi.nlm.nih.gov/11871829 METHYLPREDNISOLONE active ulcerative colitis. Sucralfate and methylprednisolone enemas in active ulcerative https://pubmed.ncbi.nlm.nih.gov/10505732 METHYLPREDNISOLONE colitis: a prospective, single-blind study.

Pyoderma gangrenosum complicating ulcerative colitis: Successful https://pubmed.ncbi.nlm.nih.gov/9658322 METHYLPREDNISOLONEtreatment with methylprednisolone pulse therapy and cyclosporine. High-dose methylprednisolone in the treatment of active ulcerative https://pubmed.ncbi.nlm.nih.gov/2303687 METHYLPREDNISOLONE colitis.

Pyoderma gangrenosum complicating ulcerative colitis: successful https://pubmed.ncbi.nlm.nih.gov/3766502 METHYLPREDNISOLONE treatment with methylprednisolone pulse therapy and . Chronic ulcerative colitis: topical treatment with methylprednisolone https://pubmed.ncbi.nlm.nih.gov/13922496 METHYLPREDNISOLONE acetate.

A double blind study of the effectiveness of 2% cream http://www.ncbi.nlm.nih.gov/pubmed/24791343 METRONIDAZOLE vs. metronidazole 1% gel in the treatment of seborrheic dermatitis Efficacy of chlorhexidine, metronidazole and combination gel in the http://www.ncbi.nlm.nih.gov/pubmed/23210197 METRONIDAZOLE treatment of gingivitis--a randomized clinical trial In vivo evaluation of a metronidazole-containing gel for the adjuvant http://www.ncbi.nlm.nih.gov/pubmed/22138847 METRONIDAZOLE treatment of chronic periodontitis: preliminary result Efficacy of 1% terbinafine cream in comparison with 0.75% http://www.ncbi.nlm.nih.gov/pubmed/21166608 METRONIDAZOLE metronidazole gel for the treatment of papulopustular rosacea Medication Title of Article PubMed Link Randomized clinical trial of metronidazole ointment versus placebo in http://www.ncbi.nlm.nih.gov/pubmed/20632322 METRONIDAZOLE perianal Crohn's disease Squeeze bottle versus saline spray after endoscopic sinus surgery http://www.ncbi.nlm.nih.gov/pubmed/25590308 MISC for chronic rhinosinusitis: a pilot multicentre trial A quantitative analysis of the intranasal delivery of topical nasal http://www.ncbi.nlm.nih.gov/pubmed/11860644 MISC drugs to the middle meatus: spray versus drop administration

A prospective randomised single-blinded clinical trial comparing the http://www.ncbi.nlm.nih.gov/pubmed/23714166 efficacy and tolerability of the nasal douching products Sterimar™ MISC and Sinus Rinse™ following functional endoscopic sinus surgery Office-Based Balloon Sinus Dilation: 1-Year Follow-up of a http://www.ncbi.nlm.nih.gov/pubmed/25740407 MISC Prospective, Multicenter Study A single-centre, before-after study of the short- and long-term http://www.ncbi.nlm.nih.gov/pubmed/23206477 MISC efficacy of Narivent(®) in the treatment of nasal congestion Sinonasal inhalation of dornase alfa in CF: A double-blind placebo- http://www.ncbi.nlm.nih.gov/pubmed/21030168 MISC controlled cross-over pilot trial Prospective, double-blind, randomized trial evaluating patient satisfaction, bleeding, and wound healing using biodegradable http://www.ncbi.nlm.nih.gov/pubmed/19344620 synthetic polyurethane foam (NasoPore) as a middle meatal spacer MISC in functional endoscopic sinus surgery The delivery of topical nasal sprays and drops to the middle meatus: http://www.ncbi.nlm.nih.gov/pubmed/11559340 MISC a semiquantitative analysis Nasal douching as a valuable adjunct in the management of chronic http://www.ncbi.nlm.nih.gov/pubmed/10229979 MISC rhinosinusitis Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with http://www.ncbi.nlm.nih.gov/pubmed/23127728 MOMETASONE oral corticosteroids.

Efficacy of nasal mometasone for the treatment of chronic sinonasal http://www.ncbi.nlm.nih.gov/pubmed/25174863 MOMETASONE disease in patients with inadequately controlled asthma. Comparative safety and efficacy of two formulations of mometasone http://www.ncbi.nlm.nih.gov/pubmed/24871808 MOMETASONE nasal spray in adult seasonal allergic rhinitis. A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients http://www.ncbi.nlm.nih.gov/pubmed/24169063 MOMETASONE with perennial allergic rhinitis. Medication Title of Article PubMed Link

Mometasone furoate nasal spray plus oxymetazoline nasal spray: http://www.ncbi.nlm.nih.gov/pubmed/23562197 MOMETASONE short-term efficacy and safety in seasonal allergic rhinitis. Safety of mometasone furoate nasal spray in the treatment of nasal http://www.ncbi.nlm.nih.gov/pubmed/23331528 MOMETASONE polyps in children. Effects of intranasal mometasone furoate on itchy ear and palate in http://www.ncbi.nlm.nih.gov/pubmed/22541408 MOMETASONE patients with seasonal allergic rhinitis.

A phase I randomized, placebo-controlled, dose-exploration study of http://www.ncbi.nlm.nih.gov/pubmed/20936994 MONTELUKAST single-dose inhaled montelukast in patients with chronic asthma. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with http://www.ncbi.nlm.nih.gov/pubmed/21545249 MONTELUKAST chronic asthma. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a http://www.ncbi.nlm.nih.gov/pubmed/24618303 MONTELUKAST randomised, double-blind, placebo-controlled study. Effect of the addition of montelukast to inhaled fluticasone propionate http://www.ncbi.nlm.nih.gov/pubmed/12480610 MONTELUKAST on airway inflammation. Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the http://www.ncbi.nlm.nih.gov/pubmed/19706339 MONTELUKAST potential as a new asthma medication. Cohort study of intracameral moxifloxacin in postoperative http://www.ncbi.nlm.nih.gov/pubmed/24526838 MOXIFLOXACIN endophthalmitis prophylaxis. Microbiota evaluation of patients with a Boston type I keratoprosthesis treated with topical 0.5% moxifloxacin and 5% http://www.ncbi.nlm.nih.gov/pubmed/22488148 MOXIFLOXACIN povidone-iodine. Efficacy and safety of adjunctive local moxifloxacin delivery in the http://www.ncbi.nlm.nih.gov/pubmed/20843236 MOXIFLOXACIN treatment of periodontitis. Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus http://www.ncbi.nlm.nih.gov/pubmed/21343458 MOXIFLOXACIN aureus. The role of topical moxifloxacin, a new antibacterial in Europe, in the http://www.ncbi.nlm.nih.gov/pubmed/21604820 MOXIFLOXACIN treatment of bacterial conjunctivitis. Safety of undiluted intracameral moxifloxacin without postoperative http://www.ncbi.nlm.nih.gov/pubmed/26577588 MOXIFLOXACIN topical antibiotics in cataract surgery Medication Title of Article PubMed Link A Case Report of Severe Corneal Toxicity following 0.5% Topical http://www.ncbi.nlm.nih.gov/pubmed/25802507 MOXIFLOXACIN Moxifloxacin Use http://www.ncbi.nlm.nih.gov/pubmed/25824259 MOXIFLOXACIN Aqueous penetration of orally and topically administered moxifloxacin Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral http://www.ncbi.nlm.nih.gov/pubmed/11587466 MUPIROCIN mupirocin. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit- http://www.ncbi.nlm.nih.gov/pubmed/19820132 MUPIROCIN site infection rates in children. The preventive effects of mupirocin against nasotracheal intubation- http://www.ncbi.nlm.nih.gov/pubmed/12818970 MUPIROCIN related bacterial carriage.

Treatment of chronic rhinosinusitis exacerbations due to methicillin- http://www.ncbi.nlm.nih.gov/pubmed/16647979 MUPIROCIN resistant Staphylococcus aureus with mupirocin irrigations. Efficacy of nasal Staphylococcus aureus eradication by topical nasal http://www.ncbi.nlm.nih.gov/pubmed/18592827 MUPIROCIN mupirocin in patients with perennial allergic rhinitis. Oral antibiotics versus topical decolonization to prevent surgical site infection after Mohs micrographic surgery--a randomized, controlled http://www.ncbi.nlm.nih.gov/pubmed/24090258 MUPIROCIN trial. Nasal lavage with mupirocin for the treatment of surgically http://www.ncbi.nlm.nih.gov/pubmed?term=18545212 MUPIROCIN recalcitrant chronic rhinosinusitis. Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis http://www.ncbi.nlm.nih.gov/pubmed?term=22170745 MUPIROCIN following endoscopic sinus surgery. Mupirocin application at the exit site in peritoneal dialysis patients: http://www.ncbi.nlm.nih.gov/pubmed/20370452 MUPIROCIN five years of experience. http://www.ncbi.nlm.nih.gov/pubmed/18090864?ordin alpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pub In vitro activity of mupirocin on clinical isolates of Staphylococcus med_ResultsPanel.Pubmed_DefaultReportPanel.Pub MUPIROCIN aureus and its potential implications in chronic rhinosinusitis. med_RVDocSum Alteration in Bacterial Culture After Treatment With Topical Mupirocin http://www.ncbi.nlm.nih.gov/pubmed/26720201 MUPIROCIN for Recalcitrant Chronic Rhinosinusitis Pitted keratolysis: successful management with mupirocin 2% http://www.ncbi.nlm.nih.gov/pubmed/26437161 MUPIROCIN ointment monotherapy Medication Title of Article PubMed Link Total Occlusive Ionic Silver-Containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal http://www.ncbi.nlm.nih.gov/pubmed/26206641 MUPIROCIN Surgery: Effect on Incisional Surgical Site Infection Anti-biofilm properties of a mupirocin spray formulation against https://www.ncbi.nlm.nih.gov/pubmed/28686044 MUPIROCIN Escherichia coli wound infections. Development of a topical mupirocin spray for antibacterial and wound- https://www.ncbi.nlm.nih.gov/pubmed/28581830 MUPIROCIN healing applications. Mupirocin in the Treatment of Staphylococcal Infections in Chronic https://www.ncbi.nlm.nih.gov/pubmed/27907108 MUPIROCIN Rhinosinusitis: A Meta-Analysis. Staphylococcus aureus resistance to topical antimicrobials in atopic https://www.ncbi.nlm.nih.gov/pubmed/27828633 MUPIROCIN dermatitis. Mupirocin reduces ciliary beat frequency of human nasal epithelial https://www.ncbi.nlm.nih.gov/pubmed/27342406 MUPIROCIN cells. Alteration in Bacterial Culture After Treatment With Topical Mupirocin https://www.ncbi.nlm.nih.gov/pubmed/26720201 MUPIROCIN for Recalcitrant Chronic Rhinosinusitis. Comparison of Topical Chlorhexidine and Mupirocin for the MUPIROCIN Prevention of Exit-Site Infection in Incident Peritoneal Dialysis https://www.ncbi.nlm.nih.gov/pubmed/28183858 Patients. Intranasal mupirocin for outbreaks of methicillin-resistant MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9331438 Staphylococcus aureus. [Review] [45 refs] Mupirocin ointment for preventing Staphylococcus aureus infections MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18843708 in nasal carriers. [Review] [45 refs] Efficacy of topical 2% mupirocin ointment for treatment of MUPIROCIN tympanostomy tube otorrhea caused by community-acquired https://www.ncbi.nlm.nih.gov/pubmed/29728181 methicillin resistant Staphylococcus aureus. Comparison of topical mupirocin and gentamicin in the prevention of MUPIROCIN peritoneal dialysis-related infections: A systematic review and meta- https://www.ncbi.nlm.nih.gov/pubmed/28341139 analysis. [Review] Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin MUPIROCIN and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin https://www.ncbi.nlm.nih.gov/pubmed/28592549 Infections. Preliminary investigations into developing all-D Omiganan for treating MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/28581672 Mupirocin-resistant MRSA skin infections. Bacterial Infections in Neonates Following Mupirocin-Based MRSA MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/28578731 Decolonization: A Multicenter Cohort Study. Medication Title of Article PubMed Link Erythrasma: A report of nine men successfully managed with MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/28537862 mupirocin 2% ointment monotherapy. Zoon Balanitis Revisited: Report of Balanitis Circumscripta MUPIROCIN Plasmacellularis Resolving With Topical Mupirocin Ointment https://www.ncbi.nlm.nih.gov/pubmed/28301626 Monotherapy. [Review] Microbiological effect of mupirocin and chlorhexidine for MUPIROCIN Staphylococcus aureus decolonization in community and nursing https://www.ncbi.nlm.nih.gov/pubmed/28215714 home based adults. MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/27376552 Distribution of high-level mupirocin resistance among clinical MRSA.

MUPIROCIN Effectiveness of Decolonization With Chlorhexidine and Mupirocin in https://www.ncbi.nlm.nih.gov/pubmed/27258958 Reducing Surgical Site Infections: A Systematic Review. [Review] Alternating Mupirocin/Gentamicin is Associated with Increased Risk MUPIROCIN of Fungal Peritonitis as Compared with Gentamicin Alone - Results of https://www.ncbi.nlm.nih.gov/pubmed/27044796 a Randomized Open-Label Controlled Trial. Pitted keratolysis: successful management with mupirocin 2% MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/26437161 ointment monotherapy. [Review] Risk factors for central line-associated bloodstream infection in MUPIROCIN patients with major burns and the efficacy of the topical application of https://www.ncbi.nlm.nih.gov/pubmed/26376765 mupirocin at the central venous catheter exit site. Long-Term Safety of Buttonhole Cannulation and Efficacy of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/26283561 Mupirocin Prophylaxis. [Review] The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis- MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/26224790 Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial. Total Occlusive Ionic Silver-Containing Dressing vs Mupirocin MUPIROCIN Ointment Application vs Conventional Dressing in Elective Colorectal https://www.ncbi.nlm.nih.gov/pubmed/26206641 Surgery: Effect on Incisional Surgical Site Infection. Drug utilization review of mupirocin ointment in a Korean university- MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/26161018 affiliated hospital. Mupirocin Resistance in Isolates of Staphylococcus spp. from Nasal MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/26019208 Swabs in a Tertiary Hospital in France. Medication Title of Article PubMed Link High prevalence of mupirocin resistance in Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/25824213 isolates from a pediatric population. Effect of mupirocin decolonization on subsequent methicillin-resistant MUPIROCIN Staphylococcus aureus infection in infants in neonatal intensive care https://www.ncbi.nlm.nih.gov/pubmed/25742074 units. TXA497 as a topical antibacterial agent: comparative MUPIROCIN antistaphylococcal, skin deposition, and skin permeation studies with https://www.ncbi.nlm.nih.gov/pubmed/25263100 mupirocin. Mupirocin-induced mutations in ileS in various genetic backgrounds MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/25122856 of methicillin-resistant Staphylococcus aureus. Patient experience with mupirocin or povidone-iodine nasal MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/24972440 decolonization.

MUPIROCIN Preventing surgical site infections: a randomized, open-label trial of https://www.ncbi.nlm.nih.gov/pubmed/24915210 nasal mupirocin ointment and nasal povidone-iodine solution. Mupirocin susceptibility in Staphylococcus aureus nasal and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/24621161 oropharyngeal isolates from Brazilian children. Decreased susceptibilities to Retapamulin, Mupirocin, and MUPIROCIN Chlorhexidine among Staphylococcus aureus isolates causing skin https://www.ncbi.nlm.nih.gov/pubmed/24614375 and soft tissue infections in otherwise healthy children. Mupirocin/chlorexidine to prevent methicillin-resistant Staphylococcus aureus infections: post hoc analysis of a placebo-controlled, MUPIROCIN randomized trial using mupirocin/chlorhexidine and https://www.ncbi.nlm.nih.gov/pubmed/24464791 polymyxin/tobramycin for the prevention of acquired infections in intubated patients. Short-term decline in all-cause acquired infections with the routine use of a decontamination regimen combining topical polymyxin, MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/24365857 tobramycin, and amphotericin B with mupirocin and chlorhexidine in the ICU: a single-center experience. Clinical relevance of mupirocin resistance in Staphylococcus aureus. MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/24144552 [Review] Dose-ranging study to assess the application of intranasal 2% MUPIROCIN mupirocin calcium ointment to eradicate Staphylococcus aureus https://www.ncbi.nlm.nih.gov/pubmed/23448592 nasal colonization. Medication Title of Article PubMed Link Prevalence of resistance to antiseptics and mupirocin among MUPIROCIN invasive coagulase-negative staphylococci from very preterm https://www.ncbi.nlm.nih.gov/pubmed/23414707 neonates in NICU: the creeping threat?. Increased peritoneal dialysis exit site infections using topical polyhexamethylene biguanide compared to mupirocin: MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/23403425 results of a safety interim analysis of an open-label prospective randomized study. Decreasing methicillin-resistant Staphylococcus aureus surgical site MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/23332373 infections with chlorhexidine and mupirocin. The effect of intraoperative mupirocin irrigation on Staphylococcus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/23192968 aureus within the maxillary sinus.

MUPIROCIN Mupirocin and chlorhexidine resistance in Staphylococcus aureus in https://www.ncbi.nlm.nih.gov/pubmed/23147738 patients with community-onset skin and soft tissue infections.

MUPIROCIN Chlorhexidine and mupirocin susceptibilities of methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/23147721 staphylococcus aureus from colonized nursing home residents. The persistence of Staphylococcus aureus decolonization after MUPIROCIN mupirocin and topical chlorhexidine: implications for patients https://www.ncbi.nlm.nih.gov/pubmed/22397861 requiring multiple or delayed procedures. Microbiological outcomes following mupirocin nasal washes for MUPIROCIN symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis https://www.ncbi.nlm.nih.gov/pubmed/22170745 following endoscopic sinus surgery.

MUPIROCIN A randomized controlled trial comparing mupirocin and polysporin https://www.ncbi.nlm.nih.gov/pubmed/22134627 triple ointments in peritoneal dialysis patients: the MP3 Study.

Prospective investigation of nasal mupirocin, hexachlorophene body MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/22083485 wash, and systemic antibiotics for prevention of recurrent community- associated methicillin-resistant Staphylococcus aureus infections. Effect of intranasal mupirocin and chlorhexidine body wash on MUPIROCIN decolonization of community-associated methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/21931262 Staphylococcus aureus. Medication Title of Article PubMed Link

Impact of combined low-level mupirocin and genotypic chlorhexidine MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/21628482 resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clinical and cost ineffectiveness of preoperative screening for methicillin-resistant Staphylococcus aureus and intranasal mupirocin MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/21145622 in preventing methicillin-resistant S aureus infections in cardiothoracic surgery. A novel chimeric lysin shows superiority to mupirocin for skin MUPIROCIN decolonization of methicillin-resistant and -sensitive Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/21098252 aureus strains. Association of high-level mupirocin resistance and multidrug-resistant MUPIROCIN methicillin-resistant Staphylococcus aureus at an academic center in https://www.ncbi.nlm.nih.gov/pubmed/21084520 the midwestern United States.

MUPIROCIN Staphylococcus aureus bacteremia and buttonhole cannulation: long- https://www.ncbi.nlm.nih.gov/pubmed/20413438 term safety and efficacy of mupirocin prophylaxis. Comparison of gentamicin and mupirocin in the prevention of exit-site MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/19886318 infection and peritonitis in peritoneal dialysis. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit- MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/19820132 site infection rates in children. Phenotypic and molecular characterization of Staphylococcus aureus MUPIROCIN isolates expressing low- and high-level mupirocin resistance in https://www.ncbi.nlm.nih.gov/pubmed/19175912 Nigeria and South Africa. Mupirocin resistance among Iranian isolates of Staphylococcus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18830185 aureus. In vitro activity of fusidic acid and mupirocin against coagulase- MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18819974 positive staphylococci from pets. Prevention of staphylococcal peritonitis in CAPD patients combining MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18711288 ablution and mupirocin. Efficacy of nasal Staphylococcus aureus eradication by topical nasal MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18592827 mupirocin in patients with perennial allergic rhinitis. Nasal lavage with mupirocin for the treatment of surgically MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18545212 recalcitrant chronic rhinosinusitis. Medication Title of Article PubMed Link Successful treatment of confluent and reticulated papillomatosis with MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18452523 topical mupirocin. A randomized controlled trial comparing mupirocin versus Polysporin MUPIROCIN Triple for the prevention of catheter-related infections in peritoneal https://www.ncbi.nlm.nih.gov/pubmed/18178950 dialysis patients (the MP3 study). Intranasal mupirocin for reduction of Staphylococcus aureus MUPIROCIN infections in surgical patients with nasal carriage: a systematic https://www.ncbi.nlm.nih.gov/pubmed/18174201 review. [Review] [43 refs]

MUPIROCIN In vitro activity of mupirocin on clinical isolates of Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/18090864 aureus and its potential implications in chronic rhinosinusitis. Intranasal mupirocin prophylaxis in elective surgery. A review of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/18063862 published studies. [Review] [33 refs]

Selective use of intranasal mupirocin and chlorhexidine bathing and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/17828692 the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients.

MUPIROCIN Mupirocin resistance in patients colonized with methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/17682986 Staphylococcus aureus in a surgical intensive care unit.

Targeted intranasal mupirocin to prevent colonization and infection MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/17682105 by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Prophylactic intranasal mupirocin ointment in the treatment of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/17565930 peritonitis in continuous ambulatory peritoneal dialysis patients. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/17173213 treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Reduction of preoperative conjunctival bacterial flora with the use of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/17471340 mupirocin nasal ointment. MUPIROCIN Impact of prophylactic mupirocin for radical esophagectomy. https://www.ncbi.nlm.nih.gov/pubmed/17109088 Medication Title of Article PubMed Link

MUPIROCIN Long-term efficacy of mupirocin in the prevention of infections with https://www.ncbi.nlm.nih.gov/pubmed/16772100 meticillin-resistant Staphylococcus aureus in a gastroenterology unit. Controlling the usage of intranasal mupirocin does impact the rate of MUPIROCIN Staphylococcus aureus deep sternal wound infections in cardiac https://www.ncbi.nlm.nih.gov/pubmed/16443093 surgery patients. Surveillance for mupirocin resistance following introduction of routine MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/16377029 peri-operative prophylaxis with nasal mupirocin. Perioperative intranasal mupirocin for the prevention of surgical-site MUPIROCIN infections: systematic review of the literature and meta-analysis. https://www.ncbi.nlm.nih.gov/pubmed/16417031 [Review] [21 refs] Efficacy and safety of combination ointment "fluticasone propionate 0.005% plus mupirocin 2.0%" for the treatment of atopic dermatitis MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/16394380 with clinical suspicion of secondary bacterial infection: an open label uncontrolled study. Unselective use of intranasal mupirocin ointment for controlling MUPIROCIN propagation of methicillin-resistant Staphylococcus aureus in a https://www.ncbi.nlm.nih.gov/pubmed/16258818 thoracic surgery ward. Effect of local mupirocin application on exit-site infection and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/16178481 peritonitis in an Indian peritoneal dialysis population. The impact of topical mupirocin on peritoneal dialysis infection in MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/16046516 Singapore General Hospital. Can mupirocin prevent methicillin-resistant Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/15987417 infections?. Use of intranasal mupirocin to prevent methicillin-resistant MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/15987397 Staphylococcus aureus infection in intensive care units. The impact of topical mupirocin on peritoneal dialysis infection rates MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/15855200 in Singapore General Hospital. Randomized, controlled trial of topical exit-site application of honey MUPIROCIN (Medihoney) versus mupirocin for the prevention of catheter- https://www.ncbi.nlm.nih.gov/pubmed/15788475 associated infections in hemodialysis patients.

MUPIROCIN Oxacillin- and mupirocin-resistant Staphylococcus aureus: in vitro https://www.ncbi.nlm.nih.gov/pubmed/15565911 activity of silver sulphadiazine and cerium nitrate in hospital strains. Medication Title of Article PubMed Link

MUPIROCIN Decrease in Staphylococcus aureus surgical-site infection rates after https://www.ncbi.nlm.nih.gov/pubmed/15350723 orthopaedic surgery after intranasal mupirocin ointment. MUPIROCIN Topical mupirocin and catheter-related bacteremia. https://www.ncbi.nlm.nih.gov/pubmed/15156458 Mupirocin prophylaxis against nosocomial Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/15023707 infections in nonsurgical patients: a randomized study. A prospective, randomized pilot evaluation of topical triple antibiotic MUPIROCIN versus mupirocin for the prevention of uncomplicated soft tissue https://www.ncbi.nlm.nih.gov/pubmed/14724869 wound infection. Mupirocin-based decolonization of Staphylococcus aureus carriers in MUPIROCIN residents of 2 long-term care facilities: a randomized, double-blind, https://www.ncbi.nlm.nih.gov/pubmed/14614669 placebo-controlled trial. Treatment of Staphylococcus aureus colonization and prophylaxis for MUPIROCIN infection with topical intranasal mupirocin: an evidence-based review. https://www.ncbi.nlm.nih.gov/pubmed/13130405 [Review] [46 refs] Randomized clinical trial of preoperative intranasal mupirocin to MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12945073 reduce surgical-site infection after digestive surgery. Intranasal mupirocin does not prevent exit-site infections in children MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12938828 receiving peritoneal dialysis. Methicillin-resistant Staphylococcus aureus whole-body decolonization among hospitalized patients with variable site MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12919762 colonization by using mupirocin in combination with octenidine dihydrochloride.

MUPIROCIN Use of perioperative mupirocin to prevent methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/12855234 Staphylococcus aureus (MRSA) orthopaedic surgical site infections. Toxic epidermal necrolysis after topical intranasal application of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12828326 mupirocin. The preventive effects of mupirocin against nasotracheal intubation- MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12818970 related bacterial carriage. Short-term effects of topical fusidic acid or mupirocin on the MUPIROCIN prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in https://www.ncbi.nlm.nih.gov/pubmed/12786834 atopic eczema. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12785407 does mupirocin remain effective?. Medication Title of Article PubMed Link

MUPIROCIN A clinical trial of mupirocin in the eradication of methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/12473473 Staphylococcus aureus nasal carriage in a digestive disease unit. Decolonization of methicillin-resistant Staphylococcus aureus using MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12390287 oral vancomycin and topical mupirocin. MUPIROCIN Intranasal mupirocin to prevent postoperative infections. https://www.ncbi.nlm.nih.gov/pubmed/12375596 MUPIROCIN Intranasal mupirocin to prevent postoperative infections. https://www.ncbi.nlm.nih.gov/pubmed/12374887 MUPIROCIN Mupirocin vs terbinafine in impetigo. https://www.ncbi.nlm.nih.gov/pubmed/12356219

MUPIROCIN A randomized controlled trial of topical exit site mupirocin application https://www.ncbi.nlm.nih.gov/pubmed/12270988 in patients with tunnelled, cuffed haemodialysis catheters. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12151194 Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method. Intranasal mupirocin to prevent postoperative Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12063371 infections. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/12007448 correlations of results from disk diffusion, Etest and reference dilution methods. Folliculitis decalvans: successful treatment with a combination of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/11990258 rifampicin and topical mupirocin. An integrated critique of the efficacy of topical mupirocin in MUPIROCIN preventing catheter-related Staphylococcus aureus infections in https://www.ncbi.nlm.nih.gov/pubmed/11979650 peritoneal dialysis clients.

MUPIROCIN A comparison of the efficacy and safety of mupirocin cream and https://www.ncbi.nlm.nih.gov/pubmed/11952661 cephalexin in the treatment of secondarily infected eczema. Topical mupirocin for eradication of MRSA colonization with MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/11732789 mupirocin-resistant strains. Reduction in gram-positive pneumonia and antibiotic consumption MUPIROCIN following the use of a SDD protocol including nasal and oral https://www.ncbi.nlm.nih.gov/pubmed/11587466 mupirocin. Medication Title of Article PubMed Link Low concentrations of mupirocin in the pharynx following intranasal MUPIROCIN application may contribute to mupirocin resistance in methicillin- https://www.ncbi.nlm.nih.gov/pubmed/11574616 resistant Staphylococcus aureus. Intranasal mupirocin reduces sternal wound infection after open heart MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/11383802 surgery in diabetics and nondiabetics. Control of a methicillin-resistant Staphylococcus aureus outbreak in a MUPIROCIN neonatal intensive care unit by unselective use of nasal mupirocin https://www.ncbi.nlm.nih.gov/pubmed/11049705 ointment. Preoperative intranasal mupirocin ointment significantly reduces MUPIROCIN postoperative infection with Staphylococcus aureus in patients https://www.ncbi.nlm.nih.gov/pubmed/10648077 undergoing upper gastrointestinal surgery. Perianal candidosis--a comparative study with mupirocin and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/10487455 nystatin. A randomized clinical trial of mupirocin in the eradication of MUPIROCIN Staphylococcus aureus nasal carriage in human immunodeficiency https://www.ncbi.nlm.nih.gov/pubmed/10438389 virus disease. Bacitracin versus mupirocin for Staphylococcus aureus nasal MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/10349956 colonization.

MUPIROCIN Emergence of mupirocin resistance in multiresistant Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/10334598 aureus clinical isolates belonging to Brazilian epidemic clone III::B:A. Opportunities for mupirocin calcium cream in the emergency MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9950412 department. [Review] [74 refs] High-level mupirocin resistance among Spanish methicillin-resistant MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/10052555 Staphylococcus aureus. Mupirocin cream is as effective as oral cephalexin in the treatment of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9866667 secondarily infected wounds. The prevalence of low- and high-level mupirocin resistance in MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9818748 staphylococci from 19 European hospitals. Staphylococcus aureus prophylaxis in hemodialysis patients using MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9621293 central venous catheter: effect of mupirocin ointment. Control of an outbreak of an epidemic methicillin-resistant MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9617681 Staphylococcus aureus also resistant to mupirocin. Medication Title of Article PubMed Link

MUPIROCIN The emergence of mupirocin resistance: a challenge to infection https://www.ncbi.nlm.nih.gov/pubmed/9511032 control and antibiotic prescribing practice. [Review] [62 refs] Comparison of oral cephalexin, topical mupirocin and topical MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9239775 bacitracin for treatment of impetigo.

MUPIROCIN Management of an outbreak of methicillin-resistant Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/9211163 aureus in a risk area with empirical intranasal mupirocin. Mupirocin resistance and methicillin-resistant Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/9032630 (MRSA). [Review] [44 refs]

MUPIROCIN Emergence of high-level mupirocin resistance in methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/8985770 Staphylococcus aureus isolated from Brazilian university hospitals. Nasal and cutaneous carriage of Staphylococcus aureus in MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/8985768 hemodialysis patients: the effect of nasal mupirocin. Cost-effectiveness of perioperative mupirocin nasal ointment in MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/8985764 cardiothoracic surgery. Blanket use of intranasal mupirocin for outbreak control and long- MUPIROCIN term prophylaxis of endemic methicillin-resistant Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/8744510 aureus in an open ward. Clinical and economic effects of mupirocin calcium on preventing MUPIROCIN Staphylococcus aureus infection in hemodialysis patients: a decision https://www.ncbi.nlm.nih.gov/pubmed/8629629 analysis. MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/8746621 An open study of mupirocin in Libyan patients with skin infections. Mupirocin resistance in coagulase-negative staphylococci, after MUPIROCIN topical prophylaxis for the reduction of colonization of central venous https://www.ncbi.nlm.nih.gov/pubmed/8586787 catheters. Mupirocin ointment with and without chlorhexidine baths in the MUPIROCIN eradication of Staphylococcus aureus nasal carriage in nursing home https://www.ncbi.nlm.nih.gov/pubmed/8585642 residents. Comparative study of mupirocin and oral co-trimoxazole plus topical MUPIROCIN fusidic acid in eradication of nasal carriage of methicillin-resistant https://www.ncbi.nlm.nih.gov/pubmed/7695302 Staphylococcus aureus. Medication Title of Article PubMed Link Mupirocin resistance: clinical and molecular epidemiology. [Review] MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/7657989 [45 refs] Reduction in Staphylococcus aureus wound colonization using nasal MUPIROCIN mupirocin and selective decontamination of the digestive tract in https://www.ncbi.nlm.nih.gov/pubmed/8198735 extensive burns. Long-term efficacy of intranasal mupirocin ointment. A prospective MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/8018006 cohort study of Staphylococcus aureus carriage. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/7999817 infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage. The efficacy of intranasal mupirocin in the prevention of MUPIROCIN staphylococcal infections: a review of recent experience. [Review] [70 https://www.ncbi.nlm.nih.gov/pubmed/7930545 refs] Comparison of mupirocin susceptibility of nasal and nonnasal MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/7874886 Staphylococcus aureus isolates. MUPIROCIN Intranasal mupirocin. https://www.ncbi.nlm.nih.gov/pubmed/7852737 Staphylococcus aureus infection in haemodialysis patients. Mupirocin MUPIROCIN as a topical strategy against nasal carriage: a review. [Review] [38 https://www.ncbi.nlm.nih.gov/pubmed/7799051 refs] Cost-effectiveness of erythromycin versus mupirocin for the MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1734386 treatment of impetigo in children. Stability of mupirocin ointment (Bactroban) admixed with other MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1639880 proprietary dermatological products.

Double-blind study comparing erythromycin and mupirocin for MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1605593 treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Prevention of post-excisional wound infections: a comparison of oral MUPIROCIN cephalexin with topical mupirocin and topical cetrimide-chlorhexidine https://www.ncbi.nlm.nih.gov/pubmed/1587669 cream. Comparison of the in-vitro activities of the topical antimicrobials MUPIROCIN azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin https://www.ncbi.nlm.nih.gov/pubmed/1506349 against methicillin-resistant Staphylococcus aureus. Medication Title of Article PubMed Link Review of mupirocin ointment in the treatment of impetigo. [Review] MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1468173 [40 refs] MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1446090 Perianal streptococcal cellulitis: treatment with topical mupirocin. Treatment of Staphylococcus aureus nasal carriers in CAPD with MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1361797 mupirocin. Minimal dose requirements for nasal mupirocin and its role in the MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1684191 control of epidemic MRSA. MUPIROCIN Overview of the role of mupirocin. [Review] [26 refs] https://www.ncbi.nlm.nih.gov/pubmed/1684188

MUPIROCIN Efficacy of mupirocin nasal ointment in eradicating Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/1674259 aureus nasal carriage in chronic haemodialysis patients.

MUPIROCIN Eradication of colonization by methicillin-resistant Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/1929333 aureus by using oral -rifampin and topical mupirocin. Topical 2% mupirocin versus 2% sodium fusidate ointment in the MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1907980 treatment of primary and secondary skin infections.

MUPIROCIN Elimination of coincident Staphylococcus aureus nasal and hand https://www.ncbi.nlm.nih.gov/pubmed/1898585 carriage with intranasal application of mupirocin calcium ointment. The efficacy of calcium mupirocin in the eradication of nasal MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/1810357 Staphylococcus aureus carriage. Nasal carriage of MRSA: the role of mupirocin and outlook for MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2129029 resistance. [Review] [56 refs] Topical Bactroban (mupirocin): efficacy in treating burn wounds MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2123203 infected with methicillin-resistant staphylococci. Mupirocin-resistant Staphylococcus aureus after long-term treatment MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2112168 of patients with epidermolysis bullosa. MUPIROCIN Mupirocin: a new topical antibiotic. https://www.ncbi.nlm.nih.gov/pubmed/2112165 MUPIROCIN The clinical development of mupirocin. [Review] [17 refs] https://www.ncbi.nlm.nih.gov/pubmed/2112164 Nasal carriage of Staphylococcus aureus treated with topical MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2567303 mupirocin (pseudomonic acid) in a children's hospital.

MUPIROCIN Efficacy and safety of 2% mupirocin ointment in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/2516463 primary and secondary skin infections--an open multicentre trial. Medication Title of Article PubMed Link Comparative double-blinded study between mupirocin and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2510312 tetracycline ointments for treating skin infections. Efficacy of mupirocin in methicillin-resistant Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2508545 burn wound infection. Topical mupirocin treatment of impetigo is equal to oral erythromycin MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2502950 therapy. MUPIROCIN Mupirocin: a new topical therapy for impetigo. https://www.ncbi.nlm.nih.gov/pubmed/2502615 Topical 2% mupirocin versus 2% fusidic acid ointment in the MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2502567 treatment of primary and secondary skin infections. Impetigo contagiosa III. Comparative efficacy of oral erythromycin MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2501775 and topical mupirocin.

MUPIROCIN Topical antibiotics in the treatment of superficial skin infections in https://www.ncbi.nlm.nih.gov/pubmed/2501394 general practice--a comparison of mupirocin with sodium fusidate. Mupirocin (2 percent) ointment in the treatment of primary and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2501071 secondary skin infections. Randomized clinical trial of topical mupirocin versus oral MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3149884 erythromycin for impetigo. MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3148127 Topical mupirocin vs. systemic erythromycin treatment for pyoderma.

MUPIROCIN Elimination of nasal carriage of methicillin-resistant Staphylococcus https://www.ncbi.nlm.nih.gov/pubmed/3141347 aureus with mupirocin during a hospital outbreak. Staphylococcal colonization in atopic dermatitis and the effect of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3139019 topical mupirocin therapy. Eradication of low-level methicillin-resistant Staphylococcus aureus MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3136203 skin colonization with topical mupirocin. MUPIROCIN Mupirocin--a new topical antibiotic. https://www.ncbi.nlm.nih.gov/pubmed/3129636 An evaluation of topical mupirocin in moderately severe primary and MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3127257 secondary skin infections. Topical mupirocin versus topical neosporin in the treatment of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/2851560 cutaneous infections. Mupirocin: a topical antibiotic with a unique structure and mechanism MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3146455 of action. [Review] [46 refs] Medication Title of Article PubMed Link Topical mupirocin versus oral erythromycin in the treatment of MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3115904 primary and secondary skin infections. MUPIROCIN Comment: topical mupirocin. https://www.ncbi.nlm.nih.gov/pubmed/3107962 Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3104272 agent. [Review] [45 refs] An outbreak of infection with a methicillin-resistant Staphylococcus MUPIROCIN aureus in a special care baby unit: value of topical mupirocin and of https://www.ncbi.nlm.nih.gov/pubmed/2889764 traditional methods of infection control. Topical mupirocin in the treatment of bacterial skin infections. MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3102197 [Review] [23 refs] A comparison of the new topical antibiotic mupirocin ('Bactroban') MUPIROCIN with oral antibiotics in the treatment of skin infections in general https://www.ncbi.nlm.nih.gov/pubmed/3102167 practice. Mupirocin. A review of its antibacterial activity, pharmacokinetic MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3098541 properties and therapeutic use. [Review] [86 refs] MUPIROCIN Topical antibiotic treatment of impetigo with mupirocin. https://www.ncbi.nlm.nih.gov/pubmed/3096221 Clinical and bacteriological efficacy of mupirocin (Bactroban): a new MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3090486 topical antibiotic. Elimination of nasal carriage of Staphylococcus aureus with MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3084442 mupirocin ('pseudomonic acid')--a controlled trial. In-vitro activity of mupirocin ('pseudomonic acid') against clinical MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3924877 isolates of Staphylococcus aureus. Antibacterial activity of mupirocin (pseudomonic acid), a new MUPIROCIN https://www.ncbi.nlm.nih.gov/pubmed/3923922 antibiotic for topical use. The effect of intraoperative mupirocin irrigation on Staphylococcus MUPIROCIN http://www.ncbi.nlm.nih.gov/pubmed/23192968 aureus within the maxillary sinus. A randomized trial of mupirocin sinonasal rinses versus saline in MUPIROCIN http://www.ncbi.nlm.nih.gov/pubmed/22865576 surgically recalcitrant staphylococcal chronic rhinosinusitis. Microbiological outcomes following mupirocin nasal washes for MUPIROCIN symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis http://www.ncbi.nlm.nih.gov/pubmed/22170745 following endoscopic sinus surgery. Nasal lavage with mupirocin for the treatment of surgically MUPIROCIN http://www.ncbi.nlm.nih.gov/pubmed/18545212 recalcitrant chronic rhinosinusitis. Medication Title of Article PubMed Link

MUPIROCIN In vitro activity of mupirocin on clinical isolates of Staphylococcus http://www.ncbi.nlm.nih.gov/pubmed/18090864 aureus and its potential implications in chronic rhinosinusitis. A randomized clinical trial of mupirocin in the eradication of MUPIROCIN Staphylococcus aureus nasal carriage in human immunodeficiency http://www.ncbi.nlm.nih.gov/pubmed/10438389 virus disease. MUPIROCIN In vitro Antimicrobial Activity of SinuSurf™. http://www.ncbi.nlm.nih.gov/pubmed/22814356 Dose-ranging study to assess the application of intranasal 2% MUPIROCIN mupirocin calcium ointment to eradicate Staphylococcus aureus http://www.ncbi.nlm.nih.gov/pubmed/23448592 nasal colonization. http://houstontx.library.ingentaconnect.com/content/o MUPIROCIN The effect of maxillary sinus irrigation on early prognostic factors cean/ajra/2013/00000027/00000005/art00007 after endoscopic sinus surgery: A preliminary study Evidence-based recommendations for antimicrobial nasal washes in MUPIROCIN http://www.ncbi.nlm.nih.gov/pubmed/?term=16539286 chronic rhinosinusitis. A diclofenac -nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding http://www.ncbi.nlm.nih.gov/pubmed/23225308 NABUMETONE capacity of HSA site II in rheumatoid arthritis. Utility of Naltrexone Treatment for Chronic Inflammatory https://www.ncbi.nlm.nih.gov/pubmed/30484835 NALTREXONE Dermatologic Conditions: A Systematic Review. Topical Naltrexone as Treatment for Type 2 Diabetic Cutaneous https://www.ncbi.nlm.nih.gov/pubmed/24940556 NALTREXONE Wounds. NALTREXONE Uremic pruritus. https://www.ncbi.nlm.nih.gov/pubmed/24402092 Investigating endogenous micro -opioid receptors in human keratinocytes as pharmacological targets using novel fluorescent https://www.ncbi.nlm.nih.gov/pubmed/29211767 NALTREXONE ligand. NALTREXONE Diabetic complications in the cornea. https://www.ncbi.nlm.nih.gov/pubmed/28404521 Topical Naltrexone Is a Safe and Effective Alternative to Standard https://www.ncbi.nlm.nih.gov/pubmed/28894635 NALTREXONE Treatment of Diabetic Wounds. Diagnosis and Management of Chronic Pruritus: An Expert https://www.ncbi.nlm.nih.gov/pubmed/28216719 NALTREXONE Consensus Review. Topical Application of Naltrexone to the Ocular Surface of Healthy https://www.ncbi.nlm.nih.gov/pubmed/26741052 NALTREXONE Volunteers: A Tolerability Study. Pharmacological interventions for pruritus in adult palliative care https://www.ncbi.nlm.nih.gov/pubmed/23749733 NALTREXONE patients. Medication Title of Article PubMed Link New therapeutic approaches in the treatment of diabetic keratopathy: https://www.ncbi.nlm.nih.gov/pubmed/20973888 NALTREXONE a review. Preparation of niosomes as an ocular delivery system for naltrexone https://www.ncbi.nlm.nih.gov/pubmed/21155387 NALTREXONE hydrochloride: physicochemical characterization. Therapeutic hotline: Treatment of prurigo nodularis and lichen https://www.ncbi.nlm.nih.gov/pubmed/20415827 NALTREXONE simplex chronicus with gabapentin. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a https://www.ncbi.nlm.nih.gov/pubmed/19683562 NALTREXONE review. [Review] [136 refs] NALTREXONE Post herpetic neuralgia, schwann cell activation and vitamin D. https://www.ncbi.nlm.nih.gov/pubmed/19635651 Treatment of pruritus with topically applied opiate receptor https://www.ncbi.nlm.nih.gov/pubmed/17320241 NALTREXONE antagonist. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy https://www.ncbi.nlm.nih.gov/pubmed/16574034 NALTREXONE volunteers. Transdermal delivery of naltrexone and its active metabolite 6-beta- https://www.ncbi.nlm.nih.gov/pubmed/16052561 NALTREXONE naltrexol in human skin in vitro and guinea pigs in vivo. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a https://www.ncbi.nlm.nih.gov/pubmed/15736197 NALTREXONE human skin equivalent. Reepithelialization of the human cornea is regulated by endogenous https://www.ncbi.nlm.nih.gov/pubmed/10634604 NALTREXONE opioids. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a http://www.ncbi.nlm.nih.gov/pubmed/20042414 NALTREXONE report of 3 new cases

Low-dose naltrexone effects on plasma chemistries and clinical http://www.ncbi.nlm.nih.gov/pubmed/8570775 NALTREXONE symptoms in autism: a double-blind, placebo-controlled study Long-term remission of adenoid cystic tongue carcinoma with low http://www.ncbi.nlm.nih.gov/pubmed/25284545 NALTREXONE dose naltrexone and vitamin D3--a case report The use of low-dose naltrexone (LDN) as a novel anti-inflammatory http://www.ncbi.nlm.nih.gov/pubmed/24526250 NALTREXONE treatment for chronic pain Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, http://www.ncbi.nlm.nih.gov/pubmed/23359310 NALTREXONE counterbalanced, crossover trial assessing daily pain levels Medication Title of Article PubMed Link Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, http://www.ncbi.nlm.nih.gov/pubmed/18027539 NALTREXONE double-blind, prospective pilot study http://www.ncbi.nlm.nih.gov/pubmed/17685875 NALTREXONE Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation http://www.ncbi.nlm.nih.gov/pubmed/24967470 NALTREXONE Off-label, low-dose naltrexone for refractory chronic low back pain NALTREXONE High-dose naltrexone therapy for cocaine-alcohol dependence http://www.ncbi.nlm.nih.gov/pubmed/19874153 Safety and tolerability of low-dose naltrexone therapy in children with http://www.ncbi.nlm.nih.gov/pubmed/23188075 NALTREXONE moderate to severe Crohn's disease: a pilot study NALTREXONE Low-dose naltrexone therapy improves active Crohn's disease http://www.ncbi.nlm.nih.gov/pubmed/17222320 http://www.ncbi.nlm.nih.gov/pubmed/24558033 NALTREXONE Low dose naltrexone for induction of remission in Crohn's disease http://www.ncbi.nlm.nih.gov/pubmed/25421416 NALTREXONE Low dose naltrexone in the treatment of dissociative symptoms Is Fibromyalgia An Endocrine/Endorphin Deficit Disorder? Is Low http://www.ncbi.nlm.nih.gov/pubmed/22480625 NALTREXONE Dose Naltrexone a New Treatment Option? Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot http://www.ncbi.nlm.nih.gov/pubmed/19453963 NALTREXONE study Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal http://www.ncbi.nlm.nih.gov/pubmed/23965429 NALTREXONE Disorders Low-dose naltreoxone for the treatment of irritable bowel syndrome: http://www.ncbi.nlm.nih.gov/pubmed/17080248 NALTREXONE a pilot study NALTREXONE Low dose naltrexone therapy in multiple sclerosis http://www.ncbi.nlm.nih.gov/pubmed/15694688 Low Dose Naltrexone for Treatment of Multiple Sclerosis: A http://www.ncbi.nlm.nih.gov/pubmed/26203498 NALTREXONE Retrospective Chart Review of Safety and Tolerability Pilot trial of low-dose naltrexone and quality of life in multiple http://www.ncbi.nlm.nih.gov/pubmed/20695007 NALTREXONE sclerosis

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic http://www.ncbi.nlm.nih.gov/pubmed/18468954 NALTREXONE pain and associated mu-opioid receptor-Gs coupling Ultra-Low Dose Oral Naltrexone Decreases Side Effects and http://www.ncbi.nlm.nih.gov/pubmed/12782427 NALTREXONE Potentiates the Effect of Methadone Effectiveness of low-dose naltrexone in the post-detoxification http://www.ncbi.nlm.nih.gov/pubmed/17873678 NALTREXONE treatment of opioid dependence Medication Title of Article PubMed Link Problem drinking and low-dose naltrexone-assisted opioid http://www.ncbi.nlm.nih.gov/pubmed/21513688 NALTREXONE detoxification

Does adding low doses of oral naltrexone to morphine alter the http://www.ncbi.nlm.nih.gov/pubmed/21075578 NALTREXONE subsequent opioid requirements and side effects in trauma patients? NALTREXONE Low-dose naltrexone for pruritus in systemic sclerosis http://www.ncbi.nlm.nih.gov/pubmed/21918649 Combined varenicline and naltrexone treatment reduces smoking http://www.ncbi.nlm.nih.gov/pubmed/25933795 NALTREXONE topography intensity in heavy-drinking smokers Varenicline, low dose naltrexone, and their combination for heavy- http://www.ncbi.nlm.nih.gov/pubmed/24733235 NALTREXONE drinking smokers: human laboratory findings Smoking and opioid detoxification: behavioral changes and response http://www.ncbi.nlm.nih.gov/pubmed/23572466 NALTREXONE to treatment Topical Application of Naltrexone to the Ocular Surface of Healthy http://www.ncbi.nlm.nih.gov/pubmed/26741052 NALTREXONE Volunteers: A Tolerability Study

Effect of once daily topical 0.3% naltrexone on tear parameters and http://www.ncbi.nlm.nih.gov/pubmed/25675975 corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: NALTREXONE a double-masked randomized placebo-controlled clinical trial Perceptions of extended-release naltrexone, methadone, and https://pubmed.ncbi.nlm.nih.gov/31570100 NALTREXONE buprenorphine treatments following release from jail. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does https://pubmed.ncbi.nlm.nih.gov/30926131 NALTREXONE Not Inhibit Ketamine's Antidepressant Activity.

Psychiatric adverse events and effects on mood with prolonged- https://pubmed.ncbi.nlm.nih.gov/30664661 NALTREXONE release naltrexone/bupropion combination therapy: a pooled analysis. https://pubmed.ncbi.nlm.nih.gov/31337235 NALTREXONE Naltrexone for the Treatment of Darier and Hailey-Hailey Diseases. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, https://pubmed.ncbi.nlm.nih.gov/31448846 NALTREXONE Placebo-Controlled Study. Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding https://pubmed.ncbi.nlm.nih.gov/31453628 NALTREXONE to Naltrexone Treatment. Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of https://pubmed.ncbi.nlm.nih.gov/31340204 NALTREXONE a Randomized Clinical Trial. Medication Title of Article PubMed Link Low-dose naltrexone: a novel adjunctive treatment in symptomatic https://pubmed.ncbi.nlm.nih.gov/31553867 NALTREXONE alopecias? Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled https://pubmed.ncbi.nlm.nih.gov/31206155 NALTREXONE Naltrexone Trial. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain https://pubmed.ncbi.nlm.nih.gov/30917675 NALTREXONE Syndromes. [Review] Hydrogels for diabetic eyes: Naltrexone loading, release profiles and https://pubmed.ncbi.nlm.nih.gov/31546391 NALTREXONE cornea penetration.

Extended-release morphine sulfate and naltrexone hydrochloride https://pubmed.ncbi.nlm.nih.gov/30293449 (EMBEDA): naltrexone-associated withdrawal and abuse-related NALTREXONE effects in patients with chronic pain and recreational opioid users. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized https://pubmed.ncbi.nlm.nih.gov/30451013 NALTREXONE controlled trials. Use of low-dose naltrexone in the treatment of severe Hailey-Hailey https://pubmed.ncbi.nlm.nih.gov/30958613 NALTREXONE disease: One case report. Low-dose naltrexone: a unique treatment for amyopathic https://pubmed.ncbi.nlm.nih.gov/31329393 NALTREXONE dermatomyositis. Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding https://pubmed.ncbi.nlm.nih.gov/31849032 NALTREXONE sequestered naltrexone. Low-dose naltrexone therapy in benign chronic pemphigus (Hailey- https://pubmed.ncbi.nlm.nih.gov/31002846 NALTREXONE Hailey disease): A case series. Should Long-Acting Depot Intramuscular Naltrexone Be Prescribed https://pubmed.ncbi.nlm.nih.gov/31106994 NALTREXONE Every 3 Weeks for Alcohol Use Disorder?.

Extended-release naltrexone (XR-NTX) for opioid use disorder in https://pubmed.ncbi.nlm.nih.gov/29493836 NALTREXONE clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Extended-release injectable naltrexone for opioid use disorder: a https://pubmed.ncbi.nlm.nih.gov/29396985 NALTREXONE systematic review. Variable response to low-dose naltrexone in patients with Darier https://pubmed.ncbi.nlm.nih.gov/30712317 NALTREXONE disease: a case series. Medication Title of Article PubMed Link Naltrexone and alcohol effects on craving for cigarettes in heavy https://pubmed.ncbi.nlm.nih.gov/30628813 NALTREXONE drinking smokers. Naltrexone ameliorates functional network abnormalities in alcohol- https://pubmed.ncbi.nlm.nih.gov/28247526 NALTREXONE dependent individuals. Effects of naltrexone on alcohol self-administration and craving: meta- https://pubmed.ncbi.nlm.nih.gov/27411969 NALTREXONE analysis of human laboratory studies. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model https://pubmed.ncbi.nlm.nih.gov/30852374 NALTREXONE therapeutic workplace: A randomized trial. Naltrexone extended-release plus bupropion extended-release for https://pubmed.ncbi.nlm.nih.gov/25803343 NALTREXONE treatment of obesity. Effect of combined naltrexone and bupropion therapy on the brain's https://pubmed.ncbi.nlm.nih.gov/23924756 NALTREXONE reactivity to food cues. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States https://pubmed.ncbi.nlm.nih.gov/31082666 NALTREXONE commercially insured cohort. Naltrexone alters responses to social and physical warmth: https://pubmed.ncbi.nlm.nih.gov/30976797 NALTREXONE implications for social bonding. Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid https://pubmed.ncbi.nlm.nih.gov/30690502 NALTREXONE Use Disorder.

Serious adverse events reported in placebo randomised controlled https://pubmed.ncbi.nlm.nih.gov/30642329 NALTREXONE trials of oral naltrexone: a systematic review and meta-analysis. Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol https://pubmed.ncbi.nlm.nih.gov/30624551 NALTREXONE Use Disorder. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs https://pubmed.ncbi.nlm.nih.gov/30566177 Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up NALTREXONE Study. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended- https://pubmed.ncbi.nlm.nih.gov/30557443 NALTREXONE Release Naltrexone to Prevent Opioid Relapse. Medication Title of Article PubMed Link Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release https://pubmed.ncbi.nlm.nih.gov/30522048 NALTREXONE naltrexone compared to treatment as usual. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral https://pubmed.ncbi.nlm.nih.gov/30336703 NALTREXONE Therapy, for the Treatment of Opioid Use Disorder. Effects of extended-release naltrexone on the brain response to drug- https://pubmed.ncbi.nlm.nih.gov/29947607 NALTREXONE related stimuli in patients with opioid use disorder. The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria: A Double-Blind, Placebo-Controlled https://pubmed.ncbi.nlm.nih.gov/29617066 NALTREXONE Trial of Naltrexone. Open-label pilot study of injectable naltrexone for cannabis https://pubmed.ncbi.nlm.nih.gov/29420073 NALTREXONE dependence.

Phosphatidylethanol in Comparison to Self-Reported Alcohol https://pubmed.ncbi.nlm.nih.gov/29080351 Consumption Among HIV-Infected Women in a Randomized NALTREXONE Controlled Trial of Naltrexone for Reducing Hazardous Drinking. Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the https://pubmed.ncbi.nlm.nih.gov/28640990 NALTREXONE Mixed Opioid Receptor Antagonist Naltrexone. Effects of naltrexone are influenced by childhood adversity during https://pubmed.ncbi.nlm.nih.gov/28267152 NALTREXONE negative emotional processing in addiction recovery. Randomized controlled trial of a mobile phone intervention for https://pubmed.ncbi.nlm.nih.gov/25909320 NALTREXONE improving adherence to naltrexone for alcohol use disorders. Effects of alcohol availability, access to alcohol, and naltrexone on self-reported craving and patterns of drinking in response to an https://pubmed.ncbi.nlm.nih.gov/22333328 NALTREXONE alcohol-cue availability procedure.

Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no https://pubmed.ncbi.nlm.nih.gov/19365548 NALTREXONE evidence for endogenous opioid pathophysiology. Oral naltrexone maintenance treatment for opioid dependence. https://pubmed.ncbi.nlm.nih.gov/21491383 NALTREXONE [Review] Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a https://pubmed.ncbi.nlm.nih.gov/29150198 NALTREXONE multicentre, open-label, randomised controlled trial. Medication Title of Article PubMed Link Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized https://pubmed.ncbi.nlm.nih.gov/29049469 NALTREXONE Clinical Noninferiority Trial. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized- https://pubmed.ncbi.nlm.nih.gov/30073637 NALTREXONE Controlled Trial.

Changes in murine respiratory dynamics induced by aerosolized https://pubmed.ncbi.nlm.nih.gov/31539569 NALTREXONE carfentanil inhalation: Efficacy of naloxone and naltrexone. Update on drug safety evaluation of naltrexone/bupropion for the https://pubmed.ncbi.nlm.nih.gov/31092063 NALTREXONE treatment of obesity. Physicochemical Stability of Compounded Naltrexone Hydrochloride https://pubmed.ncbi.nlm.nih.gov/31085781 NALTREXONE Solutions in PCCA Base SuspendIt. NALTREXONE Low Dose Naltrexone in Dermatology. https://pubmed.ncbi.nlm.nih.gov/30909326 Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic https://pubmed.ncbi.nlm.nih.gov/30894239 NALTREXONE skin response for monitoring. Naltrexone Therapy for Hailey-Hailey Disease: Confirming My https://pubmed.ncbi.nlm.nih.gov/30888948 NALTREXONE Addiction to Evidence-Based Medicine. Therapeutic Drug Monitoring and the Clinical Significance of Naltrexone Blood Levels at the Time of a First Drink: Relevance to https://pubmed.ncbi.nlm.nih.gov/30861062 NALTREXONE the Sinclair Method. A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone https://pubmed.ncbi.nlm.nih.gov/30848965 NALTREXONE or sublingual buprenorphine. Study on structural insight of the analysis of negative effects of https://pubmed.ncbi.nlm.nih.gov/30829214 NALTREXONE opioids in naltrexone with TLR4 Mutations. NALTREXONE The uses of naltrexone in dermatologic conditions. [Review] https://pubmed.ncbi.nlm.nih.gov/30582992 Utility of Naltrexone Treatment for Chronic Inflammatory https://pubmed.ncbi.nlm.nih.gov/30484835 NALTREXONE Dermatologic Conditions: A Systematic Review. Extended-release injectable naltrexone (XR-NTX): a response to https://pubmed.ncbi.nlm.nih.gov/30345640 NALTREXONE clinical issues raised by Brewer & Streel. Long-acting naltrexone has long-acting benefits and 100% induction https://pubmed.ncbi.nlm.nih.gov/30345573 NALTREXONE rates are not difficult to achieve. Medication Title of Article PubMed Link Therapeutic Drug Monitoring of Naltrexone and 6beta-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference https://pubmed.ncbi.nlm.nih.gov/30260366 NALTREXONE Ranges. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low https://pubmed.ncbi.nlm.nih.gov/30695679 NALTREXONE dose naltrexone. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or https://pubmed.ncbi.nlm.nih.gov/30384381 NALTREXONE Acamprosate, Using a Modeling Approach. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use https://pubmed.ncbi.nlm.nih.gov/30300800 NALTREXONE disorder. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine https://pubmed.ncbi.nlm.nih.gov/30266003 NALTREXONE use disorder. https://pubmed.ncbi.nlm.nih.gov/30246915 NALTREXONE Successful treatment of dermatomyositis with low-dose naltrexone. NALTREXONE Pregnancy and Naltrexone Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/30204703 Drinking goals and attainment in a naltrexone trial of young adult https://pubmed.ncbi.nlm.nih.gov/30138015 NALTREXONE heavy drinkers. Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder https://pubmed.ncbi.nlm.nih.gov/30124761 NALTREXONE Treatment During a Mobile Health Intervention. Adherence to extended release naltrexone: Patient and treatment https://pubmed.ncbi.nlm.nih.gov/30106489 NALTREXONE characteristics. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy. https://pubmed.ncbi.nlm.nih.gov/30092933 NALTREXONE [Review] Potential Risk Window for Opioid Overdose Related to Treatment https://pubmed.ncbi.nlm.nih.gov/30073490 NALTREXONE with Extended-Release Injectable Naltrexone.

Withdrawal severity and early response to treatment in the outpatient https://pubmed.ncbi.nlm.nih.gov/30028058 NALTREXONE transition from opioid use to extended release naltrexone. Compounded Low-dose Naltrexone for the Treatment of Guttate https://pubmed.ncbi.nlm.nih.gov/30021181 NALTREXONE Psoriasis: A Case Report. Medication Title of Article PubMed Link Extended-release naltrexone overlooked in opioid use disorders https://pubmed.ncbi.nlm.nih.gov/30012803 NALTREXONE guideline.

Comment on "Review of Case Narratives from Fatal Overdoses https://pubmed.ncbi.nlm.nih.gov/29956220 NALTREXONE Associated with Injectable Naltrexone for Opioid Dependence". Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with https://pubmed.ncbi.nlm.nih.gov/29956219 NALTREXONE Injectable Naltrexone for Opioid Dependence". Low-dose naltrexone (LDN): A promising treatment in immune- https://pubmed.ncbi.nlm.nih.gov/29885638 NALTREXONE related diseases and cancer therapy. [Review] The Use and Utility of Low-dose Naltrexone Capsules for Patients https://pubmed.ncbi.nlm.nih.gov/29878893 NALTREXONE with Fibromyalgia. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders https://pubmed.ncbi.nlm.nih.gov/29781884 Transitioning to the Community: Results From a Double-Blind, NALTREXONE Placebo-Controlled Trial. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, https://pubmed.ncbi.nlm.nih.gov/29744741 NALTREXONE 2D6, and 3A4 Activity in Human Liver Microsomes.

Outpatient transition to extended-release injectable naltrexone for https://pubmed.ncbi.nlm.nih.gov/29674251 NALTREXONE patients with opioid use disorder: A phase 3 randomized trial. Low dose naltrexone for induction of remission in Crohn's disease. https://pubmed.ncbi.nlm.nih.gov/29607497 NALTREXONE [Review] Review of Case Narratives from Fatal Overdoses Associated with https://pubmed.ncbi.nlm.nih.gov/29560596 NALTREXONE Injectable Naltrexone for Opioid Dependence. Effect of combined naltrexone and bupropion therapy on the brain's https://pubmed.ncbi.nlm.nih.gov/29535451 NALTREXONE functional connectivity. Low dose Naltrexone for induction of remission in inflammatory bowel https://pubmed.ncbi.nlm.nih.gov/29523156 NALTREXONE disease patients. Compulsive Sexual Behaviors Treated With Naltrexone https://pubmed.ncbi.nlm.nih.gov/29469239 NALTREXONE Monotherapy. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco https://pubmed.ncbi.nlm.nih.gov/29438157 NALTREXONE Users: A Preliminary Laboratory Study. Medication Title of Article PubMed Link Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone https://pubmed.ncbi.nlm.nih.gov/29431852 NALTREXONE in the Treatment of Alcohol Dependence. Real-time assessment of alcohol craving and naltrexone treatment https://pubmed.ncbi.nlm.nih.gov/29395188 NALTREXONE responsiveness in a randomized clinical trial.

The Safety and Efficacy of Low-Dose Naltrexone in the Management https://pubmed.ncbi.nlm.nih.gov/29377216 of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, NALTREXONE Crohn's Disease, and Other Chronic Pain Disorders. [Review] Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders https://pubmed.ncbi.nlm.nih.gov/29373393 Transitioning to the Community: Results of a Double-Blind, Placebo- NALTREXONE Controlled Randomized Trial. Implementation of a Process for Initiating Naltrexone in Patients https://pubmed.ncbi.nlm.nih.gov/29364992 NALTREXONE Hospitalized for Alcohol Detoxification or Withdrawal. Variable Response to Naltrexone in Patients With Hailey-Hailey https://pubmed.ncbi.nlm.nih.gov/29344611 NALTREXONE Disease. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and https://pubmed.ncbi.nlm.nih.gov/29326369 NALTREXONE antibiotic treatment. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in https://pubmed.ncbi.nlm.nih.gov/29324253 NALTREXONE U.S. office-based practices.

Effectiveness, Implementation and Real-World Experience with https://pubmed.ncbi.nlm.nih.gov/29273249 NALTREXONE Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian https://pubmed.ncbi.nlm.nih.gov/29265379 NALTREXONE Descent: Human Laboratory Findings from a Randomized Trial.

The Long-Term Survival of a Patient With Stage IV Renal Cell https://pubmed.ncbi.nlm.nih.gov/29258346 Carcinoma Following an Integrative Treatment Approach Including NALTREXONE the Intravenous alpha-Lipoic Acid/Low-Dose Naltrexone Protocol. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the https://pubmed.ncbi.nlm.nih.gov/29245103 NALTREXONE Veterans Health Administration. Medication Title of Article PubMed Link Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in https://pubmed.ncbi.nlm.nih.gov/29220529 NALTREXONE a Boy Post-Craniopharyngioma Resection. Effectiveness of extended release naltrexone to reduce alcohol https://pubmed.ncbi.nlm.nih.gov/29174308 NALTREXONE cravings and use behaviors during treatment and at follow-up. Low-threshold extended-release naltrexone for high utilizers of public https://pubmed.ncbi.nlm.nih.gov/29150316 NALTREXONE services with severe alcohol use disorder: A pilot study. NALTREXONE Extended-release naltrexone: good but not a panacea. https://pubmed.ncbi.nlm.nih.gov/29150200 https://pubmed.ncbi.nlm.nih.gov/28991360 NALTREXONE Low-dose naltrexone: a novel treatment for Hailey-Hailey disease. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo- https://pubmed.ncbi.nlm.nih.gov/28734107 NALTREXONE controlled trial.

Injectable naltrexone, oral naltrexone, and buprenorphine utilization https://pubmed.ncbi.nlm.nih.gov/28733097 and discontinuation among individuals treated for opioid use disorder NALTREXONE in a United States commercially insured population.

Healthcare utilization in adults with opioid dependence receiving https://pubmed.ncbi.nlm.nih.gov/28576389 NALTREXONE extended release naltrexone compared to treatment as usual. Initiation of extended release naltrexone (XR-NTX) for opioid use https://pubmed.ncbi.nlm.nih.gov/28527855 NALTREXONE disorder prior to release from prison. Barriers to initiation of extended release naltrexone among HIV- https://pubmed.ncbi.nlm.nih.gov/28527854 NALTREXONE infected adults with alcohol use disorders. Extended-release naltrexone for opioid use disorder started during or https://pubmed.ncbi.nlm.nih.gov/28479011 NALTREXONE following incarceration. Relapse to opioid use disorder after inpatient treatment: Protective https://pubmed.ncbi.nlm.nih.gov/28473233 NALTREXONE effect of injection naltrexone. Predictors of induction onto extended-release naltrexone among https://pubmed.ncbi.nlm.nih.gov/28449955 NALTREXONE unemployed heroin-dependent adults. NALTREXONE Low Dose Naltrexone in the Treatment of Fibromyalgia. https://pubmed.ncbi.nlm.nih.gov/28325149 The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los https://pubmed.ncbi.nlm.nih.gov/28291571 NALTREXONE Angeles County (2010-2015). Extended-release naltrexone and drug treatment courts: Policy and https://pubmed.ncbi.nlm.nih.gov/28274648 NALTREXONE evidence for implementing an evidence-based treatment. Medication Title of Article PubMed Link Do patient characteristics moderate the effect of extended-release https://pubmed.ncbi.nlm.nih.gov/28236511 NALTREXONE naltrexone (XR-NTX) for opioid use disorder?. Factors associated with using opiates while under extended-release https://pubmed.ncbi.nlm.nih.gov/28161142 NALTREXONE naltrexone blockade: A descriptive pilot study. Detection of naltrexone and naltrexol in patients prescribed Embeda https://pubmed.ncbi.nlm.nih.gov/29441516 NALTREXONE R.

Naltrexone and Disulfiram Treatment Response in Veterans With https://pubmed.ncbi.nlm.nih.gov/29345864 NALTREXONE Alcohol Dependence and Co-Occurring Problem-Gambling Features. https://pubmed.ncbi.nlm.nih.gov/29141063 NALTREXONE Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris. NALTREXONE Naltrexone/bupropion for obesity. [Review] https://pubmed.ncbi.nlm.nih.gov/29117992 Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release https://pubmed.ncbi.nlm.nih.gov/29041942 oxycodone and sequestered naltrexone) for moderate-to-severe NALTREXONE chronic low back pain. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or https://pubmed.ncbi.nlm.nih.gov/28918581 Obese Subjects with Major Depressive Disorder in an Open-Label, NALTREXONE Uncontrolled Study. Naltrexone for Self-Injury in Borderline Personality With Venlafaxine- https://pubmed.ncbi.nlm.nih.gov/28891834 NALTREXONE Associated Hyponatremia. Naltrexone in the Treatment of Broadly Defined Behavioral Addictions: A Review and Meta-Analysis of Randomized Controlled https://pubmed.ncbi.nlm.nih.gov/28877518 NALTREXONE Trials. [Review] Ultra-Low Doses of Naltrexone Enhance the Antiallodynic Effect of https://pubmed.ncbi.nlm.nih.gov/28868795 NALTREXONE Pregabalin or Gabapentin in Neuropathic Rats. Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat https://pubmed.ncbi.nlm.nih.gov/28806388 NALTREXONE It With... More Buprenorphine. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus https://pubmed.ncbi.nlm.nih.gov/28768314 NALTREXONE (Hailey-Hailey Disease). https://pubmed.ncbi.nlm.nih.gov/28768313 NALTREXONE Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. Featured Article: Serum [Met5]-enkephalin levels are reduced in https://pubmed.ncbi.nlm.nih.gov/28766982 NALTREXONE multiple sclerosis and restored by low-dose naltrexone. Medication Title of Article PubMed Link Gambling Disorder and Concurrent Alcohol Use Disorder Treated https://pubmed.ncbi.nlm.nih.gov/28742957 NALTREXONE With Naltrexone. Efficacy of Naltrexone for the Treatment of Alcohol Dependence in https://pubmed.ncbi.nlm.nih.gov/28728646 NALTREXONE Latino Populations. Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study https://pubmed.ncbi.nlm.nih.gov/28642209 NALTREXONE design challenges and pilot study results.

Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use https://pubmed.ncbi.nlm.nih.gov/28628701 NALTREXONE Disorder Among Adolescents and Young Adults, 2001-2014. Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans https://pubmed.ncbi.nlm.nih.gov/28605827 with Alcohol Use Disorder: A Randomized Pilot Proof-of-Concept NALTREXONE Study. Perioperative Pain Management of a Patient Taking Naltrexone https://pubmed.ncbi.nlm.nih.gov/28604472 NALTREXONE HCl/Bupropion HCl (Contrave): A Case Report. Methadone, Buprenorphine, and Naltrexone for the Treatment of https://pubmed.ncbi.nlm.nih.gov/28543191 NALTREXONE Opioid Use Disorder in Pregnant Women. [Review] A Retrospective Cohort Study of Obstetric Outcomes in Opioid- Dependent Women Treated with Implant Naltrexone, Oral https://pubmed.ncbi.nlm.nih.gov/28536980 Methadone or Sublingual Buprenorphine, and Non-Dependent NALTREXONE Controls. A Comparison of Sexual Side Effects of Antidepressants With and https://pubmed.ncbi.nlm.nih.gov/28481169 NALTREXONE Without Naltrexone.

Predictors of Naltrexone Response in a Randomized Trial: Reward- https://pubmed.ncbi.nlm.nih.gov/28409564 NALTREXONE Related Brain Activation, OPRM1 Genotype, and Smoking Status. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation https://pubmed.ncbi.nlm.nih.gov/28401564 NALTREXONE Treatment. Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking https://pubmed.ncbi.nlm.nih.gov/28379861 NALTREXONE Treatment: A Placebo-Controlled Trial. Medication Title of Article PubMed Link

Open-label Study of Injectable Extended-release Naltrexone (XR- https://pubmed.ncbi.nlm.nih.gov/28358754 NALTREXONE NTX) in Healthcare Professionals With Opioid Dependence. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with https://pubmed.ncbi.nlm.nih.gov/28357460 NALTREXONE methamphetamine use disorder. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the https://pubmed.ncbi.nlm.nih.gov/28334661 NALTREXONE community. Naltrexone in the treatment of binge eating disorder in a patient with https://pubmed.ncbi.nlm.nih.gov/28301250 NALTREXONE severe alcohol use disorder: a case report. A Systematic Review of Naltrexone for Attenuating Alcohol https://pubmed.ncbi.nlm.nih.gov/28247556 NALTREXONE Consumption in Women with Alcohol Use Disorders. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid https://pubmed.ncbi.nlm.nih.gov/28239984 NALTREXONE use disorder. Anhedonia to music and mu-opioids: Evidence from the https://pubmed.ncbi.nlm.nih.gov/28176798 NALTREXONE administration of naltrexone. Acute Generalized Erythrodermic Pustular Psoriasis Associated with https://pubmed.ncbi.nlm.nih.gov/28130024 NALTREXONE Bupropion/Naltrexone (Contrave R). Naltrexone for the treatment of comorbid tobacco and pornography https://pubmed.ncbi.nlm.nih.gov/28106937 NALTREXONE addiction.

Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Depots (CAM2038) Versus https://pubmed.ncbi.nlm.nih.gov/28070862 Intravenous and Sublingual Buprenorphine in Healthy Volunteers NALTREXONE Under Naltrexone Blockade: An Open-Label Phase 1 Study. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus https://pubmed.ncbi.nlm.nih.gov/28068780 NALTREXONE Buprenorphine. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility https://pubmed.ncbi.nlm.nih.gov/28061017 NALTREXONE randomized trial. Method-of-use study of naltrexone sustained release (SR)/bupropion https://pubmed.ncbi.nlm.nih.gov/28026920 NALTREXONE SR on body weight in individuals with obesity. Medication Title of Article PubMed Link Extended-release naltrexone for pre-release prisoners: A randomized https://pubmed.ncbi.nlm.nih.gov/28011389 NALTREXONE trial of medical mobile treatment. Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with https://pubmed.ncbi.nlm.nih.gov/27987236 NALTREXONE naltrexone. Effects of incentives for naltrexone adherence on opiate abstinence https://pubmed.ncbi.nlm.nih.gov/27936293 NALTREXONE in heroin-dependent adults. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder https://pubmed.ncbi.nlm.nih.gov/27736689 NALTREXONE on antidepressants. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and https://pubmed.ncbi.nlm.nih.gov/27732121 NALTREXONE phentermine-topiramate extended release. [Review] Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate- https://pubmed.ncbi.nlm.nih.gov/27550954 Release Oxycodone Administered Orally to Nondependent NALTREXONE Recreational Opioid Users. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate https://pubmed.ncbi.nlm.nih.gov/27480445 NALTREXONE and naltrexone. Low-Dose Naltrexone: A New Therapy Option for Complex Regional https://pubmed.ncbi.nlm.nih.gov/28333660 NALTREXONE Pain Syndrome Type I Patients. NALTREXONE Naltrexone-Associated Acute Pancreatitis. https://pubmed.ncbi.nlm.nih.gov/27922226 Guidelines and Quality Measures Should Reflect Evidence for https://pubmed.ncbi.nlm.nih.gov/27787292 NALTREXONE Effectiveness of Naltrexone. Influence of Naltrexone/Bupropion Combination Treatment on Body Mass Index in Prader-Willi Syndrome Re: "Prader-Willi Syndrome, https://pubmed.ncbi.nlm.nih.gov/27768385 Management of Impulsivity, and Hyperphagia in an Adolescent" by NALTREXONE Puri et al. A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical https://pubmed.ncbi.nlm.nih.gov/27692188 NALTREXONE Practice in Missouri. Daily relations among affect, urge, targeted naltrexone, and alcohol https://pubmed.ncbi.nlm.nih.gov/27690505 NALTREXONE use in young adults. Medication Title of Article PubMed Link Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone https://pubmed.ncbi.nlm.nih.gov/27687743 NALTREXONE treatment for opioid dependence. Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care https://pubmed.ncbi.nlm.nih.gov/27647699 NALTREXONE involving injectable naltrexone. Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: https://pubmed.ncbi.nlm.nih.gov/27627782 NALTREXONE A Randomized Clinical Trial. Naltrexone increases negatively-valenced facial responses to happy https://pubmed.ncbi.nlm.nih.gov/27588701 NALTREXONE faces in female participants. https://pubmed.ncbi.nlm.nih.gov/27561742 NALTREXONE Functional modulation on macrophage by low dose naltrexone (LDN). https://pubmed.ncbi.nlm.nih.gov/27538675 NALTREXONE Sweet taste pleasantness is modulated by morphine and naltrexone. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study https://pubmed.ncbi.nlm.nih.gov/27521809 NALTREXONE design and rationale. Naltrexone/Bupropion extended release-induced weight loss is https://pubmed.ncbi.nlm.nih.gov/27477337 NALTREXONE independent of nausea in subjects without diabetes. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release https://pubmed.ncbi.nlm.nih.gov/27436632 NALTREXONE naltrexone implant. NALTREXONE Interest in Extended Release Naltrexone among Opioid Users. https://pubmed.ncbi.nlm.nih.gov/27434137 Enhancement of Cisplatin Nephrotoxicity by Morphine and Its https://pubmed.ncbi.nlm.nih.gov/27424012 NALTREXONE Attenuation by the Opioid Antagonist Naltrexone. Reductions in Alcohol Craving Following Naltrexone Treatment for https://pubmed.ncbi.nlm.nih.gov/27402770 NALTREXONE Heavy Drinking. NALTREXONE Naltrexone: A Pan-Addiction Treatment?. [Review] https://pubmed.ncbi.nlm.nih.gov/27401883 Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis - https://pubmed.ncbi.nlm.nih.gov/27388713 NALTREXONE Comment to Naudet. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is https://pubmed.ncbi.nlm.nih.gov/27388712 NALTREXONE there a Spin?. Medication Title of Article PubMed Link

Utilizing a Two-stage Design to Investigate the Safety and Potential https://pubmed.ncbi.nlm.nih.gov/27379819 Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a NALTREXONE Treatment for Methamphetamine Use Disorder.

Investigating the KNDy Hypothesis in Humans by Coadministration of https://pubmed.ncbi.nlm.nih.gov/27379743 NALTREXONE Kisspeptin, Neurokinin B, and Naltrexone in Men. The relationship between early weight loss and weight loss at 1 year https://pubmed.ncbi.nlm.nih.gov/27328752 NALTREXONE with naltrexone ER/bupropion ER combination therapy.

Naltrexone at low doses upregulates a unique gene expression not https://pubmed.ncbi.nlm.nih.gov/27279602 NALTREXONE seen with normal doses: Implications for its use in cancer therapy.

Pharmacokinetic and pharmacodynamic evaluation of oxycodone https://pubmed.ncbi.nlm.nih.gov/27253690 NALTREXONE and naltrexone for the treatment of chronic lower back pain. [Review] Bupropion and naltrexone for smoking cessation: A double-blind https://pubmed.ncbi.nlm.nih.gov/27213949 NALTREXONE randomized placebo-controlled clinical trial. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no https://pubmed.ncbi.nlm.nih.gov/27211996 Medication-Assisted Therapy Following Inpatient Opioid NALTREXONE Detoxification. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid https://pubmed.ncbi.nlm.nih.gov/27211522 NALTREXONE users. Gender differences in treatment and clinical characteristics among https://pubmed.ncbi.nlm.nih.gov/27192330 NALTREXONE patients receiving extended release naltrexone. https://pubmed.ncbi.nlm.nih.gov/27178765 NALTREXONE Extended-release naltrexone opioid treatment at jail reentry (XOR). Opioid Antagonists and the A118G Polymorphism in the mu-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy https://pubmed.ncbi.nlm.nih.gov/27109624 NALTREXONE Drinkers Stratified by OPRM1 Genotype. High-Dose Naltrexone Treatment and Gender in Alcohol https://pubmed.ncbi.nlm.nih.gov/27046656 NALTREXONE Dependence. Medication Title of Article PubMed Link Separate and Combined Effects of Naltrexone and Extended- Release Alprazolam on the Reinforcing, Subject-Rated, and https://pubmed.ncbi.nlm.nih.gov/27043121 NALTREXONE Cardiovascular Effects of Methamphetamine. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal https://pubmed.ncbi.nlm.nih.gov/27028913 NALTREXONE Justice Offenders. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk https://pubmed.ncbi.nlm.nih.gov/26954408 NALTREXONE Factors: A Randomized Clinical Trial. Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A https://pubmed.ncbi.nlm.nih.gov/26954405 NALTREXONE Study Interrupted. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with https://pubmed.ncbi.nlm.nih.gov/26948856 NALTREXONE Buprenorphine (CURB) study. Linkage to Primary Care for Persons First Receiving Injectable https://pubmed.ncbi.nlm.nih.gov/26920817 NALTREXONE Naltrexone During Inpatient Opioid Detoxification. Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in https://pubmed.ncbi.nlm.nih.gov/26874330 NALTREXONE Humans.

Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are https://pubmed.ncbi.nlm.nih.gov/26845589 NALTREXONE there any Differences? Results from an Indirect Meta-Analysis. Predictors of Continued Use of Extended-Released Naltrexone (XR- NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin https://pubmed.ncbi.nlm.nih.gov/26823295 NALTREXONE Opioid Users in Los Angeles County. A delayed injection-site reaction in a patient receiving extended- https://pubmed.ncbi.nlm.nih.gov/26820699 NALTREXONE release naltrexone. Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic https://pubmed.ncbi.nlm.nih.gov/26814245 NALTREXONE Neuropathy. Opioids and social bonding: naltrexone reduces feelings of social https://pubmed.ncbi.nlm.nih.gov/26796966 NALTREXONE connection. Topical Application of Naltrexone to the Ocular Surface of Healthy https://pubmed.ncbi.nlm.nih.gov/26741052 NALTREXONE Volunteers: A Tolerability Study. Naltrexone alters the processing of social and emotional stimuli in https://pubmed.ncbi.nlm.nih.gov/26710657 NALTREXONE healthy adults. Medication Title of Article PubMed Link Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three https://pubmed.ncbi.nlm.nih.gov/26695349 NALTREXONE clinical trials. Naltrexone/bupropion for the treatment of obesity and obesity with https://pubmed.ncbi.nlm.nih.gov/26679384 NALTREXONE Type 2 diabetes. [Review] Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men https://pubmed.ncbi.nlm.nih.gov/26674372 NALTREXONE Who Have Sex with Men. Extended-Release Naltrexone: A Qualitative Analysis of Barriers to https://pubmed.ncbi.nlm.nih.gov/26654934 NALTREXONE Routine Use. Longitudinal findings from a randomized clinical trial of naltrexone for https://pubmed.ncbi.nlm.nih.gov/26654213 NALTREXONE young adult heavy drinkers. NALTREXONE Naltrexone: Not Just for Opioids Anymore. [Review] https://pubmed.ncbi.nlm.nih.gov/26546222 Bupropion-SR plus naltrexone-SR for the treatment of mild-to- https://pubmed.ncbi.nlm.nih.gov/26512740 NALTREXONE moderate obesity. [Review] A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed https://pubmed.ncbi.nlm.nih.gov/26339899 NALTREXONE Naltrexone in the Treatment of Pathological Gambling. A demonstration project implementing extended-release naltrexone https://pubmed.ncbi.nlm.nih.gov/26158698 NALTREXONE in Los Angeles County. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with https://pubmed.ncbi.nlm.nih.gov/27137146 NALTREXONE sequestered naltrexone. Oral and long-acting injectable naltrexone: removal of boxed warning https://pubmed.ncbi.nlm.nih.gov/26717532 NALTREXONE for hepatotoxicity. Treatment of Compulsive Pornography Use With Naltrexone: A Case https://pubmed.ncbi.nlm.nih.gov/26619775 NALTREXONE Report. Naltrexone + bupropion (Mysimba). Too risky for only modest weight https://pubmed.ncbi.nlm.nih.gov/26594724 NALTREXONE loss. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from https://pubmed.ncbi.nlm.nih.gov/26560326 NALTREXONE the criminal justice system. Naltrexone for treatment of impaired awareness of hypoglycemia in https://pubmed.ncbi.nlm.nih.gov/26345338 NALTREXONE type 1 diabetes: A randomized clinical trial. A Phase 4, Pilot, Open-Label Study of VIVITROL R (Extended- https://pubmed.ncbi.nlm.nih.gov/26299956 NALTREXONE Release Naltrexone XR-NTX) for Prisoners. Medication Title of Article PubMed Link Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for https://pubmed.ncbi.nlm.nih.gov/26280708 NALTREXONE Symptomatic Mesenteric Panniculitis. Patient-reported quality of life in a randomized placebo-controlled trial https://pubmed.ncbi.nlm.nih.gov/26222044 NALTREXONE of naltrexone/bupropion for obesity. Low Dose Naltrexone for Treatment of Multiple Sclerosis: A https://pubmed.ncbi.nlm.nih.gov/26203498 NALTREXONE Retrospective Chart Review of Safety and Tolerability. The efficacy and safety of the naltrexone/bupropion combination for https://pubmed.ncbi.nlm.nih.gov/26188223 NALTREXONE the treatment of obesity: an update. [Review] The effects of dronabinol during detoxification and the initiation of https://pubmed.ncbi.nlm.nih.gov/26187456 NALTREXONE treatment with extended release naltrexone.

Putting the brakes on the "drive to eat": Pilot effects of naltrexone https://pubmed.ncbi.nlm.nih.gov/26164674 NALTREXONE and reward-based eating on food cravings among obese women. Naltrexone ER/Bupropion ER: A Review in Obesity Management. https://pubmed.ncbi.nlm.nih.gov/26105116 NALTREXONE [Review]

Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment https://pubmed.ncbi.nlm.nih.gov/26091546 NALTREXONE of Obesity and Medication-Related Weight Gain. [Review] Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application https://pubmed.ncbi.nlm.nih.gov/26037158 to a clinical trial of oral administration of a heroin/naloxone NALTREXONE formulation.

Intranasal administration of crushed ALO-02 (extended-release https://pubmed.ncbi.nlm.nih.gov/26011742 oxycodone with sequestered naltrexone): A randomized, controlled NALTREXONE abuse-potential study in nondependent recreational opioid users. Structure-Activity Relationships of (+)-Naltrexone-Inspired Toll-like https://pubmed.ncbi.nlm.nih.gov/26010811 NALTREXONE Receptor 4 (TLR4) Antagonists. A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding https://pubmed.ncbi.nlm.nih.gov/25993547 sequestered naltrexone) for moderate-to-severe chronic low back NALTREXONE pain treatment. Naltrexone for impulse control disorders in Parkinson disease: a https://pubmed.ncbi.nlm.nih.gov/25992402 NALTREXONE placebo-controlled study. Medication Title of Article PubMed Link Naltrexone for impulse control disorders in Parkinson disease: a https://pubmed.ncbi.nlm.nih.gov/25992401 NALTREXONE placebo-controlled study. Combined varenicline and naltrexone treatment reduces smoking https://pubmed.ncbi.nlm.nih.gov/25933795 NALTREXONE topography intensity in heavy-drinking smokers. Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized https://pubmed.ncbi.nlm.nih.gov/25918964 NALTREXONE controlled trial. Baseline characteristics of patients predicting suitability for rapid https://pubmed.ncbi.nlm.nih.gov/25907815 NALTREXONE naltrexone induction. Treating Opioid Dependence With Injectable Extended-Release https://pubmed.ncbi.nlm.nih.gov/25901451 NALTREXONE Naltrexone (XR-NTX): Who Will Respond?. Views about responsibility for alcohol addiction and negative https://pubmed.ncbi.nlm.nih.gov/25886539 NALTREXONE evaluations of naltrexone.

Naltrexone Maintenance Decreases Cannabis Self-Administration https://pubmed.ncbi.nlm.nih.gov/25881117 NALTREXONE and Subjective Effects in Daily Cannabis Smokers. Extended-Release Naltrexone for Alcohol and Opioid Problems in https://pubmed.ncbi.nlm.nih.gov/25841704 NALTREXONE Missouri Parolees and Probationers. Naltrexone for impulse control disorders in Parkinson disease: a https://pubmed.ncbi.nlm.nih.gov/25825466 NALTREXONE placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/25819700 NALTREXONE Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo- https://pubmed.ncbi.nlm.nih.gov/25801501 NALTREXONE Controlled Laboratory Study. Comment on "Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated https://pubmed.ncbi.nlm.nih.gov/25793206 NALTREXONE patients". Neural correlates of adherence to extended-release naltrexone https://pubmed.ncbi.nlm.nih.gov/25781230 NALTREXONE pharmacotherapy in heroin dependence. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine https://pubmed.ncbi.nlm.nih.gov/25775099 NALTREXONE Maintenance Treatment for Opioid Dependence. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A https://pubmed.ncbi.nlm.nih.gov/25760804 NALTREXONE Randomized Clinical Trial. Medication Title of Article PubMed Link Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin- https://pubmed.ncbi.nlm.nih.gov/25757673 NALTREXONE dependent patients. Naltrexone reduces heavy drinking in problem drinkers across the https://pubmed.ncbi.nlm.nih.gov/25742215 NALTREXONE spectrum of dependence. Reduction of alcohol drinking in young adults by naltrexone: a double- blind, placebo-controlled, randomized clinical trial of efficacy and https://pubmed.ncbi.nlm.nih.gov/25742208 NALTREXONE safety. Effects of ethanol on the pharmacokinetics of extended-release https://pubmed.ncbi.nlm.nih.gov/25724154 NALTREXONE oxycodone with sequestered naltrexone (ALO-02). OPRM1 genotype and naltrexone response in depressed alcohol- https://pubmed.ncbi.nlm.nih.gov/25715171 NALTREXONE dependent patients.

Opioid treatment at release from jail using extended-release https://pubmed.ncbi.nlm.nih.gov/25703440 NALTREXONE naltrexone: a pilot proof-of-concept randomized effectiveness trial. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and https://pubmed.ncbi.nlm.nih.gov/25679122 NALTREXONE major depression. Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow- https://pubmed.ncbi.nlm.nih.gov/25655226 NALTREXONE up. Low-dose naltrexone to prevent intolerable morphine adverse events: https://pubmed.ncbi.nlm.nih.gov/25643645 NALTREXONE a forgotten remedy for a neglected, global clinical need. Social network moderators of naltrexone and behavioral treatment https://pubmed.ncbi.nlm.nih.gov/25623409 NALTREXONE effects on heavy drinking in the COMBINE study. Extended release naltrexone for alcohol use disorders: quasi- experimental effects on mortality and subsequent detoxification https://pubmed.ncbi.nlm.nih.gov/25623408 NALTREXONE episodes.

Impact of prospectively determined A118G polymorphism on https://pubmed.ncbi.nlm.nih.gov/25622123 treatment response to injectable naltrexone among NALTREXONE methamphetamine-dependent patients: an open-label, pilot study. Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data https://pubmed.ncbi.nlm.nih.gov/25609921 NALTREXONE to date. Medication Title of Article PubMed Link Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and https://pubmed.ncbi.nlm.nih.gov/25602580 NALTREXONE design of a randomized controlled effectiveness trial. Transformation of naltrexone into mesembrane and investigation of the binding properties of its intermediate derivatives to opioid https://pubmed.ncbi.nlm.nih.gov/25573119 NALTREXONE receptors. Opioid use and dropout in patients receiving oral naltrexone with or https://pubmed.ncbi.nlm.nih.gov/25555621 NALTREXONE without single administration of injection naltrexone.

Single- and multiple-dose pharmacokinetics of a hydrocodone https://pubmed.ncbi.nlm.nih.gov/25542074 bitartrate extended-release tablet formulated with abuse-deterrence NALTREXONE technology in healthy, naltrexone-blocked volunteers. Adoption of injectable naltrexone in U.S. substance use disorder https://pubmed.ncbi.nlm.nih.gov/25486403 NALTREXONE treatment programs. Sex differences in acute hormonal and subjective response to https://pubmed.ncbi.nlm.nih.gov/25459893 NALTREXONE naltrexone: The impact of menstrual cycle phase. Naltrexone and bupropion, alone or combined, do not alter the https://pubmed.ncbi.nlm.nih.gov/25459104 NALTREXONE reinforcing effects of intranasal methamphetamine. Excess mortality among opioid-using patients treated with oral https://pubmed.ncbi.nlm.nih.gov/25302627 NALTREXONE naltrexone in Australia.

Employment-based reinforcement of adherence to oral naltrexone in https://pubmed.ncbi.nlm.nih.gov/25134047 NALTREXONE unemployed injection drug users: 12-month outcomes. Varenicline, naltrexone, and their combination for heavy-drinking https://pubmed.ncbi.nlm.nih.gov/24949564 NALTREXONE smokers: preliminary neuroimaging findings.

Effect of naltrexone on neuropathic pain in mice locally transfected https://pubmed.ncbi.nlm.nih.gov/24866991 NALTREXONE with the mutant mu-opioid receptor gene in spinal cord. Extended-release naltrexone and harm reduction counseling for https://pubmed.ncbi.nlm.nih.gov/24779575 NALTREXONE chronically homeless people with alcohol dependence. Metastatic hepatocellular carcinoma with paraneoplastic itch: https://pubmed.ncbi.nlm.nih.gov/25607785 NALTREXONE effective treatment with naltrexone. Effects of naltrexone on neural and subjective response to alcohol in https://pubmed.ncbi.nlm.nih.gov/25581657 NALTREXONE treatment-seeking alcohol-dependent patients. Medication Title of Article PubMed Link A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release https://pubmed.ncbi.nlm.nih.gov/25531960 capsules (ALO-02) in patients with moderate-to-severe chronic NALTREXONE noncancer pain.

An exploratory randomised double-blind and placebo-controlled https://pubmed.ncbi.nlm.nih.gov/25519680 phase 2 study of a combination of baclofen, naltrexone and sorbitol NALTREXONE (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Predicting naltrexone response in alcohol-dependent patients: the https://pubmed.ncbi.nlm.nih.gov/25421512 NALTREXONE contribution of functional magnetic resonance imaging. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort https://pubmed.ncbi.nlm.nih.gov/25418525 NALTREXONE these agents out. https://pubmed.ncbi.nlm.nih.gov/25372849 NALTREXONE Contrave--a combination of bupropion and naltrexone for weight loss. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit https://pubmed.ncbi.nlm.nih.gov/25335648 NALTREXONE smoking. Review: In alcohol use disorders, oral naltrexone, 50 mg/d, or https://pubmed.ncbi.nlm.nih.gov/25329224 NALTREXONE acamprosate reduces return to drinking. Role of naltrexone in management of behavioral outbursts in an adolescent male diagnosed with disruptive mood dysregulation https://pubmed.ncbi.nlm.nih.gov/25325878 NALTREXONE disorder. Naltrexone in bipolar disorder with depression: a double-blind, https://pubmed.ncbi.nlm.nih.gov/25310199 NALTREXONE placebo-controlled study.

Naltrexone sustained-release/bupropion sustained-release for the https://pubmed.ncbi.nlm.nih.gov/25258511 NALTREXONE management of obesity: review of the data to date. [Review] A pilot trial of injectable, extended-release naltrexone for the https://pubmed.ncbi.nlm.nih.gov/25251201 NALTREXONE treatment of co-occurring cocaine and alcohol dependence. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid https://pubmed.ncbi.nlm.nih.gov/25240704 dependent prisoners and jail detainees who are transitioning to the NALTREXONE community. Medication Title of Article PubMed Link In vivo veritas: (+)-Naltrexone's actions define translational importance: A letter in response to Skolnick et al. 'Translational https://pubmed.ncbi.nlm.nih.gov/25109571 NALTREXONE potential of naloxone and naltrexone as TLR4 antagonists'. Translational potential of naloxone and naltrexone as TLR4 https://pubmed.ncbi.nlm.nih.gov/25109569 NALTREXONE antagonists. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof https://pubmed.ncbi.nlm.nih.gov/25102328 NALTREXONE of concept. 5-HTTLPR moderates naltrexone and psychosocial treatment https://pubmed.ncbi.nlm.nih.gov/25070809 NALTREXONE responses in heavy drinking men who have sex with men. Naltrexone as a diagnostic tool to distinguish between hyperandrogenemic and hypothalamic ovarian failure in females with https://pubmed.ncbi.nlm.nih.gov/25065344 congenital adrenal hyperplasia due to 21-hydroxylase-deficiency NALTREXONE (CAH).

Commentary on Garbutt et al. (2014): Can we predict who benefits https://pubmed.ncbi.nlm.nih.gov/25041200 NALTREXONE from naltrexone in the treatment of alcohol dependence?. Naltrexone for impulse control disorders in Parkinson disease: a https://pubmed.ncbi.nlm.nih.gov/25037206 NALTREXONE placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/24967470 NALTREXONE Off-label, low-dose naltrexone for refractory chronic low back pain. Hypothalamic-pituitary-adrenal axis response to oral naltrexone in https://pubmed.ncbi.nlm.nih.gov/24936803 NALTREXONE alcoholics during early withdrawal. Extended-release naltrexone for alcohol and opioid dependence: a https://pubmed.ncbi.nlm.nih.gov/24854219 NALTREXONE meta-analysis of healthcare utilization studies. NALTREXONE Use of naltrexone in ketamine dependence. https://pubmed.ncbi.nlm.nih.gov/24813545 Drug safety evaluation of naltrexone/bupropion for the treatment of https://pubmed.ncbi.nlm.nih.gov/24766397 NALTREXONE obesity. [Review] Opposing neural effects of naltrexone on food reward and aversion: https://pubmed.ncbi.nlm.nih.gov/24763910 NALTREXONE implications for the treatment of obesity. Naltrexone/bupropion for obesity: an investigational combination https://pubmed.ncbi.nlm.nih.gov/24754973 NALTREXONE pharmacotherapy for weight loss. [Review] Comment on "Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated https://pubmed.ncbi.nlm.nih.gov/24738071 NALTREXONE patients". Medication Title of Article PubMed Link Varenicline, low dose naltrexone, and their combination for heavy- https://pubmed.ncbi.nlm.nih.gov/24733235 NALTREXONE drinking smokers: human laboratory findings. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, https://pubmed.ncbi.nlm.nih.gov/24724887 NALTREXONE dually diagnosed veterans. Naltrexone: a review of existing sustained drug delivery systems and https://pubmed.ncbi.nlm.nih.gov/24704710 NALTREXONE emerging nano-based systems. [Review] Naltrexone implant treatment for buprenorphine dependence-- https://pubmed.ncbi.nlm.nih.gov/24695742 NALTREXONE Mauritian case series. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled https://pubmed.ncbi.nlm.nih.gov/24674234 NALTREXONE trials of extended release naltrexone.

Clinical and biological moderators of response to naltrexone in https://pubmed.ncbi.nlm.nih.gov/24661324 NALTREXONE alcohol dependence: a systematic review of the evidence. [Review] Naltrexone metabolism and concomitant drug concentrations in https://pubmed.ncbi.nlm.nih.gov/24659754 NALTREXONE chronic pain patients. NALTREXONE Treatment of fetishism with naltrexone: a case report. https://pubmed.ncbi.nlm.nih.gov/24655631

Extended release naltrexone injection is performed in the majority of https://pubmed.ncbi.nlm.nih.gov/24602363 opioid dependent patients receiving outpatient induction: a very low NALTREXONE dose naltrexone and buprenorphine open label trial. Trichotillomania successfully treated with risperidone and naltrexone: https://pubmed.ncbi.nlm.nih.gov/24598474 NALTREXONE a geriatric case report. NALTREXONE Naltrexone therapy for Crohn's disease and ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/24583747 A placebo-controlled trial of memantine as an adjunct to injectable https://pubmed.ncbi.nlm.nih.gov/24560438 NALTREXONE extended-release naltrexone for opioid dependence. Low dose naltrexone for induction of remission in Crohn's disease. https://pubmed.ncbi.nlm.nih.gov/24558033 NALTREXONE [Review] The use of low-dose naltrexone (LDN) as a novel anti-inflammatory https://pubmed.ncbi.nlm.nih.gov/24526250 NALTREXONE treatment for chronic pain. [Review] Nanoscale effects of ethanol and naltrexone on protein organization in the plasma membrane studied by photoactivated localization https://pubmed.ncbi.nlm.nih.gov/24503624 NALTREXONE microscopy (PALM). Medication Title of Article PubMed Link Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in https://pubmed.ncbi.nlm.nih.gov/24464531 NALTREXONE stimulant users. Outcome predictors for problem drinkers treated with combined https://pubmed.ncbi.nlm.nih.gov/24456403 NALTREXONE cognitive behavioral therapy and naltrexone. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, https://pubmed.ncbi.nlm.nih.gov/24424425 NALTREXONE levodopa-carbidopa, naltrexone. Treatment of refractory vulvovaginal pruritus with naltrexone, a https://pubmed.ncbi.nlm.nih.gov/24388844 NALTREXONE specific opiate antagonist. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and https://pubmed.ncbi.nlm.nih.gov/24384538 hazardous drinking prisoners with HIV who are transitioning to the NALTREXONE community. The effect of naltrexone on sleep parameters in healthy male https://pubmed.ncbi.nlm.nih.gov/24346745 NALTREXONE volunteers. A systematic review and meta-analysis of naltrexone implants for the https://pubmed.ncbi.nlm.nih.gov/24299657 NALTREXONE treatment of opioid dependence. [Review] Sustained release of naltrexone from poly(n-isopropylacrylamide) https://pubmed.ncbi.nlm.nih.gov/24218151 NALTREXONE microgels. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind https://pubmed.ncbi.nlm.nih.gov/24218048 NALTREXONE placebo-controlled pilot study. Sequestered naltrexone in sustained release morphine or oxycodone https://pubmed.ncbi.nlm.nih.gov/24206269 NALTREXONE - a way to inhibit illicit use?. [Review]

The opiate antagonist, naltrexone, in the treatment of trichotillomania: https://pubmed.ncbi.nlm.nih.gov/24145220 NALTREXONE results of a double-blind, placebo-controlled study. Phase I study of injectable, depot naltrexone for the relapse https://pubmed.ncbi.nlm.nih.gov/24107112 NALTREXONE prevention treatment of opioid dependence.

DSM IV axis II traits can influence compliance to treatment with oral https://pubmed.ncbi.nlm.nih.gov/24090623 NALTREXONE naltrexone: a preliminary study on 30 opiate dependent patients. Long-acting injectable depot naltrexone use in the Veterans' Health https://pubmed.ncbi.nlm.nih.gov/23790742 NALTREXONE Administration: a national study. Medication Title of Article PubMed Link Effects of naltrexone on adolescent alcohol cue reactivity and https://pubmed.ncbi.nlm.nih.gov/23489253 NALTREXONE sensitivity: an initial randomized trial.

Association of smoking with mu-opioid receptor availability before https://pubmed.ncbi.nlm.nih.gov/23252742 NALTREXONE and during naltrexone blockade in alcohol-dependent subjects. Injectable and implantable sustained release naltrexone in the https://pubmed.ncbi.nlm.nih.gov/23088328 NALTREXONE treatment of opioid addiction. [Review] Extended-release naltrexone modulates brain response to drug cues https://pubmed.ncbi.nlm.nih.gov/22747521 NALTREXONE in abstinent heroin-dependent patients. Predictors of dropout in an outpatient treatment for problem drinkers including cognitive-behavioral therapy and the opioid antagonist https://pubmed.ncbi.nlm.nih.gov/24172116 NALTREXONE naltrexone.

Effects of naltrexone sustained-release/bupropion sustained-release https://pubmed.ncbi.nlm.nih.gov/24144653 combination therapy on body weight and glycemic parameters in NALTREXONE overweight and obese patients with type 2 diabetes. Extended-release intramuscular naltrexone (VIVITROL R): a review of its use in the prevention of relapse to opioid dependence in https://pubmed.ncbi.nlm.nih.gov/24018540 NALTREXONE detoxified patients. [Review] Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with https://pubmed.ncbi.nlm.nih.gov/23936895 and without a sequestered naltrexone core in recreational opioid NALTREXONE users. NALTREXONE Naltrexone may block euphoria-like placebo effect. https://pubmed.ncbi.nlm.nih.gov/23925680 Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical https://pubmed.ncbi.nlm.nih.gov/23925619 NALTREXONE trial.

The placebo effect in clinical trials for alcohol dependence: an https://pubmed.ncbi.nlm.nih.gov/23889231 NALTREXONE exploratory analysis of 51 naltrexone and acamprosate studies. Naltrexone treatment for opioid dependence: does its effectiveness https://pubmed.ncbi.nlm.nih.gov/23827259 NALTREXONE depend on testing the blockade?. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a https://pubmed.ncbi.nlm.nih.gov/23805859 NALTREXONE double-blind, randomized, placebo-controlled trial. Medication Title of Article PubMed Link Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed https://pubmed.ncbi.nlm.nih.gov/23745947 morphine sulfate controlled-release tablets and placebo in NALTREXONE nondependent recreational opioid users. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine https://pubmed.ncbi.nlm.nih.gov/23736314 NALTREXONE abusers. NALTREXONE Monthly injectable naltrexone for pathological gambling. https://pubmed.ncbi.nlm.nih.gov/23732971

Naltrexone (50 mg) plus psychotherapy in alcohol-dependent https://pubmed.ncbi.nlm.nih.gov/23721530 NALTREXONE patients: a meta-analysis of randomized controlled trials. [Review] Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized https://pubmed.ncbi.nlm.nih.gov/23714324 NALTREXONE controlled trial.

A clinical trial to determine if corelease of morphine and naltrexone https://pubmed.ncbi.nlm.nih.gov/23709323 from crushed extended-release capsules induces withdrawal in opioid- NALTREXONE dependent patients: a descriptive analysis of six patients. Injectable extended-release naltrexone (XR-NTX) for opioid https://pubmed.ncbi.nlm.nih.gov/23701526 NALTREXONE dependence: long-term safety and effectiveness.

Hormonal contraceptive use diminishes salivary cortisol response to https://pubmed.ncbi.nlm.nih.gov/23672966 NALTREXONE psychosocial stress and naltrexone in healthy women. Controlled delivery of naltrexone by an intraoral device: in vivo study https://pubmed.ncbi.nlm.nih.gov/23644347 NALTREXONE on human subjects. Review: In alcohol use disorders, acamprosate is more effective for inducing abstinence while naltrexone is more effective for reducing https://pubmed.ncbi.nlm.nih.gov/23604277 NALTREXONE heavy drinking and craving. Bernard Bihari, MD: low-dose naltrexone for normalizing immune https://pubmed.ncbi.nlm.nih.gov/23594453 NALTREXONE system function. Aversion to injection limits acceptability of extended-release https://pubmed.ncbi.nlm.nih.gov/23577900 NALTREXONE naltrexone among homeless, alcohol-dependent patients. Medication Title of Article PubMed Link

Extended-release naltrexone (XR-NTX) attenuates brain responses https://pubmed.ncbi.nlm.nih.gov/23571420 NALTREXONE to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Treatment of Complex Regional Pain Syndrome (CRPS) using low https://pubmed.ncbi.nlm.nih.gov/23546884 NALTREXONE dose naltrexone (LDN). The mu-opioid receptor and treatment response to naltrexone. https://pubmed.ncbi.nlm.nih.gov/23543091 NALTREXONE [Review] NALTREXONE Naltrexone and nalmefene: any meaningful difference?. https://pubmed.ncbi.nlm.nih.gov/23540350 Combination therapy with naltrexone and bupropion for obesity https://pubmed.ncbi.nlm.nih.gov/23489381 NALTREXONE reduces total and visceral adiposity. Use of naltrexone for alcohol use disorders in the Veterans' Health https://pubmed.ncbi.nlm.nih.gov/23434041 NALTREXONE Administration: a national study. A randomized, phase 3 trial of naltrexone SR/bupropion SR on https://pubmed.ncbi.nlm.nih.gov/23408728 NALTREXONE weight and obesity-related risk factors (COR-II). A retrospective assessment of the use of naltrexone implants for the https://pubmed.ncbi.nlm.nih.gov/23398219 NALTREXONE treatment of problematic amphetamine use. The declining efficacy of naltrexone pharmacotherapy for alcohol use https://pubmed.ncbi.nlm.nih.gov/23398164 NALTREXONE disorders over time: a multivariate meta-analysis. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, https://pubmed.ncbi.nlm.nih.gov/23359310 NALTREXONE counterbalanced, crossover trial assessing daily pain levels. Naltrexone in the treatment of opioid-dependent pregnant women: https://pubmed.ncbi.nlm.nih.gov/23331881 NALTREXONE common ground. Dual dilemma-should naltrexone be used in the treatment of opioid- https://pubmed.ncbi.nlm.nih.gov/23331877 NALTREXONE dependent pregnant women?. Letter to the Editor: Shopping frenzy induced by naltrexone--a https://pubmed.ncbi.nlm.nih.gov/23302184 NALTREXONE paradoxical effect in bipolar disorder?. Assessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant https://pubmed.ncbi.nlm.nih.gov/23241479 NALTREXONE naltrexone in the treatment of heroin dependence. Employment-based reinforcement of adherence to oral naltrexone https://pubmed.ncbi.nlm.nih.gov/23205722 NALTREXONE treatment in unemployed injection drug users.

Safety and tolerability of low-dose naltrexone therapy in children with https://pubmed.ncbi.nlm.nih.gov/23188075 NALTREXONE moderate to severe Crohn's disease: a pilot study. Medication Title of Article PubMed Link Naltrexone reduction of long-term smoking cessation weight gain in https://pubmed.ncbi.nlm.nih.gov/23177384 NALTREXONE women but not men: a randomized controlled trial. The effect of naltrexone on the perception and distress in tinnitus: an https://pubmed.ncbi.nlm.nih.gov/23110786 NALTREXONE open-label pilot study.

Meta-analysis of naltrexone and acamprosate for treating alcohol use https://pubmed.ncbi.nlm.nih.gov/23075288 NALTREXONE disorders: when are these medications most helpful?. [Review] Interacting effects of naltrexone and OPRM1 and DAT1 variation on https://pubmed.ncbi.nlm.nih.gov/23032071 NALTREXONE the neural response to alcohol cues. Improving clinical outcomes for naltrexone as a management of https://pubmed.ncbi.nlm.nih.gov/22946873 NALTREXONE problem alcohol use. [Review]

Variation in OPRM1 moderates the effect of desire to drink on https://pubmed.ncbi.nlm.nih.gov/22784013 NALTREXONE subsequent drinking and its attenuation by naltrexone treatment.

Multivesicular liposomes for sustained release of naltrexone https://pubmed.ncbi.nlm.nih.gov/22759074 NALTREXONE hydrochloride: design, characterization and in vitro/in vivo evaluation.

Reduction of conditioned pain modulation in humans by naltrexone: https://pubmed.ncbi.nlm.nih.gov/22534819 NALTREXONE an exploratory study of the effects of pain catastrophizing. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. https://pubmed.ncbi.nlm.nih.gov/22471668 NALTREXONE [Review]

An open-label pharmacokinetic study of oxymorphone extended https://pubmed.ncbi.nlm.nih.gov/23264316 NALTREXONE release in the presence of naltrexone in the older adult. Naltrexone-induced Nicolau syndrome masquerading as cutaneous https://pubmed.ncbi.nlm.nih.gov/23242099 NALTREXONE abscess. NALTREXONE Naltrexone treatment of kleptomania: a case report. https://pubmed.ncbi.nlm.nih.gov/23225130 Effectiveness of naltrexone for treating pathologic skin picking https://pubmed.ncbi.nlm.nih.gov/23083028 NALTREXONE behavior in an adolescent with Prader-Willi syndrome. Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? https://pubmed.ncbi.nlm.nih.gov/23082827 NALTREXONE A meta-analysis. [Review] Medication Title of Article PubMed Link Hepatic safety of injectable extended-release naltrexone in patients https://pubmed.ncbi.nlm.nih.gov/23036218 NALTREXONE with chronic hepatitis C and HIV infection. Extended-release naltrexone plus medical management alcohol https://pubmed.ncbi.nlm.nih.gov/22985676 NALTREXONE treatment in primary care: findings at 15 months. Risk-taking propensity as a predictor of induction onto naltrexone https://pubmed.ncbi.nlm.nih.gov/22967782 NALTREXONE treatment for opioid dependence. Commentary on Kelty & Hulse (2012): is the comparison of mortality between patients prescribed implanted or oral naltrexone an https://pubmed.ncbi.nlm.nih.gov/22962958 NALTREXONE unbiased and unconfounded comparison?. Delta and kappa opioid receptor polymorphisms influence the effects https://pubmed.ncbi.nlm.nih.gov/22954510 NALTREXONE of naltrexone on subjective responses to alcohol.

Advantages of EMBEDA R (morphine sulfate and naltrexone https://pubmed.ncbi.nlm.nih.gov/22941847 NALTREXONE hydrochloride) extended-release capsules in pain management. Effects of naltrexone on smoking cessation outcomes and weight https://pubmed.ncbi.nlm.nih.gov/22926596 NALTREXONE gain in nicotine-dependent men and women. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. https://pubmed.ncbi.nlm.nih.gov/22909206 NALTREXONE [Review] Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum https://pubmed.ncbi.nlm.nih.gov/22894733 NALTREXONE with high-performance liquid chromatography. Naltrexone implant for the treatment of polydrug dependence: a https://pubmed.ncbi.nlm.nih.gov/22764364 NALTREXONE randomized controlled trial. Pharmacodynamic profile of tramadol in humans: influence of https://pubmed.ncbi.nlm.nih.gov/22623016 NALTREXONE naltrexone pretreatment. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events https://pubmed.ncbi.nlm.nih.gov/22616317 NALTREXONE during the first year. A randomized clinical trial of naltrexone and behavioral therapy for https://pubmed.ncbi.nlm.nih.gov/22612306 NALTREXONE problem drinking men who have sex with men. Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family https://pubmed.ncbi.nlm.nih.gov/22575355 NALTREXONE Health Patterns Project. Medication Title of Article PubMed Link Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine https://pubmed.ncbi.nlm.nih.gov/22551036 NALTREXONE transporter (SLC6A3) genes. Cigarette smoking predicts differential benefit from naltrexone for https://pubmed.ncbi.nlm.nih.gov/22541040 NALTREXONE alcohol dependence. Association of micro -opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic https://pubmed.ncbi.nlm.nih.gov/22515274 NALTREXONE review and meta-analysis. [Review] Acceptance of naltrexone by pregnant women enrolled in https://pubmed.ncbi.nlm.nih.gov/22494221 NALTREXONE comprehensive drug addiction treatment: an initial survey. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose https://pubmed.ncbi.nlm.nih.gov/22480625 NALTREXONE naltrexone a new treatment option?. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a https://pubmed.ncbi.nlm.nih.gov/22429255 NALTREXONE preliminary study. Opioid antagonist naltrexone for the treatment of pathological https://pubmed.ncbi.nlm.nih.gov/22426027 NALTREXONE gambling in Parkinson disease. Opioid detoxification and naltrexone induction strategies: https://pubmed.ncbi.nlm.nih.gov/22404717 NALTREXONE recommendations for clinical practice. [Review]

A multisite pilot study of extended-release injectable naltrexone https://pubmed.ncbi.nlm.nih.gov/22263713 NALTREXONE treatment for previously opioid-dependent parolees and probationers. Naltrexone does not attenuate the effects of intravenous DELTA9- https://pubmed.ncbi.nlm.nih.gov/22243563 NALTREXONE tetrahydrocannabinol in healthy humans. The combination very low-dose naltrexone-clonidine in the https://pubmed.ncbi.nlm.nih.gov/22233189 NALTREXONE management of opioid withdrawal. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol https://pubmed.ncbi.nlm.nih.gov/22089316 NALTREXONE dependence.

Opioid challenge evaluation of blockade by extended-release https://pubmed.ncbi.nlm.nih.gov/22079773 NALTREXONE naltrexone in opioid-abusing adults: dose-effects and time-course. Depot naltrexone decreases rewarding properties of sugar in patients https://pubmed.ncbi.nlm.nih.gov/21960180 NALTREXONE with opioid dependence. Medication Title of Article PubMed Link Pharmacogenetics of naltrexone in asian americans: a randomized https://pubmed.ncbi.nlm.nih.gov/21900886 NALTREXONE placebo-controlled laboratory study. Hepatic safety and antiretroviral effectiveness in HIV-infected https://pubmed.ncbi.nlm.nih.gov/21797892 NALTREXONE patients receiving naltrexone. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent https://pubmed.ncbi.nlm.nih.gov/21782353 NALTREXONE adults: a randomized controlled trial. Effects of alcohol on the pharmacokinetics of morphine sulfate and https://pubmed.ncbi.nlm.nih.gov/21593282 NALTREXONE naltrexone hydrochloride extended release capsules.

Sexual dysfunction among male patients receiving buprenorphine https://pubmed.ncbi.nlm.nih.gov/21366875 NALTREXONE and naltrexone maintenance therapy for opioid dependence.

Does adding low doses of oral naltrexone to morphine alter the https://pubmed.ncbi.nlm.nih.gov/21075578 NALTREXONE subsequent opioid requirements and side effects in trauma patients?. Naltrexone/bupropion: an investigational combination for weight loss https://pubmed.ncbi.nlm.nih.gov/22249001 NALTREXONE and maintenance. [Review] Mandatory naltrexone treatment prevents relapse among opiate- https://pubmed.ncbi.nlm.nih.gov/22107877 NALTREXONE dependent anesthesiologists returning to practice. Adherence monitoring in naltrexone pharmacotherapy trials: a https://pubmed.ncbi.nlm.nih.gov/22051215 NALTREXONE systematic review. [Review] NALTREXONE Low-dose naltrexone: tricking the body to heal itself. https://pubmed.ncbi.nlm.nih.gov/21991594 NALTREXONE Adverse events in the removal of naltrexone implants. https://pubmed.ncbi.nlm.nih.gov/21970135

Opioid titration and conversion in patients receiving morphine sulfate https://pubmed.ncbi.nlm.nih.gov/21904098 NALTREXONE and naltrexone hydrochloride extended release capsules. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent https://pubmed.ncbi.nlm.nih.gov/21902287 NALTREXONE male opioid users. Low-dose naltrexone: harnessing the body's own chemistry to treat https://pubmed.ncbi.nlm.nih.gov/21887861 NALTREXONE human ovarian cancer. NALTREXONE Injectable extended-release naltrexone for opioid dependence. https://pubmed.ncbi.nlm.nih.gov/21856478 NALTREXONE Injectable extended-release naltrexone for opioid dependence. https://pubmed.ncbi.nlm.nih.gov/21856477 Bupropion/naltrexone fixed-dose combination for the treatment of https://pubmed.ncbi.nlm.nih.gov/21850280 NALTREXONE obesity. Medication Title of Article PubMed Link Open-label pilot study of extended-release naltrexone to reduce https://pubmed.ncbi.nlm.nih.gov/21844831 NALTREXONE drinking and driving among repeat offenders. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic https://pubmed.ncbi.nlm.nih.gov/21807817 NALTREXONE evidence from a tissue culture model. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. https://pubmed.ncbi.nlm.nih.gov/21785483 NALTREXONE [Review] Extended-release naltrexone for alcohol dependence: persistence https://pubmed.ncbi.nlm.nih.gov/21761949 NALTREXONE and healthcare costs and utilization. Utilization patterns of extended-release naltrexone for alcohol https://pubmed.ncbi.nlm.nih.gov/21761946 NALTREXONE dependence. A placebo controlled trial of memantine as an adjunct to oral https://pubmed.ncbi.nlm.nih.gov/21715107 NALTREXONE naltrexone for opioid dependence. Preliminary evaluation of extended-release naltrexone in Michigan https://pubmed.ncbi.nlm.nih.gov/21696912 NALTREXONE and Missouri drug courts. Combination therapy with naltrexone and bupropion for obesity. https://pubmed.ncbi.nlm.nih.gov/21689063 NALTREXONE [Review] Low-dose naltrexone suppresses ovarian cancer and exhibits https://pubmed.ncbi.nlm.nih.gov/21685240 NALTREXONE enhanced inhibition in combination with cisplatin. Examining naltrexone and alcohol effects in a minority population: https://pubmed.ncbi.nlm.nih.gov/21679264 NALTREXONE results from an initial human laboratory study. https://pubmed.ncbi.nlm.nih.gov/21630510 NALTREXONE Synthesis of novel basic skeletons derived from naltrexone. [Review] Efficacy of extended-release naltrexone in patients with relatively https://pubmed.ncbi.nlm.nih.gov/21575016 NALTREXONE higher severity of alcohol dependence. Naltrexone depot formulations for opioid and alcohol dependence: a https://pubmed.ncbi.nlm.nih.gov/21554565 NALTREXONE systematic review. [Review] The opioid growth factor (OGF) and low dose naltrexone (LDN) https://pubmed.ncbi.nlm.nih.gov/21531450 NALTREXONE suppress human ovarian cancer progression in mice. NALTREXONE Concerns about injectable naltrexone for opioid dependence. https://pubmed.ncbi.nlm.nih.gov/21529930

Injectable extended-release naltrexone for opioid dependence: a https://pubmed.ncbi.nlm.nih.gov/21529928 NALTREXONE double-blind, placebo-controlled, multicentre randomised trial. Medication Title of Article PubMed Link Problem drinking and low-dose naltrexone-assisted opioid https://pubmed.ncbi.nlm.nih.gov/21513688 NALTREXONE detoxification. Electromembrane extraction of trace amounts of naltrexone and https://pubmed.ncbi.nlm.nih.gov/21493167 NALTREXONE nalmefene from untreated biological fluids. NALTREXONE Naltrexone for severe self-harm behavior: a case report. https://pubmed.ncbi.nlm.nih.gov/21474600 Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, https://pubmed.ncbi.nlm.nih.gov/21470065 while reducing morphine-induced subjective effects upon tampering NALTREXONE by crushing. [Review] Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and https://pubmed.ncbi.nlm.nih.gov/21470064 NALTREXONE beyond. Gabapentin combined with naltrexone for the treatment of alcohol https://pubmed.ncbi.nlm.nih.gov/21454917 NALTREXONE dependence. Effect of surfactants and pH on naltrexone (NTX) permeation across https://pubmed.ncbi.nlm.nih.gov/21443939 NALTREXONE buccal mucosa. Pruritus responsive to naltrexone in a patient with cholestatic liver https://pubmed.ncbi.nlm.nih.gov/21443039 NALTREXONE disease. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol https://pubmed.ncbi.nlm.nih.gov/21437991 NALTREXONE dependence: an open-label study. Course of weight change during naltrexone versus methadone https://pubmed.ncbi.nlm.nih.gov/21434584 NALTREXONE maintenance for opioid-dependent patients. NALTREXONE Enhancing acupuncture by low dose naltrexone. https://pubmed.ncbi.nlm.nih.gov/21415049 The effect of naltrexone on alcohol's stimulant properties and self- administration behavior in social drinkers: influence of gender and https://pubmed.ncbi.nlm.nih.gov/21410481 NALTREXONE genotype. Counselor attitudes toward the use of naltrexone in substance abuse https://pubmed.ncbi.nlm.nih.gov/21382667 NALTREXONE treatment: a multi-level modeling approach. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled https://pubmed.ncbi.nlm.nih.gov/21380937 NALTREXONE trial.

Voltammetry of naltrexone in commercial formulation and human https://pubmed.ncbi.nlm.nih.gov/21371948 NALTREXONE body fluids: Quantification and pharmacokinetic studies. Medication Title of Article PubMed Link Oral naltrexone maintenance treatment for opioid dependence. https://pubmed.ncbi.nlm.nih.gov/21328250 NALTREXONE [Review] Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled https://pubmed.ncbi.nlm.nih.gov/21320227 NALTREXONE trial. Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release https://pubmed.ncbi.nlm.nih.gov/21314752 NALTREXONE naltrexone. Intramuscular extended-release naltrexone: current evidence. https://pubmed.ncbi.nlm.nih.gov/21272018 NALTREXONE [Review] Predictors for the efficacy of naltrexone treatment in alcohol https://pubmed.ncbi.nlm.nih.gov/21266377 NALTREXONE dependence: sweet preference. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?. https://pubmed.ncbi.nlm.nih.gov/21254901 NALTREXONE [Review] The association between naltrexone treatment and symptoms of https://pubmed.ncbi.nlm.nih.gov/21192125 NALTREXONE depression in opioid-dependent patients. NALTREXONE ALSUntangled No. 8: Low dose naltrexone for ALS. https://pubmed.ncbi.nlm.nih.gov/21174518 A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of https://pubmed.ncbi.nlm.nih.gov/21146937 NALTREXONE alcohol-dependent patients. Baseline trajectories of drinking moderate acamprosate and https://pubmed.ncbi.nlm.nih.gov/21143249 NALTREXONE naltrexone effects in the COMBINE study. Topiramate for the treatment of alcohol dependence: comparison https://pubmed.ncbi.nlm.nih.gov/20975274 NALTREXONE with naltrexone. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA R) and an https://pubmed.ncbi.nlm.nih.gov/20864883 extended release morphine sulfate capsule formulation (KADIAN R) NALTREXONE in healthy adults under fasting conditions. Potentiation of buprenorphine antinociception with ultra-low dose https://pubmed.ncbi.nlm.nih.gov/20728384 NALTREXONE naltrexone in healthy subjects.

Weight loss with naltrexone SR/bupropion SR combination therapy https://pubmed.ncbi.nlm.nih.gov/20559296 NALTREXONE as an adjunct to behavior modification: the COR-BMOD trial. NALTREXONE Clinical safety of 1500 mg oral naltrexone overdose. [Review] https://pubmed.ncbi.nlm.nih.gov/22778191 Medication Title of Article PubMed Link

Recent developments in naltrexone implants and depot injections for https://pubmed.ncbi.nlm.nih.gov/21152846 NALTREXONE opiate abuse: the new kid on the block is approaching adulthood. NALTREXONE Naltrexone in the treatment of opioid dependence. [Review] https://pubmed.ncbi.nlm.nih.gov/21085073 Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation https://pubmed.ncbi.nlm.nih.gov/21075272 containing morphine and sequestered naltrexone, in patients with NALTREXONE chronic, moderate to severe pain. Food effects on the pharmacokinetics of morphine sulfate and https://pubmed.ncbi.nlm.nih.gov/20949341 NALTREXONE naltrexone hydrochloride extended release capsules. Use of oral naltrexone for severe pruritus due to cholestatic liver https://pubmed.ncbi.nlm.nih.gov/20948447 NALTREXONE disease in children. NALTREXONE Naltrexone effects in patients with dementia. https://pubmed.ncbi.nlm.nih.gov/20889669

Acute opioid withdrawal precipitated by ingestion of crushed embeda https://pubmed.ncbi.nlm.nih.gov/20862910 (morphine extended release with sequestered naltrexone): case NALTREXONE report and the focused review of the literature. [Review] Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for https://pubmed.ncbi.nlm.nih.gov/20846190 NALTREXONE naltrexone-bupropion combination?. A randomized trial of oral naltrexone for treating opioid-dependent https://pubmed.ncbi.nlm.nih.gov/20716305 NALTREXONE offenders. Challenges to antagonist blockade during sustained-release https://pubmed.ncbi.nlm.nih.gov/20707781 NALTREXONE naltrexone treatment. Pilot trial of low-dose naltrexone and quality of life in multiple https://pubmed.ncbi.nlm.nih.gov/20695007 NALTREXONE sclerosis. Morphine sulfate and naltrexone hydrochloride extended release https://pubmed.ncbi.nlm.nih.gov/20675975 NALTREXONE capsules in patients with chronic osteoarthritis pain. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, https://pubmed.ncbi.nlm.nih.gov/20673995 NALTREXONE placebo-controlled, phase 3 trial. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi- https://pubmed.ncbi.nlm.nih.gov/20673549 NALTREXONE experiment. Medication Title of Article PubMed Link A double-blind, placebo-controlled study of N-acetyl cysteine plus https://pubmed.ncbi.nlm.nih.gov/20655182 NALTREXONE naltrexone for methamphetamine dependence. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended- release capsules versus intact product and versus naltrexone https://pubmed.ncbi.nlm.nih.gov/20637968 solution: a single-dose, randomized-sequence, open-label, three-way NALTREXONE crossover trial in healthy volunteers. Reduced cannabis use after low-dose naltrexone addition to opioid https://pubmed.ncbi.nlm.nih.gov/20631574 NALTREXONE detoxification. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and https://pubmed.ncbi.nlm.nih.gov/20626723 NALTREXONE feasibility. https://pubmed.ncbi.nlm.nih.gov/20570059 NALTREXONE Retention in naltrexone implant treatment for opioid dependence. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine https://pubmed.ncbi.nlm.nih.gov/20561758 NALTREXONE patch.

Low-dose naltrexone augmentation of nicotine replacement for https://pubmed.ncbi.nlm.nih.gov/20542391 NALTREXONE smoking cessation with reduced weight gain: a randomized trial. Risk factors for craving and relapse in heroin users treated with oral https://pubmed.ncbi.nlm.nih.gov/20537615 NALTREXONE or implant naltrexone. The effect of low-dose naltrexone on quality of life of patients with https://pubmed.ncbi.nlm.nih.gov/20534644 NALTREXONE multiple sclerosis: a randomized placebo-controlled trial. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot https://pubmed.ncbi.nlm.nih.gov/20528823 NALTREXONE investigation. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. https://pubmed.ncbi.nlm.nih.gov/20509712 NALTREXONE [Review] Efficacy and tolerability of naltrexone in the management of alcohol https://pubmed.ncbi.nlm.nih.gov/20482515 NALTREXONE dependence. [Review] [37 refs] Investigation of Beckett-Casy model 3: synthesis of novel naltrexone derivatives with contracted and expanded D-rings and their https://pubmed.ncbi.nlm.nih.gov/20478707 NALTREXONE pharmacology. Medication Title of Article PubMed Link Naltrexone in adults with intellectual disability improves compulsive https://pubmed.ncbi.nlm.nih.gov/20460140 NALTREXONE and dissocial disorders: a case report. NALTREXONE Morphine/naltrexone. [Review] [28 refs] https://pubmed.ncbi.nlm.nih.gov/20443648 Naltrexone implants compared to methadone: outcomes six months https://pubmed.ncbi.nlm.nih.gov/20424458 NALTREXONE after prison release. Early adoption of injectable naltrexone for alcohol-use disorders: https://pubmed.ncbi.nlm.nih.gov/20409441 NALTREXONE findings in the private-treatment sector. Human abuse liability assessment of oxycodone combined with ultra- https://pubmed.ncbi.nlm.nih.gov/20386884 NALTREXONE low-dose naltrexone. Effects of naltrexone treatment for alcohol-related disorders on https://pubmed.ncbi.nlm.nih.gov/20374204 NALTREXONE healthcare costs in an insured population. Extended-release naltrexone for treatment of alcohol dependence in https://pubmed.ncbi.nlm.nih.gov/20363090 NALTREXONE primary care. Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in https://pubmed.ncbi.nlm.nih.gov/20356587 NALTREXONE hyperinsulinemic women with polycystic ovary syndrome. A morphine/naltrexone combination (Embeda) for pain. [Review] [2 https://pubmed.ncbi.nlm.nih.gov/20336033 NALTREXONE refs] A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol https://pubmed.ncbi.nlm.nih.gov/20231324 NALTREXONE dependence. Long-acting depot formulations of naltrexone for heroin dependence: https://pubmed.ncbi.nlm.nih.gov/20224403 NALTREXONE a review. [Review]

Naltrexone for the treatment of alcoholism: clinical findings, https://pubmed.ncbi.nlm.nih.gov/20201811 NALTREXONE mechanisms of action, and pharmacogenetics. [Review] [131 refs] Augmentation with naltrexone to treat compulsive sexual behavior: a https://pubmed.ncbi.nlm.nih.gov/20196983 NALTREXONE case series. Severe opioid withdrawal due to misuse of new combined morphine https://pubmed.ncbi.nlm.nih.gov/20171465 NALTREXONE and naltrexone product (Embeda). NALTREXONE Naltrexone implants. https://pubmed.ncbi.nlm.nih.gov/20044669 Enhanced skin permeation of naltrexone by pulsed electromagnetic https://pubmed.ncbi.nlm.nih.gov/20014281 NALTREXONE fields in human skin in vitro. Low-dose naltrexone for treatment of duodenal Crohn's disease in a https://pubmed.ncbi.nlm.nih.gov/20014017 NALTREXONE pediatric patient. Medication Title of Article PubMed Link Naltrexone and combined behavioral intervention effects on https://pubmed.ncbi.nlm.nih.gov/19969427 NALTREXONE trajectories of drinking in the COMBINE study.

Determination of naltrexone and 6beta-naltrexol in human blood: https://pubmed.ncbi.nlm.nih.gov/19946676 comparison of high-performance liquid chromatography with NALTREXONE spectrophotometric and tandem-mass-spectrometric detection.

ALO-01 (morphine sulfate and naltrexone hydrochloride) extended- https://pubmed.ncbi.nlm.nih.gov/19944650 release capsules in the treatment of chronic pain of osteoarthritis of NALTREXONE the hip or knee: pharmacokinetics, efficacy, and safety.

An open-label study of naltrexone and bupropion combination https://pubmed.ncbi.nlm.nih.gov/19926400 NALTREXONE therapy for smoking cessation in overweight and obese subjects. Acute HPA axis response to naltrexone differs in female vs. male https://pubmed.ncbi.nlm.nih.gov/19837518 NALTREXONE smokers. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a https://pubmed.ncbi.nlm.nih.gov/19683562 NALTREXONE review. [Review] [136 refs] Pregabalin versus naltrexone in alcohol dependence: a randomised, https://pubmed.ncbi.nlm.nih.gov/19346279 NALTREXONE double-blind, comparison trial. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a https://pubmed.ncbi.nlm.nih.gov/20042414 NALTREXONE report of 3 new cases. A stress-coping profile of opioid dependent individuals entering https://pubmed.ncbi.nlm.nih.gov/20025367 NALTREXONE naltrexone treatment: a comparison with healthy controls. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non- https://pubmed.ncbi.nlm.nih.gov/19888784 dependent opioid users: a randomized, double-blind, placebo- NALTREXONE controlled, crossover study. NALTREXONE High-dose naltrexone therapy for cocaine-alcohol dependence. https://pubmed.ncbi.nlm.nih.gov/19874153 NALTREXONE Two patients with eating disorders treated by naltrexone. https://pubmed.ncbi.nlm.nih.gov/19855354 Comparison of combined bupropion and naltrexone therapy for https://pubmed.ncbi.nlm.nih.gov/19846734 NALTREXONE obesity with monotherapy and placebo. Medication Title of Article PubMed Link Improving clinical outcomes in treating heroin dependence: https://pubmed.ncbi.nlm.nih.gov/19805701 NALTREXONE randomized, controlled trial of oral or implant naltrexone. Contrave, a bupropion and naltrexone combination therapy for the https://pubmed.ncbi.nlm.nih.gov/19777400 NALTREXONE potential treatment of obesity. [Review] [59 refs] Naltrexone for the treatment of alcohol dependence among African https://pubmed.ncbi.nlm.nih.gov/19717248 NALTREXONE Americans: results from the COMBINE Study. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol https://pubmed.ncbi.nlm.nih.gov/19673746 NALTREXONE dependence. P-glycoprotein is not involved in the differential oral potency of https://pubmed.ncbi.nlm.nih.gov/19656202 NALTREXONE naloxone and naltrexone.

Neuropsychological functioning in buprenorphine maintained patients https://pubmed.ncbi.nlm.nih.gov/19650155 NALTREXONE versus abstinent heroin abusers on naltrexone hydrochloride therapy. Extended naltrexone and broad spectrum treatment or motivational https://pubmed.ncbi.nlm.nih.gov/19639303 NALTREXONE enhancement therapy. Passive diffusion of naltrexone into human and animal cells and https://pubmed.ncbi.nlm.nih.gov/19605761 NALTREXONE upregulation of cell proliferation. Effects of topiramate or naltrexone on tobacco use among male https://pubmed.ncbi.nlm.nih.gov/19595518 NALTREXONE alcohol-dependent outpatients. NALTREXONE Targeted naltrexone for problem drinkers. https://pubmed.ncbi.nlm.nih.gov/19593174 Patient and provider attitudes towards monitored naltrexone https://pubmed.ncbi.nlm.nih.gov/19591067 NALTREXONE treatment of alcohol dependence in schizophrenia.

Atypical anorexia in a male patient accompanied by strong obsessive- https://pubmed.ncbi.nlm.nih.gov/19585396 NALTREXONE compulsive symptoms successfully treated with naltrexone. NALTREXONE Questionable efficacy for naltrexone in patients with Asp40. https://pubmed.ncbi.nlm.nih.gov/19581571 Naltrexone for the treatment of obesity: review and update. [Review] https://pubmed.ncbi.nlm.nih.gov/19537999 NALTREXONE [30 refs] Predicting the effect of naltrexone and acamprosate in alcohol- https://pubmed.ncbi.nlm.nih.gov/19523047 NALTREXONE dependent patients using genetic indicators. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot https://pubmed.ncbi.nlm.nih.gov/19453963 NALTREXONE study. Efficacy of oral naltrexone on pruritus in atopic eczema: a double- https://pubmed.ncbi.nlm.nih.gov/19453814 NALTREXONE blind, placebo-controlled study. Medication Title of Article PubMed Link Intermittent marijuana use is associated with improved retention in https://pubmed.ncbi.nlm.nih.gov/19444734 NALTREXONE naltrexone treatment for opiate-dependence. Chronic ulcers caused by injection of substances: healing aided by https://pubmed.ncbi.nlm.nih.gov/19380658 NALTREXONE naltrexone. Naltrexone in drug addiction: significance in the prevention of https://pubmed.ncbi.nlm.nih.gov/19377433 NALTREXONE relapse. Bupropion and naltrexone: a review of their use individually and in https://pubmed.ncbi.nlm.nih.gov/19364254 NALTREXONE combination for the treatment of obesity. [Review] [41 refs] A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological https://pubmed.ncbi.nlm.nih.gov/19340640 NALTREXONE gambling. Naltrexone decreases heavy drinking rates in smoking cessation https://pubmed.ncbi.nlm.nih.gov/19302083 NALTREXONE treatment: an exploratory study. Early outcomes following low dose naltrexone enhancement of opioid https://pubmed.ncbi.nlm.nih.gov/19283561 NALTREXONE detoxification.

Neutral antagonist activity of naltrexone and 6beta-naltrexol in naive https://pubmed.ncbi.nlm.nih.gov/19220294 NALTREXONE and opioid-dependent C6 cells expressing a mu-opioid receptor. 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and https://pubmed.ncbi.nlm.nih.gov/19217280 NALTREXONE biological studies. A double-blind, placebo-controlled study of the opiate antagonist, https://pubmed.ncbi.nlm.nih.gov/19217077 NALTREXONE naltrexone, in the treatment of kleptomania. Sweet liking phenotype, alcohol craving and response to naltrexone https://pubmed.ncbi.nlm.nih.gov/19189996 NALTREXONE treatment in alcohol dependence.

Searching for responders to acamprosate and naltrexone in https://pubmed.ncbi.nlm.nih.gov/19170666 NALTREXONE alcoholism treatment: rationale and design of the PREDICT study. Efficacy of naltrexone in the treatment of chronic refractory itching in https://pubmed.ncbi.nlm.nih.gov/19165115 NALTREXONE burn patients: preliminary report of an open trial. Effect of extended-release naltrexone (XR-NTX) on quality of life in https://pubmed.ncbi.nlm.nih.gov/19053979 NALTREXONE alcohol-dependent patients. OPRM1 Asn40Asp predicts response to naltrexone treatment: a https://pubmed.ncbi.nlm.nih.gov/19053977 NALTREXONE haplotype-based approach. NALTREXONE Low-dose naltrexone for disease prevention and quality of life. https://pubmed.ncbi.nlm.nih.gov/19041189 Medication Title of Article PubMed Link

Holidays, triggers, and willpower--is there a role for medications? A https://pubmed.ncbi.nlm.nih.gov/19038694 commentary on "The effects of extended-release naltrexone on NALTREXONE holiday drinking in alcohol-dependent patients". Human skin permeation of 3-O-alkyl carbamate prodrugs of https://pubmed.ncbi.nlm.nih.gov/18972573 NALTREXONE naltrexone. Naltrexone aversion and treatment efficacy are greatest in humans https://pubmed.ncbi.nlm.nih.gov/18955144 NALTREXONE and rats that actively consume high levels of alcohol. Effects of alcoholism typology on response to naltrexone in the https://pubmed.ncbi.nlm.nih.gov/18828797 NALTREXONE COMBINE study. NALTREXONE Effects of naltrexone on cortisol levels in heavy drinkers. https://pubmed.ncbi.nlm.nih.gov/18824022 Dose-dependent reduction of hazardous alcohol use in a placebo- https://pubmed.ncbi.nlm.nih.gov/18796184 NALTREXONE controlled trial of naltrexone for smoking cessation. The effects of extended-release naltrexone on holiday drinking in https://pubmed.ncbi.nlm.nih.gov/18775624 NALTREXONE alcohol-dependent patients. Very low dose naltrexone addition in opioid detoxification: a https://pubmed.ncbi.nlm.nih.gov/18715283 NALTREXONE randomized, controlled trial. A double-blind, placebo-controlled study of sertraline with naltrexone https://pubmed.ncbi.nlm.nih.gov/18644685 NALTREXONE for alcohol dependence. Aripiprazole in the treatment of patients with alcohol dependence: a https://pubmed.ncbi.nlm.nih.gov/18515460 NALTREXONE double-blind, comparison trial vs. naltrexone. Piperazinylalkyl prodrugs of naproxen improve in vitro skin http://www.ncbi.nlm.nih.gov/pubmed/10915963 NAPROXEN permeation Topical nonsteroidal anti-inflammatory drugs in uncomplicated http://www.ncbi.nlm.nih.gov/pubmed/16167290 NAPROXEN cataract surgery: effect of sodium naproxen Topical naproxen sodium for inhibition of miosis during cataract http://www.ncbi.nlm.nih.gov/pubmed/12032720 NAPROXEN surgery. Prospective, randomized clinical trials NAPROXEN Synthesis and in vitro skin permeation of naproxen conjugates with http://www.ncbi.nlm.nih.gov/pubmed/16305419 CONJUGATES alpha-alkylamino acids Clinical trial: endoscopic evaluation of naproxen etemesil, a naproxen NAPROXEN prodrug, vs. naproxen - a proof-of-concept, randomized, double- http://www.ncbi.nlm.nih.gov/pubmed/20804454 ETEMESIL blind, active-comparator study NAPROXEN Novel organogels for topical delivery of naproxen: design, http://www.ncbi.nlm.nih.gov/pubmed/26786600 ETEMESIL physicochemical characteristics and in vitro drug permeation Medication Title of Article PubMed Link Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in http://www.ncbi.nlm.nih.gov/pubmed/11745923 NARATRIPTAN male rats NARATRIPTAN Naratriptan http://www.ncbi.nlm.nih.gov/pubmed/10692743 NARATRIPTAN Newer intranasal migraine medications http://www.ncbi.nlm.nih.gov/pubmed/10643958 Newer formulations of the triptans: advances in migraine http://www.ncbi.nlm.nih.gov/pubmed/14524731 NARATRIPTAN management NARATRIPTAN Effect of subcutaneous naratriptan on forearm blood flow http://www.ncbi.nlm.nih.gov/pubmed/9793700

NASAL IRRIGATION http://www.ncbi.nlm.nih.gov/pubmed/11458213 DEVICES Nasal irrigation for the alleviation of sinonasal symptoms

NASAL IRRIGATION http://www.ncbi.nlm.nih.gov/pubmed/22727153 DEVICES Is nasal saline irrigation all it is cracked up to be?

NASAL IRRIGATION http://www.ncbi.nlm.nih.gov/pubmed/26750306 DEVICES Frontal sinus surgery and sinus distribution of nasal irrigation

NASAL IRRIGATION http://www.ncbi.nlm.nih.gov/pubmed/25892369 DEVICES Saline nasal irrigation for acute upper respiratory tract infections

NASAL IRRIGATION Impact of saline irrigation and topical corticosteroids on the http://www.ncbi.nlm.nih.gov/pubmed/25556553 DEVICES postsurgical sinonasal microbiota Clinical observation and quality of life in terms of nasal sinusitis after NASAL IRRIGATION radiotherapy for nasopharyngeal carcinoma: long-term results from http://www.ncbi.nlm.nih.gov/pubmed/24814695 TECHNIQUES different nasal irrigation techniques

NASAL IRRIGATION Does nasal irrigation enter paranasal sinuses in chronic http://www.ncbi.nlm.nih.gov/pubmed/18954507 TECHNIQUES rhinosinusitis? Nasal Saline for Chronic Sinonasal Symptoms: A Randomized http://www.ncbi.nlm.nih.gov/pubmed/18025315 NASAL SALINE Controlled Trial http://www.ncbi.nlm.nih.gov/pubmed/17636843 NASAL SALINE Nasal saline irrigations for the symptoms of chronic rhinosinusitis Nasal irrigation as an adjunctive treatment in allergic rhinitis: a http://www.ncbi.nlm.nih.gov/pubmed/23168142 NASAL SALINE systematic review and meta-analysis Medication Title of Article PubMed Link Limited evidence: higher efficacy of nasal saline irrigation over nasal saline spray in chronic rhinosinusitis--an update and reanalysis of the http://www.ncbi.nlm.nih.gov/pubmed/24243927 NASAL SALINE evidence base NASAL SALINE Clinical study and literature review of nasal irrigation http://www.ncbi.nlm.nih.gov/pubmed/10892694 Prospective evaluation of aerosol delivery by a powered nasal http://www.ncbi.nlm.nih.gov/pubmed/22287468 NASONEB nebulizer in the cadaver model Particle size and airflow: Implications for nasal and paranasal sinus http://www.nasoneb.com/pdfs/NasoNebparticlesizeairf NASONEB delivery low.pdf Effects of Intranasal Budesonide Delivered by Nasal Nebulizer on http://www.nasoneb.com/pdfs/EffectsIntranasalBudes Symptoms and Objective Measures of Nasal Congestion in Perennial onideDeliveredbyNasalNebulizer.pdf NASONEB Allergic Rhinitis (PAR) http://www.habanapharm.com/resource- NASONEB NasoNeb Case Study - Habana Hospital Pharmacy pdfs/NasoNeb-Case-Study.pdf Continuous vs. tapering application of the potent topical corticosteroid mometasone furoate in the treatment of vulvar lichen http://www.ncbi.nlm.nih.gov/pubmed/26280156 NASONEB sclerosus: results of a randomized trial The Efficacy and Safety of Eberconazole Nitrate 1% and Mometasone Furoate 0.1% w/w Cream in Subjects with Inflamed http://www.ncbi.nlm.nih.gov/pubmed/26216438 NASONEB Cutaneous Mycoses Growing evidence for topical mometasone fuoroate in the treatment http://www.ncbi.nlm.nih.gov/pubmed/25449823 NASONEB of Vulvar Lichen Sclerosus Decreasing bacterial cross-contamination with a pulsating nasal http://www.ncbi.nlm.nih.gov/pubmed/24827926 NEILMED irrigation device NEILMED Surfactants in the management of rhinopathologies http://www.ncbi.nlm.nih.gov/pubmed/23710951 http://www.ncbi.nlm.nih.gov/pubmed/22287307 NEILMED Irrigation penetration of nasal delivery systems: a cadaver study Radiographic Comparison of Three Methods for Nasal Saline http://www.neilmed.com/articles/laryngoscope2004.pd NEILMED Irrigation f NEILMED/RINOFLO Long-term outcome of once daily nasal irrigation for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/23712296 W pediatric chronic rhinosinusitis Efficacy of endonasal - pivalate irrigation in the NEOMYCIN https://www.ncbi.nlm.nih.gov/pubmed/3523368 treatment of chronic allergic and bacterial sinusitis NEOMYCIN- Comparison of 1-day versus 1-hour application of topical https://www.ncbi.nlm.nih.gov/pubmed/25840297 POLYMYXIN neomycin/polymyxin-B before cataract surgery Medication Title of Article PubMed Link NEOMYCIN- Ofloxacin otic drops vs neomycin- otic drops as https://www.ncbi.nlm.nih.gov/pubmed/17178938 POLYMYXIN prophylaxis against early postoperative tympanostomy tube otorrhea A double-blind comparative study of ofloxacin otic drops versus NEOMYCIN- neomycin-polymyxin B-hydrocortisone otic drops in the medical https://www.ncbi.nlm.nih.gov/pubmed/8733449 POLYMYXIN treatment of chronic suppurative otitis media Topical ophthalmic NSAIDs: a discussion with focus on nepafenac http://www.ncbi.nlm.nih.gov/pubmed/19668727 NEPAFENAC ophthalmic suspension http://www.ncbi.nlm.nih.gov/pubmed/18001248 NEPAFENAC Cystoid and diabetic macular edema treated with nepafenac 0.1% In vivo pharmacokinetics and in vitro pharmacodynamics of http://www.ncbi.nlm.nih.gov/pubmed/17720067 NEPAFENAC nepafenac, amfenac, ketorolac, and bromfenac Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of http://www.ncbi.nlm.nih.gov/pubmed/10850857 NEPAFENAC anti-inflammatory efficacy http://www.ncbi.nlm.nih.gov/pubmed/24227908 NEPAFENAC Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema Management of ocular inflammation and pain following cataract http://www.ncbi.nlm.nih.gov/pubmed/19668566 NEPAFENAC surgery: focus on bromfenac ophthalmic solution http://www.touchophthalmology.com/articles/nepafena Nepafenac in the Prevention and Treatment of Ocular Inflammation c-prevention-and-treatment-ocular-inflammation-and- and Pain Following Cataract Surgery and in the Prevention of Post- pain-following-cataract-surgery- NEPAFENAC operative Macular Oedema in Diabetic Patients Fighting ocular infections Point Counterpoint Advancements in topical http://www.eyeworld.org/article.php?sid=3264 NEVANAC ophthalmic NSAIDs Randomized controlled pilot trial of as oral therapy vs. http://www.ncbi.nlm.nih.gov/pubmed/24035211 NIFEDIPINE topical application in the treatment of fissure-in-ano. Confirmed efficacy of topical nifedipine in the treatment of facial http://www.ncbi.nlm.nih.gov/pubmed/23688162 NIFEDIPINE wrinkles. http://www.ncbi.nlm.nih.gov/pubmed/21287460 NIFEDIPINE The effect of topical nifedipine in treatment of chronic anal fissure. Topical nifedipine for the treatment of localized provoked vulvodynia: http://www.ncbi.nlm.nih.gov/pubmed/20537958 NIFEDIPINE a placebo-controlled study. Medication Title of Article PubMed Link Topical nifedipine with lidocaine ointment versus active control for pain after hemorrhoidectomy: results of a multicentre, prospective, http://www.ncbi.nlm.nih.gov/pubmed/20100408 NIFEDIPINE randomized, double-blind study. NIFEDIPINE Treatment of periocular wrinkles with topical nifedipine. http://www.ncbi.nlm.nih.gov/pubmed/19929263 Serum levels and possible haemodynamic effects following anorectal application of an ointment containing nifedipine and lignocaine : a http://www.ncbi.nlm.nih.gov/pubmed/17163278 NIFEDIPINE study in healthy volunteers. Topical 0.5% nifedipine vs. lateral internal sphincterotomy for the http://www.ncbi.nlm.nih.gov/pubmed/16091912 NIFEDIPINE treatment of chronic anal fissure: long-term follow-up. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic http://www.ncbi.nlm.nih.gov/pubmed/12794583 NIFEDIPINE anal fissure. Conservative treatment of acute thrombosed external http://www.ncbi.nlm.nih.gov/pubmed/11289288 NIFEDIPINE with topical nifedipine. Nifedipine for local use in conservative treatment of anal fissures: http://www.ncbi.nlm.nih.gov/pubmed/10458123 NIFEDIPINE preliminary results of a multicenter study. Prevention and management of chemotherapy-induced peripheral Nortriptyline neuropathy in survivors of adult cancers: American Society of Clinical https://www.ncbi.nlm.nih.gov/pubmed/24733808 Oncology clinical practice guideline. NSAIDs Topical ocular delivery of NSAIDs http://www.ncbi.nlm.nih.gov/pubmed/18437583 Microencapsulation: an acclaimed novel drug-delivery system for http://www.ncbi.nlm.nih.gov/pubmed/21175420 NSAIDs NSAIDs in arthritis Prodrugs of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), More http://www.ncbi.nlm.nih.gov/pubmed/21175420 NSAIDs Than Meets the Eye: A Critical Review NSAIDs Prodrugs: design and clinical applications. http://www.ncbi.nlm.nih.gov/pubmed/18219308 NSAIDs Prodrug designing of NSAIDs http://www.ncbi.nlm.nih.gov/pubmed/19149665 Enhancing Skin Permeation of Biphenylacetic Acid (BPA) Using Salt http://www.scipharm.at/download.asp?id=1585 NSAIDs Formation with Organic and Alkali Metal Bases

One-Day Use of Preoperative Topical Nonsteroidal Anti-Inflammatory http://www.ncbi.nlm.nih.gov/pubmed/26681407 Drug Prevents Intraoperative Prostaglandin Level Elevation During NSAIDs Femtosecond Laser-Assisted Cataract Surgery Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % http://www.ncbi.nlm.nih.gov/pubmed/26553195 NSAIDs pranoprofen) on acute central serous chorioretinopathy Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal http://www.ncbi.nlm.nih.gov/pubmed/26502088 NSAIDs Diseases Medication Title of Article PubMed Link Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of http://www.ncbi.nlm.nih.gov/pubmed/22367354 NSAIDs Drug, Delivery, and Therapeutic Outcome NSAIDS LINKED TO CHOLINE BIOISOSTERES/ ANALOGS OF http://www.ncbi.nlm.nih.gov/pubmed/21319177 ACETYLCHOLINEST ERASE (ACHE) Investigation of anticholinergic and non-steroidal anti-inflammatory INHIBITORS prodrugs which reduce chemically induced skin inflammation Antifungal topical therapy in oral chronic candidosis. A comparative http://www.ncbi.nlm.nih.gov/pubmed/12134127 NYSTATIN study Comparison of Photodynamic Therapy versus conventional antifungal therapy for the treatment of denture stomatitis: a http://www.ncbi.nlm.nih.gov/pubmed/22731617 NYSTATIN randomized clinical trial Microwave denture disinfection versus nystatin in treating patients with well-controlled type 2 diabetes and denture stomatitis: a http://www.ncbi.nlm.nih.gov/pubmed/22545252 NYSTATIN randomized clinical trial Clinical study on the dose-effect relationship of a -nystatin http://www.ncbi.nlm.nih.gov/pubmed/14650366 NYSTATIN combination in the treatment of vulvo-vaginal infections NYSTATIN Common Skin Conditions in Children: Skin Infections. https://www.ncbi.nlm.nih.gov/pubmed/28196318 Nystatin and miconazole: pharmacological and clinical evidence https://www.ncbi.nlm.nih.gov/pubmed/27416928 NYSTATIN regarding interactions with warfarin. Efficacy of nystatin for the treatment of oral candidiasis: a systematic https://www.ncbi.nlm.nih.gov/pmc/articles/PMC48011 NYSTATIN review and meta-analysis 47/

Topical gentian violet compared with nystatin oral suspension for the https://www.ncbi.nlm.nih.gov/pubmed/27677161 NYSTATIN treatment of oropharyngeal candidiasis in HIV-1-infected participants. Comprehensive report of olopatadine 0.6% nasal spray as treatment http://www.ncbi.nlm.nih.gov/pubmed/21477426 OLOPATADINE for children with seasonal allergic rhinitis. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in http://www.ncbi.nlm.nih.gov/pubmed/21352639 OLOPATADINE patients with vasomotor rhinitis. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic http://www.ncbi.nlm.nih.gov/pubmed/20302683 OLOPATADINE rhinitis. Medication Title of Article PubMed Link Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in http://www.ncbi.nlm.nih.gov/pubmed/20031007 OLOPATADINE pediatric subjects with allergic rhinitis.

Comparison of olopatadine 0.6% nasal spray versus fluticasone http://www.ncbi.nlm.nih.gov/pubmed/19549426 OLOPATADINE propionate 50 microg in the treatment of seasonal allergic rhinitis. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, http://www.ncbi.nlm.nih.gov/pubmed/19243710 randomized, double-blind, active- and placebo-controlled study in OLOPATADINE adolescents and adults. The effects of the nasal antihistamines olopatadine and azelastine in http://www.ncbi.nlm.nih.gov/pubmed/18681089 OLOPATADINE nasal allergen provocation. Safety and efficacy of olopatadine hydrochloride nasal spray for the http://www.ncbi.nlm.nih.gov/pubmed/16400902 OLOPATADINE treatment of seasonal allergic rhinitis. Safety and efficacy of olopatadine hydrochloride nasal spray for the http://www.ncbi.nlm.nih.gov/pubmed/16312171 OLOPATADINE treatment of seasonal allergic rhinitis to mountain cedar.

Efficacy and tolerability of olsalazine (dipentum) in the treatment of https://pubmed.ncbi.nlm.nih.gov/16795963 OLSALAZINE patients with ulcerative colitis--results of a field study. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative https://pubmed.ncbi.nlm.nih.gov/11149559 OLSALAZINE colitis. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or https://pubmed.ncbi.nlm.nih.gov/10102969 OLSALAZINE mesalazine. Olsalazine versus mesalazine in the treatment of mild to moderate https://pubmed.ncbi.nlm.nih.gov/9726382 OLSALAZINE ulcerative colitis.

Systemic absorption of 5-aminosalicylic acid in patients with inactive https://pubmed.ncbi.nlm.nih.gov/9262986 OLSALAZINE ulcerative colitis treated with olsalazine and mesalazine. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or https://pubmed.ncbi.nlm.nih.gov/8971292 OLSALAZINE mesalazine.

Systemic absorption of 5-aminosalicylic acid in patients with inactive https://pubmed.ncbi.nlm.nih.gov/8944370 OLSALAZINE ulcerative colitis treated with olsalazine and mesalazine. Medication Title of Article PubMed Link

Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit https://pubmed.ncbi.nlm.nih.gov/8686349 OLSALAZINE L coated mesalazine in patients with ulcerative colitis in remission. Olsalazine versus sulphasalazine for relapse prevention in ulcerative https://pubmed.ncbi.nlm.nih.gov/7872274 OLSALAZINE colitis: a multicenter study. Double-blind dose-finding study of olsalazine versus sulphasalazine https://pubmed.ncbi.nlm.nih.gov/7614099 OLSALAZINE as maintenance therapy for ulcerative colitis. Optimum dose of olsalazine for maintaining remission in ulcerative https://pubmed.ncbi.nlm.nih.gov/7959238 OLSALAZINE colitis. Pancreatitis associated with olsalazine and sulfasalazine in children https://pubmed.ncbi.nlm.nih.gov/7520936 OLSALAZINE with ulcerative colitis. OLSALAZINE Use of mesalamine and olsalazine in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/8237737 Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology https://pubmed.ncbi.nlm.nih.gov/8102399 OLSALAZINE Collaborative Research Group Clinical Trial. Mesalazine versus olsalazine for prophylaxis of ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/1360580 OLSALAZINE relapse. Comparisons of olsalazine and mesalazine in prevention of relapse in https://pubmed.ncbi.nlm.nih.gov/1354814 OLSALAZINE ulcerative colitis. Randomised comparison of olsalazine and mesalazine in prevention https://pubmed.ncbi.nlm.nih.gov/1349676 OLSALAZINE of relapses in ulcerative colitis. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double- https://pubmed.ncbi.nlm.nih.gov/1348159 blind, randomized multicenter study. The Ulcerative Colitis OLSALAZINE Multicenter Study Group. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine https://pubmed.ncbi.nlm.nih.gov/1347280 OLSALAZINE Study Group. Double-blind placebo-controlled study of olsalazine in the treatment https://pubmed.ncbi.nlm.nih.gov/2337059 OLSALAZINE of ulcerative colitis. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: https://pubmed.ncbi.nlm.nih.gov/2253912 comparison of intraluminal colonic concentrations, serum values, and OLSALAZINE urinary excretion. OLSALAZINE Olsalazine for ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/2233512 Medication Title of Article PubMed Link https://pubmed.ncbi.nlm.nih.gov/2131213 OLSALAZINE Olsalazine--a further choice in ulcerative colitis. [Review] [22 refs] Olsalazine versus placebo in the treatment of mild to moderate https://pubmed.ncbi.nlm.nih.gov/2684804 OLSALAZINE ulcerative colitis: a randomised double blind trial. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A https://pubmed.ncbi.nlm.nih.gov/2567266 OLSALAZINE double blind study. https://pubmed.ncbi.nlm.nih.gov/3227311 OLSALAZINE Olsalazine in active ulcerative colitis: dose finding study in Japan. Long-term treatment with olsalazine for ulcerative colitis: safety and https://pubmed.ncbi.nlm.nih.gov/3227309 OLSALAZINE relapse prevention: a follow-up study.

Proceedings of the First International Symposium on Olsalazine in https://pubmed.ncbi.nlm.nih.gov/3227306 OLSALAZINE the Treatment of Ulcerative Colitis. Oxford, March 1987. Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long https://pubmed.ncbi.nlm.nih.gov/3067341 OLSALAZINE term.

Olsalazine in the treatment of active ulcerative colitis: a placebo https://pubmed.ncbi.nlm.nih.gov/3067339 OLSALAZINE controlled clinical trial and assessment of drug disposition.

Olsalazine in the treatment of mild to moderate ulcerative colitis: a https://pubmed.ncbi.nlm.nih.gov/3067338 OLSALAZINE randomized, placebo-controlled, double-blind, clinical trial. Treatment of ulcerative colitis with olsalazine and sulphasalazine: https://pubmed.ncbi.nlm.nih.gov/2906479 OLSALAZINE efficacy and side-effects. Controlled trial comparing olsalazine and sulphasalazine for https://pubmed.ncbi.nlm.nih.gov/2906477 OLSALAZINE maintenance treatment of ulcerative colitis. Double-blind comparison of olsalazine and sulphasalazine in active https://pubmed.ncbi.nlm.nih.gov/2906476 OLSALAZINE ulcerative colitis. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo- https://pubmed.ncbi.nlm.nih.gov/2906474 OLSALAZINE controlled, double-blind, dose-ranging clinical trial. Controlled trial comparing olsalazine and sulphasalazine for the https://pubmed.ncbi.nlm.nih.gov/2898422 OLSALAZINE maintenance treatment of ulcerative colitis. Medication Title of Article PubMed Link Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's https://pubmed.ncbi.nlm.nih.gov/2840367 OLSALAZINE colitis. https://pubmed.ncbi.nlm.nih.gov/3428673 OLSALAZINE Influence of olsalazine on gastrointestinal transit in ulcerative colitis. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, https://pubmed.ncbi.nlm.nih.gov/2890550 OLSALAZINE placebo-controlled, double-blind, dose-ranging clinical trial. OLSALAZINE Olsalazine in active ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/3933675 ORAL Oral supplementation with a nutraceutical containing Echinacea, SUPPLEMENTATIO methionine and antioxidant/immunostimulating compounds in http://www.ncbi.nlm.nih.gov/pubmed/21566549 N patients with cutaneous viral warts.

ORAL Complementary treatment with oral pidotimod plus after http://www.ncbi.nlm.nih.gov/pubmed/20945819 SUPPLEMENTATIO laser vaporization for female genital warts: a prospective study. N ORAL SUPPLEMENTATIO http://www.ncbi.nlm.nih.gov/pubmed/20064186 N Propolis as an alternative treatment for cutaneous warts. ORAL SUPPLEMENTATIO http://www.ncbi.nlm.nih.gov/pubmed/12416358 N Cimetidine therapy for multiple warts in children ORAL SUPPLEMENTATIO http://www.ncbi.nlm.nih.gov/pubmed/10844489 N Treatment of viral warts with cimetidine: an open-label study. ORAL SUPPLEMENTATIO Delivery of to the skin by a novel liquid skin cleanser: http://www.ncbi.nlm.nih.gov/pubmed/15131729 N comparison of topical versus oral supplementation ORAL Topical alpha-tocotrienol supplementation inhibits lipid peroxidation SUPPLEMENTATIO but fails to mitigate increased transepidermal water loss after benzoyl http://www.ncbi.nlm.nih.gov/pubmed/12521598 N peroxide treatment of human skin ORAL SUPPLEMENTATIO Effects of extended systemic and topical folate supplementation on http://www.ncbi.nlm.nih.gov/pubmed/7047579 N gingivitis of pregnancy Medication Title of Article PubMed Link Ex vivo percutaneous absorption of ketamine, , diclofenac, gabapentin, orphenadrine, and pentoxifylline: comparison http://www.ncbi.nlm.nih.gov/pubmed/24579304 ORPHENADRINE of versatile cream vs. reference cream

Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double- http://www.ncbi.nlm.nih.gov/pubmed/15553107 blind cross-over study using laser somatosensory evoked potentials ORPHENADRINE obtained from capsaicin-irritated skin in healthy volunteers Micellar paclitaxel improves severe psoriasis in a prospective phase https://www.ncbi.nlm.nih.gov/pubmed/?term=1503450 PACLITAXEL II pilot study. 2 PARI SINUS A prospective controlled trial of pulsed nasal nebulizer in maximally http://www.ncbi.nlm.nih.gov/pubmed/18702903 NEBULIZER dissected cadavers PARI SINUS Pari sinus inhalation versus metered pump spray in postoperative http://www.ncbi.nlm.nih.gov/pubmed/20597040 NEBULIZER care after FESS The Effects Of Methacholine Challenge Administered Using Three https://clinicaltrials.gov/ct2/show/NCT00529477 PARI SINUSTAR Different On Small Airways Function A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, https://www.ncbi.nlm.nih.gov/pubmed/10997497 PENCICLOVIR double-blind, multicentre trial. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/9134943 PENCICLOVIR Topical Penciclovir Collaborative Study Group. Efficacy of 80% solution in comparison with cryotherapy in the http://www.ncbi.nlm.nih.gov/pubmed/19122958 PHENOL (80%) treatment of common warts of hands. Lesional blistering following narrow-band (TL-01) UVB phototherapy PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=1419769 for psoriasis: a report of four cases. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=1493096 Psoriasis symposium. Phototherapy. Multiple carcinoma in patients with psoriasis caused by psoralen- PHOTOTHERAPY ultraviolet A therapy, natural killer cell insufficiency, or intensified sun https://www.ncbi.nlm.nih.gov/pubmed/?term=1628511 exposure?. Are topical corticosteroids useful adjunctive therapy for the treatment PHOTOTHERAPY of psoriasis with ultraviolet radiation? A review of the literature. https://www.ncbi.nlm.nih.gov/pubmed/?term=1952979 [Review] [17 refs] Medication Title of Article PubMed Link Comparison of narrow-band UV-B phototherapy and PUVA PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=1972833 photochemotherapy in the treatment of psoriasis. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=1977266 Vitamin D metabolism in psoriasis before and after phototherapy. Induction of disseminated superficial actinic porokeratosis by PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=2007687 phototherapy for psoriasis. Genital tumors among men with psoriasis exposed to psoralens and PHOTOTHERAPY ultraviolet A radiation (PUVA) and ultraviolet B radiation. The https://www.ncbi.nlm.nih.gov/pubmed/?term=2320078 Photochemotherapy Follow-up Study. Is the effect of phototherapy in psoriasis partly due to an impact on PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=2461030 vitamin D metabolism?. Tin-protoporphyrin and long wave length ultraviolet light in treatment PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=2566782 of psoriasis. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=2572842 Salicylic acid and ultraviolet B for psoriasis. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=2654215 Are topical corticosteroids useful in phototherapy for psoriasis?.

PHOTOTHERAPY Palmoplantar psoriasis: experience with 8-methoxypsoralen soaks https://www.ncbi.nlm.nih.gov/pubmed/?term=2754058 plus ultraviolet A with the use of a high-output metal halide device. Elevated plasma interleukin-1 levels in humans following ultraviolet PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=2783951 light therapy for psoriasis. Effectiveness of relaxation and visualization techniques as an adjunct PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=3049703 to phototherapy and photochemotherapy of psoriasis. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=3203066 311 nm UVB phototherapy--an effective treatment for psoriasis. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=3246075 UVB phototherapy for psoriasis of skin type V. Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=3292621 in the treatment of psoriasis vulgaris. Photosensitive psoriasis provoked by a suberythematous dose of PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=3378651 ultraviolet-B light. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=3408653 A new development in UVB phototherapy of psoriasis. Medication Title of Article PubMed Link Successful ultraviolet B treatment of psoriasis is accompanied by a PHOTOTHERAPY reversal of keratinocyte pathology and by selective depletion of https://www.ncbi.nlm.nih.gov/pubmed/?term=7500051 intraepidermal T cells. Combination of methoxsalen and ultraviolet B (UVB) versus UVB PHOTOTHERAPY radiation alone in treatment of psoriasis: a bilateral comparison https://www.ncbi.nlm.nih.gov/pubmed/?term=7654566 study. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=7792227 UVB phototherapy in childhood psoriasis. Effects of topical preparations on the erythemogenicity of UVB: PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=7868718 implications for psoriasis phototherapy.

PHOTOTHERAPY Treatment of psoriasis with psoralens and ultraviolet A. A double- https://www.ncbi.nlm.nih.gov/pubmed/?term=7880762 blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Evaluation of psoralen with solar ultraviolet light (puvasol) and PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8083550 adjunctive topical tar therapy in psoriasis. Combination phototherapy of psoriasis with calcipotriol and narrow- PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8105177 band UVB. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8148279 Photoprotective action of emollients in ultraviolet therapy of psoriasis.

PHOTOTHERAPY Determination of 8-methoxypsoralen kinetics: a relevant factor in the https://www.ncbi.nlm.nih.gov/pubmed/?term=8180098 treatment of psoriasis by psoralen plus ultraviolet A therapy. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8243097 Psoriasis and ultraviolet radiation. [Review] [54 refs] Narrow-band UVB (311 nm) versus conventional broad-band UVB PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8432920 with and without dithranol in phototherapy for psoriasis. Failure of to accelerate psoriasis clearance in narrow- PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8471514 band UVB phototherapy or photochemotherapy. Efficacy of ultraviolet B phototherapy for psoriasis in patients infected PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8555008 with human immunodeficiency virus. Oral calcitriol (1,25-dihydroxyvitamin D3) does not augment UVB PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8708038 phototherapy for plaque psoriasis. PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8771865 A review of ultraviolet treatment for psoriasis at Waikato Hospital. Medication Title of Article PubMed Link An assessment of potential problems of home phototherapy PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8823554 treatment of psoriasis. Development of cutaneous tolerance to ultraviolet B during ultraviolet PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8897592 B phototherapy for psoriasis.

PHOTOTHERAPY Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin https://www.ncbi.nlm.nih.gov/pubmed/?term=8912562 D3) on vitamin D photosynthesis in patients with psoriasis. Surface dosimetry in phototherapy: comparison of three ultraviolet B PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=8977717 lamps used in the treatment of psoriasis. Malignant melanoma in patients treated for psoriasis with PHOTOTHERAPY methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The https://www.ncbi.nlm.nih.gov/pubmed/?term=9091799 PUVA Follow-Up Study. Effects of phototherapy on the production of cytokines by peripheral PHOTOTHERAPY blood mononuclear cells and on systemic antibody responses in https://www.ncbi.nlm.nih.gov/pubmed/?term=9112279 patients with psoriasis. Comparison of phototherapy with near vs. far erythemogenic doses PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=9536229 of narrow-band ultraviolet B in patients with psoriasis. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=9666830 psoriasis: three times or five times weekly treatment?. Low-dose narrow-band UVB phototherapy combined with topical PHOTOTHERAPY therapy is effective in psoriasis and does not inhibit systemic T-cell https://www.ncbi.nlm.nih.gov/pubmed/?term=9669117 activation. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis PHOTOTHERAPY and persistent risk of nonmelanoma skin cancer. PUVA Follow-up https://www.ncbi.nlm.nih.gov/pubmed/?term=9731734 Study.

PHOTOTHERAPY Dithranol embedded in crystalline monoglycerides combined with https://www.ncbi.nlm.nih.gov/pubmed/?term=9745140 phototherapy (UVB): a new approach in the treatment of psoriasis. Narrowband ultraviolet B (TL-01) phototherapy for psoriasis: which PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=9767284 incremental regimen?. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=9773769 severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Medication Title of Article PubMed Link Alterations in HIV expression in AIDS patients with psoriasis or PHOTOTHERAPY https://www.ncbi.nlm.nih.gov/pubmed/?term=9922012 pruritus treated with phototherapy. https://www.ncbi.nlm.nih.gov/pubmed/?term=1023057 PHOTOTHERAPY Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. 9 Do the known risks now outweigh the benefits?. [Review] [115 refs] Coexistence of psoriasis and familial benign chronic pemphigus: https://www.ncbi.nlm.nih.gov/pubmed/?term=1023325 PHOTOTHERAPY efficacy of ultraviolet B treatment. 0 Large increments in psoralen-ultraviolet A (PUVA) therapy are https://www.ncbi.nlm.nih.gov/pubmed/?term=1023331 PHOTOTHERAPY unsuitable for fair-skinned individuals with psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1032152 PHOTOTHERAPY Narrowband UVB phototherapy for psoriasis: results with fixed 0 increments by skin type (as opposed to percentage increments). Narrowband UV-B phototherapy vs photochemotherapy in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1032819 PHOTOTHERAPY treatment of chronic plaque-type psoriasis: a paired comparison 0 study. The efficacy of narrowband ultraviolet B phototherapy in psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1035402 PHOTOTHERAPY using objective and subjective outcome measures. 7 Topical calcipotriol combined with phototherapy for psoriasis. The https://www.ncbi.nlm.nih.gov/pubmed/?term=1049029 PHOTOTHERAPY results of two randomized trials and a review of the literature. 7 Calcipotriol-UVB Study Group. [Review] [31 refs] A randomized comparison of narrow-band TL-01 phototherapy and https://www.ncbi.nlm.nih.gov/pubmed/?term=1053463 PHOTOTHERAPY PUVA photochemotherapy for psoriasis. 5 No additional effect of calcipotriol ointment on low-dose narrow-band https://www.ncbi.nlm.nih.gov/pubmed/?term=1057038 PHOTOTHERAPY UVB phototherapy in psoriasis. 6 Evaluation of a multicentre study of synchronous application of https://www.ncbi.nlm.nih.gov/pubmed/?term=1079222 PHOTOTHERAPY narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead 5 Sea salt solution for psoriasis vulgaris. https://www.ncbi.nlm.nih.gov/pubmed/?term=1097131 PHOTOTHERAPY Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in 7 epidermal cells following UVB therapy for psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1106949 PHOTOTHERAPY A controlled study of ultraviolet A sunbed treatment of psoriasis. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1106950 PHOTOTHERAPY A controlled study of ultraviolet A sunbed treatment of psoriasis. 2 Medication Title of Article PubMed Link Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1112345 PHOTOTHERAPY treatment of plaque-type psoriasis: our experience with fitzpatrick 3 skin type IV. Transmittance properties of flurandrenolide tape for psoriasis: helpful https://www.ncbi.nlm.nih.gov/pubmed/?term=1123119 PHOTOTHERAPY adjunct to phototherapy. 7 Calcitriol 3 microg g-1 ointment in combination with ultraviolet B https://www.ncbi.nlm.nih.gov/pubmed/?term=1126000 PHOTOTHERAPY phototherapy for the treatment of plaque psoriasis: results of a 5 comparative study. Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol https://www.ncbi.nlm.nih.gov/pubmed/?term=1126003 PHOTOTHERAPY increases the responsiveness to 311-nm ultraviolet B: results of a 1 controlled, right/left study. Human papillomavirus in cutaneous squamous cell carcinoma and https://www.ncbi.nlm.nih.gov/pubmed/?term=1126054 PHOTOTHERAPY cervix of a patient with psoriasis and extensive ultraviolet radiation 8 exposure. Balneophototherapy--combined treatment of psoriasis vulgaris and https://www.ncbi.nlm.nih.gov/pubmed/?term=1130539 PHOTOTHERAPY atopic dermatitis with salt water baths and artificial ultraviolet 4 radiation. [Review] [30 refs] Phototherapy of psoriasis: comparative experience of different https://www.ncbi.nlm.nih.gov/pubmed/?term=1130683 PHOTOTHERAPY phototherapeutic approaches. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1142205 PHOTOTHERAPY Vitiligo following narrow-band TL-01 phototherapy for psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1142218 PHOTOTHERAPY Phototherapy for psoriasis. [Review] [44 refs] 7 Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=1151131 PHOTOTHERAPY psoriasis.[Erratum appears in J Invest Dermatol 2001 7 Dec;117(6):1688] A comparison of the effect of narrow-band ultraviolet B in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1153181 PHOTOTHERAPY treatment of psoriasis after salt-water baths and after 8- 1 methoxypsoralen baths. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. https://www.ncbi.nlm.nih.gov/pubmed/?term=1156873 PHOTOTHERAPY [Review] [99 refs] 7 Narrowband UVB phototherapy for the treatment of psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1176612 PHOTOTHERAPY review and update. [Review] [15 refs] 0 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1190750 PHOTOTHERAPY Phototherapy utilization for psoriasis is declining in the United States. 8 Phototherapy of psoriasis: update with practical pearls. [Review] [31 https://www.ncbi.nlm.nih.gov/pubmed/?term=1197698 PHOTOTHERAPY refs] 2 Xenon chloride ultraviolet B laser is more effective in treating https://www.ncbi.nlm.nih.gov/pubmed/?term=1200746 PHOTOTHERAPY psoriasis and in inducing T cell apoptosis than narrow-band 5 ultraviolet B. Incidence and risk factors associated with a second squamous cell https://www.ncbi.nlm.nih.gov/pubmed/?term=1206040 PHOTOTHERAPY carcinoma or basal cell carcinoma in psoralen + ultraviolet a light- 0 treated psoriasis patients. The persistent risk of genital tumors among men treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=1207757 PHOTOTHERAPY psoralen plus ultraviolet A (PUVA) for psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1216474 PHOTOTHERAPY UV-B phototherapy clears psoriasis through local effects. 5 Chronic actinic dermatitis developed during phototherapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1220768 PHOTOTHERAPY psoriasis. 2 Remarkable success of Chinese herbs in combination with a short https://www.ncbi.nlm.nih.gov/pubmed/?term=1236113 PHOTOTHERAPY course of low-dose narrow-band UVB phototherapy in severe 8 recalcitrant plaque psoriasis. Response of psoriasis to sunbed treatment: comparison of https://www.ncbi.nlm.nih.gov/pubmed/?term=1241070 PHOTOTHERAPY conventional ultraviolet A lamps with new higher ultraviolet B-emitting 8 lamps. https://www.ncbi.nlm.nih.gov/pubmed/?term=1241070 PHOTOTHERAPY A randomized, observer-blinded trial of twice vs. three times weekly 9 narrowband ultraviolet B phototherapy for chronic plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1262262 PHOTOTHERAPY Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen 4 psoralen-UV-A for the treatment of chronic plaque psoriasis. Balneo phototherapy for psoriasis. Modern application of an age-old https://www.ncbi.nlm.nih.gov/pubmed/?term=1263026 PHOTOTHERAPY treatment. [Review] [15 refs] 1 High frequency of ultraviolet mutations at the INK4a-ARF locus in https://www.ncbi.nlm.nih.gov/pubmed/?term=1264823 PHOTOTHERAPY squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated 4 psoriasis patients. Calcitriol vs. dithranol in combination with narrow-band ultraviolet B https://www.ncbi.nlm.nih.gov/pubmed/?term=1275213 PHOTOTHERAPY (311 nm) in psoriasis. 8 Medication Title of Article PubMed Link Narrowband UV-B phototherapy clears psoriasis through a https://www.ncbi.nlm.nih.gov/pubmed/?term=1275610 PHOTOTHERAPY combination of local and systemic effects. 8 The effects of ultraviolet B treatment on the expression of adhesion https://www.ncbi.nlm.nih.gov/pubmed/?term=1278683 PHOTOTHERAPY molecules by circulating T lymphocytes in psoriasis. 2 Reactivation of herpes simplex keratitis during TL01 phototherapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1282331 PHOTOTHERAPY psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1282874 PHOTOTHERAPY A randomized controlled trial of narrowband ultraviolet B vs bath- 9 psoralen plus ultraviolet A photochemotherapy for psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1285079 PHOTOTHERAPY Photometric and clinical assessment of localized UVB phototherapy 7 systems for the high-dosage treatment of stable plaque psoriasis. Balneo-phototherapy: a new holistic approach to treating psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1286189 PHOTOTHERAPY [Review] [15 refs] 1 Quantitative real-time reverse transcription-polymerase chain https://www.ncbi.nlm.nih.gov/pubmed/?term=1288043 PHOTOTHERAPY reaction analysis of drug metabolizing and cytoprotective genes in 2 psoriasis and regulation by ultraviolet radiation. Combination TL01 ultraviolet B phototherapy and topical calcipotriol https://www.ncbi.nlm.nih.gov/pubmed/?term=1289020 PHOTOTHERAPY for psoriasis: a prospective randomized placebo-controlled clinical 8 trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=1289413 PHOTOTHERAPY Phototherapy treatment of psoriasis today. [Review] [26 refs] 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1451101 PHOTOTHERAPY A quantitative review of studies comparing the efficacy of narrow- 7 band and broad-band ultraviolet B for psoriasis. [Review] [14 refs] Optimizing the frequency of outpatient short-contact dithranol https://www.ncbi.nlm.nih.gov/pubmed/?term=1467490 PHOTOTHERAPY treatment used in combination with broadband ultraviolet B for 5 psoriasis: a randomized, within-patient controlled trial. Chronic actinic dermatitis developing during narrowband UVB https://www.ncbi.nlm.nih.gov/pubmed/?term=1473853 PHOTOTHERAPY phototherapy for psoriasis. 8 The ultraviolet fingerprint dominates the mutational spectrum of the https://www.ncbi.nlm.nih.gov/pubmed/?term=1496210 PHOTOTHERAPY p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from 8 psoriasis patients. https://www.ncbi.nlm.nih.gov/pubmed/?term=1509576 PHOTOTHERAPY Phototherapy of psoriasis: review and update. [Review] [93 refs] 0 Medication Title of Article PubMed Link History of psoriasis response to sunlight does not predict outcome of https://www.ncbi.nlm.nih.gov/pubmed/?term=1524554 PHOTOTHERAPY UVB phototherapy. 4 Effectiveness and side effects of UVB-phototherapy, dithranol https://www.ncbi.nlm.nih.gov/pubmed/?term=1524694 PHOTOTHERAPY inpatient therapy and a care instruction programme of short contact 1 dithranol in moderate to severe psoriasis. Towards optimal regimens for the UVB phototherapy of psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1533906 PHOTOTHERAPY mathematical model. 8 Lack of efficacy and tolerability of topical PDT for psoriasis in https://www.ncbi.nlm.nih.gov/pubmed/?term=1534735 PHOTOTHERAPY comparison with narrowband UVB phototherapy. 6 No evidence for increased skin cancer risk in psoriasis patients https://www.ncbi.nlm.nih.gov/pubmed/?term=1537070 PHOTOTHERAPY treated with broadband or narrowband UVB phototherapy: a first 3 retrospective study. https://www.ncbi.nlm.nih.gov/pubmed/?term=1545033 PHOTOTHERAPY Phototherapy arsenal in the treatment of psoriasis. [Review] [26 refs] 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1545654 PHOTOTHERAPY Comparative efficacy of psoralen - UVA photochemotherapy versus 7 narrow band UVB phototherapy in the treatment of psoriasis. The burden of illness associated with psoriasis: cost of treatment with https://www.ncbi.nlm.nih.gov/pubmed/?term=1570121 PHOTOTHERAPY systemic therapy and phototherapy in the US. 1 Narrowband UVB phototherapy in skin conditions beyond psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1579351 PHOTOTHERAPY [Review] [61 refs] 8 Evaluation of vaseline oil applied prior to UVB TL01 phototherapy in https://www.ncbi.nlm.nih.gov/pubmed/?term=1588813 PHOTOTHERAPY the treatment of psoriasis. 0 Comparison of Psoralen ultraviolet A (PUVA) photochemotherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1592952 PHOTOTHERAPY plus topical corticosteroids with PUVA plus bland emollients in the 4 treatment of psoriasis. Wide-area 308-nm phototherapy with nonlaser light in the treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=1594902 PHOTOTHERAPY of psoriasis: results of a pilot study. 2 A positive correlation between history of psoriasis response to https://www.ncbi.nlm.nih.gov/pubmed/?term=1595310 PHOTOTHERAPY sunlight and the response to UVB phototherapy. What are the 5 consequences?. Soluble tumor necrosis factor alpha receptor type 1 in psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1599837 PHOTOTHERAPY patients treated with narrowband ultraviolet B. 0 Audit of the use of psoralen photochemotherapy (PUVA) and https://www.ncbi.nlm.nih.gov/pubmed/?term=1601962 PHOTOTHERAPY narrowband UVB phototherapy in the treatment of psoriasis. 5 Medication Title of Article PubMed Link Narrow-band ultraviolet B phototherapy in patients with psoriasis: for https://www.ncbi.nlm.nih.gov/pubmed/?term=1604391 PHOTOTHERAPY which types of psoriasis is it more effective?. 5 Treatment of localized persistent plaque psoriasis with incoherent https://www.ncbi.nlm.nih.gov/pubmed/?term=1609618 PHOTOTHERAPY narrowband ultraviolet B phototherapy. 3 A randomized controlled comparison of the efficacy of Dead Sea salt https://www.ncbi.nlm.nih.gov/pubmed/?term=1612015 PHOTOTHERAPY balneophototherapy vs. narrowband ultraviolet B monotherapy for 2 chronic plaque psoriasis. Limited availability of psoriasis and phototherapy care: an analysis of https://www.ncbi.nlm.nih.gov/pubmed/?term=1615021 PHOTOTHERAPY advertisements. 4 Therapy-resistant psoriasis treated with alefacept and subsequent https://www.ncbi.nlm.nih.gov/pubmed/?term=1615021 PHOTOTHERAPY narrow band ultraviolet B phototherapy with total clearing of 5 psoriasis. A comparative non randomized study of narrow-band (NB) (312 +/- 2 nm) UVB phototherapy versus sequential therapy with oral https://www.ncbi.nlm.nih.gov/pubmed/?term=1628030 PHOTOTHERAPY administration of low-dose Cyclosporin A and NB-UVB phototherapy 1 in patients with severe psoriasis vulgaris. Narrowband ultraviolet B therapy for psoriasis and other skin https://www.ncbi.nlm.nih.gov/pubmed/?term=1635044 PHOTOTHERAPY disorders. [Review] [52 refs] 5 A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with https://www.ncbi.nlm.nih.gov/pubmed/?term=1638476 PHOTOTHERAPY narrowband UVB phototherapy for moderate to severe psoriasis 5 vulgaris. Subepidermal bullous dermatosis with IgA antibodies against 200- https://www.ncbi.nlm.nih.gov/pubmed/?term=1640312 PHOTOTHERAPY and 280-kDa epidermal antigens after initiation of ultraviolet B 3 therapy for psoriasis. Quality of life in psoriasis improves after standardized administration https://www.ncbi.nlm.nih.gov/pubmed/?term=1640548 PHOTOTHERAPY of narrowband UVB phototherapy. 1 The role of commercial tanning beds and ultraviolet A light in the https://www.ncbi.nlm.nih.gov/pubmed/?term=1642815 PHOTOTHERAPY treatment of psoriasis. [Review] [12 refs] 3 Paired comparison of bathwater versus oral delivery of 8- https://www.ncbi.nlm.nih.gov/pubmed/?term=1643617 PHOTOTHERAPY methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic 4 palmoplantar psoriasis. Home ultraviolet B phototherapy: a cost-effective option for severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1645399 PHOTOTHERAPY psoriasis. 3 Medication Title of Article PubMed Link The effect of maintenance narrow-band ultraviolet B therapy on the https://www.ncbi.nlm.nih.gov/pubmed/?term=1653322 PHOTOTHERAPY duration of remission for psoriasis: a prospective randomized clinical 3 trial. Pseudoporphyria secondary to narrowband UVB phototherapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1663781 PHOTOTHERAPY psoriasis. 2 Depigmentation following narrowband ultraviolet B phototherapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=1671348 PHOTOTHERAPY psoriasis. 3 Selenium supplementation, soluble tumor necrosis factor-alpha https://www.ncbi.nlm.nih.gov/pubmed/?term=1682902 PHOTOTHERAPY receptor type 1, and C-reactive protein during psoriasis therapy with 9 narrowband ultraviolet B. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, https://www.ncbi.nlm.nih.gov/pubmed/?term=1686586 PHOTOTHERAPY multicenter study.[Erratum appears in J Drugs Dermatol. 2006 7 Sep;5(8):706] https://www.ncbi.nlm.nih.gov/pubmed/?term=1689266 PHOTOTHERAPY Would elimination of copayments for phototherapy decrease the cost 0 of treating psoriasis with systemic biologics? A cost analysis. Comparison of weekly and daily incremental protocols of narrowband https://www.ncbi.nlm.nih.gov/pubmed/?term=1698726 PHOTOTHERAPY ultraviolet B phototherapy for psoriasis. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1703666 PHOTOTHERAPY Nonlaser UVB-targeted phototherapy treatment of psoriasis. 5 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for https://www.ncbi.nlm.nih.gov/pubmed/?term=1710073 PHOTOTHERAPY psoriasis. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1734359 PHOTOTHERAPY Narrow-band UV-B phototherapy in childhood psoriasis. 6 Bath PUVA and saltwater baths followed by UV-B phototherapy as https://www.ncbi.nlm.nih.gov/pubmed/?term=1751921 PHOTOTHERAPY treatments for psoriasis: a randomized controlled trial. 8 Comparison of the efficacy of local narrowband ultraviolet B (NB- https://www.ncbi.nlm.nih.gov/pubmed/?term=1758431 PHOTOTHERAPY UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint 9 for palmoplantar psoriasis. Tumour necrosis factor alpha (TNF-alpha)-converting enzyme https://www.ncbi.nlm.nih.gov/pubmed/?term=1759886 PHOTOTHERAPY (TACE) and soluble TNF-alpha receptor type 1 in psoriasis patients 6 treated with narrowband ultraviolet B. Psoralen and ultraviolet a light therapy for psoriasis. [Review] [48 https://www.ncbi.nlm.nih.gov/pubmed/?term=1769981 PHOTOTHERAPY refs] 8 Medication Title of Article PubMed Link Narrowband UV-B phototherapy, alefacept, and clearance of https://www.ncbi.nlm.nih.gov/pubmed/?term=1770966 PHOTOTHERAPY psoriasis. 0

A pragmatic randomized controlled trial on the effectiveness of low https://www.ncbi.nlm.nih.gov/pubmed/?term=1771412 PHOTOTHERAPY concentrated saline spa water baths followed by ultraviolet B (UVB) 1 compared to UVB only in moderate to severe psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1785208 PHOTOTHERAPY Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker 4 of response to phototherapy in patients with psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1795363 PHOTOTHERAPY Targeted UVB phototherapy for psoriasis: a preliminary study. 2 Efficacy of local psoralen ultraviolet A treatments in psoriasis, vitiligo https://www.ncbi.nlm.nih.gov/pubmed/?term=1809324 PHOTOTHERAPY and eczema. 1 Topical 8-methoxypsoralen enhances the therapeutic results of https://www.ncbi.nlm.nih.gov/pubmed/?term=1818197 PHOTOTHERAPY targeted narrowband ultraviolet B phototherapy for plaque-type 3 psoriasis. Comparison of the efficacy of psoralen ultraviolet A with narrowband https://www.ncbi.nlm.nih.gov/pubmed/?term=1846244 PHOTOTHERAPY ultraviolet B phototherapy for the treatment of chronic plaque 6 psoriasis in patients with skin types IV and V. The duration of clinical remission of photochemotherapy and narrow- https://www.ncbi.nlm.nih.gov/pubmed/?term=1854749 PHOTOTHERAPY band UV-B phototherapy in the treatment of psoriasis: a retrospective 8 study. Patients' views on care and treatment after phototherapy for psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1860872 PHOTOTHERAPY and atopic eczema including a gender perspective. 5 Photosensitive psoriasis vulgaris inducible by a single https://www.ncbi.nlm.nih.gov/pubmed/?term=1870932 PHOTOTHERAPY suberythematous dose of ultraviolet B irradiation. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1881186 PHOTOTHERAPY Local effects of TL01 phototherapy in psoriasis. 9 Enhanced response of childhood psoriasis to narrow-band UV-B https://www.ncbi.nlm.nih.gov/pubmed/?term=1895040 PHOTOTHERAPY phototherapy with preirradiation use of . 2 Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing https://www.ncbi.nlm.nih.gov/pubmed/?term=1895441 PHOTOTHERAPY narrowband ultraviolet B phototherapy. 4 Tanning beds as an alternative for psoriasis when office-based https://www.ncbi.nlm.nih.gov/pubmed/?term=1906535 PHOTOTHERAPY phototherapy is not accessible. 5 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1907619 PHOTOTHERAPY A comparative study on the efficacy of treatment with 585 nm pulsed 0 dye laser and ultraviolet B-TL01 in plaque type psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1911275 PHOTOTHERAPY Treatment of moderate to severe plaque psoriasis with concomitant 8 efalizumab and narrow-band ultraviolet B phototherapy. A short cycle of narrow-band UVB phototherapy in the early phase of https://www.ncbi.nlm.nih.gov/pubmed/?term=1927938 PHOTOTHERAPY long-term efalizumab can provide a quicker remission of moderate 1 and severe psoriasis: a pilot study. Spectrophotometric intracutaneous analysis as an early non-invasive https://www.ncbi.nlm.nih.gov/pubmed/?term=1929278 PHOTOTHERAPY predictor of efficacy in the phototherapy of psoriasis. 3 Failure of short-term psoralen and ultraviolet A light maintenance https://www.ncbi.nlm.nih.gov/pubmed/?term=1929278 PHOTOTHERAPY treatment to prevent early relapse in patients with chronic recurring 5 plaque-type psoriasis. The effects of phototherapy on the numbers of circulating natural https://www.ncbi.nlm.nih.gov/pubmed/?term=1929278 PHOTOTHERAPY killer cells and T lymphocytes in psoriasis. 9 Continued use of home narrowband ultraviolet B light phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1938953 PHOTOTHERAPY for psoriasis after completion of a clinical trial. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1942362 PHOTOTHERAPY Home UVB phototherapy for psoriasis. 4 Vitamin D production in psoriasis patients increases less with https://www.ncbi.nlm.nih.gov/pubmed/?term=1943898 PHOTOTHERAPY narrowband than with broadband ultraviolet B phototherapy. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=1946696 PHOTOTHERAPY Narrowband ultraviolet B therapy in psoriasis: randomized double- 1 blind comparison of high-dose and low-dose irradiation regimens. Narrowband ultraviolet B phototherapy does not influence serum and https://www.ncbi.nlm.nih.gov/pubmed/?term=1949358 PHOTOTHERAPY red cell folate levels in patients with psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=1949394 PHOTOTHERAPY UVB phototherapy for psoriasis. Narrowband UVB phototherapy. 5 Itch and scratching as predictors of time to clearance of psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1953818 PHOTOTHERAPY with narrow-band ultraviolet B therapy. 5 Estimated ultraviolet doses to psoriasis patients during climate https://www.ncbi.nlm.nih.gov/pubmed/?term=1961489 PHOTOTHERAPY therapy. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1966154 PHOTOTHERAPY Retinoids and phototherapy for psoriasis. 8 Medication Title of Article PubMed Link What is the most common phototherapy prescription for psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=1966893 PHOTOTHERAPY NB-UVB or PUVA? Prescription behavior. 7 Practice of phototherapy in the treatment of moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=1971055 PHOTOTHERAPY psoriasis. [Review] [64 refs] 0 Topical 8-methoxypsoralen increases the efficacy of narrowband https://www.ncbi.nlm.nih.gov/pubmed/?term=1974724 PHOTOTHERAPY ultraviolet B in psoriasis.[Erratum appears in Photodermatol 1 Photoimmunol Photomed. 2009 Dec;25(6):335] Combination 830-nm and 633-nm light-emitting diode phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=1976489 PHOTOTHERAPY shows promise in the treatment of recalcitrant psoriasis: preliminary 3 findings. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque- https://www.ncbi.nlm.nih.gov/pubmed/?term=1976635 PHOTOTHERAPY type psoriasis using the Psoriasis Area Severity Index score 0 (improvement of 75% or greater) at 12 weeks.

Guidelines of care for the management of psoriasis and psoriatic https://www.ncbi.nlm.nih.gov/pubmed/?term=1981185 PHOTOTHERAPY arthritis: Section 5. Guidelines of care for the treatment of psoriasis 0 with phototherapy and photochemotherapy. [Review] [170 refs] https://www.ncbi.nlm.nih.gov/pubmed/?term=1991404 PHOTOTHERAPY Recovery from tanning induced by narrow-band UVB phototherapy in 3 brown-skinned individuals with psoriasis: twelve-month follow-up. Using 'number needed to treat' to express the magnitudes of benefit https://www.ncbi.nlm.nih.gov/pubmed/?term=1991963 PHOTOTHERAPY of ultraviolet B phototherapy and of antitumour necrosis factor-alpha 2 therapies for psoriasis. Comparing narrowband ultraviolet B treatment regimens for https://www.ncbi.nlm.nih.gov/pubmed/?term=1994148 PHOTOTHERAPY psoriasis. 5 A comparison of three times vs. five times weekly narrowband https://www.ncbi.nlm.nih.gov/pubmed/?term=2007083 PHOTOTHERAPY ultraviolet B phototherapy for the treatment of chronic plaque 3 psoriasis. Tumor necrosis factor-alpha-converting enzyme as a potential https://www.ncbi.nlm.nih.gov/pubmed/?term=2007083 PHOTOTHERAPY mediator of the influence of smoking on the response to treatment 7 with narrowband ultraviolet B in psoriasis patients. Phototherapy for psoriasis: what to choose and how to use: facts and https://www.ncbi.nlm.nih.gov/pubmed/?term=2008295 PHOTOTHERAPY controversies. [Review] [82 refs] 5 Medication Title of Article PubMed Link

Early administration of ultraviolet treatment is effective in pegylated https://www.ncbi.nlm.nih.gov/pubmed/?term=2008902 PHOTOTHERAPY interferon alpha-induced severe acute exacerbation of psoriasis: a 0 case report and short review of the literature. [Review] Expression of cyclin D1 and p16 in psoriasis before and after https://www.ncbi.nlm.nih.gov/pubmed/?term=2008908 PHOTOTHERAPY phototherapy. 1 Urinary mutagenicity and genotoxic risk in children with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2009637 PHOTOTHERAPY after therapeutic exposure to polycyclic aromatic hydrocarbons and 1 ultraviolet radiation. Efficacy of a far erythemogenic dose of narrow-band ultraviolet B https://www.ncbi.nlm.nih.gov/pubmed/?term=2017584 PHOTOTHERAPY phototherapy in chronic plaque-type psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2017869 PHOTOTHERAPY A review of home phototherapy for psoriasis. [Review] [59 refs] 7 Targeted phototherapy of plaque-type psoriasis using ultraviolet B- https://www.ncbi.nlm.nih.gov/pubmed/?term=2030257 PHOTOTHERAPY light-emitting diodes. 3 Narrowband ultraviolet B treatment improves vitamin D balance and https://www.ncbi.nlm.nih.gov/pubmed/?term=2033145 PHOTOTHERAPY alters antimicrobial peptide expression in skin lesions of psoriasis 0 and atopic dermatitis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2040686 PHOTOTHERAPY Cost effectiveness of home ultraviolet B phototherapy for psoriasis: 5 economic evaluation of a randomised controlled trial (PLUTO study). 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the https://www.ncbi.nlm.nih.gov/pubmed/?term=2048878 PHOTOTHERAPY IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving 8 CTLA4 signaling in a psoriasis-like skin disorder. Vitamin D status in psoriasis patients during different treatments with https://www.ncbi.nlm.nih.gov/pubmed/?term=2057990 PHOTOTHERAPY phototherapy. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2060576 PHOTOTHERAPY Effect of written emotional disclosure interventions in persons with 9 psoriasis undergoing narrow band ultraviolet B phototherapy. https://www.ncbi.nlm.nih.gov/pubmed/?term=2068723 PHOTOTHERAPY Home phototherapy for psoriasis is cost-effective. 8 Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2071621 PHOTOTHERAPY psoriasis before, during and after psoralen-ultraviolet A and 9 narrowband ultraviolet B therapy. Medication Title of Article PubMed Link Clinical and genetic predictors of response to narrowband ultraviolet https://www.ncbi.nlm.nih.gov/pubmed/?term=2071622 PHOTOTHERAPY B for the treatment of chronic plaque psoriasis. 6 Comparative evaluation of NBUVB phototherapy and PUVA https://www.ncbi.nlm.nih.gov/pubmed/?term=2082699 PHOTOTHERAPY photochemotherapy in chronic plaque psoriasis. 3

Bath psoralen+ultraviolet A photochemotherapy vs. narrow band- https://www.ncbi.nlm.nih.gov/pubmed/?term=2083169 PHOTOTHERAPY ultraviolet B in psoriasis: a comparison of clinical outcome and effect 7 on circulating T-helper and T-suppressor/cytotoxic cells. Effect of narrow-band UVB phototherapy on soluble cell adhesion https://www.ncbi.nlm.nih.gov/pubmed/?term=2092602 PHOTOTHERAPY molecules in patients with psoriasis vulgaris. 5 Narrowband ultraviolet B in the treatment of psoriasis: the journey so https://www.ncbi.nlm.nih.gov/pubmed/?term=2107930 PHOTOTHERAPY far!. [Review] 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2107931 PHOTOTHERAPY Comparative efficacy of narrow-band ultraviolet B phototherapy alone 0 and its combination with topical 8-methoxypsoralen in psoriasis. Effect of narrowband ultraviolet B phototherapy on serum folic acid https://www.ncbi.nlm.nih.gov/pubmed/?term=2134424 PHOTOTHERAPY levels in patients with psoriasis. 9 Duration of remission period of narrowband ultraviolet B therapy on https://www.ncbi.nlm.nih.gov/pubmed/?term=2135230 PHOTOTHERAPY psoriasis vulgaris. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2141226 PHOTOTHERAPY Effective treatment of psoriasis with narrow-band UVB phototherapy 0 is linked to suppression of the IFN and Th17 pathways. https://www.ncbi.nlm.nih.gov/pubmed/?term=2142962 PHOTOTHERAPY A review of phototherapy protocols for psoriasis treatment. [Review] 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2153516 PHOTOTHERAPY Phototherapy reduces serum resistin levels in psoriasis patients. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2153517 PHOTOTHERAPY A single blind randomized clinical study: the efficacy of isotretinoin 1 plus narrow band ultraviolet B in the treatment of psoriasis vulgaris. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in https://www.ncbi.nlm.nih.gov/pubmed/?term=2156406 PHOTOTHERAPY moderate to severe chronic plaque psoriasis: retrospective data 8 analysis of a patient registry. https://www.ncbi.nlm.nih.gov/pubmed/?term=2156654 PHOTOTHERAPY Evaluation of a skin protection cream for dry skin in patients 7 undergoing narrow band UVB phototherapy for psoriasis vulgaris. Medication Title of Article PubMed Link Narrowband ultraviolet B phototherapy improves the quality of life in https://www.ncbi.nlm.nih.gov/pubmed/?term=2166694 PHOTOTHERAPY patients with psoriasis. 3 Clastogenic plasma factors in psoriasis--comparison of phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2182415 PHOTOTHERAPY and anti-TNF-alpha treatments. 1 Comparison of psoralen plus ultraviolet A therapy and biologics in https://www.ncbi.nlm.nih.gov/pubmed/?term=2188403 PHOTOTHERAPY moderate to severe chronic plaque psoriasis. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2191415 PHOTOTHERAPY Disseminated superficial actinic porokeratosis in a patient undergoing 7 treatment with long-term narrowband ultraviolet B for psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2193364 PHOTOTHERAPY Phototherapy of psoriasis in the era of biologics: still in. [Review] 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2195062 PHOTOTHERAPY Successful treatment of psoriasis vulgaris with targeted narrow-band 9 ultraviolet B therapy using a new flat-type fluorescent lamp. https://www.ncbi.nlm.nih.gov/pubmed/?term=2200076 PHOTOTHERAPY A review of targeted ultraviolet B phototherapy for psoriasis. [Review] 9

Comparison of topical 8-methoxypsoralen and narrowband ultraviolet https://www.ncbi.nlm.nih.gov/pubmed/?term=2209273 PHOTOTHERAPY B with narrowband ultraviolet B alone in treatment-resistant sites in 2 plaque-type psoriasis: a placebo-controlled study. Targeted 307 nm UVB-phototherapy in psoriasis. A pilot study https://www.ncbi.nlm.nih.gov/pubmed/?term=2209277 PHOTOTHERAPY comparing a 307 nm excimer light with topical dithranol. 2 Narrowband ultraviolet B phototherapy decreased the serum IL-17E https://www.ncbi.nlm.nih.gov/pubmed/?term=2209793 PHOTOTHERAPY level in a patient with psoriasis vulgaris. 2 Weight loss in obese patients with psoriasis can be successfully https://www.ncbi.nlm.nih.gov/pubmed/?term=2212631 PHOTOTHERAPY achieved during a course of phototherapy. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2221205 PHOTOTHERAPY Narrowband ultraviolet B and biologics in psoriasis. 5 Comparative effectiveness of commonly used systemic treatments or https://www.ncbi.nlm.nih.gov/pubmed/?term=2250887 PHOTOTHERAPY phototherapy for moderate to severe plaque psoriasis in the clinical 4 practice setting. Narrowband ultraviolet B treatment for psoriasis increases serum https://www.ncbi.nlm.nih.gov/pubmed/?term=2251223 PHOTOTHERAPY vitamin A levels. 7 Reflectance confocal microscopy: an effective tool for monitoring https://www.ncbi.nlm.nih.gov/pubmed/?term=2251228 PHOTOTHERAPY ultraviolet B phototherapy in psoriasis. 2 Medication Title of Article PubMed Link Evidence-based recommendations on topical treatment and https://www.ncbi.nlm.nih.gov/pubmed/?term=2251267 PHOTOTHERAPY phototherapy of psoriasis: systematic review and expert opinion of a 5 panel of dermatologists. [Review] Topical treatment and phototherapy in psoriasis: systematic review https://www.ncbi.nlm.nih.gov/pubmed/?term=2251268 PHOTOTHERAPY and expert opinion of a panel of dermatologists. 3

Efficacy and safety of non-laser, targeted UVB phototherapy alone https://www.ncbi.nlm.nih.gov/pubmed/?term=2251558 PHOTOTHERAPY and in combination with psoralen gel or calcipotriol ointment in the 8 treatment of localized, chronic, plaque-type psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2272491 PHOTOTHERAPY Sorafenib-induced psoriasis and hand-foot skin reaction responded 8 dramatically to systemic narrowband ultraviolet B phototherapy.

A randomized controlled study of combination therapy with alefacept https://www.ncbi.nlm.nih.gov/pubmed/?term=2285923 PHOTOTHERAPY and narrow band UVB phototherapy (UVB) for moderate to severe 7 psoriasis: efficacy, onset, and duration of response. Melanoma and other malignant skin cancers in psoriatic patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2326421 PHOTOTHERAPY treated with phototherapy. Role of the p16 protein in psoriasis. 0 [Review] Phototherapy in psoriasis: a review of mechanisms of action. https://www.ncbi.nlm.nih.gov/pubmed/?term=2336414 PHOTOTHERAPY [Review] 4

The efficacy of narrow-band ultraviolet B phototherapy in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2339945 PHOTOTHERAPY treatment of patients with active chronic plaque psoriasis and its 3 effect on peripheral blood levels of various T-lymphocyte subpopulations: a clinical and flow cytometric immunophenotypical st https://www.ncbi.nlm.nih.gov/pubmed/?term=2339953 PHOTOTHERAPY Catechol-O-methyltransferase activity is higher in psoriasis patients 6 and is down-regulated by narrowband ultraviolet B treatment.

Comparison of clinical effects of psoriasis treatment regimens among https://www.ncbi.nlm.nih.gov/pubmed/?term=2341429 PHOTOTHERAPY calcipotriol alone, narrowband ultraviolet B phototherapy alone, 8 combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and na Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2357182 PHOTOTHERAPY Systemically elevated Th1-, Th2- and Th17-associated chemokines 5 in psoriasis vulgaris before and after ultraviolet B treatment. Narrowband ultraviolet B interferes with gene expression in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2363548 PHOTOTHERAPY peripheral blood T cells of patients with psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2377299 PHOTOTHERAPY Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA 7 in psoriasis: a prospective, open, randomized, multicentre study. Influence of phototherapy in psoriasis on Ki-67 antigen expression: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2390086 PHOTOTHERAPY preliminary study. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2399579 PHOTOTHERAPY Narrow-band ultraviolet B treatment boosts serum 25-hydroxyvitamin 5 D in patients with psoriasis on oral vitamin D supplementation. Catechol-O-methyltransferase activity in psoriasis patients treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2400137 PHOTOTHERAPY with psoralen plus ultraviolet A therapy. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2415101 PHOTOTHERAPY Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet 1 B or psoralen-ultraviolet A photochemotherapy for psoriasis. [Review] Psoriasis treatment: faster and long-standing results after bathing in https://www.ncbi.nlm.nih.gov/pubmed/?term=2425599 PHOTOTHERAPY geothermal seawater. A randomized trial of three UVB phototherapy 1 regimens. Efficacy of localized phototherapy and photodynamic therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2428335 PHOTOTHERAPY psoriasis: a systematic review and meta-analysis. [Review] 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2431346 PHOTOTHERAPY Phototherapy, psoriasis, and the age of biologics. [Review] 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2437747 PHOTOTHERAPY Effect of narrowband ultraviolet B therapy on serum vitamin D and 3 cathelicidin (LL-37) in patients with chronic plaque psoriasis. Phototherapy-induced erythema in patients with psoriasis and obesity https://www.ncbi.nlm.nih.gov/pubmed/?term=2460206 PHOTOTHERAPY treated with narrowband UVB phototherapy. 6 Body mass index, waist circumference and HOMA-IR correlate with https://www.ncbi.nlm.nih.gov/pubmed/?term=2464169 PHOTOTHERAPY the Psoriasis Area and Severity Index in patients with psoriasis 9 receiving phototherapy. Effect of narrowband ultraviolet B treatment on endocannabinoid https://www.ncbi.nlm.nih.gov/pubmed/?term=2464178 PHOTOTHERAPY plasma levels in patients with psoriasis. 1 Medication Title of Article PubMed Link Systemic treatment and narrowband ultraviolet B differentially affect https://www.ncbi.nlm.nih.gov/pubmed/?term=2465672 PHOTOTHERAPY cardiovascular risk markers in psoriasis. 9 Broadband ultraviolet A in the treatment of psoriasis vulgaris: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2469758 PHOTOTHERAPY randomized controlled trial. 6 Novel topical cream delivers safe and effective alternative to https://www.ncbi.nlm.nih.gov/pubmed/?term=2477391 PHOTOTHERAPY traditional psoriasis phototherapy. 5 Oxidation reduction is a key process for successful treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2490984 PHOTOTHERAPY psoriasis by narrow-band UVB phototherapy. 5 Remission period in psoriasis after multiple cycles of narrowband https://www.ncbi.nlm.nih.gov/pubmed/?term=2494298 PHOTOTHERAPY ultraviolet B phototherapy. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2511696 PHOTOTHERAPY A randomized, prospective, sham-controlled study of localized 9 narrow-band UVB phototherapy in the treatment of plaque psoriasis. Recovery of the response to biological treatments using narrow band https://www.ncbi.nlm.nih.gov/pubmed/?term=2513219 PHOTOTHERAPY ultraviolet-B in patients with moderate to severe psoriasis: a 2 retrospective study of 17 patients. Digital ultraviolet therapy: a novel therapeutic approach for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2530747 PHOTOTHERAPY targeted treatment of psoriasis vulgaris. 6 Psoriasis and daily low-emission phototherapy: effects on disease https://www.ncbi.nlm.nih.gov/pubmed/?term=2537765 PHOTOTHERAPY and vitamin D level. 7 Narrowband ultraviolet B phototherapy starting and incremental dose https://www.ncbi.nlm.nih.gov/pubmed/?term=2537778 PHOTOTHERAPY in patients with psoriasis: comparison of percentage dose and fixed 8 dose protocols. https://www.ncbi.nlm.nih.gov/pubmed/?term=2541278 PHOTOTHERAPY Phototherapy and photochemotherapy for psoriasis. [Review] 5 An evaluation of the preferences of patients with psoriasis between https://www.ncbi.nlm.nih.gov/pubmed/?term=2542046 PHOTOTHERAPY systemic psoralen plus ultraviolet A and bath psoralen plus ultraviolet 8 A. Reduction in tissue plasmin: a new mechanism of action of https://www.ncbi.nlm.nih.gov/pubmed/?term=2555733 PHOTOTHERAPY narrowband ultraviolet B in psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2556105 PHOTOTHERAPY Toll-like receptor 9 promoter polymorphism as a predictive factor of 1 narrow-band UVB phototherapy response in patients with psoriasis. Medication Title of Article PubMed Link A guide to prescribing home phototherapy for patients with psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2574831 PHOTOTHERAPY the appropriate patient, the type of unit, the treatment regimen, and 0 the potential obstacles. [Review] Home ultraviolet light therapy for psoriasis: why patients choose https://www.ncbi.nlm.nih.gov/pubmed/?term=2575648 PHOTOTHERAPY other options. 2 Understanding the role of haptoglobin in psoriasis: effects of https://www.ncbi.nlm.nih.gov/pubmed/?term=2595874 PHOTOTHERAPY ultraviolet B. 0 Narrowband ultraviolet B phototherapy in psoriasis reduces https://www.ncbi.nlm.nih.gov/pubmed/?term=2613031 PHOTOTHERAPY proinflammatory cytokine levels and improves vitiligo and neutrophilic 6 asthma. Effects of Narrow Band Ultraviolet B on Serum Levels of Vascular https://www.ncbi.nlm.nih.gov/pubmed/?term=2630832 PHOTOTHERAPY Endothelial Growth Factor and Interleukin-8 in Patients with 8 Psoriasis. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2676750 PHOTOTHERAPY Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in 5 psoriasis (DINUP): study protocol for a randomised controlled trial. Ultraviolet irradiation promotes FOXP3 transcription via p53 in https://www.ncbi.nlm.nih.gov/pubmed/?term=2678186 PHOTOTHERAPY psoriasis. 2 Ultraviolet B Phototherapy for Psoriasis: Review of Practical https://www.ncbi.nlm.nih.gov/pubmed/?term=2687295 PHOTOTHERAPY Guidelines. [Review] 3 Prospective Investigation of 25(OH)D3 Serum Concentration https://www.ncbi.nlm.nih.gov/pubmed/?term=2697704 PHOTOTHERAPY Following UVB Narrow Band Phototherapy in Patients with Psoriasis 8 and Atopic Dermatitis. Tacalcitol: A useful adjunct to narrow band ultraviolet B phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2705220 PHOTOTHERAPY in psoriasis. 0 Neutrophil/Lymphocyte Ratio, Serum Endocan, and Nesfatin-1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2707078 PHOTOTHERAPY Levels in Patients with Psoriasis Vulgaris Undergoing Phototherapy 9 Treatment. https://www.ncbi.nlm.nih.gov/pubmed/?term=2717043 PHOTOTHERAPY Effect of narrow band ultraviolet B phototherapy on T helper 17 cell 0 specific cytokines (interleukins-17, 22 and 23) in psoriasis vulgaris. The effect of phototherapy on systemic inflammatory process in https://www.ncbi.nlm.nih.gov/pubmed/?term=2731453 PHOTOTHERAPY patients with plaque psoriasis. 7 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2731995 PHOTOTHERAPY Correlation Between Severity Index and Quality of Life Index in 1 Patients With Psoriasis Assessed Before and After Phototherapy. Desired response to phototherapy vs photoaggravation in psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2737696 PHOTOTHERAPY what makes the difference?. 6 Comparison of Phototherapy Guidelines for Psoriasis: A Critical https://www.ncbi.nlm.nih.gov/pubmed/?term=2753800 PHOTOTHERAPY Appraisal and Comprehensive Review. [Review] 1

An investigation of cytochrome p450 (CYP) and glutathione S- https://www.ncbi.nlm.nih.gov/pubmed/?term=2761351 PHOTOTHERAPY transferase (GST) isoenzyme protein expression and related 2 interactions with phototherapy in patients with psoriasis vulgaris. Ultraviolet B radiation therapy for psoriasis: Pursuing the optimal https://www.ncbi.nlm.nih.gov/pubmed/?term=2763843 PHOTOTHERAPY regime. [Review] 7 Assessing the validity and response distribution of the simplified https://www.ncbi.nlm.nih.gov/pubmed/?term=2773062 PHOTOTHERAPY psoriasis index in patients receiving phototherapy. 8 C-reactive protein serum level in patients with psoriasis before and https://www.ncbi.nlm.nih.gov/pubmed/?term=2782862 PHOTOTHERAPY after treatment with narrow-band ultraviolet B. 8 Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2788399 PHOTOTHERAPY Results and Patient Assessment. 6 Challenge and perspective: the relevance of ultraviolet (UV) radiation https://www.ncbi.nlm.nih.gov/pubmed/?term=2805406 PHOTOTHERAPY and the vitamin D endocrine system (VDES) for psoriasis and other 9 inflammatory skin diseases. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2822060 PHOTOTHERAPY Phosphor for phototherapy: Review on psoriasis. [Review] 3 Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A https://www.ncbi.nlm.nih.gov/pubmed/?term=2832382 PHOTOTHERAPY systematic review and meta-analysis of randomized controlled trials. 2 [Review] Comparative evaluation of efficacy and safety of calcipotriol versus https://www.ncbi.nlm.nih.gov/pubmed/?term=2860203 PHOTOTHERAPY tacalcitol ointment, both in combination with NBUVB phototherapy in 2 the treatment of stable plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2862868 PHOTOTHERAPY A Systematic Review of Light Emitting Diode (LED) Phototherapy for 5 Treatment of Psoriasis: An Emerging Therapeutic Modality. [Review] Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2870499 PHOTOTHERAPY Serum levels of tumor necrosis factor-alpha in patients with psoriasis 2 before, during and after narrow-band UVB phototherapy. Influence of narrowband ultraviolet B phototherapy on serum tumour https://www.ncbi.nlm.nih.gov/pubmed/?term=2874859 PHOTOTHERAPY necrosis factor-like weak inducer of apoptosis (TWEAK) in patients 2 with psoriasis. Effect of availability of at-home phototherapy on the use of systemic https://www.ncbi.nlm.nih.gov/pubmed/?term=2885725 PHOTOTHERAPY medications for psoriasis. 9 "Two-step phototherapy" for treatment-resistant psoriasis on the https://www.ncbi.nlm.nih.gov/pubmed/?term=2891747 PHOTOTHERAPY lower extremities. 2 Concentration of selenium, zinc, copper, Cu/Zn ratio, total antioxidant status and c-reactive protein in the serum of patients with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2896556 PHOTOTHERAPY treated by narrow-band ultraviolet B phototherapy: A case-control 4 study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2906761 PHOTOTHERAPY A clinical review of phototherapy for psoriasis. [Review] 6 Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease. https://www.ncbi.nlm.nih.gov/pubmed/?term=2912470 PHOTOTHERAPY [Review] 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2919935 PHOTOTHERAPY Significant Changes in the Skin Microbiome in Patients with Chronic 1 Plaque Psoriasis after Treatment with Narrowband Ultraviolet B. Combining Topical Psoriasis Treatment to Enhance Systemic and https://www.ncbi.nlm.nih.gov/pubmed/?term=2924085 PHOTOTHERAPY Phototherapy: A Review of the Literature. [Review] 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2936939 PHOTOTHERAPY Current developments in phototherapy for psoriasis. [Review] 6 Metabolic syndrome affects narrow-band UVB phototherapy https://www.ncbi.nlm.nih.gov/pubmed/?term=2939026 PHOTOTHERAPY response in patients with psoriasis. 1 A non-inferiority randomized controlled clinical trial comparing Unani https://www.ncbi.nlm.nih.gov/pubmed/?term=2974936 PHOTOTHERAPY formulation & psoralen plus ultraviolet A sol in chronic plaque 3 psoriasis. Malignancy concerns with psoriasis treatments using phototherapy, PHOTOTHERAPY, https://www.ncbi.nlm.nih.gov/pubmed/?term=2008295 methotrexate, cyclosporin, and biologics: facts and controversies. METHOTREXATE 7 [Review] [47 refs] Medication Title of Article PubMed Link PHOTOTHERAPY, Methotrexate plus narrowband UVB phototherapy versus narrowband https://www.ncbi.nlm.nih.gov/pubmed/?term=1671345 METHOTREXATE, UVB phototherapy alone in the treatment of plaque-type psoriasis: a 5 PHOTOTHERAPY randomized, placebo-controlled study. PHOTOTHERAPY, Methotrexate/narrowband UVB phototherapy combination vs. https://www.ncbi.nlm.nih.gov/pubmed/?term=2001505 METHOTREXATE, narrowband UVB phototherapy in the treatment of chronic plaque- 6 PHOTOTHERAPY type psoriasis--a randomized single-blinded placebo-controlled study. PHOTOTHERAPY, Comparative study of the effect of narrowband ultraviolet B https://www.ncbi.nlm.nih.gov/pubmed/?term=2473879 METHOTREXATE, phototherapy plus methotrexate vs. narrowband ultraviolet B alone 3 PHOTOTHERAPY and methotrexate alone in the treatment of plaque-type psoriasis. PHOTOTHERAPY, Combination therapy of methotrexate plus NBUVB phototherapy is https://www.ncbi.nlm.nih.gov/pubmed/?term=2590936 METHOTREXATE, more effective than methotrexate monotherapy in the treatment of 8 PHOTOTHERAPY chronic plaque psoriasis. PHOTOTHERAPY, A case of infantile psoriasis with pseudoainhum successfully treated https://www.ncbi.nlm.nih.gov/pubmed/?term=1706205 PIMECROLIMUS, with topical pimecrolimus and low-dose narrowband UVB 8 PHOTOTHERAPY phototherapy. PHOTOTHERAPY, Combination phototherapy of psoriasis with narrow-band UVB https://www.ncbi.nlm.nih.gov/pubmed/?term=1068872 TAZAROTENE irradiation and topical tazarotene gel. 3 PHOTOTHERAPY, https://www.ncbi.nlm.nih.gov/pubmed/?term=1105058 TAZAROTENE, 7 PHOTOTHERAPY Tazarotene plus UVB phototherapy in the treatment of psoriasis. PHOTOTHERAPY, https://www.ncbi.nlm.nih.gov/pubmed/?term=2992422 TAZAROTENE, Tazarotene gel with narrow-band UVB phototherapy: a synergistic 1 PHOTOTHERAPY combination in psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1240633 PIMECROLIMUS Pimecrolimus identifies a common genomic anti-inflammatory profile, 4 is clinically highly effective in psoriasis and is well tolerated. An experimental ointment formulation of pimecrolimus is effective in https://www.ncbi.nlm.nih.gov/pubmed/?term=1460910 PIMECROLIMUS psoriasis without occlusion. 2 Current concepts and review of pimecrolimus in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=1545034 PIMECROLIMUS psoriasis. [Review] [22 refs] 1 Psoriasis of the glans penis in a child successfully treated with Elidel https://www.ncbi.nlm.nih.gov/pubmed/?term=1548231 PIMECROLIMUS (pimecrolimus) cream. 7 Medication Title of Article PubMed Link Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1552335 PIMECROLIMUS double-blind, randomized study. 1 Oral pimecrolimus in the treatment of moderate to severe chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=1594898 PIMECROLIMUS plaque-type psoriasis: a double-blind, multicentre, randomized, dose- 5 finding trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=1663840 PIMECROLIMUS Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. 0 Pimecrolimus induced tinea incognito masquerading as intertriginous https://www.ncbi.nlm.nih.gov/pubmed/?term=1807659 PIMECROLIMUS psoriasis. 9 Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16- https://www.ncbi.nlm.nih.gov/pubmed/?term=1821647 PIMECROLIMUS week open-label study. 5 Pimecrolimus 1% cream is effective in the treatment of psoriasis in https://www.ncbi.nlm.nih.gov/pubmed/?term=1910604 PIMECROLIMUS an infant. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2346153 PIMECROLIMUS Pimecrolimus for psoriasis. [Review] 6 PIMECROLIMUS, The use of topical tacrolimus and pimecrolimus to treat psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=1534748 TACROLIMUS review. [Review] [22 refs] 5 PIMECROLIMUS, Oral tazarotene and oral pimecrolimus: novel oral therapies in https://www.ncbi.nlm.nih.gov/pubmed/?term=1509896 TAZAROTENE development for psoriasis. [Review] [15 refs] 8 The role of piperacillin therapy in pulmonary exacerbations of cystic http://onlinelibrary.wiley.com/doi/10.1002/ppul.195001 PIPERACILLIN fibrosis: A controlled study 0506/full http://www.jorvet.com/wp- content/uploads/2017/04/MANJ1057-Drugs-Used-for- PIPERACILLIN Drugs Used for Inhalation Therapy Inhalation-Therapy.pdf http://www.naturallivingcenter.net/ns/DisplayMonogra PIPERACILLIN/ ph.asp?StoreID=b571dewxvcs92jj200akhmccqa7w8v TAZOBACTAM Cystic fibrosis (CF) 75&DocID=condition-cysticfibrosis PIPERACILLIN/ Topical piperacillin/tazobactam for recalcitrant pseudomonas https://www.ncbi.nlm.nih.gov/pubmed/20415627 TAZOBACTAM aeruginosa keratitis PIPERACILLIN/ Changing microbiological trends in cases of chronic suppurative otitis http://www.ejmanager.com/mnstemps/45/45- TAZOBACTAM media patients 1378909713.pdf PIPERACILLIN/ Effect of piperacillin-tazobactam coated β-tricalcium phosphate for http://www.sciencedirect.com/science/article/pii/S016 TAZOBACTAM mastoid obliteration in otitis media 5587611000632 Medication Title of Article PubMed Link

New insights in the production of aerosol antibiotics. Evaluation of the https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38146 PIPERACILLIN/ optimal aerosol production system for ampicillin-sulbactam, 30/ TAZOBACTAM meropenem, ceftazidime, cefepime and piperacillin-tazobactam http://www.ncbi.nlm.nih.gov/pubmed/22907313 POLIHEXANIDE Clinical use of the antiseptic polihexanide for genital tract infections. Randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of polyhexanide for topical decolonization of MRSA http://www.ncbi.nlm.nih.gov/pubmed/26507428 POLIHEXANIDE carriers Polyhexanide-containing solution reduces ciliary beat frequency of http://www.ncbi.nlm.nih.gov/pubmed/24902802 POLIHEXANIDE human nasal epithelial cells in vitro POLYHEXAMETHYL Polyhexamethylene biguanide for treatment of external genital warts: http://www.ncbi.nlm.nih.gov/pubmed/16479742 ENE BIGUANIDE a prospective, double-blind, randomized study. Comparison of Boric Acid and Combination Drug of Polymyxin, POLYMYXIN Neomycin and Hydrocortisone (polymyxin NH) in the Treatment of https://www.ncbi.nlm.nih.gov/pubmed/27630871 Acute Otitis Externa POLYPHENON E Polyphenon E: a new treatment for external anogenital warts. http://www.ncbi.nlm.nih.gov/pubmed/19709100 http://www.ncbi.nlm.nih.gov/pubmed/18209999 POLYPHENON E Polyphenon E. A new topical therapy for condylomata acuminata A randomized, double-blind, four-arm parallel-group, placebo- controlled Phase II/III study to investigate the clinical efficacy of two http://www.ncbi.nlm.nih.gov/pubmed/17958849 galenic formulations of Polyphenon E in the treatment of external POLYPHENON E genital warts. Polyphenon E 10% ointment: in immunocompetent adults with http://www.ncbi.nlm.nih.gov/pubmed/22667336 POLYPHENON E external genital and perianal warts.

A prospective, open, comparative study of 5% potassium hydroxide http://www.ncbi.nlm.nih.gov/pubmed/24770498 POTASSIUM solution versus cryotherapy in the treatment of genital warts in men. HYDROXIDE Randomized comparison of topical 1% versus fluorometholone 0.1% in the first year after descemet membrane http://www.ncbi.nlm.nih.gov/pubmed/25062336 PREDNISOLONE endothelial keratoplasty Hematemesis due to Drug Allergy to Oral Prednisolone in a Patient https://pubmed.ncbi.nlm.nih.gov/30568137 PREDNISOLONE with Ulcerative Colitis. Medication Title of Article PubMed Link Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy https://pubmed.ncbi.nlm.nih.gov/23961883 or in combination with low dose prednisolone after failure of first-line PREDNISOLONE medications. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving https://pubmed.ncbi.nlm.nih.gov/23452668 PREDNISOLONE prednisolone. Case of prednisolone-induced hepatitis in a patient with ulcerative https://pubmed.ncbi.nlm.nih.gov/22488866 PREDNISOLONE colitis. A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and https://pubmed.ncbi.nlm.nih.gov/21540556 neutrophilic dermatoses occurring in the setting of inflammatory PREDNISOLONE bowel disease. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded https://pubmed.ncbi.nlm.nih.gov/18296130 PREDNISOLONE randomised multi-centre controlled study. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral https://pubmed.ncbi.nlm.nih.gov/17988236 PREDNISOLONE prednisolone for active ulcerative colitis. Complement activation capacity in plasma before and during high- dose prednisolone treatment and tapering in exacerbations of https://pubmed.ncbi.nlm.nih.gov/16179087 PREDNISOLONE Crohn's disease and ulcerative colitis. The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral https://pubmed.ncbi.nlm.nih.gov/15489578 PREDNISOLONE density in acute ulcerative colitis. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe https://pubmed.ncbi.nlm.nih.gov/15297776 PREDNISOLONE ulcerative colitis. Oral prednisolone metasulphobenzoate in the treatment of active https://pubmed.ncbi.nlm.nih.gov/12795466 PREDNISOLONE ulcerative colitis. Correlation between circulating soluble ICAM-1 and prednisolone- https://pubmed.ncbi.nlm.nih.gov/12737443 PREDNISOLONE induced amelioration of ulcerative colitis. Local release of human neutrophil lipocalin (HNL), IL-8, and TNF- alpha is decreased as response to topical prednisolone treatment in https://pubmed.ncbi.nlm.nih.gov/12353856 PREDNISOLONE distal ulcerative colitis and proctitis. Medication Title of Article PubMed Link Methylprednisolone acetate versus oral prednisolone in moderately https://pubmed.ncbi.nlm.nih.gov/11871829 PREDNISOLONE active ulcerative colitis. Variability of the symptoms of chronic abacterial prostatitis/chronic pelvic pain syndrome during intermittent therapy with rectal https://pubmed.ncbi.nlm.nih.gov/11589817 PREDNISOLONE prednisolone foam for ulcerative colitis. An open-labeled, randomized study comparing systemic interferon- alpha-2A and prednisolone enemas in the treatment of left-sided https://pubmed.ncbi.nlm.nih.gov/11419834 PREDNISOLONE ulcerative colitis.

Neutrophil and eosinophil granule proteins as markers of response to https://pubmed.ncbi.nlm.nih.gov/11316151 PREDNISOLONE local prednisolone treatment in distal ulcerative colitis and proctitis. Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and https://pubmed.ncbi.nlm.nih.gov/10930896 PREDNISOLONE mesalazine. Severe complications of ulcerative colitis after high-dose https://pubmed.ncbi.nlm.nih.gov/10433019 PREDNISOLONE prednisolone and azathioprine treatment. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre https://pubmed.ncbi.nlm.nih.gov/29490024 PREDNISONE Clinical Trial. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double- https://pubmed.ncbi.nlm.nih.gov/25869389 PREDNISONE blind, randomized, parallel group study. Electrochemiluminescence immunoassay method underestimates cortisol suppression in ulcerative colitis patients treated with oral https://pubmed.ncbi.nlm.nih.gov/25152591 PREDNISONE prednisone. Hepatic failure due to hepatitis B reactivation in a patient with https://pubmed.ncbi.nlm.nih.gov/19575458 PREDNISONE ulcerative colitis treated with prednisone.

Retropharyngeal and splenic aseptic abscesses treated with https://pubmed.ncbi.nlm.nih.gov/12822884 PREDNISONE prednisone and cyclophosphamide in a patient with ulcerative colitis. PREDNISONE High dose prednisone treatment in severe ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/4818396 PREDNISONE AS MAINTENANCE TREATMENT FOR https://pubmed.ncbi.nlm.nih.gov/14238045 PREDNISONE ULCERATIVE COLITIS IN REMISSION. Out-patient treatment of ulcerative colitis. Comparison between three https://pubmed.ncbi.nlm.nih.gov/13865152 PREDNISONE doses of oral prednisone. Medication Title of Article PubMed Link An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for https://pubmed.ncbi.nlm.nih.gov/13760840 PREDNISONE ulcerative colitis. The longterm treatment of ulcerative colitis with hydrocortisone, https://pubmed.ncbi.nlm.nih.gov/13474175 PREDNISONE prednisone and prednisolone.

Rheumatoid arthritis complicated by severe ulcerative colitis, https://pubmed.ncbi.nlm.nih.gov/13331729 PREDNISONE successfully treated with prednisone and Rauwolfia: a case history. The role of immediate postoperative systemic corticosteroids when http://www.ncbi.nlm.nih.gov/pubmed/24482348 PREDNISONE utilizing a steroid-eluting spacer following sinus surgery

Comparison of ropivacaine, bupivacaine, prilocaine, and lidocaine in http://www.ncbi.nlm.nih.gov/pubmed/24119607 PRILOCAINE the management of pain and hemorrhage during nasal pack removal. An assessment of prilocaine as a topical anaesthetic agent for http://www.ncbi.nlm.nih.gov/pubmed/7941937 PRILOCAINE fibreoptic bronchoscopy in comparison with lidocaine. Comparison of topical anesthetic cream (EMLA) and diclofenac suppository for pain relief after hemorrhoidectomy: a randomized http://www.ncbi.nlm.nih.gov/pubmed/22711185 PRILOCAINE clinical trial. Randomized controlled trial of topical EMLA and breastfeeding for http://www.ncbi.nlm.nih.gov/pubmed/23812513 PRILOCAINE reducing pain during wDPT vaccination. The effect of EMLA cream on minimizing pain during venipuncture in http://www.ncbi.nlm.nih.gov/pubmed/22961215 PRILOCAINE premature infants.

Lidocaine-prilocaine (EMLA(®) ) cream as analgesia in hysteroscopy http://www.ncbi.nlm.nih.gov/pubmed/23738908 PRILOCAINE practice: a prospective, randomized, non-blinded, controlled study. Comparison between lidocaine-prilocaine cream (EMLA) and mepivacaine infiltration for pain relief during perineal repair after http://www.ncbi.nlm.nih.gov/pubmed/19560111 PRILOCAINE childbirth: a randomized trial. The analgesic efficacy of lidocaine/prilocaine (EMLA) cream during http://www.ncbi.nlm.nih.gov/pubmed/17381486 PRILOCAINE fine-needle aspiration biopsy of thyroid nodules. Eutectic mixture of (EMLA) decreases pain during http://www.ncbi.nlm.nih.gov/pubmed/17646514 PRILOCAINE humeral block placement in nonsedated patients. PRILOCAINE The role of local anaesthetics in premature ejaculation. http://www.ncbi.nlm.nih.gov/pubmed/22758648 Medication Title of Article PubMed Link Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature http://www.ncbi.nlm.nih.gov/pubmed/17129234 PRILOCAINE ejaculation. Lidocaine-prilocaine (EMLA) cream as analgesia for hysterosalpingography: a prospective, randomized, controlled, http://www.ncbi.nlm.nih.gov/pubmed/17234675 PRILOCAINE double blinded study. Randomised double blind trial of EMLA for the control of pain related http://www.ncbi.nlm.nih.gov/pubmed/9924468 PRILOCAINE to cryotherapy in the treatment of genital HPV lesions Pain during venous cannulation: Double-blind, randomized clinical trial of analgesic effect between topical amethocaine and eutectic http://www.ncbi.nlm.nih.gov/pubmed/22557744 PRILOCAINE mixture of local anesthetic Phospholipid microemulsion-based hydrogel for enhanced topical delivery of lidocaine and prilocaine: QbD-based development and http://www.ncbi.nlm.nih.gov/pubmed/24892623 PRILOCAINE evaluation Does intravaginal probiotic supplementation increase the pregnancy https://www.ncbi.nlm.nih.gov/pubmed/?term=1610229 PROBIOTIC rate in IVF-embryo transfer cycles?. 2 Topical probiotics as a therapeutic alternative for chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2812464 PROBIOTIC rhinosinusitis: A preclinical proof of concept. 1 Improving the outcome of fractional CO2 laser resurfacing using a https://www.ncbi.nlm.nih.gov/pubmed/?term=2741228 PROBIOTIC probiotic skin cream: Preliminary clinical evaluation. 7 Effects of Fermented Dairy Products on Skin: A Systematic Review. https://www.ncbi.nlm.nih.gov/pubmed/?term=2606142 PROBIOTIC [Review] 2 Topical treatment with probiotic Lactobacillus brevis CD2 inhibits https://www.ncbi.nlm.nih.gov/pubmed/?term=2448313 PROBIOTIC experimental periodontal inflammation and bone loss. 5 Topical application/formulation of probiotics: will it be a novel https://www.ncbi.nlm.nih.gov/pubmed/?term=2429623 PROBIOTIC treatment approach for diabetic foot ulcer?. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1987847 PROBIOTIC Probiotics and periodontal disease. [Review] [79 refs] 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1929112 PROBIOTIC Bacteriotherapy with Lactobacillus plantarum in burns. 0 Effect of probiotic Lactobacillus strains in children with atopic https://www.ncbi.nlm.nih.gov/pubmed/?term=1258936 PROBIOTIC dermatitis. 1 Prodrug Strategies for Enhancing the Percutaneous Absorption of http://www.ncbi.nlm.nih.gov/pubmed/25514222 PRODRUGS Drugs Medication Title of Article PubMed Link

Synthesis and hydrolytic behaviour of 2-mercaptoethyl ibuprofenate- http://www.ncbi.nlm.nih.gov/pubmed/12803773 PRODRUGS conjugate as a novel transdermal prodrug. http://mededicus.com/downloads/A-Practical-Look-at- the-Role-of-NSAIDs-in-Ophthalmology.pdf PRODRUGS A Practical Look at the Role of NSAIDs in Ophthalmology

Topical iontophoretic delivery of ionizable, biolabile aciclovir http://www.ncbi.nlm.nih.gov/pubmed/26686649 PRODRUGS prodrugs: A rational approach to improve cutaneous bioavailability Cutaneous biodistribution of ionizable, biolabile aciclovir prodrugs after short duration topical iontophoresis: Targeted intraepidermal http://www.ncbi.nlm.nih.gov/pubmed/26592154 PRODRUGS drug delivery Stereoisomeric Prodrugs to Improve Corneal Absorption of http://www.ncbi.nlm.nih.gov/pubmed/26335418 PRODRUGS Prednisolone: Synthesis and In Vitro Evaluation Improvement of Topical Palmitoylethanolamide Anti-Inflammatory http://www.ncbi.nlm.nih.gov/pubmed/26289562 PRODRUGS Activity by Pegylated Prodrugs

Nanoparticle-based topical ophthalmic formulation for sustained http://www.ncbi.nlm.nih.gov/pubmed/25564964 PRODRUGS release of stereoisomeric dipeptide prodrugs of ganciclovir PRODRUGS OF KETOPROFEN, http://www.ncbi.nlm.nih.gov/pubmed/11500258 NAPROXEN AND In vitro and in vivo evaluation of polyoxyethylene esters as dermal DICLOFENAC prodrugs of ketoprofen, naproxen and diclofenac

The risk of malaria in Ghanaian infants born to women managed in http://www.ncbi.nlm.nih.gov/pubmed/26821532 pregnancy with intermittent screening and treatment for malaria or PYRIMETHAMINE intermittent preventive treatment with sulfadoxine/pyrimethamine Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine http://www.ncbi.nlm.nih.gov/pubmed/26599634 and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive PYRIMETHAMINE Treatment of Malaria in Infants The Role of Quinine-Responsive Taste Receptor Family 2 in Airway https://www.ncbi.nlm.nih.gov/pubmed/29643854 QUININE Immune Defense and Chronic Rhinosinusitis. Medication Title of Article PubMed Link An advanced technique using an electronic taste-sensing system to evaluate the bitterness of orally disintegrating films and the https://www.ncbi.nlm.nih.gov/pubmed/28789886 QUININE evaluation of model films. QUININE Topical Irrigation Therapy for CRS (QSIND) https://clinicaltrials.gov/ct2/show/NCT02630472 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC51768 QUININE On the Nasal Administration of Sulphate of Quinine 09/?page=1 RinoFlow nasal wash and sinus system as a mechanism to deliver medications to the paranasal sinuses: results of a radiolabeled pilot http://www.ncbi.nlm.nih.gov/pubmed/10485146 RINOFLOW study RINOFLOW A comparative study of three methods of nasal irrigation http://www.ncbi.nlm.nih.gov/pubmed/15564850 Intranasal absorption of rizatriptan--in vivo pharmacokinetics and http://www.ncbi.nlm.nih.gov/pubmed/15702515 RIZATRIPTAN bioavailability study in humans. Development and evaluation of tamarind seed xyloglucan-based http://www.ncbi.nlm.nih.gov/pubmed/23121942 RIZATRIPTAN mucoadhesive buccal films of rizatriptan benzoate. Uptake and biodistribution of rizatriptan to blood and brain following http://www.ncbi.nlm.nih.gov/pubmed/17267150 RIZATRIPTAN different routes of administration in rats. Glycolic acid 15% plus salicylic acid 2%: a new therapeutic pearl for http://www.ncbi.nlm.nih.gov/pubmed/21938272 SALICYLIC ACID facial flat warts EVerT: cryotherapy versus salicylic acid for the treatment of verrucae- http://www.ncbi.nlm.nih.gov/pubmed/21899812 SALICYLIC ACID -a randomised controlled trial.

Cantharidin-podophylotoxin-salicylic acid versus cryotherapy in the http://www.ncbi.nlm.nih.gov/pubmed/21790794 SALICYLIC ACID treatment of plantar warts: a randomized prospective study. Cryotherapy versus salicylic acid for the treatment of plantar warts http://www.ncbi.nlm.nih.gov/pubmed/21652750 SALICYLIC ACID (verrucae): a randomised controlled trial. Efficacy of topical treatments for cutaneous warts: a meta-analysis http://www.ncbi.nlm.nih.gov/pubmed/21219294 SALICYLIC ACID and pooled analysis of randomized controlled trials. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized http://www.ncbi.nlm.nih.gov/pubmed/20837684 SALICYLIC ACID controlled trial. Application of cantharidin and podophyllotoxin for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/19017852 SALICYLIC ACID plantar warts. Treatment of palmoplantar warts with a diphencyprone and salicylic http://www.ncbi.nlm.nih.gov/pubmed/16866999 SALICYLIC ACID acid ointment. Medication Title of Article PubMed Link Treatment of verruca plantaris with a combination of topical http://www.ncbi.nlm.nih.gov/pubmed/16037552 SALICYLIC ACID fluorouracil and salicylic acid Plantar wart treatment with combination imiquimod and salicylic acid http://www.ncbi.nlm.nih.gov/pubmed/12905977 SALICYLIC ACID pads. http://www.ncbi.nlm.nih.gov/pubmed/3274251 SALICYLIC ACID Treatment of common warts with high-potency (26%) salicylic acid. Safety in use of cryotherapy and topical salicylic acid with http://www.ncbi.nlm.nih.gov/pubmed/23134923 SALICYLIC ACID combination in treating verruca vulgaris Cost-effectiveness of cryotherapy versus salicylic acid for the treatment of plantar warts: economic evaluation alongside a http://www.ncbi.nlm.nih.gov/pubmed/22369511 SALICYLIC ACID randomised controlled trial (EVerT trial). The EVERT (effective verruca treatments) trial protocol: a randomised controlled trial to evaluate cryotherapy versus salicylic http://www.ncbi.nlm.nih.gov/pubmed/20141630 SALICYLIC ACID acid for the treatment of verrucae

Combination therapy with hydrogen peroxide (4%), salicylic acid http://www.ncbi.nlm.nih.gov/pubmed/26875890 (0.5%) and D-panthenol (4%): efficacy and skyn tolerability in SALICYLIC ACID common acne vulgaris during sun exposure period Efficacy and tolerability of a topical gel containing 3% hydrogen peroxide, 1.5% salicylic acid and 4% d- in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/26761768 SALICYLIC ACID mild-moderate acne

Topical pyruvic acid (70%) versus topical salicylic acid (16.7%) http://www.ncbi.nlm.nih.gov/pubmed/26261815 SALICYLIC ACID compound in treatment of plantar warts: A randomized controlled trial

Effectiveness of salicylic acid for treatment of digital dermatitis http://www.ncbi.nlm.nih.gov/pubmed/26281447 SALICYLIC ACID in dairy cows compared with tetracycline spray and hydrotherapy

In vivo reflectance confocal microscopy characterization of field- http://www.ncbi.nlm.nih.gov/pubmed/25721522 SALICYLIC ACID directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis Application of cantharidin, podophyllotoxin, and salicylic acid in http://www.ncbi.nlm.nih.gov/pubmed/25739479 SALICYLIC ACID recalcitrant plantar warts. A preliminary study Whey protein/polysaccharide-stabilized oil for topical application-release and transdermal delivery of salicylic acid from oil http://www.ncbi.nlm.nih.gov/pubmed/25573437 SALICYLIC ACID powders compared to redispersed powders Medication Title of Article PubMed Link Evaluation of physicochemical properties, skin permeation and SALICYLIC ACID accumulation profiles of salicylic acid amide prodrugs as http://www.ncbi.nlm.nih.gov/pubmed/21839822 AMIDE agent SALICYLIC ACID http://www.ncbi.nlm.nih.gov/pubmed/21244220 FATTY ESTER Evaluation of salicylic acid fatty ester prodrugs for UV protection Efficacy and safety of secukinumab in the treatment of moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2310610 SECUKINUMAB severe plaque psoriasis: a randomized, double-blind, placebo- 7 controlled phase II dose-ranging study. Secukinumab induction and maintenance therapy in moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2336296 SECUKINUMAB severe plaque psoriasis: a randomized, double-blind, placebo- 9 controlled, phase II regimen-finding study. Secukinumab improves the signs and symptoms of moderate-to- severe plaque psoriasis in subjects with involvement of hands and/or https://www.ncbi.nlm.nih.gov/pubmed/?term=2433041 SECUKINUMAB feet: subanalysis of a randomized, double-blind, placebo-controlled, 5 phase 2 dose-ranging study. Secukinumab improves hand, foot and nail lesions in moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2439360 SECUKINUMAB severe plaque psoriasis: subanalysis of a randomized, double-blind, 2 placebo-controlled, regimen-finding phase 2 trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=2500739 SECUKINUMAB Secukinumab in plaque psoriasis--results of two phase 3 trials. 2 Secukinumab administration by pre-filled syringe: efficacy, safety and https://www.ncbi.nlm.nih.gov/pubmed/?term=2513241 SECUKINUMAB usability results from a randomized controlled trial in psoriasis 1 (FEATURE). Efficacy, safety and usability of secukinumab administration by https://www.ncbi.nlm.nih.gov/pubmed/?term=2524391 SECUKINUMAB autoinjector/pen in psoriasis: a randomized, controlled trial 0 (JUNCTURE). Secukinumab efficacy and safety in Japanese patients with moderate- https://www.ncbi.nlm.nih.gov/pubmed/?term=2535473 SECUKINUMAB to-severe plaque psoriasis: subanalysis from ERASURE, a 8 randomized, placebo-controlled, phase 3 study. Secukinumab in psoriasis: randomized, controlled phase 3 trial https://www.ncbi.nlm.nih.gov/pubmed/?term=2582395 SECUKINUMAB results assessing the potential to improve treatment response in 8 partial responders (STATURE). https://www.ncbi.nlm.nih.gov/pubmed/?term=2585357 SECUKINUMAB Secukinumab (Cosentyx) for psoriasis. 8 Medication Title of Article PubMed Link Secukinumab retreatment-as-needed versus fixed-interval https://www.ncbi.nlm.nih.gov/pubmed/?term=2598253 SECUKINUMAB maintenance regimen for moderate to severe plaque psoriasis: A 9 randomized, double-blind, noninferiority trial (SCULPTURE). Secukinumab is superior to ustekinumab in clearing skin of subjects https://www.ncbi.nlm.nih.gov/pubmed/?term=2609229 SECUKINUMAB with moderate to severe plaque psoriasis: CLEAR, a randomized 1 controlled trial. Secukinumab: a review in moderate to severe plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2620287 SECUKINUMAB [Review] 1 Secukinumab Improves Physical Function in Subjects With Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2626772 SECUKINUMAB Psoriasis and Psoriatic Arthritis: Results from Two Randomized, 6 Phase 3 Trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=2642803 SECUKINUMAB Secukinumab (AIN457) for the treatment of psoriasis. [Review] 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2643979 SECUKINUMAB Secukinumab distributes into dermal interstitial fluid of psoriasis 8 patients as demonstrated by open flow microperfusion. https://www.ncbi.nlm.nih.gov/pubmed/?term=2657795 SECUKINUMAB Secukinumab for treating plaque psoriasis. [Review] 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2664730 SECUKINUMAB Secukinumab (AIN-457) for the treatment of Psoriasis. [Review] 0 Acute Generalized Pustular Psoriasis Treated With the IL-17A https://www.ncbi.nlm.nih.gov/pubmed/?term=2665001 SECUKINUMAB Antibody Secukinumab. 4 Secukinumab treatment of plaque psoriasis shows early https://www.ncbi.nlm.nih.gov/pubmed/?term=2666014 SECUKINUMAB improvement in DLQI response - results of a phase II regimen-finding 3 trial. Clinical and economic review of secukinumab for moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2668152 SECUKINUMAB plaque psoriasis. [Review] 7 Perianal Dermatophytosis During Secukinumab Therapy for Plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2672015 SECUKINUMAB Psoriasis. 9 Meta-analysis of the Efficacy and Safety of Secukinumab for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2678335 SECUKINUMAB Treatment of Plaque Psoriasis. 2 Secukinumab improves patient-reported psoriasis symptoms of https://www.ncbi.nlm.nih.gov/pubmed/?term=2686651 SECUKINUMAB itching, pain, and scaling: results of two phase 3, randomized, 8 placebo-controlled clinical trials. Medication Title of Article PubMed Link Secukinumab long-term safety experience: A pooled analysis of 10 https://www.ncbi.nlm.nih.gov/pubmed/?term=2718092 SECUKINUMAB phase II and III clinical studies in patients with moderate to severe 6 plaque psoriasis. Secukinumab in the Treatment of Generalized Pustular Psoriasis: A https://www.ncbi.nlm.nih.gov/pubmed/?term=2723105 SECUKINUMAB Case report. 5 The impact of long-term secukinumab treatment on Epstein-Barr https://www.ncbi.nlm.nih.gov/pubmed/?term=2726118 SECUKINUMAB virus and cytomegalovirus loads in patients with psoriasis. 6 The impact of secukinumab treatment on the prevalence of human https://www.ncbi.nlm.nih.gov/pubmed/?term=2731752 SECUKINUMAB papillomavirus in patients with psoriasis: A pilot study. 4 Secukinumab, a fully human anti-interleukin-17A monoclonal https://www.ncbi.nlm.nih.gov/pubmed/?term=2751837 SECUKINUMAB antibody, exhibits minimal immunogenicity in patients with moderate- 6 to-severe plaque psoriasis. Assessing the overall benefit of a medication: cumulative benefit of https://www.ncbi.nlm.nih.gov/pubmed/?term=2754172 SECUKINUMAB secukinumab over time in patients with moderate-to-severe plaque 9 psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2754507 SECUKINUMAB Safety of secukinumab in the treatment of psoriasis. [Review] 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2764676 SECUKINUMAB Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks. 9 Secukinumab is superior to ustekinumab in clearing skin of subjects https://www.ncbi.nlm.nih.gov/pubmed/?term=2766307 SECUKINUMAB with moderate-to-severe plaque psoriasis up to 1 year: Results from 9 the CLEAR study. https://www.ncbi.nlm.nih.gov/pubmed/?term=2770759 SECUKINUMAB Secukinumab shows significant efficacy in palmoplantar psoriasis: 3 Results from GESTURE, a randomized controlled trial. Secukinumab Self-Administration by Prefilled Syringe Maintains https://www.ncbi.nlm.nih.gov/pubmed/?term=2774134 SECUKINUMAB Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of 0 the FEATURE Trial. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2796518 SECUKINUMAB with secukinumab and entecavir combination therapy. 8 Secukinumab administration by autoinjector maintains reduction of https://www.ncbi.nlm.nih.gov/pubmed/?term=2811180 SECUKINUMAB plaque psoriasis severity over 52 weeks: results of the randomized 1 controlled JUNCTURE trial. https://www.ncbi.nlm.nih.gov/pubmed/?term=2816202 SECUKINUMAB Secukinumab in the treatment of psoriasis: an update. [Review] 5 Medication Title of Article PubMed Link

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 https://www.ncbi.nlm.nih.gov/pubmed/?term=2826624 SECUKINUMAB response achieve greater health-related quality-of-life improvements 3 than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.[Erratum appears in J Dermatolog Population Pharmacokinetic Modeling of Secukinumab in Patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2827335 SECUKINUMAB With Moderate to Severe Psoriasis. 6 Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four https://www.ncbi.nlm.nih.gov/pubmed/?term=2839707 SECUKINUMAB Phase 3 Trials.[Erratum appears in Adv Ther. 2017 Jul;34(7):1772; 9 PMID: 28589404] Secukinumab re-initiation achieves regain of high response levels in https://www.ncbi.nlm.nih.gov/pubmed/?term=2849851 SECUKINUMAB patients who interrupt treatment for moderate to severe plaque 4 psoriasis. Image Gallery: Resolution of lichen striatus in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2850440 SECUKINUMAB coexisting chronic plaque psoriasis and vitiligo during secukinumab 5 treatment. [Review] Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: https://www.ncbi.nlm.nih.gov/pubmed/?term=2852206 SECUKINUMAB Update and commentary. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=2854787 SECUKINUMAB Anti IL-17 flared psoriasis in a patient on secukinumab. 9 Secukinumab sustains good efficacy and favourable safety in https://www.ncbi.nlm.nih.gov/pubmed/?term=2858057 SECUKINUMAB moderate-to-severe psoriasis after up to 3 years of treatment: results 9 from a double-blind extension study.

Secukinumab is superior to fumaric acid esters in treating patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2858064 SECUKINUMAB with moderate-to-severe plaque psoriasis who are naive to systemic 6 treatments: results from the randomized controlled PRIME trial.[Erratum appears in Br J Dermatol. 2017 Dec;177(6):1772; Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2860203 SECUKINUMAB with moderate-to-severe plaque psoriasis: 52-week results from the 9 CLEAR study. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A https://www.ncbi.nlm.nih.gov/pubmed/?term=2873215 SECUKINUMAB Review of the Literature. [Review] 2 Medication Title of Article PubMed Link Treatment of Moderate to Severe Psoriasis With High-Dose (450- https://www.ncbi.nlm.nih.gov/pubmed/?term=2873556 SECUKINUMAB mg) Secukinumab: Case Reports of Off-Label Use. 9 Secukinumab improves scalp pain, itching, scaling and quality of life https://www.ncbi.nlm.nih.gov/pubmed/?term=2873744 SECUKINUMAB in patients with moderate-to-severe scalp psoriasis. 0 The effect of secukinumab on moderate-to-severe scalp psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2878036 SECUKINUMAB Results of a 24-week, randomized, double-blind, placebo-controlled 4 phase 3b study. Efficacy and Safety of Secukinumab in Elderly Subjects with https://www.ncbi.nlm.nih.gov/pubmed/?term=2940496 SECUKINUMAB Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III 6 Studies. https://www.ncbi.nlm.nih.gov/pubmed/?term=2946979 SECUKINUMAB Complete response of secukinumab in palmoplantar psoriasis. 9 A case of refractory lupus nephritis complicated by psoriasis vulgaris https://www.ncbi.nlm.nih.gov/pubmed/?term=2952305 SECUKINUMAB that was controlled with secukinumab. 5 Treatment of palmar-plantar erythrodysesthesia (PPE) with topical http://www.ncbi.nlm.nih.gov/pubmed/25341548 SILDENAFIL sildenafil: a pilot study. Sildenafil in the treatment of pressure ulcer: a randomised clinical http://www.ncbi.nlm.nih.gov/pubmed/23731453 SILDENAFIL trial. Determination of the sildenafil effect on alopecia areata in childhood: http://www.ncbi.nlm.nih.gov/pubmed/16971319 SILDENAFIL An open-pilot comparison study. Manometric study of topical sildenafil (Viagra) in patients with chronic http://www.ncbi.nlm.nih.gov/pubmed/15073662 SILDENAFIL anal fissure: sildenafil reduces anal resting tone. Effect of topically applied sildenafil citrate on wound healing: http://www.ncbi.nlm.nih.gov/pubmed/25172969 SILDENAFIL experimental study. A Double-blind Placebo-controlled Evaluation of the Effect of Topical www.jrnlappliedresearch.com/articles/Vol5Iss2/Saedi. SILDENAFIL Sildenafil on Erectile Dysfunction pdf

A Phase 2a, Single-Dose, Double-Blind, Placebo-Controlled, 2-Way https://clinicaltrials.gov/ct2/show/NCT02390960?term Crossover Study Using Penile Plethysmography to Evaluate the =sildenafil+AND+topical&rank=1 Efficacy and Safety of SST-6006, a Topical Sildenafil Cream (5% SILDENAFIL w/w), Compared to Placebo in the Treatment of Erectile Dysfunction

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the https://clinicaltrials.gov/ct2/show/NCT02364882?term Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil =sildenafil+AND+topical&rank=3 SILDENAFIL Cream (5% w/w), in Healthy Postmenopausal Women Medication Title of Article PubMed Link Study to Evaluate the Efficacy and Safety of SST-6007, a Topical https://clinicaltrials.gov/ct2/show/NCT02570282?term Sildenafil Cream, Compared to Placebo in Women With Female =sildenafil+AND+topical&rank=4 SILDENAFIL Sexual Arousal Disorder Sildenafil topical product that passed phase 1 studies (SST-6006) http://www.strategicscience.com/clinical- SILDENAFIL and has two trials pending programs.html#sst6006 Silver nitrate may be far superior to podophyllin in clearing HPV http://www.ncbi.nlm.nih.gov/pubmed/19565941 SILVER NITRATE external anogenital warts. Efficacy of 10% silver nitrate solution in the treatment of common http://www.ncbi.nlm.nih.gov/pubmed/17269982 SILVER NITRATE warts: a placebo-controlled, randomized, clinical trial. http://www.ncbi.nlm.nih.gov/pubmed/8051319 SILVER NITRATE Efficacy of silver nitrate pencils in the treatment of common warts. Prospective, randomized, multi-institutional clinical trial of a silver alginate dressing to reduce lower extremity vascular surgery wound http://www.ncbi.nlm.nih.gov/pubmed/25175629 SILVER NITRATE complications Sinecatechins (Polyphenon E) ointment for treatment of external http://www.ncbi.nlm.nih.gov/pubmed/24766274 SINECATECHINS genital warts and possible future indications Treatment of recalcitrant facial verrucae vulgares with sinecatechins http://www.ncbi.nlm.nih.gov/pubmed/24341392 SINECATECHINS (greentea catechins) ointment Sinecatechins ointment 15% for the treatment of external genital http://www.ncbi.nlm.nih.gov/pubmed/23067286 SINECATECHINS warts. A cost-effectiveness analysis of sinecatechins in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/19929627 SINECATECHINS external genital warts. Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta- http://www.ncbi.nlm.nih.gov/pubmed/21294779 SINECATECHINS analysis. Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation http://www.ncbi.nlm.nih.gov/pubmed/26404110 immunomodulation with sinecatechins 15% ointment - a retrospective SINECATECHINS analysis Sinecatechins 10% ointment: a green tea extract for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/25807215 SINECATECHINS external genital warts https://www.ncbi.nlm.nih.gov/pubmed/25726894 SOAK AND SMEAR Soak and smear: An effective treatment for eczematous dermatoses Direct observed "soak and smear" therapy for severe eczematous https://www.ncbi.nlm.nih.gov/pubmed/19808003 SOAK AND SMEAR dermatitis in the combat setting Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/16365257 SOAK AND SMEAR Soak and smear: a standard technique revisited https://media.reachmd.com/uploads/related_- _client_provided_materials/aad_treatmentguidelines.p SOAK AND SMEAR Guidelines of care for the management of atopic dermatitis df http://www.jaad.org/article/S0190-9622(16)30874- SOAK AND SMEAR On the utility of soak and smear X/fulltext Comparison of Dermatology and Allergy Guidelines for Atopic http://citeseerx.ist.psu.edu/viewdoc/download?doi=10. SOAK AND SMEAR Dermatitis Management 1.1.698.7215&rep=rep1&type=pdf http://www.saudedireta.com.br/docsupload/14012073 SOAK AND SMEAR Pruritus in the Older Patient A Clinical Review 38jca130004.pdf http://hmc.pennstatehealth.org/documents/11396232/ SOAK AND SMEAR 11465309/Soak+and+smear/85fbd1a0-b831-4752- REFERENCES Soak and smear - Penn State College of Medicine a397-3a92fa1640b1 http://healthlibrary.stanford.edu/patient/cutaneous/soa SOAK AND SMEAR k_smear.pdf REFERENCES Soak and Smear - Stanford Health Library http://frontrangedermatology.net/wp- SOAK AND SMEAR content/uploads/2012/12/images_Soak_and_Smear.p REFERENCES Soak & Smear - Front Range Dermatology Associates df

SOAK AND SMEAR http://pacificderm.org/Powerpoints/ESimpson.pdf REFERENCES Oregon Health and Sciences - Can Atopic Dermatitis Be Prevented? https://www.aad.org/faculty/handout/SAM2016/accept SOAK AND SMEAR ed/BRF%20B003%20-%20Ehrlich%20- REFERENCES George Washington University - Chronic Hand Dermatitis %2010928%209139.pdf SOAK AND SMEAR https://dermatologyfoundation.org/pdf/pubs/DF_Sum WEB DERMATOLOGY FOCUS mer_2010.pdf SOAK AND SMEAR http://dermatologycentral.typepad.com/resource/2007 WEB Soak and Smear /02/soak_and_smear.html SOAK AND SMEAR http://www.skinmdcolorado.com/dermatology/pdfs/So WEB Soak and Smear - Skin MD ak-Smear.pdf http://cutaneouslymphoma.stanford.edu/documents/S SOAK AND SMEAR oak%20and%20Smear%20Pamphlet- WEB Soak and Smear - Instructions for patients FINAL%20_4_.pdf Medication Title of Article PubMed Link SOAK AND SMEAR http://healthlibrary.kucancercenter.org/NewsRecent/6, WEB Allergists: Daily Bath OK for Kids With Eczema 712344 http://www.dailymail.co.uk/health/article-3665408/A- bath-day-good-eczema-Smearing-children-moisturiser- SOAK AND SMEAR A bath a day IS good for eczema: Smearing children with moisturiser soaking-soothe-dry-skin-allergists-say.html WEB after soaking will soothe dry skin, allergists say SOAK AND SMEAR http://www.livescience.com/55231-how-to-bathe-kids- WEB For Kids with Eczema, 'Soak and Smear' with-eczema.html http://www.smartparenting.com.ph/health/your-kids- SOAK AND SMEAR Try the "Soak and Smear" Technique to Ease Eczema, Says health/-soak-and-smear-to-ease-eczema-says- WEB Research experts-a1162-20160712 SOAK AND SMEAR Eczema Treatment: Parents Get OK To 'Soak And Smear' Children http://www.medicaldaily.com/eczema-treatment-soak- WEB On A Daily Basis and-smear-childrens-health-390992 SOAK AND SMEAR Eczema: Daily 'soak and smear' or steer clear? How often should https://www.sciencedaily.com/releases/2016/06/1606 WEB you bathe your child with eczema? 29094840.htm http://www.netdoctor.co.uk/parenting/baby-and- SOAK AND SMEAR toddler/news/a26702/is-soak-and-smear-the-best-way- WEB Is 'soak and smear' the best way to bath children with eczema? to-bath-children-with-eczema/ http://www.dcallergy.com/single-post/2016/07/18/How- Often-Should-you-Bathe-a-Child-with-Eczema-The- SOAK AND SMEAR How Often Should you Bathe a Child with Eczema? The Soak and Soak-and-Smear-method WEB Smear method. SOAK AND SMEAR https://www.aad.org/practicecenter/quality/clinical- WEB Atopic dermatitis: Nonpharmacologic interventions recommendations guidelines/atopic-dermatitis/topical-therapy SOAK AND SMEAR http://www.mydr.com.au/skin-hair/eczema-q-and-a WEB What can I do to treat an eczema flare-up? SOAK AND SMEAR http://www.skintherapyletter.com/2009/14.3/1.html WEB New and Existing Therapeutic Options for Intranasal sodium citrate solution improves olfaction in post-viral https://www.ncbi.nlm.nih.gov/pubmed/27316224 SODIUM CITRATE hyposmia. SODIUM Olfactory dysfunction in acute rhinosinusitis: intranasal sodium https://www.ncbi.nlm.nih.gov/pubmed/27568351 HYALURONATE hyaluronate as adjuvant treatment. SODIUM Aerosolized sodium hypochlorite inhibits viability and allergenicity of http://www.ncbi.nlm.nih.gov/pubmed/16159635 HYPOCHLORITE mold on building materials. Medication Title of Article PubMed Link

Efficacy of sodium hypochlorite (bleach) baths to reduce http://www.ncbi.nlm.nih.gov/pubmed/26270469 SODIUM Staphylococcus aureus colonization in childhood onset moderate-to- HYPOCHLORITE severe eczema: A randomized, placebo-controlled cross-over trial Evaluation on the effects of 0.1% Peumus boldus leaf and Spiraea ulmaria plant extract combination on bacterial https://www.ncbi.nlm.nih.gov/pubmed/29482177 SPIRAEA colonization in canine atopic dermatitis: A preliminary ULMARIA randomized, placebo controlled, double-blinded study. linical Question: Nasal saline or intranasal corticosteroids to treat https://www.ncbi.nlm.nih.gov/pubmed/27328556 STEROID allergic rhinitis in children Nasal saline irrigation facilitates control of allergic rhinitis by topical https://www.ncbi.nlm.nih.gov/pubmed/19047814 STEROID steroid in children Olfaction in chronic rhinosinusitis: comparing two different endonasal https://www.ncbi.nlm.nih.gov/pubmed/27730325 STEROIDS steroid application methods. Effect of three-drug delivery modalities on olfactory function in https://www.ncbi.nlm.nih.gov/pubmed/25224684 STEROIDS chronic sinusitis. Topical corticosteroids applied with a squirt system are more effective than a nasal spray for steroid-dependent olfactory https://www.ncbi.nlm.nih.gov/pubmed/22302665 STEROIDS impairment. Treatment of postviral olfactory loss with glucocorticoids, Ginkgo https://www.ncbi.nlm.nih.gov/pubmed/19841338 STEROIDS biloba, and mometasone nasal spray. Role of leukotriene inhibitors in the postoperative management of https://www.ncbi.nlm.nih.gov/pubmed/15925911 STEROIDS nasal polyps. Placebo-controlled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/14575403 STEROIDS patients with hyposmia/anosmia. Topical corticosteroid treatment of anosmia associated with nasal https://www.ncbi.nlm.nih.gov/pubmed/9109781 STEROIDS and sinus disease. STEROIDS The treatment of hyposmia with intranasal steroids. https://www.ncbi.nlm.nih.gov/pubmed/8729495 https://www.google.com/patents/US20170232029 STREPTOMYCIN Pharmaceutical anti-infective composition for inhalation Medication Title of Article PubMed Link Association Between Fungal Contamination and Eye Bank-Prepared Endothelial Keratoplasty Tissue: Temperature-Dependent Risk https://www.ncbi.nlm.nih.gov/pubmed/28973097 Factors and Antifungal Supplementation of Optisol-Gentamicin and STREPTOMYCIN Streptomycin. SULFAMETHOXAZO Patterns of antimicrobial resistance in lesions of hidradenitis https://www.ncbi.nlm.nih.gov/pubmed/27742173 LE suppurativa. SULFAMETHOXAZO https://www.ncbi.nlm.nih.gov/pubmed/27463633 LE DRESS syndrome in ophthalmic patients. https://academic.oup.com/ofid/advance- SULFAMETHOXAZO Sulfamethoxazole-trimethoprim (co-trimoxazole) for skin and soft article/doi/10.1093/ofid/ofx232/4587928 LE tissue infections including impetigo, cellulitis and abscess Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs SULFAMETHOXAZO Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A https://www.ncbi.nlm.nih.gov/pubmed/28535235 LE Randomized Clinical Trial. SULFAMETHOXAZO Topical bactrim versus trimethoprim and against http://www.ncbi.nlm.nih.gov/pubmed/11248825 LE/TMP nocardia keratitis. SULFAMETHOXAZO http://www.ncbi.nlm.nih.gov/pubmed/15281980 LE/TMP Trimethoprim-sulphamethoxazole therapy in Nocardia keratitis. SULFAMETHOXAZO Poor rectal absorption of trimethoprim/sulphamethoxazole in treating http://www.ncbi.nlm.nih.gov/pubmed/6973756 LE/TMP Pneumocystis carinii pneumonia. 5-ASA to sulfasalazine drug switch program in patients with https://pubmed.ncbi.nlm.nih.gov/30020742 SULFASALAZINE ulcerative colitis. Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with https://pubmed.ncbi.nlm.nih.gov/28110377 SULFASALAZINE Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related https://pubmed.ncbi.nlm.nih.gov/26775891 SULFASALAZINE cancer. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative https://pubmed.ncbi.nlm.nih.gov/19637363 SULFASALAZINE colitis.

A meta-analysis of the efficacy of sulfasalazine in comparison with 5- https://pubmed.ncbi.nlm.nih.gov/18770034 aminosalicylates in the induction of improvement and maintenance of SULFASALAZINE remission in patients with ulcerative colitis. [Review] [52 refs] Sulfasalazine-induced pericarditis in a patient with ulcerative colitis https://pubmed.ncbi.nlm.nih.gov/17440739 SULFASALAZINE without recurrence when switching to mesalazine. Medication Title of Article PubMed Link Bullous eosinophilic cellulitis associated with ulcerative colitis: https://pubmed.ncbi.nlm.nih.gov/17263808 SULFASALAZINE effective treatment with sulfasalazine and glucocorticoids. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down- https://pubmed.ncbi.nlm.nih.gov/16306769 SULFASALAZINE regulation by sulfasalazine and glucocorticoid treatment. Effects of sulfasalazine on biopsy mucosal pathologies and https://pubmed.ncbi.nlm.nih.gov/16038049 SULFASALAZINE histological grading of patients with active ulcerative colitis. Sulfasalazine inhibits activation of nuclear factor-kappaB in patients https://pubmed.ncbi.nlm.nih.gov/15955209 SULFASALAZINE with ulcerative colitis. Characteristics and therapeutic efficacy of sulfasalazine in patients https://pubmed.ncbi.nlm.nih.gov/15832418 SULFASALAZINE with mildly and moderately active ulcerative colitis. Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new https://pubmed.ncbi.nlm.nih.gov/14726972 SULFASALAZINE evidence. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients https://pubmed.ncbi.nlm.nih.gov/12135032 SULFASALAZINE with ulcerative colitis.

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, https://pubmed.ncbi.nlm.nih.gov/11856080 SULFASALAZINE 3 g, as sole therapy in the management of ulcerative colitis. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed https://pubmed.ncbi.nlm.nih.gov/11856079 SULFASALAZINE active ulcerative colitis. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results https://pubmed.ncbi.nlm.nih.gov/11805567 SULFASALAZINE from a 20-year surveillance study. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative https://pubmed.ncbi.nlm.nih.gov/11515848 colitis: comparison of orally administered mesalamine and SULFASALAZINE sulfasalazine. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative https://pubmed.ncbi.nlm.nih.gov/10696629 SULFASALAZINE colitis. Sulindac causes regression of rectal polyps in familial adenomatous http://www.ncbi.nlm.nih.gov/pubmed/1650315 SULINDAC polyposis Medication Title of Article PubMed Link Treatment of colonic and rectal adenomas with sulindac in familial http://www.ncbi.nlm.nih.gov/pubmed/8385741 SULINDAC adenomatous polyposis Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial http://www.ncbi.nlm.nih.gov/pubmed/8298943 SULINDAC adenomatous polyposis Improved pharmacokinetics of sumatriptan with Breath Powered™ http://www.ncbi.nlm.nih.gov/pubmed/23992438 SUMATRIPTAN nasal delivery of sumatriptan powder. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A http://www.ncbi.nlm.nih.gov/pubmed/20656704 SUMATRIPTAN randomised, placebo-controlled study. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a http://www.ncbi.nlm.nih.gov/pubmed/19703372 SUMATRIPTAN novel bi-directional device. SUMATRIPTAN Zelrix: a novel transdermal formulation of sumatriptan. http://www.ncbi.nlm.nih.gov/pubmed/19438727 Sumatriptan nasal spray in adolescent migraineurs: a randomized, http://www.ncbi.nlm.nih.gov/pubmed/16492230 SUMATRIPTAN double-blind, placebo-controlled, acute study. Long-term tolerability of sumatriptan nasal spray in adolescent http://www.ncbi.nlm.nih.gov/pubmed/15546259 SUMATRIPTAN patients with migraine SUMATRIPTAN Pharmacokinetics of sumatriptan nasal spray in children http://www.ncbi.nlm.nih.gov/pubmed/15051742 Nasal sumatriptan is effective in treatment of migraine attacks in http://www.ncbi.nlm.nih.gov/pubmed/15037686 SUMATRIPTAN children: A randomized trial SUMATRIPTAN Pharmacokinetics of sumatriptan nasal spray in adolescents http://www.ncbi.nlm.nih.gov/pubmed/12856385 A prospective double-blind study of nasal sumatriptan versus IV http://www.ncbi.nlm.nih.gov/pubmed/12811706 SUMATRIPTAN ketorolac in migraine Intranasal sumatriptan in cluster headache: randomized placebo- http://www.ncbi.nlm.nih.gov/pubmed/12601104 SUMATRIPTAN controlled double-blind study A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the http://www.ncbi.nlm.nih.gov/pubmed/12100090 SUMATRIPTAN timing of butorphanol administration Treatment of acute cluster headache with 20 mg sumatriptan nasal http://www.ncbi.nlm.nih.gov/pubmed/11954875 SUMATRIPTAN spray--an open pilot study SUMATRIPTAN Effectiveness of nasal sumatriptan in 5- to 12-year-old children http://www.ncbi.nlm.nih.gov/pubmed/11554957 Sumatriptan nasal spray and cognitive function during migraine: http://www.ncbi.nlm.nih.gov/pubmed/11318884 SUMATRIPTAN results of an open-label study Medication Title of Article PubMed Link

A randomized, double-blind, placebo-controlled study of sumatriptan http://www.ncbi.nlm.nih.gov/pubmed/11061765 SUMATRIPTAN nasal spray in the treatment of acute migraine in adolescents

A clinical comparison of sumatriptan nasal spray and http://www.ncbi.nlm.nih.gov/pubmed/10954953 SUMATRIPTAN dihydroergotamine nasal spray in the acute treatment of migrain Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life http://www.ncbi.nlm.nih.gov/pubmed/10891800 SUMATRIPTAN in migraine patients http://www.ncbi.nlm.nih.gov/pubmed/10227648 SUMATRIPTAN Intranasal sumatriptan for the acute treatment of migraine in children Sumatriptan nasal spray: a dose-ranging study in the acute treatment http://www.ncbi.nlm.nih.gov/pubmed/10209349 SUMATRIPTAN of migrain Sumatriptan nasal spray (20 mg/dose) in the acute treatment of http://www.ncbi.nlm.nih.gov/pubmed/9793702 SUMATRIPTAN cluster headache Multiple-attack efficacy and tolerability of sumatriptan nasal spray in http://www.ncbi.nlm.nih.gov/pubmed/9596457 SUMATRIPTAN the treatment of migraine Sumatriptan nasal spray for the acute treatment of migraine. Results http://www.ncbi.nlm.nih.gov/pubmed/9371898 SUMATRIPTAN of two clinical studies Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple http://www.ncbi.nlm.nih.gov/pubmed/9209776 SUMATRIPTAN intranasal doses Lack of pharmacokinetic interaction between butorphanol tartrate http://www.ncbi.nlm.nih.gov/pubmed/7650235 SUMATRIPTAN nasal spray and sumatriptan succinate Intranasal sumatriptan for the acute treatment of migraine. http://www.ncbi.nlm.nih.gov/pubmed/7964913 SUMATRIPTAN International Intranasal Sumatriptan Study Group A sumatriptan iontophoretic transdermal system for the acute http://www.ncbi.nlm.nih.gov/pubmed/22694484 SUMATRIPTAN treatment of migraine Transdermal sumatriptan for acute treatment of migraineurs with http://www.ncbi.nlm.nih.gov/pubmed/22229837 SUMATRIPTAN baseline nausea A unique iontophoretic patch for optimal transdermal delivery of http://www.ncbi.nlm.nih.gov/pubmed/17577644 SUMATRIPTAN sumatriptan Trimigren in stopping migraine attacks: an open prospective multicenter comparative study of rectal suppository and tablet forms http://www.ncbi.nlm.nih.gov/pubmed/20037525 SUMATRIPTAN of sumatriptan Medication Title of Article PubMed Link Effect of 5-HT1 agonist (sumatriptan) on anorectal function in irritable http://www.ncbi.nlm.nih.gov/pubmed/16570352 SUMATRIPTAN bowel syndrome patients A dose-defining study of sumatriptan suppositories in the acute http://www.ncbi.nlm.nih.gov/pubmed/10692752 SUMATRIPTAN treatment of migraine Sumatriptan suppositories for the acute treatment of migraine. http://www.ncbi.nlm.nih.gov/pubmed/9536565 SUMATRIPTAN S2B351 Study Group Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy http://www.ncbi.nlm.nih.gov/pubmed/9209775 SUMATRIPTAN volunteers SUMATRIPTAN Pharmacokinetics of sumatriptan nasal spray in adolescents. http://www.ncbi.nlm.nih.gov/pubmed/12856385 A prospective double-blind study of nasal sumatriptan versus IV http://www.ncbi.nlm.nih.gov/pubmed/12811706 SUMATRIPTAN ketorolac in migraine. Efficacy of sumatriptan nasal spray in recurrent migrainous http://www.ncbi.nlm.nih.gov/pubmed/12656711 SUMATRIPTAN headache: an open prospective study. Intranasal sumatriptan in cluster headache: randomized placebo- http://www.ncbi.nlm.nih.gov/pubmed/12601104 SUMATRIPTAN controlled double-blind study. Sumatriptan nasal spray for migraine: a review of studies in patients http://www.ncbi.nlm.nih.gov/pubmed/12469987 SUMATRIPTAN aged 17 years and younger. SUMATRIPTAN Clinical pharmacokinetics of intranasal sumatriptan. http://www.ncbi.nlm.nih.gov/pubmed/12190330 A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the http://www.ncbi.nlm.nih.gov/pubmed/12100090 SUMATRIPTAN timing of butorphanol administration. Treatment of acute cluster headache with 20 mg sumatriptan nasal http://www.ncbi.nlm.nih.gov/pubmed/11954875 SUMATRIPTAN spray--an open pilot study. Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in http://www.ncbi.nlm.nih.gov/pubmed/11745923 SUMATRIPTAN male rats. SUMATRIPTAN The sumatriptan nasal spray: a review of clinical trials. http://www.ncbi.nlm.nih.gov/pubmed/11678814 http://www.ncbi.nlm.nih.gov/pubmed/11554957 SUMATRIPTAN Effectiveness of nasal sumatriptan in 5- to 12-year-old children. Sumatriptan nasal spray and cognitive function during migraine: http://www.ncbi.nlm.nih.gov/pubmed/11318884 SUMATRIPTAN results of an open-label study.

One-year tolerability and efficacy of sumatriptan nasal spray in http://www.ncbi.nlm.nih.gov/pubmed/11192144 SUMATRIPTAN adolescents with migraine: results of a multicenter, open-label study. Medication Title of Article PubMed Link

A randomized, double-blind, placebo-controlled study of sumatriptan http://www.ncbi.nlm.nih.gov/pubmed/11061765 SUMATRIPTAN nasal spray in the treatment of acute migraine in adolescents.

A clinical comparison of sumatriptan nasal spray and http://www.ncbi.nlm.nih.gov/pubmed/10954953 SUMATRIPTAN dihydroergotamine nasal spray in the acute treatment of migraine. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life http://www.ncbi.nlm.nih.gov/pubmed/10891800 SUMATRIPTAN in migraine patients]. Sumatriptan nasal spray in the acute treatment of migraine: a review http://www.ncbi.nlm.nih.gov/pubmed/10595285 SUMATRIPTAN of clinical studies. http://www.ncbi.nlm.nih.gov/pubmed/10227648 SUMATRIPTAN Intranasal sumatriptan for the acute treatment of migraine in children. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant TACROLIMUS https://www.ncbi.nlm.nih.gov/pubmed/?term=1376102 psoriasis. IL-8/IL-8 receptor expression in psoriasis and the response to TACROLIMUS https://www.ncbi.nlm.nih.gov/pubmed/?term=7531627 systemic tacrolimus (FK506) therapy.

TACROLIMUS Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot https://www.ncbi.nlm.nih.gov/pubmed/?term=9762021 study.[Erratum appears in Arch Dermatol 1998 Nov;134(11):1386] https://www.ncbi.nlm.nih.gov/pubmed/?term=1041752 TACROLIMUS Tacrolimus ointment improves psoriasis in a microplaque assay. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1124364 TACROLIMUS Topical tacrolimus is effective for facial lesions of psoriasis. 5 Tacrolimus ointment for the treatment of psoriasis on the face and https://www.ncbi.nlm.nih.gov/pubmed/?term=1266402 TACROLIMUS intertriginous areas. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1292680 TACROLIMUS Deep dermatophytosis during topical tacrolimus therapy for psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1293225 TACROLIMUS Topical tacrolimus for facial psoriasis. 7 A case of generalized pustular psoriasis treated with topical https://www.ncbi.nlm.nih.gov/pubmed/?term=1297517 TACROLIMUS tacrolimus.[Erratum appears in Arch Dermatol. 2003 5 Nov;139(11):1406] https://www.ncbi.nlm.nih.gov/pubmed/?term=1469349 TACROLIMUS Topical tacrolimus: an effective therapy for facial psoriasis. 2 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1552335 TACROLIMUS Tacrolimus ointment is effective for facial and intertriginous psoriasis. 0 Topical tacrolimus ointment combined with 6% salicylic acid gel for https://www.ncbi.nlm.nih.gov/pubmed/?term=1565514 TACROLIMUS plaque psoriasis treatment. 0 Tacrolimus ointment for the treatment of severe facial plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1575230 TACROLIMUS psoriasis. 5 Generalized pustular psoriasis successfully treated with topical https://www.ncbi.nlm.nih.gov/pubmed/?term=1578784 TACROLIMUS tacrolimus. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1617231 TACROLIMUS Proven efficacy of tacrolimus for facial and intertriginous psoriasis. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=1619880 TACROLIMUS Topical tacrolimus in the treatment of inverse psoriasis in children. 4 Successful treatment of genital and facial psoriasis with tacrolimus https://www.ncbi.nlm.nih.gov/pubmed/?term=1622320 TACROLIMUS ointment 0.1%. 3 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in https://www.ncbi.nlm.nih.gov/pubmed/?term=1658598 TACROLIMUS mild to moderate plaque psoriasis: Results of a randomized, open- 6 label, observer-blinded study. Topical tacrolimus for the treatment of psoriasis on the face, https://www.ncbi.nlm.nih.gov/pubmed/?term=1667380 TACROLIMUS genitalia, intertriginous areas and corporal plaques. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1677410 TACROLIMUS Tacrolimus ointment 0.1% alone and in combination with medium- 1 dose UVA1 in the treatment of palmar or plantar psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1698727 TACROLIMUS Successful treatment with topical tacrolimus for oral psoriasis. 5 Tacrolimus ointment is effective for psoriasis on the face and https://www.ncbi.nlm.nih.gov/pubmed/?term=1730065 TACROLIMUS intertriginous areas in pediatric patients. 8 Treatment of inverse psoriasis with excimer therapy and tacrolimus https://www.ncbi.nlm.nih.gov/pubmed/?term=1733869 TACROLIMUS ointment. 8 Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=1793551 TACROLIMUS plaque psoriasis involving facial or genitofemoral areas: a double- 7 blind, randomized controlled trial. Medication Title of Article PubMed Link Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, https://www.ncbi.nlm.nih.gov/pubmed/?term=1828440 TACROLIMUS epidermal proliferation, keratinization, T-cell subsets and HLA-DR 0 expression. Efficacy and tolerability of topical tacrolimus ointment for the https://www.ncbi.nlm.nih.gov/pubmed/?term=1884509 TACROLIMUS treatment of male genital psoriasis. 2

Evaluation of methylprednisolone aceponate, tacrolimus and https://www.ncbi.nlm.nih.gov/pubmed/?term=2108403 TACROLIMUS combination thereof in the psoriasis plaque test using sum score, 20- 7 MHz-ultrasonography and optical coherence tomography. https://www.ncbi.nlm.nih.gov/pubmed/?term=2169055 TACROLIMUS Palmoplantar pustular psoriasis: clinical and video thermographic 3 evaluation before and after topical tacrolimus treatment. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled https://www.ncbi.nlm.nih.gov/pubmed/?term=2278869 TACROLIMUS open-label study. 7 Polymeric micelle nanocarriers for the cutaneous delivery of https://www.ncbi.nlm.nih.gov/pubmed/?term=2505789 TACROLIMUS tacrolimus: a targeted approach for the treatment of psoriasis. 6 Combination of everolimus and tacrolimus: a potentially effective https://www.ncbi.nlm.nih.gov/pubmed/?term=2528535 TACROLIMUS regimen for recalcitrant psoriasis. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2622209 TACROLIMUS Sterile Corneal Infiltrates Secondary to Psoriasis Exacerbations: 8 Topical Tacrolimus as an Alternative Treatment Option. https://www.ncbi.nlm.nih.gov/pubmed/?term=2655373 TACROLIMUS Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in 4 Adult Patients With Refractory Severe Plaque Psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2713087 TACROLIMUS Topical tacrolimus 0.03% for the treatment of ocular psoriasis. 0 Combination Therapy of Tacrolimus and Chinese Herb Medicated https://www.ncbi.nlm.nih.gov/pubmed/?term=2891443 TACROLIMUS Bath in Children with Inverse Psoriasis. 5 Safety, efficacy and duration of therapeutic effect of tazarotene used TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9035703 in the treatment of plaque psoriasis. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: TAZAROTENE vehicle-controlled study of safety, efficacy, and duration of https://www.ncbi.nlm.nih.gov/pubmed/?term=9216528 therapeutic effect. Medication Title of Article PubMed Link Tazarotene: the first receptor-selective topical retinoid for the TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9270551 treatment of psoriasis. [Review] [34 refs] Molecular mechanisms of tazarotene action in psoriasis. [Review] [33 TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9270552 refs] Clinical safety of tazarotene in the treatment of plaque psoriasis. TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9270553 [Review] [50 refs] Tazarotene gel: efficacy and safety in plaque psoriasis. [Review] [19 TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9270554 refs] The safety and efficacy of tazarotene gel, a topical acetylenic TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9449910 retinoid, in the treatment of psoriasis. Once-daily tazarotene gel versus twice-daily fluocinonide cream in TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9591815 the treatment of plaque psoriasis. TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9640392 Genital ulcers in a psoriasis patient using topical tazarotene. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9777766 plaque psoriasis. The pathogenesis of psoriasis and the mechanism of action of TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9777790 tazarotene. [Review] [27 refs] The management of psoriasis-tazarotene: the bottom line. [Review] TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9787992 [0 refs] Tazarotene 0.1% gel in combination with mometasone furoate cream TAZAROTENE https://www.ncbi.nlm.nih.gov/pubmed/?term=9951595 in plaque psoriasis: a photographic tracking study. Combination treatment of psoriasis with photochemotherapy and https://www.ncbi.nlm.nih.gov/pubmed/?term=1041784 TAZAROTENE tazarotene gel, a receptor-selective topical retinoid. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1055404 TAZAROTENE Clinical pharmacokinetics and drug metabolism of tazarotene: a 5 novel topical treatment for acne and psoriasis. [Review] [65 refs] https://www.ncbi.nlm.nih.gov/pubmed/?term=1069271 TAZAROTENE Tazarotene--a topical retinoid for psoriasis. [Review] [10 refs] 2 Combination therapy with tazarotene plus a topical corticosteroid for https://www.ncbi.nlm.nih.gov/pubmed/?term=1073113 TAZAROTENE the treatment of plaque psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=1073113 TAZAROTENE The role of tazarotene in the treatment of psoriasis. [Review] [20 refs] 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1089882 TAZAROTENE Tazarotene combination treatments in psoriasis. [Review] [31 refs] 8 Medication Title of Article PubMed Link Strategies to optimize efficacy, duration of remission, and safety in https://www.ncbi.nlm.nih.gov/pubmed/?term=1089882 TAZAROTENE the treatment of plaque psoriasis by using tazarotene in combination 9 with a corticosteroid. [Review] [10 refs] https://www.ncbi.nlm.nih.gov/pubmed/?term=1095581 TAZAROTENE Expression of a retinoid-inducible tumor suppressor, Tazarotene- 1 inducible gene-3, is decreased in psoriasis and skin cancer. An observation study evaluating the treatment of plaque psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1114708 TAZAROTENE with tazarotene gels, alone and with an emollient and/or 8 corticosteroid. Duration of improvement in psoriasis after treatment with tazarotene https://www.ncbi.nlm.nih.gov/pubmed/?term=1127796 TAZAROTENE 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of 0 maintenance treatments. Investigator-masked comparison of tazarotene gel q.d. plus https://www.ncbi.nlm.nih.gov/pubmed/?term=1142252 TAZAROTENE mometasone furoate cream q.d. vs. mometasone furoate cream 9 b.i.d. in the treatment of plaque psoriasis. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double- https://www.ncbi.nlm.nih.gov/pubmed/?term=1176612 TAZAROTENE blind, randomized, vehicle-controlled study. 2 A clinical evaluation of tazarotene 0.1% gel, with and without a high- https://www.ncbi.nlm.nih.gov/pubmed/?term=1199218 TAZAROTENE or mid-high-potency corticosteroid, in patients with stable plaque 0 psoriasis. Topical tazarotene therapy for psoriasis, acne vulgaris, and https://www.ncbi.nlm.nih.gov/pubmed/?term=1200701 TAZAROTENE photoaging. [Review] [21 refs] 1 Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and https://www.ncbi.nlm.nih.gov/pubmed/?term=1273450 TAZAROTENE efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 6 12 weeks. https://www.ncbi.nlm.nih.gov/pubmed/?term=1277148 TAZAROTENE Short-contact therapy with tazarotene in psoriasis vulgaris. 2 Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an https://www.ncbi.nlm.nih.gov/pubmed/?term=1289022 TAZAROTENE open, prospective study. 7 The efficacy of topical tazarotene monotherapy and combination https://www.ncbi.nlm.nih.gov/pubmed/?term=1464093 TAZAROTENE therapies in psoriasis. [Review] [45 refs] 2 Tazarotene: therapeutic strategies in the treatment of psoriasis, acne https://www.ncbi.nlm.nih.gov/pubmed/?term=1508758 TAZAROTENE and photoaging. [Review] [65 refs] 9 Medication Title of Article PubMed Link Comparison of tazarotene 0.1% gel plus petrolatum once daily https://www.ncbi.nlm.nih.gov/pubmed/?term=1604040 TAZAROTENE versus calcipotriol 0.005% ointment twice daily in the treatment of 9 plaque psoriasis. Topical tazarotene: a review of its use in the treatment of plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1606071 TAZAROTENE psoriasis. [Review] [57 refs] 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1654991 TAZAROTENE Short contact therapy with tazarotene in psoriasis vulgaris. 9 Receptor-selective retinoids for psoriasis: focus on tazarotene. https://www.ncbi.nlm.nih.gov/pubmed/?term=1660528 TAZAROTENE [Review] [67 refs] 9

Comparison of clinical efficacy of topical tazarotene 0.1% cream with https://www.ncbi.nlm.nih.gov/pubmed/?term=1731903 TAZAROTENE topical clobetasol propionate 0.05% cream in chronic plaque 7 psoriasis: a double-blind, randomized, right-left comparison study. https://www.ncbi.nlm.nih.gov/pubmed/?term=1754289 TAZAROTENE Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. 9 https://www.ncbi.nlm.nih.gov/pubmed/?term=1905240 TAZAROTENE Comparative study of calcipotriol (0.005%) ointment and tazarotene 6 (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2281839 TAZAROTENE Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. 5 A comparison of the effects of topical treatment of calcipotriol, https://www.ncbi.nlm.nih.gov/pubmed/?term=2428637 TAZAROTENE camptothecin, clobetasol and tazarotene on an imiquimod-induced 1 psoriasis-like mouse model. Periungual pyogenic granulomas due to topical tazarotene for nail https://www.ncbi.nlm.nih.gov/pubmed/?term=2481976 TAZAROTENE psoriasis. 5 A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a https://www.ncbi.nlm.nih.gov/pubmed/?term=2830161 TAZAROTENE Halobetasol/Tazarotene Fixed Combination in the Treatment of 4 Plaque Psoriasis. TAZAROTENE, https://www.ncbi.nlm.nih.gov/pubmed/?term=1112203 Calcipotriol vs. tazarotene as combination therapy with narrowband PHOTOTHERAPY 3 ultraviolet B (311 nm): efficacy in patients with severe psoriasis. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, TAZAROTENEPHOT https://www.ncbi.nlm.nih.gov/pubmed/?term=1236642 tacalcitol plus PUVA and tazarotene plus PUVA in patients with OTHERAPY 3 chronic plaque-type psoriasis. Medication Title of Article PubMed Link Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: http://www.ncbi.nlm.nih.gov/pubmed/18808418 assessment of its safety and efficacy. TELLURIUM Effect of topical tetracycline on seroma formation in the Lichtenstein http://www.ncbi.nlm.nih.gov/pubmed/24670025 TETRACYCLINE technique: a prospective randomized study TETRACYCLINE Topical tetracycline in the treatment of acne vulgaris http://www.ncbi.nlm.nih.gov/pubmed/19112759 TETRACYCLINE Tetracycline gel as an adjunct to surgical root debridement http://www.ncbi.nlm.nih.gov/pubmed/18686768 Clinical and microbiological comparisons of isotretinoin vs. http://www.ncbi.nlm.nih.gov/pubmed/17533492 TETRACYCLINE tetracycline in acne vulgaris TETRACYCLINE Topical antibiotic treatment of impetigo with tetracycline http://www.ncbi.nlm.nih.gov/pubmed/16361729 Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot https://www.ncbi.nlm.nih.gov/pubmed/23165381 THEOPHYLLINE study. Characterization and Correction of Olfactory Deficits in Kidney https://www.ncbi.nlm.nih.gov/pubmed/28775001 THEOPHYLLINE Disease.

THEOPHYLLINE Improved smell function with increased nasal mucus sonic hedgehog https://www.ncbi.nlm.nih.gov/pubmed/27923495 (oral) in hyposmic patients after treatment with oral theophylline. THEOPHYLLINE An open-label controlled trial of theophylline for treatment of patients https://www.ncbi.nlm.nih.gov/pubmed/19359985 (oral) with hyposmia. THEOPHYLLINE https://www.ncbi.nlm.nih.gov/pubmed/27178503 (oral) Initiation of smell function in patients with congenital hyposmia. THEOPHYLLINE Effect of slow-release theophylline on nasal antigen challenge in https://www.ncbi.nlm.nih.gov/pubmed/9648963 (oral) subjects with allergic rhinitis. THEOPHYLLINE Comparative monitoring of oral theophylline treatment in blood https://www.ncbi.nlm.nih.gov/pubmed/22377744 (oral) serum, saliva, and nasal mucus. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo- https://www.ncbi.nlm.nih.gov/pubmed/?term=2604258 TILDRAKIZUMAB controlled trial.[Erratum appears in Br J Dermatol. 2016 9 Jun;174(6):1426; PMID: 27317290]

The potential utility of tildrakizumab: an interleukin-23 inhibitor for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2804273 TILDRAKIZUMAB treatment of psoriasis. [Review][Erratum appears in Expert Opin 2 Investig Drugs. 2017 Feb;26(2):263; PMID: 28114863] Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2827173 TILDRAKIZUMAB Tildrakizumab for treating psoriasis. [Review] 5 Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult http://www.ncbi.nlm.nih.gov/pubmed?term=17099030 TOBRAMYCIN bronchiectasis.

Inhaled tobramycin (TOBI): a review of its use in the management of http://www.ncbi.nlm.nih.gov/pubmed/14609360 TOBRAMYCIN Pseudomonas aeruginosa infections in patients with cystic fibrosis. http://www.ncbi.nlm.nih.gov/pubmed/16569351 TOBRAMYCIN Inhaled tobramycin in children with acute bacterial rhinopharyngitis.

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis http://www.ncbi.nlm.nih.gov/pubmed/15562142 TOBRAMYCIN and chronic bronchial infection with Pseudomonas aeruginosa. Colonization in patients receiving and not receiving topical http://www.ncbi.nlm.nih.gov/pubmed/7952561 TOBRAMYCIN antimicrobial prophylaxis. [Effect of Inhalation of Tobramycin for 12 Months on Reduction of http://www.ncbi.nlm.nih.gov/pubmed/23836249 TOBRAMYCIN Hospitalisation Rate in Severe COPD]. [Nebulized colistin versus tobramycin in the treatment of chronic http://www.ncbi.nlm.nih.gov/pubmed/23369499 TOBRAMYCIN Pseudomonas colonization in cystic fibrosis patients].

A formulation of aerosolized tobramycin (Bramitob) in the treatment http://www.ncbi.nlm.nih.gov/pubmed/17536872 of patients with cystic fibrosis and Pseudomonas aeruginosa TOBRAMYCIN infection: a double-blind, placebo-controlled, multicenter study. A pilot study of the safety and efficacy of tobramycin solution for http://www.ncbi.nlm.nih.gov/pubmed/15821224 TOBRAMYCIN inhalation in patients with severe bronchiectasis. TOBRAMYCIN Aerosol antibiotics in cystic fibrosis. http://www.ncbi.nlm.nih.gov/pubmed/19393109 Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the http://www.ncbi.nlm.nih.gov/pubmed/18759658 TOBRAMYCIN PortaNeb compressor. Aerosolized tobramycin in the treatment of ventilator-associated http://www.ncbi.nlm.nih.gov/pubmed/17381399 TOBRAMYCIN pneumonia: a pilot study. Bronchial reactions to the inhalation of high-dose tobramycin in cystic http://www.ncbi.nlm.nih.gov/pubmed/12166559 TOBRAMYCIN fibrosis. Clinical pharmacology study of Bramitob, a tobramycin solution for http://www.ncbi.nlm.nih.gov/pubmed/17536870 TOBRAMYCIN nebulization, in comparison with Tobi. Medication Title of Article PubMed Link Colistin-tobramycin combinations are superior to monotherapy http://www.ncbi.nlm.nih.gov/pubmed/20942647 TOBRAMYCIN concerning the killing of biofilm Pseudomonas aeruginosa. Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, http://www.ncbi.nlm.nih.gov/pubmed/24836961 TOBRAMYCIN efficacy and safety profiles of T100 and TNS.

Comparison of two treatment regimens for eradication of http://www.ncbi.nlm.nih.gov/pubmed/22762867 TOBRAMYCIN Pseudomonas aeruginosa infection in children with cystic fibrosis. Disposition of instilled versus nebulized tobramycin and imipenem in http://www.ncbi.nlm.nih.gov/pubmed/15215224 TOBRAMYCIN ventilated intensive care unit (ICU) patients. Dry powder in cystic fibrosis: same old drugs but different http://www.ncbi.nlm.nih.gov/pubmed/25221853 TOBRAMYCIN benefits? Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and http://www.ncbi.nlm.nih.gov/pubmed/19470318 TOBRAMYCIN observational study'. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with http://www.ncbi.nlm.nih.gov/pubmed/17536871 TOBRAMYCIN Pseudomonas aeruginosa.

Efficiency of pulmonary administration of tobramycin solution for http://www.ncbi.nlm.nih.gov/pubmed/12527599 TOBRAMYCIN inhalation in cystic fibrosis using an improved drug delivery system. Evaluation of bronchial constriction in children with cystic fibrosis http://www.ncbi.nlm.nih.gov/pubmed/12226034 TOBRAMYCIN after inhaling two different preparations of tobramycin. Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower http://www.ncbi.nlm.nih.gov/pubmed/19149503 TOBRAMYCIN respiratory tract infections. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis http://www.ncbi.nlm.nih.gov/pubmed/22095545 TOBRAMYCIN with pseudomonas airway infection. Inhaled amiloride and tobramycin solutions fail to eradicate http://www.ncbi.nlm.nih.gov/pubmed/23046902 TOBRAMYCIN Burkholderia dolosa in patients with cystic fibrosis. TOBRAMYCIN Inhaled antibiotics for lower airway infections. http://www.ncbi.nlm.nih.gov/pubmed/24673698 Inhaled versus systemic antibiotics and airway inflammation in http://www.ncbi.nlm.nih.gov/pubmed/20146365 TOBRAMYCIN children with cystic fibrosis and Pseudomonas. Long-term benefits of inhaled tobramycin in children with cystic http://www.ncbi.nlm.nih.gov/pubmed/17435382 TOBRAMYCIN fibrosis: first clinical observations from Poland. Medication Title of Article PubMed Link Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet http://www.ncbi.nlm.nih.gov/pubmed/20884302 TOBRAMYCIN nebuliser in healthy and cystic fibrosis subjects. Novel tobramycin inhalation powder in cystic fibrosis subjects: http://www.ncbi.nlm.nih.gov/pubmed/17352404 TOBRAMYCIN pharmacokinetics and safety. TOBRAMYCIN Ocular pain after intravitreal injection. http://www.ncbi.nlm.nih.gov/pubmed/23330822

Pharmacokinetic and tolerability profiles of tobramycin nebuliser http://www.ncbi.nlm.nih.gov/pubmed/23232039 solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI TOBRAMYCIN LC Plus(®) nebulisers in cystic fibrosis patients. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas http://www.ncbi.nlm.nih.gov/pubmed/18613006 TOBRAMYCIN infection in cystic fibrosis: a pilot project. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill http://www.ncbi.nlm.nih.gov/pubmed/17530217 TOBRAMYCIN patients. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin http://www.ncbi.nlm.nih.gov/pubmed/22292487 TOBRAMYCIN 0.3% ophthalmic suspension in pediatric subjects. Safety of inhaled (Tobi®) and intravenous tobramycin in young http://www.ncbi.nlm.nih.gov/pubmed/24565869 TOBRAMYCIN children with cystic fibrosis. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic http://www.ncbi.nlm.nih.gov/pubmed/23135343 TOBRAMYCIN fibrosis: a randomised study. Safety, efficacy and convenience of tobramycin inhalation powder in http://www.ncbi.nlm.nih.gov/pubmed/21075062 TOBRAMYCIN cystic fibrosis patients: The EAGER trial. Significant microbiological effect of inhaled tobramycin in young http://www.ncbi.nlm.nih.gov/pubmed/12480612 TOBRAMYCIN children with cystic fibrosis.

Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis http://www.ncbi.nlm.nih.gov/pubmed/24596456 patients with upper airway Pseudomonas aeruginosa colonization: TOBRAMYCIN results of a randomized, double-blind, placebo-controlled pilot study. Sputum tobramycin concentrations in cystic fibrosis patients with http://www.ncbi.nlm.nih.gov/pubmed/22620494 TOBRAMYCIN repeated administration of inhaled tobramycin. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary http://www.ncbi.nlm.nih.gov/pubmed/16236892 TOBRAMYCIN exacerbations in patients with cystic fibrosis. Medication Title of Article PubMed Link Tobramycin inhalation powder manufactured by improved process in http://www.ncbi.nlm.nih.gov/pubmed/23672633 TOBRAMYCIN cystic fibrosis: the randomized EDIT trial. Treatment of early Pseudomonas aeruginosa infection in patients http://www.ncbi.nlm.nih.gov/pubmed/19996339 TOBRAMYCIN with cystic fibrosis: the ELITE trial. Treatment with tobramycin solution for inhalation reduces http://www.ncbi.nlm.nih.gov/pubmed/15334509 TOBRAMYCIN hospitalizations in young CF subjects with mild lung disease. Incidence of corneal infections after laser in situ keratomileusis and surface ablation when moxifloxacin and tobramycin are used as http://www.ncbi.nlm.nih.gov/pubmed/26096523 TOBRAMYCIN postoperative treatment TOBRAMYCIN Inhaled antibiotics to treat lung infection. http://www.ncbi.nlm.nih.gov/pubmed/24237172 TOBRAMYCIN Inhaled antibiotics: dry or wet? http://www.ncbi.nlm.nih.gov/pubmed/25323242 Tobramycin inhalation powder for the treatment of pulmonary TOBRAMYCIN Pseudomonas aeruginosa infection in patients with cystic fibrosis: a https://www.ncbi.nlm.nih.gov/pubmed/28470103 review based on clinical evidence Tobramycin inhalation powder: a review of its use in the treatment of TOBRAMYCIN chronic Pseudomonas aeruginosa infection in patients with cystic https://www.ncbi.nlm.nih.gov/pubmed/24194436 fibrosis Inhaled amiloride and tobramycin solutions fail to eradicate TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/23046902 Burkholderia dolosa in patients with cystic fibrosis

A formulation of aerosolized tobramycin (Bramitob) in the treatment TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/17536872 of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study Topical tobramycin and gentamicin sulfate in the treatment of ocular TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/7341065 infections: multicenter study Aerosolized Tobramycin in The Treatment of Ventilator-Associated http://online.liebertpub.com/doi/abs/10.1089/sur.2006. TOBRAMYCIN Pneumonia: A Pilot Study 051 A pilot study to investigate the efficacy of tobramycin-dexamethasone TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/23205334 ointment in promoting wound healing TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/16569351 Inhaled tobramycin in children with acute bacterial rhinopharyngitis Evidence-based recommendations for antimicrobial nasal washes in TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/16539286 chronic rhinosinusitis Medication Title of Article PubMed Link Treatment of chronic rhinosinusitis refractory to other treatments with TOBRAMYCIN topical antibiotic therapy delivered by means of a large-particle https://www.ncbi.nlm.nih.gov/pubmed/11555764 nebulizer: results of a controlled trial Nebulized tobramycin: prevention of pneumonias in patients with TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/21955974 severe cerebral palsy Nebulized Gentamicin as an Alternative to Nebulized Tobramycin for TOBRAMYCIN https://www.ncbi.nlm.nih.gov/pubmed/28337076 Tracheitis in Pediatric Patients TOBRAMYCIN [Diagnostics and treatment of infectious keratitis]. https://www.ncbi.nlm.nih.gov/pubmed/28758436 Corneal melting and perforation under topical moxifloxacin and http://onlinelibrary.wiley.com/doi/10.1111/j.1755- TOBRAMYCIN tobramycin: case report 3768.2017.0S024/full Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2292494 TOFACITINIB treatment of psoriasis: a Phase 2b randomized placebo-controlled 9 dose-ranging study. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, https://www.ncbi.nlm.nih.gov/pubmed/?term=2329427 TOFACITINIB placebo-controlled study in patients with moderate-to-severe 6 psoriasis. A randomized phase 2a efficacy and safety trial of the topical Janus https://www.ncbi.nlm.nih.gov/pubmed/?term=2338737 TOFACITINIB kinase inhibitor tofacitinib in the treatment of chronic plaque 4 psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2358351 TOFACITINIB Tofacitinib and other kinase inhibitors in the treatment of psoriasis. 5 Effect of tofacitinib, a Janus kinase inhibitor, on haematological https://www.ncbi.nlm.nih.gov/pubmed/?term=2385576 TOFACITINIB parameters during 12 weeks of psoriasis treatment. 1 The relationship between pruritus and the clinical signs of psoriasis in https://www.ncbi.nlm.nih.gov/pubmed/?term=2428922 TOFACITINIB patients receiving tofacitinib. 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2459556 TOFACITINIB Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs 7 of moderate-to-severe plaque psoriasis in different body regions. Killing two birds with one stone: oral tofacitinib reverses alopecia https://www.ncbi.nlm.nih.gov/pubmed/?term=2494065 TOFACITINIB universalis in a patient with plaque psoriasis. 1 Tofacitinib withdrawal and retreatment in moderate-to-severe chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2541818 TOFACITINIB plaque psoriasis: a randomized controlled trial. 6 Tofacitinib for the treatment of moderate-to-severe psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2566645 TOFACITINIB [Review] 1 Medication Title of Article PubMed Link Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV https://www.ncbi.nlm.nih.gov/pubmed/?term=2595185 TOFACITINIB viral load in patients with plaque psoriasis. 7 Oral tofacitinib for psoriasis: what happens with interrupted https://www.ncbi.nlm.nih.gov/pubmed/?term=2596321 TOFACITINIB treatment?. 7 Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2614971 TOFACITINIB plaque psoriasis: results from two randomized, placebo-controlled, 7 phase III trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=2626772 TOFACITINIB Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque 1 Psoriasis: Challenges of the Intra-Subject Study Design. Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2626773 TOFACITINIB Psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2638051 TOFACITINIB XELJANZ (Tofacitinib) for Chronic Plaque Psoriasis. [Review] 0 Profile of tofacitinib citrate and its potential in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2688908 TOFACITINIB moderate-to-severe chronic plaque psoriasis. [Review] 1 Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2689919 TOFACITINIB randomized phase-III studies and 1 open-label long-term extension 9 study. Tofacitinib attenuates pathologic immune pathways in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2705972 TOFACITINIB psoriasis: A randomized phase 2 study. 9 Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2716826 TOFACITINIB Chronic Plaque Psoriasis in Patient Subgroups from Two 6 Randomised Phase 3 Trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=2726793 TOFACITINIB Tofacitinib for the treatment of psoriasis. [Review] 3 Pregnancy Outcomes in the Tofacitinib Safety Databases for https://www.ncbi.nlm.nih.gov/pubmed/?term=2728242 TOFACITINIB Rheumatoid Arthritis and Psoriasis. 8 Successful Treatment of Refractory Alopecia Areata Universalis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2734921 TOFACITINIB Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a 7 Young Woman. Effects of tofacitinib on cardiovascular risk factors and cardiovascular https://www.ncbi.nlm.nih.gov/pubmed/?term=2749896 TOFACITINIB outcomes based on phase III and long-term extension data in 0 patients with plaque psoriasis. Medication Title of Article PubMed Link

Early clinical response to tofacitinib treatment as a predictor of https://www.ncbi.nlm.nih.gov/pubmed/?term=2753824 TOFACITINIB subsequent efficacy: Results from two phase 3 studies of patients 7 with moderate-to-severe plaque psoriasis.[Erratum appears in J Dermatolog Treat. 2017 Feb;28(1):x; PMID: 28201942] Effect of tofacitinib withdrawal and re-treatment on patient-reported https://www.ncbi.nlm.nih.gov/pubmed/?term=2760036 TOFACITINIB outcomes: results from a Phase 3 study in patients with moderate to 7 severe chronic plaque psoriasis. Tofacitinib improves pruritus and health-related quality of life up to 52 https://www.ncbi.nlm.nih.gov/pubmed/?term=2769273 TOFACITINIB weeks: Results from 2 randomized phase III trials in patients with 3 moderate to severe plaque psoriasis. Treatment of plaque psoriasis with an ointment formulation of the https://www.ncbi.nlm.nih.gov/pubmed/?term=2771617 TOFACITINIB Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical 2 trial. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2813387 TOFACITINIB treatment of plaque psoriasis. 7 https://www.ncbi.nlm.nih.gov/pubmed/?term=2831732 TOFACITINIB Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase 8 Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic https://www.ncbi.nlm.nih.gov/pubmed/?term=2832940 TOFACITINIB Plaque Psoriasis. [Review] 4 Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52- https://www.ncbi.nlm.nih.gov/pubmed/?term=2839610 TOFACITINIB week, randomized, controlled phase 3 studies in patients with 2 moderate-to-severe plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=2871108 TOFACITINIB Herpes zoster in psoriasis patients treated with tofacitinib. 4 Tofacitinib for the treatment of moderate to severe chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2871418 TOFACITINIB psoriasis in Japanese patients: Subgroup analyses from a 0 randomized, placebo-controlled phase 3 trial. Effect of tofacitinib on lipid levels and lipid-related parameters in https://www.ncbi.nlm.nih.gov/pubmed/?term=2875100 TOFACITINIB patients with moderate to severe psoriasis. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2909428 TOFACITINIB Tofacitinib: A New Oral Therapy for Psoriasis. [Review] 2 Medication Title of Article PubMed Link Validation of the Itch Severity Item as a Measurement Tool for https://www.ncbi.nlm.nih.gov/pubmed/?term=2918279 TOFACITINIB Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib 0 Program. Rapid Onset of Tofacitinib Induction Therapy for the Treatment of https://pubmed.ncbi.nlm.nih.gov/31003697 TOFACITINIB Ulcerative Colitis. An economic evaluation of tofacitinib for the treatment of moderately- to-severely active ulcerative colitis: modeling the cost of treatment https://pubmed.ncbi.nlm.nih.gov/31012362 TOFACITINIB strategies in the United States. Combination Therapy With Vedolizumab and Tofacitinib in a Patient https://pubmed.ncbi.nlm.nih.gov/30114486 TOFACITINIB With Ulcerative Colitis and Spondyloarthropathy. TOFACITINIB Efficacy of tofacitinib treatment in ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/31101342 Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging https://pubmed.ncbi.nlm.nih.gov/29377257 TOFACITINIB phase 2 trial. Outcomes of Pregnancies With Maternal/Paternal Exposure in the https://pubmed.ncbi.nlm.nih.gov/29982686 TOFACITINIB Tofacitinib Safety Databases for Ulcerative Colitis. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving https://pubmed.ncbi.nlm.nih.gov/29850873 TOFACITINIB Tofacitinib. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for https://pubmed.ncbi.nlm.nih.gov/30012431 TOFACITINIB Patients With Ulcerative Colitis. TOFACITINIB Tofacitinib for the treatment of ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/30285500

TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS https://pubmed.ncbi.nlm.nih.gov/30043874 TOFACITINIB REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Positioning Tofacitinib in the Treatment Algorithm of Moderate to https://pubmed.ncbi.nlm.nih.gov/29697791 TOFACITINIB Severe Ulcerative Colitis. [Review] Editorial: tofacitinib and biologics for moderate-to-severe ulcerative https://pubmed.ncbi.nlm.nih.gov/29341281 TOFACITINIB colitis-what is best in class?. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative https://pubmed.ncbi.nlm.nih.gov/29341277 TOFACITINIB colitis-what is best in class? Authors' reply. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to- https://pubmed.ncbi.nlm.nih.gov/29205421 TOFACITINIB severe ulcerative colitis. Medication Title of Article PubMed Link Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance https://pubmed.ncbi.nlm.nih.gov/29028981 TOFACITINIB Studies. Tofacitinib as Induction and Maintenance Therapy for Ulcerative https://pubmed.ncbi.nlm.nih.gov/28770978 TOFACITINIB Colitis. Tofacitinib as Induction and Maintenance Therapy for Ulcerative https://pubmed.ncbi.nlm.nih.gov/28767341 TOFACITINIB Colitis. TOFACITINIB IBD: Tofacitinib effective in ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/28513630 TOFACITINIB Tofacitinib for Ulcerative Colitis - A Promising Step Forward. https://pubmed.ncbi.nlm.nih.gov/28467881 Tofacitinib as Induction and Maintenance Therapy for Ulcerative https://pubmed.ncbi.nlm.nih.gov/28467869 TOFACITINIB Colitis. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in https://pubmed.ncbi.nlm.nih.gov/27194530 TOFACITINIB Patients with Ulcerative Colitis. TOFACITINIB Tofacitinib for the treatment of ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/27177233 TOFACITINIB Tofacitinib in ulcerative colitis. [Review] https://pubmed.ncbi.nlm.nih.gov/27140405 Randomized trial of tofacitinib in active ulcerative colitis: analysis of https://pubmed.ncbi.nlm.nih.gov/25651782 TOFACITINIB efficacy based on patient-reported outcomes. TOFACITINIB Tofacitinib in active ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/23150971 TOFACITINIB Tofacitinib in active ulcerative colitis. https://pubmed.ncbi.nlm.nih.gov/23150970 https://pubmed.ncbi.nlm.nih.gov/22894574 TOFACITINIB Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. http://www.google.com/patents/EP2361083A1?cl=en TOPIRAMATE Composition for treatment of epithelial tissue Intranasal delivery of antiepileptic medications for treatment of http://www.ncbi.nlm.nih.gov/pubmed/19332330 TOPIRAMATE seizures. TOPIRAMATE Relative bioavailability of topiramate administered rectally. http://www.ncbi.nlm.nih.gov/pubmed/12837560 TRICHLOROACETIC Comparative study of topical 80% trichloroacetic acid with 35% http://www.ncbi.nlm.nih.gov/pubmed/23135096 ACID trichloroacetic acid in the treatment of the common wart. TRICHLOROACETIC Adjunctive trichloroacetic acid therapy enhances squaric acid http://www.ncbi.nlm.nih.gov/pubmed/23134989 ACID response to verruca vulgaris. TRICHLOROACETIC Treatment of external genital warts comparing cryotherapy (liquid http://www.ncbi.nlm.nih.gov/pubmed/8108758 ACID nitrogen) and trichloroacetic acid Assessment of efficacy and tolerability of different concentrations of TRICHLOROACETIC trichloroacetic acid vs. carbon dioxide laser in treatment of http://www.ncbi.nlm.nih.gov/pubmed/26251333 ACID xanthelasma palpebrarum Medication Title of Article PubMed Link TRICHLOROACETIC http://www.ncbi.nlm.nih.gov/pubmed/26132456 ACID Accidental Trichloroacetic Acid Burn in a Gynecology Office Comparison of lesion improvement in lupoid leishmaniasis patients TRICHLOROACETIC with two treatment approaches: trichloroacetic Acid and intralesional http://www.ncbi.nlm.nih.gov/pubmed/25775661 ACID meglumine antimoniate

TRICHLOROACETIC Comparative study of trichloroacetic acid vs. photodynamic therapy http://www.ncbi.nlm.nih.gov/pubmed/25660106 ACID with topical 5-aminolevulinic acid for actinic keratosis of the scalp Clinical comparison of topical solutions containing trimethoprim in http://www.ncbi.nlm.nih.gov/pubmed/3049861 TRIMETHOPRIM treating ocular surface bacterial infections Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow https://www.ncbi.nlm.nih.gov/pubmed/27098102 TRIMETHOPRIM Left Ventricular Assist Devices. TRIMETHOPRIM Guidelines of care for the management of acne vulgaris. https://www.ncbi.nlm.nih.gov/pubmed/26897386 Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the http://onlinelibrary.wiley.com/doi/10.1111/aor.12726/fu Incidence of Driveline Infections in Patients With Continuous-Flow ll TRIMETHOPRIM Left Ventricular Assist Devices Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients http://www.ncbi.nlm.nih.gov/pubmed/25667293 UREA with advanced hepatocellular carcinoma

Combination treatment of oral terbinafine with topical terbinafine and http://www.ncbi.nlm.nih.gov/pubmed/24697872 UREA 10% urea ointment in hyperkeratotic type tinea pedis Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to -urea ointment for removal of the clinically http://www.ncbi.nlm.nih.gov/pubmed/23467055 infected nail in toenail onychomycosis: a randomized evaluator- UREA blinded controlled study

An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet http://www.ncbi.nlm.nih.gov/pubmed/23009311 in Type 2 diabetic patients in comparison with glycerol-based UREA emollient cream. A randomized, assessor-blinded, controlled trial Medication Title of Article PubMed Link Treatment of distal subungual onychomycosis with a topical preparation of urea, and lactic acid: results of a 24- http://www.ncbi.nlm.nih.gov/pubmed/22681227 UREA week, double-blind, placebo-controlled study Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.- http://www.ncbi.nlm.nih.gov/pubmed/22007909 left study in comparison with standard glycerol-based emollient UREA cream Efficacy of topical hydrating and emollient lotion containing 10% urea ISDIN® plus dexpanthenol (Ureadin Rx 10) in the treatment of skin http://www.ncbi.nlm.nih.gov/pubmed/21956268 xerosis and pruritus in hemodialyzed patients: an open prospective UREA pilot trial Clinical evaluation of 35% urea in a water-lipid-based foam containing lactic acid for treatment of mild-to-moderate xerosis of the http://www.ncbi.nlm.nih.gov/pubmed/21406699 UREA foot Clinical evaluation of 40% urea and 12% ammonium lactate in the http://www.ncbi.nlm.nih.gov/pubmed/11978141 UREA treatment of xerosis

Treatment of seborrhoeic dermatitis of the scalp with a topical http://www.ncbi.nlm.nih.gov/pubmed/21966947 solution of urea, lactic acid, and propylene glycol (K301): results of UREA two double-blind, randomised, placebo-controlled studies A randomized, double-blind, placebo-controlled study to evaluate the UREA + AMMONIUM efficacy in AD of liquid soap containing 12% ammonium lactate + http://www.ncbi.nlm.nih.gov/pubmed/19486056 LACTATE 20% urea

UREA + BENZOYL A multicenter efficacy and tolerability evaluation of benzoyl peroxide http://www.ncbi.nlm.nih.gov/pubmed/16703780 PEROXIDE in a 10% urea vehicle for the treatment of acne vulgaris Treatment with a barrier-strengthening moisturizing cream delays UREA + relapse of atopic dermatitis: a prospective and randomized controlled http://www.ncbi.nlm.nih.gov/pubmed/19508310 BETAMETHASONE clinical trial Bifonazole (Mycospor cream) in the treatment of moccasin-type tinea pedis. Comparison between combination therapy of bifonazole cream http://www.ncbi.nlm.nih.gov/pubmed/10907343 UREA + + 10% urea ointment (Urepearl) and occlusive dressing therapy with BIFONAZOLE the same agents UREA + http://www.ncbi.nlm.nih.gov/pubmed/10990584 BIFONAZOLE Onychomycosis in children: treatment with bifonazole-urea Medication Title of Article PubMed Link UREA + http://www.ncbi.nlm.nih.gov/pubmed/15186053 The use of 40% urea cream in the treatment of moccasin tinea pedi Ambulatory external treatment of psoriasis vulgaris: comparison of http://www.ncbi.nlm.nih.gov/pubmed/?term=dexameth the effectiveness of a dithranol and a glucocorticoid-containing asone+urea+topical UREA + DITHRANOL preparation An open assessment of 0.1% dithranol in a 17% urea base http://www.ncbi.nlm.nih.gov/pubmed/6342960 UREA + DITHRANOL ('Psoradrate' 0.1%) in the treatment of psoriasis of children A double-blind comparison of 0.1% dithranol in a 17% urea base ("Psoradrate") and base alone in the treatment of active chronic http://www.ncbi.nlm.nih.gov/pubmed/350501 UREA + DITHRANOL psoriasis Treatment of chronic plaque psoriasis with dithranol and urea http://www.ncbi.nlm.nih.gov/pubmed/7048339 UREA + DITHRANOL creams: a double-blind study A double-blind study comparing the effect of glycerin and urea on http://www.ncbi.nlm.nih.gov/pubmed/12013198 UREA + GLYCERIN dry, eczematous skin in atopic patients A double-blind comparison of 1% hydrocortisone plus 10% urea UREA + ('Alphaderm') and 0.1% betamethasone 17-valerate in the treatment http://www.ncbi.nlm.nih.gov/pubmed/343995 HYDROCORTISONE of non-infective inflammatory dermatoses

UREA + Topical treatment with urea-hydrocortisone in atopic dermatitis. A http://www.ncbi.nlm.nih.gov/pubmed/1107090 HYDROCORTISONE controlled study against betamethasone 17-valerate

UREA + A new urea/hydrocortisone powder-cream compared with other http://www.ncbi.nlm.nih.gov/pubmed/4614954 HYDROCORTISONE topical corticosteroid preparations: a six-centre study

UREA + http://www.ncbi.nlm.nih.gov/pubmed/2681076 HYDROCORTISONE Urea in combination with corticosteroids in treating eczema

UREA + Comparison of a modified hydrocortisone/urea cream and http://www.ncbi.nlm.nih.gov/pubmed/3582724 HYDROCORTISONE betamethasone valerate cream in the treatment of dry eczema

UREA + Controlled trial of the treatment of atopic eczema with a urea- http://www.ncbi.nlm.nih.gov/pubmed/4715126 HYDROCORTISONE hydrocortisone preparation versus betamethasone 17-valerate

UREA + Long-term study "Neurodermatitis therapy using urea-containing http://www.ncbi.nlm.nih.gov/pubmed/1555939 HYDROCORTISONE Externa". Experience report of a pediatrician Medication Title of Article PubMed Link Treatment of non-inflammatory dermatoses. A double-blind UREA + comparison of 1% hydrocortisone plus 10% urea and 0.05% http://www.ncbi.nlm.nih.gov/pubmed/364458 HYDROCORTISONE fluocinonide.

UREA + http://www.ncbi.nlm.nih.gov/pubmed/4459060 HYDROCORTISONE Alphaderm- hydrocortisone in a new urea base. http://archderm.jamanetwork.com/article.aspx?articlei UREA + d=533702 HYDROCORTISONE Percutaneous penetration of hydrocortisone with urea.

Usefulness of lanoconazole (Astat) cream in the treatment of http://www.ncbi.nlm.nih.gov/pubmed/11486456 UREA + hyperkeratotic type tinea pedis. Comparative study of monotherapy LANOCONAZOLE and combination therapy with 10% urea ointment (Pastaron) Urea plus ceramides and vitamins: improving the efficacy of a topical http://www.ncbi.nlm.nih.gov/pubmed/18679637 UREA + VITAMINS urea preparation by addition of ceramides and vitamins Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: a double-blind, randomized, http://www.ncbi.nlm.nih.gov/pubmed/23586591 UREA 40% placebo-controlled multicenter study A comparative evaluation of combination therapy of fluconazole 1%and urea 40% compared with fluconazole 1% alone in a nail http://www.ncbi.nlm.nih.gov/pubmed/21781012 UREA 40% lacquer for treatment of onychomycosis: therapeutic trial. http://www.ncbi.nlm.nih.gov/pubmed/15186053 UREA 40% The use of 40% urea cream in the treatment of moccasin tinea pedis. Topical treatment of onychomycosis by occlusive dressing using http://www.ncbi.nlm.nih.gov/pubmed/9487003 UREA 40% bifonazole cream containing 40% urea UREA REVIEW Urea: a comprehensive review of the clinical literature http://escholarship.org/uc/item/11x463rp https://www.ncbi.nlm.nih.gov/pubmed/?term=1848672 USTEKINUMAB Ustekinumab for chronic plaque psoriasis. 4

Efficacy and safety of ustekinumab, a human interleukin-12/23 https://www.ncbi.nlm.nih.gov/pubmed/?term=1848673 USTEKINUMAB monoclonal antibody, in patients with psoriasis: 76-week results from 9 a randomised, double-blind, placebo-controlled trial (PHOENIX 1).[Erratum appears in Lancet. 2008 May 31;371(9627):1838] Medication Title of Article PubMed Link

Efficacy and safety of ustekinumab, a human interleukin-12/23 https://www.ncbi.nlm.nih.gov/pubmed/?term=1848674 USTEKINUMAB monoclonal antibody, in patients with psoriasis: 52-week results from 0 a randomised, double-blind, placebo-controlled trial (PHOENIX 2). https://www.ncbi.nlm.nih.gov/pubmed/?term=1906085 USTEKINUMAB Ustekinumab poised to enter the psoriasis market. 1 Population pharmacokinetic modeling of ustekinumab, a human https://www.ncbi.nlm.nih.gov/pubmed/?term=1917929 USTEKINUMAB monoclonal antibody targeting IL-12/23p40, in patients with moderate 5 to severe plaque psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1953783 USTEKINUMAB Ustekinumab: a new option in psoriasis therapy. [Review] [115 refs] 3 Ustekinumab: treatment of adult moderate-to-severe chronic plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=1967180 USTEKINUMAB psoriasis. [Review] [37 refs] 2 Ustekinumab for the treatment of moderate to severe psoriasis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1984603 USTEKINUMAB [Review] [4 refs] 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=1990318 USTEKINUMAB Ustekinumab improves health-related quality of life in patients with 3 moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Population-based exposure-efficacy modeling of ustekinumab in https://www.ncbi.nlm.nih.gov/pubmed/?term=1993403 USTEKINUMAB patients with moderate to severe plaque psoriasis. 0 https://www.ncbi.nlm.nih.gov/pubmed/?term=2020847 USTEKINUMAB Ustekinumab (Stelara) for psoriasis. 3 Ustekinumab induces rapid clearing of erythrodermic psoriasis after https://www.ncbi.nlm.nih.gov/pubmed/?term=2022292 USTEKINUMAB failure of antitumour necrosis factor therapies. 6 Anti-p40 antibodies ustekinumab and briakinumab: blockade of https://www.ncbi.nlm.nih.gov/pubmed/?term=2043030 USTEKINUMAB interleukin-12 and interleukin-23 in the treatment of psoriasis. 7 [Review] [20 refs] Observational case series on a group of patients with severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2045634 USTEKINUMAB psoriasis who failed to respond to antitumour necrosis factor alpha 4 biologics and switched to ustekinumab. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2046266 USTEKINUMAB psoriasis: Results from a randomized, double-blind, placebo- 4 controlled phase III trial. Medication Title of Article PubMed Link Ustekinumab for the treatment of psoriasis: review of three https://www.ncbi.nlm.nih.gov/pubmed/?term=2050272 USTEKINUMAB multicenter clinical trials. 3 Positive treatment effects of ustekinumab in psoriasis: analysis of https://www.ncbi.nlm.nih.gov/pubmed/?term=2053664 USTEKINUMAB lesional and systemic parameters. 6 Impact of weight on the efficacy and safety of ustekinumab in https://www.ncbi.nlm.nih.gov/pubmed/?term=2059929 USTEKINUMAB patients with moderate to severe psoriasis: rationale for dosing 3 recommendations. Formulary review of 2 new biologic agents: tocilizumab for https://www.ncbi.nlm.nih.gov/pubmed/?term=2063583 USTEKINUMAB rheumatoid arthritis and ustekinumab for plaque psoriasis. [Review] 1 [55 refs] Ustekinumab in the treatment of severe rupioid psoriasis: A case https://www.ncbi.nlm.nih.gov/pubmed/?term=2066491 USTEKINUMAB report. 7 Ustekinumab: effective in a patient with severe recalcitrant https://www.ncbi.nlm.nih.gov/pubmed/?term=2071621 USTEKINUMAB generalized pustular psoriasis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2098072 USTEKINUMAB Efficacy of ustekinumab in palmoplantar psoriasis. 4 Ustekinumab decreases work limitations, improves work productivity, https://www.ncbi.nlm.nih.gov/pubmed/?term=2103429 USTEKINUMAB and reduces work days missed in patients with moderate-to-severe 0 psoriasis: results from PHOENIX 2. https://www.ncbi.nlm.nih.gov/pubmed/?term=2107908 USTEKINUMAB Ustekinumab for rapid treatment of nail psoriasis. 3 Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF https://www.ncbi.nlm.nih.gov/pubmed/?term=2110866 USTEKINUMAB agent-exposed patients with psoriasis vulgaris. 8 Pustular psoriasis development after initial ustekinumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2123306 USTEKINUMAB administration in chronic plaque psoriasis. 2 Ustekinumab for the treatment of an adolescent patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2123306 USTEKINUMAB recalcitrant plaque psoriasis. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2125488 USTEKINUMAB Flare of pustular psoriasis after initiating ustekinumab therapy. 1 https://www.ncbi.nlm.nih.gov/pubmed/?term=2126735 USTEKINUMAB Comparative assessment of biologics in treatment of psoriasis: drug 8 design and clinical effectiveness of ustekinumab. [Review] Medication Title of Article PubMed Link Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of https://www.ncbi.nlm.nih.gov/pubmed/?term=2132753 USTEKINUMAB physician's global assessment score for ustekinumab in patients with 8 psoriasis. Cardiovascular safety of ustekinumab in patients with moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2133246 USTEKINUMAB severe psoriasis: results of integrated analyses of data from phase II 7 and III clinical studies. https://www.ncbi.nlm.nih.gov/pubmed/?term=2142625 USTEKINUMAB Ustekinumab for the treatment of psoriasis. [Review] 3 Development of the IL-12/23 antagonist ustekinumab in psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2143494 USTEKINUMAB past, present, and future perspectives. [Review] 0 Impact of ustekinumab on health-related quality of life and sexual https://www.ncbi.nlm.nih.gov/pubmed/?term=2152137 USTEKINUMAB difficulties associated with psoriasis: results from two phase III 5 clinical trials. Ustekinumab treats psoriasis refractory to seven conventional and https://www.ncbi.nlm.nih.gov/pubmed/?term=2154908 USTEKINUMAB biologic therapies. 9 Exacerbation and change of psoriasis morphology in a patient https://www.ncbi.nlm.nih.gov/pubmed/?term=2156159 USTEKINUMAB treated with ustekinumab. 0 Bounded outcome score modeling: application to treating psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2168806 USTEKINUMAB with ustekinumab. 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2178720 USTEKINUMAB Ustekinumab for the treatment of HIV psoriasis. 6 Ustekinumab in nail psoriasis: an open-label, uncontrolled, https://www.ncbi.nlm.nih.gov/pubmed/?term=2179780 USTEKINUMAB nonrandomized study. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2185656 USTEKINUMAB Rapid response of scalp psoriasis to ustekinumab. 1 Ustekinumab: a review of its use in the management of moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2190229 USTEKINUMAB severe plaque psoriasis. [Review] 6 Practical experience of ustekinumab in the treatment of psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2192953 USTEKINUMAB experience from a multicentre, retrospective case cohort study 6 across the U.K. and Ireland.

Long-term safety experience of ustekinumab in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2193032 USTEKINUMAB moderate-to-severe psoriasis (Part I of II): results from analyses of 8 general safety parameters from pooled Phase 2 and 3 clinical trials. Medication Title of Article PubMed Link

Long-term safety experience of ustekinumab in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2197857 USTEKINUMAB moderate to severe psoriasis (Part II of II): results from analyses of 2 infections and malignancy from pooled phase II and III clinical trials.

Efficacy of ustekinumab in nail psoriasis and improvement in nail- https://www.ncbi.nlm.nih.gov/pubmed/?term=2213404 USTEKINUMAB associated quality of life in a population treated with ustekinumab for 6 cutaneous psoriasis: an open prospective unblinded study. Differential response of chronic plaque psoriasis to briakinumab vs. https://www.ncbi.nlm.nih.gov/pubmed/?term=2216998 USTEKINUMAB ustekinumab. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2220141 USTEKINUMAB Spotlight on ustekinumab in moderate to severe plaque psoriasis. 9 Ustekinumab: a review in the treatment of plaque psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2227019 USTEKINUMAB psoriatic arthritis. [Review] 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2230933 USTEKINUMAB The rapid onset of multiple squamous cell carcinomas in two patients 4 commenced on ustekinumab as treatment of psoriasis. Long-term efficacy of ustekinumab in patients with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2235625 USTEKINUMAB severe psoriasis: results from the PHOENIX 1 trial through up to 3 8 years. Sustained efficacy of ustekinumab in refractory erythrodermic https://www.ncbi.nlm.nih.gov/pubmed/?term=2236431 USTEKINUMAB psoriasis after failure of antitumor necrosis factor therapies. 6 Investigator-initiated, open-label trial of ustekinumab for the https://www.ncbi.nlm.nih.gov/pubmed/?term=2239068 USTEKINUMAB treatment of moderate-to-severe palmoplantar psoriasis. 8 An update on the long-term safety experience of ustekinumab: https://www.ncbi.nlm.nih.gov/pubmed/?term=2239558 USTEKINUMAB results from the psoriasis clinical development program with up to 0 four years of follow-up. Response to ustekinumab in a patient with both severe psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2243802 USTEKINUMAB hypertrophic cutaneous lupus. 8 Ustekinumab biotherapy and real-time psoriasis capacitance https://www.ncbi.nlm.nih.gov/pubmed/?term=2253602 USTEKINUMAB mapping: a pilot study. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2275160 USTEKINUMAB Ustekinumab for psoriasis and psoriatic arthritis. [Review][Erratum 2 appears in J Rheumatol Suppl. 2012 Sep 1;39(9):1908] Medication Title of Article PubMed Link Ustekinumab in psoriasis immunopathology with emphasis on the https://www.ncbi.nlm.nih.gov/pubmed/?term=2275427 USTEKINUMAB Th17-IL23 axis: a primer. [Review] 8 Long-term combination therapy of ustekinumab and dapsone in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2278410 USTEKINUMAB patient with psoriasis and dermatitis herpetiformis Duhring. 6 The safety of ustekinumab treatment in patients with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2280361 USTEKINUMAB severe psoriasis and latent tuberculosis infection. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2282358 USTEKINUMAB Development of the IL-12/23 antagonist ustekinumab in psoriasis: 2 past, present, and future perspectives--an update. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2285923 USTEKINUMAB The safety of ustekinumab in psoriasis. [Review] 4 Ustekinumab for treatment of plaque psoriasis in a patient with Down https://www.ncbi.nlm.nih.gov/pubmed/?term=2285924 USTEKINUMAB syndrome. 9 Ustekinumab treatment of TNF antagonist-induced paradoxical https://www.ncbi.nlm.nih.gov/pubmed/?term=2289027 USTEKINUMAB psoriasis flare in a patient with psoriatic arthritis: case report and 5 review. [Review] Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF- https://www.ncbi.nlm.nih.gov/pubmed/?term=2291344 USTEKINUMAB blockers fail. 9 Challenging regional psoriasis and ustekinumab biotherapy: impact https://www.ncbi.nlm.nih.gov/pubmed/?term=2292772 USTEKINUMAB of the patterns of disease. [Review] 0 Development of linear IgA bullous dermatosis in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2298027 USTEKINUMAB psoriasis taking ustekinumab. 4

Safety and effectiveness of ustekinumab and antitumour necrosis https://www.ncbi.nlm.nih.gov/pubmed/?term=2298545 USTEKINUMAB factor therapy in patients with psoriasis and chronic viral hepatitis B 1 or C: a retrospective, multicentre study in a clinical setting. Hepatitis B virus reactivation during therapy with ustekinumab for https://www.ncbi.nlm.nih.gov/pubmed/?term=2312126 USTEKINUMAB psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive 0 patient. https://www.ncbi.nlm.nih.gov/pubmed/?term=2313499 USTEKINUMAB Treatment of severe psoriasis with ustekinumab during pregnancy. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2314830 USTEKINUMAB Successful long-term triple disease control by ustekinumab in a 7 patient with Behcet's disease, psoriasis and hidradenitis suppurativa. Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2321068 USTEKINUMAB Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2325163 USTEKINUMAB Ustekinumab improves psoriasis without altering T cell cytokine 2 production, differentiation, and T cell receptor repertoire diversity. A successful treatment with ustekinumab in a case of antilaminin- https://www.ncbi.nlm.nih.gov/pubmed/?term=2325297 USTEKINUMAB gamma1 pemphigoid associated with psoriasis. 2 Inflammatory arthritis following ustekinumab treatment for psoriasis: https://www.ncbi.nlm.nih.gov/pubmed/?term=2327855 USTEKINUMAB a report of two cases. 9 Ustekinumab improves psoriasis-related gene expression in https://www.ncbi.nlm.nih.gov/pubmed/?term=2327863 USTEKINUMAB noninvolved psoriatic skin without inhibition of the antimicrobial 2 response. https://www.ncbi.nlm.nih.gov/pubmed/?term=2327900 USTEKINUMAB Long-term efficacy of ustekinumab in patients with moderate-to- 3 severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Long-term safety of ustekinumab in patients with moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2330163 USTEKINUMAB psoriasis: final results from 5 years of follow-up. 2 Ustekinumab does not increase body mass index in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2332091 USTEKINUMAB chronic plaque psoriasis: a prospective cohort study. 6 Ustekinumab for the treatment of nail psoriasis in heavily treated https://www.ncbi.nlm.nih.gov/pubmed/?term=2333078 USTEKINUMAB psoriatic patients. 2 Two cases of hepatitis B in patients with moderate to severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2337752 USTEKINUMAB psoriasis with ustekinumab. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2341416 USTEKINUMAB Psoriasis treated with ustekinumab in a patient with hepatitis C. 8 Concurrent treatment of chronic psoriasis and asthma with https://www.ncbi.nlm.nih.gov/pubmed/?term=2346980 USTEKINUMAB ustekinumab. 9

Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion https://www.ncbi.nlm.nih.gov/pubmed/?term=2352114 USTEKINUMAB nor TNFAIP3 polymorphism predisposes to clinical response to 9 interleukin 12/23 blocker ustekinumab.[Erratum appears in Br J Dermatol. 2016 Jul;175(1):228-9; PMID: 27484281] https://www.ncbi.nlm.nih.gov/pubmed/?term=2354591 USTEKINUMAB The efficacy of ustekinumab in psoriasis. [Review] 5 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2358199 USTEKINUMAB Ustekinumab in the treatment of severe paediatric psoriasis. 9 Psoriasis vulgaris complicated by eosinophilic pneumonia during https://www.ncbi.nlm.nih.gov/pubmed/?term=2372815 USTEKINUMAB ustekinumab treatment. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2374596 USTEKINUMAB Long-term safety of ustekinumab for psoriasis. [Review] 5 The safety profile of ustekinumab in the treatment of patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2374617 USTEKINUMAB psoriasis and concurrent hepatitis B or C. 0 Resident Rounds. Part III A. Serendipitous improvement in moderate https://www.ncbi.nlm.nih.gov/pubmed/?term=2383919 USTEKINUMAB to severe acne in psoriasis patients treated with ustekinumab: a two- 4 case series. https://www.ncbi.nlm.nih.gov/pubmed/?term=2408504 USTEKINUMAB Adherence to ustekinumab in psoriasis patients. 2 Immune response to pneumococcus and tetanus toxoid in patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2408504 USTEKINUMAB with moderate-to-severe psoriasis following long-term ustekinumab 7 use. Ustekinumab improves nail disease in patients with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2411738 USTEKINUMAB severe psoriasis: results from PHOENIX 1. 9 Successful management of ustekinumab-induced pustular psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2418322 USTEKINUMAB without therapy discontinuation. 7 Ustekinumab: moving the target from psoriasis to Crohn's disease. https://www.ncbi.nlm.nih.gov/pubmed/?term=2441046 USTEKINUMAB [Review] 8 https://www.ncbi.nlm.nih.gov/pubmed/?term=2441387 USTEKINUMAB Recalcitrant psoriasis responding to new bilogic drug: ustekinumab. 3 Ustekinumab dosing, persistence, and discontinuation patterns in https://www.ncbi.nlm.nih.gov/pubmed/?term=2455261 USTEKINUMAB patients with moderate-to-severe psoriasis. 2 Monoclonal gammopathy of undetermined significance (MGUS) in patients with psoriasis may be associated with long-term treatment https://www.ncbi.nlm.nih.gov/pubmed/?term=2459367 USTEKINUMAB with efalizumab, but not with anti-TNF-alpha treatments or 8 ustekinumab. https://www.ncbi.nlm.nih.gov/pubmed/?term=2472188 USTEKINUMAB Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. 3 Successful treatment of ustekinumab in a severe psoriasis patient https://www.ncbi.nlm.nih.gov/pubmed/?term=2475447 USTEKINUMAB with human immunodeficiency virus infection. 6 Medication Title of Article PubMed Link Ustekinumab in severe complicated erythrodermic psoriasis: rapid https://www.ncbi.nlm.nih.gov/pubmed/?term=2481381 USTEKINUMAB clearing, safety, and sustained remission. 6 Immunoglobulin G4-related disease in a psoriasis vulgaris patient https://www.ncbi.nlm.nih.gov/pubmed/?term=2493091 USTEKINUMAB treated with ustekinumab. 5 Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar https://www.ncbi.nlm.nih.gov/pubmed/?term=2496280 USTEKINUMAB pustular psoriasis. 8 Systematic review and meta-analysis of ustekinumab for moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2503959 USTEKINUMAB severe psoriasis. [Review] 3 Some clinical factors affecting quality of the response to ustekinumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2504015 USTEKINUMAB for psoriasis. 9 The use of ustekinumab in a patient with severe psoriasis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2505475 USTEKINUMAB positive HBV serology. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2511696 USTEKINUMAB Ustekinumab treatment for psoriasis in 119 patients maintained on 6 therapy for a minimum of one year: a review. [Review] https://www.ncbi.nlm.nih.gov/pubmed/?term=2511697 USTEKINUMAB Safety and effectiveness of ustekinumab for treatment of moderate 7 to severe psoriasis: a prospective study in a clinical setting. Latent tuberculosis reactivation in a patient with erythrodermic https://www.ncbi.nlm.nih.gov/pubmed/?term=2512023 USTEKINUMAB psoriasis under treatment with ustekinumab and a low dose steroid, 3 despite isoniazid chemoprophylaxis. Acute systemic sarcoidosis complicating ustekinumab therapy for https://www.ncbi.nlm.nih.gov/pubmed/?term=2514177 USTEKINUMAB chronic plaque psoriasis. 4 Therapeutic effect and safety of ustekinumab for plaque psoriasis: a https://www.ncbi.nlm.nih.gov/pubmed/?term=2526487 USTEKINUMAB meta-analysis. 9

Long-term efficacy and safety of ustekinumab, with and without https://www.ncbi.nlm.nih.gov/pubmed/?term=2530793 USTEKINUMAB dosing adjustment, in patients with moderate-to-severe psoriasis: 1 results from the PHOENIX 2 study through 5 years of follow-up. Ustekinumab improves psoriasis without suppressing tumor antigen- https://www.ncbi.nlm.nih.gov/pubmed/?term=2534244 USTEKINUMAB specific cytotoxic T lymphocytes. 4 Efficacy and safety of ustekinumab treatment in elderly patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2534630 USTEKINUMAB psoriasis. 1 Ustekinumab treatment in a patient with psoriasis and systemic lupus https://www.ncbi.nlm.nih.gov/pubmed/?term=2541335 USTEKINUMAB erythematosus. 8 Medication Title of Article PubMed Link Inadvertent pregnancy during ustekinumab therapy in a patient with https://www.ncbi.nlm.nih.gov/pubmed/?term=2541389 USTEKINUMAB plaque psoriasis and impetigo herpetiformis. 5 Good efficacy and tolerability of ustekinumab in a patient with severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2544509 USTEKINUMAB psoriasis under haemodialysis. 2 Observational cases report of a group of severe plaque type https://www.ncbi.nlm.nih.gov/pubmed/?term=2550971 USTEKINUMAB psoriasis patients treated with ustekinumab. 0 Gastric mucosa-associated lymphoid tissue lymphoma in a patient https://www.ncbi.nlm.nih.gov/pubmed/?term=2552946 USTEKINUMAB with severe psoriasis receiving ustekinumab. 4 Onset of psoriatic arthritis during ustekinumab treatment for https://www.ncbi.nlm.nih.gov/pubmed/?term=2555708 USTEKINUMAB psoriasis: a case series of seven patients. 1 Systematic review and meta-analysis of ustekinumab for moderate to https://www.ncbi.nlm.nih.gov/pubmed/?term=2570394 USTEKINUMAB severe psoriasis: comment. 4 Successful treatment of severe psoriasis in an adolescent with https://www.ncbi.nlm.nih.gov/pubmed/?term=2572784 USTEKINUMAB ustekinumab. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=2579094 USTEKINUMAB Pregnancy during Ustekinumab Treatment for Severe Psoriasis. 7 The correlation of clinical efficacy, serum trough levels and antidrug https://www.ncbi.nlm.nih.gov/pubmed/?term=2586515 USTEKINUMAB antibodies in ustekinumab-treated patients with psoriasis in a clinical- 3 practice setting. Ustekinumab treatment in patients with psoriasis undergoing https://www.ncbi.nlm.nih.gov/pubmed/?term=2595960 USTEKINUMAB hemodialysis. 2 Successful treatment with ustekinumab of psoriasis vulgaris in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2610378 USTEKINUMAB patient undergoing hemodialysis. 8 Potential serum biomarkers of treatment response to ustekinumab in https://www.ncbi.nlm.nih.gov/pubmed/?term=2613466 USTEKINUMAB patients with psoriasis: a pilot study. 7 Safety Surveillance for Ustekinumab and Other Psoriasis Treatments https://www.ncbi.nlm.nih.gov/pubmed/?term=2615178 USTEKINUMAB From the Psoriasis Longitudinal Assessment and Registry 7 (PSOLAR). Paradoxical psoriatic arthritis in a patient with psoriasis treated with https://www.ncbi.nlm.nih.gov/pubmed/?term=2624285 USTEKINUMAB ustekinumab. [Review] 7 Ustekinumab in adolescent patients age 12 to 17 years with https://www.ncbi.nlm.nih.gov/pubmed/?term=2625998 USTEKINUMAB moderate-to-severe plaque psoriasis: results of the randomized 9 phase 3 CADMUS study. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased https://www.ncbi.nlm.nih.gov/pubmed/?term=2626773 USTEKINUMAB Ustekinumab Efficacy in Psoriasis Patients. 6 Medication Title of Article PubMed Link

Development of clinical prediction models for good or bad response https://www.ncbi.nlm.nih.gov/pubmed/?term=2636779 USTEKINUMAB to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, 9 based on the BIOBADADERM cohort. https://www.ncbi.nlm.nih.gov/pubmed/?term=2637724 USTEKINUMAB Ustekinumab as therapy for psoriasis in a 2-year-old girl. 8 Successful treatment of psoriasis with ustekinumab in patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2643696 USTEKINUMAB multiple sclerosis. 7 The cost-effectiveness of ustekinumab for moderate-to-severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2648818 USTEKINUMAB psoriasis. [Review] 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=2655939 USTEKINUMAB Successful pregnancy outcome under prolonged ustekinumab 3 treatment in a patient with Crohn's disease and paradoxical psoriasis. Safety of ustekinumab for the treatment of psoriasis vulgaris with https://www.ncbi.nlm.nih.gov/pubmed/?term=2664326 USTEKINUMAB myotonic dystrophy. 0 IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab https://www.ncbi.nlm.nih.gov/pubmed/?term=2667806 USTEKINUMAB Response Prediction in Psoriasis. 0 Interstitial pneumonia in two patients with psoriasis during https://www.ncbi.nlm.nih.gov/pubmed/?term=2670379 USTEKINUMAB ustekinumab treatment. 1 Different Responses to Ustekinumab of Two HLA-Cw6-positive https://www.ncbi.nlm.nih.gov/pubmed/?term=2671466 USTEKINUMAB Homozygous Twins with Psoriasis. 0 HLA-C*06 and response to ustekinumab in Caucasian patients with https://www.ncbi.nlm.nih.gov/pubmed/?term=2677577 USTEKINUMAB psoriasis: Outcome and long-term follow-up. 8 Efficacy and safety of ustekinumab in a group of 22 elderly patients https://www.ncbi.nlm.nih.gov/pubmed/?term=2702850 USTEKINUMAB with psoriasis over a 2-year period. 5 Five-year experience with Ustekinumab for psoriasis: real-life data of https://www.ncbi.nlm.nih.gov/pubmed/?term=2703836 USTEKINUMAB a single centre. 3 A prospective, interventional assessment of the impact of https://www.ncbi.nlm.nih.gov/pubmed/?term=2705238 USTEKINUMAB ustekinumab treatment on psoriasis-related work productivity and 7 activity impairment. Safety of ustekinumab in severe psoriasis with chronic hepatitis B. https://www.ncbi.nlm.nih.gov/pubmed/?term=2708894 USTEKINUMAB [Review] 4 https://www.ncbi.nlm.nih.gov/pubmed/?term=2722227 USTEKINUMAB Inverse psoriasis treated with ustekinumab. 7 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=2733394 USTEKINUMAB Generalized pustular psoriasis treated with ustekinumab. 8 HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results https://www.ncbi.nlm.nih.gov/pubmed/?term=2747672 USTEKINUMAB from the Ustekinumab Phase 3 Psoriasis Program. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=2786484 USTEKINUMAB Clinical factors predicting the therapeutic response to ustekinumab in 1 patients with moderate to severe chronic plaque psoriasis. Ustekinumab in the treatment of palmoplantar pustular psoriasis - a https://www.ncbi.nlm.nih.gov/pubmed/?term=2787906 USTEKINUMAB case series of nine patients. 7 Pharmacogenetics of ustekinumab in patients with moderate-to- https://www.ncbi.nlm.nih.gov/pubmed/?term=2797733 USTEKINUMAB severe plaque psoriasis. 4 Use of TNF-inhibitors and ustekinumab for psoriasis during https://www.ncbi.nlm.nih.gov/pubmed/?term=2807183 USTEKINUMAB pregnancy: A patient series. 7 Morphea in a Patient With Psoriasis on Treatment With https://www.ncbi.nlm.nih.gov/pubmed/?term=2811082 USTEKINUMAB Ustekinumab: Comorbidity or Adverse Effect?. [Review] 5 Varicella zoster virus meningitis under ustekinumab because of https://www.ncbi.nlm.nih.gov/pubmed/?term=2815033 USTEKINUMAB plaque psoriasis. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=2820242 USTEKINUMAB Clearance of annular pustular psoriasis with ustekinumab. 2 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a https://www.ncbi.nlm.nih.gov/pubmed/?term=2830086 USTEKINUMAB Psoriasis Patient Treated With Ustekinumab. 2 Cutaneous mucinosis in a patient taking ustekinumab for https://www.ncbi.nlm.nih.gov/pubmed/?term=2832951 USTEKINUMAB palmoplantar psoriasis. 5 Treatment of psoriasis with ustekinumab improved skin tightening in https://www.ncbi.nlm.nih.gov/pubmed/?term=2842200 USTEKINUMAB systemic sclerosis. 2 Risankizumab versus ustekinumab for moderate-to-severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2842330 USTEKINUMAB psoriasis. 1 No evidence for induction of autoantibodies or autoimmunity during https://www.ncbi.nlm.nih.gov/pubmed/?term=2850838 USTEKINUMAB treatment of psoriasis with ustekinumab. 7 Risankizumab versus ustekinumab for moderate-to-severe plaque https://www.ncbi.nlm.nih.gov/pubmed/?term=2850853 USTEKINUMAB psoriasis. 6 Long-term therapy with ustekinumab for psoriasis in a patient with a https://www.ncbi.nlm.nih.gov/pubmed/?term=2873067 USTEKINUMAB history of malignant melanoma. 4 Successful ustekinumab treatment of noninfectious uveitis and https://www.ncbi.nlm.nih.gov/pubmed/?term=2883397 USTEKINUMAB concomitant severe psoriatic arthritis and plaque psoriasis. 3 Medication Title of Article PubMed Link Serial QuantiFERON-TB Gold testing in patients with psoriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=2888609 USTEKINUMAB treated with ustekinumab. 9 Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of https://www.ncbi.nlm.nih.gov/pubmed/?term=2908463 USTEKINUMAB therapeutic response to ustekinumab. 9 Excellent response to ustekinumab in a 9-year-old girl with severe https://www.ncbi.nlm.nih.gov/pubmed/?term=2920547 USTEKINUMAB psoriasis. 9 http://www.ncbi.nlm.nih.gov/pubmed/2796369 VANCOMYCIN Reduction of sternal infection by application of topical vancomycin. Topical vancomycin for chronic suppurative otitis media with http://www.ncbi.nlm.nih.gov/pubmed/15453944 VANCOMYCIN methicillin-resistant Staphylococcus aureus otorrhoea. The effect of topical vancomycin applied to sternotomy incisions on http://www.ncbi.nlm.nih.gov/pubmed?term=21951032 VANCOMYCIN postoperative serum vancomycin levels.

Topical vancomycin in combination with perioperative antibiotics and http://www.ncbi.nlm.nih.gov/pubmed/25129595 VANCOMYCIN tight glycemic control helps to eliminate sternal wound infections. Topical intrawound application of vancomycin powder in addition to intravenous administration of antibiotics: A meta-analysis on the deep http://www.ncbi.nlm.nih.gov/pubmed/25281550 VANCOMYCIN infection after spinal surgeries. Oral care with vancomycin paste for reduction in incidence of alpha- http://www.ncbi.nlm.nih.gov/pubmed/7749765 VANCOMYCIN hemolytic streptococcal sepsis.

Cefazolin-Gentamicin versus Vancomycin-Ceftazidime Eye Drops for http://www.ncbi.nlm.nih.gov/pubmed/23056669 VANCOMYCIN Bacterial Corneal Ulcers;a Randomized Clinical Trial. A Retrospective Study on the Protective Effects of Topical http://www.ncbi.nlm.nih.gov/pubmed/26749522 VANCOMYCIN Vancomycin in Patients Undergoing Multilevel Spinal Fusion Effect of Corneal Thickness on the Penetration of Topical http://www.ncbi.nlm.nih.gov/pubmed/26258280 VANCOMYCIN Vancomycin Comparing the ocular surface effects of topical vancomycin and http://www.ncbi.nlm.nih.gov/pubmed/26100380 VANCOMYCIN linezolid for treating bacterial keratitis Reducing surgical site infections following craniotomy: examination of http://www.ncbi.nlm.nih.gov/pubmed/26090835 VANCOMYCIN the use of topical vancomycin Superficial Vancomycin Coating of Bone Cement in Orthopedic Revision Surgery: A Safe Technique to Enhance Local Antibiotic https://www.ncbi.nlm.nih.gov/pubmed/28111125 VANCOMYCIN Concentrations. Medication Title of Article PubMed Link A review of the application of vancomycin powder to posterior spinal fusion wounds with a focus on side effects and infection. A https://www.ncbi.nlm.nih.gov/pubmed/27858249 VANCOMYCIN prospective study. Serum and Wound Vancomycin Levels After Intrawound https://www.ncbi.nlm.nih.gov/pubmed/27633945 VANCOMYCIN Administration in Primary Total Joint Arthroplasty. Re-appraisal of topical 1% voriconazole and 5% natamycin in the http://www.ncbi.nlm.nih.gov/pubmed/25740805 VORICONAZOLE treatment of fungal keratitis in a randomised trial Penetration of 1% voriconazole eye drops into human vitreous http://www.ncbi.nlm.nih.gov/pubmed/19723128 VORICONAZOLE humour: a prospective, open-label study Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for http://www.ncbi.nlm.nih.gov/pubmed/17060517 VORICONAZOLE fungal keratitis Association between in vitro susceptibility to natamycin and http://www.ncbi.nlm.nih.gov/pubmed/24746358 VORICONAZOLE voriconazole and clinical outcomes in fungal keratitis

Comparative evaluation of topical versus intrastromal voriconazole as http://www.ncbi.nlm.nih.gov/pubmed/23246119 VORICONAZOLE an adjunct to natamycin in recalcitrant fungal keratitis The mycotic ulcer treatment trial: a randomized trial comparing http://www.ncbi.nlm.nih.gov/pubmed/23710492 VORICONAZOLE natamycin vs voriconazole Comparison of natamycin and voriconazole for the treatment of http://www.ncbi.nlm.nih.gov/pubmed/20547942 VORICONAZOLE fungal keratitis VORICONAZOLE Aspergillus tracheobronchitis in a lung transplant recipient https://www.ncbi.nlm.nih.gov/pubmed/21700233 VORICONAZOLE https://www.ncbi.nlm.nih.gov/pubmed/27647245 Topical voriconazole as an effective treatment for fungal keratitis Successful treatment of Beauveria bassiana fungal keratitis with VORICONAZOLE https://www.ncbi.nlm.nih.gov/pubmed/26603426 topical voriconazole Re-appraisal of topical 1% voriconazole and 5% natamycin in the VORICONAZOLE https://www.ncbi.nlm.nih.gov/pubmed/25740805 treatment of fungal keratitis in a randomised trial Topical Voriconazole Solution for Cutaneous Aspergillosis in a http://pediatrics.aappublications.org/content/118/2/e5 VORICONAZOLE Pediatric Patient After Bone Marrow Transplant 06?download=true https://www.ncbi.nlm.nih.gov/pmc/articles/PMC42829 VORICONAZOLE Invasive maxillary sinus aspergillosis: A case report successfully 18/ treated with voriconazole and surgical debridement Inhaled Voriconazole for Prevention of Invasive Pulmonary VORICONAZOLE http://aac.asm.org/content/53/6/2613.full Aspergillosis Medication Title of Article PubMed Link VORICONAZOLE https://www.ncbi.nlm.nih.gov/pubmed/28360537 Successful treatment of Chrysosporium keratitis with voriconazole Successful use of topical voriconazole 1% alone as first-line VORICONAZOLE https://www.ncbi.nlm.nih.gov/pubmed/19861430 antifungal therapy against Candida albicans keratitis VORICONAZOLE Topical Voriconazole as a Novel Treatment for Fungal Keratitis http://aac.asm.org/content/50/1/262.full https://www.ncbi.nlm.nih.gov/pubmed/27647245 VORICONAZOLE [Topical voriconazole as an effective treatment for fungal keratitis]. Successful treatment of Beauveria bassiana fungal keratitis with https://www.ncbi.nlm.nih.gov/pubmed/26603426 VORICONAZOLE topical voriconazole. VORICONAZOLE Update on the Management of Infectious Keratitis. https://www.ncbi.nlm.nih.gov/pubmed/28942073 Effect of pretreatment with antifungal agents on clinical outcomes in https://www.ncbi.nlm.nih.gov/pubmed/27329780 VORICONAZOLE fungal keratitis.

Contact-Lens-Associated Purpureocillium Keratitis: Risk Factors, https://www.ncbi.nlm.nih.gov/pubmed/25723808 VORICONAZOLE Microbiologic Characteristics, Clinical Course, and Outcomes. https://www.ncbi.nlm.nih.gov/pubmed/?term=3056233 VORICONAZOLE Natamycin versus voriconazole for fungal keratitis. [Spanish, English] 7 Successful treatment of a recurrent Aspergillus niger otomycosis with https://www.ncbi.nlm.nih.gov/pubmed/?term=2967376 VORICONAZOLE local application of voriconazole. 9 Periocular contact dermatitis with use of topical voriconazole 1% in https://www.ncbi.nlm.nih.gov/pubmed/?term=3021978 VORICONAZOLE mycotic keratitis. 5 Voriconazole Concentrations in Plasma and Epithelial Lining Fluid https://www.ncbi.nlm.nih.gov/pubmed/?term=2860960 VORICONAZOLE after Inhalation and Oral Treatment. 8 Clinically Significant Enhancement of Voriconazole Efficacy by https://www.ncbi.nlm.nih.gov/pubmed/?term=2948951 VORICONAZOLE Moxifloxacin and Gentamicin in Fungal Keratitis. 5 Highly respirable dry powder inhalable formulation of voriconazole https://www.ncbi.nlm.nih.gov/pubmed/?term=2660973 VORICONAZOLE with enhanced pulmonary bioavailability. 3 Successful treatment of Beauveria bassiana fungal keratitis with https://www.ncbi.nlm.nih.gov/pubmed/?term=2660342 VORICONAZOLE topical voriconazole. 6 Risk factors for low vision related functioning in the Mycotic Ulcer https://www.ncbi.nlm.nih.gov/pubmed/?term=2653105 VORICONAZOLE Treatment Trial: a randomised trial comparing natamycin with 1 voriconazole. Development of an inhaled controlled release voriconazole dry https://www.ncbi.nlm.nih.gov/pubmed/?term=2592317 VORICONAZOLE powder formulation for the treatment of respiratory fungal infection. 1 Medication Title of Article PubMed Link Re-appraisal of topical 1% voriconazole and 5% natamycin in the https://www.ncbi.nlm.nih.gov/pubmed/?term=2574080 VORICONAZOLE treatment of fungal keratitis in a randomised trial. 5 Does topical voriconazole trigger dysplastic changes on the ocular https://www.ncbi.nlm.nih.gov/pubmed/?term=2462117 VORICONAZOLE surface?. 1 Topical voriconazole therapy of Purpureocillium lilacinum keratitis https://www.ncbi.nlm.nih.gov/pubmed/?term=2497413 VORICONAZOLE that occurred in disposable soft contact lens wearers. 3 Association between in vitro susceptibility to natamycin and https://www.ncbi.nlm.nih.gov/pubmed/?term=2474635 VORICONAZOLE voriconazole and clinical outcomes in fungal keratitis. 8 Phototoxic dermatoses in pediatric BMT patients receiving https://www.ncbi.nlm.nih.gov/pubmed/?term=2461992 VORICONAZOLE voriconazole. 2 The mycotic ulcer treatment trial: a randomized trial comparing https://www.ncbi.nlm.nih.gov/pubmed/?term=2371049 VORICONAZOLE natamycin vs voriconazole. 2 Comparative evaluation of topical versus intrastromal voriconazole as https://www.ncbi.nlm.nih.gov/pubmed/?term=2324611 VORICONAZOLE an adjunct to natamycin in recalcitrant fungal keratitis. 9 Factors affecting treatment outcomes with voriconazole in cases with https://www.ncbi.nlm.nih.gov/pubmed/?term=2258044 VORICONAZOLE fungal keratitis. 0 Intracameral and topical voriconazole for fungal corneal https://www.ncbi.nlm.nih.gov/pubmed/?term=2241061 VORICONAZOLE endoexudates. 3 Treatment of Alternaria keratitis with intrastromal and topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2152186 VORICONAZOLE in combination with intrastromal, topical, and oral 4 voriconazole. Treatment of microsporidia keratitis with topical voriconazole https://www.ncbi.nlm.nih.gov/pubmed/?term=2148287 VORICONAZOLE monotherapy. 8 The effects of intrastromal voriconazole injection and topical https://www.ncbi.nlm.nih.gov/pubmed/?term=2144806 VORICONAZOLE voriconazole in the treatment of recalcitrant Fusarium keratitis. 3 Voriconazole versus natamycin as primary treatment in fungal https://www.ncbi.nlm.nih.gov/pubmed/?term=2110597 VORICONAZOLE corneal ulcers. 4 Single and multidose ocular kinetics and stability analysis of https://www.ncbi.nlm.nih.gov/pubmed/?term=2095818 VORICONAZOLE extemporaneous formulation of topical voriconazole in humans. 3 Successful topical application of caspofungin in the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2062506 VORICONAZOLE fungal keratitis refractory to voriconazole. 1 Comparison of natamycin and voriconazole for the treatment of https://www.ncbi.nlm.nih.gov/pubmed/?term=2054794 VORICONAZOLE fungal keratitis. 2 Medication Title of Article PubMed Link Treatment with voriconazole in 3 eyes with resistant Acanthamoeba https://www.ncbi.nlm.nih.gov/pubmed/?term=1987508 VORICONAZOLE keratitis. 9 Successful use of topical voriconazole 1% alone as first-line https://www.ncbi.nlm.nih.gov/pubmed/?term=1986143 VORICONAZOLE antifungal therapy against Candida albicans keratitis. 0 Penetration of 1% voriconazole eye drops into human vitreous https://www.ncbi.nlm.nih.gov/pubmed/?term=1972312 VORICONAZOLE humour: a prospective, open-label study. 8 Successful salvage treatment of Scedosporium apiospermum https://www.ncbi.nlm.nih.gov/pubmed/?term=1943596 VORICONAZOLE keratitis with topical voriconazole after failure of natamycin. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1933748 VORICONAZOLE Topical and oral voriconazole in the treatment of fungal keratitis. 0 Alternaria keratitis: clinical presentation and resolution with topical https://www.ncbi.nlm.nih.gov/pubmed/?term=1909242 VORICONAZOLE fluconazole or intrastromal voriconazole and topical caspofungin. 3 Aqueous and vitreous concentrations following topical administration https://www.ncbi.nlm.nih.gov/pubmed/?term=1819521 VORICONAZOLE of 1% voriconazole in humans. 3 https://www.ncbi.nlm.nih.gov/pubmed/?term=1746687 VORICONAZOLE Management of tunnel fungal infection with voriconazole. 2 https://www.ncbi.nlm.nih.gov/pubmed/?term=1718805 VORICONAZOLE Topical and oral voriconazole in the treatment of fungal keratitis. 2 Successful topical therapy with voriconazole: pseudallescheriasis https://www.ncbi.nlm.nih.gov/pubmed/?term=1711089 VORICONAZOLE after injury. 2 Voriconazole concentration in human aqueous humor and plasma https://www.ncbi.nlm.nih.gov/pubmed/?term=1706051 VORICONAZOLE during topical or combined topical and systemic administration for 7 fungal keratitis. https://www.ncbi.nlm.nih.gov/pubmed/?term=1723881 VORICONAZOLE Voriconazole and fungal keratitis: a report of two treatment failures. 0 Topical voriconazole solution for cutaneous aspergillosis in a https://www.ncbi.nlm.nih.gov/pubmed/?term=1681600 VORICONAZOLE pediatric patient after bone marrow transplant. 5 https://www.ncbi.nlm.nih.gov/pubmed/?term=1637769 VORICONAZOLE Topical voriconazole as a novel treatment for fungal keratitis. 6 https://www.ncbi.nlm.nih.gov/pubmed/?term=1637179 VORICONAZOLE Voriconazole in the management of Alternaria keratitis. 4 Successful treatment of Fusarium keratitis with cornea https://www.ncbi.nlm.nih.gov/pubmed/?term=1590925 VORICONAZOLE transplantation and topical and systemic voriconazole. 2 Medication Title of Article PubMed Link https://www.ncbi.nlm.nih.gov/pubmed/?term=1560647 VORICONAZOLE Effect of voriconazole on a corneal abscess caused by fusarium. 8 Voriconazole in fungal keratitis caused by Scedosporium https://www.ncbi.nlm.nih.gov/pubmed/?term=1475506 VORICONAZOLE apiospermum. 5 Nebulized voriconazole in infections with Scedosporium VORICONAZOLE http://www.ncbi.nlm.nih.gov/pubmed/24263169 apiospermum--case report and review of the literature. Inhaled Voriconazole - An efficient Treatment against invasive http://www.atsjournals.org/doi/abs/10.1164/ajrccm- VORICONAZOLE aspergillosis conference.2012.185.1_MeetingAbstracts.A6088 Inhaled voriconazole for prevention of invasive pulmonary VORICONAZOLE http://www.ncbi.nlm.nih.gov/pubmed/19289523 aspergillosis. http://www.ncbi.nlm.nih.gov/pubmed/?term=O.+Hilber Remarkably efficient inhaled antifungal monotherapy for invasive VORICONAZOLE g%2C+E.+Bendstrup%2C+J.+Mortensen%2C+C.+An pulmonary aspergillosis. dersen Pulmonary Delivery of Voriconazole Loaded Nanoparticles Providing VORICONAZOLE a Prolonged Drug Level in Lungs: A Promise for Treating Fungal http://www.ncbi.nlm.nih.gov/pubmed/25941882 Infection. Development of an inhaled controlled release voriconazole dry VORICONAZOLE http://www.ncbi.nlm.nih.gov/pubmed/25923171 powder formulation for the treatment of respiratory fungal infection. Poly-lactide-co-glycolide nanoparticles containing voriconazole for VORICONAZOLE http://www.ncbi.nlm.nih.gov/pubmed/22633899 pulmonary delivery: in vitro and in vivo study. Dose tolerability of chronically inhaled voriconazole solution in VORICONAZOLE http://www.ncbi.nlm.nih.gov/pubmed/19524030 rodents. http://www.ncbi.nlm.nih.gov/pubmed/23589387 XYLITOL Tooth-surface-specific effects of xylitol: randomized trial results Inhaled hyaluronic acid as ancillary treatment in children with http://www.ncbi.nlm.nih.gov/pubmed/25316142 XYLITOL bacterial acute rhinopharyngitis ZINC Topical zinc sulphate solution for treatment of viral warts. http://www.ncbi.nlm.nih.gov/pubmed/17768472 Topical zinc oxide vs. salicylic acid-lactic acid combination in the http://www.ncbi.nlm.nih.gov/pubmed/17442091 ZINC treatment of warts. ZINC Oral zinc sulfate treatment for viral warts: an open-label study. http://www.ncbi.nlm.nih.gov/pubmed/21352302 ZINC Zinc deficiency in patients with persistent viral warts. http://www.ncbi.nlm.nih.gov/pubmed/20378032 Medication Title of Article PubMed Link

Oral zinc sulfate for unresponsive cutaneous viral warts: too good to http://www.ncbi.nlm.nih.gov/pubmed/20055878 ZINC be true? A double-blind, randomized, placebo-controlled trial. Oral zinc sulphate in the treatment of recalcitrant viral warts: http://www.ncbi.nlm.nih.gov/pubmed/11952542 ZINC randomized placebo-controlled clinical trial. http://www.ncbi.nlm.nih.gov/pubmed/26885780 ZINC Zinc Pyrithione: A Topical Antimicrobial With Complex Pharmaceutics Zinc oxide as a new antimicrobial preservative of topical products: http://www.ncbi.nlm.nih.gov/pubmed/25527211 ZINC interactions with common formulation ingredients The role of zinc in the treatment of acne: A review of the https://www.ncbi.nlm.nih.gov/pubmed/29193602 ZINC ACETATE literature. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal https://www.ncbi.nlm.nih.gov/pubmed/22064530 ZINC ACETATE challenge [Management of acne vulgaris: focus on clindamycin and zinc]. https://www.ncbi.nlm.nih.gov/pubmed/19082570 ZINC ACETATE In-vitro and in-vivo efficacy of zinc acetate against https://www.ncbi.nlm.nih.gov/pubmed/10603662 propionibacteria alone and in combination with erythromycin. ZINC ACETATE A literature assessment of the use of miscellaneous topical agents, growth factors, and skin https://www.ncbi.nlm.nih.gov/pubmed/7894932 ZINC ACETATE equivalents for the treatment of pressure ulcers. ZOLMITRIPTAM The impact of migraine: a case study http://www.ncbi.nlm.nih.gov/pubmed/17847668 ZOLMITRIPTAM Intranasal zolmitriptan for the treatment of acute migraine http://www.ncbi.nlm.nih.gov/pubmed/24024604 Influence of polymeric microcarriers on the in vivo intranasal uptake http://www.ncbi.nlm.nih.gov/pubmed/23153670 ZOLMITRIPTAM of an anti-migraine drug for brain targeting Zolmitriptan nasal spray in the acute treatment of cluster headache: a http://www.ncbi.nlm.nih.gov/pubmed/17724283 ZOLMITRIPTAM double-blind study ZOLMITRIPTAM Efficacy of zolmitriptan nasal spray in adolescent migraine http://www.ncbi.nlm.nih.gov/pubmed/17671066 Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing http://www.ncbi.nlm.nih.gov/pubmed/17177580 ZOLMITRIPTAM surveillance study Medication Title of Article PubMed Link

Effectiveness of intranasal zolmitriptan in acute cluster headache: a http://www.ncbi.nlm.nih.gov/pubmed/16966497 ZOLMITRIPTAM randomized, placebo-controlled, double-blind crossover study Symptomatic treatment of migraine with zolmitriptan: experience with http://www.ncbi.nlm.nih.gov/pubmed/16832773 ZOLMITRIPTAM 82 patients ZOLMITRIPTAM Experience with intranasal zolmitriptan in cluster headache http://www.ncbi.nlm.nih.gov/pubmed/16575626 Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo- http://www.ncbi.nlm.nih.gov/pubmed/15697326 ZOLMITRIPTAM controlled study Zolmitriptan nasal spray exhibits good long-term safety and http://www.ncbi.nlm.nih.gov/pubmed/15663608 ZOLMITRIPTAM tolerability in migraine: results of the INDEX trial Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE http://www.ncbi.nlm.nih.gov/pubmed/15663607 ZOLMITRIPTAM Study Tolerability and consistency of effect of zolmitriptan nasal spray in a http://www.ncbi.nlm.nih.gov/pubmed/12921494 ZOLMITRIPTAM long-term migraine treatment trial

Speed of onset and efficacy of zolmitriptan nasal spray in the acute http://www.ncbi.nlm.nih.gov/pubmed/12828501 treatment of migraine: a randomised, double-blind, placebo- ZOLMITRIPTAM controlled, dose-ranging study versus zolmitriptan tablet Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy http://www.ncbi.nlm.nih.gov/pubmed/12412823 ZOLMITRIPTAM volunteers Preliminary studies of the pharmacokinetics and tolerability of http://www.ncbi.nlm.nih.gov/pubmed/12412822 ZOLMITRIPTAM zolmitriptan nasal spray in healthy volunteers Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post- http://www.ncbi.nlm.nih.gov/pubmed/26819941 ZONISAMIDE Marketing Surveillance Study Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance http://www.ncbi.nlm.nih.gov/pubmed/26476459 ZONISAMIDE Varenicline-Induced Smoking Cessation